{
  "albuterol": {
    "name": "Albuterol (ProAir, Ventolin)",
    "genericName": "Albuterol Sulfate",
    "formula": "C13H21NO3",
    "molecularWeight": "239.31 g/mol",
    "brandNames": ["ProAir HFA", "Ventolin HFA", "Proventil HFA", "AccuNeb"],
    "category": "Bronchodilator",
    "drugClass": "Short-Acting Beta-2 Agonist (SABA)",
    "pubchemCID": "2083",
    "indications": "Treatment or prevention of bronchospasm in asthma or COPD; prevention of exercise-induced bronchoconstriction.",
    "moaSteps": [
      "Albuterol acts as a selective beta-2 adrenergic agonist.",
      "Binding to beta-2 receptors in the lung stimulates adenyl cyclase.",
      "This increases intracellular cyclic AMP (cAMP) levels.",
      "Increased cAMP activates protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular calcium concentrations.",
      "The result is relaxation of bronchial smooth muscle and bronchodilation."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed following inhalation. Bronchodilation begins within 5 minutes, peaks within 0.5 to 2 hours, and lasts 3 to 6 hours.",
      "distribution": "Systemic levels are low after inhalation. Plasma protein binding is approximately 10%. It does not cross the blood-brain barrier to a significant extent.",
      "metabolism": "Hepatic metabolism is extensive. It is metabolized by sulfotransferase enzymes (SULTIA3) to an inactive sulfate conjugate (4'-O-sulfate).",
      "excretion": "Primarily excreted in the urine (80-100%) as unchanged drug and metabolites. A small portion (<20%) is excreted in feces. The elimination half-life is roughly 3-5 hours."
    },
    "dose": {
        "initialDose": "2 puffs (180 mcg) inhaled every 4-6 hours PRN",
        "maxDose": "Typically 8 puffs per day (varies by severity)",
        "notes": "For Exercise-Induced Bronchospasm: 2 puffs 15-30 minutes prior to exercise. For Nebulizer: 2.5 mg 3-4 times daily."
    },
    "adverseEffects": {
      "common": [
        "Tremor (skeletal muscle)",
        "Nervousness and anxiety",
        "Headache",
        "Tachycardia (rapid heartbeat)",
        "Palpitations",
        "Throat irritation/Cough",
        "Muscle cramps",
        "Nausea",
        "Dizziness",
        "Insomnia"
      ],
      "serious": [
        "Paradoxical Bronchospasm (life-threatening)",
        "Significant Hypokalemia (low potassium)",
        "Cardiac Arrhythmias (e.g., atrial fibrillation, SVT)",
        "Myocardial Ischemia",
        "Severe Hypersensitivity Reactions (Angioedema, Urticaria)",
        "Hyperglycemia (in high doses)"
      ]
    },
    "precautions": [
      "**Paradoxical Bronchospasm:** Can produce life-threatening bronchospasm upon inhalation; discontinue immediately if this occurs.",
      "**Cardiovascular Effects:** Use with caution in patients with history of arrhythmias, QT prolongation, or hypertension.",
      "**Hypokalemia:** Beta-agonists can produce significant decreases in serum potassium; monitor in patients on diuretics.",
      "**Diabetes Mellitus:** Large doses may increase blood glucose and aggravate ketoacidosis.",
      "**Hyperthyroidism:** Use with caution in patients with thyrotoxicosis as it may stimulate thyroid activity.",
      "**Seizure Disorders:** Albuterol may lower the seizure threshold in susceptible patients.",
      "**Do Not Exceed Recommended Dose:** Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.",
      "**Hypersensitivity:** Rare cases of urticaria, angioedema, and rash have occurred.",
      "**Co-administration with Beta-Blockers:** Beta-blockers may block the pulmonary effect of albuterol and produce severe bronchospasm in asthmatics.",
      "**Labor and Delivery:** May inhibit uterine contractility due to beta-2 relaxation effects.",
      "**Geriatric Use:** Start at the lower end of the dosing range due to higher frequency of decreased hepatic/cardiac function.",
      "**Lactose Allergy:** Some dry powder inhalers contain lactose and may contain trace milk proteins."
    ],
    "contraindications": [
      "Hypersensitivity to albuterol",
      "Severe hypersensitivity to milk proteins (for dry powder inhalers)"
    ],
    "interactions": {
        "drug": ["Beta-blockers (Propranolol, Carvedilol)", "Loop Diuretics (Furosemide)", "Thiazide Diuretics", "MAOIs", "Tricyclic Antidepressants", "Digoxin"],
        "food": ["Caffeine (may enhance stimulant effects)"]
    },
    "pregnancyCategory": "Category C"
  },
  "allopurinol": {
    "name": "Allopurinol (Zyloprim)",
    "genericName": "Allopurinol",
    "formula": "C5H4N4O",
    "molecularWeight": "136.11 g/mol",
    "brandNames": ["Zyloprim", "Aloprim", "Lopurin"],
    "category": "Antigout Agent",
    "drugClass": "Xanthine Oxidase Inhibitor",
    "pubchemCID": "13540190",
    "indications": "Management of gout signs and symptoms (prophylaxis); management of patients with leukemia, lymphoma, and malignancies receiving cancer therapy (to prevent tumor lysis syndrome).",
    "moaSteps": [
      "Allopurinol and its primary active metabolite, oxypurinol, act as inhibitors of the enzyme xanthine oxidase.",
      "Xanthine oxidase is the catalyst responsible for the conversion of hypoxanthine to xanthine, and xanthine to uric acid.",
      "By inhibiting this enzyme, the production of uric acid is decreased.",
      "This lowers plasma and urinary uric acid concentrations, preventing crystal deposition."
    ],
    "pharmacokinetics": {
      "absorption": "Approximately 80-90% is absorbed from the GI tract following oral administration. Peak plasma concentrations occur at 1.5 hours for allopurinol and 4.5 hours for oxypurinol.",
      "distribution": "Widely distributed into tissue. Negligible protein binding. It distributes into breast milk.",
      "metabolism": "Rapidly oxidized by xanthine oxidase and aldehyde oxidase in the liver to its active metabolite, oxypurinol.",
      "excretion": "Allopurinol is excreted in urine (~12%) and feces. Oxypurinol is excreted primarily in the urine via glomerular filtration and tubular reabsorption. The half-life of allopurinol is 1-2 hours; oxypurinol is 15-25 hours.",
      "notes": "Dose adjustment is critical in renal impairment due to accumulation of oxypurinol."
    },
    "dose": {
        "initialDose": "100 mg PO once daily",
        "maxDose": "800 mg/day",
        "notes": "Titrate by 100mg weekly until serum uric acid < 6 mg/dL. Administer after meals to reduce gastric irritation. Doses >300mg should be divided."
    },
    "adverseEffects": {
      "common": [
        "Maculopapular rash",
        "Pruritus (itching)",
        "Nausea and vomiting",
        "Diarrhea",
        "Acute gout flare (upon initiation)",
        "Drowsiness",
        "Headache",
        "Abdominal pain",
        "Taste disturbance",
        "Elevated liver enzymes"
      ],
      "serious": [
        "Stevens-Johnson Syndrome (SJS)",
        "Toxic Epidermal Necrolysis (TEN)",
        "Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)",
        "Severe Hepatotoxicity / Hepatitis",
        "Bone Marrow Suppression (leukopenia, thrombocytopenia)",
        "Renal Failure"
      ]
    },
    "precautions": [
      "**HLA-B*5801 Screening:** Patients of Han Chinese, Thai, or Korean descent possess a higher risk for severe cutaneous reactions (SCAR) and should be screened for the HLA-B*5801 allele before starting.",
      "**Skin Rash:** Discontinue immediately at the first appearance of skin rash or other signs of allergic reaction. It may precede SJS/TEN.",
      "**Acute Gout Flares:** Do not start allopurinol during an active gout attack. When initiating therapy, provide prophylaxis (colchicine or NSAID) for up to 6 months.",
      "**Renal Impairment:** Dose reduction is required in patients with decreased creatinine clearance to prevent oxypurinol toxicity.",
      "**Hepatic Impairment:** Monitor liver function tests (LFTs) periodically, as hepatotoxicity can occur.",
      "**Bone Marrow Depression:** Monitor blood counts, especially in patients receiving concomitant chemotherapeutic agents.",
      "**Fluid Intake:** Patients should maintain fluid intake sufficient to yield a urinary output of at least 2 liters/day to prevent renal stones.",
      "**Drowsiness:** May cause drowsiness; caution patients regarding driving or operating machinery.",
      "**Mercaptopurine/Azathioprine Interaction:** Allopurinol inhibits the metabolism of these drugs. Their dose must be reduced to 25-33% of the usual dose if used concurrently.",
      "**Asymptomatic Hyperuricemia:** Generally not indicated for treatment of asymptomatic hyperuricemia.",
      "**Pregnancy:** Use only if clearly needed (Category C).",
      "**Lactation:** Allopurinol and oxypurinol are excreted in breast milk; use with caution."
    ],
    "contraindications": [
      "Patients who have developed a severe reaction to allopurinol in the past",
      "Concurrent use with Didanosine (increases risk of toxicity)"
    ],
    "interactions": {
        "drug": ["Azathioprine (Major)", "Mercaptopurine (Major)", "Warfarin (increases INR)", "Ampicillin/Amoxicillin (increases rash risk)", "Theophylline", "Thiazide diuretics"],
        "food": ["Alcohol (decreases efficacy by increasing uric acid)"]
    },
    "pregnancyCategory": "Category C"
  },
  "amitriptyline": {
    "name": "Amitriptyline (Elavil)",
    "genericName": "Amitriptyline HCl",
    "formula": "C20H23N",
    "molecularWeight": "277.4 g/mol",
    "brandNames": ["Elavil", "Vanatrip"],
    "category": "Antidepressant",
    "drugClass": "Tricyclic Antidepressant (TCA)",
    "pubchemCID": "2160",
    "indications": "Treatment of Major Depressive Disorder (MDD). Off-label uses include neuropathic pain, migraine prophylaxis, fibromyalgia, and insomnia.",
    "moaSteps": [
      "Amitriptyline inhibits the neuronal membrane reuptake of serotonin and norepinephrine.",
      "This increases the synaptic concentration of these neurotransmitters in the CNS.",
      "It also has high affinity for alpha-adrenergic, histamine (H1), and muscarinic (M1) cholinergic receptors.",
      "The antagonism of these other receptors contributes to its side effect profile (sedation, hypotension, anticholinergic effects)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and well absorbed following oral administration. Peak plasma concentrations are reached within 2-12 hours.",
      "distribution": "Widely distributed throughout the body. It is highly protein-bound (>95%) to plasma and tissue proteins. It crosses the placenta and enters breast milk.",
      "metabolism": "Extensively metabolized in the liver via CYP2D6 (demethylation) to its active metabolite, nortriptyline. Also involves CYP2C19.",
      "excretion": "Excreted primarily in the urine as metabolites (glucuronide or sulfate conjugates). Little unchanged drug appears in urine. Elimination half-life ranges from 10 to 50 hours.",
      "notes": "Genetic polymorphisms in CYP2D6 can significantly affect drug levels."
    },
    "dose": {
        "initialDose": "25-50 mg PO at bedtime",
        "maxDose": "150-300 mg/day (Hospitalized patients)",
        "notes": "For neuropathic pain/migraine, doses are lower (e.g., 10-25 mg HS). Taper gradually to discontinue to avoid cholinergic rebound."
    },
    "adverseEffects": {
      "common": [
        "Dry mouth (Xerostomia)",
        "Drowsiness/Sedation",
        "Dizziness (Orthostatic hypotension)",
        "Constipation",
        "Blurred vision",
        "Weight gain",
        "Urinary retention",
        "Tachycardia",
        "Confusion (especially in elderly)",
        "Sexual dysfunction"
      ],
      "serious": [
        "Suicidal thoughts and behaviors (Boxed Warning)",
        "QT Prolongation / Torsades de Pointes",
        "Serotonin Syndrome",
        "Bone marrow suppression (rare)",
        "Seizures",
        "Paralytic ileus",
        "Increased intraocular pressure"
      ]
    },
    "precautions": [
      "**Suicidality:** Boxed Warning regarding increased risk of suicidal thinking in children and young adults during early treatment.",
      "**Anticholinergic Effects:** Use with extreme caution in patients with urinary retention, benign prostatic hyperplasia (BPH), or untreated narrow-angle glaucoma.",
      "**Cardiovascular Disease:** Can cause conduction defects, arrhythmias, and tachycardia. Avoid in recent MI or heart block.",
      "**Orthostatic Hypotension:** Caution in patients prone to falls; advise patients to change positions slowly.",
      "**Seizure History:** TCAs lower the seizure threshold; use with caution in epileptics.",
      "**Serotonin Syndrome:** Risk increases when used with other serotonergic agents (SSRIs, SNRIs, Triptans, Tramadol).",
      "**Bipolar Disorder:** May precipitate a manic/mixed episode in patients with bipolar disorder.",
      "**Liver Dysfunction:** Metabolism may be impaired; use lower doses.",
      "**Discontinuation Syndrome:** Abrupt cessation can cause nausea, headache, and malaise. Taper slowly.",
      "**Surgery:** Discontinue therapy several days before elective surgery if possible due to hypertensive risks with anesthesia.",
      "**CYP2D6 Metabolizers:** Poor metabolizers of CYP2D6 will have higher plasma concentrations and risk of toxicity.",
      "**Elderly:** Beers Criteria medication. Avoid use due to strong anticholinergic and sedative properties.",
      "**Diabetes:** Can alter blood glucose levels."
    ],
    "contraindications": [
      "Hypersensitivity to amitriptyline",
      "Concomitant use of MAOIs (within 14 days)",
      "Acute recovery phase following Myocardial Infarction (MI)",
      "Cisapride use (QT prolongation risk)"
    ],
    "interactions": {
        "drug": ["MAOIs (Fatal)", "SSRIs (Fluoxetine, Paroxetine)", "Anticholinergics (Atropine, Benztropine)", "CNS Depressants", "Antiarrhythmics", "Warfarin", "Tramadol"],
        "food": ["Alcohol (additive CNS depression)", "Grapefruit juice (mild effect)"]
    },
    "pregnancyCategory": "Category C"
  },
  "amiodarone": {
    "name": "Amiodarone (Pacerone)",
    "genericName": "Amiodarone HCl",
    "formula": "C25H29I2NO3",
    "molecularWeight": "645.3 g/mol",
    "brandNames": ["Pacerone", "Cordarone", "Nexterone"],
    "category": "Antiarrhythmic",
    "drugClass": "Class III Antiarrhythmic",
    "pubchemCID": "2157",
    "indications": "Treatment of life-threatening recurrent ventricular arrhythmias (VF/VT). Off-label for atrial fibrillation/flutter rate and rhythm control.",
    "moaSteps": [
      "Amiodarone is primarily a Class III antiarrhythmic that prolongs the myocardial cell-action potential duration and refractory period by blocking potassium channels.",
      "It also inhibits sodium channels (Class I activity).",
      "It exerts non-competitive antisympathetic action (Class II - Beta-blocking activity).",
      "It has weak calcium channel blocking properties (Class IV activity).",
      "It relaxes smooth muscle, decreases cardiac workload, and myocardial oxygen consumption."
    ],
    "pharmacokinetics": {
      "absorption": "Absorption is slow and variable (approx 50% bioavailability). Peak concentrations occur 3-7 hours after a dose.",
      "distribution": "Extremely large volume of distribution (~60 L/kg). It accumulates extensively in adipose tissue, liver, lung, and spleen. It is >96% protein bound.",
      "metabolism": "Metabolized by the liver via CYP3A4 and CYP2C8 to the major active metabolite, desethylamiodarone.",
      "excretion": "Excreted via the biliary tract into feces. Urinary excretion is negligible. The terminal half-life is extremely long, ranging from 40 to 55 days (and up to 100 days).",
      "notes": "Because of the long half-life, loading doses are required, and drug effects persist for months after discontinuation."
    },
    "dose": {
        "initialDose": "Loading: 800-1600 mg/day PO in divided doses for 1-3 weeks",
        "maxDose": "Maintenance: 200-400 mg/day",
        "notes": "IV Dosing differs. Lowest effective dose should be used to minimize toxicity. 200mg is standard for AFib."
    },
    "adverseEffects": {
      "common": [
        "Nausea and vomiting",
        "Fatigue/Malaise",
        "Tremor",
        "Lack of coordination",
        "Constipation",
        "Insomnia",
        "Headache",
        "Corneal microdeposits (halos around lights)",
        "Photosensitivity (sunburn risk)",
        "Anorexia"
      ],
      "serious": [
        "Pulmonary Toxicity (Fibrosis/Pneumonitis - Fatal)",
        "Hepatotoxicity (Cirrhosis, Hepatitis)",
        "Proarrhythmia (Torsades de Pointes)",
        "Thyroid Dysfunction (Hypothyroidism or Hyperthyroidism)",
        "Optic Neuropathy/Neuritis (Blindness)",
        "Blue-gray skin discoloration (Smurf syndrome)",
        "Bradycardia/Heart Block",
        "Severe Hypersensitivity (SJS/TEN)"
      ]
    },
    "precautions": [
      "**Pulmonary Toxicity:** Boxed Warning. Presents as cough or dyspnea. Baseline CXR required. Discontinue if fibrosis is suspected.",
      "**Liver Injury:** Boxed Warning. Monitor LFTs at baseline and every 6 months. Hepatoxicity can be fatal.",
      "**Proarrhythmic Effects:** Boxed Warning. Can worsen arrhythmias. QT prolongation can lead to Torsades de Pointes.",
      "**Thyroid Abnormalities:** Contains iodine. Can cause hypo- or hyperthyroidism. Monitor TSH at baseline and every 3-6 months.",
      "**Ocular Toxicity:** Routine eye exams required. Corneal microdeposits are common; optic neuritis is rare but can cause blindness.",
      "**Skin Discoloration:** Long-term use can turn skin a blue-gray color, which may not be reversible.",
      "**Photosensitivity:** Patients must wear sunscreen and protective clothing as they burn very easily.",
      "**Bradycardia/Heart Block:** Can cause severe sinus bradycardia or AV block.",
      "**Surgery:** Volatile anesthetics may cause myocardial depression; inform the anesthesiologist.",
      "**Electrolyte Imbalances:** Hypokalemia and hypomagnesemia must be corrected before use to reduce arrhythmia risk.",
      "**Drug Interactions:** Potent inhibitor of CYP3A4, CYP2C9, and P-glycoprotein. Increases levels of Warfarin (bleeding) and Digoxin (toxicity).",
      "**Pregnancy:** Category D. Use only if life-threatening. Can cause fetal thyroid toxicity.",
      "**Lactation:** Excreted in breast milk; breastfeeding is not recommended.",
      "**Very Long Half-Life:** Adverse effects and interactions can persist for months after stopping the drug."
    ],
    "contraindications": [
      "Severe sinus node dysfunction",
      "Second or third-degree AV block (unless pacemaker is present)",
      "Cardiogenic shock",
      "Hypersensitivity to amiodarone or iodine"
    ],
    "interactions": {
        "drug": ["Warfarin (Decrease warfarin dose by 50%)", "Digoxin (Decrease digoxin dose by 50%)", "Simvastatin (Max 20mg)", "Sofosbuvir (Severe bradycardia)", "Beta-blockers", "Calcium Channel Blockers"],
        "food": ["Grapefruit juice (increases amiodarone levels significantly)"]
    },
    "pregnancyCategory": "Category D"
  },
  "amlodipine": {
    "name": "Amlodipine (Norvasc)",
    "genericName": "Amlodipine Besylate",
    "formula": "C20H25ClN2O5",
    "molecularWeight": "408.9 g/mol",
    "brandNames": ["Norvasc", "Katerzia"],
    "category": "Antihypertensive",
    "drugClass": "Calcium Channel Blocker (Dihydropyridine)",
    "pubchemCID": "2162",
    "indications": "Treatment of Hypertension, Chronic Stable Angina, and Vasospastic (Prinzmetal's) Angina.",
    "moaSteps": [
      "Amlodipine is a dihydropyridine calcium antagonist.",
      "It inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle.",
      "It has a greater selectivity for vascular smooth muscle than for cardiac muscle.",
      "This inhibition causes peripheral arterial vasodilation.",
      "Vasodilation reduces systemic vascular resistance (afterload) and lowers blood pressure."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed following oral administration. Bioavailability is 64-90%. Peak plasma concentrations occur between 6-12 hours post-dose.",
      "distribution": "Ex Vivo protein binding is approximately 93%. Volume of distribution is 21 L/kg.",
      "metabolism": "Extensively metabolized in the liver (approx 90%) via CYP3A4 to inactive metabolites.",
      "excretion": "Excreted in the urine (10% as unchanged drug, 60% as metabolites). Elimination half-life is prolonged, ranging from 30 to 50 hours.",
      "notes": "Steady-state plasma levels are reached after 7 to 8 days of consecutive daily dosing."
    },
    "dose": {
        "initialDose": "5 mg PO once daily",
        "maxDose": "10 mg/day",
        "notes": "Small, fragile, or elderly patients, or those with hepatic insufficiency: Start at 2.5 mg daily."
    },
    "adverseEffects": {
      "common": [
        "Peripheral Edema (swelling of ankles/feet)",
        "Flushing",
        "Palpitations",
        "Dizziness/Lightheadedness",
        "Fatigue",
        "Headache",
        "Abdominal pain",
        "Nausea",
        "Somnolence",
        "Pruritus"
      ],
      "serious": [
        "Severe Hypotension",
        "Worsening Angina (reflex tachycardia)",
        "Myocardial Infarction (rare, upon initiation)",
        "Hypersensitivity reactions",
        "Leukopenia/Thrombocytopenia (rare)"
      ]
    },
    "precautions": [
      "**Hypotension:** Symptomatic hypotension is possible, particularly in patients with severe aortic stenosis.",
      "**Increased Angina/MI:** Rarely, patients may develop worsening angina or acute MI upon starting therapy or increasing dose due to reflex tachycardia.",
      "**Hepatic Impairment:** Since amlodipine is extensively metabolized by the liver, the half-life is prolonged in liver failure. Start with a lower dose (2.5 mg).",
      "**Severe Coronary Artery Disease:** Use with caution; verify no worsening of ischemia.",
      "**Heart Failure:** generally safe in stable heart failure, but avoid in unstable heart failure.",
      "**Peripheral Edema:** A dose-dependent side effect. Not related to fluid retention but rather vasodilation; diuretics may not help.",
      "**Aortic Stenosis:** Vasodilators can reduce coronary perfusion in severe stenosis; use with caution.",
      "**Withdrawal:** Although rebound hypertension is rare, gradual discontinuation is recommended.",
      "**Elderly Patients:** Clearance is decreased in the elderly; start at the lower end of the dosing range.",
      "**CYP3A4 Inhibitors:** Co-administration with strong CYP3A4 inhibitors (diltiazem, ketoconazole) can increase amlodipine exposure.",
      "**Pregnancy:** Category C. Use only if potential benefit justifies risk.",
      "**Driving:** May cause dizziness; caution with driving initially."
    ],
    "contraindications": [
      "Known hypersensitivity to amlodipine",
      "Severe hypotension (<90 mmHg systolic)"
    ],
    "interactions": {
        "drug": ["Simvastatin (Do not exceed 20mg Simvastatin)", "CYP3A4 Inhibitors (Diltiazem, Clarithromycin)", "Cyclosporine/Tacrolimus (levels may increase)", "Sildenafil (additive hypotension)"],
        "food": ["Grapefruit juice (can increase drug levels)", "Alcohol"]
    },
    "pregnancyCategory": "Category C"
  },"acetaminophen": {
    "name": "Acetaminophen (Tylenol)",
    "genericName": "Acetaminophen (Paracetamol)",
    "formula": "C8H9NO2",
    "molecularWeight": "151.16 g/mol",
    "brandNames": ["Tylenol", "Ofirmev", "Mapap", "FeverAll"],
    "category": "Analgesic / Antipyretic",
    "drugClass": "Non-opioid Analgesic",
    "pubchemCID": "1983",
    "indications": "Temporary relief of mild to moderate pain and reduction of fever.",
    "moaSteps": [
      "Exact mechanism is not fully understood.",
      "It inhibits the synthesis of prostaglandins in the central nervous system (CNS) likely via COX-3 inhibition.",
      "It blocks pain impulse generation peripherally.",
      "Antipyresis is produced by inhibition of the hypothalamic heat-regulating center."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and almost completely absorbed from the GI tract. Peak plasma levels occur in 30-60 minutes.",
      "distribution": "Widely distributed into most body tissues except fat. Crosses the placenta.",
      "metabolism": "Metabolized by the liver via glucuronidation and sulfation. A small amount is metabolized by CYP450 (CYP2E1) to a toxic intermediate (NAPQI), which is normally detoxified by glutathione.",
      "excretion": "Excreted in urine as metabolites. Half-life is 2-3 hours."
    },
    "dose": {
      "initialDose": "325-650 mg PO every 4-6 hours",
      "maxDose": "4,000 mg/day (Adults)",
      "notes": "Limit to < 3,000 mg/day in chronic use or mild hepatic impairment to prevent toxicity."
    },
    "adverseEffects": {
      "common": [
        "Nausea",
        "Vomiting",
        "Insomnia",
        "Headache",
        "Constipation (with chronic use)"
      ],
      "serious": [
        "Hepatotoxicity (Acute Liver Failure) - BOXED WARNING",
        "Steven-Johnson Syndrome (SJS)",
        "Toxic Epidermal Necrolysis (TEN)",
        "Anaphylaxis"
      ]
    },
    "precautions": [
      "**Hepatotoxicity:** Exceeding the max daily dose can cause fatal liver damage. Avoid alcohol.",
      "**Combination Products:** Many OTC cough/cold and opioid medications contain acetaminophen; warn patients to check labels to avoid overdose.",
      "**G6PD Deficiency:** Use with caution, risk of hemolysis.",
      "**Malnutrition:** Chronic malnutrition depletes glutathione, increasing toxicity risk."
    ],
    "contraindications": [
      "Severe hepatic impairment",
      "Severe active liver disease",
      "Hypersensitivity to acetaminophen"
    ],
    "interactions": {
      "drug": ["Warfarin (prolongs INR with chronic high doses)", "Isoniazid (hepatotoxicity)", "Carbamazepine", "Phenytoin"],
      "food": ["Alcohol (significantly increases risk of liver damage)"]
    },
    "pregnancyCategory": "Category B"
  },
  "acyclovir": {
    "name": "Acyclovir (Zovirax)",
    "genericName": "Acyclovir",
    "formula": "C8H11N5O3",
    "molecularWeight": "225.20 g/mol",
    "brandNames": ["Zovirax", "Sitavig"],
    "category": "Antiviral",
    "drugClass": "Synthetic Nucleoside Analogue",
    "pubchemCID": "2022",
    "indications": "Treatment of Herpes Simplex Virus (HSV-1, HSV-2) and Varicella-Zoster Virus (Shingles, Chickenpox).",
    "moaSteps": [
      "Acyclovir is a prodrug that must be phosphorylated by viral thymidine kinase to acyclovir monophosphate.",
      "Host cell kinases convert it to acyclovir triphosphate.",
      "Acyclovir triphosphate competes with deoxyguanosine triphosphate for viral DNA polymerase.",
      "Incorporation into the DNA chain causes premature chain termination, halting viral replication."
    ],
    "pharmacokinetics": {
      "absorption": "Poor oral bioavailability (15-30%). Unaffected by food.",
      "distribution": "Widely distributed into tissues and body fluids (including CSF). Protein binding is low (9-33%).",
      "metabolism": "Minimal hepatic metabolism.",
      "excretion": "Primarily excreted unchanged in the urine via glomerular filtration and tubular secretion. Half-life is 2.5-3.3 hours."
    },
    "dose": {
      "initialDose": "400-800 mg PO 2-5 times daily (indication dependent)",
      "maxDose": "Varies by protocol (e.g., 4g/day for shingles)",
      "notes": "IV hydration is critical for IV administration to prevent crystal nephropathy."
    },
    "adverseEffects": {
      "common": [
        "Nausea/Vomiting",
        "Diarrhea",
        "Headache",
        "Malaise"
      ],
      "serious": [
        "Acute Renal Failure (Crystalluria)",
        "Neurotoxicity (Confusion, Hallucinations, Seizures)",
        "Thrombotic Thrombocytopenic Purpura (TTP) in immunocompromised"
      ]
    },
    "precautions": [
      "**Renal Impairment:** Dose adjustment is required to prevent accumulation and neurotoxicity.",
      "**Hydration:** Maintain adequate hydration to prevent precipitation of acyclovir crystals in renal tubules.",
      "**Neurologic Effects:** Elderly patients and those with renal failure are at higher risk for tremors, confusion, and seizures."
    ],
    "contraindications": [
      "Hypersensitivity to acyclovir or valacyclovir"
    ],
    "interactions": {
      "drug": ["Probenecid (decreases elimination)", "Nephrotoxic agents (Aminoglycosides, NSAIDs)", "Tenofovir"],
      "food": ["No significant food interactions."]
    },
    "pregnancyCategory": "Category B"
  },
  "adalimumab": {
    "name": "Adalimumab (Humira)",
    "genericName": "Adalimumab",
    "formula": "C6428H9912N1694O1987S46",
    "molecularWeight": "~148 kDa",
    "brandNames": ["Humira", "Amjevita", "Cyltezo"],
    "category": "Biologic DMARD",
    "drugClass": "Tumor Necrosis Factor (TNF) Alpha Inhibitor",
    "pubchemCID": "None (Protein)",
    "indications": "Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease, Ulcerative Colitis, Plaque Psoriasis.",
    "moaSteps": [
      "Adalimumab is a recombinant human IgG1 monoclonal antibody.",
      "It binds specifically to tumor necrosis factor-alpha (TNF-alpha).",
      "This blocks TNF-alpha interaction with p55 and p75 cell surface receptors.",
      "Neutralizing TNF-alpha reduces the inflammatory cascade and alters cell migration/adhesion involved in autoimmune damage."
    ],
    "pharmacokinetics": {
      "absorption": "Given subcutaneously. Bioavailability is 64%. Peak concentration reached in 131 hours.",
      "distribution": "Limited distribution, primarily in vascular compartment and synovial fluid.",
      "metabolism": "Degraded into small peptides and amino acids via catabolic pathways.",
      "excretion": "Clearance is slow. Elimination half-life is approximately 2 weeks (10-20 days)."
    },
    "dose": {
      "initialDose": "Example: 40 mg SubQ every other week",
      "maxDose": "Varies by indication (e.g., 160mg loading dose)",
      "notes": "Rotate injection sites. Store in refrigerator."
    },
    "adverseEffects": {
      "common": [
        "Injection site reactions (redness, itching)",
        "Upper respiratory infections",
        "Sinusitis",
        "Headache",
        "Rash"
      ],
      "serious": [
        "Serious Infections (TB, fungal, bacterial sepsis) - BOXED WARNING",
        "Malignancy (Lymphoma) - BOXED WARNING",
        "Demyelinating disease (MS-like symptoms)",
        "Heart Failure exacerbation",
        "Lupus-like syndrome"
      ]
    },
    "precautions": [
      "**Infection Risk:** Do not start if patient has an active infection. Withhold if serious infection develops.",
      "**Tuberculosis:** Test for latent TB prior to initiation. Reactivation can be fatal.",
      "**Hepatitis B:** Screen for HBV; reactivation can occur.",
      "**Heart Failure:** Use with caution in Class III/IV CHF; can worsen outcomes.",
      "**Live Vaccines:** Avoid live vaccines during therapy."
    ],
    "contraindications": [
      "Active serious infection (sepsis, abscess, TB)",
      "Hypersensitivity to adalimumab"
    ],
    "interactions": {
      "drug": ["Abatacept (increased infection risk)", "Anakinra", "Live Vaccines", "Immunosuppressants (additive effect)"],
      "food": ["None known"]
    },
    "pregnancyCategory": "Category B"
  },
  "alprazolam": {
    "name": "Alprazolam (Xanax)",
    "genericName": "Alprazolam",
    "formula": "C17H13ClN4",
    "molecularWeight": "308.76 g/mol",
    "brandNames": ["Xanax", "Xanax XR", "Niravam"],
    "category": "Anxiolytic",
    "drugClass": "Benzodiazepine (Short-acting)",
    "pubchemCID": "2118",
    "indications": "Generalized Anxiety Disorder (GAD), Panic Disorder (with or without agoraphobia).",
    "moaSteps": [
      "Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA-A neuron within the CNS.",
      "This enhances the inhibitory effect of GABA (gamma-aminobutyric acid) on neuronal excitability.",
      "Increased chloride ion influx hyperpolarizes the neuron.",
      "Result is anxiolysis, sedation, skeletal muscle relaxation, and anticonvulsant activity."
    ],
    "pharmacokinetics": {
      "absorption": "Readily absorbed. Peak plasma concentrations occur in 1-2 hours.",
      "distribution": "80% protein bound. Crosses the blood-brain barrier and placenta.",
      "metabolism": "Metabolized in the liver by CYP3A4 to 4-hydroxyalprazolam and alpha-hydroxyalprazolam (less active).",
      "excretion": "Excreted in urine. Half-life is 11-12 hours in healthy adults (longer in elderly/obese)."
    },
    "dose": {
      "initialDose": "0.25-0.5 mg PO three times daily",
      "maxDose": "4 mg/day (up to 10mg in panic disorder)",
      "notes": "Must be tapered slowly to discontinue to avoid withdrawal seizures."
    },
    "adverseEffects": {
      "common": [
        "Drowsiness / Sedation",
        "Dizziness",
        "Fatigue",
        "Dry mouth",
        "Cognitive impairment / Memory issues",
        "Changes in libido"
      ],
      "serious": [
        "Respiratory Depression (especially with opioids) - BOXED WARNING",
        "Dependency / Abuse / Withdrawal Seizures",
        "Suicidal ideation",
        "Paradoxical reactions (agitation, rage)"
      ]
    },
    "precautions": [
      "**Concomitant Opioid Use:** Profound sedation, respiratory depression, coma, and death may result.",
      "**Dependence:** High potential for abuse and physical dependence (Schedule IV).",
      "**Withdrawal:** Abrupt cessation can cause life-threatening withdrawal symptoms (seizures). Taper over weeks/months.",
      "**CNS Depression:** Avoid driving or operating machinery.",
      "**Depression:** Use caution in patients with depression; may worsen suicidal tendencies."
    ],
    "contraindications": [
      "Acute narrow-angle glaucoma",
      "Concurrent use with potent CYP3A4 inhibitors (itraconazole, ketoconazole)",
      "Hypersensitivity to benzodiazepines"
    ],
    "interactions": {
      "drug": ["Opioids (Fatal respiratory depression)", "Alcohol", "CYP3A4 Inhibitors (Ketoconazole, Clarithromycin)", "CNS Depressants"],
      "food": ["Grapefruit juice (increases drug levels)", "Alcohol (additive CNS depression)"]
    },
    "pregnancyCategory": "Category D"
  },
  "amoxicillin": {
    "name": "Amoxicillin (Amoxil)",
    "genericName": "Amoxicillin",
    "formula": "C16H19N3O5S",
    "molecularWeight": "365.4 g/mol",
    "brandNames": ["Amoxil", "Moxatag"],
    "category": "Antibiotic",
    "drugClass": "Penicillin (Aminopenicillin)",
    "pubchemCID": "33613",
    "indications": "Infections of the ear, nose, and throat; genitourinary tract; skin; and lower respiratory tract. H. pylori eradication.",
    "moaSteps": [
      "Amoxicillin is a beta-lactam antibiotic.",
      "It binds to Penicillin-Binding Proteins (PBPs) located inside the bacterial cell wall.",
      "This binding inhibits the final stage of bacterial cell wall synthesis (peptidoglycan cross-linking).",
      "Cell wall autolytic enzymes are activated, leading to bacterial cell lysis and death (bactericidal)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed (74-92% bioavailability). Stable in gastric acid.",
      "distribution": "Diffuses into most body tissues and fluids. Poor CSF penetration unless meninges are inflamed.",
      "metabolism": "Partially metabolized in the liver to penicilloic acid.",
      "excretion": "Primarily excreted unchanged in the urine (60%). Half-life is short (~1 hour)."
    },
    "dose": {
      "initialDose": "500 mg PO every 8-12 hours",
      "maxDose": "Maximum generally 2-3g/day (varies by infection)",
      "notes": "Renal adjustment required if CrCl < 30 mL/min."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea",
        "Nausea / Vomiting",
        "Rash (maculopapular)",
        "Headache",
        "Yeast infection (Candidiasis)"
      ],
      "serious": [
        "Anaphylaxis (Type I Hypersensitivity)",
        "Stevens-Johnson Syndrome",
        "Clostridioides difficile-associated diarrhea (CDAD)",
        "Seizures (in renal failure/high doses)"
      ]
    },
    "precautions": [
      "**Hypersensitivity:** Serious and occasionally fatal anaphylactic reactions have been reported. Verify penicillin allergy status.",
      "**Mononucleosis:** High risk of developing a rash if administered to patients with Mono (EBV).",
      "**Superinfection:** Prolonged use may result in fungal or bacterial superinfection (e.g., C. diff).",
      "**Renal Impairment:** Adjust dose in severe renal dysfunction."
    ],
    "contraindications": [
      "History of severe hypersensitivity (anaphylaxis/SJS) to penicillins"
    ],
    "interactions": {
      "drug": ["Warfarin (increases INR)", "Methotrexate (increases toxicity)", "Allopurinol (increases rash risk)", "Oral Contraceptives (potential efficacy reduction)"],
      "food": ["Generally can be taken with or without food."]
    },
    "pregnancyCategory": "Category B"
  },
  "apixaban": {
    "name": "Apixaban (Eliquis)",
    "genericName": "Apixaban",
    "formula": "C25H25N5O4",
    "molecularWeight": "459.5 g/mol",
    "brandNames": ["Eliquis"],
    "category": "Anticoagulant",
    "drugClass": "Direct Factor Xa Inhibitor (DOAC)",
    "pubchemCID": "10182969",
    "indications": "Stroke prevention in nonvalvular atrial fibrillation; treatment/prophylaxis of DVT and PE.",
    "moaSteps": [
      "Selectively and reversibly inhibits free and clot-bound Factor Xa.",
      "Factor Xa is the catalyst for the conversion of prothrombin to thrombin.",
      "By inhibiting Factor Xa, apixaban decreases thrombin generation and thrombus development.",
      "It does not require antithrombin III for antithrombotic activity."
    ],
    "pharmacokinetics": {
      "absorption": "Bioavailability ~50%. Absorbed in stomach/small intestine.",
      "distribution": "Plasma protein binding ~87%.",
      "metabolism": "Metabolized primarily by CYP3A4/5. Also a substrate of P-gp.",
      "excretion": "Eliminated in urine (~27%) and feces (biliary). Half-life is ~12 hours.",
      "notes": "Renal function affects dosing."
    },
    "dose": {
      "initialDose": "5 mg PO twice daily (AFib)",
      "maxDose": "10 mg twice daily (DVT Treatment initiation)",
      "notes": "Reduce to 2.5mg BID if 2 of 3: Age ≥80, Weight ≤60kg, Creatinine ≥1.5."
    },
    "adverseEffects": {
      "common": [
        "Minor bleeding (epistaxis, gingival bleeding, bruising)",
        "Nausea",
        "Anemia"
      ],
      "serious": [
        "Major Hemorrhage (GI, Intracranial)",
        "Spinal/Epidural Hematoma (Risk of paralysis) - BOXED WARNING",
        "Thrombosis upon premature discontinuation"
      ]
    },
    "precautions": [
      "**Bleeding Risk:** Can cause serious and potentially fatal bleeding. Promptly evaluate signs of blood loss.",
      "**Neuraxial Anesthesia:** Boxed warning for spinal/epidural hematoma causing paralysis in patients receiving neuraxial anesthesia.",
      "**Discontinuation:** Premature stopping increases risk of thrombotic events. Bridge with heparin if stopping for surgery.",
      "**Prosthetic Valves:** Not recommended for patients with mechanical heart valves.",
      "**Reversal:** Andexanet alfa is the specific reversal agent."
    ],
    "contraindications": [
      "Active pathological bleeding",
      "Severe hypersensitivity to apixaban"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4/P-gp inhibitors (Ketoconazole, Ritonavir)", "Strong CYP3A4/P-gp inducers (Rifampin, Carbamazepine)", "Antiplatelets (Aspirin, Clopidogrel - bleeding risk)", "NSAIDs"],
      "food": ["Grapefruit juice (mild interaction, usually not clinically significant)"]
    },
    "pregnancyCategory": "Category B"
  },
  "aripiprazole": {
    "name": "Aripiprazole (Abilify)",
    "genericName": "Aripiprazole",
    "formula": "C23H27Cl2N3O2",
    "molecularWeight": "448.39 g/mol",
    "brandNames": ["Abilify", "Aristada"],
    "category": "Antipsychotic",
    "drugClass": "Atypical Antipsychotic (Second Generation)",
    "pubchemCID": "60795",
    "indications": "Schizophrenia, Bipolar I Disorder (manic/mixed), Major Depressive Disorder (adjunct), Irritability associated with Autism.",
    "moaSteps": [
      "Acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors.",
      "Acts as an antagonist at serotonin 5-HT2A receptors.",
      "Stabilizes dopamine system: Stimulates receptors in areas of low dopamine (improving negative symptoms) and blocks them in areas of high dopamine (improving positive symptoms)."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed (87% bioavailability). High fat meal delays Tmax but not extent.",
      "distribution": "High volume of distribution; >99% protein bound.",
      "metabolism": "Metabolized by liver via CYP2D6 and CYP3A4 to active metabolite dehydro-aripiprazole.",
      "excretion": "Excreted in feces and urine. Half-life is ~75 hours (very long).",
      "notes": "CYP2D6 poor metabolizers require dose reduction."
    },
    "dose": {
      "initialDose": "10-15 mg PO once daily",
      "maxDose": "30 mg/day",
      "notes": "Depression adjunct usually starts lower (2-5 mg)."
    },
    "adverseEffects": {
      "common": [
        "Akathisia (inner restlessness)",
        "Anxiety / Insomnia",
        "Nausea / Vomiting",
        "Constipation",
        "Weight gain (less than other atypicals)",
        "Lightheadedness"
      ],
      "serious": [
        "Suicidal Thoughts (Children/Young Adults) - BOXED WARNING",
        "Increased mortality in elderly with dementia - BOXED WARNING",
        "Neuroleptic Malignant Syndrome (NMS)",
        "Tardive Dyskinesia",
        "Hyperglycemia / Diabetes"
      ]
    },
    "precautions": [
      "**Suicidality:** Monitor for worsening depression or suicidal ideation.",
      "**Dementia-Related Psychosis:** Not approved; increased risk of death (cardiovascular/infectious).",
      "**Metabolic Changes:** Monitor glucose, lipids, and weight, though risk is lower than with olanzapine.",
      "**Orthostatic Hypotension:** Use caution in cardiovascular disease.",
      "**Leukopenia/Neutropenia:** Monitor CBC in patients with history of low WBC.",
      "**Impulse Control:** Rare reports of pathological gambling or compulsive eating."
    ],
    "contraindications": [
      "Hypersensitivity to aripiprazole"
    ],
    "interactions": {
      "drug": ["CYP3A4/2D6 Inhibitors (Fluoxetine, Quinidine - Reduce dose)", "CYP3A4 Inducers (Carbamazepine - Increase dose)", "Benzodiazepines (sedation)", "Antihypertensives (hypotension)"],
      "food": ["Grapefruit juice (may increase levels)"]
    },
    "pregnancyCategory": "Category C"
  },
  "aspirin": {
    "name": "Aspirin (Bayer)",
    "genericName": "Acetylsalicylic Acid",
    "formula": "C9H8O4",
    "molecularWeight": "180.16 g/mol",
    "brandNames": ["Bayer", "Ecotrin", "Bufferin"],
    "category": "Antiplatelet / NSAID",
    "drugClass": "Salicylate",
    "pubchemCID": "2244",
    "indications": "Secondary prevention of MI/Stroke (Antiplatelet); Pain/Fever/Inflammation (Analgesic); Acute Coronary Syndrome.",
    "moaSteps": [
      "Irreversibly inhibits Cyclooxygenase-1 and 2 (COX-1 and COX-2) enzymes.",
      "Inhibition of COX-1 in platelets prevents the formation of Thromboxane A2 (TXA2).",
      "TXA2 is a potent platelet aggregator and vasoconstrictor.",
      "Because platelets cannot regenerate COX, the effect lasts for the life of the platelet (7-10 days)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed from stomach and intestine.",
      "distribution": "Widely distributed. Crosses placenta.",
      "metabolism": "Hydrolyzed to salicylic acid (active) in plasma and liver.",
      "excretion": "Excreted in urine. Half-life of aspirin is 15-20 mins; salicylic acid is 2-30 hours (dose-dependent)."
    },
    "dose": {
      "initialDose": "81 mg PO daily (Prevention)",
      "maxDose": "325-650 mg q4h (Analgesia) - Max 4g/day",
      "notes": "162-325 mg chewed immediately for suspected Heart Attack."
    },
    "adverseEffects": {
      "common": [
        "Dyspepsia / Heartburn",
        "Nausea",
        "Easy bruising",
        "Epigastric discomfort"
      ],
      "serious": [
        "GI Bleeding / Ulceration",
        "Hemorrhagic Stroke",
        "Bronchospasm (Aspirin-exacerbated respiratory disease)",
        "Reye's Syndrome (in children with viral infection)",
        "Tinnitus (sign of toxicity)"
      ]
    },
    "precautions": [
      "**Bleeding Risk:** Increases risk of GI and intracranial bleeding.",
      "**Reye's Syndrome:** Do not use in children/teenagers for viral infections (chickenpox/flu).",
      "**Samter's Triad:** Caution in patients with asthma, nasal polyps, and aspirin sensitivity (can cause severe bronchospasm).",
      "**Surgery:** Stop 7-10 days prior to elective surgery."
    ],
    "contraindications": [
      "Hypersensitivity to NSAIDs/Salicylates",
      "Asthma with rhinitis/nasal polyps",
      "Children/Teens with viral infection"
    ],
    "interactions": {
      "drug": ["Warfarin/Anticoagulants (Major bleeding risk)", "Ibuprofen (blocks antiplatelet effect if taken together)", "Methotrexate", "Corticosteroids (ulcer risk)"],
      "food": ["Alcohol (increases GI bleeding risk)"]
    },
    "pregnancyCategory": "Category D (Third Trimester)"
  },
  "atenolol": {
    "name": "Atenolol (Tenormin)",
    "genericName": "Atenolol",
    "formula": "C14H22N2O3",
    "molecularWeight": "266.34 g/mol",
    "brandNames": ["Tenormin"],
    "category": "Antihypertensive",
    "drugClass": "Beta-Blocker (Beta-1 Selective)",
    "pubchemCID": "2249",
    "indications": "Hypertension, Angina Pectoris, Acute Myocardial Infarction.",
    "moaSteps": [
      "Selectively blocks beta-1 adrenergic receptors located chiefly in cardiac muscle.",
      "Reduces resting and exercise heart rate.",
      "Decreases myocardial contractility and cardiac output.",
      "Reduces systolic and diastolic blood pressure.",
      "At high doses, selectivity is lost and it may block beta-2 receptors (bronchial)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid but incomplete (50%) absorption.",
      "distribution": "Low protein binding (6-16%). Poor CNS penetration (low lipid solubility) - fewer nightmares than propranolol.",
      "metabolism": "Minimal hepatic metabolism.",
      "excretion": "Excreted largely unchanged in urine. Half-life is 6-7 hours."
    },
    "dose": {
      "initialDose": "25-50 mg PO once daily",
      "maxDose": "100 mg/day",
      "notes": "Dose adjustment needed in renal impairment."
    },
    "adverseEffects": {
      "common": [
        "Bradycardia",
        "Cold extremities",
        "Fatigue / Lethargy",
        "Dizziness",
        "Depression"
      ],
      "serious": [
        "Heart Block (2nd/3rd degree)",
        "Bronchospasm (at high doses)",
        "Heart Failure worsening",
        "Masking of Hypoglycemia symptoms"
      ]
    },
    "precautions": [
      "**Abrupt Cessation:** BOXED WARNING. Do not stop abruptly; can cause angina exacerbation or MI. Taper over 1-2 weeks.",
      "**Diabetes:** May mask signs of hypoglycemia (tachycardia/tremor).",
      "**Bronchospastic Disease:** Use with caution; although beta-1 selective, high doses can compromise airways.",
      "**Renal Impairment:** Accumulates in kidney failure; reduce dose.",
      "**Peripheral Vascular Disease:** May precipitate or aggravate symptoms of arterial insufficiency."
    ],
    "contraindications": [
      "Sinus bradycardia",
      "Heart block greater than first degree",
      "Cardiogenic shock",
      "Decompensated heart failure"
    ],
    "interactions": {
      "drug": ["Calcium Channel Blockers (Verapamil/Diltiazem - additive bradycardia)", "Digoxin", "NSAIDs (may decrease antihypertensive effect)", "Clonidine"],
      "food": ["None significant"]
    },
    "pregnancyCategory": "Category D"
  },
  "atorvastatin": {
    "name": "Atorvastatin (Lipitor)",
    "genericName": "Atorvastatin Calcium",
    "formula": "C33H35FN2O5",
    "molecularWeight": "558.64 g/mol",
    "brandNames": ["Lipitor"],
    "category": "Antilipemic Agent",
    "drugClass": "HMG-CoA Reductase Inhibitor (Statin)",
    "pubchemCID": "60823",
    "indications": "Hyperlipidemia, Heterozygous/Homozygous Familial Hypercholesterolemia, Prevention of Cardiovascular Disease.",
    "moaSteps": [
      "Competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis.",
      "This reduction in liver cholesterol synthesis stimulates upregulation of LDL receptors on hepatocyte membranes.",
      "Increased LDL receptors enhance the uptake and catabolism of LDL from the blood.",
      "Also reduces VLDL and triglycerides and modestly increases HDL."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Low bioavailability (14%) due to extensive first-pass metabolism.",
      "distribution": "High protein binding (>98%).",
      "metabolism": "Metabolized by CYP3A4 to active ortho- and parahydroxylated metabolites.",
      "excretion": "Primarily biliary excretion. Half-life is 14 hours, but HMG-CoA reductase inhibition lasts 20-30 hours due to active metabolites."
    },
    "dose": {
      "initialDose": "10-20 mg PO once daily",
      "maxDose": "80 mg/day",
      "notes": "Can be taken at any time of day (unlike short-acting statins)."
    },
    "adverseEffects": {
      "common": [
        "Myalgia (Muscle pain)",
        "Diarrhea",
        "Nasopharyngitis",
        "Arthralgia",
        "Dyspepsia"
      ],
      "serious": [
        "Rhabdomyolysis (Muscle breakdown -> Renal failure)",
        "Hepatotoxicity (Elevated Transaminases)",
        "Immune-mediated necrotizing myopathy (Rare)"
      ]
    },
    "precautions": [
      "**Skeletal Muscle Effects:** Risk of myopathy/rhabdomyolysis. Discontinue if CPK is markedly elevated or myopathy is diagnosed.",
      "**Liver Dysfunction:** Monitor LFTs if clinical signs of liver injury occur.",
      "**Diabetes:** Slight increase in HbA1c and fasting glucose reported.",
      "**CYP3A4 Interactions:** Concurrent use with strong CYP3A4 inhibitors increases myopathy risk."
    ],
    "contraindications": [
      "Active liver disease",
      "Pregnancy / Lactation",
      "Hypersensitivity to atorvastatin"
    ],
    "interactions": {
      "drug": ["Cyclosporine", "Clarithromycin/Erythromycin", "Azole Antifungals", "Gemfibrozil (avoid combination)", "Digoxin"],
      "food": ["Grapefruit juice (large quantities >1.2L/day can increase levels)"]
    },
    "pregnancyCategory": "Category X"
  },"acetylcysteine": {
    "name": "Acetylcysteine (Mucomyst, Acetadote)",
    "genericName": "Acetylcysteine (N-Acetylcysteine)",
    "formula": "C5H9NO3S",
    "molecularWeight": "163.19 g/mol",
    "brandNames": ["Acetadote", "Mucomyst", "Cetylev"],
    "category": "Antidote / Mucolytic",
    "drugClass": "Cysteine Derivative",
    "pubchemCID": "12035",
    "indications": "Antidote for acetaminophen (paracetamol) overdose; mucolytic agent for pulmonary diseases (CF, COPD) with viscous mucus.",
    "moaSteps": [
      "As an antidote, it replenishes hepatic glutathione stores.",
      "Glutathione is required to detoxify NAPQI, the toxic metabolite of acetaminophen.",
      "As a mucolytic, it splits the disulfide bonds that link mucoproteins in mucus.",
      "This decreases the viscosity of pulmonary secretions, facilitating removal."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed orally. Bioavailability is low (4-10%) due to first-pass metabolism.",
      "distribution": "Protein binding is 83%. Crosses the placenta.",
      "metabolism": "Extensively metabolized in the liver to cysteine and disulfides.",
      "excretion": "Excreted in urine (22-30%). Half-life is 5.6 hours (adults)."
    },
    "dose": {
      "initialDose": "Antidote: 150 mg/kg IV loading dose over 60 min",
      "maxDose": "Protocol dependent (e.g. 21-hour IV regimen)",
      "notes": "Oral regimen involves 140 mg/kg loading, then 70 mg/kg q4h x 17 doses."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting (sulfur smell)",
        "Flushing",
        "Rash",
        "Pruritus"
      ],
      "serious": [
        "Anaphylactoid reactions (IV formulation)",
        "Bronchospasm (especially in asthmatics)",
        "Hypotension"
      ]
    },
    "precautions": [
      "**Anaphylactoid Reactions:** IV administration can cause flushing, rash, and hypotension. Can typically be managed by slowing infusion rate.",
      "**Asthma:** Use with caution (especially inhaled); may induce bronchospasm.",
      "**Fluid Overload:** The IV regimen involves significant fluid volume; caution in heart failure/renal failure."
    ],
    "contraindications": [
      "Hypersensitivity to acetylcysteine"
    ],
    "interactions": {
      "drug": ["Nitroglycerin (may enhance hypotension)", "Activated Charcoal (may absorb oral acetylcysteine)"],
      "food": ["None significant"]
    },
    "pregnancyCategory": "Category B"
  },
  "adenosine": {
    "name": "Adenosine (Adenocard)",
    "genericName": "Adenosine",
    "formula": "C10H13N5O4",
    "molecularWeight": "267.24 g/mol",
    "brandNames": ["Adenocard", "Adenoscan"],
    "category": "Antiarrhythmic",
    "drugClass": "Class V Antiarrhythmic (Purine Nucleoside)",
    "pubchemCID": "60961",
    "indications": "Conversion of Paroxysmal Supraventricular Tachycardia (PSVT) to sinus rhythm.",
    "moaSteps": [
      "Slows conduction time through the AV node.",
      "Interrupts the reentry pathways through the AV node.",
      "Restores normal sinus rhythm in patients with PSVT.",
      "Causes transient heart block at the AV node."
    ],
    "pharmacokinetics": {
      "absorption": "Administered IV.",
      "distribution": "Rapidly taken up by erythrocytes and vascular endothelial cells.",
      "metabolism": "Rapidly metabolized by adenosine deaminase.",
      "excretion": "Half-life is extremely short (<10 seconds)."
    },
    "dose": {
      "initialDose": "6 mg IV rapid bolus (over 1-2 sec)",
      "maxDose": "12 mg repeat dose if needed",
      "notes": "Must be followed immediately by 20 mL saline flush. Administer in large proximal vein."
    },
    "adverseEffects": {
      "common": [
        "Flushing",
        "Dyspnea / Chest pressure",
        "Lightheadedness",
        "Nausea",
        "Transient asystole (feeling of 'doom')"
      ],
      "serious": [
        "Prolonged Asystole / Cardiac Arrest",
        "Ventricular Fibrillation",
        "Bronchoconstriction",
        "Cerebrovascular Accident"
      ]
    },
    "precautions": [
      "**Transient Asystole:** Patients will often experience a few seconds of flatline on the monitor; warn them of the sensation.",
      "**Asthma/COPD:** Can precipitate severe bronchoconstriction.",
      "**Heart Block:** Can worsen pre-existing AV block."
    ],
    "contraindications": [
      "Second or third-degree AV block (without pacemaker)",
      "Sick sinus syndrome (without pacemaker)",
      "Known hypersensitivity"
    ],
    "interactions": {
      "drug": ["Theophylline/Caffeine (antagonize effects - may require higher dose)", "Dipyridamole (potentiates effect - reduce dose)", "Carbamazepine (increases heart block risk)"],
      "food": ["Caffeine (antagonizes effect)"]
    },
    "pregnancyCategory": "Category C"
  },
  "albendazole": {
    "name": "Albendazole (Albenza)",
    "genericName": "Albendazole",
    "formula": "C12H15N3O2S",
    "molecularWeight": "265.33 g/mol",
    "brandNames": ["Albenza"],
    "category": "Anthelmintic",
    "drugClass": "Benzimidazole",
    "pubchemCID": "2082",
    "indications": "Neurocysticercosis (pork tapeworm), Hydatid disease (dog tapeworm). Off-label: Pinworm, Hookworm, Ascariasis.",
    "moaSteps": [
      "Binds to the colchicine-sensitive site of beta-tubulin in the parasite.",
      "Inhibits microtubule polymerization/assembly.",
      "Disrupts glucose uptake and depletes glycogen stores in the worm.",
      "Leads to immobilization and death of the parasite."
    ],
    "pharmacokinetics": {
      "absorption": "Poorly absorbed (<5%). Absorption increases 5-fold with a fatty meal.",
      "distribution": "Widely distributed, including cyst fluids and CSF (active metabolite).",
      "metabolism": "Rapidly metabolized in liver to active metabolite albendazole sulfoxide.",
      "excretion": "Excreted in bile and urine. Half-life is 8-12 hours."
    },
    "dose": {
      "initialDose": "400 mg PO twice daily",
      "maxDose": "800 mg/day",
      "notes": "Take with a high-fat meal to increase absorption."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Abdominal pain",
        "Nausea / Vomiting",
        "Elevated LFTs"
      ],
      "serious": [
        "Bone Marrow Suppression (Aplastic Anemia, Agranulocytosis)",
        "Severe Hepatotoxicity",
        "Acute Renal Failure"
      ]
    },
    "precautions": [
      "**Bone Marrow Suppression:** Monitor blood counts (CBC) at start of each cycle and every 2 weeks.",
      "**Hepatotoxicity:** Monitor LFTs regularly; discontinue if enzymes significantly elevated.",
      "**Pregnancy:** Teratogenic in animals. Exclude pregnancy before starting.",
      "**Neurocysticercosis:** Initiation can cause inflammatory reaction (seizures, elevated ICP) due to dying cysts; co-administer corticosteroids."
    ],
    "contraindications": [
      "Hypersensitivity to benzimidazoles"
    ],
    "interactions": {
      "drug": ["Dexamethasone (increases albendazole levels)", "Praziquantel (increases levels)", "Cimetidine", "Theophylline"],
      "food": ["Fatty meals significantly increase absorption (desirable)."]
    },
    "pregnancyCategory": "Category C"
  },
  "alendronate": {
    "name": "Alendronate (Fosamax)",
    "genericName": "Alendronate Sodium",
    "formula": "C4H12NO7P2Na",
    "molecularWeight": "271.08 g/mol",
    "brandNames": ["Fosamax", "Binosto"],
    "category": "Bone Resorption Inhibitor",
    "drugClass": "Bisphosphonate",
    "pubchemCID": "2088",
    "indications": "Treatment and prevention of osteoporosis (postmenopausal women, men); Glucocorticoid-induced osteoporosis; Paget's disease.",
    "moaSteps": [
      "Localizes preferentially to sites of bone resorption.",
      "Inhibits osteoclast activity (cells that break down bone).",
      "Does not inhibit osteoclast recruitment or attachment, but inhibits their function.",
      "Increases bone mineral density (BMD) by allowing osteoblasts to rebuild bone without unopposed resorption."
    ],
    "pharmacokinetics": {
      "absorption": "Poor oral bioavailability (0.6%). Decreased by 60% with coffee/juice.",
      "distribution": "Transiently distributes to soft tissue, then redistributes to bone or is excreted.",
      "metabolism": "Not metabolized.",
      "excretion": "Excreted in urine. Terminal half-life in bone is >10 years."
    },
    "dose": {
      "initialDose": "70 mg PO once weekly (Treatment)",
      "maxDose": "10 mg daily or 70 mg weekly",
      "notes": "Must be taken with plain water, 30 min before first food/drink, and patient must remain upright for 30 min."
    },
    "adverseEffects": {
      "common": [
        "Abdominal pain",
        "Dyspepsia / Acid reflux",
        "Nausea",
        "Musculoskeletal pain"
      ],
      "serious": [
        "Esophageal Erosions / Ulcers",
        "Osteonecrosis of the Jaw (ONJ)",
        "Atypical Femoral Fractures",
        "Severe incapacitating bone/joint pain",
        "Hypocalcemia"
      ]
    },
    "precautions": [
      "**Esophageal Irritation:** Strict administration instructions must be followed to prevent esophageal injury.",
      "**Osteonecrosis of the Jaw:** Risk is higher with cancer, chemo, or poor dental hygiene. Dental exam recommended before starting.",
      "**Atypical Fractures:** Report new thigh/groin pain immediately.",
      "**Hypocalcemia:** Correct hypocalcemia before initiating therapy.",
      "**Renal Impairment:** Not recommended if CrCl < 35 mL/min."
    ],
    "contraindications": [
      "Esophageal abnormalities (stricture, achalasia)",
      "Inability to stand/sit upright for at least 30 minutes",
      "Hypocalcemia"
    ],
    "interactions": {
      "drug": ["Calcium supplements/Antacids (interfere with absorption)", "Aspirin/NSAIDs (increase GI irritation)"],
      "food": ["Food, coffee, juice, mineral water reduce absorption to near zero."]
    },
    "pregnancyCategory": "Category C"
  },
  "alteplase": {
    "name": "Alteplase (Activase)",
    "genericName": "Alteplase (tPA)",
    "formula": "C2569H3894N746O781S40",
    "molecularWeight": "~59 kDa",
    "brandNames": ["Activase", "Cathflo"],
    "category": "Thrombolytic",
    "drugClass": "Tissue Plasminogen Activator",
    "pubchemCID": "None (Protein)",
    "indications": "Acute Ischemic Stroke, Acute Myocardial Infarction (STEMI), Acute Massive Pulmonary Embolism.",
    "moaSteps": [
      "Binds to fibrin in a thrombus.",
      "Converts entrapped plasminogen to plasmin.",
      "Plasmin degrades the fibrin matrix of the clot.",
      "This initiates local fibrinolysis and clot dissolution."
    ],
    "pharmacokinetics": {
      "absorption": "IV administration.",
      "distribution": "Rapidly cleared from plasma.",
      "metabolism": "Hepatic metabolism.",
      "excretion": "Clearance via liver. Initial half-life is <5 minutes."
    },
    "dose": {
      "initialDose": "Stroke: 0.9 mg/kg (max 90mg). 10% bolus, 90% infusion over 60 min.",
      "maxDose": "90 mg total for stroke",
      "notes": "Must be administered within 3-4.5 hours of symptom onset for stroke."
    },
    "adverseEffects": {
      "common": [
        "Bleeding (puncture sites, gums)",
        "Bruising"
      ],
      "serious": [
        "Intracranial Hemorrhage (Fatal)",
        "Internal Bleeding (GI, GU)",
        "Angioedema (Orolingual)",
        "Cholesterol Embolization"
      ]
    },
    "precautions": [
      "**Bleeding:** Most significant risk. Contraindicated in active bleeding or high bleeding risk.",
      "**Time Window:** Benefit decreases and hemorrhage risk increases with time. Adhere strictly to 3-4.5 hour window for stroke.",
      "**Angioedema:** Monitor for tongue swelling, especially in patients on ACE inhibitors."
    ],
    "contraindications": [
      "Active internal bleeding",
      "History of recent intracranial hemorrhage",
      "Severe uncontrolled hypertension (>185/110)",
      "Intracranial surgery or trauma within 3 months",
      "Current anticoagulant use with elevated INR"
    ],
    "interactions": {
      "drug": ["Anticoagulants (Warfarin, Heparin - increased bleeding)", "Antiplatelets (Aspirin - increased bleeding)", "ACE Inhibitors (increased angioedema risk)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "amantadine": {
    "name": "Amantadine (Gocovri)",
    "genericName": "Amantadine HCl",
    "formula": "C10H17N",
    "molecularWeight": "151.25 g/mol",
    "brandNames": ["Gocovri", "Osmolex ER", "Symmetrel"],
    "category": "Antiparkinson Agent / Antiviral",
    "drugClass": "Adamantane / NMDA Receptor Antagonist",
    "pubchemCID": "2130",
    "indications": "Parkinson's Disease (treats dyskinesia), Drug-induced Extrapyramidal Symptoms (EPS). Historically for Influenza A (high resistance now).",
    "moaSteps": [
      "Mechanism in Parkinson's is not fully known.",
      "Appears to potentiate dopaminergic responses (releasing dopamine or blocking reuptake).",
      "Acts as a weak, non-competitive NMDA receptor antagonist.",
      "Anticholinergic properties may help with tremors."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "Large volume of distribution. Crosses blood-brain barrier.",
      "metabolism": "Minimal metabolism.",
      "excretion": "Excreted unchanged in urine. Half-life is 12-18 hours (prolonged in renal impairment)."
    },
    "dose": {
      "initialDose": "100 mg PO twice daily",
      "maxDose": "400 mg/day",
      "notes": "Reduce dose in renal impairment and elderly."
    },
    "adverseEffects": {
      "common": [
        "Nausea",
        "Dizziness / Lightheadedness",
        "Insomnia",
        "Dry mouth",
        "Constipation",
        "Livedo reticularis (mottled skin)"
      ],
      "serious": [
        "Suicidal Ideation / Depression",
        "Hallucinations / Psychosis",
        "Seizures",
        "Heart Failure",
        "Neuroleptic Malignant Syndrome (upon withdrawal)"
      ]
    },
    "precautions": [
      "**Renal Impairment:** Drug accumulates rapidly; strict dose adjustment required.",
      "**Suicidality:** Monitor for depression and suicidal tendencies.",
      "**Impulse Control:** May induce compulsive behaviors (gambling, spending).",
      "**Withdrawal:** Abrupt discontinuation can trigger NMS-like signs (fever, rigidity)."
    ],
    "contraindications": [
      "Hypersensitivity to amantadine"
    ],
    "interactions": {
      "drug": ["Anticholinergics (additive effects)", "CNS Stimulants", "Memantine (avoid combination - additive NMDA effect)"],
      "food": ["Alcohol (increased CNS effects)"]
    },
    "pregnancyCategory": "Category C"
  },
  "amikacin": {
    "name": "Amikacin (Amikin)",
    "genericName": "Amikacin Sulfate",
    "formula": "C22H43N5O13",
    "molecularWeight": "585.6 g/mol",
    "brandNames": ["Amikin", "Arikayce"],
    "category": "Antibiotic",
    "drugClass": "Aminoglycoside",
    "pubchemCID": "37768",
    "indications": "Severe infections due to multidrug-resistant Gram-negative bacteria (Pseudomonas, Acinetobacter) and Mycobacterium avium complex (MAC).",
    "moaSteps": [
      "Binds irreversibly to the 30S ribosomal subunit of bacteria.",
      "Interferes with the initiation complex between mRNA and the ribosome.",
      "Causes misreading of the genetic code and inhibition of protein synthesis.",
      "Bactericidal effect."
    ],
    "pharmacokinetics": {
      "absorption": "Not absorbed orally; given IV or IM.",
      "distribution": "Distributes into extracellular fluid. Poor CNS penetration.",
      "metabolism": "Not metabolized.",
      "excretion": "Excreted unchanged by glomerular filtration. Half-life 2-3 hours."
    },
    "dose": {
      "initialDose": "15 mg/kg/day IV (divided q8h or q12h)",
      "maxDose": "1.5 g/day",
      "notes": "Therapeutic drug monitoring (peaks/troughs) required to prevent toxicity."
    },
    "adverseEffects": {
      "common": [
        "Injection site pain"
      ],
      "serious": [
        "Nephrotoxicity (Acute Tubular Necrosis) - BOXED WARNING",
        "Ototoxicity (Hearing loss, Vertigo) - BOXED WARNING",
        "Neuromuscular Blockade (Respiratory paralysis)"
      ]
    },
    "precautions": [
      "**Renal Toxicity:** Reversible but common. Monitor Creatinine/BUN.",
      "**Ototoxicity:** Can cause permanent sensorineural hearing loss. Risk increases with loop diuretics.",
      "**Neuromuscular Blockade:** Can cause respiratory paralysis, especially if given with anesthesia or muscle relaxants.",
      "**Hydration:** Keep patient well hydrated."
    ],
    "contraindications": [
      "Hypersensitivity to aminoglycosides"
    ],
    "interactions": {
      "drug": ["Loop Diuretics (Furosemide - increases ototoxicity)", "Nephrotoxic drugs (Vancomycin, Amphotericin)", "Neuromuscular blockers"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "amphetamine": {
    "name": "Amphetamine/Dextroamphetamine (Adderall)",
    "genericName": "Amphetamine Mixed Salts",
    "formula": "C9H13N",
    "molecularWeight": "135.21 g/mol",
    "brandNames": ["Adderall", "Adderall XR", "Mydayis"],
    "category": "CNS Stimulant",
    "drugClass": "Sympathomimetic Amine",
    "pubchemCID": "3007",
    "indications": "Attention Deficit Hyperactivity Disorder (ADHD), Narcolepsy.",
    "moaSteps": [
      "Promotes release of dopamine and norepinephrine from presynaptic nerve terminals.",
      "Blocks the reuptake of norepinephrine and dopamine.",
      "Inhibits Monoamine Oxidase (MAO) enzymes (at high doses).",
      "Increases levels of catecholamines in the synapse, improving focus and arousal."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed. Acidic diet decreases absorption.",
      "distribution": "Widely distributed, crosses BBB.",
      "metabolism": "Hepatic metabolism (CYP2D6).",
      "excretion": "Excreted in urine. Acidification of urine accelerates excretion."
    },
    "dose": {
      "initialDose": "5-10 mg PO daily or twice daily",
      "maxDose": "40-60 mg/day (varies by age/indication)",
      "notes": "Avoid evening doses to prevent insomnia."
    },
    "adverseEffects": {
      "common": [
        "Insomnia",
        "Decreased appetite / Anorexia",
        "Weight loss",
        "Dry mouth",
        "Anxiety / Jitteriness",
        "Tachycardia"
      ],
      "serious": [
        "Sudden Cardiac Death / MI (in structural heart disease)",
        "Psychosis / Mania",
        "Peripheral Vasculopathy (Raynaud's)",
        "Abuse and Dependence - BOXED WARNING"
      ]
    },
    "precautions": [
      "**Abuse Potential:** High potential for abuse (Schedule II).",
      "**Cardiovascular:** Avoid in patients with known structural cardiac abnormalities; risk of sudden death.",
      "**Psychiatric:** Can exacerbate psychosis or bipolar mania.",
      "**Growth:** Monitor growth in children; can cause growth suppression."
    ],
    "contraindications": [
      "Advanced arteriosclerosis",
      "Symptomatic cardiovascular disease",
      "Moderate to severe hypertension",
      "Hyperthyroidism",
      "History of drug abuse",
      "MAOI use within 14 days"
    ],
    "interactions": {
      "drug": ["MAOIs (Hypertensive crisis)", "Antacids (increase absorption/toxicity)", "Antihypertensives (decreased efficacy)"],
      "food": ["Acidic juices (Vitamin C) decrease absorption/effect."]
    },
    "pregnancyCategory": "Category C"
  },
  "amphotericin": {
    "name": "Amphotericin B (Ambisome)",
    "genericName": "Amphotericin B (Liposomal)",
    "formula": "C47H73NO17",
    "molecularWeight": "924.1 g/mol",
    "brandNames": ["AmBisome", "Abelcet", "Fungizone"],
    "category": "Antifungal",
    "drugClass": "Polyene Antifungal",
    "pubchemCID": "5280965",
    "indications": "Severe, life-threatening invasive fungal infections (Aspergillus, Candida, Cryptococcus, Zygomycetes).",
    "moaSteps": [
      "Binds to ergosterol, the primary sterol in the fungal cell membrane.",
      "Creates transmembrane pores (channels) in the fungal wall.",
      "Causes leakage of intracellular ions (potassium, magnesium) and small molecules.",
      "Leads to cell death (fungicidal)."
    ],
    "pharmacokinetics": {
      "absorption": "IV only.",
      "distribution": "Widely distributed; liposomal form concentrates in liver/spleen.",
      "metabolism": "Unknown.",
      "excretion": "Very slow elimination via urine and bile. Half-life 15 days."
    },
    "dose": {
      "initialDose": "3-5 mg/kg IV daily (Liposomal)",
      "maxDose": "Varies by infection",
      "notes": "Liposomal formulation is less toxic than conventional deoxycholate."
    },
    "adverseEffects": {
      "common": [
        "Infusion reactions (Fever, Chills - 'Shake and Bake')",
        "Nausea / Vomiting",
        "Hypokalemia",
        "Hypomagnesemia",
        "Anemia"
      ],
      "serious": [
        "Nephrotoxicity (Renal Tubular Acidosis) - Dose limiting",
        "Anaphylaxis",
        "Leukopenia"
      ]
    },
    "precautions": [
      "**Nephrotoxicity:** Almost all patients experience some decline in renal function. Hydration (saline loading) helps reduce risk.",
      "**Infusion Reactions:** Pre-medicate with acetaminophen, diphenhydramine, and/or corticosteroids.",
      "**Electrolytes:** Aggressive replacement of Potassium and Magnesium is usually required."
    ],
    "contraindications": [
      "Known hypersensitivity"
    ],
    "interactions": {
      "drug": ["Nephrotoxic drugs (Aminoglycosides, Cyclosporine)", "Digoxin (toxicity due to hypokalemia)", "Corticosteroids (worsen hypokalemia)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "ampicillin": {
    "name": "Ampicillin",
    "genericName": "Ampicillin",
    "formula": "C16H19N3O4S",
    "molecularWeight": "349.4 g/mol",
    "brandNames": ["Omnipen", "Principen"],
    "category": "Antibiotic",
    "drugClass": "Penicillin (Aminopenicillin)",
    "pubchemCID": "6249",
    "indications": "Respiratory tract infections, Meningitis (Listeria), Endocarditis, GU infections.",
    "moaSteps": [
      "Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs).",
      "Prevents cross-linkage of peptidoglycan chains.",
      "Leads to cell lysis.",
      "Similar to Amoxicillin but better coverage for Shigella/Listeria, worse oral absorption."
    ],
    "pharmacokinetics": {
      "absorption": "Oral absorption is approx 50% (decreased by food). IV/IM used for severe infections.",
      "distribution": "Good penetration into CSF with inflammation.",
      "metabolism": "Partial hepatic metabolism.",
      "excretion": "Excreted unchanged in urine. Half-life ~1-1.5 hours."
    },
    "dose": {
      "initialDose": "1-2 g IV every 4-6 hours",
      "maxDose": "12 g/day",
      "notes": "Oral form rarely used now due to poor absorption/diarrhea."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea (higher rate than amoxicillin)",
        "Rash (maculopapular)",
        "Nausea"
      ],
      "serious": [
        "Anaphylaxis",
        "Clostridioides difficile colitis",
        "Seizures (high doses/renal failure)"
      ]
    },
    "precautions": [
      "**Hypersensitivity:** Cross-reactivity with cephalosporins/carbapenems possible.",
      "**Rash:** Common in patients with Mononucleosis (EBV).",
      "**Renal Impairment:** Dose adjustment required."
    ],
    "contraindications": [
      "Hypersensitivity to penicillins"
    ],
    "interactions": {
      "drug": ["Allopurinol (rash)", "Warfarin", "Oral contraceptives"],
      "food": ["Food decreases oral absorption."]
    },
    "pregnancyCategory": "Category B"
  },
  "anastrozole": {
    "name": "Anastrozole (Arimidex)",
    "genericName": "Anastrozole",
    "formula": "C17H19N5",
    "molecularWeight": "293.37 g/mol",
    "brandNames": ["Arimidex"],
    "category": "Antineoplastic",
    "drugClass": "Aromatase Inhibitor (Non-steroidal)",
    "pubchemCID": "2187",
    "indications": "Adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women.",
    "moaSteps": [
      "Selectively and potently inhibits the aromatase enzyme.",
      "Aromatase converts androgens (adrenal) to estrogens (estrone/estradiol) in peripheral tissues.",
      "Lowers serum estradiol concentrations by approx 80%.",
      "Does not inhibit adrenal corticosteroid synthesis."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "40% protein bound.",
      "metabolism": "Hepatic metabolism (N-dealkylation, hydroxylation).",
      "excretion": "Excreted in urine and feces. Half-life 50 hours."
    },
    "dose": {
      "initialDose": "1 mg PO once daily",
      "maxDose": "1 mg/day",
      "notes": "No renal/hepatic adjustment for mild-moderate impairment."
    },
    "adverseEffects": {
      "common": [
        "Hot flashes",
        "Arthralgia / Joint stiffness",
        "Fatigue",
        "Mood disturbances",
        "Vaginal dryness"
      ],
      "serious": [
        "Decreased Bone Mineral Density (Osteoporosis/Fractures)",
        "Hypercholesterolemia",
        "Ischemic cardiovascular events (rare)"
      ]
    },
    "precautions": [
      "**Bone Health:** Increases risk of osteoporosis. BMD monitoring required.",
      "**Lipids:** Monitor cholesterol levels.",
      "**Pregnancy:** Can cause fetal harm. Contraindicated in pre-menopausal women (unless ovarian suppression used)."
    ],
    "contraindications": [
      "Pregnancy",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Estrogens (diminish effect)", "Tamoxifen (do not use together)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category X"
  },
  "atomoxetine": {
    "name": "Atomoxetine (Strattera)",
    "genericName": "Atomoxetine",
    "formula": "C17H21NO",
    "molecularWeight": "255.35 g/mol",
    "brandNames": ["Strattera"],
    "category": "ADHD Agent",
    "drugClass": "Selective Norepinephrine Reuptake Inhibitor (NRI)",
    "pubchemCID": "54841",
    "indications": "Attention Deficit Hyperactivity Disorder (ADHD).",
    "moaSteps": [
      "Selectively inhibits the presynaptic norepinephrine transporter.",
      "Increases norepinephrine levels in the prefrontal cortex.",
      "Unlike amphetamines, it does not increase dopamine in the nucleus accumbens (low abuse potential)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed.",
      "distribution": "High protein binding (98%).",
      "metabolism": "Major substrate of CYP2D6.",
      "excretion": "Excreted in urine. Half-life 5 hours (up to 24h in poor metabolizers)."
    },
    "dose": {
      "initialDose": "40 mg PO daily (Adults)",
      "maxDose": "100 mg/day",
      "notes": "Requires titration over 2-4 weeks."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting / Dyspepsia",
        "Fatigue / Somnolence",
        "Decreased appetite",
        "Dry mouth",
        "Erectile dysfunction"
      ],
      "serious": [
        "Suicidal Ideation (Children/Adolescents) - BOXED WARNING",
        "Severe Liver Injury",
        "Sudden Cardiac Death (structural heart disease)"
      ]
    },
    "precautions": [
      "**Suicidality:** Monitor for clinical worsening or suicidal thoughts.",
      "**Liver Injury:** Discontinue if jaundice or lab evidence of liver injury occurs.",
      "**Cardiovascular:** Check BP/HR; caution in hypertension/tachycardia."
    ],
    "contraindications": [
      "MAOI use within 14 days",
      "Narrow-angle glaucoma",
      "Pheochromocytoma",
      "Severe cardiovascular disorders"
    ],
    "interactions": {
      "drug": ["MAOIs (Fatal)", "CYP2D6 Inhibitors (Fluoxetine, Paroxetine - increase atomoxetine levels)", "Albuterol (potentiates cardiovascular effects)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "atropine": {
    "name": "Atropine",
    "genericName": "Atropine Sulfate",
    "formula": "C17H23NO3",
    "molecularWeight": "289.37 g/mol",
    "brandNames": ["Atropen", "Isopto Atropine"],
    "category": "Anticholinergic / Antidote",
    "drugClass": "Muscarinic Antagonist",
    "pubchemCID": "174174",
    "indications": "Symptomatic Bradycardia, Organophosphate/Carbamate Poisoning, Preoperative secretion reduction.",
    "moaSteps": [
      "Competitively blocks acetylcholine at muscarinic receptors.",
      "Increases heart rate by blocking vagal effects on the SA/AV nodes.",
      "Reduces salivary, bronchial, and sweat gland secretions.",
      "Relaxes smooth muscle in bronchi and GI tract."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed IM/IV/Endotracheal.",
      "distribution": "Crosses blood-brain barrier.",
      "metabolism": "Hepatic metabolism.",
      "excretion": "Excreted in urine. Half-life 2-4 hours."
    },
    "dose": {
      "initialDose": "Bradycardia: 0.5 - 1 mg IV every 3-5 min",
      "maxDose": "3 mg (Total vagolytic dose)",
      "notes": "Poisoning requires massive doses until secretions dry."
    },
    "adverseEffects": {
      "common": [
        "Dry mouth",
        "Blurred vision / Dilated pupils",
        "Tachycardia",
        "Constipation",
        "Urinary retention",
        "Flushing (hot, red skin)"
      ],
      "serious": [
        "Tachyarrhythmias",
        "Acute Glaucoma precipitation",
        "Delirium / Hallucinations ('Mad as a hatter')",
        "Hyperthermia (reduced sweating)"
      ]
    },
    "precautions": [
      "**Glaucoma:** Can induce acute angle-closure glaucoma.",
      "**Ischemia:** Tachycardia increases myocardial oxygen demand; caution in MI.",
      "**Heat Prostration:** Suppresses sweating; risk of hyperthermia in hot environments.",
      "**Dosing:** Doses <0.5 mg can cause paradoxical bradycardia."
    ],
    "contraindications": [
      "Narrow-angle glaucoma",
      "Thyrotoxicosis",
      "Obstructive GI/GU disease"
    ],
    "interactions": {
      "drug": ["Other anticholinergics (Antihistamines, TCAs - additive toxicity)", "Potassium chloride (GI lesions)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "azathioprine": {
    "name": "Azathioprine (Imuran)",
    "genericName": "Azathioprine",
    "formula": "C9H7N7O2S",
    "molecularWeight": "277.26 g/mol",
    "brandNames": ["Imuran", "Azasan"],
    "category": "Immunosuppressant",
    "drugClass": "Purine Antimetabolite",
    "pubchemCID": "2265",
    "indications": "Prevention of renal transplant rejection, Rheumatoid Arthritis. Off-label: Crohn's, UC, Lupus.",
    "moaSteps": [
      "Prodrug converted to 6-mercaptopurine (6-MP).",
      "6-MP acts as a purine antagonist.",
      "Incorporates into DNA and RNA, inhibiting synthesis and cell proliferation.",
      "Specifically affects rapidly dividing T and B lymphocytes."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "Widely distributed.",
      "metabolism": "Metabolized by Xanthine Oxidase (XO) and TPMT.",
      "excretion": "Excreted in urine. Half-life < 3 hours (metabolites longer)."
    },
    "dose": {
      "initialDose": "1-3 mg/kg PO daily",
      "maxDose": "2.5 mg/kg/day (Maintenance)",
      "notes": "Check TPMT genotype before starting."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting",
        "Infection susceptibility",
        "Malaise"
      ],
      "serious": [
        "Bone Marrow Suppression (Leukopenia, Thrombocytopenia) - BOXED WARNING",
        "Malignancy (Lymphoma, Skin cancer) - BOXED WARNING",
        "Severe Pancreatitis",
        "Hepatotoxicity"
      ]
    },
    "precautions": [
      "**TPMT Deficiency:** Patients with low Thiopurine S-Methyltransferase activity are at high risk of severe myelotoxicity. Genetic testing recommended.",
      "**Malignancy:** Chronic immunosuppression increases risk of lymphoma and skin cancer.",
      "**Infection:** Monitor for opportunistic infections."
    ],
    "contraindications": [
      "Pregnancy (unless benefit > risk)",
      "Prior alkylating agent therapy (risk of malignancy)"
    ],
    "interactions": {
      "drug": ["Allopurinol/Febuxostat (Inhibits metabolism -> Fatal toxicity. Reduce Aza dose by 75%)", "ACE Inhibitors (Anemia)", "Warfarin"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "azithromycin": {
    "name": "Azithromycin (Zithromax)",
    "genericName": "Azithromycin",
    "formula": "C38H72N2O12",
    "molecularWeight": "749.0 g/mol",
    "brandNames": ["Zithromax", "Z-Pak"],
    "category": "Antibiotic",
    "drugClass": "Macrolide",
    "pubchemCID": "447043",
    "indications": "Community-Acquired Pneumonia (CAP), Pharyngitis, Chlamydia, COPD Exacerbations.",
    "moaSteps": [
      "Binds to the 50S ribosomal subunit of susceptible bacteria.",
      "Inhibits RNA-dependent protein synthesis.",
      "Bacteriostatic (can be bactericidal at high concentrations).",
      "Concentrates in phagocytes/fibroblasts, delivering drug to site of infection."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid absorption (37% bioavailability).",
      "distribution": "Extensive tissue distribution (levels 10-100x plasma). Long tissue half-life.",
      "metabolism": "Not significantly metabolized by CYP450.",
      "excretion": "Biliary excretion. Half-life 68 hours."
    },
    "dose": {
      "initialDose": "500 mg PO Day 1, then 250 mg Days 2-5 (Z-Pak)",
      "maxDose": "1200 mg (weekly prophylaxis)",
      "notes": "Single 1g dose for Chlamydia."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea / Abdominal pain",
        "Nausea",
        "Headache"
      ],
      "serious": [
        "QT Prolongation / Torsades de Pointes",
        "Hepatotoxicity",
        "Clostridioides difficile colitis",
        "Severe hypersensitivity (DRESS)"
      ]
    },
    "precautions": [
      "**QT Prolongation:** Can prolong QT interval; avoid in patients with known QT issues, bradycardia, or low potassium/magnesium.",
      "**Myasthenia Gravis:** Can exacerbate symptoms (muscle weakness).",
      "**Hepatotoxicity:** Stop if liver injury signs appear."
    ],
    "contraindications": [
      "Hypersensitivity to macrolides",
      "History of cholestatic jaundice with prior use"
    ],
    "interactions": {
      "drug": ["Warfarin (may increase INR)", "Digoxin (increased levels)", "QT prolonging drugs (Amiodarone, Sotalol)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },"abacavir": {
    "name": "Abacavir (Ziagen)",
    "genericName": "Abacavir Sulfate",
    "formula": "C14H18N6O",
    "molecularWeight": "286.33 g/mol",
    "brandNames": ["Ziagen"],
    "category": "Antiretroviral",
    "drugClass": "Nucleoside Reverse Transcriptase Inhibitor (NRTI)",
    "pubchemCID": "441300",
    "indications": "Treatment of HIV-1 infection (in combination with other antiretroviral agents).",
    "moaSteps": [
      "Abacavir is a guanosine analogue.",
      "Intracellularly converted to the active metabolite carbovir triphosphate.",
      "Competes with the natural substrate dGTP for incorporation into viral DNA.",
      "Causes inhibition of HIV reverse transcriptase and chain termination."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed (83% bioavailability).",
      "distribution": "Distributes into extravascular space and CSF.",
      "metabolism": "Metabolized by alcohol dehydrogenase and glucuronosyltransferase.",
      "excretion": "Excreted in urine (metabolites) and feces. Half-life 1.5 hours."
    },
    "dose": {
      "initialDose": "300 mg PO twice daily OR 600 mg once daily",
      "maxDose": "600 mg/day",
      "notes": "Screen for HLA-B*5701 allele prior to initiation."
    },
    "adverseEffects": {
      "common": [
        "Nausea",
        "Headache",
        "Malaise / Fatigue",
        "Dreams / Sleep disorders"
      ],
      "serious": [
        "Hypersensitivity Reaction (Fatal) - BOXED WARNING",
        "Lactic Acidosis",
        "Severe Hepatomegaly with Steatosis",
        "Myocardial Infarction (associated risk)"
      ]
    },
    "precautions": [
      "**Hypersensitivity:** Patients with HLA-B*5701 allele are at high risk for fatal hypersensitivity. STRICTLY CONTRAINDICATED if positive.",
      "**Rechallenge:** NEVER rechallenge a patient who has had a hypersensitivity reaction.",
      "**Liver Disease:** Dose reduction needed in mild impairment; contraindicated in moderate/severe."
    ],
    "contraindications": [
      "Presence of HLA-B*5701 allele",
      "Moderate to severe hepatic impairment",
      "Prior hypersensitivity reaction"
    ],
    "interactions": {
      "drug": ["Alcohol (increases abacavir levels)", "Methadone (may require methadone dose increase)", "Ribavirin"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "acarbose": {
    "name": "Acarbose (Precose)",
    "genericName": "Acarbose",
    "formula": "C25H43NO18",
    "molecularWeight": "645.6 g/mol",
    "brandNames": ["Precose"],
    "category": "Antidiabetic",
    "drugClass": "Alpha-Glucosidase Inhibitor",
    "pubchemCID": "41774",
    "indications": "Type 2 Diabetes Mellitus (as adjunct to diet and exercise).",
    "moaSteps": [
      "Competitively inhibits alpha-glucosidase enzymes (maltase, sucrase) in the brush border of the small intestine.",
      "Delays the breakdown of sucrose and complex carbohydrates into glucose.",
      "Retards glucose absorption, lowering postprandial blood glucose spikes."
    ],
    "pharmacokinetics": {
      "absorption": "Minimal systemic absorption (<2%). Acts locally in GI tract.",
      "distribution": "Not applicable.",
      "metabolism": "Metabolized by intestinal bacteria.",
      "excretion": "Excreted in feces. Renal excretion of absorbed drug."
    },
    "dose": {
      "initialDose": "25 mg PO three times daily with the first bite of each main meal",
      "maxDose": "100 mg three times daily (>60kg)",
      "notes": "Titrate slowly to reduce GI side effects."
    },
    "adverseEffects": {
      "common": [
        "Flatulence (gas)",
        "Diarrhea",
        "Abdominal pain / distension"
      ],
      "serious": [
        "Elevated liver enzymes (at high doses)",
        "Ileus / Bowel obstruction"
      ]
    },
    "precautions": [
      "**Hypoglycemia:** Acarbose alone does not cause hypoglycemia, but if it occurs with insulin/sulfonylurea, treat with ORAL GLUCOSE (dextrose), not sucrose (cane sugar), as sucrose breakdown is inhibited.",
      "**GI Disease:** Avoid in IBD, colonic ulceration, or obstruction.",
      "**Liver:** Monitor transaminases every 3 months for first year."
    ],
    "contraindications": [
      "Diabetic ketoacidosis",
      "Cirrhosis",
      "Inflammatory bowel disease",
      "Colonic ulceration"
    ],
    "interactions": {
      "drug": ["Digestive enzymes (Amylase/Pancreatin - reduce efficacy)", "Digoxin (may decrease levels)"],
      "food": ["Take with first bite of meal."]
    },
    "pregnancyCategory": "Category B"
  },
  "adapalene": {
    "name": "Adapalene (Differin)",
    "genericName": "Adapalene",
    "formula": "C28H28O3",
    "molecularWeight": "412.52 g/mol",
    "brandNames": ["Differin", "Epiduo"],
    "category": "Acne Agent",
    "drugClass": "Retinoid",
    "pubchemCID": "60164",
    "indications": "Topical treatment of acne vulgaris.",
    "moaSteps": [
      "Binds to specific retinoic acid nuclear receptors (RAR-beta and RAR-gamma).",
      "Modulates gene expression and cellular differentiation.",
      "Normalizes the differentiation of follicular epithelial cells, preventing microcomedone formation.",
      "Possesses anti-inflammatory properties."
    ],
    "pharmacokinetics": {
      "absorption": "Minimal systemic absorption through skin.",
      "distribution": "Concentrates in the follicle.",
      "metabolism": "Not significant.",
      "excretion": "Biliary excretion of absorbed amount."
    },
    "dose": {
      "initialDose": "Apply thin film once daily at bedtime",
      "maxDose": "N/A",
      "notes": "Wash face before application. Acne may worsen initially."
    },
    "adverseEffects": {
      "common": [
        "Erythema (Redness)",
        "Scaling / Dryness",
        "Pruritus (Itching)",
        "Burning sensation"
      ],
      "serious": [
        "Severe dermatitis",
        "Photosensitivity (sunburn)"
      ]
    },
    "precautions": [
      "**Photosensitivity:** Increases sensitivity to sunlight. Use sunscreen and protective clothing.",
      "**Irritation:** Avoid concomitant use of harsh soaps, alcohol-containing toners, or other peeling agents.",
      "**Mucous Membranes:** Avoid contact with eyes, lips, and mucous membranes."
    ],
    "contraindications": [
      "Hypersensitivity to adapalene"
    ],
    "interactions": {
      "drug": ["Other topical acne products (Benzoyl peroxide, Salicylic acid - increased irritation)", "Sulfur/Resorcinol"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "albumin": {
    "name": "Albumin (Human)",
    "genericName": "Albumin Human",
    "formula": "Protein",
    "molecularWeight": "66.5 kDa",
    "brandNames": ["Albutein", "Albunex", "Flexbumin"],
    "category": "Plasma Volume Expander",
    "drugClass": "Blood Derivative",
    "pubchemCID": "None (Protein)",
    "indications": "Hypovolemia (shock), Hypoalbuminemia (burns, ARDS), Ascites (paracentesis adjunct).",
    "moaSteps": [
      "Increases intravascular oncotic pressure.",
      "Mobilizes fluids from the interstitial space into the intravascular space.",
      "Restores blood volume and maintains cardiac output."
    ],
    "pharmacokinetics": {
      "absorption": "IV administration.",
      "distribution": "Confined to intravascular space initially.",
      "metabolism": "Catabolized like endogenous albumin.",
      "excretion": "Half-life is 15-20 days."
    },
    "dose": {
      "initialDose": "25 g IV (varies widely by indication)",
      "maxDose": "Dependent on clinical response",
      "notes": "Available as 5% (isotonic/hypooncotic) and 25% (hyperoncotic) solutions."
    },
    "adverseEffects": {
      "common": [
        "Fluid overload (edema)",
        "Headache",
        "Nausea"
      ],
      "serious": [
        "Pulmonary Edema (from rapid expansion)",
        "Anaphylaxis",
        "Hemolysis (if hypotonic water used as diluent - fatal)"
      ]
    },
    "precautions": [
      "**Fluid Overload:** Rapid infusion can cause circulatory overload and pulmonary edema. Monitor breath sounds and JVP.",
      "**Dilution:** 25% albumin must NOT be diluted with sterile water (hemolysis risk); use saline or D5W.",
      "**Blood Product:** Derived from human plasma; remote theoretical risk of viral transmission."
    ],
    "contraindications": [
      "Severe anemia",
      "Heart failure (relative contraindication due to volume load)",
      "Hypersensitivity to albumin"
    ],
    "interactions": {
      "drug": ["ACE Inhibitors (increased risk of atypical reactions)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "alfuzosin": {
    "name": "Alfuzosin (Uroxatral)",
    "genericName": "Alfuzosin",
    "formula": "C19H27N5O4",
    "molecularWeight": "389.45 g/mol",
    "brandNames": ["Uroxatral"],
    "category": "BPH Agent",
    "drugClass": "Alpha-1 Adrenergic Blocker (Uroselective)",
    "pubchemCID": "2092",
    "indications": "Benign Prostatic Hyperplasia (BPH).",
    "moaSteps": [
      "Selectively blocks alpha-1 adrenergic receptors in the lower urinary tract.",
      "Relaxes smooth muscle in the bladder neck and prostate.",
      "Improves urine flow and reduces BPH symptoms.",
      "Uroselectivity minimizes systemic hypotension compared to non-selective blockers."
    ],
    "pharmacokinetics": {
      "absorption": "50% bioavailability. Meal increases absorption.",
      "distribution": "82-90% protein bound.",
      "metabolism": "Extensive hepatic metabolism (CYP3A4).",
      "excretion": "Feces (69%) and urine (24%). Half-life 10 hours."
    },
    "dose": {
      "initialDose": "10 mg ER PO once daily immediately after the same meal",
      "maxDose": "10 mg/day",
      "notes": "Do not crush or chew ER tablets."
    },
    "adverseEffects": {
      "common": [
        "Dizziness",
        "Upper respiratory infection",
        "Headache",
        "Fatigue"
      ],
      "serious": [
        "QT Prolongation",
        "Hypotension / Syncope",
        "Intraoperative Floppy Iris Syndrome (IFIS)",
        "Priapism"
      ]
    },
    "precautions": [
      "**QT Prolongation:** Use caution in patients with congenital QT prolongation or on other QT drugs.",
      "**Hypotension:** Caution in patients on antihypertensives.",
      "**Cataract Surgery:** Inform ophthalmologist of use; risk of IFIS.",
      "**Renal/Hepatic:** Moderate to severe hepatic impairment is a contraindication."
    ],
    "contraindications": [
      "Moderate/Severe hepatic impairment",
      "Concomitant use with potent CYP3A4 inhibitors (Ketoconazole, Ritonavir)"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inhibitors (increases levels)", "Other Alpha-blockers (hypotension)", "PDE-5 Inhibitors (Sildenafil - additive hypotension)", "QT prolonging drugs"],
      "food": ["Take with food to ensure absorption."]
    },
    "pregnancyCategory": "Category B"
  },
  "aliskiren": {
    "name": "Aliskiren (Tekturna)",
    "genericName": "Aliskiren",
    "formula": "C30H53N3O6",
    "molecularWeight": "551.8 g/mol",
    "brandNames": ["Tekturna"],
    "category": "Antihypertensive",
    "drugClass": "Direct Renin Inhibitor",
    "pubchemCID": "5493444",
    "indications": "Hypertension.",
    "moaSteps": [
      "Directly inhibits renin at its point of activation.",
      "Prevents the conversion of angiotensinogen to angiotensin I.",
      "Reduces levels of angiotensin I, angiotensin II, and aldosterone.",
      "Decreases plasma renin activity (PRA)."
    ],
    "pharmacokinetics": {
      "absorption": "Poor bioavailability (2.5%). High fat meal decreases absorption.",
      "distribution": "Widely distributed.",
      "metabolism": "Minimal metabolism (CYP3A4).",
      "excretion": "Primarily biliary/fecal. Half-life 24 hours."
    },
    "dose": {
      "initialDose": "150 mg PO once daily",
      "maxDose": "300 mg/day",
      "notes": "Avoid high fat meals."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea (dose-related)",
        "Dyspepsia",
        "Headache",
        "Nasopharyngitis"
      ],
      "serious": [
        "Renal Impairment / Failure",
        "Hyperkalemia",
        "Angioedema",
        "Hypotension"
      ]
    },
    "precautions": [
      "**Fetal Toxicity:** BOXED WARNING. Discontinue as soon as pregnancy is detected.",
      "**Diabetes:** Contraindicated in patients with diabetes taking ACE inhibitors or ARBs (increased risk of renal failure/hyperkalemia).",
      "**Renal Impairment:** Monitor creatinine and potassium.",
      "**Angioedema:** Can occur; discontinue immediately."
    ],
    "contraindications": [
      "Concomitant use with ACEIs or ARBs in patients with diabetes",
      "Pregnancy"
    ],
    "interactions": {
      "drug": ["Cyclosporine/Itraconazole (increase aliskiren levels)", "ACEIs/ARBs (increased toxicity)", "Furosemide (aliskiren reduces furosemide efficacy)"],
      "food": ["High fat meals decrease absorption."]
    },
    "pregnancyCategory": "Category D"
  },
  "amiloride": {
    "name": "Amiloride",
    "genericName": "Amiloride HCl",
    "formula": "C6H8ClN7O",
    "molecularWeight": "229.63 g/mol",
    "brandNames": ["Midamor"],
    "category": "Diuretic",
    "drugClass": "Potassium-Sparing Diuretic",
    "pubchemCID": "2159",
    "indications": "Hypertension, Heart Failure (adjunct to prevent hypokalemia), Lithium-induced Polyuria.",
    "moaSteps": [
      "Blocks epithelial sodium channels (ENaC) in the distal tubule and collecting duct.",
      "Inhibits sodium reabsorption.",
      "Since sodium reabsorption is coupled to potassium secretion, blocking Na+ entry indirectly decreases K+ excretion.",
      "Net effect is weak diuresis and potassium retention."
    ],
    "pharmacokinetics": {
      "absorption": "50% bioavailability.",
      "distribution": "Extravascular distribution.",
      "metabolism": "Not metabolized.",
      "excretion": "Excreted unchanged in urine and feces. Half-life 6-9 hours."
    },
    "dose": {
      "initialDose": "5 mg PO once daily",
      "maxDose": "20 mg/day",
      "notes": "Usually combined with thiazides or loop diuretics."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting",
        "Abdominal pain",
        "Headache",
        "Dizziness"
      ],
      "serious": [
        "Severe Hyperkalemia (Fatal arrhythmias) - BOXED WARNING",
        "Hyponatremia"
      ]
    },
    "precautions": [
      "**Hyperkalemia:** Risk is high (Boxed Warning), especially in renal impairment, elderly, or diabetics. Monitor K+ strictly.",
      "**Renal Impairment:** Contraindicated if CrCl < 30 mL/min.",
      "**Diabetes:** Glucose tolerance may be altered."
    ],
    "contraindications": [
      "Hyperkalemia (>5.5 mEq/L)",
      "Concomitant use of other potassium-sparing agents (spironolactone, triamterene) or K+ supplements",
      "Renal failure"
    ],
    "interactions": {
      "drug": ["ACE Inhibitors / ARBs (Hyperkalemia)", "Lithium (Amiloride reduces lithium toxicity/polyuria but monitor levels)", "NSAIDs (reduce diuretic efficacy)"],
      "food": ["Avoid potassium-rich foods/salt substitutes."]
    },
    "pregnancyCategory": "Category B"
  },
  "aminocaproic_acid": {
    "name": "Aminocaproic Acid (Amicar)",
    "genericName": "Aminocaproic Acid",
    "formula": "C6H13NO2",
    "molecularWeight": "131.17 g/mol",
    "brandNames": ["Amicar"],
    "category": "Hemostatic Agent",
    "drugClass": "Antifibrinolytic",
    "pubchemCID": "2165",
    "indications": "Enhancement of hemostasis when fibrinolysis contributes to bleeding (e.g., cardiac surgery, dental procedures in hemophiliacs).",
    "moaSteps": [
      "Binds competitively to plasminogen.",
      "Blocks the binding of plasminogen to fibrin and the subsequent conversion to plasmin.",
      "Inhibits fibrinolysis (clot breakdown).",
      "Stabilizes the clot."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed orally.",
      "distribution": "Widely distributed.",
      "metabolism": "Minimal hepatic metabolism.",
      "excretion": "Excreted in urine. Half-life 2 hours."
    },
    "dose": {
      "initialDose": "4-5 g IV/PO loading dose over 1 hr",
      "maxDose": "30 g/day (1 g/hr maintenance)",
      "notes": "Rapid IV injection can cause hypotension/bradycardia."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Diarrhea",
        "Dizziness",
        "Hypotension (if IV too fast)",
        "Myopathy / Muscle weakness"
      ],
      "serious": [
        "Thrombosis (DVT, PE)",
        "Rhabdomyolysis",
        "Intra-renal obstruction (clots in ureter)"
      ]
    },
    "precautions": [
      "**Thrombosis:** Increased risk of clotting events. Do not use in DIC (Disseminated Intravascular Coagulation) without heparin.",
      "**Upper Urinary Tract Bleeding:** Contraindicated; can cause glomerular capillary thrombosis or clots obstructing renal pelvis.",
      "**Skeletal Muscle:** Monitor CPK; myopathy and necrosis reported."
    ],
    "contraindications": [
      "Active intravascular clotting (DIC)",
      "Hematuria of upper urinary tract origin (risk of obstruction)"
    ],
    "interactions": {
      "drug": ["Factor IX Complex concentrates (Increased thrombosis risk - avoid concurrent use)", "Estrogens"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "aprepitant": {
    "name": "Aprepitant (Emend)",
    "genericName": "Aprepitant",
    "formula": "C23H21F7N4O3",
    "molecularWeight": "534.43 g/mol",
    "brandNames": ["Emend"],
    "category": "Antiemetic",
    "drugClass": "Substance P/Neurokinin 1 (NK1) Receptor Antagonist",
    "pubchemCID": "135413536",
    "indications": "Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) and Postoperative Nausea and Vomiting (PONV).",
    "moaSteps": [
      "Selectively blocks the Neurokinin-1 (NK1) receptor in the CNS.",
      "Inhibits the binding of Substance P, the key neurotransmitter involved in delayed vomiting.",
      "Augments the antiemetic activity of 5-HT3 antagonists and corticosteroids.",
      "Effective primarily for the delayed phase of CINV."
    ],
    "pharmacokinetics": {
      "absorption": "Mean bioavailability 60-65%.",
      "distribution": "Crosses BBB. High protein binding.",
      "metabolism": "Extensively metabolized by CYP3A4.",
      "excretion": "Eliminated in feces and urine. Half-life 9-13 hours."
    },
    "dose": {
      "initialDose": "125 mg PO Day 1, then 80 mg Days 2-3",
      "maxDose": "Protocol dependent",
      "notes": "Usually given with Dexamethasone and a 5-HT3 antagonist (e.g., Ondansetron)."
    },
    "adverseEffects": {
      "common": [
        "Fatigue / Asthenia",
        "Hiccups",
        "Constipation / Diarrhea",
        "Headache"
      ],
      "serious": [
        "Hypersensitivity / Anaphylaxis",
        "Stevens-Johnson Syndrome"
      ]
    },
    "precautions": [
      "**CYP3A4 Interactions:** Aprepitant is a moderate CYP3A4 inhibitor. Increases levels of corticosteroids (reduce dexamethasone dose by 50%).",
      "**Warfarin:** Can decrease INR (induces CYP2C9); monitor closely.",
      "**Oral Contraceptives:** Can reduce efficacy; use backup method."
    ],
    "contraindications": [
      "Hypersensitivity",
      "Concurrent use with Pimozide or Cisapride (QT prolongation risk)"
    ],
    "interactions": {
      "drug": ["Dexamethasone (increase levels)", "Warfarin (decrease INR)", "Oral Contraceptives (decrease efficacy)", "Pimozide (contraindicated)"],
      "food": ["Grapefruit juice (increases levels)"]
    },
    "pregnancyCategory": "Category B"
  },
  "argatroban": {
    "name": "Argatroban",
    "genericName": "Argatroban",
    "formula": "C23H36N6O5S",
    "molecularWeight": "508.6 g/mol",
    "brandNames": ["Argatroban"],
    "category": "Anticoagulant",
    "drugClass": "Direct Thrombin Inhibitor",
    "pubchemCID": "92722",
    "indications": "Heparin-Induced Thrombocytopenia (HIT); Percutaneous Coronary Intervention (PCI) in patients with HIT.",
    "moaSteps": [
      "Directly and reversibly binds to the catalytic site of thrombin (Factor IIa).",
      "Inhibits thrombin's ability to convert fibrinogen to fibrin.",
      "Also inhibits thrombin-induced platelet aggregation.",
      "Effective against both free and clot-bound thrombin."
    ],
    "pharmacokinetics": {
      "absorption": "IV administration.",
      "distribution": "Primarily in extracellular fluid.",
      "metabolism": "Hepatic metabolism via hydroxylation/aromatization.",
      "excretion": "Excreted in feces via bile. Half-life 39-51 minutes.",
      "notes": "Does not require antithrombin III."
    },
    "dose": {
      "initialDose": "2 mcg/kg/min continuous IV infusion",
      "maxDose": "10 mcg/kg/min",
      "notes": "Adjust to maintain aPTT 1.5-3 times baseline."
    },
    "adverseEffects": {
      "common": [
        "Bleeding",
        "Hypotension",
        "Chest pain"
      ],
      "serious": [
        "Major Hemorrhage",
        "Allergic reactions (rare)"
      ]
    },
    "precautions": [
      "**Hepatic Impairment:** Major dose reduction required (start 0.5 mcg/kg/min) as drug is hepatically cleared.",
      "**INR Interference:** Falsely elevates INR. When bridging to warfarin, stop argatroban only when INR > 4.",
      "**Bleeding:** No specific antidote exists."
    ],
    "contraindications": [
      "Active major bleeding",
      "Severe hypersensitivity"
    ],
    "interactions": {
      "drug": ["Oral Anticoagulants (additive bleeding)", "Antiplatelets", "Thrombolytics"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "armodafinil": {
    "name": "Armodafinil (Nuvigil)",
    "genericName": "Armodafinil",
    "formula": "C15H15NO2S",
    "molecularWeight": "273.35 g/mol",
    "brandNames": ["Nuvigil"],
    "category": "Wakefulness Promoting Agent",
    "drugClass": "Eugeroic (R-enantiomer of Modafinil)",
    "pubchemCID": "9600107",
    "indications": "Narcolepsy, Obstructive Sleep Apnea (adjunct), Shift Work Disorder.",
    "moaSteps": [
      "Exact mechanism unknown.",
      "Binds to the dopamine transporter (DAT) and inhibits dopamine reuptake.",
      "Increases dopamine levels in the brain.",
      "Does not bind to norepinephrine or serotonin receptors directly.",
      "Has a longer half-life than the racemic modafinil."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "Apparent volume of distribution 42L.",
      "metabolism": "Hepatic metabolism (CYP3A4 and amide hydrolysis).",
      "excretion": "Excreted in urine. Half-life 15 hours."
    },
    "dose": {
      "initialDose": "150 mg PO once daily",
      "maxDose": "250 mg/day",
      "notes": "Take in morning for narcolepsy; 1 hour before shift for shift work."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Nausea",
        "Insomnia",
        "Anxiety / Nervousness",
        "Dry mouth"
      ],
      "serious": [
        "Serious Rash (SJS/TEN)",
        "Psychiatric symptoms (Mania, Hallucinations)",
        "Angioedema",
        "Multi-organ hypersensitivity"
      ]
    },
    "precautions": [
      "**Serious Rash:** Rare cases of SJS/TEN reported. Discontinue at first sign of rash.",
      "**Psychiatric:** Caution in history of psychosis/mania.",
      "**Cardiovascular:** Not recommended in history of LV hypertrophy or MVP."
    ],
    "contraindications": [
      "Hypersensitivity to modafinil or armodafinil"
    ],
    "interactions": {
      "drug": ["Steroidal Contraceptives (reduced efficacy - CYP3A4 induction)", "Cyclosporine (reduced levels)", "Omeprazole (increased omeprazole levels)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "asenapine": {
    "name": "Asenapine (Saphris)",
    "genericName": "Asenapine Maleate",
    "formula": "C17H16ClNO",
    "molecularWeight": "285.8 g/mol",
    "brandNames": ["Saphris", "Secuado"],
    "category": "Antipsychotic",
    "drugClass": "Atypical Antipsychotic (Second Generation)",
    "pubchemCID": "54844",
    "indications": "Schizophrenia, Bipolar I Disorder (manic/mixed).",
    "moaSteps": [
      "High affinity antagonist at serotonin 5-HT2A and dopamine D2 receptors.",
      "Also has high affinity for alpha-adrenergic and histamine H1 receptors.",
      "Receptor blockade modulates neurotransmission to improve psychotic symptoms."
    ],
    "pharmacokinetics": {
      "absorption": "Sublingual absorption (35% bioavailability). Swallowing reduces bioavailability to <2%.",
      "distribution": "Rapid distribution.",
      "metabolism": "Glucuronidation (UGT1A4) and CYP1A2.",
      "excretion": "Urine and feces. Half-life 24 hours."
    },
    "dose": {
      "initialDose": "5-10 mg Sublingual twice daily",
      "maxDose": "20 mg/day",
      "notes": "Must not eat or drink for 10 minutes after administration."
    },
    "adverseEffects": {
      "common": [
        "Somnolence / Sedation",
        "Oral hypoesthesia (numbing of mouth)",
        "Akathisia",
        "Weight gain"
      ],
      "serious": [
        "Neuroleptic Malignant Syndrome (NMS)",
        "Tardive Dyskinesia",
        "Severe Allergic Reactions (Anaphylaxis/Angioedema)",
        "Hyperglycemia"
      ]
    },
    "precautions": [
      "**Administration:** Crucial to instruct patient on sublingual use (do not swallow/chew/eat).",
      "**Hypersensitivity:** Type I reactions occur; contraindicated in prior hypersensitivity.",
      "**Metabolic:** Monitor weight, glucose, lipids.",
      "**Elderly:** Increased mortality in dementia-related psychosis."
    ],
    "contraindications": [
      "Severe hepatic impairment",
      "History of hypersensitivity"
    ],
    "interactions": {
      "drug": ["CYP1A2 Inhibitors (Fluvoxamine - increases levels)", "Antihypertensives (hypotension)", "CNS depressants"],
      "food": ["Eating/drinking within 10 mins reduces absorption."]
    },
    "pregnancyCategory": "Category C"
  },
  "atazanavir": {
    "name": "Atazanavir (Reyataz)",
    "genericName": "Atazanavir Sulfate",
    "formula": "C38H52N6O7",
    "molecularWeight": "704.9 g/mol",
    "brandNames": ["Reyataz"],
    "category": "Antiretroviral",
    "drugClass": "Protease Inhibitor (PI)",
    "pubchemCID": "148192",
    "indications": "Treatment of HIV-1 infection.",
    "moaSteps": [
      "Binds to the active site of HIV-1 protease.",
      "Prevents the cleavage of viral polyprotein precursors.",
      "Results in the formation of immature, non-infectious viral particles."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Requires food.",
      "distribution": "86% protein bound.",
      "metabolism": "Extensively metabolized by CYP3A4.",
      "excretion": "Biliary/fecal excretion. Half-life 7 hours."
    },
    "dose": {
      "initialDose": "300 mg PO once daily + Ritonavir 100 mg (Booster)",
      "maxDose": "400 mg/day (unboosted)",
      "notes": "Requires acidic gastric pH for absorption."
    },
    "adverseEffects": {
      "common": [
        "Hyperbilirubinemia (Jaundice/Scleral icterus)",
        "Nausea",
        "Headache",
        "Rash"
      ],
      "serious": [
        "Nephrolithiasis / Cholelithiasis",
        "PR Interval Prolongation",
        "Hyperglycemia / Diabetes",
        "Severe skin reactions (SJS)"
      ]
    },
    "precautions": [
      "**Hyperbilirubinemia:** Inhibits UGT1A1, causing unconjugated hyperbilirubinemia (Gilbert's-like). Cosmetic concern but usually not hepatotoxic.",
      "**Acid Suppressants:** PPIs and H2 blockers significantly reduce absorption. Administer at least 12 hours apart or avoid PPIs.",
      "**Cardiac:** Caution in preexisting conduction system disease."
    ],
    "contraindications": [
      "Concomitant use with drugs dependent on CYP3A4 (Simvastatin, Lovastatin, Pimozide)",
      "Use with PPIs (if unboosted)"
    ],
    "interactions": {
      "drug": ["Acid Reducers (PPIs/H2RAs - decrease efficacy)", "Tenofovir (decreases atazanavir levels)", "Warfarin"],
      "food": ["Must be taken with food."]
    },
    "pregnancyCategory": "Category B"
  },
  "azelastine": {
    "name": "Azelastine (Astelin)",
    "genericName": "Azelastine HCl",
    "formula": "C22H24ClN3O",
    "molecularWeight": "381.9 g/mol",
    "brandNames": ["Astelin", "Astepro", "Optivar"],
    "category": "Antihistamine",
    "drugClass": "H1 Receptor Antagonist (Second Generation)",
    "pubchemCID": "2267",
    "indications": "Seasonal Allergic Rhinitis, Vasomotor Rhinitis, Allergic Conjunctivitis.",
    "moaSteps": [
      "Competitively antagonizes histamine at the H1 receptor.",
      "Inhibits the release of inflammatory mediators (leukotrienes, kinins) from mast cells.",
      "Reduces nasal congestion, itching, and sneezing."
    ],
    "pharmacokinetics": {
      "absorption": "Systemic absorption occurs after intranasal use (40% bioavailability).",
      "distribution": "Moderate protein binding.",
      "metabolism": "Hepatic via CYP450 to active metabolite desmethylazelastine.",
      "excretion": "Fecal excretion. Half-life 22 hours."
    },
    "dose": {
      "initialDose": "1-2 sprays per nostril twice daily",
      "maxDose": "2 sprays per nostril BID",
      "notes": "Prime pump before first use."
    },
    "adverseEffects": {
      "common": [
        "Bitter taste (Dysgeusia)",
        "Somnolence / Drowsiness",
        "Nasal burning / Epistaxis",
        "Headache"
      ],
      "serious": [
        "Anosmia (rare)",
        "Severe drowsiness (if combined with alcohol)"
      ]
    },
    "precautions": [
      "**CNS Depression:** Can cause drowsiness despite being 'second generation'. Caution driving.",
      "**Technique:** Instruct patient not to tilt head back to avoid bitter taste (drainage down throat).",
      "**Alcohol:** Avoid alcohol due to additive CNS effects."
    ],
    "contraindications": [
      "Hypersensitivity to azelastine"
    ],
    "interactions": {
      "drug": ["CNS Depressants (Alcohol, Benzodiazepines)", "Cimetidine (increases levels)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "aztreonam": {
    "name": "Aztreonam (Azactam)",
    "genericName": "Aztreonam",
    "formula": "C13H17N5O8S2",
    "molecularWeight": "435.4 g/mol",
    "brandNames": ["Azactam", "Cayston"],
    "category": "Antibiotic",
    "drugClass": "Monobactam",
    "pubchemCID": "5742",
    "indications": "Gram-negative infections (Pseudomonas, E. coli, Klebsiella) in patients with Penicillin allergy. Cystic Fibrosis (Inhaled).",
    "moaSteps": [
      "Binds to penicillin-binding protein 3 (PBP3) of Gram-negative bacteria.",
      "Inhibits bacterial cell wall synthesis.",
      "Causes filamentation and cell lysis.",
      "No activity against Gram-positive bacteria or anaerobes."
    ],
    "pharmacokinetics": {
      "absorption": "IV/IM only (poor oral absorption).",
      "distribution": "Widely distributed, including CSF and bronchial secretions.",
      "metabolism": "Hepatic metabolism (minor).",
      "excretion": "Excreted unchanged in urine. Half-life 1.7 hours."
    },
    "dose": {
      "initialDose": "1-2 g IV every 8 hours",
      "maxDose": "8 g/day",
      "notes": "Dose adjust in renal impairment."
    },
    "adverseEffects": {
      "common": [
        "Injection site reactions",
        "Rash",
        "Diarrhea",
        "Nausea"
      ],
      "serious": [
        "Anaphylaxis (rare)",
        "Clostridioides difficile colitis",
        "Hepatotoxicity (transient LFT elevation)"
      ]
    },
    "precautions": [
      "**Cross-Reactivity:** Has very low cross-reactivity with penicillins/cephalosporins (except Ceftazidime). Safe for most penicillin-allergic patients.",
      "**Spectrum:** Strictly Gram-negative coverage. Must combine with other agents for empiric therapy.",
      "**Renal:** Accumulates in renal failure."
    ],
    "contraindications": [
      "Hypersensitivity to aztreonam",
      "History of allergy to Ceftazidime (similar side chain)"
    ],
    "interactions": {
      "drug": ["Aminoglycosides (synergy against Pseudomonas)", "Mycophenolate"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },"baclofen": {
    "name": "Baclofen (Lioresal)",
    "genericName": "Baclofen",
    "formula": "C10H12ClNO2",
    "molecularWeight": "213.66 g/mol",
    "brandNames": ["Lioresal", "Gablofen"],
    "category": "Muscle Relaxant",
    "drugClass": "GABA-B Receptor Agonist",
    "pubchemCID": "2284",
    "indications": "Spasticity resulting from multiple sclerosis (MS) or spinal cord injuries.",
    "moaSteps": [
      "Acts as an agonist at GABA-B receptors in the spinal cord.",
      "Hyperpolarizes afferent terminals and inhibits both monosynaptic and polysynaptic reflexes.",
      "Restricts calcium influx into presynaptic terminals, reducing the release of excitatory neurotransmitters (glutamate/aspartate).",
      "Reduces muscle tone and spasticity."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly and almost completely absorbed.",
      "distribution": "Widely distributed; crosses blood-brain barrier.",
      "metabolism": "Minimal hepatic metabolism (15%).",
      "excretion": "Excreted primarily unchanged in urine (70-80%). **Half-life: 2 to 4 hours.**"
    },
    "dose": {
      "initialDose": "5 mg PO three times daily",
      "maxDose": "80 mg/day",
      "notes": "Intrathecal pump used for severe cases."
    },
    "adverseEffects": {
      "common": [
        "Drowsiness / Sedation",
        "Dizziness",
        "Weakness / Fatigue",
        "Hypotension",
        "Nausea"
      ],
      "serious": [
        "Withdrawal Syndrome (Hallucinations, Seizures, Rhabdomyolysis) - BOXED WARNING (Intrathecal)",
        "Respiratory Depression",
        "Coma (Overdose)"
      ]
    },
    "precautions": [
      "**Withdrawal:** Abrupt discontinuation can cause severe rebound spasticity, organ failure, and death. Taper slowly.",
      "**Renal Impairment:** Reduce dose significantly as it is renally cleared.",
      "**Seizures:** May lower seizure threshold in epileptics."
    ],
    "contraindications": [
      "Hypersensitivity to baclofen"
    ],
    "interactions": {
      "drug": ["CNS Depressants (Alcohol, Opioids - additive sedation)", "Antihypertensives (additive hypotension)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "beclomethasone": {
    "name": "Beclomethasone (Qvar)",
    "genericName": "Beclomethasone Dipropionate",
    "formula": "C28H37ClO7",
    "molecularWeight": "521.0 g/mol",
    "brandNames": ["Qvar RediHaler", "Beconase AQ"],
    "category": "Corticosteroid",
    "drugClass": "Inhaled Corticosteroid (ICS)",
    "pubchemCID": "23978",
    "indications": "Maintenance treatment of Asthma; Seasonal/Perennial Allergic Rhinitis (Nasal).",
    "moaSteps": [
      "Binds to intracellular glucocorticoid receptors.",
      "Translocates to the nucleus and modulates gene transcription.",
      "Inhibits the production of inflammatory cytokines (leukotrienes, prostaglandins).",
      "Reduces airway inflammation, edema, and mucus hypersecretion."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed from lungs.",
      "distribution": "87% protein bound.",
      "metabolism": "Rapidly hydrolyzed in the lung to the active metabolite (17-BMP).",
      "excretion": "Excreted in feces (60%) and urine. **Half-life: 2.8 hours (active metabolite).**"
    },
    "dose": {
      "initialDose": "40-80 mcg inhaled twice daily",
      "maxDose": "320 mcg twice daily",
      "notes": "Rinse mouth after use to prevent thrush."
    },
    "adverseEffects": {
      "common": [
        "Oral Candidiasis (Thrush)",
        "Dysphonia (Hoarseness)",
        "Cough",
        "Headache"
      ],
      "serious": [
        "Paradoxical Bronchospasm",
        "Adrenal Suppression (high doses)",
        "Glaucoma / Cataracts (long term)",
        "Decreased Bone Mineral Density"
      ]
    },
    "precautions": [
      "**Thrush:** Rinse mouth with water and spit after every use.",
      "**Acute Asthma:** Not a rescue inhaler. Do not use for status asthmaticus.",
      "**Growth:** Monitor growth in children (potential for temporary suppression)."
    ],
    "contraindications": [
      "Primary treatment of status asthmaticus",
      "Hypersensitivity to milk proteins (some formulations)"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 inhibitors (Ritonavir - may increase systemic exposure)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "benazepril": {
    "name": "Benazepril (Lotensin)",
    "genericName": "Benazepril HCl",
    "formula": "C24H28N2O5",
    "molecularWeight": "424.5 g/mol",
    "brandNames": ["Lotensin"],
    "category": "Antihypertensive",
    "drugClass": "ACE Inhibitor",
    "pubchemCID": "5362124",
    "indications": "Hypertension.",
    "moaSteps": [
      "Benazepril is a prodrug converted to benazeprilat.",
      "Inhibits Angiotensin-Converting Enzyme (ACE).",
      "Prevents conversion of Angiotensin I to Angiotensin II (a potent vasoconstrictor).",
      "Reduces aldosterone secretion and increases bradykinin levels (vasodilator)."
    ],
    "pharmacokinetics": {
      "absorption": "37% bioavailability.",
      "distribution": "96% protein bound.",
      "metabolism": "Hepatic cleavage to active metabolite benazeprilat.",
      "excretion": "Excreted in urine and bile. **Half-life: 10-11 hours (effective).**"
    },
    "dose": {
      "initialDose": "10 mg PO once daily",
      "maxDose": "40 mg/day",
      "notes": "Reduce to 5mg if on diuretic or renal impairment."
    },
    "adverseEffects": {
      "common": [
        "Dry Cough (bradykinin-mediated)",
        "Dizziness",
        "Headache",
        "Fatigue"
      ],
      "serious": [
        "Angioedema (Swelling of face/lips/throat) - Emergency",
        "Hyperkalemia",
        "Renal Failure (in renal artery stenosis)",
        "Fetal Toxicity - BOXED WARNING"
      ]
    },
    "precautions": [
      "**Fetal Toxicity:** Discontinue immediately if pregnancy is detected. Lethal to fetus.",
      "**Angioedema:** Higher risk in Black patients. Stop drug immediately.",
      "**Hyperkalemia:** Monitor K+ levels, especially if on potassium supplements or spironolactone."
    ],
    "contraindications": [
      "History of angioedema with ACE inhibitors",
      "Pregnancy",
      "Concomitant use with Aliskiren in diabetics"
    ],
    "interactions": {
      "drug": ["Potassium-sparing diuretics (Hyperkalemia)", "Lithium (Toxicity)", "NSAIDs (Renal failure)"],
      "food": ["Potassium substitutes (Salt substitutes)"]
    },
    "pregnancyCategory": "Category D"
  },
  "benzonatate": {
    "name": "Benzonatate (Tessalon)",
    "genericName": "Benzonatate",
    "formula": "C30H53NO11",
    "molecularWeight": "603.7 g/mol",
    "brandNames": ["Tessalon Perles"],
    "category": "Antitussive",
    "drugClass": "Non-narcotic Antitussive",
    "pubchemCID": "7699",
    "indications": "Symptomatic relief of cough.",
    "moaSteps": [
      "Chemically related to local anesthetics (tetracaine).",
      "Anesthetizes the stretch receptors located in the respiratory passages, lungs, and pleura.",
      "Dampens the cough reflex at its source.",
      "Does not depress the respiratory center in the CNS."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed; onset within 15-20 mins.",
      "distribution": "Unknown.",
      "metabolism": "Hydrolyzed to para-aminobenzoic acid (PABA).",
      "excretion": "Excreted in urine. **Half-life: approx 1 hour (but effect lasts 3-8 hours).**"
    },
    "dose": {
      "initialDose": "100-200 mg PO three times daily PRN",
      "maxDose": "600 mg/day",
      "notes": "Swallow whole. Do not chew."
    },
    "adverseEffects": {
      "common": [
        "Sedation",
        "Headache",
        "Dizziness",
        "GI upset"
      ],
      "serious": [
        "Oropharyngeal Anesthesia (if chewed) -> Choking/Aspiration",
        "Severe Hypersensitivity (Bronchospasm/Collapse)",
        "Psychiatric effects (confusion/hallucinations)"
      ]
    },
    "precautions": [
      "**Choking Risk:** Capsules must be swallowed whole. Chewing numbs the mouth and throat, disabling the gag reflex.",
      "**Pediatric Safety:** Keep away from children. Accidental ingestion of even 1-2 pills can be fatal in young children."
    ],
    "contraindications": [
      "Hypersensitivity to benzonatate or PABA (tetracaine/procaine)"
    ],
    "interactions": {
      "drug": ["None significant"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "benztropine": {
    "name": "Benztropine (Cogentin)",
    "genericName": "Benztropine Mesylate",
    "formula": "C21H25NO",
    "molecularWeight": "307.43 g/mol",
    "brandNames": ["Cogentin"],
    "category": "Antiparkinson Agent",
    "drugClass": "Anticholinergic",
    "pubchemCID": "12015",
    "indications": "Parkinson's Disease, Drug-induced Extrapyramidal Symptoms (EPS) / Dystonia.",
    "moaSteps": [
      "Selectively blocks cholinergic (muscarinic) receptors in the striatum.",
      "Restores the balance between dopamine and acetylcholine.",
      "Reduces tremor and rigidity (less effective for bradykinesia).",
      "Also blocks dopamine reuptake (weakly)."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "Crosses blood-brain barrier.",
      "metabolism": "Hepatic.",
      "excretion": "Renal excretion. **Half-life: 12 to 24 hours.**"
    },
    "dose": {
      "initialDose": "1-2 mg PO/IM daily or BID",
      "maxDose": "6 mg/day",
      "notes": "Use IM/IV for acute dystonic reactions."
    },
    "adverseEffects": {
      "common": [
        "Dry mouth",
        "Blurred vision",
        "Constipation",
        "Urinary retention",
        "Tachycardia"
      ],
      "serious": [
        "Paralytic Ileus",
        "Heat Stroke (due to decreased sweating)",
        "Psychosis / Delirium",
        "Acute Glaucoma"
      ]
    },
    "precautions": [
      "**Heat Sensitivity:** Inhibits sweating; risk of hyperthermia in hot weather.",
      "**Elderly (Beers Criteria):** Avoid use due to high risk of confusion, constipation, and falls.",
      "**Tardive Dyskinesia:** May exacerbate TD."
    ],
    "contraindications": [
      "Narrow-angle glaucoma",
      "Pyloric/Duodenal obstruction",
      "Prostatic hypertrophy with retention"
    ],
    "interactions": {
      "drug": ["Other Anticholinergics (Additive toxicity)", "Antipsychotics (decreases efficacy)", "Digoxin"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "betamethasone": {
    "name": "Betamethasone (Celestone)",
    "genericName": "Betamethasone",
    "formula": "C22H29FO5",
    "molecularWeight": "392.5 g/mol",
    "brandNames": ["Celestone", "Diprolene", "Luxiq"],
    "category": "Corticosteroid",
    "drugClass": "Glucocorticoid (Long-acting)",
    "pubchemCID": "9782",
    "indications": "Severe Inflammation, Fetal Lung Maturation (Antenatal), Dermatoses (Topical).",
    "moaSteps": [
      "Potent glucocorticoid with minimal mineralocorticoid activity.",
      "Enters cells and binds to glucocorticoid receptors.",
      "Inhibits synthesis of prostaglandins and leukotrienes.",
      "Induces surfactant production in fetal lungs."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (oral/IM).",
      "distribution": "Widely distributed. Crosses placenta.",
      "metabolism": "Hepatic metabolism.",
      "excretion": "Urine. **Half-life: 6.5 hours (Plasma); 36-54 hours (Biological).**"
    },
    "dose": {
      "initialDose": "0.6-7.2 mg PO/IM daily",
      "maxDose": "Varies by severity",
      "notes": "Antenatal: 12 mg IM q24h x 2 doses."
    },
    "adverseEffects": {
      "common": [
        "Insomnia",
        "Hyperglycemia",
        "Fluid retention",
        "Increased appetite",
        "Mood changes"
      ],
      "serious": [
        "Adrenal Suppression",
        "Peptic Ulceration",
        "Osteoporosis (chronic)",
        "Psychosis"
      ]
    },
    "precautions": [
      "**Diabetes:** Causes significant hyperglycemia; monitor glucose.",
      "**Infection:** Masks signs of infection; avoid live vaccines.",
      "**Stopping:** Taper slowly after long-term use to prevent adrenal crisis."
    ],
    "contraindications": [
      "Systemic fungal infections",
      "Live vaccines (if immunosuppressive dose)",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["NSAIDs (Ulcer risk)", "Warfarin (Variable INR)", "Diuretics (Hypokalemia)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "bicalutamide": {
    "name": "Bicalutamide (Casodex)",
    "genericName": "Bicalutamide",
    "formula": "C18H14F4N2O4S",
    "molecularWeight": "430.37 g/mol",
    "brandNames": ["Casodex"],
    "category": "Antineoplastic",
    "drugClass": "Non-steroidal Androgen Receptor Antagonist",
    "pubchemCID": "2375",
    "indications": "Metastatic Prostate Cancer (Stage D2) - used in combination with LHRH analog.",
    "moaSteps": [
      "Competitively binds to cytosol androgen receptors in prostatic tissue.",
      "Inhibits the action of androgens (testosterone/DHT).",
      "Induces apoptosis and regression of prostate tumors.",
      "Prevents the 'flare' associated with initial LHRH agonist therapy."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed. Unaffected by food.",
      "distribution": "96% protein bound.",
      "metabolism": "Extensive hepatic metabolism via oxidation and glucuronidation.",
      "excretion": "Excreted in urine and feces. **Half-life: 5.8 days (Active R-enantiomer).**"
    },
    "dose": {
      "initialDose": "50 mg PO once daily",
      "maxDose": "50 mg/day (150 mg for monotherapy - off label)",
      "notes": "Start at the same time as LHRH agonist."
    },
    "adverseEffects": {
      "common": [
        "Hot flashes",
        "Gynecomastia / Breast pain",
        "Fatigue",
        "Back pain",
        "Constipation"
      ],
      "serious": [
        "Hepatotoxicity (Severe liver injury)",
        "Teratogenicity",
        "Cardiac Failure (rare)"
      ]
    },
    "precautions": [
      "**Hepatotoxicity:** Monitor serum transaminases regularly. Discontinue if ALT > 2x ULN.",
      "**Gynecomastia:** Common; tamoxifen may help reduce this.",
      "**Glucose:** May decrease glucose tolerance."
    ],
    "contraindications": [
      "Women (especially pregnant women - Category X)",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Warfarin (Bicalutamide displaces warfarin -> Increases INR significantly)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category X"
  },
  "bimatoprost": {
    "name": "Bimatoprost (Lumigan, Latisse)",
    "genericName": "Bimatoprost",
    "formula": "C25H37NO4",
    "molecularWeight": "415.6 g/mol",
    "brandNames": ["Lumigan", "Latisse"],
    "category": "Glaucoma Agent",
    "drugClass": "Prostaglandin Analog",
    "pubchemCID": "5311027",
    "indications": "Open-angle Glaucoma / Ocular Hypertension (Lumigan); Hypotrichosis of eyelashes (Latisse).",
    "moaSteps": [
      "Synthetic analog of prostaglandin F2-alpha.",
      "Increases the outflow of aqueous humor via both the trabecular meshwork and uveoscleral pathways.",
      "Lowers intraocular pressure (IOP).",
      "Prolongs the anagen (growth) phase of eyelashes."
    ],
    "pharmacokinetics": {
      "absorption": "Absorbed through cornea.",
      "distribution": "Systemic levels are very low.",
      "metabolism": "Hydrolysis, oxidation, and N-deethylation.",
      "excretion": "Urine and feces. **Half-life: 45 minutes (Systemic elimination).**"
    },
    "dose": {
      "initialDose": "1 drop in affected eye(s) once daily in the evening",
      "maxDose": "Do not exceed once daily (decreases efficacy)",
      "notes": "Remove contact lenses before applying."
    },
    "adverseEffects": {
      "common": [
        "Conjunctival hyperemia (Red eyes)",
        "Eye pruritus",
        "Eyelash darkening/thickening",
        "Periocular skin pigmentation (darkening around eyes)"
      ],
      "serious": [
        "Iris Pigmentation (Permanent brown discoloration)",
        "Macular Edema"
      ]
    },
    "precautions": [
      "**Iris Pigmentation:** Can permanently turn blue/green eyes brown.",
      "**Lashes:** Changes to eyelashes (length, thickness, color) are usually reversible upon stopping.",
      "**Inflammation:** Use caution in active intraocular inflammation (uveitis)."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Latanoprost (paradoxical increase in IOP if used together)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "bisoprolol": {
    "name": "Bisoprolol (Zebeta)",
    "genericName": "Bisoprolol Fumarate",
    "formula": "C18H31NO4",
    "molecularWeight": "325.4 g/mol",
    "brandNames": ["Zebeta"],
    "category": "Antihypertensive",
    "drugClass": "Beta-Blocker (Beta-1 Selective)",
    "pubchemCID": "2405",
    "indications": "Hypertension, Heart Failure (HFrEF).",
    "moaSteps": [
      "Highly selective inhibitor of beta-1 adrenergic receptors in the heart.",
      "Decreases heart rate and cardiac contractility.",
      "Reduces renin release by the kidneys.",
      "Lowers myocardial oxygen demand."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed (80% bioavailability).",
      "distribution": "30% protein bound.",
      "metabolism": "50% metabolized in liver, 50% excreted unchanged.",
      "excretion": "Balanced renal/hepatic clearance. **Half-life: 9 to 12 hours.**"
    },
    "dose": {
      "initialDose": "2.5 - 5 mg PO once daily",
      "maxDose": "20 mg/day (10 mg for Heart Failure)",
      "notes": "Start low (1.25 mg) for heart failure."
    },
    "adverseEffects": {
      "common": [
        "Bradycardia",
        "Fatigue",
        "Dizziness",
        "Diarrhea"
      ],
      "serious": [
        "Heart Block",
        "Bronchospasm (at high doses)",
        "Worsening Heart Failure (initial)",
        "Masking Hypoglycemia"
      ]
    },
    "precautions": [
      "**Abrupt Cessation:** BOXED WARNING. Taper over 1-2 weeks to avoid angina/MI.",
      "**Heart Failure:** Initiating can transiently worsen symptoms; titrate slowly.",
      "**Diabetes:** Masks tachycardia of hypoglycemia.",
      "**Bronchospasm:** Safer than non-selective betas in COPD, but caution still required."
    ],
    "contraindications": [
      "Cardiogenic shock",
      "Decompensated heart failure",
      "2nd or 3rd degree AV block"
    ],
    "interactions": {
      "drug": ["Calcium Channel Blockers (Diltiazem - Bradycardia)", "Clonidine", "Digoxin"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "bivalirudin": {
    "name": "Bivalirudin (Angiomax)",
    "genericName": "Bivalirudin",
    "formula": "C98H138N24O33",
    "molecularWeight": "2180 Da",
    "brandNames": ["Angiomax"],
    "category": "Anticoagulant",
    "drugClass": "Direct Thrombin Inhibitor",
    "pubchemCID": "16129704",
    "indications": "Percutaneous Coronary Intervention (PCI), Heparin-Induced Thrombocytopenia (HIT) during PCI.",
    "moaSteps": [
      "Synthetic peptide analogue of hirudin.",
      "Binds specifically and reversibly to both the catalytic site and the anion-binding exosite of thrombin.",
      "Inhibits fibrin formation and platelet activation.",
      "Does not require cofactors (like antithrombin) to function."
    ],
    "pharmacokinetics": {
      "absorption": "IV administration.",
      "distribution": "Rapid distribution.",
      "metabolism": "Proteolytic cleavage (20%) and renal.",
      "excretion": "Renal and enzymatic. **Half-life: 25 minutes.**"
    },
    "dose": {
      "initialDose": "0.75 mg/kg IV bolus",
      "maxDose": "Followed by 1.75 mg/kg/hr infusion",
      "notes": "Dose adjust for renal impairment."
    },
    "adverseEffects": {
      "common": [
        "Bleeding (puncture site)",
        "Back pain",
        "Nausea",
        "Hypotension"
      ],
      "serious": [
        "Major Hemorrhage (Retroperitoneal, Intracranial)",
        "Coronary Artery Stent Thrombosis",
        "Anaphylaxis"
      ]
    },
    "precautions": [
      "**Bleeding:** No specific reversal agent exists (unlike heparin). Discontinue infusion.",
      "**Renal Impairment:** Drug accumulates; reduce infusion rate.",
      "**Stent Thrombosis:** Acute stent thrombosis has been reported (usually <4 hours)."
    ],
    "contraindications": [
      "Active major bleeding",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Heparin / Warfarin (Additive bleeding)", "Thrombolytics", "Glycoprotein IIb/IIIa inhibitors"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "brimonidine": {
    "name": "Brimonidine (Alphagan P)",
    "genericName": "Brimonidine Tartrate",
    "formula": "C11H10BrN5",
    "molecularWeight": "292.1 g/mol",
    "brandNames": ["Alphagan P", "Mirvaso"],
    "category": "Glaucoma Agent",
    "drugClass": "Alpha-2 Adrenergic Agonist",
    "pubchemCID": "2435",
    "indications": "Open-angle Glaucoma, Ocular Hypertension. Topical gel for Rosacea erythema.",
    "moaSteps": [
      "Highly selective alpha-2 adrenergic agonist.",
      "Decreases aqueous humor production (ciliary body).",
      "Increases uveoscleral outflow.",
      "Provides neuroprotection to retinal ganglion cells (theoretical)."
    ],
    "pharmacokinetics": {
      "absorption": "Systemic absorption occurs after drops.",
      "distribution": "Crosses blood-brain barrier.",
      "metabolism": "Hepatic metabolism.",
      "excretion": "Excreted in urine. **Half-life: 2 to 3 hours (Systemic).**"
    },
    "dose": {
      "initialDose": "1 drop in affected eye(s) three times daily",
      "maxDose": "TID",
      "notes": "Space 5 min apart from other eye drops."
    },
    "adverseEffects": {
      "common": [
        "Eye redness / Burning",
        "Dry mouth",
        "Fatigue / Drowsiness",
        "Headache"
      ],
      "serious": [
        "Hypotension / Bradycardia",
        "Apnea (in infants)",
        "Allergic Conjunctivitis"
      ]
    },
    "precautions": [
      "**Pediatrics:** CONTRAINDICATED in children < 2 years (risk of CNS depression and apnea).",
      "**Contact Lenses:** Remove before use (wait 15 min) if contains benzalkonium chloride.",
      "**CNS Effects:** Can cause fatigue and drowsiness; caution driving."
    ],
    "contraindications": [
      "Neonates and infants (<2 years)",
      "Hypersensitivity",
      "Concomitant MAOI therapy"
    ],
    "interactions": {
      "drug": ["MAOIs (Hypertensive crisis)", "CNS Depressants (Additive)", "Antihypertensives (Hypotension)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "bromocriptine": {
    "name": "Bromocriptine (Parlodel)",
    "genericName": "Bromocriptine Mesylate",
    "formula": "C32H40BrN5O5",
    "molecularWeight": "654.6 g/mol",
    "brandNames": ["Parlodel", "Cycloset"],
    "category": "Dopamine Agonist",
    "drugClass": "Ergot Derivative",
    "pubchemCID": "31101",
    "indications": "Parkinson's Disease, Hyperprolactinemia, Acromegaly, Type 2 Diabetes (Cycloset).",
    "moaSteps": [
      "Directly stimulates dopamine D2 receptors in the corpus striatum (Parkinson's).",
      "Inhibits prolactin secretion from the anterior pituitary.",
      "Resets hypothalamic circadian activities to improve insulin resistance (Diabetes mechanism)."
    ],
    "pharmacokinetics": {
      "absorption": "28% absorbed (low bioavailability due to first-pass).",
      "distribution": "90-96% protein bound.",
      "metabolism": "Extensive hepatic metabolism (CYP3A4).",
      "excretion": "Biliary/Fecal excretion. **Half-life: 15 hours (Biphasic elimination).**"
    },
    "dose": {
      "initialDose": "1.25 mg PO daily or BID",
      "maxDose": "Proloctinoma: Up to 15 mg/day; Parkinson's: Up to 100 mg/day (rarely used that high)",
      "notes": "Take with food to minimize nausea."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting",
        "Orthostatic Hypotension",
        "Headache",
        "Dizziness",
        "Nasal congestion"
      ],
      "serious": [
        "Pleural / Retroperitoneal Fibrosis (Ergot effect)",
        "Psychosis / Hallucinations",
        "Sudden sleep attacks",
        "Stroke/Seizure (Postpartum use - rare)"
      ]
    },
    "precautions": [
      "**Fibrosis:** Long-term use linked to fibrotic valve/lung changes. Monitor ESR/CXR.",
      "**Hypotension:** Significant first-dose hypotension. Titrate slowly.",
      "**Postpartum:** No longer recommended for lactation suppression (stroke risk)."
    ],
    "contraindications": [
      "Uncontrolled hypertension",
      "Postpartum women (for lactation suppression)",
      "Hypersensitivity to ergot alkaloids"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inhibitors (Erythromycin - toxicity)", "Antipsychotics (antagonize effect)", "Sympathomimetics"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "budesonide": {
    "name": "Budesonide (Pulmicort, Entocort)",
    "genericName": "Budesonide",
    "formula": "C25H34O6",
    "molecularWeight": "430.5 g/mol",
    "brandNames": ["Pulmicort", "Entocort EC", "Uceris", "Symbicort (combo)"],
    "category": "Corticosteroid",
    "drugClass": "Glucocorticoid",
    "pubchemCID": "5281004",
    "indications": "Asthma (Inhaled), Crohn's Disease / Ulcerative Colitis (Oral/Rectal), Allergic Rhinitis (Nasal).",
    "moaSteps": [
      "Potent anti-inflammatory corticosteroid with high first-pass metabolism.",
      "Inhibits multiple cell types (mast cells, eosinophils) and mediators (histamine, cytokines) involved in inflammation.",
      "Oral enteric-coated forms target the ileum/colon for local effect with less systemic absorption."
    ],
    "pharmacokinetics": {
      "absorption": "Complete, but systemic availability low (10%) due to first-pass.",
      "distribution": "Moderate protein binding.",
      "metabolism": "Rapid hepatic metabolism via CYP3A4.",
      "excretion": "Urine and feces. **Half-life: 2 to 3 hours.**"
    },
    "dose": {
      "initialDose": "Inhaled: 180-360 mcg BID; Oral: 9 mg daily (Crohn's)",
      "maxDose": "Varies by route",
      "notes": "Taper oral dose after 8 weeks."
    },
    "adverseEffects": {
      "common": [
        "Oral Thrush (Inhaled)",
        "Dysphonia",
        "Headache",
        "Respiratory infection"
      ],
      "serious": [
        "Adrenal Suppression",
        "Glaucoma",
        "Reduced Bone Density",
        "Paradoxical Bronchospasm"
      ]
    },
    "precautions": [
      "**Systemic Effects:** Less likely than prednisone, but possible (moon face, acne) with chronic use or CYP3A4 inhibitors.",
      "**Thrush:** Rinse mouth after inhalation.",
      "**Infection:** Avoid exposure to chickenpox/measles."
    ],
    "contraindications": [
      "Status asthmaticus",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Ketoconazole / Ritonavir (Increase budesonide levels significantly)", "Antacids (dissolve enteric coating prematurely)"],
      "food": ["Grapefruit juice (Avoid - doubles systemic exposure)"]
    },
    "pregnancyCategory": "Category B"
  },
  "bupropion": {
    "name": "Bupropion (Wellbutrin)",
    "genericName": "Bupropion HCl",
    "formula": "C13H18ClNO",
    "molecularWeight": "239.74 g/mol",
    "brandNames": ["Wellbutrin XL", "Zyban", "Aplenzin"],
    "category": "Antidepressant",
    "drugClass": "Dopamine/Norepinephrine Reuptake Inhibitor (DNRI)",
    "pubchemCID": "444",
    "indications": "Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), Smoking Cessation.",
    "moaSteps": [
      "Inhibits the neuronal reuptake of norepinephrine and dopamine.",
      "Does not inhibit serotonin reuptake (no sexual side effects).",
      "Acts as a non-competitive antagonist at nicotinic acetylcholine receptors (smoking cessation mechanism)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed.",
      "distribution": "Widely distributed.",
      "metabolism": "Extensive hepatic metabolism (CYP2B6) to active metabolites (hydroxybupropion).",
      "excretion": "Urine. **Half-life: 21 hours (+/- 9h); Metabolites longer.**"
    },
    "dose": {
      "initialDose": "150 mg XL PO once daily",
      "maxDose": "450 mg/day (never exceed 150mg per IR dose)",
      "notes": "Swallow whole. Do not crush (seizure risk)."
    },
    "adverseEffects": {
      "common": [
        "Insomnia",
        "Dry mouth",
        "Tremor",
        "Weight loss",
        "Anxiety / Agitation"
      ],
      "serious": [
        "Seizures (Dose-dependent risk) - BOXED WARNING",
        "Suicidality (Young adults) - BOXED WARNING",
        "Hypertension",
        "Psychosis / Mania"
      ]
    },
    "precautions": [
      "**Seizure Risk:** Risk increases with doses >450mg, history of seizures, eating disorders, or abrupt alcohol withdrawal.",
      "**Suicidality:** Monitor for worsening depression.",
      "**Insomnia:** Avoid bedtime dosing."
    ],
    "contraindications": [
      "Seizure disorder",
      "Bulimia or Anorexia nervosa",
      "Abrupt discontinuation of alcohol/sedatives",
      "MAOI use within 14 days"
    ],
    "interactions": {
      "drug": ["MAOIs (Toxic)", "CYP2D6 substrates (Bupropion inhibits CYP2D6 -> increases levels of SSRIs, Beta-blockers)", "Alcohol (lowers seizure threshold)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "buspirone": {
    "name": "Buspirone (Buspar)",
    "genericName": "Buspirone HCl",
    "formula": "C21H31N5O2",
    "molecularWeight": "385.5 g/mol",
    "brandNames": ["Buspar"],
    "category": "Anxiolytic",
    "drugClass": "Azapirone",
    "pubchemCID": "2478",
    "indications": "Generalized Anxiety Disorder (GAD).",
    "moaSteps": [
      "Acts as a partial agonist at serotonin 5-HT1A receptors.",
      "Has moderate affinity for dopamine D2 receptors.",
      "Does not affect GABA receptors (unlike benzodiazepines).",
      "Lacks sedative, anticonvulsant, or muscle relaxant properties."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Low bioavailability due to first-pass.",
      "distribution": "86% protein bound.",
      "metabolism": "Extensive hepatic metabolism via CYP3A4.",
      "excretion": "Urine and feces. **Half-life: 2 to 3 hours.**"
    },
    "dose": {
      "initialDose": "7.5 mg PO twice daily",
      "maxDose": "60 mg/day",
      "notes": "Takes 2-4 weeks for full anxiolytic effect."
    },
    "adverseEffects": {
      "common": [
        "Dizziness",
        "Nausea",
        "Headache",
        "Nervousness / Excitement"
      ],
      "serious": [
        "Serotonin Syndrome (rare, if combined)",
        "Akathisia / Extrapyramidal symptoms (rare)"
      ]
    },
    "precautions": [
      "**Delayed Onset:** Not effective for acute panic attacks or PRN use. Patient expectation management is key.",
      "**Benzodiazepine Withdrawal:** Buspirone does not block withdrawal symptoms from benzos.",
      "**Renal/Hepatic:** Avoid in severe impairment."
    ],
    "contraindications": [
      "Hypersensitivity",
      "Concomitant MAOI use"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inhibitors (Erythromycin, Ketoconazole - increase buspirone levels)", "MAOIs (Hypertensive crisis)", "SSRIs (Serotonin syndrome risk)"],
      "food": ["Grapefruit juice (increases levels significantly)"]
    },
    "pregnancyCategory": "Category B"
  },"bedaquiline": {
    "name": "Bedaquiline (Sirturo)",
    "genericName": "Bedaquiline Fumarate",
    "formula": "C32H31BrN2O2",
    "molecularWeight": "555.5 g/mol",
    "brandNames": ["Sirturo"],
    "category": "Antimycobacterial",
    "drugClass": "Diarylquinoline",
    "pubchemCID": "5388906",
    "indications": "Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB) in adults and children (part of combination therapy).",
    "moaSteps": [
      "Inhibits mycobacterial ATP synthase (Unit c).",
      "Interferes with the generation of ATP (energy) in Mycobacterium tuberculosis.",
      "Leads to bacterial cell death.",
      "Highly specific to mycobacteria; does not inhibit human ATP synthase."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed. Food increases bioavailability twofold.",
      "distribution": "High protein binding (>99.9%).",
      "metabolism": "Hepatic metabolism via CYP3A4.",
      "excretion": "Fecal excretion. **Half-life: ~5.5 months (Terminal elimination phase).**"
    },
    "dose": {
      "initialDose": "400 mg PO once daily for 2 weeks",
      "maxDose": "Then 200 mg 3 times/week for 22 weeks",
      "notes": "Must be taken with food to ensure absorption."
    },
    "adverseEffects": {
      "common": [
        "Nausea",
        "Arthralgia",
        "Headache",
        "Hemoptysis",
        "Chest pain"
      ],
      "serious": [
        "QT Prolongation - BOXED WARNING",
        "Increased Mortality (observed in initial trials) - BOXED WARNING",
        "Hepatotoxicity"
      ]
    },
    "precautions": [
      "**QT Prolongation:** Monitor ECG frequently. Avoid use with other QT prolonging drugs (e.g., fluoroquinolones, macrolides) if possible.",
      "**Mortality:** Use only when an effective treatment regimen cannot otherwise be provided.",
      "**CYP3A4:** Avoid strong CYP3A4 inducers (Rifampin) as they reduce efficacy."
    ],
    "contraindications": [
      "Hypersensitivity to bedaquiline"
    ],
    "interactions": {
      "drug": ["Rifampin (reduces bedaquiline levels)", "Ketoconazole (increases levels)", "QT prolonging drugs"],
      "food": ["Take with food."]
    },
    "pregnancyCategory": "Category B"
  },
  "belimumab": {
    "name": "Belimumab (Benlysta)",
    "genericName": "Belimumab",
    "formula": "C6388H9904N1716O2002S46",
    "molecularWeight": "147 kDa",
    "brandNames": ["Benlysta"],
    "category": "Immunosuppressant",
    "drugClass": "Monoclonal Antibody (BLyS Inhibitor)",
    "pubchemCID": "None (Protein)",
    "indications": "Systemic Lupus Erythematosus (SLE), Lupus Nephritis.",
    "moaSteps": [
      "Specific inhibitor of B-lymphocyte stimulator (BLyS).",
      "Binds to soluble BLyS and prevents it from binding to B-cell receptors.",
      "Inhibits the survival of B cells, including autoreactive B cells.",
      "Reduces the differentiation of B cells into immunoglobulin-producing plasma cells."
    ],
    "pharmacokinetics": {
      "absorption": "IV or Subcutaneous administration.",
      "distribution": "Small volume of distribution.",
      "metabolism": "Degraded by proteolytic enzymes.",
      "excretion": "Clearance via catabolism. **Half-life: 19.4 days.**"
    },
    "dose": {
      "initialDose": "10 mg/kg IV every 2 weeks x 3 doses, then every 4 weeks",
      "maxDose": "Protocol dependent",
      "notes": "Pre-medicate to prevent infusion reactions."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Diarrhea",
        "Fever",
        "Nasopharyngitis",
        "Injection site reactions"
      ],
      "serious": [
        "Serious Infections (Pneumonia, Sepsis)",
        "Depression / Suicidality",
        "Hypersensitivity / Anaphylaxis",
        "PML (Progressive Multifocal Leukoencephalopathy) - Rare"
      ]
    },
    "precautions": [
      "**Infections:** Do not start in active infection. Monitor closely.",
      "**Mental Health:** Associated with increased risk of depression and suicide.",
      "**Live Vaccines:** Avoid concurrent use.",
      "**Infusion Reactions:** Monitor during and after infusion."
    ],
    "contraindications": [
      "Previous anaphylaxis to belimumab"
    ],
    "interactions": {
      "drug": ["Cyclophosphamide (limited data)", "Other biologics (increased infection risk)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "bendamustine": {
    "name": "Bendamustine (Treanda)",
    "genericName": "Bendamustine HCl",
    "formula": "C16H21Cl2N3O2",
    "molecularWeight": "358.26 g/mol",
    "brandNames": ["Treanda", "Bendeka", "Belrapzo"],
    "category": "Antineoplastic",
    "drugClass": "Alkylating Agent",
    "pubchemCID": "65628",
    "indications": "Chronic Lymphocytic Leukemia (CLL), Indolent B-cell Non-Hodgkin Lymphoma (NHL).",
    "moaSteps": [
      "Bifunctional alkylating agent.",
      "Forms covalent bonds (cross-links) with DNA (both single and double-strand).",
      "Disrupts DNA function and synthesis.",
      "Induces apoptosis in both dividing and non-dividing cells."
    ],
    "pharmacokinetics": {
      "absorption": "IV administration.",
      "distribution": "95% protein bound.",
      "metabolism": "Hepatic metabolism via hydrolysis and CYP1A2.",
      "excretion": "Urine and feces. **Half-life: 40 minutes (intermediate half-life).**"
    },
    "dose": {
      "initialDose": "100 mg/m2 IV on Days 1 and 2 of a 28-day cycle",
      "maxDose": "Varies by regimen",
      "notes": "Protect from light."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting",
        "Fatigue",
        "Fever",
        "Diarrhea"
      ],
      "serious": [
        "Myelosuppression (Severe neutropenia/thrombocytopenia)",
        "Infections (Pneumonia, Sepsis)",
        "Tumor Lysis Syndrome",
        "Skin Reactions (SJS/TEN)",
        "Secondary Malignancies"
      ]
    },
    "precautions": [
      "**Myelosuppression:** Delay treatment if ANC < 1,000. Monitor CBC weekly.",
      "**Infections:** Reactivation of Hepatitis B, CMV, and Herpes Zoster can occur.",
      "**Tumor Lysis:** Use prophylaxis (allopurinol/hydration) in high-risk patients.",
      "**Extravasation:** Vesicant; ensure good IV access."
    ],
    "contraindications": [
      "Known hypersensitivity to bendamustine or polyethylene glycol (PEG)"
    ],
    "interactions": {
      "drug": ["CYP1A2 Inhibitors (Ciprofloxacin - increases levels)", "CYP1A2 Inducers (Omeprazole/Smoking - decreases levels)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "betaxolol": {
    "name": "Betaxolol (Betoptic)",
    "genericName": "Betaxolol HCl",
    "formula": "C18H29NO3",
    "molecularWeight": "307.43 g/mol",
    "brandNames": ["Betoptic S", "Kerlone"],
    "category": "Glaucoma Agent / Antihypertensive",
    "drugClass": "Beta-Blocker (Beta-1 Selective)",
    "pubchemCID": "2369",
    "indications": "Ocular Hypertension / Glaucoma (Ophthalmic); Hypertension (Oral).",
    "moaSteps": [
      "Selectively blocks beta-1 adrenergic receptors.",
      "Ophthalmic: Reduces aqueous humor production in the ciliary body.",
      "Oral: Reduces cardiac output and sympathetic outflow.",
      "Low lipid solubility (less CNS side effects)."
    ],
    "pharmacokinetics": {
      "absorption": "Complete systemic absorption (oral).",
      "distribution": "50% protein bound.",
      "metabolism": "Hepatic metabolism.",
      "excretion": "Renal excretion. **Half-life: 14 to 22 hours.**"
    },
    "dose": {
      "initialDose": "Ophthalmic: 1 drop BID; Oral: 10 mg daily",
      "maxDose": "Oral: 20 mg/day",
      "notes": "Ophthalmic suspension is better tolerated than solution."
    },
    "adverseEffects": {
      "common": [
        "Transient eye discomfort (stinging)",
        "Blurred vision",
        "Bradycardia (systemic absorption)",
        "Dizziness"
      ],
      "serious": [
        "Bronchospasm (rare with drops but possible)",
        "Heart Block",
        "Heart Failure exacerbation"
      ]
    },
    "precautions": [
      "**Pulmonary Disease:** Although beta-1 selective, use caution in severe asthma/COPD.",
      "**Systemic Absorption:** Eye drops can be absorbed systemically; compress lacrimal sac after use.",
      "**Diabetes:** May mask hypoglycemia."
    ],
    "contraindications": [
      "Sinus bradycardia",
      "Greater than 1st-degree AV block",
      "Cardiogenic shock"
    ],
    "interactions": {
      "drug": ["Oral beta-blockers (additive systemic effects)", "Calcium channel blockers", "Reserpine"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "bethanechol": {
    "name": "Bethanechol (Urecholine)",
    "genericName": "Bethanechol Chloride",
    "formula": "C7H17ClN2O2",
    "molecularWeight": "196.68 g/mol",
    "brandNames": ["Urecholine"],
    "category": "Cholinergic Agonist",
    "drugClass": "Muscarinic Agonist",
    "pubchemCID": "2370",
    "indications": "Non-obstructive urinary retention (postpartum, postoperative), Neurogenic bladder.",
    "moaSteps": [
      "Directly stimulates muscarinic acetylcholine receptors.",
      "Increases tone of the detrusor muscle of the bladder.",
      "Produces a contraction strong enough to initiate micturition.",
      "Also increases gastric motility and lower esophageal sphincter tone."
    ],
    "pharmacokinetics": {
      "absorption": "Poorly absorbed orally.",
      "distribution": "Does not cross blood-brain barrier.",
      "metabolism": "Degraded by cholinesterase.",
      "excretion": "Renal excretion. **Half-life: Unknown (Effects last 1-6 hours).**"
    },
    "dose": {
      "initialDose": "10-50 mg PO three to four times daily",
      "maxDose": "200 mg/day",
      "notes": "Take on empty stomach to avoid nausea."
    },
    "adverseEffects": {
      "common": [
        "Abdominal cramping / Diarrhea",
        "Salivation",
        "Flushing / Sweating",
        "Urinary urgency"
      ],
      "serious": [
        "Bronchoconstriction / Asthmatic attack",
        "Bradycardia / Hypotension",
        "Seizures"
      ]
    },
    "precautions": [
      "**Asthma:** Can precipitate bronchoconstriction.",
      "**Cardiovascular:** May cause reflex tachycardia or hypotension.",
      "**GI/GU Obstruction:** Do not use if strength of muscle contraction could cause rupture (e.g., stones, mechanical obstruction)."
    ],
    "contraindications": [
      "Mechanical GI or GU obstruction",
      "Asthma / COPD",
      "Hyperthyroidism",
      "Peptic ulcer disease",
      "Epilepsy"
    ],
    "interactions": {
      "drug": ["Anticholinergics (antagonize effect)", "Cholinesterase inhibitors (additive toxicity)"],
      "food": ["Take 1 hour before or 2 hours after meals."]
    },
    "pregnancyCategory": "Category C"
  },
  "bevacizumab": {
    "name": "Bevacizumab (Avastin)",
    "genericName": "Bevacizumab",
    "formula": "C6638H10160N1720O2108S44",
    "molecularWeight": "149 kDa",
    "brandNames": ["Avastin", "Mvasi", "Zirabev"],
    "category": "Antineoplastic",
    "drugClass": "Monoclonal Antibody (VEGF Inhibitor)",
    "pubchemCID": "None (Protein)",
    "indications": "Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma.",
    "moaSteps": [
      "Recombinant humanized monoclonal IgG1 antibody.",
      "Binds to Vascular Endothelial Growth Factor (VEGF-A).",
      "Prevents VEGF from interacting with receptors (Flt-1, KDR) on endothelial cells.",
      "Inhibits angiogenesis (formation of new blood vessels) required for tumor growth."
    ],
    "pharmacokinetics": {
      "absorption": "IV administration.",
      "distribution": "Limited to vascular space.",
      "metabolism": "Proteolytic catabolism.",
      "excretion": "Clearance varies by body weight. **Half-life: ~20 days (range 11-50 days).**"
    },
    "dose": {
      "initialDose": "5-10 mg/kg IV every 2 weeks",
      "maxDose": "15 mg/kg every 3 weeks",
      "notes": "Do not administer as IV push."
    },
    "adverseEffects": {
      "common": [
        "Hypertension",
        "Fatigue",
        "Epistaxis (nose bleed)",
        "Proteinuria"
      ],
      "serious": [
        "GI Perforation (Fatal) - BOXED WARNING",
        "Wound Healing Complications - BOXED WARNING",
        "Severe Hemorrhage - BOXED WARNING",
        "Arterial Thromboembolic Events (Stroke, MI)",
        "PRES (Posterior Reversible Encephalopathy Syndrome)"
      ]
    },
    "precautions": [
      "**Surgery:** Discontinue at least 28 days prior to elective surgery. Do not restart until wound is fully healed.",
      "**Hypertension:** Monitor BP regularly; may require antihypertensive therapy.",
      "**Proteinuria:** Monitor urine protein; suspend if >2g/24hr."
    ],
    "contraindications": [
      "None (other than hypersensitivity)",
      "Recent hemoptysis (specifically in lung cancer)"
    ],
    "interactions": {
      "drug": ["Sunitinib (Microangiopathic hemolytic anemia risk)", "Anthracyclines (Cardiotoxicity)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "bictegravir": {
    "name": "Bictegravir (Biktarvy)",
    "genericName": "Bictegravir (in combination)",
    "formula": "C21H18F3N3O5",
    "molecularWeight": "449.4 g/mol",
    "brandNames": ["Biktarvy (combo with Emtricitabine/TAF)"],
    "category": "Antiretroviral",
    "drugClass": "Integrase Strand Transfer Inhibitor (INSTI)",
    "pubchemCID": "91666313",
    "indications": "Treatment of HIV-1 infection.",
    "moaSteps": [
      "Binds to the integrase active site and blocks the strand transfer step of retroviral DNA integration.",
      "Prevents integration of HIV-1 DNA into the host genome.",
      "Halts formation of the HIV-1 provirus and propagation of infection."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed. Can be taken with or without food.",
      "distribution": "High protein binding (>99%).",
      "metabolism": "Hepatic via CYP3A4 and UGT1A1.",
      "excretion": "Feces and urine. **Half-life: ~17.3 hours.**"
    },
    "dose": {
      "initialDose": "50 mg (as part of fixed-dose Biktarvy) PO once daily",
      "maxDose": "One tablet daily",
      "notes": "Do not take with antacids."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea",
        "Nausea",
        "Headache",
        "Fatigue"
      ],
      "serious": [
        "Lactic Acidosis / Hepatomegaly (Class effect)",
        "Immune Reconstitution Syndrome",
        "New onset or worsening renal impairment (due to TAF component)"
      ]
    },
    "precautions": [
      "**Hepatitis B:** Severe acute exacerbation of Hep B can occur if discontinued (due to Emtricitabine/TAF).",
      "**Cations:** polyvalent cations (Mg, Al, Ca) bind bictegravir and reduce absorption. Space dosing by 2 hours."
    ],
    "contraindications": [
      "Concomitant use with Dofetilide",
      "Concomitant use with Rifampin (lowers bictegravir levels)"
    ],
    "interactions": {
      "drug": ["Dofetilide (Contraindicated - increased levels)", "Rifampin (Contraindicated)", "Antacids (chelating effect)", "Metformin (Bictegravir increases metformin levels)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "bismuth": {
    "name": "Bismuth Subsalicylate (Pepto-Bismol)",
    "genericName": "Bismuth Subsalicylate",
    "formula": "C7H5BiO4",
    "molecularWeight": "362.1 g/mol",
    "brandNames": ["Pepto-Bismol", "Kaopectate"],
    "category": "Antidiarrheal / Antacid",
    "drugClass": "Salicylate",
    "pubchemCID": "16682734",
    "indications": "Diarrhea, Dyspepsia, H. pylori eradication.",
    "moaSteps": [
      "Bismuth: Exhibits antimicrobial activity directly against bacterial and viral pathogens; binds enterotoxins.",
      "Salicylate: Inhibits prostaglandin synthesis, reducing intestinal inflammation and hypermotility.",
      "Stimulates fluid and electrolyte absorption."
    ],
    "pharmacokinetics": {
      "absorption": "Bismuth: <1% absorbed. Salicylate: >90% absorbed.",
      "distribution": "Salicylate distributes widely.",
      "metabolism": "Hydrolyzed in stomach to bismuth oxychloride and salicylic acid.",
      "excretion": "Bismuth: Feces. Salicylate: Urine. **Half-life: Bismuth (fecal) 5 days; Salicylate 2-5 hours.**"
    },
    "dose": {
      "initialDose": "524 mg PO every 30-60 min PRN",
      "maxDose": "4200 mg/day",
      "notes": "Shake liquid well."
    },
    "adverseEffects": {
      "common": [
        "Black tongue (harmless)",
        "Black stools (harmless - do not confuse with melena)",
        "Constipation"
      ],
      "serious": [
        "Salicylism (Tinnitus, Nausea, Vomiting)",
        "Reye's Syndrome (in children/teens)",
        "Neurotoxicity (Bismuth encephalopathy - rare)"
      ]
    },
    "precautions": [
      "**Reye's Syndrome:** Do not use in children/teens recovering from flu/chickenpox (contains salicylate).",
      "**Bleeding:** Caution in patients with bleeding disorders or ulcers.",
      "**Stool Color:** Warn patient about black stool."
    ],
    "contraindications": [
      "Hypersensitivity to salicylates (aspirin)",
      "Active GI bleeding"
    ],
    "interactions": {
      "drug": ["Warfarin (increases bleeding risk)", "Tetracyclines (decreases absorption)", "Aspirin (additive toxicity)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "bleomycin": {
    "name": "Bleomycin",
    "genericName": "Bleomycin Sulfate",
    "formula": "Mixture of cytotoxic glycopeptides",
    "molecularWeight": "~1415 Da",
    "brandNames": ["Blenoxane"],
    "category": "Antineoplastic",
    "drugClass": "Antitumor Antibiotic",
    "pubchemCID": "5360373",
    "indications": "Hodgkin's Lymphoma, Testicular Carcinoma, Squamous Cell Carcinomas, Malignant Pleural Effusion (Sclerosing agent).",
    "moaSteps": [
      "Binds to DNA (intercalation).",
      "Iron-dependent production of free radicals.",
      "Causes single- and double-strand DNA breaks.",
      "Cell cycle phase-specific (G2 and M phase)."
    ],
    "pharmacokinetics": {
      "absorption": "IV, IM, or SC administration.",
      "distribution": "High concentrations in skin/lungs (due to low hydrolase activity there).",
      "metabolism": "Degraded by bleomycin hydrolase in tissues.",
      "excretion": "Renal excretion. **Half-life: 2 to 4 hours (Prolonged in renal failure).**"
    },
    "dose": {
      "initialDose": "10-20 units/m2 IV/IM/SC weekly or biweekly",
      "maxDose": "400 units (Cumulative Lifetime Dose)",
      "notes": "Exceeding 400u drastically increases pulmonary fibrosis risk."
    },
    "adverseEffects": {
      "common": [
        "Hyperpigmentation",
        "Skin thickening / Striae",
        "Fever / Chills",
        "Stomatitis",
        "Alopecia"
      ],
      "serious": [
        "Pulmonary Fibrosis (Pneumonitis) - BOXED WARNING",
        "Idiosyncratic Reaction (Hypotension, Confusion, Fever)",
        "Severe Hyperpyrexia"
      ]
    },
    "precautions": [
      "**Pulmonary Toxicity:** Dose-limiting. Monitor PFTs/CXR. Risk increases with age, renal failure, and cumulative dose >400u.",
      "**Oxygen:** Patients with prior bleomycin may be sensitive to high FiO2 during surgery (precipitate lung injury).",
      "**Renal Impairment:** Reduce dose."
    ],
    "contraindications": [
      "Hypersensitivity",
      "Previous idiosyncratic reaction"
    ],
    "interactions": {
      "drug": ["Cisplatin (Decreases bleomycin clearance -> increased toxicity)", "Digoxin (decreased levels)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "bortezomib": {
    "name": "Bortezomib (Velcade)",
    "genericName": "Bortezomib",
    "formula": "C19H25BN4O4",
    "molecularWeight": "384.2 g/mol",
    "brandNames": ["Velcade"],
    "category": "Antineoplastic",
    "drugClass": "Proteasome Inhibitor",
    "pubchemCID": "387447",
    "indications": "Multiple Myeloma, Mantle Cell Lymphoma.",
    "moaSteps": [
      "Reversibly inhibits the 26S proteasome (chymotrypsin-like activity).",
      "Prevents degradation of ubiquitinated proteins.",
      "Accumulation of proteins disrupts cell signaling (e.g., NF-kappaB blockade).",
      "Induces cell cycle arrest and apoptosis."
    ],
    "pharmacokinetics": {
      "absorption": "IV or Subcutaneous.",
      "distribution": "Large volume of distribution.",
      "metabolism": "Hepatic via CYP3A4, 2C19.",
      "excretion": "Biliary/Fecal. **Half-life: 9 to 15 hours (Initial); 40-193 hours (Terminal).**"
    },
    "dose": {
      "initialDose": "1.3 mg/m2 SubQ or IV on days 1, 4, 8, 11 of 21-day cycle",
      "maxDose": "Protocol dependent",
      "notes": "SubQ administration has less neuropathy than IV."
    },
    "adverseEffects": {
      "common": [
        "Peripheral Neuropathy (Sensory, painful)",
        "Fatigue",
        "Nausea / Diarrhea",
        "Thrombocytopenia"
      ],
      "serious": [
        "Severe Neuropathy",
        "Heart Failure",
        "Pulmonary Toxicity (ARDS)",
        "PRES (Posterior Reversible Encephalopathy Syndrome)"
      ]
    },
    "precautions": [
      "**Neuropathy:** Dose modification required for new/worsening neuropathy.",
      "**Herpes Zoster:** Reactivation common; antiviral prophylaxis (acyclovir) recommended.",
      "**Hypotension:** Adjust antihypertensives.",
      "**Tumor Lysis:** Monitor uric acid."
    ],
    "contraindications": [
      "Hypersensitivity to bortezomib, boron, or mannitol",
      "Intrathecal administration (FATAL)"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inhibitors (Ketoconazole - Toxicity)", "Strong CYP3A4 Inducers (Rifampin - Failure)", "Oral Hypoglycemics"],
      "food": ["Green tea (EGCG) may antagonize effect."]
    },
    "pregnancyCategory": "Category D"
  },
  "bosentan": {
    "name": "Bosentan (Tracleer)",
    "genericName": "Bosentan",
    "formula": "C27H29N5O6S",
    "molecularWeight": "551.6 g/mol",
    "brandNames": ["Tracleer"],
    "category": "Pulmonary Hypertension Agent",
    "drugClass": "Endothelin Receptor Antagonist (ERA)",
    "pubchemCID": "5360373",
    "indications": "Pulmonary Arterial Hypertension (PAH) (WHO Group 1).",
    "moaSteps": [
      "Competitively antagonizes endothelin-1 (ET-1) at both ET-A and ET-B receptors.",
      "ET-1 is a potent vasoconstrictor and promoter of fibrosis.",
      "Blockade leads to vasodilation of pulmonary vascular beds.",
      "Reduces pulmonary vascular resistance and improves exercise capacity."
    ],
    "pharmacokinetics": {
      "absorption": "50% bioavailability.",
      "distribution": "98% protein bound.",
      "metabolism": "Hepatic via CYP2C9 and CYP3A4. Potent inducer of CYP enzymes.",
      "excretion": "Biliary/Fecal. **Half-life: 5 hours.**"
    },
    "dose": {
      "initialDose": "62.5 mg PO twice daily for 4 weeks",
      "maxDose": "125 mg twice daily",
      "notes": "Available only through REMS program."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Flushing",
        "Nasopharyngitis",
        "Edema (Fluid retention)"
      ],
      "serious": [
        "Hepatotoxicity (ALT/AST elevation) - BOXED WARNING",
        "Teratogenicity - BOXED WARNING",
        "Decrease in Hemoglobin/Hematocrit",
        "Fluid Overload / Heart Failure"
      ]
    },
    "precautions": [
      "**Hepatotoxicity:** Monthly LFT monitoring required.",
      "**Pregnancy:** Requires monthly pregnancy tests (REMS). Contraception failure possible (CYP induction).",
      "**Fluid Retention:** Monitor weight; diuretics may be needed."
    ],
    "contraindications": [
      "Pregnancy",
      "Concomitant use of Cyclosporine or Glyburide",
      "Moderate/Severe hepatic impairment"
    ],
    "interactions": {
      "drug": ["Hormonal Contraceptives (Failure risk)", "Cyclosporine (Increased bosentan levels)", "Warfarin (Decreased INR)", "Simvastatin (Decreased efficacy)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category X"
  },
  "brexpiprazole": {
    "name": "Brexpiprazole (Rexulti)",
    "genericName": "Brexpiprazole",
    "formula": "C25H27N3O2S",
    "molecularWeight": "433.6 g/mol",
    "brandNames": ["Rexulti"],
    "category": "Antipsychotic",
    "drugClass": "Atypical Antipsychotic (SDAM)",
    "pubchemCID": "11977753",
    "indications": "Schizophrenia, Adjunctive treatment of Major Depressive Disorder (MDD).",
    "moaSteps": [
      "Serotonin-Dopamine Activity Modulator (SDAM).",
      "Partial agonist at serotonin 5-HT1A and dopamine D2 receptors.",
      "Antagonist at serotonin 5-HT2A and noradrenergic alpha-1B/2C receptors.",
      "More potent 5-HT1A agonist and less potent D2 intrinsic activity than aripiprazole."
    ],
    "pharmacokinetics": {
      "absorption": "95% bioavailability. Unaffected by food.",
      "distribution": "High protein binding.",
      "metabolism": "Hepatic via CYP3A4 and CYP2D6.",
      "excretion": "Urine and feces. **Half-life: 91 hours (Parent drug).**"
    },
    "dose": {
      "initialDose": "0.5 - 1 mg PO once daily",
      "maxDose": "4 mg/day (Schizophrenia)",
      "notes": "Titrate weekly."
    },
    "adverseEffects": {
      "common": [
        "Akathisia",
        "Weight gain",
        "Nasopharyngitis",
        "Restlessness"
      ],
      "serious": [
        "Suicidality (Young adults) - BOXED WARNING",
        "Increased mortality in elderly dementia - BOXED WARNING",
        "Neuroleptic Malignant Syndrome",
        "Hyperglycemia / Dyslipidemia"
      ]
    },
    "precautions": [
      "**Akathisia:** Dose-dependent. Monitor closely.",
      "**Metabolic:** Monitor weight, glucose, lipids.",
      "**CYP Metabolizers:** Poor CYP2D6 metabolizers require dose reduction."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["CYP3A4/2D6 Inhibitors (Increase levels - reduce dose)", "CYP3A4 Inducers (Decrease levels - increase dose)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "brivaracetam": {
    "name": "Brivaracetam (Briviact)",
    "genericName": "Brivaracetam",
    "formula": "C11H20N2O2",
    "molecularWeight": "212.3 g/mol",
    "brandNames": ["Briviact"],
    "category": "Anticonvulsant",
    "drugClass": "SV2A Ligand (Racetam)",
    "pubchemCID": "9838899",
    "indications": "Partial-onset seizures.",
    "moaSteps": [
      "Binds with high affinity to Synaptic Vesicle Protein 2A (SV2A) in the brain.",
      "Affinity is 20-fold higher than levetiracetam.",
      "Modulates neurotransmitter release.",
      "Exact physiological role of SV2A protein binding is not fully understood."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid and complete absorption.",
      "distribution": "Weak protein binding.",
      "metabolism": "Hydrolysis and CYP2C19.",
      "excretion": "Renal excretion. **Half-life: 9 hours.**"
    },
    "dose": {
      "initialDose": "50 mg PO/IV twice daily",
      "maxDose": "200 mg/day",
      "notes": "No titration required (unlike levetiracetam)."
    },
    "adverseEffects": {
      "common": [
        "Somnolence / Sedation",
        "Dizziness",
        "Fatigue",
        "Nausea / Vomiting"
      ],
      "serious": [
        "Psychiatric Adverse Reactions (Aggression, Irritability - less than Keppra)",
        "Suicidal ideation",
        "Hypersensitivity (Angioedema)"
      ]
    },
    "precautions": [
      "**Psychiatric:** Monitor for behavioral changes, though incidence of rage is lower than with levetiracetam.",
      "**Withdrawal:** Taper slowly to avoid breakthrough seizures.",
      "**Hepatic:** Reduce dose in hepatic impairment."
    ],
    "contraindications": [
      "Hypersensitivity to brivaracetam"
    ],
    "interactions": {
      "drug": ["Rifampin (decreases levels)", "Carbamazepine/Phenytoin (may alter levels)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "buprenorphine": {
    "name": "Buprenorphine (Subutex, Belbuca)",
    "genericName": "Buprenorphine",
    "formula": "C29H41NO4",
    "molecularWeight": "467.6 g/mol",
    "brandNames": ["Subutex", "Belbuca", "Butrans"],
    "category": "Opioid Analgesic",
    "drugClass": "Partial Opioid Agonist",
    "pubchemCID": "644073",
    "indications": "Opioid Use Disorder (OUD), Chronic Severe Pain.",
    "moaSteps": [
      "Partial agonist at the mu-opioid receptor.",
      "High affinity but low intrinsic activity (ceiling effect for respiratory depression).",
      "Antagonist at the kappa-opioid receptor.",
      "Slow dissociation from receptor results in long duration of action."
    ],
    "pharmacokinetics": {
      "absorption": "Poor oral bioavail; Sublingual (30-50%) or Transdermal used.",
      "distribution": "96% protein bound.",
      "metabolism": "Hepatic via CYP3A4 to norbuprenorphine.",
      "excretion": "Feces and urine. **Half-life: 24 to 42 hours.**"
    },
    "dose": {
      "initialDose": "Induction: 2-4 mg SL; Pain: 5 mcg/hr patch",
      "maxDose": "24 mg/day (SL for OUD)",
      "notes": "Can precipitate withdrawal if given too soon after full agonist."
    },
    "adverseEffects": {
      "common": [
        "Sedation",
        "Constipation",
        "Headache",
        "Nausea",
        "Sweating"
      ],
      "serious": [
        "Respiratory Depression (Overdose, though ceiling effect exists)",
        "QT Prolongation (high doses)",
        "Severe Withdrawal (if stopped abruptly)",
        "Adrenal Insufficiency"
      ]
    },
    "precautions": [
      "**Precipitated Withdrawal:** Must wait for mild withdrawal symptoms (COWS score) before induction.",
      "**CNS Depression:** Additive with alcohol/benzos.",
      "**Liver:** Monitor LFTs; cytolytic hepatitis reported.",
      "**QT:** Avoid in Long QT syndrome."
    ],
    "contraindications": [
      "Hypersensitivity",
      "Significant respiratory depression",
      "Severe bronchial asthma"
    ],
    "interactions": {
      "drug": ["Benzodiazepines (Respiratory collapse)", "CYP3A4 Inhibitors/Inducers", "Other Opioids (antagonizes effect)"],
      "food": ["Alcohol"]
    },
    "pregnancyCategory": "Category C"
  },
  "butalbital": {
    "name": "Butalbital (Fioricet, Fiorinal)",
    "genericName": "Butalbital",
    "formula": "C11H16N2O3",
    "molecularWeight": "224.26 g/mol",
    "brandNames": ["Fioricet (with APAP/Caf)", "Fiorinal (with ASA/Caf)"],
    "category": "Analgesic / Barbiturate",
    "drugClass": "Barbiturate",
    "pubchemCID": "2479",
    "indications": "Tension Headaches.",
    "moaSteps": [
      "Binds to GABA-A receptors at a distinct site from benzodiazepines.",
      "Increases the duration of chloride channel opening.",
      "Enhances inhibitory GABA transmission.",
      "Causes CNS depression and muscle relaxation."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "Widely distributed.",
      "metabolism": "Hepatic.",
      "excretion": "Renal. **Half-life: ~35 hours.**"
    },
    "dose": {
      "initialDose": "1-2 tablets (50mg butalbital) PO every 4 hours",
      "maxDose": "6 tablets/day",
      "notes": "Limit use to prevent medication overuse headache."
    },
    "adverseEffects": {
      "common": [
        "Drowsiness / Sedation",
        "Dizziness",
        "Lightheadedness",
        "Intoxicated feeling"
      ],
      "serious": [
        "Respiratory Depression",
        "Dependence / Abuse",
        "Withdrawal Seizures",
        "Stevens-Johnson Syndrome"
      ]
    },
    "precautions": [
      "**Medication Overuse Headache:** Frequent use leads to rebound headaches. Limit to <3 days/week.",
      "**Dependence:** Barbiturates have high abuse liability.",
      "**CNS Depression:** Do not drive or drink alcohol.",
      "**Porphyria:** Barbiturates induce porphyrin synthesis; contraindicated."
    ],
    "contraindications": [
      "Porphyria",
      "Hypersensitivity to barbiturates"
    ],
    "interactions": {
      "drug": ["Alcohol/Sedatives (Additive depression)", "Warfarin (Barbiturates induce CYP enzymes -> reduce warfarin effect)", "Oral Contraceptives"],
      "food": ["Alcohol"]
    },
    "pregnancyCategory": "Category C"
  },"bacitracin": {
    "name": "Bacitracin",
    "genericName": "Bacitracin",
    "formula": "C66H103N17O16S",
    "molecularWeight": "1422.7 g/mol",
    "brandNames": ["Baciguent", "Baci-IM"],
    "category": "Antibiotic",
    "drugClass": "Polypeptide Antibiotic",
    "pubchemCID": "439542",
    "indications": "Topical: Skin infection prevention. IM: Infants with staphylococcal pneumonia (rarely used due to toxicity).",
    "moaSteps": [
      "Interferes with the dephosphorylation of the C55-isoprenyl pyrophosphate.",
      "Inhibits bacterial cell wall synthesis.",
      "Active mainly against Gram-positive bacteria (Staph/Strep)."
    ],
    "pharmacokinetics": {
      "absorption": "Poor oral/topical absorption. Rapid IM absorption.",
      "distribution": "Widely distributed after IM.",
      "metabolism": "Minimal.",
      "excretion": "Glomerular filtration. **Half-life: 1.5 hours.**"
    },
    "dose": {
      "initialDose": "Topical: Apply 1-3 times daily",
      "maxDose": "IM: 900 units/kg/day (rare)",
      "notes": "Systemic use limited by nephrotoxicity."
    },
    "adverseEffects": {
      "common": [
        "Skin rash",
        "Itching",
        "Redness"
      ],
      "serious": [
        "Nephrotoxicity (Renal failure - Systemic use) - BOXED WARNING",
        "Anaphylaxis"
      ]
    },
    "precautions": [
      "**Nephrotoxicity:** Systemic bacitracin is highly toxic to kidneys. Monitor BUN/Cr daily if used IM.",
      "**Hypersensitivity:** Allergic contact dermatitis is common."
    ],
    "contraindications": [
      "Hypersensitivity",
      "Severe renal impairment (for IM use)"
    ],
    "interactions": {
      "drug": ["Nephrotoxic drugs (Aminoglycosides - additive toxicity)", "Neuromuscular blockers"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "baloxavir": {
    "name": "Baloxavir Marboxil (Xofluza)",
    "genericName": "Baloxavir Marboxil",
    "formula": "C27H23F2N3O7S",
    "molecularWeight": "571.55 g/mol",
    "brandNames": ["Xofluza"],
    "category": "Antiviral",
    "drugClass": "Endonuclease Inhibitor",
    "pubchemCID": "124081896",
    "indications": "Treatment and post-exposure prophylaxis of acute uncomplicated Influenza (A and B).",
    "moaSteps": [
      "Inhibits the cap-dependent endonuclease activity of the viral polymerase acid (PA) protein.",
      "Prevents 'cap snatching' required for viral mRNA replication.",
      "Halts viral replication at an early stage."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed.",
      "distribution": "93% protein bound.",
      "metabolism": "Hydrolyzed to active metabolite (baloxavir) via UGT1A3.",
      "excretion": "Feces. **Half-life: 79.1 hours.**"
    },
    "dose": {
      "initialDose": "40 mg (Weight 40-80kg) or 80 mg (>80kg) Single Dose",
      "maxDose": "Single dose only",
      "notes": "Avoid dairy/calcium at time of dosing."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea",
        "Bronchitis",
        "Nausea",
        "Headache"
      ],
      "serious": [
        "Anaphylaxis",
        "Multiforme erythema"
      ]
    },
    "precautions": [
      "**Cations:** Do not take with dairy, calcium, magnesium, iron, or antacids (chelation reduces absorption).",
      "**Secondary Infection:** Monitor for bacterial complications of flu."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Polyvalent cations (Calcium, Magnesium, Iron - reduce absorption)", "Live Flu Vaccine (antagonizes vaccine)"],
      "food": ["Dairy products reduce absorption."]
    },
    "pregnancyCategory": "Category C"
  },
  "balsalazide": {
    "name": "Balsalazide (Colazal)",
    "genericName": "Balsalazide Disodium",
    "formula": "C17H13N3Na2O6",
    "molecularWeight": "437.3 g/mol",
    "brandNames": ["Colazal"],
    "category": "GI Agent",
    "drugClass": "5-Aminosalicylate (5-ASA)",
    "pubchemCID": "5360373",
    "indications": "Ulcerative Colitis (Mild to Moderate active).",
    "moaSteps": [
      "Prodrug cleaved by colonic bacteria to release mesalamine (5-ASA).",
      "5-ASA blocks production of arachidonic acid metabolites (prostaglandins/leukotrienes) in the colon mucosa.",
      "Reduces local inflammation.",
      "Systemic absorption is minimal compared to sulfasalazine."
    ],
    "pharmacokinetics": {
      "absorption": "Prodrug <1% absorbed; Mesalamine acting locally.",
      "distribution": "Concentrates in colon.",
      "metabolism": "Colonic bacterial azoreduction.",
      "excretion": "Feces (65%). **Half-life: ~1 hour (Parent), 12 hours (Metabolites).**"
    },
    "dose": {
      "initialDose": "2.25 g PO three times daily",
      "maxDose": "6.75 g/day",
      "notes": "Take up to 8-12 weeks."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Abdominal pain",
        "Diarrhea",
        "Nausea"
      ],
      "serious": [
        "Renal Impairment",
        "Mesalamine-induced acute intolerance syndrome (worsening colitis)",
        "Hepatic failure (rare)"
      ]
    },
    "precautions": [
      "**Renal:** Monitor renal function; mesalamine can cause interstitial nephritis.",
      "**Intolerance:** Some patients develop cramping/fever/rash; stop drug.",
      "**Pyloric Stenosis:** Capsules may be retained in stomach."
    ],
    "contraindications": [
      "Hypersensitivity to salicylates (aspirin) or mesalamine"
    ],
    "interactions": {
      "drug": ["Azathioprine/6-MP (increased bone marrow suppression)", "Antacids"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "baricitinib": {
    "name": "Baricitinib (Olumiant)",
    "genericName": "Baricitinib",
    "formula": "C16H17N7O2S",
    "molecularWeight": "371.4 g/mol",
    "brandNames": ["Olumiant"],
    "category": "DMARD",
    "drugClass": "Janus Kinase (JAK) Inhibitor",
    "pubchemCID": "44205240",
    "indications": "Rheumatoid Arthritis, Alopecia Areata, COVID-19 (hospitalized).",
    "moaSteps": [
      "Inhibits Janus Kinase (JAK) 1 and 2 enzymes.",
      "Blocks the signaling pathway of various cytokines (interferons, interleukins).",
      "Prevents phosphorylation of STATs and gene transcription involved in inflammation and immune activation."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed.",
      "distribution": "50% protein bound.",
      "metabolism": "CYP3A4 (<10%).",
      "excretion": "Urine (75%). **Half-life: 12 hours.**"
    },
    "dose": {
      "initialDose": "2 mg PO once daily",
      "maxDose": "4 mg/day (Alopecia)",
      "notes": "Adjust for GFR < 60."
    },
    "adverseEffects": {
      "common": [
        "Upper respiratory infection",
        "Nausea",
        "Herpes Simplex/Zoster",
        "Acne"
      ],
      "serious": [
        "Serious Infections (TB, fungal) - BOXED WARNING",
        "Thrombosis (DVT/PE) - BOXED WARNING",
        "Malignancy (Lymphoma) - BOXED WARNING",
        "Major Adverse Cardiovascular Events (MACE) - BOXED WARNING"
      ]
    },
    "precautions": [
      "**Thrombosis:** Increased risk of DVT/PE. Avoid in high-risk patients.",
      "**Infection:** Screen for TB and Hepatitis B before starting.",
      "**GI Perforation:** Use caution in patients with diverticulitis."
    ],
    "contraindications": [
      "Pregnancy (Category D equivalent - fetal harm)",
      "Active serious infection"
    ],
    "interactions": {
      "drug": ["Probenecid (increases baricitinib levels - halve dose)", "Live Vaccines", "Biologic DMARDs (do not combine)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "basiliximab": {
    "name": "Basiliximab (Simulect)",
    "genericName": "Basiliximab",
    "formula": "C6946H10766N1866O2172S42",
    "molecularWeight": "144 kDa",
    "brandNames": ["Simulect"],
    "category": "Immunosuppressant",
    "drugClass": "Monoclonal Antibody (IL-2 Receptor Antagonist)",
    "pubchemCID": "None (Protein)",
    "indications": "Prophylaxis of acute organ rejection in renal transplantation.",
    "moaSteps": [
      "Chimeric (mouse/human) monoclonal antibody.",
      "Binds specifically to the alpha chain (CD25) of the IL-2 receptor on activated T-cells.",
      "Competitively inhibits IL-2 binding.",
      "Prevents T-cell proliferation and activation involved in rejection."
    ],
    "pharmacokinetics": {
      "absorption": "IV administration.",
      "distribution": "Confined to vascular space.",
      "metabolism": "Proteolytic catabolism.",
      "excretion": "Clearance is slow. **Half-life: 7.2 days (children) to 13.4 days (adults).**"
    },
    "dose": {
      "initialDose": "20 mg IV within 2 hours of surgery",
      "maxDose": "20 mg repeat dose 4 days later",
      "notes": "Two dose regimen."
    },
    "adverseEffects": {
      "common": [
        "Constipation",
        "Nausea",
        "Headache",
        "Abdominal pain"
      ],
      "serious": [
        "Severe Hypersensitivity (Anaphylaxis) - BOXED WARNING",
        "Cytokine Release Syndrome",
        "New onset diabetes (post-transplant)"
      ]
    },
    "precautions": [
      "**Hypersensitivity:** Can cause severe anaphylaxis. Have epinephrine ready.",
      "**Infection:** Adds to overall immunosuppression load."
    ],
    "contraindications": [
      "Known hypersensitivity"
    ],
    "interactions": {
      "drug": ["None specific (safely combined with cyclosporine/steroids)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "bempedoic_acid": {
    "name": "Bempedoic Acid (Nexletol)",
    "genericName": "Bempedoic Acid",
    "formula": "C19H36O5",
    "molecularWeight": "344.5 g/mol",
    "brandNames": ["Nexletol"],
    "category": "Antilipemic",
    "drugClass": "ACL Inhibitor",
    "pubchemCID": "10425558",
    "indications": "Hypercholesterolemia (HeFH) or established ASCVD requiring additional LDL lowering.",
    "moaSteps": [
      "Prodrug activated in the liver by ACSVL1.",
      "Inhibits Adenosine Triphosphate-Citrate Lyase (ACL).",
      "ACL is an enzyme upstream of HMG-CoA reductase in the cholesterol synthesis pathway.",
      "Reduces hepatic cholesterol synthesis and upregulates LDL receptors."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "99% protein bound.",
      "metabolism": "Glucuronidation (UGT2B7).",
      "excretion": "Urine (70%) and feces. **Half-life: 21 hours.**"
    },
    "dose": {
      "initialDose": "180 mg PO once daily",
      "maxDose": "180 mg/day",
      "notes": "Can be taken with or without food."
    },
    "adverseEffects": {
      "common": [
        "Upper respiratory infection",
        "Muscle spasms",
        "Back pain",
        "Abdominal pain"
      ],
      "serious": [
        "Hyperuricemia / Gout",
        "Tendon Rupture"
      ]
    },
    "precautions": [
      "**Hyperuricemia:** Inhibits renal tubular OAT2, increasing uric acid. Caution in gout history.",
      "**Tendon Rupture:** Risk of tendon injury (Achilles) reported.",
      "**Myopathy:** Risk increases if combined with high dose simvastatin."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Simvastatin (>20mg) and Pravastatin (>40mg) - Increased myopathy risk"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C (Avoid)"
  },
  "benralizumab": {
    "name": "Benralizumab (Fasenra)",
    "genericName": "Benralizumab",
    "formula": "C6494H10002N1710O2026S44",
    "molecularWeight": "148 kDa",
    "brandNames": ["Fasenra"],
    "category": "Asthma Biologic",
    "drugClass": "Monoclonal Antibody (IL-5 Receptor Antagonist)",
    "pubchemCID": "None (Protein)",
    "indications": "Severe Eosinophilic Asthma (Add-on maintenance).",
    "moaSteps": [
      "Binds directly to the alpha subunit of the IL-5 receptor on eosinophils.",
      "Prevents IL-5 signaling (critical for eosinophil survival).",
      "Induces apoptosis of eosinophils via Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC).",
      "Results in near-complete depletion of blood eosinophils."
    ],
    "pharmacokinetics": {
      "absorption": "Subcutaneous (59% bioavailability).",
      "distribution": "Central/Peripheral.",
      "metabolism": "Degraded by proteolysis.",
      "excretion": "Elimination half-life is long. **Half-life: ~15.5 days.**"
    },
    "dose": {
      "initialDose": "30 mg SubQ every 4 weeks for 3 doses",
      "maxDose": "Then 30 mg every 8 weeks",
      "notes": "Available as pre-filled syringe/pen."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Pharyngitis",
        "Fever",
        "Injection site reactions"
      ],
      "serious": [
        "Hypersensitivity / Anaphylaxis",
        "Helminth Infection (theoretical risk)"
      ]
    },
    "precautions": [
      "**Parasitic Infection:** Eosinophils fight parasites. Treat pre-existing helminth infections before starting.",
      "**Corticosteroid Withdrawal:** Do not abruptly stop systemic steroids upon initiation.",
      "**Hypersensitivity:** Rash, urticaria, angioedema reported."
    ],
    "contraindications": [
      "Hypersensitivity to benralizumab"
    ],
    "interactions": {
      "drug": ["None specific"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "benzocaine": {
    "name": "Benzocaine",
    "genericName": "Benzocaine",
    "formula": "C9H11NO2",
    "molecularWeight": "165.19 g/mol",
    "brandNames": ["Orajel", "Anbesol", "Cepacol"],
    "category": "Local Anesthetic",
    "drugClass": "Ester Anesthetic",
    "pubchemCID": "2337",
    "indications": "Topical pain relief (mouth ulcers, teething, sunburn, hemorrhoids).",
    "moaSteps": [
      "Reversibly binds to sodium channels in the neuronal membrane.",
      "Decreases permeability to sodium ions.",
      "Inhibits depolarization and blocks conduction of nerve impulses.",
      "Provides local numbness."
    ],
    "pharmacokinetics": {
      "absorption": "Minimal through intact skin; rapid through mucous membranes.",
      "distribution": "Local.",
      "metabolism": "Hydrolyzed by plasma cholinesterases.",
      "excretion": "Metabolites in urine. **Half-life: Unknown (Duration 10-20 min).**"
    },
    "dose": {
      "initialDose": "Apply thin layer to affected area up to 4 times daily",
      "maxDose": "Usage varies by product concentration (5-20%)",
      "notes": "Do not use over large areas."
    },
    "adverseEffects": {
      "common": [
        "Burning / Stinging",
        "Edema",
        "Erythema"
      ],
      "serious": [
        "Methemoglobinemia (Cyanosis, Hypoxia) - BOXED WARNING"
      ]
    },
    "precautions": [
      "**Methemoglobinemia:** Can convert hemoglobin to methemoglobin, impairing oxygen transport. Symptoms: gray skin, rapid heart rate, shortness of breath. Emergency.",
      "**Teething:** FDA warns against use in children < 2 years due to methemoglobinemia risk.",
      "**Broken Skin:** Increased absorption on abraded skin."
    ],
    "contraindications": [
      "History of methemoglobinemia",
      "Children < 2 years (OTC teething products)",
      "Hypersensitivity to ester anesthetics (PABA)"
    ],
    "interactions": {
      "drug": ["Sulfonamides (Benzocaine metabolizes to PABA, antagonizing sulfas)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "benzoyl_peroxide": {
    "name": "Benzoyl Peroxide",
    "genericName": "Benzoyl Peroxide",
    "formula": "C14H10O4",
    "molecularWeight": "242.23 g/mol",
    "brandNames": ["Benoxyl", "PanOxyl", "Proactiv"],
    "category": "Acne Agent",
    "drugClass": "Keratolytic / Antibacterial",
    "pubchemCID": "7187",
    "indications": "Acne Vulgaris.",
    "moaSteps": [
      "Releases free-radical oxygen species upon contact with skin.",
      "Oxidizes bacterial proteins.",
      "Bactericidal against *Cutibacterium acnes* (anaerobic).",
      "Has mild keratolytic and comedolytic activity (unclogs pores)."
    ],
    "pharmacokinetics": {
      "absorption": "Absorbed through skin (converted to benzoic acid).",
      "distribution": "Local.",
      "metabolism": "Rapidly metabolized in skin to benzoic acid.",
      "excretion": "Urine (as benzoate). **Half-life: N/A (Rapid conversion).**"
    },
    "dose": {
      "initialDose": "Apply 2.5% to 10% gel/wash once or twice daily",
      "maxDose": "10% formulation",
      "notes": "Start with lower concentration to minimize irritation."
    },
    "adverseEffects": {
      "common": [
        "Dryness / Peeling",
        "Erythema (Redness)",
        "Contact Dermatitis",
        "Bleaching of hair/fabric"
      ],
      "serious": [
        "Severe hypersensitivity (facial swelling)"
      ]
    },
    "precautions": [
      "**Bleaching:** Will bleach colored towels, sheets, and clothing. Wash hands after use.",
      "**Sun Sensitivity:** Increases sensitivity to sunlight; use sunscreen.",
      "**Irritation:** Do not combine with harsh exfoliants initially."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Tretinoin (Some formulations unstable if mixed)", "Dapsone topical (Orange skin discoloration)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "besifloxacin": {
    "name": "Besifloxacin (Besivance)",
    "genericName": "Besifloxacin",
    "formula": "C19H21ClN3O3",
    "molecularWeight": "393.8 g/mol",
    "brandNames": ["Besivance"],
    "category": "Antibiotic (Ophthalmic)",
    "drugClass": "Fluoroquinolone",
    "pubchemCID": "10176287",
    "indications": "Bacterial Conjunctivitis.",
    "moaSteps": [
      "Inhibits bacterial DNA gyrase and Topoisomerase IV.",
      "Prevents DNA replication, transcription, and repair.",
      "Broad spectrum bactericidal activity against ocular pathogens."
    ],
    "pharmacokinetics": {
      "absorption": "Minimal systemic absorption.",
      "distribution": "Local (Tears).",
      "metabolism": "N/A.",
      "excretion": "N/A. **Half-life: ~7 hours (in tears).**"
    },
    "dose": {
      "initialDose": "1 drop in affected eye(s) 3 times daily",
      "maxDose": "TID",
      "notes": "Use for 7 days."
    },
    "adverseEffects": {
      "common": [
        "Eye redness",
        "Blurred vision",
        "Eye pruritus",
        "Headache"
      ],
      "serious": [
        "Superinfection",
        "Hypersensitivity (rare with drops)"
      ]
    },
    "precautions": [
      "**Contact Lenses:** Do not wear contact lenses during active infection.",
      "**Prolonged Use:** May lead to fungal overgrowth.",
      "**Hypersensitivity:** Avoid if history of severe reaction to oral quinolones."
    ],
    "contraindications": [
      "Hypersensitivity to fluoroquinolones"
    ],
    "interactions": {
      "drug": ["None significant with drops"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "bexarotene": {
    "name": "Bexarotene (Targretin)",
    "genericName": "Bexarotene",
    "formula": "C24H28O2",
    "molecularWeight": "348.5 g/mol",
    "brandNames": ["Targretin"],
    "category": "Antineoplastic",
    "drugClass": "Retinoid (RXR Selective)",
    "pubchemCID": "82146",
    "indications": "Cutaneous T-Cell Lymphoma (CTCL).",
    "moaSteps": [
      "Selectively binds to Retinoid X Receptors (RXR).",
      "Forms heterodimers with other nuclear receptors (RAR, VDR, PPAR).",
      "Regulates gene expression involved in cell differentiation and apoptosis.",
      "Inhibits growth of tumor cell lines."
    ],
    "pharmacokinetics": {
      "absorption": "Single dose linear. Fat meal increases AUC.",
      "distribution": ">99% protein bound.",
      "metabolism": "Hepatic via CYP3A4.",
      "excretion": "Biliary/Feces. **Half-life: 7 hours.**"
    },
    "dose": {
      "initialDose": "300 mg/m2/day PO",
      "maxDose": "Based on BSA",
      "notes": "Take with food."
    },
    "adverseEffects": {
      "common": [
        "Hyperlipidemia (severe)",
        "Hypothyroidism",
        "Headache",
        "Rash / Dry skin",
        "Leukopenia"
      ],
      "serious": [
        "Acute Pancreatitis (due to triglycerides)",
        "Teratogenicity - BOXED WARNING",
        "Liver Failure"
      ]
    },
    "precautions": [
      "**Lipids:** Causes massive triglyceride elevation. Monitor fasting lipids weekly; start lipid-lowering agent (fibrates) prophylactically.",
      "**Hypothyroidism:** Rapidly lowers TSH/T4. Replace thyroid hormone.",
      "**Pregnancy:** Highly teratogenic (Category X). Two forms of contraception required."
    ],
    "contraindications": [
      "Pregnancy",
      "History of pancreatitis (if due to triglycerides)"
    ],
    "interactions": {
      "drug": ["Gemfibrozil (Increases bexarotene levels significantly - AVOID)", "CYP3A4 Inhibitors (Ketoconazole)", "Warfarin"],
      "food": ["Grapefruit juice (increases levels)"]
    },
    "pregnancyCategory": "Category X"
  },
  "bisacodyl": {
    "name": "Bisacodyl (Dulcolax)",
    "genericName": "Bisacodyl",
    "formula": "C22H19NO4",
    "molecularWeight": "361.4 g/mol",
    "brandNames": ["Dulcolax", "Correctol"],
    "category": "Laxative",
    "drugClass": "Stimulant Laxative",
    "pubchemCID": "2391",
    "indications": "Constipation, Bowel preparation before surgery/colonoscopy.",
    "moaSteps": [
      "Hydrolyzed by intestinal brush border enzymes.",
      "Directly stimulates nerve endings in the colonic mucosa.",
      "Increases intestinal motility (peristalsis).",
      "Promotes fluid accumulation in the colon."
    ],
    "pharmacokinetics": {
      "absorption": "Minimal (<5%). Acts locally.",
      "distribution": "Local.",
      "metabolism": "Hydrolyzed in gut.",
      "excretion": "Feces. **Half-life: 16 hours (metabolites).**"
    },
    "dose": {
      "initialDose": "5-15 mg PO once daily; 10 mg PR (Suppository)",
      "maxDose": "30 mg (Bowel prep)",
      "notes": "Do not crush or chew (enteric coated)."
    },
    "adverseEffects": {
      "common": [
        "Abdominal cramping",
        "Diarrhea",
        "Nausea",
        "Rectal burning (suppository)"
      ],
      "serious": [
        "Electrolyte Imbalance (Hypokalemia) with chronic use",
        "Atonic colon (Laxative dependence)"
      ]
    },
    "precautions": [
      "**Administration:** Swallow whole. Do not take within 1 hour of milk or antacids (dissolves coating -> gastric irritation).",
      "**Dependence:** Chronic use may lead to loss of normal bowel function.",
      "**Dehydration:** Ensure adequate fluid intake."
    ],
    "contraindications": [
      "Intestinal obstruction",
      "Severe abdominal pain of unknown origin",
      "Acute surgical abdomen"
    ],
    "interactions": {
      "drug": ["Antacids / H2 Blockers / PPIs (premature dissolution)", "Diuretics (additive hypokalemia)"],
      "food": ["Milk (premature dissolution)"]
    },
    "pregnancyCategory": "Category C"
  },
  "blinatumomab": {
    "name": "Blinatumomab (Blincyto)",
    "genericName": "Blinatumomab",
    "formula": "Protein",
    "molecularWeight": "54 kDa",
    "brandNames": ["Blincyto"],
    "category": "Antineoplastic",
    "drugClass": "Bispecific T-cell Engager (BiTE)",
    "pubchemCID": "None (Protein)",
    "indications": "B-cell precursor Acute Lymphoblastic Leukemia (ALL).",
    "moaSteps": [
      "Bispecific antibody construct.",
      "One arm binds CD19 on B-cells (tumor).",
      "Other arm binds CD3 on cytotoxic T-cells.",
      "Forming a synapse between the T-cell and tumor cell.",
      "Activates T-cells to release perforins/granzymes and lyse the tumor cell."
    ],
    "pharmacokinetics": {
      "absorption": "IV Continuous Infusion.",
      "distribution": "Vascular space.",
      "metabolism": "Catabolism into peptides.",
      "excretion": "Not cleared by kidneys/liver. **Half-life: 2.1 hours.**"
    },
    "dose": {
      "initialDose": "Continuous IV infusion for 28 days (dose ramps up)",
      "maxDose": "28 mcg/day",
      "notes": "Hospitalization required for initiation."
    },
    "adverseEffects": {
      "common": [
        "Pyrexia",
        "Headache",
        "Edema",
        "Tremor"
      ],
      "serious": [
        "Cytokine Release Syndrome (CRS) - BOXED WARNING",
        "Neurological Toxicity (Encephalopathy, Seizures) - BOXED WARNING",
        "Severe Infection",
        "Tumor Lysis Syndrome"
      ]
    },
    "precautions": [
      "**CRS:** Can be life-threatening. Monitor for fever, hypotension, hypoxia. Stop infusion and treat (Tocilizumab).",
      "**Neurotoxicity:** Confusion, disorientation, tremor, seizures. May require steroid treatment.",
      "**Preparation:** Very specific IV bag preparation requirements."
    ],
    "contraindications": [
      "Known hypersensitivity"
    ],
    "interactions": {
      "drug": ["None specific"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "bosutinib": {
    "name": "Bosutinib (Bosulif)",
    "genericName": "Bosutinib",
    "formula": "C26H29Cl2N5O3",
    "molecularWeight": "530.4 g/mol",
    "brandNames": ["Bosulif"],
    "category": "Antineoplastic",
    "drugClass": "Tyrosine Kinase Inhibitor (BCR-ABL)",
    "pubchemCID": "5328940",
    "indications": "Chronic Myelogenous Leukemia (CML) (Ph+).",
    "moaSteps": [
      "Inhibits the Bcr-Abl kinase that promotes CML cell growth.",
      "Also inhibits Src family kinases.",
      "Blocks signaling pathways responsible for leukemic cell proliferation.",
      "Effective against many imatinib-resistant mutations."
    ],
    "pharmacokinetics": {
      "absorption": "Food increases absorption.",
      "distribution": "94% protein bound.",
      "metabolism": "Hepatic via CYP3A4.",
      "excretion": "Feces (91%). **Half-life: 22.5 hours.**"
    },
    "dose": {
      "initialDose": "400 mg PO once daily",
      "maxDose": "600 mg/day",
      "notes": "Take with food."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea (very common)",
        "Nausea",
        "Rash",
        "Abdominal pain",
        "Fatigue"
      ],
      "serious": [
        "Hepatotoxicity (ALT/AST elevation)",
        "Fluid Retention (Pleural/Pericardial effusion)",
        "Myelosuppression",
        "Renal toxicity"
      ]
    },
    "precautions": [
      "**Diarrhea:** Manage with anti-diarrheals and hydration. Can be severe.",
      "**Liver:** Monitor hepatic function monthly for 3 months.",
      "**Myelosuppression:** Monitor CBC.",
      "**Fluid Retention:** Monitor weight and pulmonary symptoms."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inhibitors/Inducers", "PPIs (reduce absorption - use short acting antacids instead)"],
      "food": ["Grapefruit juice"]
    },
    "pregnancyCategory": "Category D"
  },
  "brentuximab": {
    "name": "Brentuximab Vedotin (Adcetris)",
    "genericName": "Brentuximab Vedotin",
    "formula": "Antibody-Drug Conjugate",
    "molecularWeight": "153 kDa",
    "brandNames": ["Adcetris"],
    "category": "Antineoplastic",
    "drugClass": "Antibody-Drug Conjugate (Anti-CD30)",
    "pubchemCID": "None (Protein)",
    "indications": "Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma (ALCL).",
    "moaSteps": [
      "Binds to CD30 on the surface of tumor cells.",
      "Internalized by endocytosis.",
      "Linker is cleaved by proteases in the lysosome.",
      "Releases MMAE (Monomethyl auristatin E), a microtubule disrupting agent.",
      "MMAE induces cell cycle arrest (G2/M) and apoptosis."
    ],
    "pharmacokinetics": {
      "absorption": "IV administration.",
      "distribution": "MMAE is 68-82% protein bound.",
      "metabolism": "MMAE via CYP3A4.",
      "excretion": "Feces. **Half-life: 4-6 days.**"
    },
    "dose": {
      "initialDose": "1.8 mg/kg IV every 3 weeks",
      "maxDose": "180 mg per dose",
      "notes": "Max 16 cycles."
    },
    "adverseEffects": {
      "common": [
        "Peripheral Neuropathy",
        "Fatigue",
        "Nausea",
        "Neutropenia"
      ],
      "serious": [
        "PML (Progressive Multifocal Leukoencephalopathy) - BOXED WARNING",
        "Severe Neutropenia",
        "Stevens-Johnson Syndrome",
        "Tumor Lysis Syndrome"
      ]
    },
    "precautions": [
      "**Neuropathy:** Cumulative risk; sensory and motor. Dose reduction may be needed.",
      "**PML:** Monitor for new neurological signs.",
      "**Infection:** Reactivation of latent infections possible."
    ],
    "contraindications": [
      "Concomitant use with Bleomycin (pulmonary toxicity)"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inhibitors (Increases MMAE toxicity)", "Bleomycin (Contraindicated)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "brinzolamide": {
    "name": "Brinzolamide (Azopt)",
    "genericName": "Brinzolamide",
    "formula": "C12H21N3O5S3",
    "molecularWeight": "383.5 g/mol",
    "brandNames": ["Azopt"],
    "category": "Glaucoma Agent",
    "drugClass": "Carbonic Anhydrase Inhibitor",
    "pubchemCID": "68844",
    "indications": "Open-angle Glaucoma, Ocular Hypertension.",
    "moaSteps": [
      "Inhibits carbonic anhydrase II in the ciliary processes of the eye.",
      "Decreases bicarbonate formation.",
      "Reduces sodium and fluid transport.",
      "Decreases aqueous humor secretion and lowers IOP."
    ],
    "pharmacokinetics": {
      "absorption": "Systemic absorption occurs; binds to RBCs.",
      "distribution": "Accumulates in RBCs.",
      "metabolism": "Hepatic.",
      "excretion": "Urine. **Half-life: 111 days (in RBCs).**"
    },
    "dose": {
      "initialDose": "1 drop in affected eye(s) three times daily",
      "maxDose": "TID",
      "notes": "Shake suspension well."
    },
    "adverseEffects": {
      "common": [
        "Blurred vision",
        "Bitter taste (Dysgeusia)",
        "Eye discomfort",
        "Foreign body sensation"
      ],
      "serious": [
        "Sulfonamide Hypersensitivity (SJS/TEN - rare but possible systemically)",
        "Corneal Edema"
      ]
    },
    "precautions": [
      "**Sulfa Allergy:** It is a sulfonamide; can cause systemic reactions in allergic patients.",
      "**Corneal Health:** Caution in patients with low endothelial cell counts.",
      "**Contact Lenses:** Remove before use (benzalkonium chloride)."
    ],
    "contraindications": [
      "Hypersensitivity to sulfonamides"
    ],
    "interactions": {
      "drug": ["Oral Carbonic Anhydrase Inhibitors (Additive systemic effects - not recommended)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "bromfenac": {
    "name": "Bromfenac (Prolensa)",
    "genericName": "Bromfenac",
    "formula": "C15H12BrNO3",
    "molecularWeight": "334.16 g/mol",
    "brandNames": ["Prolensa", "Bromsite"],
    "category": "Ophthalmic NSAID",
    "drugClass": "NSAID",
    "pubchemCID": "2473",
    "indications": "Postoperative inflammation and pain following cataract surgery.",
    "moaSteps": [
      "Inhibits cyclooxygenase 1 and 2 (COX-1/COX-2).",
      "Blocks prostaglandin synthesis in the eye.",
      "Reduces inflammation, pain, and miosis (pupil constriction) during surgery."
    ],
    "pharmacokinetics": {
      "absorption": "Systemic levels significant only with chronic use.",
      "distribution": "Local eye tissues.",
      "metabolism": "Unknown.",
      "excretion": "Unknown. **Half-life: Unknown (local effect).**"
    },
    "dose": {
      "initialDose": "1 drop daily starting 1 day prior to surgery",
      "maxDose": "Once daily",
      "notes": "Continue for 14 days post-op."
    },
    "adverseEffects": {
      "common": [
        "Eye irritation",
        "Foreign body sensation",
        "Eye redness"
      ],
      "serious": [
        "Corneal Melt / Perforation (with prolonged use)",
        "Slowed wound healing",
        "Bleeding tendency (ocular)"
      ]
    },
    "precautions": [
      "**Corneal Health:** NSAIDs can cause keratitis. Stop if corneal breakdown occurs.",
      "**Bleeding:** May increase bleeding time of ocular tissues during surgery.",
      "**Cross-sensitivity:** Caution in aspirin-sensitive patients."
    ],
    "contraindications": [
      "Hypersensitivity to NSAIDs/Aspirin",
      "Sulfite allergy (some formulations)"
    ],
    "interactions": {
      "drug": ["Topical Steroids (Delayed healing)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "bumetanide": {
    "name": "Bumetanide (Bumex)",
    "genericName": "Bumetanide",
    "formula": "C17H20N2O5S",
    "molecularWeight": "364.4 g/mol",
    "brandNames": ["Bumex"],
    "category": "Diuretic",
    "drugClass": "Loop Diuretic",
    "pubchemCID": "2471",
    "indications": "Edema associated with Heart Failure, Renal Disease, or Liver Disease.",
    "moaSteps": [
      "Inhibits the Na+/K+/2Cl- cotransporter in the ascending limb of the loop of Henle.",
      "Prevents reabsorption of sodium and chloride.",
      "Causes profound diuresis and natriuresis.",
      "40 times more potent than furosemide on a mg-for-mg basis."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid and almost complete (80-90%).",
      "distribution": "95% protein bound.",
      "metabolism": "Hepatic (oxidation).",
      "excretion": "Urine (80%). **Half-life: 1 to 1.5 hours.**"
    },
    "dose": {
      "initialDose": "0.5 - 2 mg PO/IV once daily",
      "maxDose": "10 mg/day",
      "notes": "1 mg Bumetanide ≈ 40 mg Furosemide."
    },
    "adverseEffects": {
      "common": [
        "Muscle cramps",
        "Dizziness",
        "Hypotension",
        "Headache"
      ],
      "serious": [
        "Severe Electrolyte Imbalance (Hypokalemia, Hypomagnesemia)",
        "Dehydration / Hypovolemia",
        "Ototoxicity (Hearing loss)",
        "Renal Failure"
      ]
    },
    "precautions": [
      "**Electrolytes:** Profound depletion of K+, Mg+, Na+. Monitor frequently.",
      "**Sulfa Allergy:** Structurally a sulfonamide; cross-reactivity is rare but possible.",
      "**Ototoxicity:** Risk with rapid IV injection or high doses."
    ],
    "contraindications": [
      "Anuria",
      "Hepatic coma",
      "Severe electrolyte depletion"
    ],
    "interactions": {
      "drug": ["Lithium (toxicity)", "Digoxin (toxicity via hypokalemia)", "NSAIDs (reduced diuretic effect)", "Aminoglycosides (ototoxicity)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "bupivacaine": {
    "name": "Bupivacaine (Marcaine)",
    "genericName": "Bupivacaine HCl",
    "formula": "C18H28N2O",
    "molecularWeight": "288.43 g/mol",
    "brandNames": ["Marcaine", "Exparel"],
    "category": "Anesthetic",
    "drugClass": "Amide Local Anesthetic",
    "pubchemCID": "2474",
    "indications": "Local/Regional Anesthesia (Nerve block, Epidural, Spinal, Infiltration).",
    "moaSteps": [
      "Blocks voltage-gated sodium channels in the neuronal membrane.",
      "Prevents depolarization and propagation of nerve impulses.",
      "Long duration of action.",
      "More sensory-selective than motor-selective at lower concentrations."
    ],
    "pharmacokinetics": {
      "absorption": "Systemic absorption rate depends on site/vascularity.",
      "distribution": "95% protein bound.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Urine. **Half-life: 2.7 hours (Adults); 8.1 hours (Neonates).**"
    },
    "dose": {
      "initialDose": "Varies by procedure (e.g., 0.25% or 0.5% solution)",
      "maxDose": "175 mg (without epi); 225 mg (with epi) per dose",
      "notes": "Do NOT use 0.75% for obstetrical anesthesia (cardiac arrest risk)."
    },
    "adverseEffects": {
      "common": [
        "Hypotension (Neuraxial)",
        "Bradycardia",
        "Nausea",
        "Urinary retention"
      ],
      "serious": [
        "Systemic Toxicity (LAST): Seizures, Arrhythmias, Cardiac Arrest",
        "Chondrolysis (intra-articular infusion)",
        "High Spinal (Respiratory paralysis)"
      ]
    },
    "precautions": [
      "**Cardiotoxicity:** More cardiotoxic than lidocaine. Resuscitation is difficult (lipid emulsion therapy required).",
      "**IV Injection:** Avoid accidental intravascular injection (aspirate before injecting).",
      "**Obstetrics:** 0.75% concentration banned for OB use."
    ],
    "contraindications": [
      "Hypersensitivity to amide anesthetics",
      "IV Regional Anesthesia (Bier Block) - Risk of cardiac arrest",
      "Paracervical block in obstetrics"
    ],
    "interactions": {
      "drug": ["Other local anesthetics (Additive toxicity)", "Beta-blockers (Increased risk of toxicity)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "busulfan": {
    "name": "Busulfan (Myleran)",
    "genericName": "Busulfan",
    "formula": "C6H14O6S2",
    "molecularWeight": "246.3 g/mol",
    "brandNames": ["Myleran", "Busulfex"],
    "category": "Antineoplastic",
    "drugClass": "Alkylating Agent",
    "pubchemCID": "2478",
    "indications": "Chronic Myelogenous Leukemia (CML), Bone Marrow Transplant Conditioning.",
    "moaSteps": [
      "Bifunctional alkylating agent.",
      "Forms DNA-DNA cross-links (guanine-adenine).",
      "Interferes with DNA replication and RNA transcription.",
      "Cytotoxic to non-dividing and dividing cells (cell cycle nonspecific)."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed orally.",
      "distribution": "Crosses blood-brain barrier.",
      "metabolism": "Hepatic (glutathione conjugation).",
      "excretion": "Urine. **Half-life: 2.5 hours.**"
    },
    "dose": {
      "initialDose": "CML: 60 mcg/kg/day PO",
      "maxDose": "Maintain WBC 10k-20k",
      "notes": "IV dosing for transplant is weight/AUC based."
    },
    "adverseEffects": {
      "common": [
        "Myelosuppression (severe)",
        "Nausea / Vomiting",
        "Mucositis",
        "Skin hyperpigmentation ('Busulfan tan')"
      ],
      "serious": [
        "Pulmonary Fibrosis ('Busulfan lung')",
        "Hepatic Veno-Occlusive Disease (VOD/SOS)",
        "Seizures (high dose)",
        "Secondary Malignancies"
      ]
    },
    "precautions": [
      "**Pulmonary Fibrosis:** Can occur years after therapy. Monitor for cough/dyspnea.",
      "**Seizures:** High IV doses penetrate CNS; seizure prophylaxis (Phenytoin/Levetiracetam) required.",
      "**Veno-Occlusive Disease:** High risk in transplant; potentially fatal liver toxicity."
    ],
    "contraindications": [
      "Failure to respond to previous course"
    ],
    "interactions": {
      "drug": ["Acetaminophen (Decreases clearance -> increased toxicity)", "Metronidazole (Increases toxicity)", "Itraconazole"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "carboplatin": {
    "name": "Carboplatin",
    "genericName": "Carboplatin",
    "formula": "C6H12N2O4Pt",
    "molecularWeight": "371.25 g/mol",
    "brandNames": ["Paraplatin"],
    "category": "Antineoplastic",
    "drugClass": "Platinum Coordination Complex",
    "pubchemCID": "426756",
    "indications": "Ovarian Cancer, Lung Cancer, Head and Neck Cancer.",
    "moaSteps": [
      "Forms reactive platinum complexes that bind to nucleophilic groups in DNA.",
      "Induces inter-strand and intra-strand DNA cross-links.",
      "Inhibits DNA replication and transcription.",
      "leads to cell cycle arrest and apoptosis."
    ],
    "pharmacokinetics": {
      "absorption": "IV administration.",
      "distribution": "Widely distributed.",
      "metabolism": "Minimally metabolized; degrades by aquation.",
      "excretion": "Renal. **Half-life: 2-3 hours (Initial); >24 hours (Terminal platinum).**"
    },
    "dose": {
      "initialDose": "Target AUC 4-6 (Calvert Formula)",
      "maxDose": "Dependent on GFR",
      "notes": "Dose = Target AUC x (GFR + 25)."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting (less than cisplatin)",
        "Weakness",
        "Alopecia (mild)"
      ],
      "serious": [
        "Bone Marrow Suppression (Thrombocytopenia - Dose Limiting) - BOXED WARNING",
        "Anaphylaxis (risk increases with more cycles)",
        "Nephrotoxicity / Neurotoxicity (less than cisplatin)"
      ]
    },
    "precautions": [
      "**Myelosuppression:** Thrombocytopenia is the main dose-limiting toxicity. Nadir is Day 21.",
      "**Hypersensitivity:** Risk increases after 6th or 7th cycle.",
      "**Renal Function:** Use Calvert formula to dose based on renal function to prevent toxicity."
    ],
    "contraindications": [
      "Severe bone marrow depression",
      "Significant bleeding",
      "Hypersensitivity to platinum compounds"
    ],
    "interactions": {
      "drug": ["Aminoglycosides (additive nephrotoxicity/ototoxicity)", "Taxanes (give taxane first to limit toxicity)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "carvedilol": {
    "name": "Carvedilol (Coreg)",
    "genericName": "Carvedilol",
    "formula": "C24H26N2O4",
    "molecularWeight": "406.5 g/mol",
    "brandNames": ["Coreg", "Coreg CR"],
    "category": "Antihypertensive / HF Agent",
    "drugClass": "Non-selective Beta Blocker / Alpha-1 Blocker",
    "pubchemCID": "2585",
    "indications": "Heart Failure (HFrEF), Hypertension, Left Ventricular Dysfunction post-MI.",
    "moaSteps": [
      "Non-selective beta-adrenergic blocking activity (beta-1 and beta-2).",
      "Alpha-1 adrenergic blocking activity.",
      "Alpha-blockade causes vasodilation and reduces peripheral vascular resistance.",
      "Beta-blockade prevents reflex tachycardia and reduces cardiac work.",
      "Also possesses antioxidant properties."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid absorption; food decreases rate but not extent.",
      "distribution": "98% protein bound.",
      "metabolism": "Extensive hepatic metabolism (CYP2D6/2C9).",
      "excretion": "Biliary/Feces. **Half-life: 7 to 10 hours.**"
    },
    "dose": {
      "initialDose": "3.125 mg PO twice daily (Heart Failure)",
      "maxDose": "25 mg BID (<85kg) or 50 mg BID (>85kg)",
      "notes": "Take with food to reduce orthostatic hypotension."
    },
    "adverseEffects": {
      "common": [
        "Dizziness / Lightheadedness",
        "Fatigue",
        "Hypotension",
        "Weight gain",
        "Bradycardia"
      ],
      "serious": [
        "Worsening Heart Failure (during initiation)",
        "Bronchospasm",
        "Masking Hypoglycemia",
        "Severe Bradycardia / Heart Block"
      ]
    },
    "precautions": [
      "**Heart Failure:** Initiation can transiently worsen fluid retention. Titrate slowly every 2 weeks.",
      "**Bronchospasm:** Contraindicated in asthma due to beta-2 blockade.",
      "**Diabetes:** May mask hypoglycemia symptoms and worsen glycemic control.",
      "**Surgery:** Do not withdraw abruptly prior to major surgery."
    ],
    "contraindications": [
      "Bronchial asthma or bronchospastic COPD",
      "2nd or 3rd degree AV block",
      "Severe bradycardia",
      "Decompensated heart failure requiring IV inotropes"
    ],
    "interactions": {
      "drug": ["CYP2D6 Inhibitors (Fluoxetine - increase levels)", "Digoxin (increased digoxin levels)", "Insulin (hypoglycemia masking)", "Clonidine"],
      "food": ["Take with food to minimize orthostasis."]
    },
    "pregnancyCategory": "Category C"
  },
  "cefazolin": {
    "name": "Cefazolin (Ancef)",
    "genericName": "Cefazolin",
    "formula": "C14H14N8O4S3",
    "molecularWeight": "454.5 g/mol",
    "brandNames": ["Ancef"],
    "category": "Antibiotic",
    "drugClass": "Cephalosporin (1st Generation)",
    "pubchemCID": "33255",
    "indications": "Surgical Prophylaxis, Skin/Soft Tissue Infections, Bacteremia, Endocarditis (MSSA).",
    "moaSteps": [
      "Binds to penicillin-binding proteins (PBPs).",
      "Inhibits bacterial cell wall synthesis.",
      "Excellent activity against Gram-positive cocci (Staph/Strep).",
      "Limited Gram-negative activity (Proteus, E. coli, Klebsiella)."
    ],
    "pharmacokinetics": {
      "absorption": "IV/IM only.",
      "distribution": "Widely distributed (poor CSF penetration).",
      "metabolism": "Not metabolized.",
      "excretion": "Excreted unchanged in urine. **Half-life: 1.8 hours.**"
    },
    "dose": {
      "initialDose": "1-2 g IV every 8 hours",
      "maxDose": "12 g/day",
      "notes": "Drug of choice for surgical prophylaxis."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea",
        "Rash",
        "Injection site phlebitis"
      ],
      "serious": [
        "Anaphylaxis",
        "Clostridioides difficile colitis",
        "Seizures (high doses in renal failure)",
        "Neutropenia (prolonged use)"
      ]
    },
    "precautions": [
      "**Penicillin Allergy:** Cross-reactivity is low (<5%), but avoid in patients with history of anaphylaxis to penicillin.",
      "**Renal Impairment:** Dose adjustment required to prevent seizure risk.",
      "**CNS Toxicity:** Seizures possible in renal failure."
    ],
    "contraindications": [
      "Hypersensitivity to cephalosporins"
    ],
    "interactions": {
      "drug": ["Probenecid (increases cefazolin levels)", "Warfarin (may increase INR)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "cefepime": {
    "name": "Cefepime (Maxipime)",
    "genericName": "Cefepime",
    "formula": "C19H24N6O5S2",
    "molecularWeight": "480.6 g/mol",
    "brandNames": ["Maxipime"],
    "category": "Antibiotic",
    "drugClass": "Cephalosporin (4th Generation)",
    "pubchemCID": "5479537",
    "indications": "Febrile Neutropenia, Hospital-Acquired Pneumonia, Severe Skin Infections, Intra-abdominal infections.",
    "moaSteps": [
      "Binds to penicillin-binding proteins (PBPs).",
      "Inhibits bacterial cell wall synthesis.",
      "Zwitterionic structure allows rapid penetration of Gram-negative outer membrane.",
      "Broadest spectrum cephalosporin (Pseudomonas coverage + Gram-positive)."
    ],
    "pharmacokinetics": {
      "absorption": "IV/IM only.",
      "distribution": "Widely distributed, including CSF.",
      "metabolism": "Minimal (15%).",
      "excretion": "Excreted unchanged in urine. **Half-life: 2 hours.**"
    },
    "dose": {
      "initialDose": "1-2 g IV every 8-12 hours",
      "maxDose": "6 g/day (Febrile neutropenia)",
      "notes": "Strict renal adjustment required."
    },
    "adverseEffects": {
      "common": [
        "Rash",
        "Diarrhea",
        "Positive Coombs test"
      ],
      "serious": [
        "Neurotoxicity (Encephalopathy, Seizures, Myoclonus) - especially in renal failure",
        "Anaphylaxis",
        "Clostridioides difficile colitis"
      ]
    },
    "precautions": [
      "**Neurotoxicity:** Serious life-threatening encephalopathy can occur, primarily in patients with renal impairment whose dose was not adjusted.",
      "**Superinfection:** Risk of C. diff or fungal infection.",
      "**Renal:** Adjust dose if CrCl < 60 mL/min."
    ],
    "contraindications": [
      "Hypersensitivity to cephalosporins"
    ],
    "interactions": {
      "drug": ["Aminoglycosides (Renal toxicity)", "Furosemide"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "ceftriaxone": {
    "name": "Ceftriaxone (Rocephin)",
    "genericName": "Ceftriaxone",
    "formula": "C18H18N8O7S3",
    "molecularWeight": "554.6 g/mol",
    "brandNames": ["Rocephin"],
    "category": "Antibiotic",
    "drugClass": "Cephalosporin (3rd Generation)",
    "pubchemCID": "5479530",
    "indications": "Community-Acquired Pneumonia, Meningitis, Gonorrhea, Pyelonephritis, Lyme Disease.",
    "moaSteps": [
      "Inhibits bacterial cell wall synthesis by binding to PBPs.",
      "High stability against beta-lactamases.",
      "Excellent Gram-negative coverage (except Pseudomonas) and good Strep/Staph coverage."
    ],
    "pharmacokinetics": {
      "absorption": "IV/IM only.",
      "distribution": "Excellent tissue/CSF penetration. High protein binding.",
      "metabolism": "Not metabolized.",
      "excretion": "Dual elimination: Urine (33-67%) and Bile/Feces. **Half-life: 5.8 to 8.7 hours (allows once-daily dosing).**"
    },
    "dose": {
      "initialDose": "1-2 g IV once daily",
      "maxDose": "4 g/day (2g q12h for Meningitis)",
      "notes": "Gonorrhea: Single 500mg IM dose."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea",
        "Injection site pain (IM)",
        "Eosinophilia",
        "Rash"
      ],
      "serious": [
        "Biliary Sludge / Pseudolithiasis",
        "Hemolytic Anemia",
        "Anaphylaxis",
        "Kernicterus (in neonates)"
      ]
    },
    "precautions": [
      "**Neonates:** Contraindicated in hyperbilirubinemic neonates (displaces bilirubin -> kernicterus) and with calcium-containing IVs (precipitation).",
      "**Biliary Sludge:** Can cause gallbladder precipitation/pain; usually reversible.",
      "**No Renal Adjustment:** Unique among cephalosporins; safe in renal failure without adjustment."
    ],
    "contraindications": [
      "Hypersensitivity to cephalosporins",
      "Neonates < 28 days old receiving calcium"
    ],
    "interactions": {
      "drug": ["Calcium-containing IV solutions (Precipitation in lungs/kidneys - FATAL in neonates)", "Warfarin (Increases INR)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "celecoxib": {
    "name": "Celecoxib (Celebrex)",
    "genericName": "Celecoxib",
    "formula": "C17H14F3N3O2S",
    "molecularWeight": "381.4 g/mol",
    "brandNames": ["Celebrex"],
    "category": "NSAID",
    "drugClass": "COX-2 Selective Inhibitor",
    "pubchemCID": "2662",
    "indications": "Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Acute Pain.",
    "moaSteps": [
      "Selectively inhibits Cyclooxygenase-2 (COX-2) enzyme.",
      "Inhibits prostaglandin synthesis involved in pain and inflammation.",
      "Spares COX-1 enzyme, maintaining gastric mucosal protection and platelet function."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "97% protein bound.",
      "metabolism": "Hepatic via CYP2C9.",
      "excretion": "Feces and urine. **Half-life: 11 hours.**"
    },
    "dose": {
      "initialDose": "100-200 mg PO daily or BID",
      "maxDose": "400 mg/day",
      "notes": "Use lowest effective dose for shortest duration."
    },
    "adverseEffects": {
      "common": [
        "Dyspepsia",
        "Hypertension",
        "Headache",
        "Diarrhea"
      ],
      "serious": [
        "Cardiovascular Thrombotic Events (MI/Stroke) - BOXED WARNING",
        "GI Bleeding / Ulceration - BOXED WARNING",
        "Renal Failure",
        "Sulfonamide Hypersensitivity (SJS/TEN)"
      ]
    },
    "precautions": [
      "**Cardiovascular Risk:** Increased risk of MI/Stroke compared to non-selective NSAIDs. Avoid in heart disease.",
      "**Sulfa Allergy:** Contains a sulfonamide moiety. Caution/Avoid in severe sulfa allergy.",
      "**GI Risk:** Lower than other NSAIDs, but still present.",
      "**CABG:** Contraindicated for post-op pain in CABG surgery."
    ],
    "contraindications": [
      "Active GI bleeding",
      "History of asthma/urticaria after NSAID/Aspirin use",
      "Severe sulfa allergy",
      "Post-CABG surgery"
    ],
    "interactions": {
      "drug": ["Warfarin (CYP2C9 interaction - Increases INR)", "Lithium (Toxicity)", "ACE Inhibitors (Renal toxicity)", "Fluconazole (Increases celecoxib levels)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C (Avoid >30 weeks - D)"
  },
  "cephalexin": {
    "name": "Cephalexin (Keflex)",
    "genericName": "Cephalexin",
    "formula": "C16H17N3O4S",
    "molecularWeight": "347.4 g/mol",
    "brandNames": ["Keflex"],
    "category": "Antibiotic",
    "drugClass": "Cephalosporin (1st Generation)",
    "pubchemCID": "27447",
    "indications": "Skin/Soft Tissue Infections (Cellulitis), UTIs, Strep Pharyngitis.",
    "moaSteps": [
      "Inhibits bacterial cell wall synthesis.",
      "Active against Gram-positive cocci (Staph aureus, Strep).",
      "Some activity against E. coli, Proteus, Klebsiella."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed.",
      "distribution": "Widely distributed (Poor CSF).",
      "metabolism": "Not metabolized.",
      "excretion": "Excreted unchanged in urine. **Half-life: 0.9 hours.**"
    },
    "dose": {
      "initialDose": "500 mg PO every 6-12 hours",
      "maxDose": "4 g/day",
      "notes": "Renal adjustment needed."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea",
        "Nausea",
        "Rash"
      ],
      "serious": [
        "Anaphylaxis",
        "Clostridioides difficile colitis",
        "Stevens-Johnson Syndrome"
      ]
    },
    "precautions": [
      "**Penicillin Allergy:** Cross-reactivity possible.",
      "**C. diff:** Consider if severe diarrhea develops.",
      "**Renal:** Accumulates in renal impairment."
    ],
    "contraindications": [
      "Hypersensitivity to cephalosporins"
    ],
    "interactions": {
      "drug": ["Probenecid (Increased levels)", "Metformin (Increased metformin levels - rare)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "cetirizine": {
    "name": "Cetirizine (Zyrtec)",
    "genericName": "Cetirizine HCl",
    "formula": "C21H25ClN2O3",
    "molecularWeight": "388.9 g/mol",
    "brandNames": ["Zyrtec"],
    "category": "Antihistamine",
    "drugClass": "H1 Receptor Antagonist (Second Generation)",
    "pubchemCID": "2678",
    "indications": "Allergic Rhinitis, Urticaria (Hives).",
    "moaSteps": [
      "Potent and selective antagonist of peripheral H1 receptors.",
      "Inhibits histamine-mediated allergic response.",
      "Minimally crosses blood-brain barrier (less sedation than 1st gen)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed.",
      "distribution": "93% protein bound.",
      "metabolism": "Minimal hepatic metabolism.",
      "excretion": "Urine (primary) and feces. **Half-life: 8.3 hours.**"
    },
    "dose": {
      "initialDose": "5-10 mg PO once daily",
      "maxDose": "10 mg/day",
      "notes": "Start with 5 mg in elderly."
    },
    "adverseEffects": {
      "common": [
        "Somnolence / Drowsiness (more than loratadine/fexofenadine)",
        "Dry mouth",
        "Fatigue"
      ],
      "serious": [
        "Hypersensitivity",
        "Aggressive reaction/Hallucinations (rare, peds)"
      ]
    },
    "precautions": [
      "**Sedation:** Can cause drowsiness in ~14% of patients; caution driving.",
      "**Alcohol:** Additive CNS depression.",
      "**Renal:** Dose adjust if GFR < 50."
    ],
    "contraindications": [
      "Hypersensitivity to cetirizine or hydroxyzine"
    ],
    "interactions": {
      "drug": ["CNS Depressants", "Theophylline"],
      "food": ["Food delays absorption but not extent."]
    },
    "pregnancyCategory": "Category B"
  },
  "ciprofloxacin": {
    "name": "Ciprofloxacin (Cipro)",
    "genericName": "Ciprofloxacin",
    "formula": "C17H18FN3O3",
    "molecularWeight": "331.3 g/mol",
    "brandNames": ["Cipro"],
    "category": "Antibiotic",
    "drugClass": "Fluoroquinolone",
    "pubchemCID": "2764",
    "indications": "UTIs, Pyelonephritis, Infectious Diarrhea, Intra-abdominal infections, Anthrax prophylaxis.",
    "moaSteps": [
      "Inhibits bacterial DNA gyrase (Topoisomerase II) and Topoisomerase IV.",
      "Prevents DNA replication, transcription, repair, and recombination.",
      "Bactericidal against broad range of Gram-negative bacteria (including Pseudomonas)."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed (70-80%).",
      "distribution": "Wide tissue distribution (prostate, lung).",
      "metabolism": "Partial hepatic metabolism.",
      "excretion": "Urine and feces. **Half-life: 4 hours.**"
    },
    "dose": {
      "initialDose": "250-500 mg PO every 12 hours",
      "maxDose": "1500 mg/day",
      "notes": "Do not take with dairy/calcium."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Diarrhea",
        "Dizziness",
        "Insomnia / Anxiety"
      ],
      "serious": [
        "Tendinitis / Tendon Rupture - BOXED WARNING",
        "Peripheral Neuropathy - BOXED WARNING",
        "CNS Effects (Seizures/Psychosis) - BOXED WARNING",
        "Exacerbation of Myasthenia Gravis - BOXED WARNING",
        "QT Prolongation",
        "Aortic Aneurysm Rupture"
      ]
    },
    "precautions": [
      "**Tendon Rupture:** Risk increased in elderly, steroid use, and transplant patients.",
      "**Cations:** Absorption reduced by antacids, iron, calcium, dairy.",
      "**Aortic Aneurysm:** Avoid in high-risk patients.",
      "**Pediatrics:** Generally avoided due to joint/cartilage concerns."
    ],
    "contraindications": [
      "Hypersensitivity to fluoroquinolones",
      "Concomitant tizanidine use"
    ],
    "interactions": {
      "drug": ["Tizanidine (Severe hypotension - Contraindicated)", "Warfarin (Increases INR)", "Theophylline (Toxicity)", "Antacids/Calcium (Blocks absorption)"],
      "food": ["Dairy products (calcium) block absorption."]
    },
    "pregnancyCategory": "Category C"
  },
  "cisplatin": {
    "name": "Cisplatin (Platinol)",
    "genericName": "Cisplatin",
    "formula": "Cl2H6N2Pt",
    "molecularWeight": "300.05 g/mol",
    "brandNames": ["Platinol"],
    "category": "Antineoplastic",
    "drugClass": "Platinum Coordination Complex",
    "pubchemCID": "84691",
    "indications": "Testicular Cancer, Ovarian Cancer, Bladder Cancer, Lung Cancer.",
    "moaSteps": [
      "Forms reactive platinum complexes that bind to DNA.",
      "Creates intra-strand and inter-strand DNA cross-links.",
      "Inhibits DNA replication and transcription.",
      "Induces apoptosis."
    ],
    "pharmacokinetics": {
      "absorption": "IV administration.",
      "distribution": "Widely distributed; high concentrations in kidneys/liver/prostate.",
      "metabolism": "Non-enzymatic inactivation.",
      "excretion": "Renal (prolonged retention). **Half-life: 20-30 min (Initial); >24 hours (Terminal platinum).**"
    },
    "dose": {
      "initialDose": "20 mg/m2 daily for 5 days per cycle",
      "maxDose": "100 mg/m2 per cycle",
      "notes": "Aggressive pre/post hydration required."
    },
    "adverseEffects": {
      "common": [
        "Severe Nausea / Vomiting (Highly emetogenic)",
        "Alopecia",
        "Magnesium/Potassium wasting"
      ],
      "serious": [
        "Nephrotoxicity (Dose limiting) - BOXED WARNING",
        "Ototoxicity (Hearing loss) - BOXED WARNING",
        "Peripheral Neuropathy - BOXED WARNING",
        "Myelosuppression - BOXED WARNING"
      ]
    },
    "precautions": [
      "**Nephrotoxicity:** Cumulative damage. Vigorous hydration (NS + Mannitol) essential before/after.",
      "**Ototoxicity:** High frequency hearing loss; often irreversible.",
      "**Emetogenic:** Requires triple antiemetic therapy (NK1 antagonist + 5-HT3 antagonist + Dexamethasone)."
    ],
    "contraindications": [
      "Pre-existing renal impairment",
      "Hearing impairment",
      "Myelosuppression",
      "Hypersensitivity to platinum"
    ],
    "interactions": {
      "drug": ["Aminoglycosides (Additive nephrotoxicity/ototoxicity)", "Loop Diuretics (Ototoxicity)", "Phenytoin (Decreased levels)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "citalopram": {
    "name": "Citalopram (Celexa)",
    "genericName": "Citalopram Hydrobromide",
    "formula": "C20H21FN2O",
    "molecularWeight": "324.4 g/mol",
    "brandNames": ["Celexa"],
    "category": "Antidepressant",
    "drugClass": "SSRI",
    "pubchemCID": "2771",
    "indications": "Major Depressive Disorder (MDD). Off-label: Anxiety, OCD.",
    "moaSteps": [
      "Selectively inhibits the reuptake of serotonin (5-HT) in the CNS.",
      "Increases synaptic serotonin levels.",
      "Enhances serotonergic neurotransmission.",
      "Has minimal effect on norepinephrine or dopamine reuptake."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed (80% bioavailability).",
      "distribution": "80% protein bound.",
      "metabolism": "Hepatic via CYP2C19 and CYP3A4.",
      "excretion": "Urine and feces. **Half-life: 35 hours.**"
    },
    "dose": {
      "initialDose": "20 mg PO once daily",
      "maxDose": "40 mg/day (20 mg in elderly)",
      "notes": "Doses >40mg restricted due to QT risk."
    },
    "adverseEffects": {
      "common": [
        "Nausea",
        "Dry mouth",
        "Somnolence / Insomnia",
        "Sexual dysfunction",
        "Sweating"
      ],
      "serious": [
        "Suicidal Ideation (Young adults) - BOXED WARNING",
        "QT Prolongation / Torsades de Pointes",
        "Serotonin Syndrome",
        "Hyponatremia (SIADH)"
      ]
    },
    "precautions": [
      "**QT Prolongation:** Dose-dependent. Max 20mg/day for age >60, liver dysfunction, or CYP2C19 poor metabolizers.",
      "**Serotonin Syndrome:** Caution with other serotonergic drugs.",
      "**Withdrawal:** Taper to avoid discontinuation syndrome (dizziness, paresthesia)."
    ],
    "contraindications": [
      "Concomitant MAOI use",
      "Congenital Long QT Syndrome",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["MAOIs (Fatal)", "QT prolonging drugs (Amiodarone, Antipsychotics)", "NSAIDs (Bleeding risk)", "Omeprazole (Increases citalopram levels)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "clarithromycin": {
    "name": "Clarithromycin (Biaxin)",
    "genericName": "Clarithromycin",
    "formula": "C38H69NO13",
    "molecularWeight": "748.0 g/mol",
    "brandNames": ["Biaxin", "Biaxin XL"],
    "category": "Antibiotic",
    "drugClass": "Macrolide",
    "pubchemCID": "84029",
    "indications": "H. pylori eradication, Pneumonia (CAP), Bronchitis, MAC prophylaxis, Strep Pharyngitis.",
    "moaSteps": [
      "Binds to the 50S ribosomal subunit of susceptible bacteria.",
      "Inhibits RNA-dependent protein synthesis.",
      "Bacteriostatic (Bactericidal at high concentrations).",
      "Active metabolite (14-OH clarithromycin) is also antimicrobial."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed (50% bioavailable due to first-pass).",
      "distribution": "Good tissue penetration.",
      "metabolism": "Hepatic metabolism (CYP3A4) to active metabolite.",
      "excretion": "Urine and Feces. **Half-life: 3-7 hours (Dose dependent).**"
    },
    "dose": {
      "initialDose": "250-500 mg PO twice daily",
      "maxDose": "1000 mg/day",
      "notes": "Metallic taste is common."
    },
    "adverseEffects": {
      "common": [
        "Dysgeusia (Metallic taste)",
        "Diarrhea / Nausea",
        "Abdominal pain",
        "Headache"
      ],
      "serious": [
        "QT Prolongation / Arrhythmias",
        "Hepatotoxicity",
        "Clostridioides difficile colitis",
        "Exacerbation of Myasthenia Gravis"
      ]
    },
    "precautions": [
      "**Cardiac:** Increased risk of cardiovascular mortality in patients with heart disease.",
      "**QT Prolongation:** Avoid in Long QT syndrome or with other QT drugs.",
      "**CYP3A4:** Potent inhibitor; many drug interactions.",
      "**Renal:** Reduce dose if CrCl < 30."
    ],
    "contraindications": [
      "History of cholestatic jaundice/hepatic dysfunction with prior use",
      "Concomitant use with statins (Simvastatin/Lovastatin), colchicine, or ergotamine",
      "QT prolongation history"
    ],
    "interactions": {
      "drug": ["Statins (Rhabdomyolysis risk - Contraindicated)", "Colchicine (Fatal toxicity)", "Warfarin (Increased INR)", "Digoxin"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "clindamycin": {
    "name": "Clindamycin (Cleocin)",
    "genericName": "Clindamycin",
    "formula": "C18H33ClN2O5S",
    "molecularWeight": "425.0 g/mol",
    "brandNames": ["Cleocin"],
    "category": "Antibiotic",
    "drugClass": "Lincosamide",
    "pubchemCID": "29029",
    "indications": "Anaerobic infections, Skin/Soft Tissue (MRSA), aspiration pneumonia, dental infections.",
    "moaSteps": [
      "Binds to the 50S ribosomal subunit of bacteria.",
      "Inhibits protein synthesis.",
      "Bacteriostatic.",
      "Excellent activity against anaerobes and Gram-positive cocci (including MRSA)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed (90%).",
      "distribution": "Good tissue/bone penetration. Poor CSF.",
      "metabolism": "Hepatic metabolism (CYP3A4).",
      "excretion": "Urine and feces. **Half-life: 3 hours.**"
    },
    "dose": {
      "initialDose": "150-450 mg PO every 6 hours",
      "maxDose": "1.8 g/day (Oral); 4.8 g/day (IV)",
      "notes": "Stay upright for 30 min to avoid esophagitis."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea (high incidence)",
        "Nausea",
        "Rash",
        "Esophagitis"
      ],
      "serious": [
        "Clostridioides difficile Colitis (High Risk) - BOXED WARNING",
        "Severe skin reactions (SJS/DRESS)",
        "Hepatotoxicity"
      ]
    },
    "precautions": [
      "**C. diff:** Associated with the highest risk of C. diff infection among antibiotics. Discontinue if significant diarrhea occurs.",
      "**Atopy:** Use caution in patients with history of asthma/allergies."
    ],
    "contraindications": [
      "Hypersensitivity to clindamycin or lincomycin"
    ],
    "interactions": {
      "drug": ["Neuromuscular Blockers (Enhanced blockade)", "Erythromycin (Antagonistic effect)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "clonazepam": {
    "name": "Clonazepam (Klonopin)",
    "genericName": "Clonazepam",
    "formula": "C15H10ClN3O3",
    "molecularWeight": "315.7 g/mol",
    "brandNames": ["Klonopin"],
    "category": "Anticonvulsant / Anxiolytic",
    "drugClass": "Benzodiazepine",
    "pubchemCID": "2802",
    "indications": "Panic Disorder, Seizure Disorders (Lennox-Gastaut, Absence).",
    "moaSteps": [
      "Binds to benzodiazepine receptors on the GABA-A receptor complex.",
      "Enhances the inhibitory effect of GABA.",
      "Increases chloride influx, hyperpolarizing neurons.",
      "Produces sedation, anxiolysis, and anticonvulsant effects."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "85% protein bound.",
      "metabolism": "Hepatic via CYP3A4.",
      "excretion": "Urine. **Half-life: 30 to 40 hours (Long acting).**"
    },
    "dose": {
      "initialDose": "0.25-0.5 mg PO twice daily",
      "maxDose": "4 mg/day (Panic); 20 mg/day (Seizure)",
      "notes": "Taper slowly."
    },
    "adverseEffects": {
      "common": [
        "Sedation / Drowsiness",
        "Ataxia / Dizziness",
        "Cognitive impairment",
        "Depression"
      ],
      "serious": [
        "Respiratory Depression (with opioids) - BOXED WARNING",
        "Abuse / Dependence - BOXED WARNING",
        "Suicidal Ideation",
        "Withdrawal Seizures"
      ]
    },
    "precautions": [
      "**Dependence:** Long-term use leads to physical dependence. Abrupt cessation can cause status epilepticus.",
      "**Opioids:** Concomitant use can result in profound sedation and death.",
      "**Saliva:** May increase salivation (issue in patients with difficulty swallowing)."
    ],
    "contraindications": [
      "Significant liver disease",
      "Acute narrow-angle glaucoma",
      "Hypersensitivity to benzodiazepines"
    ],
    "interactions": {
      "drug": ["Opioids (Fatal respiratory depression)", "Alcohol (Additive CNS depression)", "CYP3A4 Inhibitors"],
      "food": ["Alcohol"]
    },
    "pregnancyCategory": "Category D"
  },
  "clonidine": {
    "name": "Clonidine (Catapres)",
    "genericName": "Clonidine HCl",
    "formula": "C9H9Cl2N3",
    "molecularWeight": "230.1 g/mol",
    "brandNames": ["Catapres", "Kapvay", "Duraclon"],
    "category": "Antihypertensive / ADHD Agent",
    "drugClass": "Alpha-2 Adrenergic Agonist (Central)",
    "pubchemCID": "2803",
    "indications": "Hypertension, ADHD, Opioid Withdrawal (off-label).",
    "moaSteps": [
      "Stimulates alpha-2 adrenergic receptors in the brainstem (nucleus tractus solitarius).",
      "Reduces sympathetic outflow from the CNS.",
      "Decreases peripheral resistance, renal vascular resistance, heart rate, and blood pressure."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "Lipid soluble; crosses BBB.",
      "metabolism": "Hepatic (50%).",
      "excretion": "Urine (50% unchanged). **Half-life: 12 to 16 hours.**"
    },
    "dose": {
      "initialDose": "0.1 mg PO twice daily",
      "maxDose": "2.4 mg/day",
      "notes": "Transdermal patch applied weekly."
    },
    "adverseEffects": {
      "common": [
        "Dry mouth (Xerostomia)",
        "Drowsiness / Sedation",
        "Dizziness",
        "Constipation"
      ],
      "serious": [
        "Rebound Hypertension (upon abrupt cessation)",
        "Bradycardia / AV Block",
        "Hypotension"
      ]
    },
    "precautions": [
      "**Rebound Hypertension:** Sudden discontinuation can cause dangerous spike in BP, nervousness, and agitation. Taper over 2-4 days.",
      "**CNS Depression:** Additive with alcohol/sedatives.",
      "**Bradycardia:** Caution in patients with sinus node dysfunction."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Beta-blockers (Potentiates bradycardia; rebound HTN risk)", "CNS depressants", "TCAs (Decrease efficacy)"],
      "food": ["Alcohol"]
    },
    "pregnancyCategory": "Category C"
  },
  "clopidogrel": {
    "name": "Clopidogrel (Plavix)",
    "genericName": "Clopidogrel Bisulfate",
    "formula": "C16H16ClNO2S",
    "molecularWeight": "321.8 g/mol",
    "brandNames": ["Plavix"],
    "category": "Antiplatelet",
    "drugClass": "P2Y12 ADP Receptor Inhibitor (Thienopyridine)",
    "pubchemCID": "60606",
    "indications": "Acute Coronary Syndrome (ACS), Recent MI/Stroke, Peripheral Arterial Disease (PAD).",
    "moaSteps": [
      "Prodrug requiring hepatic bioactivation.",
      "Active metabolite irreversibly blocks the P2Y12 component of ADP receptors on the platelet surface.",
      "Prevents activation of the GPIIb/IIIa receptor complex.",
      "Reduces platelet aggregation for the life of the platelet (7-10 days)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed.",
      "distribution": "98% protein bound.",
      "metabolism": "Prodrug; activated by CYP2C19.",
      "excretion": "Urine and feces. **Half-life: 6 hours (Active metabolite: 30 mins, but effect is irreversible).**"
    },
    "dose": {
      "initialDose": "75 mg PO once daily",
      "maxDose": "300-600 mg Loading Dose (ACS)",
      "notes": "Poor Metabolizers of CYP2C19 show reduced response."
    },
    "adverseEffects": {
      "common": [
        "Bleeding / Bruising",
        "Dyspepsia",
        "Rash"
      ],
      "serious": [
        "Major Hemorrhage (GI, Intracranial)",
        "Thrombotic Thrombocytopenic Purpura (TTP)",
        "Hypersensitivity"
      ]
    },
    "precautions": [
      "**CYP2C19 Poor Metabolizers:** Boxed Warning. Reduced efficacy in these patients; consider alternative (Prasugrel/Ticagrelor).",
      "**Bleeding:** Stop 5 days prior to elective surgery.",
      "**TTP:** Rare but fatal; requires urgent plasmapheresis."
    ],
    "contraindications": [
      "Active pathological bleeding (Peptic ulcer, Intracranial hemorrhage)",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Omeprazole/Esomeprazole (Inhibit CYP2C19 -> reduce efficacy)", "NSAIDs/Warfarin (Bleeding risk)", "Repaglinide"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },"dabigatran": {
    "name": "Dabigatran (Pradaxa)",
    "genericName": "Dabigatran Etexilate",
    "formula": "C34H41N7O5",
    "molecularWeight": "627.7 g/mol",
    "brandNames": ["Pradaxa"],
    "category": "Anticoagulant",
    "drugClass": "Direct Thrombin Inhibitor (DOAC)",
    "pubchemCID": "9578572",
    "indications": "Stroke prevention in nonvalvular atrial fibrillation, DVT/PE treatment and prophylaxis.",
    "moaSteps": [
      "Prodrug converted to dabigatran.",
      "Specific, reversible, direct thrombin inhibitor.",
      "Inhibits both free and fibrin-bound thrombin.",
      "Prevents conversion of fibrinogen into fibrin, preventing clot formation."
    ],
    "pharmacokinetics": {
      "absorption": "Low bioavailability (3-7%). Acidic environment required.",
      "distribution": "35% protein bound.",
      "metabolism": "Hydrolysis by esterases (not CYP450).",
      "excretion": "Renal (80%). **Half-life: 12 to 17 hours.**"
    },
    "dose": {
      "initialDose": "150 mg PO twice daily",
      "maxDose": "300 mg/day",
      "notes": "Swallow whole; do not open capsules (increases bioavailability by 75% -> bleeding risk)."
    },
    "adverseEffects": {
      "common": [
        "Dyspepsia / Gastritis",
        "Bleeding (Gingival, Epistaxis)",
        "Abdominal pain"
      ],
      "serious": [
        "Major Hemorrhage (GI, Intracranial)",
        "Thrombosis (if stopped prematurely) - BOXED WARNING",
        "Spinal/Epidural Hematoma"
      ]
    },
    "precautions": [
      "**Gastritis:** Tartaric acid core causes significant dyspepsia. Take with food.",
      "**Moisture:** Keep in original bottle. Discard 4 months after opening.",
      "**Reversal:** Idarucizumab (Praxbind) is the specific antidote.",
      "**Renal:** Contraindicated if CrCl < 15 (or < 30 in some guidelines)."
    ],
    "contraindications": [
      "Active pathological bleeding",
      "Mechanical prosthetic heart valve",
      "Severe renal impairment"
    ],
    "interactions": {
      "drug": ["P-gp Inhibitors (Dronedarone, Ketoconazole - Increase levels)", "P-gp Inducers (Rifampin - Decrease levels)", "Antiplatelets (Bleeding)"],
      "food": ["None significant"]
    },
    "pregnancyCategory": "Category C"
  },
  "dapagliflozin": {
    "name": "Dapagliflozin (Farxiga)",
    "genericName": "Dapagliflozin",
    "formula": "C21H25ClO6",
    "molecularWeight": "408.9 g/mol",
    "brandNames": ["Farxiga"],
    "category": "Antidiabetic",
    "drugClass": "SGLT2 Inhibitor",
    "pubchemCID": "9887712",
    "indications": "Type 2 Diabetes, Heart Failure (HFrEF and HFpEF), Chronic Kidney Disease.",
    "moaSteps": [
      "Inhibits Sodium-Glucose Cotransporter 2 (SGLT2) in the proximal renal tubule.",
      "Reduces reabsorption of filtered glucose.",
      "Promotes urinary glucose excretion (glycosuria).",
      "Also causes osmotic diuresis and natriuresis (benefits in HF)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed (78% bioavailability).",
      "distribution": "91% protein bound.",
      "metabolism": "UGT1A9 glucuronidation.",
      "excretion": "Urine (75%) and Feces. **Half-life: 12.9 hours.**"
    },
    "dose": {
      "initialDose": "5-10 mg PO once daily",
      "maxDose": "10 mg/day",
      "notes": "Requires eGFR > 25-30 mL/min for initiation."
    },
    "adverseEffects": {
      "common": [
        "Genital Mycotic Infections",
        "Urinary Tract Infections",
        "Polyuria",
        "Back pain"
      ],
      "serious": [
        "Diabetic Ketoacidosis (Euglycemic)",
        "Fournier's Gangrene",
        "Volume Depletion / Hypotension",
        "Pyelonephritis"
      ]
    },
    "precautions": [
      "**Ketoacidosis:** Stop before surgery (3 days) to prevent euglycemic DKA.",
      "**Hydration:** Ensure adequate fluid intake to prevent hypotension.",
      "**Hygiene:** Advise on genital hygiene to prevent yeast infections."
    ],
    "contraindications": [
      "Dialysis patients",
      "History of hypersensitivity"
    ],
    "interactions": {
      "drug": ["Insulin/Sulfonylureas (Hypoglycemia risk)", "Diuretics (Hypotension)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "daptomycin": {
    "name": "Daptomycin (Cubicin)",
    "genericName": "Daptomycin",
    "formula": "C72H101N17O26",
    "molecularWeight": "1620.7 g/mol",
    "brandNames": ["Cubicin"],
    "category": "Antibiotic",
    "drugClass": "Cyclic Lipopeptide",
    "pubchemCID": "16129629",
    "indications": "Complicated Skin/Soft Tissue Infections (MRSA), Staph aureus Bacteremia, Right-sided Endocarditis.",
    "moaSteps": [
      "Binds to bacterial cell membranes in a calcium-dependent manner.",
      "Causes rapid depolarization of membrane potential.",
      "Leads to potassium efflux.",
      "Inhibits DNA/RNA/protein synthesis causing cell death.",
      "Ineffective in lungs (inactivated by surfactant)."
    ],
    "pharmacokinetics": {
      "absorption": "IV only.",
      "distribution": "Confined primarily to extracellular fluid. 92% protein bound.",
      "metabolism": "Minimal.",
      "excretion": "Renal. **Half-life: 8 to 9 hours.**"
    },
    "dose": {
      "initialDose": "4-6 mg/kg IV every 24 hours",
      "maxDose": "10-12 mg/kg (High dose)",
      "notes": "Do NOT use for Pneumonia."
    },
    "adverseEffects": {
      "common": [
        "Injection site reaction",
        "Headache",
        "Diarrhea"
      ],
      "serious": [
        "Rhabdomyolysis / Myopathy",
        "Eosinophilic Pneumonia",
        "Peripheral Neuropathy",
        "C. diff colitis"
      ]
    },
    "precautions": [
      "**Myopathy:** CPK monitoring required weekly. Discontinue if CPK > 5x ULN with symptoms or > 10x ULN without.",
      "**Pneumonia:** Inactivated by pulmonary surfactant; do not use for CAP/HAP.",
      "**Renal:** Dose adjust if CrCl < 30 (Every 48h dosing)."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Statins (Additive risk of myopathy - hold statin during therapy)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "darunavir": {
    "name": "Darunavir (Prezista)",
    "genericName": "Darunavir",
    "formula": "C27H37N3O7S",
    "molecularWeight": "547.7 g/mol",
    "brandNames": ["Prezista"],
    "category": "Antiretroviral",
    "drugClass": "Protease Inhibitor (PI)",
    "pubchemCID": "213039",
    "indications": "Treatment of HIV-1 infection (must be boosted).",
    "moaSteps": [
      "Inhibits HIV-1 protease.",
      "Prevents cleavage of Gag-Pol polyprotein precursors.",
      "Results in the formation of immature, non-infectious viral particles.",
      "High genetic barrier to resistance."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed with food.",
      "distribution": "95% protein bound.",
      "metabolism": "Extensive hepatic metabolism (CYP3A4).",
      "excretion": "Feces. **Half-life: 15 hours (with Ritonavir boosting).**"
    },
    "dose": {
      "initialDose": "800 mg + 100 mg Ritonavir (or 150mg Cobicistat) PO once daily",
      "maxDose": "600/100 mg BID (Treatment experienced)",
      "notes": "Must be boosted."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea",
        "Nausea",
        "Headache",
        "Rash"
      ],
      "serious": [
        "Hepatotoxicity",
        "Severe Skin Reactions (SJS/TEN)",
        "Hyperglycemia / Diabetes",
        "Hyperlipidemia"
      ]
    },
    "precautions": [
      "**Sulfa Allergy:** Contains a sulfonamide moiety; use with caution.",
      "**Hepatotoxicity:** Monitor LFTs, especially in Hep B/C co-infection.",
      "**Interactions:** Potent CYP3A4 inhibitor (when boosted)."
    ],
    "contraindications": [
      "Severe hepatic impairment",
      "Co-administration with drugs highly dependent on CYP3A4 (Simvastatin, Lovastatin, Alfuzosin)"
    ],
    "interactions": {
      "drug": ["Statins (Toxicity)", "Fluticasone (Cushing's syndrome)", "Rifampin"],
      "food": ["Must take with food."]
    },
    "pregnancyCategory": "Category C"
  },
  "denosumab": {
    "name": "Denosumab (Prolia, Xgeva)",
    "genericName": "Denosumab",
    "formula": "Human IgG2 monoclonal antibody",
    "molecularWeight": "147 kDa",
    "brandNames": ["Prolia", "Xgeva"],
    "category": "Bone Resorption Inhibitor",
    "drugClass": "RANK Ligand Inhibitor",
    "pubchemCID": "None (Protein)",
    "indications": "Osteoporosis (Prolia), Bone metastases from solid tumors (Xgeva), Giant cell tumor of bone.",
    "moaSteps": [
      "Binds to RANKL (Receptor Activator of Nuclear Factor kappa-B Ligand).",
      "Prevents RANKL from binding to RANK on osteoclast precursors.",
      "Inhibits osteoclast formation, function, and survival.",
      "Decreases bone resorption and increases bone mass."
    ],
    "pharmacokinetics": {
      "absorption": "Subcutaneous.",
      "distribution": "Lymphatic/Vascular.",
      "metabolism": "Reticuloendothelial system degradation.",
      "excretion": "None (clearance independent of kidney/liver). **Half-life: ~25 to 28 days.**"
    },
    "dose": {
      "initialDose": "Prolia: 60 mg SubQ every 6 months",
      "maxDose": "Xgeva: 120 mg SubQ every 4 weeks",
      "notes": "Ensure Calcium/Vitamin D sufficiency."
    },
    "adverseEffects": {
      "common": [
        "Back pain",
        "Extremity pain",
        "Musculoskeletal pain",
        "Cystitis"
      ],
      "serious": [
        "Osteonecrosis of the Jaw (ONJ)",
        "Atypical Femoral Fracture",
        "Hypocalcemia (Severe)",
        "Serious Infections (Skin/Cellulitis)"
      ]
    },
    "precautions": [
      "**Hypocalcemia:** Pre-existing hypocalcemia must be corrected. Higher risk in severe renal impairment.",
      "**Dental:** Dental exam required prior to start. ONJ risk increases with duration.",
      "**Rebound:** Discontinuation leads to rapid bone loss and risk of vertebral fractures. Transition to bisphosphonate recommended."
    ],
    "contraindications": [
      "Hypocalcemia",
      "Pregnancy (Fetal harm)",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Immunosuppressants (Increased infection risk)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category X (Prolia); D (Xgeva)"
  },
  "desmopressin": {
    "name": "Desmopressin (DDAVP)",
    "genericName": "Desmopressin Acetate",
    "formula": "C46H64N14O12S2",
    "molecularWeight": "1069.2 g/mol",
    "brandNames": ["DDAVP", "Nocdurna", "Stimate"],
    "category": "Hormone",
    "drugClass": "Vasopressin Analog",
    "pubchemCID": "27991",
    "indications": "Diabetes Insipidus (Central), Nocturnal Enuresis, Hemophilia A / von Willebrand Disease (to increase Factor VIII/vWF).",
    "moaSteps": [
      "Synthetic analog of arginine vasopressin (ADH).",
      "Selective agonist at V2 receptors in renal collecting ducts.",
      "Increases water reabsorption (antidiuretic).",
      "Also stimulates release of Factor VIII and vWF from endothelial cells."
    ],
    "pharmacokinetics": {
      "absorption": "Oral (low bioavail), Intranasal, IV.",
      "distribution": "Does not cross BBB.",
      "metabolism": "Minimal.",
      "excretion": "Urine. **Half-life: 1.5 to 2.5 hours (IV/IN); prolonged effect.**"
    },
    "dose": {
      "initialDose": "0.1-0.2 mg PO daily/BID",
      "maxDose": "1.2 mg/day (Diabetes Insipidus)",
      "notes": "Fluid restriction recommended 1 hour before and 8 hours after dose."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Nausea",
        "Flushing",
        "Rhinitis (Nasal spray)"
      ],
      "serious": [
        "Hyponatremia / Water Intoxication (Seizures/Coma)",
        "Thrombosis (rare)"
      ]
    },
    "precautions": [
      "**Hyponatremia:** Boxed Warning. Can cause fatal water intoxication. Restrict fluid intake, especially in elderly/children.",
      "**Intranasal:** Not recommended for enuresis (high hyponatremia risk).",
      "**Cardiac:** Caution in patients susceptible to fluid overload."
    ],
    "contraindications": [
      "Hyponatremia or history of",
      "Moderate-Severe renal impairment (CrCl < 50)",
      "Heart Failure (uncontrolled)"
    ],
    "interactions": {
      "drug": ["Loop diuretics (Hyponatremia)", "NSAIDs (Water retention)", "TCAs/SSRIs (Increase hyponatremia risk)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "desvenlafaxine": {
    "name": "Desvenlafaxine (Pristiq)",
    "genericName": "Desvenlafaxine Succinate",
    "formula": "C16H25NO2",
    "molecularWeight": "263.4 g/mol",
    "brandNames": ["Pristiq", "Khedezla"],
    "category": "Antidepressant",
    "drugClass": "SNRI",
    "pubchemCID": "125017",
    "indications": "Major Depressive Disorder (MDD).",
    "moaSteps": [
      "Active metabolite of venlafaxine (O-desmethylvenlafaxine).",
      "Inhibits the reuptake of serotonin and norepinephrine.",
      "Does not require CYP2D6 for activation (unlike venlafaxine).",
      "More consistent plasma levels across metabolizer types."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed (80%).",
      "distribution": "30% protein bound.",
      "metabolism": "Conjugation (UGT). CYP3A4 (Minor).",
      "excretion": "Urine. **Half-life: 11 hours.**"
    },
    "dose": {
      "initialDose": "50 mg PO once daily",
      "maxDose": "100 mg/day (little benefit > 50mg)",
      "notes": "Ghost tablet in stool."
    },
    "adverseEffects": {
      "common": [
        "Nausea",
        "Dizziness",
        "Insomnia",
        "Sweating (Hyperhidrosis)",
        "Sexual dysfunction"
      ],
      "serious": [
        "Suicidality (Young adults) - BOXED WARNING",
        "Serotonin Syndrome",
        "Hypertension",
        "Seizures"
      ]
    },
    "precautions": [
      "**Hypertension:** Dose-dependent increase in diastolic BP. Monitor BP.",
      "**Discontinuation:** Severe withdrawal syndrome ('Brain zaps'). Taper slowly.",
      "**Ghost Tablet:** Inert matrix shell may appear in stool; drug is absorbed."
    ],
    "contraindications": [
      "MAOI use within 14 days",
      "Hypersensitivity to venlafaxine"
    ],
    "interactions": {
      "drug": ["MAOIs (Fatal)", "Antiplatelets/Anticoagulants (Bleeding risk)", "Serotonergic agents"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "dexamethasone": {
    "name": "Dexamethasone (Decadron)",
    "genericName": "Dexamethasone",
    "formula": "C22H29FO5",
    "molecularWeight": "392.5 g/mol",
    "brandNames": ["Decadron", "DexPak"],
    "category": "Corticosteroid",
    "drugClass": "Glucocorticoid (Long-acting)",
    "pubchemCID": "5743",
    "indications": "Inflammation, Cerebral Edema, Multiple Myeloma, CINV prophylaxis, COVID-19 (Severe).",
    "moaSteps": [
      "Potent synthetic glucocorticoid (25x potency of hydrocortisone).",
      "Zero mineralocorticoid activity (no salt retention).",
      "Inhibits inflammatory cytokines and cell migration.",
      "Induces apoptosis in myeloma cells."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Widely distributed.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Urine. **Half-life: 4 hours (Plasma); 36-54 hours (Biologic).**"
    },
    "dose": {
      "initialDose": "0.75 - 9 mg PO/IV daily",
      "maxDose": "40 mg (High dose pulse)",
      "notes": "Take with food."
    },
    "adverseEffects": {
      "common": [
        "Insomnia / Agitation",
        "Hyperglycemia",
        "Increased appetite",
        "Fluid retention"
      ],
      "serious": [
        "Adrenal Suppression",
        "Peptic Ulcer",
        "Psychosis ('Steroid rage')",
        "Osteoporosis",
        "Infection masking"
      ]
    },
    "precautions": [
      "**Adrenal Axis:** Suppression occurs with chronic use. Taper slowly.",
      "**Diabetes:** Significant hyperglycemia.",
      "**Infection:** Use caution in active infection.",
      "**Vaccines:** Avoid live vaccines."
    ],
    "contraindications": [
      "Systemic fungal infections",
      "Live vaccines (if immunosuppressed)",
      "Cerebral malaria"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inducers (Phenytoin - Decrease levels)", "NSAIDs (GI Bleed risk)", "Warfarin"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "dexmedetomidine": {
    "name": "Dexmedetomidine (Precedex)",
    "genericName": "Dexmedetomidine",
    "formula": "C13H16N2",
    "molecularWeight": "200.3 g/mol",
    "brandNames": ["Precedex"],
    "category": "Sedative",
    "drugClass": "Alpha-2 Adrenergic Agonist",
    "pubchemCID": "5311068",
    "indications": "Sedation in ICU (intubated), Procedural sedation.",
    "moaSteps": [
      "Selective alpha-2 adrenergic agonist.",
      "Acts on the Locus Coeruleus to induce sedation resembling natural sleep.",
      "Provides analgesia and anxiolysis.",
      "Minimal respiratory depression (unlike propofol/opioids)."
    ],
    "pharmacokinetics": {
      "absorption": "IV (also Intranasal/Sublingual).",
      "distribution": "94% protein bound.",
      "metabolism": "Hepatic (Glucuronidation/CYP2A6).",
      "excretion": "Urine. **Half-life: 2 to 2.5 hours.**"
    },
    "dose": {
      "initialDose": "1 mcg/kg loading dose (optional)",
      "maxDose": "0.2 - 1.4 mcg/kg/hr infusion",
      "notes": "Loading dose often omitted to prevent hypotension."
    },
    "adverseEffects": {
      "common": [
        "Hypotension",
        "Bradycardia",
        "Dry mouth"
      ],
      "serious": [
        "Severe Bradycardia / Sinus Arrest",
        "Transient Hypertension (during loading dose)"
      ]
    },
    "precautions": [
      "**Cardiovascular:** Can cause significant bradycardia and hypotension. Caution in heart block or high vagal tone.",
      "**Transient HTN:** Rapid bolus activates peripheral alpha-2B receptors causing vasoconstriction.",
      "**Withdrawal:** Tachycardia/HTN possible after stopping prolonged (>24h) infusion."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Anesthetics/Sedatives/Opioids (Significant enhancement of effect - reduce doses)", "Beta-blockers (Additive bradycardia)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "diazepam": {
    "name": "Diazepam (Valium)",
    "genericName": "Diazepam",
    "formula": "C16H13ClN2O",
    "molecularWeight": "284.7 g/mol",
    "brandNames": ["Valium", "Diastat"],
    "category": "Anxiolytic / Anticonvulsant",
    "drugClass": "Benzodiazepine (Long-acting)",
    "pubchemCID": "3016",
    "indications": "Anxiety, Muscle Spasm, Alcohol Withdrawal, Status Epilepticus.",
    "moaSteps": [
      "Potentiates GABA via binding to benzodiazepine receptors on GABA-A complex.",
      "Increases frequency of chloride channel opening.",
      "Hyperpolarizes neurons, inhibiting firing.",
      "Strong muscle relaxant properties."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Highly lipid soluble; huge volume of distribution.",
      "metabolism": "Hepatic (CYP3A4/2C19) to active metabolites (Desmethyldiazepam).",
      "excretion": "Urine. **Half-life: 20-50 hours (Parent); up to 100 hours (Metabolites).**"
    },
    "dose": {
      "initialDose": "2-10 mg PO 2-4 times daily",
      "maxDose": "40 mg/day (Oral); Higher in Status Epilepticus",
      "notes": "Rectal gel (Diastat) for seizures."
    },
    "adverseEffects": {
      "common": [
        "Sedation / Drowsiness",
        "Fatigue",
        "Ataxia / Muscle weakness",
        "Amnesia"
      ],
      "serious": [
        "Respiratory Depression (with opioids) - BOXED WARNING",
        "Dependence / Abuse",
        "Withdrawal Seizures",
        "Paradoxical Aggression"
      ]
    },
    "precautions": [
      "**Accumulation:** Active metabolites accumulate, especially in elderly/obese. Prolonged sedation ('Hangover').",
      "**Phlebitis:** IV diazepam precipitates easily; use large vein or emulsion formulation.",
      "**Elderly:** Beers Criteria drug; avoid due to falls/confusion."
    ],
    "contraindications": [
      "Severe respiratory insufficiency",
      "Acute narrow-angle glaucoma",
      "Myasthenia Gravis",
      "Sleep apnea"
    ],
    "interactions": {
      "drug": ["Opioids (Fatal)", "Alcohol", "CYP Inhibitors"],
      "food": ["Grapefruit juice"]
    },
    "pregnancyCategory": "Category D"
  },
  "diclofenac": {
    "name": "Diclofenac (Voltaren)",
    "genericName": "Diclofenac Sodium",
    "formula": "C14H11Cl2NO2",
    "molecularWeight": "296.1 g/mol",
    "brandNames": ["Voltaren", "Flector", "Cambia"],
    "category": "NSAID",
    "drugClass": "Acetic Acid Derivative",
    "pubchemCID": "3033",
    "indications": "Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Acute Pain.",
    "moaSteps": [
      "Inhibits COX-1 and COX-2 enzymes.",
      "Decreases production of prostaglandins.",
      "More COX-2 selective than ibuprofen/naproxen (approaching celecoxib).",
      "Potent anti-inflammatory and analgesic."
    ],
    "pharmacokinetics": {
      "absorption": "Complete but 50% first-pass metabolism.",
      "distribution": "Synovial fluid concentrations exceed plasma levels.",
      "metabolism": "Hepatic (CYP2C9).",
      "excretion": "Urine and Bile. **Half-life: 2 hours.**"
    },
    "dose": {
      "initialDose": "50 mg PO 2-3 times daily",
      "maxDose": "150-200 mg/day",
      "notes": "Topical gel (1%) safer for elderly."
    },
    "adverseEffects": {
      "common": [
        "Dyspepsia",
        "Abdominal pain",
        "Fluid retention"
      ],
      "serious": [
        "Cardiovascular Thrombosis (MI/Stroke) - Highest risk among non-selective NSAIDs - BOXED WARNING",
        "GI Bleeding / Ulceration - BOXED WARNING",
        "Hepatotoxicity",
        "Renal Failure"
      ]
    },
    "precautions": [
      "**Cardiovascular:** Avoid in patients with CVD; risk similar to COX-2 inhibitors.",
      "**Liver:** Elevations in LFTs common; monitor within 8 weeks.",
      "**Renal:** Avoid in advanced renal disease."
    ],
    "contraindications": [
      "CABG surgery (peri-operative)",
      "Aspirin triad (Asthma/Polyps/Allergy)",
      "Active GI bleed"
    ],
    "interactions": {
      "drug": ["Warfarin", "ACE Inhibitors (Renal failure)", "Lithium", "Methotrexate"],
      "food": ["Food delays absorption."]
    },
    "pregnancyCategory": "Category C (Avoid >30wks)"
  },
  "digoxin": {
    "name": "Digoxin (Lanoxin)",
    "genericName": "Digoxin",
    "formula": "C41H64O14",
    "molecularWeight": "780.9 g/mol",
    "brandNames": ["Lanoxin"],
    "category": "Antiarrhythmic / Inotrope",
    "drugClass": "Cardiac Glycoside",
    "pubchemCID": "2724385",
    "indications": "Heart Failure (HFrEF), Atrial Fibrillation (Rate control).",
    "moaSteps": [
      "Inhibits Na+/K+ ATPase pump in myocardial cells.",
      "Increases intracellular sodium, reducing calcium efflux via Na+/Ca++ exchanger.",
      "Increased intracellular calcium increases contractility (Positive Inotrope).",
      "Increases vagal tone (parasympathetic), slowing AV node conduction (Negative Chronotrope)."
    ],
    "pharmacokinetics": {
      "absorption": "60-80% (Tablet). P-gp substrate.",
      "distribution": "Large Vd (skeletal muscle binding).",
      "metabolism": "Minimal.",
      "excretion": "Renal (unchanged). **Half-life: 36 to 48 hours (prolonged in renal failure).**"
    },
    "dose": {
      "initialDose": "0.125 - 0.25 mg PO once daily",
      "maxDose": "Therapeutic Drug Monitoring based",
      "notes": "Target: 0.5-0.9 ng/mL for HF; slightly higher for AFib."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting / Anorexia (Early toxicity)",
        "Fatigue",
        "Visual disturbances (Yellow/Green halos)"
      ],
      "serious": [
        "Arrhythmias (PVCs, Heart Block, VT/VF)",
        "Hyperkalemia (in acute toxicity)",
        "Delirium"
      ]
    },
    "precautions": [
      "**Narrow Therapeutic Index:** Toxicity is common. Risk increased by Hypokalemia, Hypomagnesemia, and Hypercalcemia.",
      "**Renal:** Dose reduction mandatory in renal impairment.",
      "**Antidote:** Digoxin Immune Fab (Digibind)."
    ],
    "contraindications": [
      "Ventricular Fibrillation",
      "Wolff-Parkinson-White (WPW) syndrome with AFib"
    ],
    "interactions": {
      "drug": ["Amiodarone/Verapamil/Quinidine (Increase digoxin levels - halve dose)", "Diuretics (Hypokalemia -> Toxicity)", "Antacids"],
      "food": ["Fiber (bran) decreases absorption."]
    },
    "pregnancyCategory": "Category C"
  },
  "diltiazem": {
    "name": "Diltiazem (Cardizem)",
    "genericName": "Diltiazem HCl",
    "formula": "C22H26N2O4S",
    "molecularWeight": "414.5 g/mol",
    "brandNames": ["Cardizem", "Tiazac", "Cartia XT"],
    "category": "Antihypertensive / Antiarrhythmic",
    "drugClass": "Calcium Channel Blocker (Non-Dihydropyridine)",
    "pubchemCID": "39186",
    "indications": "Hypertension, Angina, Atrial Fibrillation (Rate control).",
    "moaSteps": [
      "Inhibits calcium ion influx into vascular smooth muscle and myocardium.",
      "Intermediate selectivity between vascular (nifedipine) and cardiac (verapamil) effects.",
      "Relaxes coronary vascular smooth muscle (Angina).",
      "Slows AV node conduction (AFib)."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "70-80% protein bound.",
      "metabolism": "Extensive hepatic (CYP3A4).",
      "excretion": "Urine and Bile. **Half-life: 3.5 to 4.5 hours (IR); longer for ER.**"
    },
    "dose": {
      "initialDose": "30 mg PO QID or 120-180 mg ER daily",
      "maxDose": "480 mg/day",
      "notes": "Do not crush ER/CD capsules."
    },
    "adverseEffects": {
      "common": [
        "Edema (lower extremities)",
        "Headache",
        "Dizziness",
        "Constipation (less than Verapamil)"
      ],
      "serious": [
        "Bradycardia / Heart Block",
        "Worsening Heart Failure (HFrEF)",
        "Hepatotoxicity"
      ]
    },
    "precautions": [
      "**Heart Failure:** Avoid in HFrEF; negative inotropic effect can worsen failure.",
      "**Conduction:** Caution in Sick Sinus Syndrome or AV block.",
      "**Interactions:** Moderate CYP3A4 inhibitor."
    ],
    "contraindications": [
      "Sick sinus syndrome / 2nd-3rd degree AV block (without pacemaker)",
      "Severe hypotension",
      "Acute MI with pulmonary congestion"
    ],
    "interactions": {
      "drug": ["Simvastatin/Lovastatin (Increase myopathy risk - limit statin dose)", "Beta-blockers (Additive bradycardia)", "Cyclosporine (Increased levels)"],
      "food": ["Alcohol"]
    },
    "pregnancyCategory": "Category C"
  },
  "diphenhydramine": {
    "name": "Diphenhydramine (Benadryl)",
    "genericName": "Diphenhydramine HCl",
    "formula": "C17H21NO",
    "molecularWeight": "255.35 g/mol",
    "brandNames": ["Benadryl", "ZzzQuil"],
    "category": "Antihistamine",
    "drugClass": "H1 Receptor Antagonist (First Generation)",
    "pubchemCID": "3100",
    "indications": "Allergic reactions, Insomnia, Motion Sickness, Antitussive, EPS treatment.",
    "moaSteps": [
      "Competes with histamine for H1-receptor sites on effector cells.",
      "Prevents histamine-mediated responses.",
      "Possesses significant anticholinergic (antimuscarinic) and sedative effects.",
      "Crosses blood-brain barrier readily."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Widely distributed, including CNS.",
      "metabolism": "Hepatic (CYP2D6).",
      "excretion": "Urine. **Half-life: 2.4 to 9.3 hours (Prolonged in elderly).**"
    },
    "dose": {
      "initialDose": "25-50 mg PO/IV every 4-6 hours",
      "maxDose": "300-400 mg/day",
      "notes": "Tolerance to sedative effects develops quickly."
    },
    "adverseEffects": {
      "common": [
        "Sedation / Drowsiness",
        "Dry mouth / eyes",
        "Urinary retention",
        "Constipation",
        "Confusion (Elderly)"
      ],
      "serious": [
        "Paradoxical Excitation (Children)",
        "Seizures (Overdose)",
        "Arrhythmias (Overdose)"
      ]
    },
    "precautions": [
      "**Elderly:** Beers Criteria drug. Avoid due to anticholinergic toxicity (falls, confusion, retention).",
      "**Glaucoma/Prostate:** Can worsen narrow-angle glaucoma and BPH symptoms.",
      "**Pediatrics:** Do not use for sedation; paradoxical hyperactivity common."
    ],
    "contraindications": [
      "Neonates/Premature infants",
      "Nursing mothers",
      "Acute asthma attack"
    ],
    "interactions": {
      "drug": ["CNS Depressants (Alcohol/Benzos - Additive)", "Anticholinergics (Additive toxicity)", "Metoprolol (Diphenhydramine inhibits CYP2D6)"],
      "food": ["Alcohol"]
    },
    "pregnancyCategory": "Category B"
  },
  "divalproex": {
    "name": "Divalproex (Depakote)",
    "genericName": "Divalproex Sodium (Valproic Acid)",
    "formula": "C16H31NaO4",
    "molecularWeight": "310.41 g/mol",
    "brandNames": ["Depakote", "Depakene"],
    "category": "Anticonvulsant / Mood Stabilizer",
    "drugClass": "Valproate",
    "pubchemCID": "Wait... (Complex)",
    "indications": "Epilepsy (Broad spectrum), Bipolar Mania, Migraine Prophylaxis.",
    "moaSteps": [
      "Increases GABA concentrations in the brain (inhibits GABA transaminase).",
      "Blocks voltage-gated sodium channels.",
      "Blockade of T-type calcium channels.",
      "Broad spectrum activity."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (ER is slower).",
      "distribution": "80-90% protein bound (Saturable).",
      "metabolism": "Extensive hepatic (Glucuronidation/Oxidation).",
      "excretion": "Urine. **Half-life: 9 to 16 hours.**"
    },
    "dose": {
      "initialDose": "250-500 mg PO daily",
      "maxDose": "60 mg/kg/day",
      "notes": "Therapeutic range: 50-100 mcg/mL."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting",
        "Tremor",
        "Weight gain",
        "Alopecia",
        "Thrombocytopenia"
      ],
      "serious": [
        "Hepatotoxicity (Fatal) - BOXED WARNING",
        "Pancreatitis - BOXED WARNING",
        "Fetal Neural Tube Defects - BOXED WARNING",
        "Hyperammonemia (Encephalopathy)"
      ]
    },
    "precautions": [
      "**Pregnancy:** Highly teratogenic (IQ reduction, Spina Bifida). Avoid in women of childbearing potential unless essential.",
      "**Liver:** Monitor LFTs baseline and frequently.",
      "**Ammonia:** Check ammonia if mental status changes occur (VPA inhibits urea cycle)."
    ],
    "contraindications": [
      "Hepatic disease",
      "Urea cycle disorders",
      "Pregnancy (for migraine prophylaxis)"
    ],
    "interactions": {
      "drug": ["Lamotrigine (Valproate doubles lamotrigine levels -> SJS risk)", "Carbamazepine/Phenytoin (Displacement)", "Meropenem (Lowers valproate levels significantly)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category X (Migraine); D (Seizures)"
  },
  "dobutamine": {
    "name": "Dobutamine",
    "genericName": "Dobutamine",
    "formula": "C18H23NO3",
    "molecularWeight": "301.38 g/mol",
    "brandNames": ["Dobutrex"],
    "category": "Inotrope",
    "drugClass": "Adrenergic Agonist (Beta-1 Selective)",
    "pubchemCID": "36811",
    "indications": "Cardiac Decompensation (Cardiogenic Shock, severe Heart Failure).",
    "moaSteps": [
      "Direct agonist at beta-1 adrenergic receptors.",
      "Increases myocardial contractility (positive inotropy) and stroke volume.",
      "Mild beta-2 (vasodilation) and alpha-1 activity.",
      "Net effect: Increased Cardiac Output with mild decrease in SVR (afterload)."
    ],
    "pharmacokinetics": {
      "absorption": "IV only.",
      "distribution": "Extensive.",
      "metabolism": "Hepatic (Methylation by COMT).",
      "excretion": "Urine. **Half-life: 2 minutes.**"
    },
    "dose": {
      "initialDose": "2-5 mcg/kg/min IV infusion",
      "maxDose": "20-40 mcg/kg/min",
      "notes": "Titrate to hemodynamic response."
    },
    "adverseEffects": {
      "common": [
        "Tachycardia",
        "Hypertension (or Hypotension)",
        "Premature Ventricular Contractions (PVCs)"
      ],
      "serious": [
        "Ventricular Tachycardia / Arrhythmias",
        "Myocardial Ischemia (Increased O2 demand)",
        "Hypokalemia"
      ]
    },
    "precautions": [
      "**Ischemia:** Increases myocardial oxygen consumption; can worsen ischemia in CAD.",
      "**Arrhythmias:** Continuous ECG monitoring required.",
      "**Hypovolemia:** Correct volume depletion before starting."
    ],
    "contraindications": [
      "Idiopathic Hypertrophic Subaortic Stenosis (IHSS)",
      "Hypersensitivity to sulfites"
    ],
    "interactions": {
      "drug": ["Beta-blockers (Antagonize effect)", "MAOIs (Severe hypertension)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "dolutegravir": {
    "name": "Dolutegravir (Tivicay)",
    "genericName": "Dolutegravir",
    "formula": "C20H19F2N3O5",
    "molecularWeight": "419.4 g/mol",
    "brandNames": ["Tivicay"],
    "category": "Antiretroviral",
    "drugClass": "Integrase Strand Transfer Inhibitor (INSTI)",
    "pubchemCID": "54726191",
    "indications": "HIV-1 Infection.",
    "moaSteps": [
      "Binds to the integrase active site.",
      "Blocks the strand transfer step of retroviral DNA integration.",
      "Prevents HIV DNA from integrating into host CD4 cell DNA.",
      "Prevents viral replication."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic (UGT1A1 and CYP3A4).",
      "excretion": "Feces and Urine. **Half-life: 14 hours.**"
    },
    "dose": {
      "initialDose": "50 mg PO once daily",
      "maxDose": "50 mg BID (if resistance/interactions)",
      "notes": "Separate from antacids."
    },
    "adverseEffects": {
      "common": [
        "Insomnia",
        "Headache",
        "Weight gain (Class effect)",
        "Fatigue"
      ],
      "serious": [
        "Hypersensitivity (Rash/Organ dysfunction)",
        "Hepatotoxicity",
        "Immune Reconstitution Syndrome",
        "Neural Tube Defects (Risk initially raised, now considered minimal)"
      ]
    },
    "precautions": [
      "**Cations:** Chelation with Aluminum/Magnesium/Calcium. Take 2 hours before or 6 hours after antacids/laxatives.",
      "**Weight Gain:** Significant weight gain observed compared to other classes.",
      "**Hepatotoxicity:** Monitor LFTs."
    ],
    "contraindications": [
      "Co-administration with Dofetilide (Toxic levels)"
    ],
    "interactions": {
      "drug": ["Dofetilide (Contraindicated)", "Metformin (Increases metformin levels - cap metformin dose)", "Rifampin/Carbamazepine (Decrease levels - use BID dosing)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B (Updated from concern)"
  },
  "donepezil": {
    "name": "Donepezil (Aricept)",
    "genericName": "Donepezil HCl",
    "formula": "C24H29NO3",
    "molecularWeight": "379.5 g/mol",
    "brandNames": ["Aricept"],
    "category": "Anti-Alzheimer's Agent",
    "drugClass": "Acetylcholinesterase Inhibitor",
    "pubchemCID": "3152",
    "indications": "Alzheimer's Disease (Mild to Severe).",
    "moaSteps": [
      "Reversibly and non-competitively inhibits acetylcholinesterase (AChE).",
      "Increases concentration of acetylcholine in the synaptic cleft.",
      "Enhances cholinergic transmission in the CNS.",
      "Symptomatic improvement (does not halt disease progression)."
    ],
    "pharmacokinetics": {
      "absorption": "100% bioavailability.",
      "distribution": "96% protein bound.",
      "metabolism": "Hepatic (CYP2D6/3A4).",
      "excretion": "Urine and Feces. **Half-life: 70 hours.**"
    },
    "dose": {
      "initialDose": "5 mg PO once daily at bedtime",
      "maxDose": "23 mg/day",
      "notes": "Titrate after 4-6 weeks."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Diarrhea",
        "Insomnia / Vivid dreams",
        "Muscle cramps",
        "Fatigue"
      ],
      "serious": [
        "Bradycardia / Heart Block",
        "Syncope",
        "GI Bleeding (increased acid)",
        "Seizures",
        "Rhabdomyolysis (rare)"
      ]
    },
    "precautions": [
      "**Cardiac:** Can cause vagotonic effects (bradycardia). Caution in Sick Sinus Syndrome.",
      "**GI:** Increases gastric acid; caution in ulcer history.",
      "**Weight:** Monitor for weight loss.",
      "**Anesthesia:** Prohibits metabolism of succinylcholine (prolonged effect)."
    ],
    "contraindications": [
      "Hypersensitivity to piperidine derivatives"
    ],
    "interactions": {
      "drug": ["Anticholinergics (Antagonistic)", "NSAIDs (GI Bleed risk)", "Beta-blockers (Additive bradycardia)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "doxorubicin": {
    "name": "Doxorubicin (Adriamycin)",
    "genericName": "Doxorubicin HCl",
    "formula": "C27H29NO11",
    "molecularWeight": "543.5 g/mol",
    "brandNames": ["Adriamycin", "Rubex"],
    "category": "Antineoplastic",
    "drugClass": "Anthracycline Antibiotic",
    "pubchemCID": "31703",
    "indications": "Breast Cancer, Lymphomas, Sarcomas, Leukemias.",
    "moaSteps": [
      "Intercalates between DNA base pairs, inhibiting replication/transcription.",
      "Inhibits Topoisomerase II, causing DNA strand breaks.",
      "Generates free radicals (iron-dependent), damaging cell membranes.",
      "Non-phase specific."
    ],
    "pharmacokinetics": {
      "absorption": "IV only.",
      "distribution": "Widely distributed. Does not cross BBB.",
      "metabolism": "Hepatic metabolism.",
      "excretion": "Biliary (50%). **Half-life: 20 to 48 hours (Terminal).**"
    },
    "dose": {
      "initialDose": "60-75 mg/m2 IV every 21 days",
      "maxDose": "Lifetime cumulative: 450-550 mg/m2",
      "notes": "Exceeding lifetime dose drastically increases heart failure risk."
    },
    "adverseEffects": {
      "common": [
        "Alopecia (Total)",
        "Nausea / Vomiting",
        "Red urine (harmless)",
        "Stomatitis"
      ],
      "serious": [
        "Cardiotoxicity (CHF) - BOXED WARNING",
        "Myelosuppression - BOXED WARNING",
        "Secondary Malignancies (AML)",
        "Extravasation Necrosis (Vesicant) - BOXED WARNING"
      ]
    },
    "precautions": [
      "**Cardiotoxicity:** Irreversible cardiomyopathy. Baseline and periodic ECHO/MUGA required. Dexrazoxane used for cardioprotection.",
      "**Vesicant:** Severe tissue necrosis if leaked. Central line preferred.",
      "**Red Urine:** Warn patient urine will turn red for 1-2 days (not blood)."
    ],
    "contraindications": [
      "Pre-existing severe myocardial insufficiency",
      "Recent MI",
      "Severe Arrhythmias",
      "Previous max cumulative dose"
    ],
    "interactions": {
      "drug": ["Trastuzumab (Enhanced cardiotoxicity)", "Cyclophosphamide (Hemorrhagic cystitis risk increased)", "Paclitaxel"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "doxycycline": {
    "name": "Doxycycline (Vibramycin)",
    "genericName": "Doxycycline Hyclate",
    "formula": "C22H24N2O8",
    "molecularWeight": "444.4 g/mol",
    "brandNames": ["Vibramycin", "Doryx", "Oracea"],
    "category": "Antibiotic",
    "drugClass": "Tetracycline",
    "pubchemCID": "54671203",
    "indications": "Acne, Lyme Disease, Malaria Prophylaxis, Pneumonia (Atypical), Chlamydia, MRSA skin infections.",
    "moaSteps": [
      "Binds reversibly to the 30S ribosomal subunit.",
      "Blocks binding of aminoacyl-tRNA to the mRNA-ribosome complex.",
      "Inhibits bacterial protein synthesis.",
      "Bacteriostatic."
    ],
    "pharmacokinetics": {
      "absorption": "High (90-100%). Less affected by food/calcium than other tetracyclines.",
      "distribution": "Good tissue penetration (skin/prostate). Poor CSF.",
      "metabolism": "Minimal.",
      "excretion": "Feces (via bile) and Urine. **Half-life: 18 to 22 hours.**"
    },
    "dose": {
      "initialDose": "100 mg PO twice daily",
      "maxDose": "200 mg/day",
      "notes": "Take with full glass of water, remain upright."
    },
    "adverseEffects": {
      "common": [
        "GI Upset / Nausea",
        "Photosensitivity",
        "Esophagitis / Esophageal Ulceration"
      ],
      "serious": [
        "Tooth Discoloration (Children < 8, though short courses may be safe)",
        "Increased Intracranial Pressure (Pseudotumor Cerebri)",
        "Severe Skin Reactions (SJS)"
      ]
    },
    "precautions": [
      "**Esophagitis:** Take with plenty of water and stay upright for 30 mins to prevent pills sticking in esophagus.",
      "**Sun:** Avoid direct sunlight (severe sunburns).",
      "**Cations:** Separate from Calcium, Iron, Magnesium, Antacids by 2 hours."
    ],
    "contraindications": [
      "Hypersensitivity",
      "Pregnancy (Category D - affects fetal bone/teeth)",
      "Children < 8 years (Relative - depends on duration)"
    ],
    "interactions": {
      "drug": ["Isotretinoin (Pseudotumor Cerebri risk)", "Warfarin (Increases INR)", "Oral Contraceptives (Reduced efficacy - controversial)", "Antacids"],
      "food": ["Dairy (Calcium) decreases absorption (less than other tetracyclines)."]
    },
    "pregnancyCategory": "Category D"
  },"dalbavancin": {
    "name": "Dalbavancin (Dalvance)",
    "genericName": "Dalbavancin",
    "formula": "C88H100Cl2N10O28",
    "molecularWeight": "1816.7 g/mol",
    "brandNames": ["Dalvance"],
    "category": "Antibiotic",
    "drugClass": "Lipoglycopeptide",
    "pubchemCID": "16132272",
    "indications": "Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by Gram-positive organisms (including MRSA).",
    "moaSteps": [
      "Interferes with cell wall synthesis by binding to the D-alanyl-D-alanine terminus of cell wall peptidoglycan.",
      "Prevents cross-linking (transpeptidation) and transglycosylation.",
      "Possesses a lipophilic side chain that anchors to the bacterial membrane, enhancing potency.",
      "Bactericidal against Gram-positives."
    ],
    "pharmacokinetics": {
      "absorption": "IV administration.",
      "distribution": "93% protein bound.",
      "metabolism": "Minimal.",
      "excretion": "Urine and Feces. **Half-life: 346 hours (approx 2 weeks) - Allows for single-dose regimen.**"
    },
    "dose": {
      "initialDose": "1500 mg IV Single Dose",
      "maxDose": "1500 mg",
      "notes": "Alternative regimen: 1000 mg Day 1, 500 mg Day 8."
    },
    "adverseEffects": {
      "common": [
        "Nausea",
        "Headache",
        "Diarrhea"
      ],
      "serious": [
        "Hypersensitivity / Anaphylaxis",
        "Red Man Syndrome (rapid infusion)",
        "Clostridioides difficile colitis",
        "ALT elevation"
      ]
    },
    "precautions": [
      "**Infusion Rate:** Infuse over 30 minutes to minimize 'Red Man Syndrome' (flushing, pruritus) caused by histamine release.",
      "**Long Half-life:** Adverse reactions may persist for weeks due to slow elimination."
    ],
    "contraindications": [
      "Hypersensitivity to dalbavancin or glycopeptides (vancomycin - caution)"
    ],
    "interactions": {
      "drug": ["None known (Minimal CYP interaction)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "dantrolene": {
    "name": "Dantrolene (Dantrium)",
    "genericName": "Dantrolene Sodium",
    "formula": "C14H10N4O5",
    "molecularWeight": "314.3 g/mol",
    "brandNames": ["Dantrium", "Ryanodex"],
    "category": "Muscle Relaxant / Antidote",
    "drugClass": "Ryanodine Receptor Antagonist",
    "pubchemCID": "2953",
    "indications": "Malignant Hyperthermia (MH), Spasticity (Upper motor neuron disorders), Neuroleptic Malignant Syndrome (off-label).",
    "moaSteps": [
      "Direct-acting skeletal muscle relaxant.",
      "Dissociates the excitation-contraction coupling.",
      "Interferes with the release of calcium from the sarcoplasmic reticulum via the ryanodine receptor channel.",
      "Reduces intracellular calcium concentration, preventing catabolic processes in MH."
    ],
    "pharmacokinetics": {
      "absorption": "Oral absorption is incomplete (70%). IV for emergencies.",
      "distribution": "High tissue binding.",
      "metabolism": "Hepatic (hydroxylation/acetylation).",
      "excretion": "Urine and bile. **Half-life: 4 to 8 hours.**"
    },
    "dose": {
      "initialDose": "MH Crisis: 2.5 mg/kg IV push, repeat PRN",
      "maxDose": "10 mg/kg (Cumulative IV dose)",
      "notes": "Oral maintenance: 25-100 mg QID."
    },
    "adverseEffects": {
      "common": [
        "Muscle weakness (significant)",
        "Drowsiness",
        "Diarrhea",
        "Dysphagia"
      ],
      "serious": [
        "Hepatotoxicity (Fatal liver failure with chronic oral use) - BOXED WARNING",
        "Respiratory Depression",
        "Pleural Effusion (chronic use)"
      ]
    },
    "precautions": [
      "**Hepatotoxicity:** Boxed warning for oral use. Monitor LFTs. Risk highest in females >35 years taking estrogens.",
      "**Weakness:** Can cause severe weakness; caution in patients with pre-existing pulmonary compromise.",
      "**Extravasation:** IV solution is alkaline and irritating to veins."
    ],
    "contraindications": [
      "Active hepatic disease (for oral spasticity use)"
    ],
    "interactions": {
      "drug": ["Verapamil/Diltiazem (Cardiovascular collapse/Hyperkalemia in MH crisis - Avoid combination)", "CNS Depressants"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "dapsone": {
    "name": "Dapsone",
    "genericName": "Dapsone",
    "formula": "C12H12N2O2S",
    "molecularWeight": "248.3 g/mol",
    "brandNames": ["Aczone (Topical)"],
    "category": "Antibiotic / Anti-inflammatory",
    "drugClass": "Sulfone",
    "pubchemCID": "2955",
    "indications": "Leprosy (Hansen's Disease), Dermatitis Herpetiformis, Pneumocystis jirovecii Pneumonia (PCP) prophylaxis/treatment.",
    "moaSteps": [
      "Inhibits the synthesis of dihydrofolic acid (similar to sulfonamides).",
      "Inhibits bacterial and protozoal growth.",
      "Anti-inflammatory mechanism in skin diseases involves inhibition of neutrophil migration and adherence."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid and complete.",
      "distribution": "Distributed to all tissues.",
      "metabolism": "Hepatic (N-acetylation and N-hydroxylation).",
      "excretion": "Urine. **Half-life: 10 to 50 hours (Average 28h).**"
    },
    "dose": {
      "initialDose": "100 mg PO daily",
      "maxDose": "300 mg/day",
      "notes": "Check G6PD status before initiation."
    },
    "adverseEffects": {
      "common": [
        "Hemolysis (dose-dependent)",
        "Methemoglobinemia",
        "Nausea",
        "Rash"
      ],
      "serious": [
        "Severe Hemolytic Anemia (in G6PD deficiency)",
        "Agranulocytosis",
        "Dapsone Hypersensitivity Syndrome (DRESS)",
        "Peripheral Neuropathy"
      ]
    },
    "precautions": [
      "**G6PD Deficiency:** Contraindicated or used with extreme caution; severe hemolysis occurs.",
      "**Methemoglobinemia:** Causes oxidation of hemoglobin. Monitor for cyanosis/shortness of breath.",
      "**Hypersensitivity Syndrome:** Fever, rash, organ involvement. Discontinue immediately."
    ],
    "contraindications": [
      "Severe hypersensitivity to sulfonamides/sulfones"
    ],
    "interactions": {
      "drug": ["Rifampin (Decreases dapsone levels 7-10 fold)", "Trimethoprim (Increases dapsone levels)", "Probenecid"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "daratumumab": {
    "name": "Daratumumab (Darzalex)",
    "genericName": "Daratumumab",
    "formula": "Human IgG1k monoclonal antibody",
    "molecularWeight": "148 kDa",
    "brandNames": ["Darzalex", "Darzalex Faspro"],
    "category": "Antineoplastic",
    "drugClass": "Monoclonal Antibody (Anti-CD38)",
    "pubchemCID": "None (Protein)",
    "indications": "Multiple Myeloma (Monotherapy or combination).",
    "moaSteps": [
      "Binds to CD38, a transmembrane glycoprotein highly expressed on myeloma cells.",
      "Induces cell lysis via Complement-Dependent Cytotoxicity (CDC), Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), and apoptosis.",
      "Also modulates the tumor microenvironment."
    ],
    "pharmacokinetics": {
      "absorption": "IV or Subcutaneous (with hyaluronidase).",
      "distribution": "Vascular space.",
      "metabolism": "Catabolism.",
      "excretion": "Clearance decreases over time. **Half-life: ~18 days (after multiple doses).**"
    },
    "dose": {
      "initialDose": "16 mg/kg IV weekly (weeks 1-8)",
      "maxDose": "Maintenance every 4 weeks",
      "notes": "Pre-medicate with steroids/antipyretics/antihistamines."
    },
    "adverseEffects": {
      "common": [
        "Infusion reactions (High rate)",
        "Fatigue",
        "Nausea",
        "Upper respiratory infection"
      ],
      "serious": [
        "Severe Infusion Reactions (Bronchospasm, Hypoxia)",
        "Interference with Serological Testing (Type & Screen)",
        "Neutropenia / Thrombocytopenia"
      ]
    },
    "precautions": [
      "**Blood Typing:** Binds to CD38 on RBCs, causing pan-agglutination in indirect Coombs test. MUST type and screen patient BEFORE first dose (blood bank nightmare otherwise).",
      "**Herpes Zoster:** Reactivation risk; antiviral prophylaxis recommended.",
      "**Infusion Reactions:** High risk with first dose."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["None specific (Interferes with blood bank compatibility testing)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "dasatinib": {
    "name": "Dasatinib (Sprycel)",
    "genericName": "Dasatinib",
    "formula": "C22H26ClN7O2S",
    "molecularWeight": "488.0 g/mol",
    "brandNames": ["Sprycel"],
    "category": "Antineoplastic",
    "drugClass": "Tyrosine Kinase Inhibitor (BCR-ABL)",
    "pubchemCID": "3062316",
    "indications": "Chronic Myeloid Leukemia (Ph+ CML), Ph+ Acute Lymphoblastic Leukemia (ALL).",
    "moaSteps": [
      "Inhibits BCR-ABL kinase, SRC family kinases, c-KIT, and PDGFR.",
      "Potent inhibitor (325x more potent than imatinib).",
      "Effective against many imatinib-resistant mutations.",
      "Induces apoptosis in leukemic cells."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed.",
      "distribution": "96% protein bound.",
      "metabolism": "Extensive hepatic (CYP3A4).",
      "excretion": "Feces. **Half-life: 3 to 5 hours.**"
    },
    "dose": {
      "initialDose": "100 mg PO once daily",
      "maxDose": "140 mg/day",
      "notes": "Swallow whole; do not crush."
    },
    "adverseEffects": {
      "common": [
        "Myelosuppression",
        "Fluid retention",
        "Diarrhea",
        "Headache",
        "Rash"
      ],
      "serious": [
        "Pleural Effusion (High incidence)",
        "Pulmonary Arterial Hypertension (PAH) - Reversible upon stopping",
        "QT Prolongation",
        "Hemorrhage"
      ]
    },
    "precautions": [
      "**Pleural Effusion:** Occurs in ~30% of patients. Manage with diuretics/steroids or dose interruption.",
      "**PAH:** Evaluate for signs of underlying cardiopulmonary disease prior to starting.",
      "**QT Prolongation:** Monitor ECG and electrolytes."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Antacids/H2RAs/PPIs (Significantly reduce absorption - Avoid PPIs)", "CYP3A4 Inhibitors/Inducers", "Anticoagulants (Bleeding risk)"],
      "food": ["Grapefruit juice"]
    },
    "pregnancyCategory": "Category D"
  },
  "deferasirox": {
    "name": "Deferasirox (Exjade, Jadenu)",
    "genericName": "Deferasirox",
    "formula": "C21H15N3O4",
    "molecularWeight": "373.4 g/mol",
    "brandNames": ["Exjade", "Jadenu"],
    "category": "Chelating Agent",
    "drugClass": "Iron Chelator",
    "pubchemCID": "167551",
    "indications": "Chronic Iron Overload due to blood transfusions (Transfusional Hemosiderosis) or Non-transfusion-dependent Thalassemia.",
    "moaSteps": [
      "Tridentate iron chelator.",
      "Binds iron with high affinity in a 2:1 ratio.",
      "Promotes excretion of iron, primarily via feces.",
      "Reduces liver iron concentration and serum ferritin."
    ],
    "pharmacokinetics": {
      "absorption": "Jadenu (Film-coated) better absorbed than Exjade (dispersible).",
      "distribution": "99% protein bound.",
      "metabolism": "Glucuronidation (UGT1A1).",
      "excretion": "Feces. **Half-life: 8 to 16 hours.**"
    },
    "dose": {
      "initialDose": "14 mg/kg PO daily (Jadenu)",
      "maxDose": "28 mg/kg/day",
      "notes": "Monitor Ferritin monthly."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting",
        "Diarrhea",
        "Abdominal pain",
        "Skin rash"
      ],
      "serious": [
        "Renal Failure (Fatal) - BOXED WARNING",
        "Hepatic Failure (Fatal) - BOXED WARNING",
        "GI Hemorrhage - BOXED WARNING",
        "Bone marrow suppression"
      ]
    },
    "precautions": [
      "**Renal/Hepatic:** Monitor Creatinine and LFTs prior to start and monthly. Fatalities reported.",
      "**GI Bleed:** Risk is higher in elderly or those on anticoagulants/NSAIDs.",
      "**Vision/Hearing:** Auditory and ocular disturbances reported; testing recommended."
    ],
    "contraindications": [
      "Creatinine clearance < 40 mL/min",
      "Platelets < 50,000",
      "High risk myelodysplastic syndrome"
    ],
    "interactions": {
      "drug": ["Aluminum-containing antacids (Bind drug)", "Theophylline (Deferasirox inhibits CYP1A2)", "NSAIDs (GI toxicity)"],
      "food": ["Take on empty stomach (Exjade) or light meal (Jadenu)."]
    },
    "pregnancyCategory": "Category C"
  },
  "desipramine": {
    "name": "Desipramine (Norpramin)",
    "genericName": "Desipramine HCl",
    "formula": "C18H22N2",
    "molecularWeight": "266.4 g/mol",
    "brandNames": ["Norpramin"],
    "category": "Antidepressant",
    "drugClass": "Tricyclic Antidepressant (Secondary Amine)",
    "pubchemCID": "2995",
    "indications": "Depression. Off-label: Neuropathic pain, ADHD.",
    "moaSteps": [
      "Potent inhibitor of norepinephrine reuptake.",
      "Weak inhibitor of serotonin reuptake.",
      "Secondary amine structure results in less anticholinergic and sedative effects than tertiary amines (e.g., Amitriptyline).",
      "Downregulates beta-adrenergic receptors."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed.",
      "distribution": "High volume of distribution.",
      "metabolism": "Hepatic via CYP2D6.",
      "excretion": "Urine. **Half-life: 12 to 24 hours.**"
    },
    "dose": {
      "initialDose": "25-50 mg PO daily",
      "maxDose": "300 mg/day",
      "notes": "Taper off to prevent cholinergic rebound."
    },
    "adverseEffects": {
      "common": [
        "Dry mouth",
        "Constipation",
        "Insomnia (activating)",
        "Orthostatic Hypotension"
      ],
      "serious": [
        "Suicidality - BOXED WARNING",
        "Arrhythmias / QT Prolongation",
        "Seizures",
        "Hepatic failure"
      ]
    },
    "precautions": [
      "**Cardiac:** Avoid in recent MI or conduction defects. Baseline ECG recommended.",
      "**Seizure:** Lowers seizure threshold.",
      "**Suicide:** Monitor for worsening depression/suicidality.",
      "**Elderly:** Use with caution, though preferred over amitriptyline if a TCA is needed."
    ],
    "contraindications": [
      "MAOI use within 14 days",
      "Acute recovery phase of MI"
    ],
    "interactions": {
      "drug": ["MAOIs (Fatal)", "CYP2D6 Inhibitors (Fluoxetine - Toxicity)", "Clonidine (Hypertensive crisis)", "Alcohol"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "desloratadine": {
    "name": "Desloratadine (Clarinex)",
    "genericName": "Desloratadine",
    "formula": "C19H19ClN2",
    "molecularWeight": "310.8 g/mol",
    "brandNames": ["Clarinex"],
    "category": "Antihistamine",
    "drugClass": "H1 Receptor Antagonist (Second Generation)",
    "pubchemCID": "124087",
    "indications": "Seasonal/Perennial Allergic Rhinitis, Chronic Idiopathic Urticaria.",
    "moaSteps": [
      "Major active metabolite of loratadine.",
      "Long-acting, tricyclic histamine antagonist.",
      "Selective peripheral H1 receptor antagonist.",
      "Does not readily penetrate the CNS (non-sedating)."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "82-87% protein bound.",
      "metabolism": "Hepatic (UGT).",
      "excretion": "Urine and Feces. **Half-life: 27 hours.**"
    },
    "dose": {
      "initialDose": "5 mg PO once daily",
      "maxDose": "5 mg/day",
      "notes": "Dose every other day in renal/hepatic impairment."
    },
    "adverseEffects": {
      "common": [
        "Dry mouth",
        "Fatigue",
        "Pharyngitis",
        "Myalgia"
      ],
      "serious": [
        "Hypersensitivity (Rash, Edema)",
        "Seizures (very rare)"
      ]
    },
    "precautions": [
      "**Renal/Hepatic:** Dose adjustment required.",
      "**Sedation:** Rare at recommended doses, but possible."
    ],
    "contraindications": [
      "Hypersensitivity to desloratadine or loratadine"
    ],
    "interactions": {
      "drug": ["Erythromycin/Ketoconazole (Increase plasma levels but usually no clinical effect)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "dexlansoprazole": {
    "name": "Dexlansoprazole (Dexilant)",
    "genericName": "Dexlansoprazole",
    "formula": "C16H14F3N3O2S",
    "molecularWeight": "369.4 g/mol",
    "brandNames": ["Dexilant"],
    "category": "Acid Reducer",
    "drugClass": "Proton Pump Inhibitor (PPI)",
    "pubchemCID": "9578005",
    "indications": "Erosive Esophagitis (healing/maintenance), GERD.",
    "moaSteps": [
      "R-enantiomer of lansoprazole.",
      "Irreversibly binds to H+/K+ ATPase enzyme system (proton pump) of gastric parietal cells.",
      "Suppresses gastric acid secretion.",
      "Dual Delayed Release formulation provides two peaks of absorption (pH dependent)."
    ],
    "pharmacokinetics": {
      "absorption": "Dual release (1-2 hours and 4-5 hours).",
      "distribution": "96% protein bound.",
      "metabolism": "Hepatic via CYP2C19 and CYP3A4.",
      "excretion": "Feces and Urine. **Half-life: 1 to 2 hours (but effect lasts >24h due to irreversible binding).**"
    },
    "dose": {
      "initialDose": "30-60 mg PO once daily",
      "maxDose": "60 mg/day",
      "notes": "Can be taken without regard to food (unique among PPIs)."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea",
        "Abdominal pain",
        "Flatulence",
        "Nausea"
      ],
      "serious": [
        "Clostridioides difficile infection",
        "Osteoporosis-related fractures (long term)",
        "Hypomagnesemia",
        "Acute Interstitial Nephritis"
      ]
    },
    "precautions": [
      "**C. diff:** Consider in persistent diarrhea.",
      "**Bone Fracture:** High dose/long term use associated with hip/wrist/spine fractures.",
      "**B12 Deficiency:** May cause malabsorption of B12 with long-term use."
    ],
    "contraindications": [
      "Hypersensitivity",
      "Concomitant Rilpivirine use"
    ],
    "interactions": {
      "drug": ["Rilpivirine/Atazanavir (Reduced antiviral absorption - Contraindicated)", "Methotrexate (Increased MTX toxicity)", "Clopidogrel (Minor interaction compared to Omeprazole)"],
      "food": ["None (Dual release technology allows flexibility)."]
    },
    "pregnancyCategory": "Category B"
  },
  "dexmethylphenidate": {
    "name": "Dexmethylphenidate (Focalin)",
    "genericName": "Dexmethylphenidate",
    "formula": "C14H19NO2",
    "molecularWeight": "233.3 g/mol",
    "brandNames": ["Focalin", "Focalin XR"],
    "category": "CNS Stimulant",
    "drugClass": "Phenethylamine",
    "pubchemCID": "5282446",
    "indications": "ADHD.",
    "moaSteps": [
      "d-threo-enantiomer of racemic methylphenidate (more pharmacologically active).",
      "Blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron.",
      "Increases extraneuronal dopamine in the CNS."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Crosses BBB.",
      "metabolism": "De-esterification (non-microsomal).",
      "excretion": "Urine. **Half-life: 2 to 3 hours.**"
    },
    "dose": {
      "initialDose": "2.5 mg PO twice daily",
      "maxDose": "20 mg/day (Children); 40 mg/day (Adults)",
      "notes": "Dose is half that of racemic methylphenidate (Ritalin)."
    },
    "adverseEffects": {
      "common": [
        "Insomnia",
        "Anorexia / Weight loss",
        "Abdominal pain",
        "Anxiety"
      ],
      "serious": [
        "Sudden Cardiac Death (structural defects)",
        "Psychosis / Mania",
        "Abuse / Dependence - BOXED WARNING",
        "Priapism"
      ]
    },
    "precautions": [
      "**Cardiac:** Avoid in structural heart abnormalities. Monitor BP/HR.",
      "**Growth:** Monitor height/weight in children.",
      "**Psychiatric:** Can exacerbate underlying psychosis/bipolar."
    ],
    "contraindications": [
      "MAOI use within 14 days",
      "Glaucoma",
      "Severe anxiety/agitation",
      "Motor tics / Tourette's"
    ],
    "interactions": {
      "drug": ["MAOIs (Hypertensive crisis)", "Antihypertensives (Reduced efficacy)", "Antacids (Alter release of XR)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "dextromethorphan": {
    "name": "Dextromethorphan (Delsym)",
    "genericName": "Dextromethorphan",
    "formula": "C18H25NO",
    "molecularWeight": "271.4 g/mol",
    "brandNames": ["Delsym", "Robitussin DM"],
    "category": "Antitussive",
    "drugClass": "Morphinan Derivative",
    "pubchemCID": "5360696",
    "indications": "Cough suppression (non-productive). Pseudobulbar affect (with quinidine).",
    "moaSteps": [
      "D-isomer of the codeine analog levorphanol (lacks analgesic/addictive properties at normal doses).",
      "Acts on the cough center in the medulla to elevate the threshold for coughing.",
      "At high doses, acts as an NMDA receptor antagonist and Sigma-1 receptor agonist (dissociative effects)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Widely distributed.",
      "metabolism": "Extensive hepatic via CYP2D6.",
      "excretion": "Urine. **Half-life: 2 to 4 hours (Extensive metabolizers); up to 24h (Poor metabolizers).**"
    },
    "dose": {
      "initialDose": "10-20 mg PO every 4 hours",
      "maxDose": "120 mg/day",
      "notes": "Abuse potential at high doses ('Robotripping')."
    },
    "adverseEffects": {
      "common": [
        "Drowsiness / Dizziness",
        "Nausea",
        "Constipation"
      ],
      "serious": [
        "Serotonin Syndrome (with SSRIs/MAOIs)",
        "Respiratory Depression (Overdose)",
        "Psychosis / Hallucinations (Abuse)"
      ]
    },
    "precautions": [
      "**Serotonin Syndrome:** Has weak serotonin reuptake inhibition properties. Caution with SSRIs/SNRIs.",
      "**Productive Cough:** Should not be used for persistent cough (smoking/asthma) or productive cough (retains secretions).",
      "**Abuse:** Monitor for misuse."
    ],
    "contraindications": [
      "MAOI use within 14 days"
    ],
    "interactions": {
      "drug": ["MAOIs (Fatal)", "SSRIs (Serotonin syndrome)", "Quinidine (Inhibits metabolism -> toxicity)"],
      "food": ["Grapefruit juice"]
    },
    "pregnancyCategory": "Category C"
  },
  "dicyclomine": {
    "name": "Dicyclomine (Bentyl)",
    "genericName": "Dicyclomine HCl",
    "formula": "C19H35NO2",
    "molecularWeight": "309.5 g/mol",
    "brandNames": ["Bentyl"],
    "category": "Antispasmodic",
    "drugClass": "Anticholinergic",
    "pubchemCID": "3042",
    "indications": "Irritable Bowel Syndrome (IBS) - Functional bowel/irritable colon.",
    "moaSteps": [
      "Blocks acetylcholine at muscarinic receptors on smooth muscle.",
      "Direct relaxation of smooth muscle in the GI tract.",
      "Reduces colonic motility and prevents spasms."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Wide.",
      "metabolism": "Extensive.",
      "excretion": "Urine and Feces. **Half-life: 1.8 hours (Initial); 9-10 hours (Terminal).**"
    },
    "dose": {
      "initialDose": "20 mg PO QID",
      "maxDose": "160 mg/day",
      "notes": "Start low (10-20mg) to assess tolerance."
    },
    "adverseEffects": {
      "common": [
        "Dry mouth",
        "Dizziness",
        "Blurred vision",
        "Nausea"
      ],
      "serious": [
        "Paralytic Ileus",
        "Psychosis / Confusion",
        "Heat Stroke (decreased sweating)",
        "Respiratory depression (Infants)"
      ]
    },
    "precautions": [
      "**Heat:** Decreases sweating; risk of hyperthermia.",
      "**Drowsiness:** Caution driving.",
      "**Glaucoma/Retention:** Can worsen narrow-angle glaucoma and urinary retention."
    ],
    "contraindications": [
      "Infants < 6 months (Fatal apnea)",
      "Obstructive Uropathy / GI Obstruction",
      "Severe Ulcerative Colitis (Megacolon risk)",
      "Myasthenia Gravis"
    ],
    "interactions": {
      "drug": ["Anticholinergics (Additive)", "Antacids (Decrease absorption)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "dipyridamole": {
    "name": "Dipyridamole (Persantine)",
    "genericName": "Dipyridamole",
    "formula": "C24H40N8O4",
    "molecularWeight": "504.6 g/mol",
    "brandNames": ["Persantine"],
    "category": "Antiplatelet / Diagnostic Agent",
    "drugClass": "Phosphodiesterase Inhibitor",
    "pubchemCID": "3108",
    "indications": "Prevention of thromboembolism post-heart valve replacement (with warfarin), Chemical Stress Testing (IV).",
    "moaSteps": [
      "Inhibits the uptake of adenosine into erythrocytes/platelets/endothelial cells.",
      "Increases local concentrations of adenosine (vasodilator/platelet inhibitor).",
      "Inhibits phosphodiesterase (PDE), increasing cAMP in platelets.",
      "Prevents platelet aggregation."
    ],
    "pharmacokinetics": {
      "absorption": "Variable/Slow.",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic (Glucuronidation).",
      "excretion": "Bile/Feces. **Half-life: 10 to 12 hours.**"
    },
    "dose": {
      "initialDose": "75-100 mg PO QID",
      "maxDose": "400 mg/day",
      "notes": "Aggrenox is a specific combo with aspirin for stroke."
    },
    "adverseEffects": {
      "common": [
        "Headache (Vasodilation)",
        "Dizziness",
        "Flushing",
        "GI upset"
      ],
      "serious": [
        "Coronary Steal (Worsening ischemia in CAD during stress test)",
        "Hypotension",
        "Bronchospasm (IV)"
      ]
    },
    "precautions": [
      "**Coronary Steal:** IV dipyridamole dilates healthy vessels, stealing blood from stenotic vessels. Use caution in severe CAD.",
      "**Hypotension:** Peripheral vasodilation can drop BP.",
      "**Beers Criteria:** Avoid in elderly due to orthostasis."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Adenosine (Dipyridamole blocks uptake -> Potentiates adenosine effect markedly)", "Cholinesterase Inhibitors (Worsens Myasthenia Gravis)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "disulfiram": {
    "name": "Disulfiram (Antabuse)",
    "genericName": "Disulfiram",
    "formula": "C10H20N2S4",
    "molecularWeight": "296.5 g/mol",
    "brandNames": ["Antabuse"],
    "category": "Alcohol Deterrent",
    "drugClass": "Aldehyde Dehydrogenase Inhibitor",
    "pubchemCID": "3117",
    "indications": "Alcohol Use Disorder (Deterrent therapy).",
    "moaSteps": [
      "Irreversibly inhibits aldehyde dehydrogenase.",
      "Blocks the oxidation of acetaldehyde (alcohol metabolite) to acetate.",
      "Ingestion of alcohol leads to accumulation of acetaldehyde (5-10x normal).",
      "Causes 'Disulfiram-Alcohol Reaction': flushing, throbbing headache, nausea, vomiting, weakness."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (80%).",
      "distribution": "Lipid soluble.",
      "metabolism": "Hepatic.",
      "excretion": "Lung (carbon disulfide) and Urine. **Half-life: 60 to 120 hours (Effects last up to 14 days due to irreversible inhibition).**"
    },
    "dose": {
      "initialDose": "500 mg PO daily for 1-2 weeks",
      "maxDose": "250 mg/day (Maintenance)",
      "notes": "Do not administer until patient has abstained for 12 hours."
    },
    "adverseEffects": {
      "common": [
        "Metallic/Garlic taste",
        "Drowsiness",
        "Headache"
      ],
      "serious": [
        "Hepatotoxicity (Fatal Hepatitis)",
        "Severe Reaction with Alcohol (MI, CHF, Respiratory depression, Death)",
        "Psychosis",
        "Optic Neuritis"
      ]
    },
    "precautions": [
      "**Alcohol:** Reaction can occur with small amounts (mouthwash, sauces, vinegar). Reaction can be fatal.",
      "**Hepatotoxicity:** Monitor LFTs baseline and frequently.",
      "**Duration:** Reaction can occur up to 2 weeks after stopping drug."
    ],
    "contraindications": [
      "Alcohol intoxication or use within 12 hours",
      "Severe myocardial disease / Coronary occlusion",
      "Psychosis",
      "Concurrent Metronidazole use"
    ],
    "interactions": {
      "drug": ["Alcohol (Severe reaction)", "Metronidazole (Psychosis/Confusion)", "Warfarin (Increases INR)", "Phenytoin (Toxicity)"],
      "food": ["Alcohol (in any form)"]
    },
    "pregnancyCategory": "Category C"
  },
  "docetaxel": {
    "name": "Docetaxel (Taxotere)",
    "genericName": "Docetaxel",
    "formula": "C43H53NO14",
    "molecularWeight": "807.9 g/mol",
    "brandNames": ["Taxotere"],
    "category": "Antineoplastic",
    "drugClass": "Taxane (Microtubule Stabilizer)",
    "pubchemCID": "148124",
    "indications": "Breast Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Gastric Cancer.",
    "moaSteps": [
      "Binds to free tubulin and promotes the assembly of tubulin into stable microtubules.",
      "Inhibits microtubule depolymerization (disassembly).",
      "Results in bundles of stable microtubules and blockade of the cell cycle in M-phase (Mitosis).",
      "Induces apoptosis."
    ],
    "pharmacokinetics": {
      "absorption": "IV only.",
      "distribution": "94% protein bound.",
      "metabolism": "Hepatic via CYP3A4.",
      "excretion": "Feces. **Half-life: 11 hours (Terminal).**"
    },
    "dose": {
      "initialDose": "75-100 mg/m2 IV every 3 weeks",
      "maxDose": "Based on BSA",
      "notes": "Pre-medicate with Dexamethasone 8mg BID starting 1 day prior."
    },
    "adverseEffects": {
      "common": [
        "Alopecia (Total)",
        "Fluid Retention (Edema)",
        "Nail changes",
        "Stomatitis"
      ],
      "serious": [
        "Neutropenia (Dose-limiting) - BOXED WARNING",
        "Hypersensitivity (Anaphylaxis) - BOXED WARNING",
        "Fluid Retention (Severe effusion) - BOXED WARNING",
        "Toxic death in hepatic impairment"
      ]
    },
    "precautions": [
      "**Fluid Retention:** Dexamethasone premedication is mandatory to reduce edema/effusions.",
      "**Hepatic:** Contraindicated in severe hepatic impairment (high risk of toxic death). Monitor Bilirubin/AST/ALT.",
      "**Neutropenia:** Monitor CBC frequently."
    ],
    "contraindications": [
      "Neutrophil count < 1500",
      "Severe hypersensitivity to polysorbate 80",
      "Severe hepatic impairment"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inhibitors (Ketoconazole - increases toxicity)", "Doxorubicin"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "dofetilide": {
    "name": "Dofetilide (Tikosyn)",
    "genericName": "Dofetilide",
    "formula": "C19H27N3O5S2",
    "molecularWeight": "441.6 g/mol",
    "brandNames": ["Tikosyn"],
    "category": "Antiarrhythmic",
    "drugClass": "Class III Antiarrhythmic",
    "pubchemCID": "71329",
    "indications": "Maintenance of Normal Sinus Rhythm in Atrial Fibrillation/Flutter.",
    "moaSteps": [
      "Selectively blocks the rapid component of the delayed rectifier potassium current (IKr).",
      "Prolongs the action potential duration and effective refractory period.",
      "Does not affect sodium channels (no conduction slowing) or beta receptors.",
      "Pure Class III agent."
    ],
    "pharmacokinetics": {
      "absorption": "90% bioavailability.",
      "distribution": "60-70% protein bound.",
      "metabolism": "CYP3A4 (minor).",
      "excretion": "Renal (80%). **Half-life: 10 hours.**"
    },
    "dose": {
      "initialDose": "500 mcg PO twice daily",
      "maxDose": "500 mcg BID",
      "notes": "Must be initiated in hospital for 3 days to monitor QT."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Chest pain",
        "Dizziness"
      ],
      "serious": [
        "Torsades de Pointes (Fatal Arrhythmia) - BOXED WARNING"
      ]
    },
    "precautions": [
      "**QT Prolongation:** Risk of Torsades is dose-dependent and renal-dependent. ECG monitoring mandatory during initiation.",
      "**Renal:** Dose must be adjusted based on Creatinine Clearance. Contraindicated if CrCl < 20.",
      "**Electrolytes:** Hypokalemia/Hypomagnesemia increase arrhythmia risk; correct before use."
    ],
    "contraindications": [
      "QTc > 440 msec",
      "Severe renal impairment (CrCl < 20)",
      "Concomitant use with Cimetidine, Dolutegravir, HCTZ, Ketoconazole, Trimethoprim, Verapamil"
    ],
    "interactions": {
      "drug": ["HCTZ / Trimethoprim / Cimetidine / Dolutegravir (Inhibit renal secretion -> Toxic levels -> Torsades)", "QT prolonging drugs"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "dorzolamide": {
    "name": "Dorzolamide (Trusopt)",
    "genericName": "Dorzolamide HCl",
    "formula": "C10H16N2O5S3",
    "molecularWeight": "324.4 g/mol",
    "brandNames": ["Trusopt", "Cosopt (with Timolol)"],
    "category": "Glaucoma Agent",
    "drugClass": "Carbonic Anhydrase Inhibitor",
    "pubchemCID": "5284538",
    "indications": "Open-angle Glaucoma, Ocular Hypertension.",
    "moaSteps": [
      "Inhibits carbonic anhydrase II in the ciliary body.",
      "Decreases bicarbonate formation.",
      "Reduces sodium and fluid transport.",
      "Decreases aqueous humor secretion and lowers Intraocular Pressure (IOP)."
    ],
    "pharmacokinetics": {
      "absorption": "Systemic absorption occurs.",
      "distribution": "Accumulates in RBCs (binds CA-II).",
      "metabolism": "Metabolite active.",
      "excretion": "Urine. **Half-life: ~4 months (due to RBC binding).**"
    },
    "dose": {
      "initialDose": "1 drop in affected eye(s) TID",
      "maxDose": "TID",
      "notes": "Often used in combo with beta-blockers."
    },
    "adverseEffects": {
      "common": [
        "Bitter taste (Dysgeusia)",
        "Stinging / Burning",
        "Blurred vision"
      ],
      "serious": [
        "Sulfonamide Hypersensitivity (SJS/TEN - rare)",
        "Corneal Edema",
        "Kidney stones (systemic effect)"
      ]
    },
    "precautions": [
      "**Sulfa Allergy:** It is a sulfonamide; can cause systemic reactions.",
      "**Corneal Health:** Caution in corneal endothelial decompensation.",
      "**Contacts:** Remove lenses before use."
    ],
    "contraindications": [
      "Hypersensitivity to sulfonamides",
      "Severe renal impairment"
    ],
    "interactions": {
      "drug": ["Oral CA inhibitors (Additive systemic toxicity)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "doxazosin": {
    "name": "Doxazosin (Cardura)",
    "genericName": "Doxazosin Mesylate",
    "formula": "C23H25N5O5",
    "molecularWeight": "451.5 g/mol",
    "brandNames": ["Cardura", "Cardura XL"],
    "category": "BPH Agent / Antihypertensive",
    "drugClass": "Alpha-1 Blocker",
    "pubchemCID": "3157",
    "indications": "Benign Prostatic Hyperplasia (BPH), Hypertension.",
    "moaSteps": [
      "Selectively blocks postsynaptic alpha-1 adrenergic receptors.",
      "Relaxes smooth muscle in the bladder neck and prostate (improves flow).",
      "Relaxes vascular smooth muscle (decreases Total Peripheral Resistance and BP)."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "98% protein bound.",
      "metabolism": "Extensive hepatic (CYP3A4).",
      "excretion": "Feces. **Half-life: 22 hours.**"
    },
    "dose": {
      "initialDose": "1 mg PO once daily",
      "maxDose": "8 mg (BPH); 16 mg (HTN)",
      "notes": "Titrate slowly to prevent syncope."
    },
    "adverseEffects": {
      "common": [
        "Dizziness / Lightheadedness",
        "Fatigue",
        "Headache",
        "Edema"
      ],
      "serious": [
        "Orthostatic Hypotension / Syncope (First-dose phenomenon)",
        "Priapism",
        "Intraoperative Floppy Iris Syndrome (IFIS)"
      ]
    },
    "precautions": [
      "**First-Dose Effect:** Profound hypotension and syncope can occur with first dose or increase. Give at bedtime.",
      "**Cataract Surgery:** Inform surgeon; risk of IFIS.",
      "**Priapism:** Rare but requires urgent treatment."
    ],
    "contraindications": [
      "Hypersensitivity to quinazolines"
    ],
    "interactions": {
      "drug": ["PDE-5 Inhibitors (Sildenafil - Additive hypotension)", "Other antihypertensives"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "doxepin": {
    "name": "Doxepin (Silenor, Sinequan)",
    "genericName": "Doxepin HCl",
    "formula": "C19H21NO",
    "molecularWeight": "279.4 g/mol",
    "brandNames": ["Silenor", "Sinequan"],
    "category": "Antidepressant / Hypnotic",
    "drugClass": "Tricyclic Antidepressant (TCA)",
    "pubchemCID": "3158",
    "indications": "Depression / Anxiety (High dose), Insomnia (Low dose - Silenor), Topical for Pruritus.",
    "moaSteps": [
      "Inhibits reuptake of serotonin and norepinephrine (Antidepressant).",
      "Potent H1 receptor antagonist (Sedative/Hypnotic).",
      "Anticholinergic and alpha-blocking activity."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "Widely distributed.",
      "metabolism": "Hepatic (CYP2D6).",
      "excretion": "Urine. **Half-life: 8 to 24 hours (Parent); 30+ hours (Metabolite).**"
    },
    "dose": {
      "initialDose": "Depression: 25-75 mg daily; Insomnia: 3-6 mg daily",
      "maxDose": "300 mg/day (Depression)",
      "notes": "Low dose (3-6mg) acts purely as histamine blocker."
    },
    "adverseEffects": {
      "common": [
        "Sedation / Somnolence",
        "Dry mouth",
        "Constipation",
        "Weight gain"
      ],
      "serious": [
        "Suicidality - BOXED WARNING",
        "Arrhythmias / QT Prolongation",
        "Glaucoma",
        "Urinary Retention"
      ]
    },
    "precautions": [
      "**Suicide:** Monitor for worsening depression.",
      "**Anticholinergic:** High doses cause significant dry mouth, blurred vision, retention. Low doses (Silenor) are generally spared.",
      "**Cardiac:** Avoid in conduction abnormalities."
    ],
    "contraindications": [
      "MAOI use within 14 days",
      "Narrow-angle glaucoma",
      "Urinary retention"
    ],
    "interactions": {
      "drug": ["MAOIs (Fatal)", "CNS Depressants", "Cimetidine (Increased levels)"],
      "food": ["High fat meal delays absorption."]
    },
    "pregnancyCategory": "Category C"
  },
  "duloxetine": {
    "name": "Duloxetine (Cymbalta)",
    "genericName": "Duloxetine",
    "formula": "C18H19NOS",
    "molecularWeight": "297.4 g/mol",
    "brandNames": ["Cymbalta"],
    "category": "Antidepressant",
    "drugClass": "SNRI",
    "pubchemCID": "60835",
    "indications": "Major Depressive Disorder, Generalized Anxiety, Diabetic Neuropathy, Fibromyalgia, Chronic Musculoskeletal Pain.",
    "moaSteps": [
      "Potent inhibitor of serotonin and norepinephrine reuptake.",
      "Weak inhibitor of dopamine reuptake.",
      "Enhances descending inhibitory pain pathways in the CNS (Analgesic effect).",
      "Lacks affinity for muscarinic/histamine/alpha receptors."
    ],
    "pharmacokinetics": {
      "absorption": "Good absorption (delayed by food).",
      "distribution": "90% protein bound.",
      "metabolism": "Hepatic (CYP1A2 and CYP2D6).",
      "excretion": "Urine (metabolites). **Half-life: 12 hours.**"
    },
    "dose": {
      "initialDose": "30-60 mg PO once daily",
      "maxDose": "120 mg/day (Effectiveness >60mg not demonstrated)",
      "notes": "Swallow whole."
    },
    "adverseEffects": {
      "common": [
        "Nausea (very common)",
        "Dry mouth",
        "Insomnia / Somnolence",
        "Sweating",
        "Constipation"
      ],
      "serious": [
        "Suicidality - BOXED WARNING",
        "Hepatotoxicity",
        "Serotonin Syndrome",
        "Hypertension",
        "Severe Withdrawal Syndrome"
      ]
    },
    "precautions": [
      "**Hepatotoxicity:** Avoid in patients with substantial alcohol use or liver disease. Hepatic failure reported.",
      "**BP:** Can increase blood pressure.",
      "**Withdrawal:** Abrupt cessation causes 'brain zaps', dizziness, nausea. Taper slowly."
    ],
    "contraindications": [
      "MAOI use within 14 days",
      "Uncontrolled narrow-angle glaucoma"
    ],
    "interactions": {
      "drug": ["MAOIs (Fatal)", "CYP1A2 Inhibitors (Ciprofloxacin - Avoid combo)", "Antiplatelets (Bleeding risk)", "Thioridazine"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },"efavirenz": {
    "name": "Efavirenz (Sustiva)",
    "genericName": "Efavirenz",
    "formula": "C14H9ClF3NO2",
    "molecularWeight": "315.7 g/mol",
    "brandNames": ["Sustiva", "Atripla (combo)"],
    "category": "Antiretroviral",
    "drugClass": "Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)",
    "pubchemCID": "64139",
    "indications": "Treatment of HIV-1 infection.",
    "moaSteps": [
      "Binds directly to the HIV-1 reverse transcriptase enzyme (allosteric site).",
      "Induces a conformational change in the enzyme.",
      "Blocks the RNA-dependent and DNA-dependent DNA polymerase activities.",
      "Does not require intracellular phosphorylation."
    ],
    "pharmacokinetics": {
      "absorption": "Increased by high-fat meals (leading to toxicity).",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic via CYP2B6 and CYP3A4.",
      "excretion": "Feces and Urine. **Half-life: 40 to 55 hours.**"
    },
    "dose": {
      "initialDose": "600 mg PO once daily",
      "maxDose": "600 mg/day",
      "notes": "Take on an empty stomach at bedtime to reduce CNS side effects."
    },
    "adverseEffects": {
      "common": [
        "Dizziness / Vivid dreams",
        "Insomnia / Somnolence",
        "Rash",
        "Impaired concentration"
      ],
      "serious": [
        "Severe Psychiatric Symptoms (Depression, Suicidality, Psychosis)",
        "Hepatotoxicity",
        "QT Prolongation",
        "Neural tube defects (First trimester - controversial)"
      ]
    },
    "precautions": [
      "**CNS Effects:** 50% of patients experience CNS symptoms. Usually resolve after 2-4 weeks. Avoid in history of severe psychiatric illness.",
      "**Empty Stomach:** Taking with food increases absorption significantly and worsens CNS toxicity.",
      "**Hepatotoxicity:** Monitor liver enzymes."
    ],
    "contraindications": [
      "Hypersensitivity",
      "Concurrent use with Voriconazole (Efavirenz significantly reduces voriconazole levels)"
    ],
    "interactions": {
      "drug": ["Voriconazole (Contraindicated)", "Oral Contraceptives (Reduced efficacy)", "Benzodiazepines (Midazolam - Increased levels)"],
      "food": ["High fat meals increase absorption and toxicity."]
    },
    "pregnancyCategory": "Category D"
  },
  "eletriptan": {
    "name": "Eletriptan (Relpax)",
    "genericName": "Eletriptan",
    "formula": "C22H26N2O2S",
    "molecularWeight": "382.5 g/mol",
    "brandNames": ["Relpax"],
    "category": "Antimigraine",
    "drugClass": "Serotonin 5-HT1B/1D Receptor Agonist (Triptan)",
    "pubchemCID": "77993",
    "indications": "Acute treatment of Migraine with or without aura.",
    "moaSteps": [
      "Binds to 5-HT1B/1D receptors on intracranial blood vessels and sensory nerve endings.",
      "Causes vasoconstriction of dilated cranial arteries.",
      "Inhibits the release of pro-inflammatory neuropeptides (CGRP).",
      "Relieves migraine pain and associated symptoms."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed (50%).",
      "distribution": "85% protein bound.",
      "metabolism": "Hepatic via CYP3A4.",
      "excretion": "Non-renal clearance. **Half-life: ~4 hours.**"
    },
    "dose": {
      "initialDose": "20-40 mg PO at onset",
      "maxDose": "80 mg/day",
      "notes": "May repeat after 2 hours if partial relief."
    },
    "adverseEffects": {
      "common": [
        "Dizziness",
        "Nausea",
        "Chest pressure / tightness",
        "Paresthesia"
      ],
      "serious": [
        "Coronary Vasospasm / MI",
        "Serotonin Syndrome",
        "Hypertensive Crisis",
        "Stroke"
      ]
    },
    "precautions": [
      "**Cardiovascular:** Contraindicated in CAD, history of MI, or uncontrolled HTN due to vasoconstrictive effects.",
      "**Overuse:** Limit use to <10 days/month to prevent medication overuse headache.",
      "**CYP3A4:** Do not use within 72 hours of potent CYP3A4 inhibitors."
    ],
    "contraindications": [
      "Ischemic heart disease / Angina",
      "Uncontrolled hypertension",
      "Use of MAOIs within 14 days",
      "Potent CYP3A4 inhibitor use"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inhibitors (Ketoconazole - Toxicity)", "SSRIs/SNRIs (Serotonin Syndrome risk)", "Ergotamine (Vasospasm)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "empagliflozin": {
    "name": "Empagliflozin (Jardiance)",
    "genericName": "Empagliflozin",
    "formula": "C23H27ClO7",
    "molecularWeight": "450.9 g/mol",
    "brandNames": ["Jardiance"],
    "category": "Antidiabetic",
    "drugClass": "SGLT2 Inhibitor",
    "pubchemCID": "11949646",
    "indications": "Type 2 Diabetes, Heart Failure (HFrEF and HFpEF), Chronic Kidney Disease.",
    "moaSteps": [
      "Inhibits Sodium-Glucose Cotransporter 2 (SGLT2) in the proximal tubule.",
      "Blocks glucose reabsorption, increasing urinary glucose excretion.",
      "Causes osmotic diuresis and natriuresis, reducing preload and afterload.",
      "Slows progression of kidney disease."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "86% protein bound.",
      "metabolism": "Glucuronidation (UGT).",
      "excretion": "Urine and Feces. **Half-life: 12.4 hours.**"
    },
    "dose": {
      "initialDose": "10 mg PO once daily",
      "maxDose": "25 mg/day",
      "notes": "Approved for non-diabetic Heart Failure."
    },
    "adverseEffects": {
      "common": [
        "Genital Mycotic Infections",
        "UTIs",
        "Increased urination",
        "Thirst"
      ],
      "serious": [
        "Fournier's Gangrene (Necrotizing Fasciitis)",
        "Diabetic Ketoacidosis (Euglycemic)",
        "Urosepsis",
        "Volume Depletion / Hypotension"
      ]
    },
    "precautions": [
      "**Fournier's Gangrene:** Rare but serious. Advise patients to seek help for genital pain/swelling.",
      "**Ketoacidosis:** Can occur with normal blood sugar. Stop prior to surgery.",
      "**Volume:** Caution in elderly on diuretics."
    ],
    "contraindications": [
      "Dialysis patients",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Diuretics (Potentiates hypotension)", "Insulin (Hypoglycemia risk)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "emtricitabine": {
    "name": "Emtricitabine (Emtriva)",
    "genericName": "Emtricitabine (FTC)",
    "formula": "C8H10FN3O3S",
    "molecularWeight": "247.2 g/mol",
    "brandNames": ["Emtriva", "Truvada (combo)", "Descovy (combo)"],
    "category": "Antiretroviral",
    "drugClass": "Nucleoside Reverse Transcriptase Inhibitor (NRTI)",
    "pubchemCID": "60877",
    "indications": "HIV-1 Infection, Pre-Exposure Prophylaxis (PrEP - in combo).",
    "moaSteps": [
      "Cytidine analogue.",
      "Phosphorylated intracellularly to emtricitabine 5'-triphosphate.",
      "Competes with natural substrate deoxycytidine triphosphate.",
      "Inhibits HIV reverse transcriptase by chain termination."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (93% bioavailable).",
      "distribution": "<4% protein bound.",
      "metabolism": "Minimal.",
      "excretion": "Renal (Glomerular/Tubular). **Half-life: 10 hours.**"
    },
    "dose": {
      "initialDose": "200 mg PO once daily",
      "maxDose": "200 mg/day",
      "notes": "Also active against Hepatitis B."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Diarrhea",
        "Nausea",
        "Hyperpigmentation (Palms/Soles)"
      ],
      "serious": [
        "Lactic Acidosis / Severe Hepatomegaly (Class effect)",
        "Severe Acute Exacerbation of Hepatitis B (upon withdrawal)"
      ]
    },
    "precautions": [
      "**Hepatitis B:** Test all patients for HBV. If discontinued in HBV+ patient, severe flare can occur.",
      "**Renal:** Dose interval adjustment needed if CrCl < 50."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Lamivudine (Antagonistic - do not use together)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "enalapril": {
    "name": "Enalapril (Vasotec)",
    "genericName": "Enalapril Maleate",
    "formula": "C20H28N2O5",
    "molecularWeight": "376.4 g/mol",
    "brandNames": ["Vasotec", "Epaned"],
    "category": "Antihypertensive",
    "drugClass": "ACE Inhibitor",
    "pubchemCID": "5388962",
    "indications": "Hypertension, Heart Failure (HFrEF), Asymptomatic Left Ventricular Dysfunction.",
    "moaSteps": [
      "Prodrug converted to enalaprilat in the liver.",
      "Inhibits Angiotensin-Converting Enzyme (ACE).",
      "Reduces conversion of Angiotensin I to Angiotensin II.",
      "Decreases vasoconstriction and aldosterone secretion.",
      "Inhibits breakdown of bradykinin (vasodilator)."
    ],
    "pharmacokinetics": {
      "absorption": "60% absorbed.",
      "distribution": "50-60% protein bound.",
      "metabolism": "Hepatic hydrolysis to active enalaprilat.",
      "excretion": "Renal. **Half-life: 11 hours (Enalaprilat).**"
    },
    "dose": {
      "initialDose": "5 mg PO once daily",
      "maxDose": "40 mg/day (divided)",
      "notes": "Start 2.5 mg in Heart Failure."
    },
    "adverseEffects": {
      "common": [
        "Cough (Dry, non-productive)",
        "Dizziness / Hypotension",
        "Headache",
        "Hyperkalemia"
      ],
      "serious": [
        "Angioedema (Airway swelling) - Emergency",
        "Renal Failure (in renal artery stenosis)",
        "Fetal Toxicity - BOXED WARNING",
        "Agranulocytosis (rare)"
      ]
    },
    "precautions": [
      "**Fetal Toxicity:** Discontinue immediately in pregnancy.",
      "**Angioedema:** Higher risk in Black patients. Contraindicated if prior history.",
      "**Renal:** Monitor K+ and Cr. Transient rise in Cr is common."
    ],
    "contraindications": [
      "History of ACEI-associated angioedema",
      "Pregnancy",
      "Concomitant Aliskiren in diabetes"
    ],
    "interactions": {
      "drug": ["Potassium-sparing diuretics (Hyperkalemia)", "NSAIDs (Renal failure)", "Lithium"],
      "food": ["Salt substitutes (Potassium)"]
    },
    "pregnancyCategory": "Category D"
  },
  "enoxaparin": {
    "name": "Enoxaparin (Lovenox)",
    "genericName": "Enoxaparin Sodium",
    "formula": "Depolymerized Heparin",
    "molecularWeight": "4500 Da (average)",
    "brandNames": ["Lovenox"],
    "category": "Anticoagulant",
    "drugClass": "Low Molecular Weight Heparin (LMWH)",
    "pubchemCID": "None (Biologic)",
    "indications": "DVT/PE Treatment and Prophylaxis, Acute Coronary Syndromes (STEMI/NSTEMI/Unstable Angina).",
    "moaSteps": [
      "Potentiates the activity of Antithrombin III.",
      "Inhibits Factor Xa and Thrombin (Factor IIa).",
      "Has higher ratio of anti-Xa to anti-IIa activity (approx 4:1) compared to unfractionated heparin.",
      "Prevents clot formation and propagation."
    ],
    "pharmacokinetics": {
      "absorption": "High bioavailability (SubQ).",
      "distribution": "Vascular space.",
      "metabolism": "Hepatic desulfation/depolymerization.",
      "excretion": "Renal. **Half-life: 4.5 to 7 hours.**"
    },
    "dose": {
      "initialDose": "1 mg/kg SubQ every 12 hours (Treatment)",
      "maxDose": "Weight based",
      "notes": "Prophylaxis: 40 mg daily. Renal dose adjust needed."
    },
    "adverseEffects": {
      "common": [
        "Bleeding / Bruising",
        "Injection site hematoma",
        "Elevation of liver enzymes"
      ],
      "serious": [
        "Spinal/Epidural Hematoma (Paralysis) - BOXED WARNING",
        "Major Hemorrhage",
        "Heparin-Induced Thrombocytopenia (HIT)",
        "Osteoporosis (Long term)"
      ]
    },
    "precautions": [
      "**Neuraxial Anesthesia:** Do not place or remove epidural catheters while fully anticoagulated. Risk of spinal hematoma.",
      "**Renal Impairment:** Accumulates if CrCl < 30. Reduce dose to 1 mg/kg daily.",
      "**HIT:** Less risk than heparin, but cross-reactivity exists."
    ],
    "contraindications": [
      "Active major bleeding",
      "History of HIT (Heparin-Induced Thrombocytopenia)",
      "Hypersensitivity to pork products"
    ],
    "interactions": {
      "drug": ["Antiplatelets/NSAIDs (Additive bleeding)", "Warfarin"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "entacapone": {
    "name": "Entacapone (Comtan)",
    "genericName": "Entacapone",
    "formula": "C14H15N3O5",
    "molecularWeight": "305.3 g/mol",
    "brandNames": ["Comtan", "Stalevo (combo)"],
    "category": "Antiparkinson Agent",
    "drugClass": "COMT Inhibitor",
    "pubchemCID": "5281081",
    "indications": "Parkinson's Disease (Adjunct to Levodopa/Carbidopa for 'wearing-off').",
    "moaSteps": [
      "Selective and reversible inhibitor of catechol-O-methyltransferase (COMT) in the periphery.",
      "Prevents the degradation of levodopa to 3-O-methyldopa.",
      "Increases the bioavailability and half-life of levodopa.",
      "Allows more levodopa to cross the blood-brain barrier."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly absorbed.",
      "distribution": "98% protein bound.",
      "metabolism": "Hepatic glucuronidation and isomerization.",
      "excretion": "Feces (90%). **Half-life: 0.4 to 0.7 hours (Short, but effect relies on COMT inhibition).**"
    },
    "dose": {
      "initialDose": "200 mg PO with each levodopa dose",
      "maxDose": "1600 mg/day",
      "notes": "Must be taken WITH levodopa; no effect alone."
    },
    "adverseEffects": {
      "common": [
        "Dyskinesia (due to increased dopamine)",
        "Urine Discoloration (Orange/Brown)",
        "Diarrhea",
        "Nausea"
      ],
      "serious": [
        "Severe Colitis / Diarrhea",
        "Rhabdomyolysis",
        "Neuroleptic Malignant Syndrome (upon withdrawal)",
        "Hallucinations"
      ]
    },
    "precautions": [
      "**Urine Color:** Warn patient urine may turn harmless orange-brown.",
      "**Diarrhea:** Can cause severe delayed diarrhea (weeks/months later); may require discontinuation.",
      "**Dyskinesia:** May need to reduce levodopa dose upon initiation."
    ],
    "contraindications": [
      "History of hypersensitivity"
    ],
    "interactions": {
      "drug": ["Non-selective MAOIs", "Drugs metabolized by COMT (Epinephrine, Isoproterenol - tachycardia)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "entecavir": {
    "name": "Entecavir (Baraclude)",
    "genericName": "Entecavir",
    "formula": "C12H15N5O3",
    "molecularWeight": "277.3 g/mol",
    "brandNames": ["Baraclude"],
    "category": "Antiviral",
    "drugClass": "Nucleoside Analog",
    "pubchemCID": "135398508",
    "indications": "Chronic Hepatitis B Virus (HBV) infection.",
    "moaSteps": [
      "Guanosine nucleoside analogue.",
      "Phosphorylated to active triphosphate form.",
      "Competes with natural substrate deoxyguanosine triphosphate.",
      "Inhibits HBV polymerase (reverse transcriptase) at three steps: priming, reverse transcription, and DNA synthesis."
    ],
    "pharmacokinetics": {
      "absorption": "Food delays absorption significantly.",
      "distribution": "Extensive tissue distribution.",
      "metabolism": "Minimal.",
      "excretion": "Renal. **Half-life: 128 to 149 hours (Terminal accumulation).**"
    },
    "dose": {
      "initialDose": "0.5 mg PO once daily (Nucleoside-naive)",
      "maxDose": "1 mg/day (Lamivudine-refractory)",
      "notes": "Take on empty stomach (2 hours before/after meal)."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Fatigue",
        "Dizziness",
        "Nausea"
      ],
      "serious": [
        "Lactic Acidosis / Severe Hepatomegaly - BOXED WARNING",
        "Severe Acute Exacerbation of Hepatitis B (upon discontinuation) - BOXED WARNING",
        "HIV Resistance (if untreated HIV present) - BOXED WARNING"
      ]
    },
    "precautions": [
      "**HIV Coinfection:** Do not use alone in HIV/HBV coinfection; induces HIV resistance (M184V). Test HIV status first.",
      "**Withdrawal:** Monitor hepatic function for months after stopping.",
      "**Renal:** Dose adjust if CrCl < 50."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Drugs reducing renal function (increases levels)"],
      "food": ["Food decreases absorption significantly."]
    },
    "pregnancyCategory": "Category C"
  },
  "eplerenone": {
    "name": "Eplerenone (Inspra)",
    "genericName": "Eplerenone",
    "formula": "C24H30O6",
    "molecularWeight": "414.5 g/mol",
    "brandNames": ["Inspra"],
    "category": "Antihypertensive / Diuretic",
    "drugClass": "Selective Aldosterone Receptor Antagonist (SARA)",
    "pubchemCID": "443872",
    "indications": "Heart Failure post-MI, Hypertension.",
    "moaSteps": [
      "Selectively binds to mineralocorticoid receptors.",
      "Blocks the binding of aldosterone.",
      "Inhibits sodium and water reabsorption in the kidney.",
      "Reduces potassium excretion.",
      "Less affinity for androgen/progesterone receptors than Spironolactone (less gynecomastia)."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "50% protein bound.",
      "metabolism": "Hepatic via CYP3A4.",
      "excretion": "Urine and Feces. **Half-life: 4 to 6 hours.**"
    },
    "dose": {
      "initialDose": "25 mg PO once daily",
      "maxDose": "50 mg/day",
      "notes": "Check Potassium before starting."
    },
    "adverseEffects": {
      "common": [
        "Dizziness",
        "Fatigue",
        "Flu-like symptoms"
      ],
      "serious": [
        "Hyperkalemia (Fatal Arrhythmias)",
        "Renal impairment"
      ]
    },
    "precautions": [
      "**Hyperkalemia:** Contraindicated if K+ > 5.5 mEq/L or CrCl < 30 mL/min. Monitor K+ at 1 week and 1 month.",
      "**CYP3A4:** Contraindicated with potent CYP3A4 inhibitors.",
      "**Diabetes:** Higher risk of hyperkalemia in diabetics with proteinuria."
    ],
    "contraindications": [
      "Serum Potassium > 5.5 mEq/L",
      "Creatinine Clearance < 30 mL/min",
      "Concomitant strong CYP3A4 inhibitors (Ketoconazole, Ritonavir)"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inhibitors (Toxicity)", "ACEIs/ARBs (Hyperkalemia risk)", "NSAIDs (Renal risk)", "Lithium"],
      "food": ["Grapefruit juice (increases levels)"]
    },
    "pregnancyCategory": "Category B"
  },
  "epoetin": {
    "name": "Epoetin Alfa (Epogen, Procrit)",
    "genericName": "Epoetin Alfa",
    "formula": "Glycoprotein",
    "molecularWeight": "30.4 kDa",
    "brandNames": ["Epogen", "Procrit", "Retacrit"],
    "category": "Hematopoietic Agent",
    "drugClass": "Erythropoiesis-Stimulating Agent (ESA)",
    "pubchemCID": "None (Protein)",
    "indications": "Anemia due to CKD, Chemotherapy, or Zidovudine; Surgery (reduction of allogeneic blood transfusion).",
    "moaSteps": [
      "Induces erythropoiesis by stimulating the division and differentiation of committed erythroid progenitor cells.",
      "Induces the release of reticulocytes from the bone marrow into the bloodstream.",
      "Bio-identical to endogenous erythropoietin."
    ],
    "pharmacokinetics": {
      "absorption": "SC or IV.",
      "distribution": "Plasma and marrow.",
      "metabolism": "Degradation.",
      "excretion": "Urine. **Half-life: 4 to 13 hours (IV); longer for SC.**"
    },
    "dose": {
      "initialDose": "50-100 units/kg IV/SC 3 times weekly (CKD)",
      "maxDose": "Titrate to Hgb",
      "notes": "Do not target Hgb > 11 g/dL."
    },
    "adverseEffects": {
      "common": [
        "Hypertension",
        "Headache",
        "Joint pain",
        "Injection site pain"
      ],
      "serious": [
        "Cardiovascular Events (MI, Stroke) - BOXED WARNING",
        "Thromboembolism (DVT/PE) - BOXED WARNING",
        "Tumor Progression (in cancer) - BOXED WARNING",
        "Pure Red Cell Aplasia (PRCA)"
      ]
    },
    "precautions": [
      "**Target Hgb:** Targeting Hgb > 11 g/dL increases risk of death and cardiovascular events. Use lowest dose necessary to avoid transfusion.",
      "**Hypertension:** Can exacerbate HTN; control BP before starting.",
      "**Cancer:** Shortens survival in some cancers."
    ],
    "contraindications": [
      "Uncontrolled hypertension",
      "Pure Red Cell Aplasia",
      "Hypersensitivity to albumin/mammalian cell-derived products"
    ],
    "interactions": {
      "drug": ["None specific"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "eptifibatide": {
    "name": "Eptifibatide (Integrilin)",
    "genericName": "Eptifibatide",
    "formula": "C35H49N11O9S2",
    "molecularWeight": "831.96 g/mol",
    "brandNames": ["Integrilin"],
    "category": "Antiplatelet",
    "drugClass": "Glycoprotein IIb/IIIa Inhibitor",
    "pubchemCID": "123631",
    "indications": "Acute Coronary Syndrome (ACS), Percutaneous Coronary Intervention (PCI).",
    "moaSteps": [
      "Cyclic heptapeptide.",
      "Reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa receptors.",
      "Final common pathway inhibition of platelet clumping."
    ],
    "pharmacokinetics": {
      "absorption": "IV administration.",
      "distribution": "25% protein bound.",
      "metabolism": "Peptide hydrolysis (minimal).",
      "excretion": "Renal. **Half-life: 2.5 hours.**"
    },
    "dose": {
      "initialDose": "180 mcg/kg IV bolus",
      "maxDose": "2 mcg/kg/min infusion",
      "notes": "Reduce infusion by 50% if CrCl < 50."
    },
    "adverseEffects": {
      "common": [
        "Bleeding (Access site)",
        "Hypotension"
      ],
      "serious": [
        "Major Hemorrhage",
        "Thrombocytopenia (Immune-mediated)",
        "Anaphylaxis"
      ]
    },
    "precautions": [
      "**Bleeding:** Most common side effect. Discontinue if major bleed occurs.",
      "**Thrombocytopenia:** Platelet count can drop precipitously within hours. Monitor count.",
      "**Renal:** Clearance depends on kidneys; dose adjust."
    ],
    "contraindications": [
      "Active abnormal bleeding",
      "Severe hypertension (>200/110)",
      "Major surgery within 6 weeks",
      "Stroke within 30 days",
      "Dialysis dependency"
    ],
    "interactions": {
      "drug": ["Thrombolytics/Anticoagulants/Antiplatelets (Additive bleeding risk)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "erlotinib": {
    "name": "Erlotinib (Tarceva)",
    "genericName": "Erlotinib",
    "formula": "C22H23N3O4",
    "molecularWeight": "393.4 g/mol",
    "brandNames": ["Tarceva"],
    "category": "Antineoplastic",
    "drugClass": "EGFR Tyrosine Kinase Inhibitor (TKI)",
    "pubchemCID": "176870",
    "indications": "Non-Small Cell Lung Cancer (NSCLC) with EGFR mutation, Pancreatic Cancer.",
    "moaSteps": [
      "Reversibly inhibits the kinase activity of the Epidermal Growth Factor Receptor (EGFR/HER1).",
      "Prevents autophosphorylation of tyrosine residues.",
      "Inhibits downstream signaling involved in cell proliferation and survival."
    ],
    "pharmacokinetics": {
      "absorption": "60% absorbed; food increases to 100%.",
      "distribution": "93% protein bound.",
      "metabolism": "Hepatic via CYP3A4 and CYP1A2.",
      "excretion": "Feces. **Half-life: 36.2 hours.**"
    },
    "dose": {
      "initialDose": "150 mg PO once daily (NSCLC)",
      "maxDose": "150 mg/day",
      "notes": "Take on empty stomach (1 hr before/2 hrs after food)."
    },
    "adverseEffects": {
      "common": [
        "Acneiform Rash (correlates with response)",
        "Diarrhea",
        "Fatigue",
        "Anorexia"
      ],
      "serious": [
        "Interstitial Lung Disease (Fatal)",
        "Hepatotoxicity / Renal Failure",
        "GI Perforation",
        "Bullous skin disorders (SJS/TEN)"
      ]
    },
    "precautions": [
      "**Lung Disease:** Monitor for new pulmonary symptoms (dyspnea, cough, fever). Discontinue if ILD suspected.",
      "**Rash:** Manage with topical antibiotics/steroids. Sun protection required.",
      "**Smoking:** Induces CYP1A2, reducing drug levels. Dose increase may be needed in smokers."
    ],
    "contraindications": [
      "None absolute (other than hypersensitivity)"
    ],
    "interactions": {
      "drug": ["PPIs/H2 Blockers (Reduce absorption - Avoid)", "CYP3A4 Inhibitors/Inducers", "Warfarin (INR elevation)"],
      "food": ["Grapefruit juice (increases levels). Take on empty stomach."]
    },
    "pregnancyCategory": "Category D"
  },
  "ertapenem": {
    "name": "Ertapenem (Invanz)",
    "genericName": "Ertapenem",
    "formula": "C22H25N3O7S",
    "molecularWeight": "475.5 g/mol",
    "brandNames": ["Invanz"],
    "category": "Antibiotic",
    "drugClass": "Carbapenem",
    "pubchemCID": "150610",
    "indications": "Complicated Intra-abdominal infections, Skin infections, Community-Acquired Pneumonia, UTIs.",
    "moaSteps": [
      "Binds to penicillin-binding proteins (PBPs).",
      "Inhibits bacterial cell wall synthesis.",
      "Broad spectrum: Gram-positives, Gram-negatives (ESBLs), Anaerobes.",
      "**Does NOT cover Pseudomonas or Acinetobacter.**"
    ],
    "pharmacokinetics": {
      "absorption": "IV/IM only.",
      "distribution": "High protein binding (95%).",
      "metabolism": "Hydrolysis by renal dehydropeptidase.",
      "excretion": "Urine. **Half-life: 4 hours (Allows once-daily dosing).**"
    },
    "dose": {
      "initialDose": "1 g IV/IM once daily",
      "maxDose": "1 g/day",
      "notes": "Convenient for outpatient parenteral therapy (OPAT)."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea",
        "Infusion vein inflammation",
        "Nausea",
        "Headache"
      ],
      "serious": [
        "Seizures (especially in renal impairment)",
        "Anaphylaxis",
        "Clostridioides difficile colitis"
      ]
    },
    "precautions": [
      "**Seizures:** Risk with carbapenems, especially if renal function not accounted for. Avoid in unstable epilepsy.",
      "**Spectrum:** Remember 'Ertapenem is the Exception' - lacks Pseudomonas coverage.",
      "**Valproic Acid:** Rapidly lowers VPA levels, causing breakthrough seizures."
    ],
    "contraindications": [
      "Hypersensitivity to carbapenems/beta-lactams",
      "Severe hypersensitivity to lidocaine (if used as IM diluent)"
    ],
    "interactions": {
      "drug": ["Valproic Acid (Contraindicated - Loss of seizure control)", "Probenecid"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "erythromycin": {
    "name": "Erythromycin",
    "genericName": "Erythromycin",
    "formula": "C37H67NO13",
    "molecularWeight": "733.9 g/mol",
    "brandNames": ["E.E.S.", "Ery-Tab", "Erythrocin"],
    "category": "Antibiotic",
    "drugClass": "Macrolide",
    "pubchemCID": "12560",
    "indications": "Respiratory tract infections, Pertussis, Chlamydia, Gastroparesis (Prokinetic).",
    "moaSteps": [
      "Binds to the 50S ribosomal subunit.",
      "Inhibits protein synthesis (translocation step).",
      "Bacteriostatic.",
      "Also acts as a motilin receptor agonist (stimulates GI motility)."
    ],
    "pharmacokinetics": {
      "absorption": "Variable; acid-labile.",
      "distribution": "Widely distributed.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Bile/Feces. **Half-life: 1.5 to 2 hours.**"
    },
    "dose": {
      "initialDose": "250-500 mg PO every 6 hours",
      "maxDose": "4 g/day",
      "notes": "GI intolerance is dose-limiting."
    },
    "adverseEffects": {
      "common": [
        "Severe GI upset (Nausea/Vomiting/Cramps)",
        "Diarrhea",
        "Phlebitis (IV)"
      ],
      "serious": [
        "QT Prolongation / Torsades de Pointes",
        "Hepatotoxicity (Estolate formulation)",
        "Infantile Hypertrophic Pyloric Stenosis",
        "Ototoxicity (High dose)"
      ]
    },
    "precautions": [
      "**Interactions:** Potent CYP3A4 inhibitor. Many dangerous interactions.",
      "**QT:** Avoid in patients with QT prolongation or on other QT drugs.",
      "**Infants:** Use in neonates associated with pyloric stenosis."
    ],
    "contraindications": [
      "Concomitant use with Simvastatin, Lovastatin, Ergotamine, Pimozide",
      "History of cholestatic jaundice with use"
    ],
    "interactions": {
      "drug": ["Statins (Rhabdomyolysis - Contraindicated)", "Warfarin (Bleeding)", "Carbamazepine/Theophylline (Toxicity)", "Digoxin"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "escitalopram": {
    "name": "Escitalopram (Lexapro)",
    "genericName": "Escitalopram Oxalate",
    "formula": "C20H21FN2O",
    "molecularWeight": "324.4 g/mol",
    "brandNames": ["Lexapro"],
    "category": "Antidepressant",
    "drugClass": "SSRI",
    "pubchemCID": "146570",
    "indications": "Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD).",
    "moaSteps": [
      "S-enantiomer of citalopram (most active isomer).",
      "Highly selective inhibitor of serotonin reuptake.",
      "Increases synaptic serotonin.",
      "Minimal effect on NE/DA reuptake."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "56% protein bound.",
      "metabolism": "Hepatic (CYP3A4/2C19).",
      "excretion": "Urine. **Half-life: 27 to 32 hours.**"
    },
    "dose": {
      "initialDose": "10 mg PO once daily",
      "maxDose": "20 mg/day",
      "notes": "10 mg Escitalopram ≈ 20-40 mg Citalopram."
    },
    "adverseEffects": {
      "common": [
        "Nausea",
        "Insomnia / Somnolence",
        "Sexual Dysfunction (Anorgasmia/Libido)",
        "Sweating"
      ],
      "serious": [
        "Suicidal Ideation (Young adults) - BOXED WARNING",
        "Serotonin Syndrome",
        "QT Prolongation (Less than Citalopram but possible)",
        "Hyponatremia"
      ]
    },
    "precautions": [
      "**Suicide:** Monitor for worsening depression.",
      "**Sexual Side Effects:** Common cause of non-adherence.",
      "**Bleeding:** Caution with NSAIDs (impairs platelet aggregation).",
      "**Withdrawal:** Taper slowly."
    ],
    "contraindications": [
      "MAOI use within 14 days",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["MAOIs (Fatal)", "Serotonergic agents (Triptans, Tramadol)", "NSAIDs (Bleeding risk)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "esomeprazole": {
    "name": "Esomeprazole (Nexium)",
    "genericName": "Esomeprazole Magnesium",
    "formula": "C17H19N3O3S",
    "molecularWeight": "345.4 g/mol",
    "brandNames": ["Nexium"],
    "category": "Acid Reducer",
    "drugClass": "Proton Pump Inhibitor (PPI)",
    "pubchemCID": "9568614",
    "indications": "GERD, Erosive Esophagitis, H. pylori eradication, Zollinger-Ellison Syndrome, NSAID ulcer prophylaxis.",
    "moaSteps": [
      "S-isomer of omeprazole.",
      "Irreversibly binds to the H+/K+ ATPase pump in parietal cells.",
      "Blocks the final step of acid production.",
      "Provides better acid control than omeprazole due to slower metabolism."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (acid labile, enteric coated).",
      "distribution": "97% protein bound.",
      "metabolism": "Hepatic via CYP2C19.",
      "excretion": "Urine (80%). **Half-life: 1 to 1.5 hours (Duration >24h).**"
    },
    "dose": {
      "initialDose": "20-40 mg PO once daily",
      "maxDose": "40 mg BID (Zollinger-Ellison)",
      "notes": "Take 1 hour before meals."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Diarrhea",
        "Abdominal pain",
        "Flatulence"
      ],
      "serious": [
        "Clostridioides difficile infection",
        "Osteoporosis / Fracture",
        "Hypomagnesemia",
        "Acute Interstitial Nephritis",
        "B12 Deficiency (long term)"
      ]
    },
    "precautions": [
      "**Bone Health:** Calcium citrate recommended for long-term users.",
      "**Infection:** Pneumonia and C. diff risk increased.",
      "**Magnesium:** Monitor Mg in long-term use."
    ],
    "contraindications": [
      "Hypersensitivity",
      "Concomitant Rilpivirine"
    ],
    "interactions": {
      "drug": ["Clopidogrel (Reduces efficacy - controversial)", "Rilpivirine/Atazanavir (Decreased absorption - Contraindicated)", "Methotrexate (Toxic levels)"],
      "food": ["Food decreases absorption. Take on empty stomach."]
    },
    "pregnancyCategory": "Category C"
  },
  "estradiol": {
    "name": "Estradiol (Estrace, Climara)",
    "genericName": "Estradiol",
    "formula": "C18H24O2",
    "molecularWeight": "272.4 g/mol",
    "brandNames": ["Estrace", "Climara", "Vivelle-Dot", "Vagifem"],
    "category": "Hormone",
    "drugClass": "Estrogen",
    "pubchemCID": "5757",
    "indications": "Vasomotor symptoms of menopause (Hot flashes), Vulvar/Vaginal atrophy, Hypogonadism, Osteoporosis prevention.",
    "moaSteps": [
      "Binds to nuclear estrogen receptors (ER-alpha and ER-beta).",
      "Modulates gene transcription.",
      "Develops/maintains female sexual characteristics.",
      "Inhibits bone resorption.",
      "Reduces LH/FSH via negative feedback."
    ],
    "pharmacokinetics": {
      "absorption": "Micronized oral well absorbed but high first-pass. Transdermal bypasses liver.",
      "distribution": "Sex hormone binding globulin (SHBG) bound.",
      "metabolism": "Hepatic (CYP3A4) to estrone/estriol.",
      "excretion": "Urine. **Half-life: 13 to 20 hours.**"
    },
    "dose": {
      "initialDose": "0.5-1 mg PO daily; 0.025-0.05 mg patch twice weekly",
      "maxDose": "Symptom dependent",
      "notes": "Must add Progestin if uterus is intact (to prevent endometrial cancer)."
    },
    "adverseEffects": {
      "common": [
        "Breast tenderness",
        "Nausea",
        "Fluid retention / Bloating",
        "Headache"
      ],
      "serious": [
        "Endometrial Cancer (unopposed estrogen) - BOXED WARNING",
        "Thromboembolism (VTE/PE/Stroke) - BOXED WARNING",
        "Breast Cancer risk - BOXED WARNING",
        "Dementia risk (Age > 65) - BOXED WARNING"
      ]
    },
    "precautions": [
      "**Thrombosis:** Increases clotting factors. Contraindicated in history of VTE/Stroke.",
      "**Cancer:** Estrogen-dependent tumors (Breast/Uterine) are contraindications.",
      "**Surgery:** Stop 4-6 weeks prior to major surgery."
    ],
    "contraindications": [
      "Undiagnosed vaginal bleeding",
      "History of DVT/PE/Stroke/MI",
      "Breast cancer (known or suspected)",
      "Pregnancy"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inducers (St. John's Wort, Rifampin - reduce efficacy)", "Thyroid hormone (increases TBG, may need higher levothyroxine dose)"],
      "food": ["Grapefruit juice (increases levels)"]
    },
    "pregnancyCategory": "Category X"
  },
  "etanercept": {
    "name": "Etanercept (Enbrel)",
    "genericName": "Etanercept",
    "formula": "Dimercaprol fusion protein",
    "molecularWeight": "150 kDa",
    "brandNames": ["Enbrel", "Erelzi"],
    "category": "Biologic DMARD",
    "drugClass": "TNF Alpha Inhibitor",
    "pubchemCID": "None (Protein)",
    "indications": "Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Juvenile Idiopathic Arthritis.",
    "moaSteps": [
      "Recombinant dimeric fusion protein (TNFR receptor linked to IgG1 Fc).",
      "Acts as a soluble decoy receptor.",
      "Binds to TNF-alpha and TNF-beta.",
      "Prevents TNF from interacting with cell surface receptors.",
      "Reduces inflammation."
    ],
    "pharmacokinetics": {
      "absorption": "Subcutaneous (60% bioavailable).",
      "distribution": "Vascular.",
      "metabolism": "Proteolysis.",
      "excretion": "N/A. **Half-life: 102 hours (~4.25 days).**"
    },
    "dose": {
      "initialDose": "50 mg SubQ once weekly",
      "maxDose": "50 mg twice weekly (Psoriasis induction)",
      "notes": "Rotate injection sites."
    },
    "adverseEffects": {
      "common": [
        "Injection site reaction",
        "Upper respiratory infection",
        "Headache"
      ],
      "serious": [
        "Serious Infections (TB, Sepsis, Fungal) - BOXED WARNING",
        "Malignancy (Lymphoma) - BOXED WARNING",
        "Demyelinating Disease (MS-like)",
        "Heart Failure exacerbation",
        "Lupus-like syndrome"
      ]
    },
    "precautions": [
      "**Infection:** Do not start in active infection. TB screening mandatory.",
      "**Live Vaccines:** Contraindicated.",
      "**Hep B:** Reactivation possible.",
      "**Neurologic:** Stop if demyelinating disorders occur."
    ],
    "contraindications": [
      "Sepsis",
      "Active serious infection",
      "Concurrent Anakinra/Abatacept"
    ],
    "interactions": {
      "drug": ["Live Vaccines", "Cyclophosphamide", "Other Biologics"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "ethambutol": {
    "name": "Ethambutol (Myambutol)",
    "genericName": "Ethambutol HCl",
    "formula": "C10H24N2O2",
    "molecularWeight": "204.3 g/mol",
    "brandNames": ["Myambutol"],
    "category": "Antimycobacterial",
    "drugClass": "Antitubercular Agent",
    "pubchemCID": "14052",
    "indications": "Pulmonary Tuberculosis (TB) - part of RIPE therapy.",
    "moaSteps": [
      "Inhibits arabinosyl transferase enzymes.",
      "Disrupts the synthesis of arabinogalactan, a key component of the mycobacterial cell wall.",
      "Bacteriostatic against actively dividing bacilli."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed (80%).",
      "distribution": "Widely distributed (except CSF unless inflamed).",
      "metabolism": "Partial hepatic.",
      "excretion": "Urine (50% unchanged). **Half-life: 3 to 4 hours.**"
    },
    "dose": {
      "initialDose": "15-25 mg/kg PO once daily",
      "maxDose": "2.5 g/day",
      "notes": "Renal adjustment needed."
    },
    "adverseEffects": {
      "common": [
        "Hyperuricemia (Gout)",
        "GI upset",
        "Dizziness"
      ],
      "serious": [
        "Optic Neuritis (Retrobulbar) - Dose dependent",
        "Blindness (Red-Green color loss)",
        "Peripheral Neuropathy"
      ]
    },
    "precautions": [
      "**Vision:** Optic neuritis is main concern. Baseline and monthly vision tests (acuity/color) required. Stop immediately if changes occur (usually reversible).",
      "**Children:** Avoid in young children who cannot report vision changes.",
      "**Renal:** Accumulates in renal failure; dose adjustment critical to prevent eye toxicity."
    ],
    "contraindications": [
      "Known optic neuritis",
      "Hypersensitivity",
      "Children < 13 years (Precaution)"
    ],
    "interactions": {
      "drug": ["Aluminum Hydroxide (Decreases absorption - separate by 4h)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "ezetimibe": {
    "name": "Ezetimibe (Zetia)",
    "genericName": "Ezetimibe",
    "formula": "C24H21F2NO3",
    "molecularWeight": "409.4 g/mol",
    "brandNames": ["Zetia"],
    "category": "Antilipemic",
    "drugClass": "Cholesterol Absorption Inhibitor",
    "pubchemCID": "150311",
    "indications": "Hyperlipidemia (Adjunct to statin or monotherapy).",
    "moaSteps": [
      "Localizes at the brush border of the small intestine.",
      "Inhibits the sterol transporter Niemann-Pick C1-Like 1 (NPC1L1).",
      "Blocks absorption of dietary and biliary cholesterol.",
      "Reduces hepatic cholesterol stores and increases LDL clearance."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "99% protein bound.",
      "metabolism": "Intestine/Liver glucuronidation (Active metabolite). Enterohepatic recycling.",
      "excretion": "Feces (78%). **Half-life: 22 hours.**"
    },
    "dose": {
      "initialDose": "10 mg PO once daily",
      "maxDose": "10 mg/day",
      "notes": "Modest LDL reduction (18%) alone; synergistic with statins."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea",
        "Upper respiratory infection",
        "Arthralgia",
        "Fatigue"
      ],
      "serious": [
        "Elevated Transaminases (with statins)",
        "Myopathy / Rhabdomyolysis (rare alone)",
        "Hypersensitivity (Angioedema)"
      ]
    },
    "precautions": [
      "**Liver:** Monitor LFTs when used with statin.",
      "**Hepatic Impairment:** Not recommended in moderate/severe impairment (levels increase significantly).",
      "**Cyclosporine:** Increases levels of both drugs."
    ],
    "contraindications": [
      "Active liver disease (when used with statin)",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Cyclosporine (Increased levels)", "Fibrates (Cholelithiasis risk - avoid gemfibrozil)", "Bile Acid Sequestrants (Bind ezetimibe - separate dose)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },"famotidine": {
    "name": "Famotidine (Pepcid)",
    "genericName": "Famotidine",
    "formula": "C8H15N7O2S3",
    "molecularWeight": "337.4 g/mol",
    "brandNames": ["Pepcid", "Pepcid AC"],
    "category": "Acid Reducer",
    "drugClass": "Histamine H2 Antagonist",
    "pubchemCID": "3325",
    "indications": "GERD, Peptic Ulcer Disease, Zollinger-Ellison Syndrome, Stress Ulcer Prophylaxis.",
    "moaSteps": [
      "Competitively inhibits histamine at H2 receptors of the gastric parietal cells.",
      "Inhibits basal, nocturnal, and food-stimulated gastric acid secretion.",
      "Reduces both the volume and the hydrogen ion concentration of gastric juice."
    ],
    "pharmacokinetics": {
      "absorption": "Incompletely absorbed (40-45% bioavailability).",
      "distribution": "Minimal protein binding.",
      "metabolism": "Minimal hepatic metabolism.",
      "excretion": "Urine (unchanged). **Half-life: 2.5 to 3.5 hours.**"
    },
    "dose": {
      "initialDose": "20 mg PO/IV twice daily",
      "maxDose": "160 mg/day (Hypersecretory conditions)",
      "notes": "Dose reduce in renal impairment."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Dizziness",
        "Constipation / Diarrhea"
      ],
      "serious": [
        "QT Prolongation (in renal failure)",
        "Delirium (in elderly/renal failure)",
        "Blood dyscrasias (rare)"
      ]
    },
    "precautions": [
      "**Renal Impairment:** CNS adverse effects (confusion, delirium) are common if dose not reduced in renal failure (CrCl < 50).",
      "**Elderly:** Beers Criteria - avoid in delirium risk."
    ],
    "contraindications": [
      "Hypersensitivity to H2 blockers"
    ],
    "interactions": {
      "drug": ["Cefpodoxime/Cefuroxime (Reduced absorption due to pH change)", "Tizanidine (Avoid)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "febuxostat": {
    "name": "Febuxostat (Uloric)",
    "genericName": "Febuxostat",
    "formula": "C16H16N2O3S",
    "molecularWeight": "316.4 g/mol",
    "brandNames": ["Uloric"],
    "category": "Antigout Agent",
    "drugClass": "Xanthine Oxidase Inhibitor",
    "pubchemCID": "134018",
    "indications": "Chronic management of Hyperuricemia in Gout.",
    "moaSteps": [
      "Non-purine selective inhibitor of xanthine oxidase.",
      "Inhibits the conversion of hypoxanthine to xanthine and xanthine to uric acid.",
      "More potent and selective than allopurinol."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed (85%).",
      "distribution": "99% protein bound.",
      "metabolism": "Extensive hepatic (UGT and oxidation).",
      "excretion": "Urine and Feces. **Half-life: 5 to 8 hours.**"
    },
    "dose": {
      "initialDose": "40 mg PO once daily",
      "maxDose": "80 mg/day",
      "notes": "Use prophylaxis (NSAID/Colchicine) when starting."
    },
    "adverseEffects": {
      "common": [
        "Liver enzyme elevation",
        "Nausea",
        "Arthralgia",
        "Rash"
      ],
      "serious": [
        "Cardiovascular Death (Higher risk than Allopurinol) - BOXED WARNING",
        "Stevens-Johnson Syndrome",
        "Hepatic Failure"
      ]
    },
    "precautions": [
      "**Cardiovascular Risk:** Boxed warning for higher rate of CV death compared to allopurinol. Reserve for patients who fail allopurinol.",
      "**Gout Flare:** Initiation precipitates flares; cover with prophylaxis for 6 months."
    ],
    "contraindications": [
      "Concomitant use of Azathioprine or Mercaptopurine"
    ],
    "interactions": {
      "drug": ["Azathioprine/Mercaptopurine (Fatal toxicity - Contraindicated)", "Theophylline"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "fenofibrate": {
    "name": "Fenofibrate (Tricor)",
    "genericName": "Fenofibrate",
    "formula": "C20H21ClO4",
    "molecularWeight": "360.8 g/mol",
    "brandNames": ["Tricor", "Trilipix", "Antara"],
    "category": "Antilipemic",
    "drugClass": "Fibric Acid Derivative (Fibrate)",
    "pubchemCID": "3339",
    "indications": "Hypertriglyceridemia, Mixed Dyslipidemia.",
    "moaSteps": [
      "Activates Peroxisome Proliferator-Activated Receptor alpha (PPAR-alpha).",
      "Increases lipolysis and elimination of triglyceride-rich particles via lipoprotein lipase.",
      "Reduces production of apoprotein C-III (an inhibitor of lipoprotein lipase).",
      "Significantly lowers triglycerides and raises HDL."
    ],
    "pharmacokinetics": {
      "absorption": "Increased by food.",
      "distribution": "99% protein bound.",
      "metabolism": "Active metabolite fenofibric acid.",
      "excretion": "Urine. **Half-life: 20 hours.**"
    },
    "dose": {
      "initialDose": "145 mg (Tricor) PO once daily",
      "maxDose": "145 mg/day",
      "notes": "Dosing varies by formulation (nanocrystal vs micronized)."
    },
    "adverseEffects": {
      "common": [
        "Abdominal pain",
        "Back pain",
        "Nausea",
        "Headache"
      ],
      "serious": [
        "Rhabdomyolysis (especially with statins)",
        "Cholelithiasis (Gallstones)",
        "Pancreatitis",
        "Hepatotoxicity"
      ]
    },
    "precautions": [
      "**Renal:** Contraindicated in severe renal impairment. Accumulates rapidly.",
      "**Muscle:** Risk of myopathy increases when used with statins (though safer than gemfibrozil).",
      "**Gallstones:** Increases biliary cholesterol excretion."
    ],
    "contraindications": [
      "Severe renal impairment (CrCl < 30)",
      "Active liver disease",
      "Gallbladder disease",
      "Nursing mothers"
    ],
    "interactions": {
      "drug": ["Warfarin (Increases INR - reduce warfarin by 1/3)", "Statins (Myopathy risk)", "Cyclosporine (Nephrotoxicity)"],
      "food": ["Take with food (some formulations)."]
    },
    "pregnancyCategory": "Category C"
  },
  "fentanyl": {
    "name": "Fentanyl (Duragesic)",
    "genericName": "Fentanyl",
    "formula": "C22H28N2O",
    "molecularWeight": "336.5 g/mol",
    "brandNames": ["Duragesic (Patch)", "Sublimaze (IV)", "Actiq (Lozenge)"],
    "category": "Opioid Analgesic",
    "drugClass": "Synthetic Opioid Agonist",
    "pubchemCID": "3345",
    "indications": "Severe chronic pain (Patch), Anesthesia adjunct (IV), Breakthrough cancer pain (Lozenge/Spray).",
    "moaSteps": [
      "Potent agonist at mu-opioid receptors in the CNS.",
      "Increases pain threshold and alters pain perception.",
      "Inhibits ascending pain pathways.",
      "Approx 50-100x more potent than morphine."
    ],
    "pharmacokinetics": {
      "absorption": "Transdermal (slow onset), IV (immediate), Transmucosal (rapid).",
      "distribution": "Highly lipid soluble; rapid redistribution.",
      "metabolism": "Hepatic via CYP3A4.",
      "excretion": "Urine. **Half-life: 3-12 hours (IV); 20-27 hours (Patch - due to skin depot).**"
    },
    "dose": {
      "initialDose": "25 mcg/hr Patch every 72 hours (Opioid tolerant only)",
      "maxDose": "Titrate to effect",
      "notes": "Patch is NOT for acute pain or opioid-naive patients."
    },
    "adverseEffects": {
      "common": [
        "Sedation",
        "Constipation",
        "Nausea / Vomiting",
        "Pruritus"
      ],
      "serious": [
        "Respiratory Depression (Fatal) - BOXED WARNING",
        "Serotonin Syndrome",
        "Adrenal Insufficiency",
        "Chest Wall Rigidity (Rapid IV)"
      ]
    },
    "precautions": [
      "**Heat:** Heat applied to patch (heating pad, fever) drastically increases absorption -> Fatal Overdose.",
      "**Opioid Naive:** Patch/Transmucosal forms contraindicated in opioid-naive patients.",
      "**Disposal:** Fold patch and flush; lethal to children/pets."
    ],
    "contraindications": [
      "Opioid naive patients (for patch/transmucosal)",
      "Severe respiratory depression",
      "Acute/Post-op pain (for patch)"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inhibitors (Fatal toxicity)", "Benzodiazepines (Respiratory collapse)", "MAOIs"],
      "food": ["Grapefruit juice (increases levels)"]
    },
    "pregnancyCategory": "Category C"
  },
  "fexofenadine": {
    "name": "Fexofenadine (Allegra)",
    "genericName": "Fexofenadine HCl",
    "formula": "C32H39NO4",
    "molecularWeight": "501.7 g/mol",
    "brandNames": ["Allegra"],
    "category": "Antihistamine",
    "drugClass": "H1 Receptor Antagonist (Second Generation)",
    "pubchemCID": "3348",
    "indications": "Seasonal Allergic Rhinitis, Chronic Idiopathic Urticaria.",
    "moaSteps": [
      "Active metabolite of terfenadine.",
      "Selectively antagonizes peripheral histamine H1 receptors.",
      "Does not cross the blood-brain barrier.",
      "True 'non-sedating' antihistamine."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "60-70% protein bound.",
      "metabolism": "Minimal (~5%).",
      "excretion": "Feces and Urine. **Half-life: 14.4 hours.**"
    },
    "dose": {
      "initialDose": "60 mg PO BID or 180 mg once daily",
      "maxDose": "180 mg/day",
      "notes": "Do not take with fruit juice."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Nausea",
        "Dizziness"
      ],
      "serious": [
        "Hypersensitivity (Angioedema, Rash)"
      ]
    },
    "precautions": [
      "**Fruit Juice:** Apple, orange, and grapefruit juice reduce absorption by inhibiting OATP transporters. Separate by 4 hours.",
      "**Renal:** Dose adjustment recommended in renal impairment."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Antacids (Aluminum/Magnesium - reduce absorption)", "Ketoconazole/Erythromycin (Increase levels but no QT risk)"],
      "food": ["Fruit juices (Decrease efficacy)"]
    },
    "pregnancyCategory": "Category C"
  },
  "fidaxomicin": {
    "name": "Fidaxomicin (Dificid)",
    "genericName": "Fidaxomicin",
    "formula": "C52H74Cl2O18",
    "molecularWeight": "1058.0 g/mol",
    "brandNames": ["Dificid"],
    "category": "Antibiotic",
    "drugClass": "Macrolide (Macrocyclic)",
    "pubchemCID": "10066669",
    "indications": "Clostridioides difficile-associated diarrhea (CDAD).",
    "moaSteps": [
      "Inhibits RNA synthesis by binding to RNA polymerase (distinct site from rifamycins).",
      "Bactericidal against C. difficile.",
      "Narrow spectrum; spares normal gut flora (Bacteroides) unlike vancomycin."
    ],
    "pharmacokinetics": {
      "absorption": "Minimal systemic absorption.",
      "distribution": "Confined to GI tract.",
      "metabolism": "Hydrolysis in gut.",
      "excretion": "Feces. **Half-life: ~117 hours (Fecal recovery).**"
    },
    "dose": {
      "initialDose": "200 mg PO twice daily for 10 days",
      "maxDose": "400 mg/day",
      "notes": "Superior to vancomycin for preventing recurrence."
    },
    "adverseEffects": {
      "common": [
        "Nausea",
        "Vomiting",
        "Abdominal pain"
      ],
      "serious": [
        "GI Hemorrhage (rare)",
        "Bowel obstruction",
        "Hypersensitivity"
      ]
    },
    "precautions": [
      "**Systemic Infection:** Not effective for systemic infections; acts locally in the gut.",
      "**Hypersensitivity:** Caution in macrolide allergy (though structure differs)."
    ],
    "contraindications": [
      "Hypersensitivity to fidaxomicin"
    ],
    "interactions": {
      "drug": ["Cyclosporine (Increases fidaxomicin levels)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "filgrastim": {
    "name": "Filgrastim (Neupogen)",
    "genericName": "Filgrastim (G-CSF)",
    "formula": "Protein",
    "molecularWeight": "18.8 kDa",
    "brandNames": ["Neupogen", "Zarxio", "Granix"],
    "category": "Colony Stimulating Factor",
    "drugClass": "Recombinant Human G-CSF",
    "pubchemCID": "None (Biologic)",
    "indications": "Neutropenia (Chemotherapy-induced), Severe Chronic Neutropenia, Bone Marrow Transplant, PBPC mobilization.",
    "moaSteps": [
      "Binds to G-CSF receptors on hematopoietic cells.",
      "Stimulates proliferation, differentiation, and activation of neutrophils.",
      "Increases neutrophil migration and cytotoxicity.",
      "Shortens duration of severe neutropenia."
    ],
    "pharmacokinetics": {
      "absorption": "SC or IV.",
      "distribution": "Bone marrow / Plasma.",
      "metabolism": "Degradation.",
      "excretion": "Clearance is non-linear (neutrophil-mediated). **Half-life: 3.5 hours.**"
    },
    "dose": {
      "initialDose": "5 mcg/kg/day SC or IV",
      "maxDose": "Continue until ANC > 10,000",
      "notes": "Start at least 24 hours after chemo."
    },
    "adverseEffects": {
      "common": [
        "Bone Pain (Medullary bone pain)",
        "Nausea",
        "Fever",
        "Fatigue"
      ],
      "serious": [
        "Splenic Rupture (Fatal) - Rare",
        "ARDS (Acute Respiratory Distress Syndrome)",
        "Capillary Leak Syndrome",
        "Sickle Cell Crisis"
      ]
    },
    "precautions": [
      "**Spleen:** Monitor for left upper quadrant pain (splenomegaly/rupture).",
      "**Sickle Cell:** Can precipitate severe crisis.",
      "**Timing:** Do not give within 24 hours of cytotoxic chemo."
    ],
    "contraindications": [
      "History of serious allergic reactions to human G-CSF (E. coli derived)"
    ],
    "interactions": {
      "drug": ["Lithium (Potentiates neutrophil release)", "Chemotherapy (Avoid concurrent use)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "finasteride": {
    "name": "Finasteride (Proscar, Propecia)",
    "genericName": "Finasteride",
    "formula": "C23H36N2O2",
    "molecularWeight": "372.5 g/mol",
    "brandNames": ["Proscar (BPH)", "Propecia (Alopecia)"],
    "category": "BPH Agent / Alopecia Agent",
    "drugClass": "5-Alpha Reductase Inhibitor",
    "pubchemCID": "57363",
    "indications": "Benign Prostatic Hyperplasia (BPH), Androgenetic Alopecia (Male Pattern Baldness).",
    "moaSteps": [
      "Inhibits Type II 5-alpha reductase.",
      "Blocks conversion of testosterone to dihydrotestosterone (DHT).",
      "Reduces prostate size and improves urine flow.",
      "Halts hair loss dependent on DHT."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "Crosses BBB.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Feces and Urine. **Half-life: 6 hours (up to 8h in elderly).**"
    },
    "dose": {
      "initialDose": "5 mg PO daily (BPH); 1 mg daily (Alopecia)",
      "maxDose": "5 mg/day",
      "notes": "Takes 6-12 months for full BPH effect."
    },
    "adverseEffects": {
      "common": [
        "Decreased libido",
        "Erectile dysfunction",
        "Ejaculatory disorder",
        "Gynecomastia"
      ],
      "serious": [
        "High-grade Prostate Cancer risk (controversial)",
        "Male Breast Cancer",
        "Depression"
      ]
    },
    "precautions": [
      "**Handling:** Pregnant women should NOT handle crushed tablets (teratogenic to male fetus).",
      "**PSA:** Reduces PSA by ~50%. Double the PSA value when screening for cancer.",
      "**Sexual dysfunction:** May persist after discontinuation (Post-Finasteride Syndrome)."
    ],
    "contraindications": [
      "Pregnancy (Category X)",
      "Women and Children"
    ],
    "interactions": {
      "drug": ["None clinically significant"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category X"
  },
  "flecainide": {
    "name": "Flecainide (Tambocor)",
    "genericName": "Flecainide Acetate",
    "formula": "C17H20F6N2O3",
    "molecularWeight": "414.4 g/mol",
    "brandNames": ["Tambocor"],
    "category": "Antiarrhythmic",
    "drugClass": "Class IC Antiarrhythmic",
    "pubchemCID": "3356",
    "indications": "Paroxysmal Atrial Fibrillation/Flutter (Prevention), PSVT, Ventricular Tachycardia (life-threatening).",
    "moaSteps": [
      "Potent blocker of fast sodium channels (Nav1.5).",
      "Markedly slows conduction velocity in the atria, His-Purkinje system, and ventricles.",
      "Does not significantly affect repolarization (QT).",
      "Also blocks Potassium channels (IKr) at high doses."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "40% protein bound.",
      "metabolism": "Hepatic (CYP2D6).",
      "excretion": "Urine. **Half-life: 12 to 27 hours.**"
    },
    "dose": {
      "initialDose": "50 mg PO twice daily",
      "maxDose": "300 mg/day (400 mg rarely)",
      "notes": "Must combine with AV nodal blocker for AFib."
    },
    "adverseEffects": {
      "common": [
        "Dizziness",
        "Visual disturbances (blurred vision)",
        "Dyspnea",
        "Headache"
      ],
      "serious": [
        "Proarrhythmia (1:1 conduction in A-Flutter, VT) - BOXED WARNING",
        "Increased Mortality in Post-MI patients (CAST Trial) - BOXED WARNING",
        "Heart Failure exacerbation"
      ]
    },
    "precautions": [
      "**CAST Trial:** Contraindicated in structural heart disease (CAD, MI, LVH) due to increased mortality.",
      "**Proarrhythmia:** Can organize AFib into A-Flutter with 1:1 conduction -> rapid ventricular rate. Always use with Beta-blocker or CCB.",
      "**Renal:** Dose adjust if CrCl < 35."
    ],
    "contraindications": [
      "Structural heart disease (MI, HF)",
      "2nd/3rd degree AV block",
      "Right bundle branch block with left hemiblock (without pacemaker)"
    ],
    "interactions": {
      "drug": ["CYP2D6 Inhibitors (Fluoxetine - Increases toxicity)", "Digoxin (Increases digoxin levels)", "Beta-blockers (Additive negative inotropy)"],
      "food": ["Milk decreases absorption in infants."]
    },
    "pregnancyCategory": "Category C"
  },
  "fluconazole": {
    "name": "Fluconazole (Diflucan)",
    "genericName": "Fluconazole",
    "formula": "C13H12F2N6O",
    "molecularWeight": "306.3 g/mol",
    "brandNames": ["Diflucan"],
    "category": "Antifungal",
    "drugClass": "Triazole Antifungal",
    "pubchemCID": "3365",
    "indications": "Candidiasis (Vaginal, Oropharyngeal, Esophageal), Cryptococcal Meningitis, Prophylaxis in BMT.",
    "moaSteps": [
      "Inhibits fungal cytochrome P450 enzyme 14-alpha-demethylase.",
      "Prevents conversion of lanosterol to ergosterol.",
      "Disrupts fungal cell membrane synthesis and integrity.",
      "Fungistatic."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (>90% bioavailability).",
      "distribution": "Excellent tissue/CSF penetration.",
      "metabolism": "Minimal hepatic.",
      "excretion": "Urine (80% unchanged). **Half-life: 30 hours (allows single dose).**"
    },
    "dose": {
      "initialDose": "150 mg PO Single Dose (Vaginal)",
      "maxDose": "800 mg/day (Systemic)",
      "notes": "Renal adjustment needed."
    },
    "adverseEffects": {
      "common": [
        "Nausea",
        "Headache",
        "Abdominal pain",
        "Diarrhea"
      ],
      "serious": [
        "QT Prolongation / Torsades de Pointes",
        "Hepatotoxicity (rare but fatal)",
        "Severe skin reactions (SJS/TEN)",
        "Anaphylaxis"
      ]
    },
    "precautions": [
      "**QT Prolongation:** Risk factors include hypokalemia and other QT drugs.",
      "**Liver:** Monitor LFTs in prolonged therapy.",
      "**Pregnancy:** Single 150mg dose generally considered safe; high doses are teratogenic."
    ],
    "contraindications": [
      "Hypersensitivity to azoles",
      "Concomitant use with Terfenadine or Cisapride"
    ],
    "interactions": {
      "drug": ["Warfarin (Significant INR increase)", "Phenytoin (Toxicity)", "Statins (Myopathy)", "Rifampin (Reduces fluconazole levels)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C (D for high doses)"
  },
  "fludrocortisone": {
    "name": "Fludrocortisone (Florinef)",
    "genericName": "Fludrocortisone Acetate",
    "formula": "C23H31FO6",
    "molecularWeight": "422.5 g/mol",
    "brandNames": ["Florinef"],
    "category": "Corticosteroid",
    "drugClass": "Mineralocorticoid",
    "pubchemCID": "91464",
    "indications": "Addison's Disease (Adrenocortical insufficiency), Salt-losing Adrenogenital Syndrome, Orthostatic Hypotension (off-label).",
    "moaSteps": [
      "Very potent mineralocorticoid activity; moderate glucocorticoid activity.",
      "Acts on distal tubules to increase sodium reabsorption and potassium/hydrogen excretion.",
      "Maintains blood pressure and volume."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Widely distributed.",
      "metabolism": "Hepatic.",
      "excretion": "Urine. **Half-life: 3.5 hours (Biological half-life 18-36h).**"
    },
    "dose": {
      "initialDose": "0.1 mg PO daily",
      "maxDose": "0.2 mg/day",
      "notes": "Monitor BP and Potassium."
    },
    "adverseEffects": {
      "common": [
        "Hypertension",
        "Edema",
        "Hypokalemia",
        "Headache"
      ],
      "serious": [
        "Heart Failure (Fluid overload)",
        "Cardiomegaly",
        "Severe Hypokalemia",
        "Anaphylaxis"
      ]
    },
    "precautions": [
      "**Electrolytes:** Potent cause of hypokalemia. Supplement K+ if needed.",
      "**Heart Failure:** Can precipitate CHF due to sodium retention.",
      "**Infection:** Masks signs of infection."
    ],
    "contraindications": [
      "Systemic fungal infections",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Diuretics (Antagonize effect)", "Digoxin (Hypokalemia toxicity)", "Amphotericin B (Severe hypokalemia)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "flumazenil": {
    "name": "Flumazenil (Romazicon)",
    "genericName": "Flumazenil",
    "formula": "C15H14FN3O3",
    "molecularWeight": "303.3 g/mol",
    "brandNames": ["Romazicon"],
    "category": "Antidote",
    "drugClass": "Benzodiazepine Antagonist",
    "pubchemCID": "3369",
    "indications": "Reversal of Benzodiazepine sedation/overdose.",
    "moaSteps": [
      "Competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine receptor complex.",
      "Reverses sedation, respiratory depression, and amnesia.",
      "Does NOT reverse effects of opioids or alcohol."
    ],
    "pharmacokinetics": {
      "absorption": "IV administration.",
      "distribution": "Rapid.",
      "metabolism": "Hepatic.",
      "excretion": "Urine. **Half-life: 40 to 80 minutes (Short).**"
    },
    "dose": {
      "initialDose": "0.2 mg IV over 15 sec",
      "maxDose": "3 mg (Cumulative)",
      "notes": "Short half-life means sedation may reoccur (resedation)."
    },
    "adverseEffects": {
      "common": [
        "Agitation",
        "Dizziness",
        "Nausea",
        "Pain at injection site"
      ],
      "serious": [
        "Seizures (Boxed Warning)",
        "Cardiac Arrhythmias",
        "Withdrawal symptoms"
      ]
    },
    "precautions": [
      "**Seizures:** Boxed Warning. High risk in patients on chronic benzos (withdrawal) or TCAs/mixed overdose. DO NOT USE in unknown overdose.",
      "**Resedation:** Monitor patient for at least 2 hours after reversal.",
      "**Head Injury:** May increase ICP."
    ],
    "contraindications": [
      "Tricyclic Antidepressant overdose",
      "Chronic Benzodiazepine users (seizure risk)",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["None (it antagonizes benzos)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "fluoxetine": {
    "name": "Fluoxetine (Prozac)",
    "genericName": "Fluoxetine HCl",
    "formula": "C17H18F3NO",
    "molecularWeight": "309.3 g/mol",
    "brandNames": ["Prozac", "Sarafem"],
    "category": "Antidepressant",
    "drugClass": "SSRI",
    "pubchemCID": "3386",
    "indications": "Major Depressive Disorder, OCD, Bulimia Nervosa, Panic Disorder, PMDD.",
    "moaSteps": [
      "Selectively inhibits serotonin reuptake in the CNS.",
      "Enhances serotonergic neurotransmission.",
      "Activating properties (good for fatigue/psychomotor retardation)."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "94% protein bound.",
      "metabolism": "Hepatic (CYP2D6) to active metabolite Norfluoxetine.",
      "excretion": "Urine. **Half-life: 4-6 days (Parent); 4-16 days (Metabolite).**"
    },
    "dose": {
      "initialDose": "20 mg PO daily",
      "maxDose": "80 mg/day",
      "notes": "Long half-life = 'Self tapering'."
    },
    "adverseEffects": {
      "common": [
        "Insomnia / Anxiety (Activating)",
        "Nausea",
        "Sexual Dysfunction",
        "Tremor"
      ],
      "serious": [
        "Suicidality (Young adults) - BOXED WARNING",
        "Serotonin Syndrome",
        "QT Prolongation",
        "Mania activation"
      ]
    },
    "precautions": [
      "**Half-life:** Due to extremely long half-life, wait 5 weeks before starting MAOI after stopping fluoxetine.",
      "**Suicide:** Monitor for worsening.",
      "**Weight:** Can cause anorexia/weight loss initially."
    ],
    "contraindications": [
      "MAOI use (or within 5 weeks of stopping Fluoxetine)",
      "Pimozide / Thioridazine use"
    ],
    "interactions": {
      "drug": ["MAOIs (Fatal)", "Tamoxifen (Fluoxetine inhibits CYP2D6 -> failure of tamoxifen)", "Tricyclics (Toxicity)", "Warfarin"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "fluticasone": {
    "name": "Fluticasone (Flonase, Flovent)",
    "genericName": "Fluticasone Propionate",
    "formula": "C25H31F3O5S",
    "molecularWeight": "500.6 g/mol",
    "brandNames": ["Flonase (Nasal)", "Flovent (Inhaled)", "Cutivate (Topical)"],
    "category": "Corticosteroid",
    "drugClass": "Glucocorticoid",
    "pubchemCID": "5311101",
    "indications": "Allergic Rhinitis, Asthma maintenance, Eosinophilic Esophagitis (swallowed).",
    "moaSteps": [
      "Potent vasoconstrictive and anti-inflammatory activity.",
      "Binds to glucocorticoid receptors with high affinity.",
      "Inhibits mast cells, eosinophils, macrophages, and mediators (histamine, cytokines).",
      "Low systemic bioavailability reduces side effects."
    ],
    "pharmacokinetics": {
      "absorption": "<2% systemic bioavailability (Nasal/Inhaled).",
      "distribution": "Large Vd.",
      "metabolism": "Extensive hepatic (CYP3A4).",
      "excretion": "Feces. **Half-life: 7.8 hours (IV); 10 hours (Inhaled).**"
    },
    "dose": {
      "initialDose": "2 sprays per nostril daily (Nasal)",
      "maxDose": "Varies by formulation",
      "notes": "Rinse mouth after inhaler."
    },
    "adverseEffects": {
      "common": [
        "Epistaxis (Nasal)",
        "Headache",
        "Oral Candidiasis (Inhaled)",
        "Throat irritation"
      ],
      "serious": [
        "Nasal Septal Perforation",
        "Glaucoma / Cataracts",
        "Adrenal Suppression (high dose/ritonavir interaction)",
        "Paradoxical Bronchospasm"
      ]
    },
    "precautions": [
      "**Ritonavir:** Strong CYP3A4 inhibition leads to Cushing's Syndrome even with nasal spray. Avoid combination.",
      "**Growth:** Monitor height in children.",
      "**Eyes:** Regular exams for long-term users."
    ],
    "contraindications": [
      "Status asthmaticus (Inhaled)",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Ritonavir/Ketoconazole (Systemic steroid toxicity)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "fondaparinux": {
    "name": "Fondaparinux (Arixtra)",
    "genericName": "Fondaparinux",
    "formula": "C31H53N3O49S8",
    "molecularWeight": "1728.8 g/mol",
    "brandNames": ["Arixtra"],
    "category": "Anticoagulant",
    "drugClass": "Factor Xa Inhibitor (Synthetic Pentasaccharide)",
    "pubchemCID": "636378",
    "indications": "DVT/PE Treatment and Prophylaxis, Acute Coronary Syndrome (NSTEMI/STEMI).",
    "moaSteps": [
      "Synthetic pentasaccharide.",
      "Selectively binds to Antithrombin III.",
      "Potentiates neutralization of Factor Xa.",
      "No effect on Thrombin (Factor IIa).",
      "Does not affect platelet function (No HIT risk)."
    ],
    "pharmacokinetics": {
      "absorption": "100% bioavailable (SC).",
      "distribution": "Blood volume.",
      "metabolism": "Not metabolized.",
      "excretion": "Renal (Unchanged). **Half-life: 17 to 21 hours.**"
    },
    "dose": {
      "initialDose": "2.5 mg SC daily (Prophylaxis)",
      "maxDose": "7.5 mg (<100kg) or 10 mg (>100kg) for Treatment",
      "notes": "Contraindicated in low body weight < 50kg for prophylaxis."
    },
    "adverseEffects": {
      "common": [
        "Bleeding (Injection site)",
        "Anemia",
        "Insomnia"
      ],
      "serious": [
        "Spinal/Epidural Hematoma - BOXED WARNING",
        "Major Hemorrhage",
        "Thrombocytopenia (Rare, not HIT)"
      ]
    },
    "precautions": [
      "**Renal:** Contraindicated if CrCl < 30 mL/min. Accumulates significantly.",
      "**Weight:** Contraindicated for prophylaxis in patients < 50 kg (bleed risk).",
      "**HIT:** Safe alternative in history of HIT."
    ],
    "contraindications": [
      "Severe renal impairment (CrCl < 30)",
      "Body weight < 50 kg (for prophylaxis)",
      "Active major bleeding",
      "Bacterial endocarditis"
    ],
    "interactions": {
      "drug": ["Anticoagulants/Antiplatelets (Additive risk)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "formoterol": {
    "name": "Formoterol (Perforomist)",
    "genericName": "Formoterol Fumarate",
    "formula": "C19H24N2O4",
    "molecularWeight": "344.4 g/mol",
    "brandNames": ["Perforomist", "Foradil", "Symbicort (combo)"],
    "category": "Bronchodilator",
    "drugClass": "Long-Acting Beta-2 Agonist (LABA)",
    "pubchemCID": "3410",
    "indications": "COPD, Asthma (concomitant with ICS), Prevention of exercise-induced bronchospasm.",
    "moaSteps": [
      "Selective beta-2 adrenergic agonist.",
      "Stimulates adenyl cyclase -> increases cAMP.",
      "Relaxes bronchial smooth muscle.",
      "Rapid onset (1-3 min) but long duration (12 hours)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "60% protein bound.",
      "metabolism": "Direct glucuronidation.",
      "excretion": "Urine and Feces. **Half-life: 10 hours.**"
    },
    "dose": {
      "initialDose": "12 mcg Inhaled twice daily",
      "maxDose": "24 mcg/day",
      "notes": "Max dose strictly limited."
    },
    "adverseEffects": {
      "common": [
        "Tremor",
        "Palpitations",
        "Dry mouth",
        "Nausea"
      ],
      "serious": [
        "Asthma-related death (Monotherapy) - BOXED WARNING (Historical)",
        "Paradoxical Bronchospasm",
        "Arrhythmias / Hypokalemia",
        "Anaphylaxis"
      ]
    },
    "precautions": [
      "**Asthma Monotherapy:** Contraindicated. Must be used with an Inhaled Corticosteroid (ICS).",
      "**Acute Symptoms:** Not a rescue inhaler.",
      "**Cardiac:** Use caution in arrhythmia/ischemia."
    ],
    "contraindications": [
      "Asthma (without concomitant ICS)",
      "Status asthmaticus"
    ],
    "interactions": {
      "drug": ["Beta-blockers (Antagonism)", "Diuretics (Potentiate hypokalemia)", "QT prolonging drugs"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "fosfomycin": {
    "name": "Fosfomycin (Monurol)",
    "genericName": "Fosfomycin Tromethamine",
    "formula": "C3H7O4P",
    "molecularWeight": "138.06 g/mol",
    "brandNames": ["Monurol"],
    "category": "Antibiotic",
    "drugClass": "Phosphonic Acid Derivative",
    "pubchemCID": "446987",
    "indications": "Uncomplicated Urinary Tract Infection (Acute Cystitis) in women.",
    "moaSteps": [
      "Inhibits pyruvyl transferase (MurA).",
      "Blocks the first step in bacterial cell wall synthesis.",
      "Bactericidal.",
      "Broad spectrum (E. coli, ESBLs, Enterococcus faecalis)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (37% bioavailable).",
      "distribution": "Kidneys/Bladder/Prostate.",
      "metabolism": "None.",
      "excretion": "Urine (Unchanged). **Half-life: 5.7 hours (Urine concentrations persist >48h).**"
    },
    "dose": {
      "initialDose": "3 g PO Single Dose",
      "maxDose": "3 g (one dose)",
      "notes": "Mix powder with cool water. Not for Pyelonephritis."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea",
        "Vaginitis",
        "Nausea",
        "Headache"
      ],
      "serious": [
        "Clostridioides difficile colitis",
        "Anaphylaxis",
        "Aplastic Anemia (rare)"
      ]
    },
    "precautions": [
      "**Pyelonephritis:** Do not use; tissue levels insufficient.",
      "**Multiple Doses:** Not recommended (lower efficacy, more side effects).",
      "**Vaginitis:** Common side effect."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Metoclopramide (Decreases absorption)"],
      "food": ["Food reduces absorption (Take on empty stomach preferred)."]
    },
    "pregnancyCategory": "Category B"
  },
  "fosphenytoin": {
    "name": "Fosphenytoin (Cerebyx)",
    "genericName": "Fosphenytoin Sodium",
    "formula": "C16H13N2O6P",
    "molecularWeight": "362.2 g/mol",
    "brandNames": ["Cerebyx"],
    "category": "Anticonvulsant",
    "drugClass": "Hydantoin (Prodrug)",
    "pubchemCID": "56046",
    "indications": "Status Epilepticus, Seizure prevention during neurosurgery.",
    "moaSteps": [
      "Water-soluble prodrug of phenytoin.",
      "Rapidly converted to phenytoin by phosphatases in blood/tissue.",
      "Phenytoin stabilizes neuronal membranes by blocking voltage-gated sodium channels.",
      "Less infusion site toxicity than phenytoin."
    ],
    "pharmacokinetics": {
      "absorption": "IV/IM.",
      "distribution": "High protein binding.",
      "metabolism": "Rapid conversion to Phenytoin (Half-life 15 min).",
      "excretion": "Urine. **Half-life: Phenytoin kinetics (Non-linear).**"
    },
    "dose": {
      "initialDose": "15-20 mg PE/kg IV (Loading)",
      "maxDose": "150 mg PE/min infusion",
      "notes": "Dosed in Phenytoin Equivalents (PE)."
    },
    "adverseEffects": {
      "common": [
        "Pruritus / Paresthesia (during infusion)",
        "Nystagmus",
        "Dizziness",
        "Somnolence"
      ],
      "serious": [
        "Cardiovascular Collapse (Hypotension/Arrhythmia with rapid infusion) - BOXED WARNING",
        "Stevens-Johnson Syndrome / DRESS",
        "Purple Glove Syndrome"
      ]
    },
    "precautions": [
      "**Cardiac:** Monitor ECG/BP during loading. Risk is less than phenytoin but present.",
      "**Dosing Error:** Confusion between PE (Phenytoin Equivalents) and mg. Prescribe in PE.",
      "**HLA-B*1502:** Avoid in carriers (SJS risk)."
    ],
    "contraindications": [
      "Sinus bradycardia",
      "2nd/3rd degree AV block",
      "Adams-Stokes syndrome"
    ],
    "interactions": {
      "drug": ["See Phenytoin interactions (Inducer of CYP3A4, UGT)", "Warfarin", "Contraceptives"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "fulvestrant": {
    "name": "Fulvestrant (Faslodex)",
    "genericName": "Fulvestrant",
    "formula": "C32H47F5O3S",
    "molecularWeight": "606.8 g/mol",
    "brandNames": ["Faslodex"],
    "category": "Antineoplastic",
    "drugClass": "Estrogen Receptor Downregulator (SERD)",
    "pubchemCID": "104741",
    "indications": "Hormone Receptor positive Metastatic Breast Cancer (Postmenopausal).",
    "moaSteps": [
      "Competitively binds to estrogen receptors (ER) with affinity comparable to estradiol.",
      "Induces a conformational change leading to downregulation and degradation of the ER.",
      "Pure anti-estrogen (no agonist activity).",
      "Inhibits tumor growth."
    ],
    "pharmacokinetics": {
      "absorption": "IM administration (Slow).",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic (CYP3A4/Glucuronidation).",
      "excretion": "Feces (>90%). **Half-life: 40 days.**"
    },
    "dose": {
      "initialDose": "500 mg IM Days 1, 15, 29",
      "maxDose": "500 mg monthly maintenance",
      "notes": "Two 5mL injections required per dose."
    },
    "adverseEffects": {
      "common": [
        "Injection site pain",
        "Hot flashes",
        "Fatigue",
        "Nausea / Bone pain"
      ],
      "serious": [
        "Injection site nerve injury (Sciatic)",
        "Hypersensitivity",
        "Bleeding (due to IM route)"
      ]
    },
    "precautions": [
      "**Injection:** Administer slowly (1-2 mins per injection) in gluteal muscle to avoid sciatic nerve damage.",
      "**Bleeding:** Caution in patients on anticoagulants (large IM volume).",
      "**Hepatic:** Dose adjust in moderate impairment."
    ],
    "contraindications": [
      "Hypersensitivity",
      "Pregnancy"
    ],
    "interactions": {
      "drug": ["None clinically significant (CYP3A4 inducers/inhibitors have no effect on safety/efficacy)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "furosemide": {
    "name": "Furosemide (Lasix)",
    "genericName": "Furosemide",
    "formula": "C12H11ClN2O5S",
    "molecularWeight": "330.7 g/mol",
    "brandNames": ["Lasix"],
    "category": "Diuretic",
    "drugClass": "Loop Diuretic",
    "pubchemCID": "3440",
    "indications": "Edema (Heart Failure, Liver, Renal), Hypertension, Pulmonary Edema.",
    "moaSteps": [
      "Inhibits the Na+/K+/2Cl- cotransporter in the thick ascending limb of the Loop of Henle.",
      "Prevents reabsorption of sodium, chloride, and potassium.",
      "Disrupts the renal medullary osmotic gradient, preventing urine concentration.",
      "Promotes excretion of water, Na+, Cl-, K+, Mg+, Ca++."
    ],
    "pharmacokinetics": {
      "absorption": "Variable (average 60%).",
      "distribution": "95% protein bound.",
      "metabolism": "Minimal hepatic.",
      "excretion": "Urine. **Half-life: 0.5 to 2 hours (Prolonged in renal/heart failure).**"
    },
    "dose": {
      "initialDose": "20-40 mg PO/IV daily",
      "maxDose": "600 mg/day (High dose in renal failure)",
      "notes": "IV is 2x as potent as PO (1:2 ratio)."
    },
    "adverseEffects": {
      "common": [
        "Polyuria",
        "Hypokalemia",
        "Hypomagnesemia",
        "Dizziness / Orthostasis"
      ],
      "serious": [
        "Ototoxicity (Tinnitus/Hearing loss)",
        "Severe Electrolyte Imbalance / Arrhythmias",
        "Dehydration / AKI",
        "Severe skin reactions (SJS)"
      ]
    },
    "precautions": [
      "**Ototoxicity:** Risk with rapid IV push or high doses, especially with other ototoxic drugs.",
      "**Sulfa Allergy:** Cross-reactivity is rare but possible.",
      "**Electrolytes:** Monitor K+/Mg+ closely; supplementation often needed.",
      "**Gout:** Can cause hyperuricemia."
    ],
    "contraindications": [
      "Anuria",
      "Hepatic coma / Severe electrolyte depletion"
    ],
    "interactions": {
      "drug": ["Aminoglycosides (Ototoxicity)", "Lithium (Toxicity)", "NSAIDs (Reduced diuretic effect)", "Digoxin (Toxicity via hypokalemia)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },"famciclovir": {
    "name": "Famciclovir (Famvir)",
    "genericName": "Famciclovir",
    "formula": "C14H19N5O4",
    "molecularWeight": "321.3 g/mol",
    "brandNames": ["Famvir"],
    "category": "Antiviral",
    "drugClass": "Guanosine Analogue",
    "pubchemCID": "3324",
    "indications": "Herpes Zoster (Shingles), Herpes Simplex (Genital Herpes, Cold Sores).",
    "moaSteps": [
      "Prodrug of penciclovir.",
      "Phosphorylated by viral thymidine kinase in infected cells.",
      "Inhibits viral DNA polymerase.",
      "Prevents viral DNA replication and chain elongation."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed (77% bioavailability).",
      "distribution": "Low protein binding.",
      "metabolism": "Rapidly converted to penciclovir in intestinal wall/liver.",
      "excretion": "Urine. **Half-life: 2 to 3 hours.**"
    },
    "dose": {
      "initialDose": "500 mg PO every 8 hours (Shingles)",
      "maxDose": "1500 mg/day",
      "notes": "Renal adjustment required."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Nausea",
        "Fatigue"
      ],
      "serious": [
        "Acute Renal Failure (rare, in dehydration)",
        "Confusion (elderly)",
        "Severe dermatologic reactions (SJS/TEN)"
      ]
    },
    "precautions": [
      "**Renal Impairment:** Dosage adjustment is critical to prevent neurotoxicity.",
      "**Timing:** Most effective if started within 48-72 hours of rash onset."
    ],
    "contraindications": [
      "Hypersensitivity to famciclovir or penciclovir"
    ],
    "interactions": {
      "drug": ["Probenecid (Increases levels)", "Digoxin (Monitor levels)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "faricimab": {
    "name": "Faricimab (Vabysmo)",
    "genericName": "Faricimab-svoa",
    "formula": "Bispecific Antibody",
    "molecularWeight": "149 kDa",
    "brandNames": ["Vabysmo"],
    "category": "Ophthalmic Agent",
    "drugClass": "Bispecific Angiopoietin-2 and VEGF Inhibitor",
    "pubchemCID": "None (Biologic)",
    "indications": "Neovascular (Wet) Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME).",
    "moaSteps": [
      "First bispecific antibody for ocular use.",
      "Binds to and inhibits Vascular Endothelial Growth Factor-A (VEGF-A).",
      "Binds to and inhibits Angiopoietin-2 (Ang-2).",
      "Ang-2 inhibition reduces vascular instability and inflammation, complementing VEGF suppression."
    ],
    "pharmacokinetics": {
      "absorption": "Intravitreal injection.",
      "distribution": "Local ocular tissues.",
      "metabolism": "Proteolysis.",
      "excretion": "N/A. **Half-life: ~7.5 days.**"
    },
    "dose": {
      "initialDose": "6 mg Intravitreal injection every 4 weeks x 4 doses",
      "maxDose": "6 mg every 8-16 weeks (maintenance)",
      "notes": "Allows for extended dosing intervals compared to pure VEGF inhibitors."
    },
    "adverseEffects": {
      "common": [
        "Conjunctival hemorrhage",
        "Eye pain",
        "Increased Intraocular Pressure (IOP)",
        "Floaters"
      ],
      "serious": [
        "Endophthalmitis (Infection inside eye)",
        "Retinal Detachment",
        "Arterial Thromboembolic Events (Low systemic risk)"
      ]
    },
    "precautions": [
      "**Endophthalmitis:** Instruct patients to report eye pain/redness immediately.",
      "**IOP:** Monitor pressure post-injection.",
      "**Perfusion:** Transient increase in IOP may compromise optic nerve perfusion."
    ],
    "contraindications": [
      "Ocular or periocular infection",
      "Active intraocular inflammation"
    ],
    "interactions": {
      "drug": ["None specific"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "felodipine": {
    "name": "Felodipine (Plendil)",
    "genericName": "Felodipine",
    "formula": "C18H19Cl2NO4",
    "molecularWeight": "384.2 g/mol",
    "brandNames": ["Plendil"],
    "category": "Antihypertensive",
    "drugClass": "Calcium Channel Blocker (Dihydropyridine)",
    "pubchemCID": "3333",
    "indications": "Hypertension.",
    "moaSteps": [
      "Inhibits influx of extracellular calcium across myocardial and vascular smooth muscle cell membranes.",
      "Selectively dilates peripheral arterioles.",
      "Reduces systemic vascular resistance and blood pressure.",
      "Minimal effect on cardiac conduction."
    ],
    "pharmacokinetics": {
      "absorption": "Complete but extensive first-pass (20% bioavailable).",
      "distribution": "99% protein bound.",
      "metabolism": "Extensive hepatic (CYP3A4).",
      "excretion": "Urine. **Half-life: 11 to 16 hours.**"
    },
    "dose": {
      "initialDose": "5 mg PO once daily",
      "maxDose": "10 mg/day",
      "notes": "Swallow whole (ER formulation)."
    },
    "adverseEffects": {
      "common": [
        "Peripheral Edema (Ankle swelling)",
        "Flushing / Headache",
        "Gingival Hyperplasia",
        "Dizziness"
      ],
      "serious": [
        "Hypotension",
        "Angina exacerbation (Reflex tachycardia)",
        "Syncope"
      ]
    },
    "precautions": [
      "**Edema:** Dose-dependent peripheral edema is common; not responsive to diuretics.",
      "**Heart Failure:** Use with caution; negative inotropy is weak but present.",
      "**Dental:** Maintain good oral hygiene to reduce gum overgrowth."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inhibitors (Azoles/Macrolides - Toxicity)", "CYP3A4 Inducers (Carbamazepine - Failure)"],
      "food": ["Grapefruit juice (Significant increase in levels)"]
    },
    "pregnancyCategory": "Category C"
  },
  "fesoterodine": {
    "name": "Fesoterodine (Toviaz)",
    "genericName": "Fesoterodine Fumarate",
    "formula": "C26H37NO7",
    "molecularWeight": "475.6 g/mol",
    "brandNames": ["Toviaz"],
    "category": "Urinary Antispasmodic",
    "drugClass": "Antimuscarinic",
    "pubchemCID": "6918537",
    "indications": "Overactive Bladder (Urge incontinence, urgency, frequency).",
    "moaSteps": [
      "Prodrug rapidly hydrolyzed to 5-hydroxymethyl tolterodine (5-HMT).",
      "Competitively acts as an antagonist at muscarinic receptors in the bladder.",
      "Inhibits involuntary detrusor muscle contractions.",
      "Increases residual urine volume and decreases bladder muscle tone."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "50% protein bound.",
      "metabolism": "Hydrolysis to 5-HMT (active) then CYP2D6/3A4.",
      "excretion": "Urine. **Half-life: 7 hours.**"
    },
    "dose": {
      "initialDose": "4 mg PO once daily",
      "maxDose": "8 mg/day",
      "notes": "Swallow whole."
    },
    "adverseEffects": {
      "common": [
        "Dry mouth",
        "Constipation",
        "Dry eyes",
        "Dyspepsia"
      ],
      "serious": [
        "Urinary Retention",
        "Angioedema",
        "Heat Stroke (decreased sweating)"
      ]
    },
    "precautions": [
      "**Retention:** Caution in significant bladder outflow obstruction.",
      "**GI:** Caution in decreased GI motility or severe constipation.",
      "**Myasthenia Gravis:** May exacerbate symptoms."
    ],
    "contraindications": [
      "Urinary retention",
      "Gastric retention",
      "Uncontrolled narrow-angle glaucoma"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inhibitors (Max dose 4mg)", "Anticholinergics (Additive toxicity)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "fezolinetant": {
    "name": "Fezolinetant (Veozah)",
    "genericName": "Fezolinetant",
    "formula": "C16H15F2N5O2S",
    "molecularWeight": "379.4 g/mol",
    "brandNames": ["Veozah"],
    "category": "Menopause Agent",
    "drugClass": "Neurokinin 3 (NK3) Receptor Antagonist",
    "pubchemCID": "67207777",
    "indications": "Moderate to severe Vasomotor Symptoms (Hot flashes) due to Menopause.",
    "moaSteps": [
      "Blocks Neurokinin B (NKB) binding on the kisspeptin/neurokinin B/dynorphin (KNDy) neurons.",
      "KNDy neurons in the hypothalamus regulate thermoregulation.",
      "In menopause, decreased estrogen leads to unopposed NKB activity and hypertrophy of KNDy neurons, causing hot flashes.",
      "Fezolinetant restores the balance, reducing hot flash frequency/severity without hormones."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "50% protein bound.",
      "metabolism": "Hepatic via CYP1A2.",
      "excretion": "Urine. **Half-life: 9.6 hours.**"
    },
    "dose": {
      "initialDose": "45 mg PO once daily",
      "maxDose": "45 mg/day",
      "notes": "Baseline LFTs required."
    },
    "adverseEffects": {
      "common": [
        "Abdominal pain",
        "Diarrhea",
        "Insomnia",
        "Back pain",
        "Hot flush (paradoxical - rare)"
      ],
      "serious": [
        "Elevated Transaminases (ALT/AST) - FDA Warning"
      ]
    },
    "precautions": [
      "**Liver Injury:** Can cause hepatocellular injury. LFTs required at baseline, 3 months, 6 months, and 9 months. Stop if ALT > 3x ULN.",
      "**Habit Forming:** None; non-hormonal, non-controlled."
    ],
    "contraindications": [
      "Cirrhosis",
      "Severe renal impairment (eGFR < 30)",
      "Concomitant use with CYP1A2 inhibitors"
    ],
    "interactions": {
      "drug": ["CYP1A2 Inhibitors (Fluvoxamine, Ciprofloxacin, Enoxacin - Contraindicated due to increased levels)", "Smoking (Induces CYP1A2 - reduces efficacy)"],
      "food": ["Caffeine (CYP1A2 substrate - potential interaction)"]
    },
    "pregnancyCategory": "Category N/A (Post-menopausal use)"
  },
  "finerenone": {
    "name": "Finerenone (Kerendia)",
    "genericName": "Finerenone",
    "formula": "C21H22N4O3",
    "molecularWeight": "378.4 g/mol",
    "brandNames": ["Kerendia"],
    "category": "MRA (Non-steroidal)",
    "drugClass": "Selective Mineralocorticoid Receptor Antagonist",
    "pubchemCID": "44631872",
    "indications": "Chronic Kidney Disease (CKD) associated with Type 2 Diabetes (to reduce eGFR decline, kidney failure, CV death, and hospitalization).",
    "moaSteps": [
      "Non-steroidal, selective antagonist of the mineralocorticoid receptor (MR).",
      "Blocks MR overactivation by aldosterone/cortisol, which drives fibrosis and inflammation in the kidney and heart.",
      "Compared to spironolactone, it has higher potency, selectivity, and reduced risk of hyperkalemia."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "92% protein bound.",
      "metabolism": "Hepatic via CYP3A4 (90%).",
      "excretion": "Urine and Feces. **Half-life: 2 to 3 hours.**"
    },
    "dose": {
      "initialDose": "10-20 mg PO once daily",
      "maxDose": "20 mg/day",
      "notes": "Dose based on eGFR and Potassium."
    },
    "adverseEffects": {
      "common": [
        "Hyperkalemia",
        "Hypotension",
        "Hyponatremia"
      ],
      "serious": [
        "Severe Hyperkalemia (requiring hospitalization)"
      ]
    },
    "precautions": [
      "**Hyperkalemia:** Monitor serum K+ at 4 weeks. Withhold if K+ > 5.5 mEq/L.",
      "**GFR:** Initiate only if eGFR > 25 mL/min.",
      "**Diet:** Avoid high potassium diet/salt substitutes."
    ],
    "contraindications": [
      "Concomitant treatment with strong CYP3A4 inhibitors",
      "Adrenal insufficiency"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inhibitors (Contraindicated)", "Moderate CYP3A4 Inhibitors (Monitor K+)", "Potassium supplements"],
      "food": ["Grapefruit juice (Increases levels - Avoid)"]
    },
    "pregnancyCategory": "Category C"
  },
  "fingolimod": {
    "name": "Fingolimod (Gilenya)",
    "genericName": "Fingolimod",
    "formula": "C19H33NO2",
    "molecularWeight": "307.5 g/mol",
    "brandNames": ["Gilenya", "Tascenso ODT"],
    "category": "Multiple Sclerosis Agent",
    "drugClass": "Sphingosine 1-Phosphate (S1P) Receptor Modulator",
    "pubchemCID": "107970",
    "indications": "Relapsing forms of Multiple Sclerosis (MS).",
    "moaSteps": [
      "Metabolized to fingolimod-phosphate.",
      "Binds to S1P receptors on lymphocytes.",
      "Induces receptor internalization and degradation.",
      "Prevents lymphocytes from exiting lymph nodes.",
      "Reduces infiltration of autoreactive lymphocytes into the CNS."
    ],
    "pharmacokinetics": {
      "absorption": "Slow absorption.",
      "distribution": "99% protein bound.",
      "metabolism": "Reversible phosphorylation and CYP4F2.",
      "excretion": "Urine. **Half-life: 6 to 9 days.**"
    },
    "dose": {
      "initialDose": "0.5 mg PO once daily",
      "maxDose": "0.5 mg/day",
      "notes": "First dose requires 6-hour cardiac monitoring."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Flu-like symptoms",
        "Diarrhea",
        "Back pain"
      ],
      "serious": [
        "Bradyarrhythmia / AV Block (First dose)",
        "Macular Edema",
        "PML (Progressive Multifocal Leukoencephalopathy)",
        "Severe infections (VZV, Cryptococcus)",
        "Liver Injury"
      ]
    },
    "precautions": [
      "**First Dose Effect:** Causes bradycardia/AV block. Must observe ECG/HR for 6 hours after first dose.",
      "**Macular Edema:** Eye exam needed at baseline and 3-4 months.",
      "**Infection:** Avoid live vaccines. Monitor for signs of meningitis/PML.",
      "**Pregnancy:** Teratogenic. Use contraception for 2 months after stopping."
    ],
    "contraindications": [
      "Recent MI/Stroke/Heart Failure (Class III/IV)",
      "2nd/3rd degree AV block",
      "QTc > 500 msec"
    ],
    "interactions": {
      "drug": ["Class Ia/III Antiarrhythmics (Contraindicated)", "Beta-blockers (Potentiate bradycardia)", "Live Vaccines"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C (Fetal harm)"
  },
  "flibanserin": {
    "name": "Flibanserin (Addyi)",
    "genericName": "Flibanserin",
    "formula": "C20H21F3N4O",
    "molecularWeight": "390.4 g/mol",
    "brandNames": ["Addyi"],
    "category": "HSDD Agent",
    "drugClass": "Serotonin 5-HT1A Agonist / 5-HT2A Antagonist",
    "pubchemCID": "6918248",
    "indications": "Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women.",
    "moaSteps": [
      "Agonist at 5-HT1A receptors.",
      "Antagonist at 5-HT2A receptors.",
      "Reduces serotonin inhibition of sexual desire.",
      "Increases dopamine and norepinephrine levels in the prefrontal cortex (improving desire)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "98% protein bound.",
      "metabolism": "Extensive hepatic (CYP3A4).",
      "excretion": "Urine and Feces. **Half-life: 11 hours.**"
    },
    "dose": {
      "initialDose": "100 mg PO once daily at bedtime",
      "maxDose": "100 mg/day",
      "notes": "Discontinue if no improvement after 8 weeks."
    },
    "adverseEffects": {
      "common": [
        "Dizziness",
        "Somnolence",
        "Nausea",
        "Fatigue"
      ],
      "serious": [
        "Severe Hypotension",
        "Syncope (especially with alcohol)"
      ]
    },
    "precautions": [
      "**Alcohol:** Interaction can cause severe hypotension/syncope. Wait at least 2 hours after drinking 1-2 drinks before taking dose. Skip dose if >3 drinks consumed.",
      "**Hypotension:** Take at bedtime to minimize syncope risk.",
      "**Liver:** Contraindicated in hepatic impairment."
    ],
    "contraindications": [
      "Use with strong CYP3A4 inhibitors",
      "Hepatic impairment"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inhibitors (Severe hypotension)", "CNS Depressants"],
      "food": ["Grapefruit juice (Increases levels)"]
    },
    "pregnancyCategory": "Category C"
  },
  "flucytosine": {
    "name": "Flucytosine (Ancobon)",
    "genericName": "Flucytosine",
    "formula": "C4H4FN3O",
    "molecularWeight": "129.09 g/mol",
    "brandNames": ["Ancobon"],
    "category": "Antifungal",
    "drugClass": "Pyrimidine Analog",
    "pubchemCID": "3366",
    "indications": "Serious infections by Candida and Cryptococcus (Meningitis, Endocarditis) - Usually with Amphotericin B.",
    "moaSteps": [
      "Transported into fungal cells via cytosine permease.",
      "Deaminated to 5-fluorouracil (5-FU) by fungal cytosine deaminase.",
      "5-FU incorporates into fungal RNA (protein synthesis inhibition) and inhibits DNA synthesis.",
      "Selective toxicity (humans lack cytosine deaminase)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid and complete (Oral only).",
      "distribution": "Excellent CSF penetration.",
      "metabolism": "Minimal.",
      "excretion": "Urine (Unchanged). **Half-life: 3 to 4 hours (Prolonged in renal failure).**"
    },
    "dose": {
      "initialDose": "50-150 mg/kg/day PO divided q6h",
      "maxDose": "Adjust by creatinine clearance",
      "notes": "Monitor peak levels (target 50-100 mcg/mL)."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting",
        "Diarrhea",
        "Rash"
      ],
      "serious": [
        "Bone Marrow Suppression (Leukopenia/Thrombocytopenia) - BOXED WARNING",
        "Hepatotoxicity",
        "Enterocolitis (Severe)",
        "Renal Failure"
      ]
    },
    "precautions": [
      "**Renal:** Drug accumulates rapidly in renal failure; toxicity is high. Strict dose adjustment required.",
      "**Bone Marrow:** Dose-dependent suppression. Monitor CBC frequently.",
      "**Resistance:** Resistance develops rapidly if used alone; always combine (e.g., with Amphotericin B)."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Cytarabine (Antagonizes flucytosine activity)", "Nephrotoxic drugs (Amphotericin B increases flucytosine levels by reducing renal clearance)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "fludarabine": {
    "name": "Fludarabine (Fludara)",
    "genericName": "Fludarabine Phosphate",
    "formula": "C10H13FN5O7P",
    "molecularWeight": "365.2 g/mol",
    "brandNames": ["Fludara"],
    "category": "Antineoplastic",
    "drugClass": "Purine Antimetabolite",
    "pubchemCID": "656578",
    "indications": "Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin Lymphoma, AML (salvage).",
    "moaSteps": [
      "Fluorinated nucleotide analog of antiviral agent vidarabine.",
      "Metabolized to triphosphate form.",
      "Inhibits DNA polymerase alpha, ribonucleotide reductase, and DNA primase.",
      "Inhibits DNA synthesis and repair.",
      "Induces apoptosis in both dividing and resting cells."
    ],
    "pharmacokinetics": {
      "absorption": "IV administration.",
      "distribution": "Widely distributed.",
      "metabolism": "Intracellular phosphorylation.",
      "excretion": "Urine. **Half-life: 20 hours.**"
    },
    "dose": {
      "initialDose": "25 mg/m2 IV daily for 5 days",
      "maxDose": "Repeat every 28 days",
      "notes": "Adjust for renal function."
    },
    "adverseEffects": {
      "common": [
        "Myelosuppression (Severe)",
        "Fever / Infection",
        "Nausea",
        "Fatigue"
      ],
      "serious": [
        "Severe Neurotoxicity (Blindness, Coma, Death) - BOXED WARNING",
        "Autoimmune Hemolytic Anemia - BOXED WARNING",
        "Tumor Lysis Syndrome",
        "Pneumonia (PCP/Opportunistic)"
      ]
    },
    "precautions": [
      "**Neurotoxicity:** High doses cause severe CNS damage. Use standard doses.",
      "**Immunosuppression:** Causes profound T-cell depletion. Prophylaxis for PCP (Bactrim) and Herpes/VZV required.",
      "**Hemolysis:** Monitor for hemolysis; stop drug if occurs (Coombs test)."
    ],
    "contraindications": [
      "Severe renal impairment (CrCl < 30)",
      "Decompensated hemolytic anemia"
    ],
    "interactions": {
      "drug": ["Pentostatin (Fatal pulmonary toxicity - Contraindicated)", "Live vaccines"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "fluorouracil": {
    "name": "Fluorouracil (5-FU, Efudex)",
    "genericName": "Fluorouracil",
    "formula": "C4H3FN2O2",
    "molecularWeight": "130.08 g/mol",
    "brandNames": ["Adrucil (IV)", "Efudex (Topical)", "Carac"],
    "category": "Antineoplastic",
    "drugClass": "Antimetabolite (Pyrimidine Analog)",
    "pubchemCID": "3385",
    "indications": "Colorectal, Breast, Gastric, Pancreatic Cancers. Topical: Actinic Keratosis, Basal Cell Carcinoma.",
    "moaSteps": [
      "Converted to F-dUMP, which binds tightly to thymidylate synthase.",
      "Inhibits thymidylate synthase, blocking methylation of dUMP to dTMP.",
      "Depletes thymidine pools, halting DNA synthesis (Thymineless death).",
      "Also incorporates into RNA (F-UTP), disrupting protein synthesis."
    ],
    "pharmacokinetics": {
      "absorption": "IV or Topical.",
      "distribution": "Penetrates CSF/Effusions.",
      "metabolism": "Rapid catabolism by Dihydropyrimidine Dehydrogenase (DPD) in liver.",
      "excretion": "Respiratory (CO2) and Urine. **Half-life: 16 minutes (very short).**"
    },
    "dose": {
      "initialDose": "Varies by protocol (e.g., 400 mg/m2 IV)",
      "maxDose": "Protocol dependent",
      "notes": "Leucovorin enhances binding to thymidylate synthase (increasing efficacy/toxicity)."
    },
    "adverseEffects": {
      "common": [
        "Stomatitis / Mucositis",
        "Diarrhea",
        "Nausea",
        "Hand-Foot Syndrome"
      ],
      "serious": [
        "Coronary Vasospasm / Ischemia",
        "Severe Myelosuppression",
        "Neurotoxicity (Cerebellar)",
        "Severe toxicity in DPD deficiency"
      ]
    },
    "precautions": [
      "**DPD Deficiency:** Patients lacking DPD enzyme cannot metabolize 5-FU, leading to fatal toxicity. Testing available.",
      "**Cardiotoxicity:** Can cause angina/MI even in healthy hearts.",
      "**Mucositis:** Oral cryotherapy (ice chips) during bolus can reduce sores."
    ],
    "contraindications": [
      "Poor nutritional state",
      "Depressed bone marrow function",
      "Serious infection",
      "Known DPD deficiency"
    ],
    "interactions": {
      "drug": ["Leucovorin (Potentiates effect)", "Warfarin (Increases INR)", "Metronidazole"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "fluphenazine": {
    "name": "Fluphenazine (Prolixin)",
    "genericName": "Fluphenazine HCl / Decanoate",
    "formula": "C22H26F3N3OS",
    "molecularWeight": "437.5 g/mol",
    "brandNames": ["Prolixin"],
    "category": "Antipsychotic",
    "drugClass": "Phenothiazine (High Potency)",
    "pubchemCID": "3392",
    "indications": "Schizophrenia, Psychotic Disorders.",
    "moaSteps": [
      "Potent antagonist at postsynaptic dopamine D2 receptors in the mesolimbic system.",
      "High potency means strong antipsychotic effect with less sedation/anticholinergic effects than low potency agents (like chlorpromazine).",
      "High risk of Extrapyramidal Symptoms (EPS)."
    ],
    "pharmacokinetics": {
      "absorption": "Oral (rapid), IM Decanoate (slow release).",
      "distribution": "Crosses BBB.",
      "metabolism": "Hepatic.",
      "excretion": "Urine/Feces. **Half-life: 14 to 24 hours (Oral); 2 to 4 weeks (Decanoate).**"
    },
    "dose": {
      "initialDose": "2.5-10 mg PO daily",
      "maxDose": "40 mg/day (Oral); 100 mg/month (Decanoate)",
      "notes": "Decanoate requires oral overlap."
    },
    "adverseEffects": {
      "common": [
        "Extrapyramidal Symptoms (Dystonia, Parkinsonism, Akathisia)",
        "Prolactin elevation",
        "Dry mouth",
        "Constipation"
      ],
      "serious": [
        "Tardive Dyskinesia (Permanent)",
        "Neuroleptic Malignant Syndrome (NMS)",
        "QT Prolongation",
        "Blood dyscrasias"
      ]
    },
    "precautions": [
      "**EPS:** High risk. Prophylactic benztropine often used.",
      "**Tardive Dyskinesia:** Monitor for involuntary movements; can be irreversible.",
      "**Temperature:** Impairs thermoregulation (Heat stroke risk)."
    ],
    "contraindications": [
      "Severe CNS depression / Coma",
      "Subcortical brain damage",
      "Blood dyscrasias"
    ],
    "interactions": {
      "drug": ["CNS Depressants", "Anticholinergics (Additive)", "Levodopa (Antagonism)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "flurbiprofen": {
    "name": "Flurbiprofen (Ansaid, Ocufen)",
    "genericName": "Flurbiprofen",
    "formula": "C15H13FO2",
    "molecularWeight": "244.26 g/mol",
    "brandNames": ["Ansaid (Oral)", "Ocufen (Ophthalmic)"],
    "category": "NSAID",
    "drugClass": "Propionic Acid Derivative",
    "pubchemCID": "3394",
    "indications": "Rheumatoid Arthritis, Osteoarthritis. Ophthalmic: Inhibition of intraoperative miosis.",
    "moaSteps": [
      "Inhibits COX-1 and COX-2 enzymes.",
      "Reduces prostaglandin synthesis.",
      "Ophthalmic: Prevents surgically induced miosis (pupil constriction) by blocking prostaglandins that constrict the iris sphincter."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic (CYP2C9).",
      "excretion": "Urine. **Half-life: 6 hours.**"
    },
    "dose": {
      "initialDose": "50 mg PO QID",
      "maxDose": "300 mg/day",
      "notes": "Ophthalmic: 1 drop q30min before surgery."
    },
    "adverseEffects": {
      "common": [
        "Dyspepsia",
        "Abdominal pain",
        "Fluid retention",
        "Stinging (Drops)"
      ],
      "serious": [
        "GI Bleeding / Ulceration - BOXED WARNING",
        "CV Thrombotic Events - BOXED WARNING",
        "Renal Failure",
        "Increased bleeding time (Ocular)"
      ]
    },
    "precautions": [
      "**Ophthalmic:** Can increase bleeding of ocular tissues during surgery.",
      "**Cross-sensitivity:** Avoid in aspirin-sensitive asthma.",
      "**Renal:** Avoid long-term use in renal disease."
    ],
    "contraindications": [
      "CABG peri-operative pain",
      "Active GI bleed",
      "Aspirin allergy"
    ],
    "interactions": {
      "drug": ["Warfarin", "ACE Inhibitors", "Lithium", "Aspirin"],
      "food": ["Food delays absorption."]
    },
    "pregnancyCategory": "Category C (Avoid > 30 weeks)"
  },
  "fluvastatin": {
    "name": "Fluvastatin (Lescol)",
    "genericName": "Fluvastatin",
    "formula": "C24H26FNO4",
    "molecularWeight": "411.5 g/mol",
    "brandNames": ["Lescol", "Lescol XL"],
    "category": "Antilipemic",
    "drugClass": "HMG-CoA Reductase Inhibitor (Statin)",
    "pubchemCID": "446155",
    "indications": "Hyperlipidemia, Mixed Dyslipidemia, Atherosclerosis progression slowing.",
    "moaSteps": [
      "Competitively inhibits HMG-CoA reductase.",
      "Reduces cholesterol synthesis in the liver.",
      "Upregulates LDL receptors, increasing clearance of LDL from blood."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid and complete.",
      "distribution": "98% protein bound.",
      "metabolism": "Hepatic via CYP2C9 (Different from Atorvastatin/Simvastatin which are 3A4).",
      "excretion": "Feces. **Half-life: 3 hours (IR); 9 hours (XL).**"
    },
    "dose": {
      "initialDose": "20-40 mg PO at bedtime",
      "maxDose": "80 mg/day (as XL or 40mg BID)",
      "notes": "Less potent than Atorvastatin/Rosuvastatin."
    },
    "adverseEffects": {
      "common": [
        "Muscle pain (Myalgia)",
        "Headache",
        "Abdominal pain",
        "Nausea"
      ],
      "serious": [
        "Rhabdomyolysis",
        "Hepatotoxicity",
        "Immune-mediated necrotizing myopathy"
      ]
    },
    "precautions": [
      "**Muscle:** Risk of myopathy. Stop if CPK markedly elevated.",
      "**Drug Interactions:** Fewer than 3A4 statins, but still caution with Gemfibrozil.",
      "**Liver:** Monitor LFTs if symptoms occur."
    ],
    "contraindications": [
      "Active liver disease",
      "Pregnancy / Nursing"
    ],
    "interactions": {
      "drug": ["Gemfibrozil (Increases risk of myopathy)", "Fluconazole (CYP2C9 inhibition - increases levels)", "Warfarin"],
      "food": ["None significant"]
    },
    "pregnancyCategory": "Category X"
  },
  "fluvoxamine": {
    "name": "Fluvoxamine (Luvox)",
    "genericName": "Fluvoxamine Maleate",
    "formula": "C15H21F3N2O2",
    "molecularWeight": "318.3 g/mol",
    "brandNames": ["Luvox", "Luvox CR"],
    "category": "Antidepressant",
    "drugClass": "SSRI",
    "pubchemCID": "5324346",
    "indications": "Obsessive Compulsive Disorder (OCD), Social Anxiety Disorder.",
    "moaSteps": [
      "Potent and selective serotonin reuptake inhibitor.",
      "Little to no affinity for dopamine, adrenergic, histamine, or cholinergic receptors.",
      "Strong agonist at Sigma-1 receptors (anti-inflammatory/cognitive effects)."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "80% protein bound.",
      "metabolism": "Hepatic (CYP1A2 and 2D6).",
      "excretion": "Urine. **Half-life: 15 hours.**"
    },
    "dose": {
      "initialDose": "50 mg PO at bedtime",
      "maxDose": "300 mg/day",
      "notes": "Doses >100mg should be divided."
    },
    "adverseEffects": {
      "common": [
        "Nausea (High incidence)",
        "Somnolence / Insomnia",
        "Sexual dysfunction",
        "Sweating"
      ],
      "serious": [
        "Suicidality - BOXED WARNING",
        "Serotonin Syndrome",
        "Hyponatremia",
        "Bleeding risk"
      ]
    },
    "precautions": [
      "**CYP1A2 Inhibition:** Potent inhibitor of CYP1A2. Increases levels of Caffeine, Theophylline, Clozapine, Tizanidine significantly.",
      "**Suicide:** Monitor closely.",
      "**Smoking:** Smoking induces CYP1A2, lowering fluvoxamine levels."
    ],
    "contraindications": [
      "Concomitant Tizanidine, Thioridazine, Alosetron, Pimozide",
      "MAOI use within 14 days"
    ],
    "interactions": {
      "drug": ["Caffeine (Toxic jitters)", "Tizanidine (Severe hypotension - Contraindicated)", "Warfarin (Increases INR)", "Clozapine (Increases clozapine levels 5-10x)"],
      "food": ["Caffeine (Metabolism inhibited)"]
    },
    "pregnancyCategory": "Category C"
  },
  "fosamprenavir": {
    "name": "Fosamprenavir (Lexiva)",
    "genericName": "Fosamprenavir Calcium",
    "formula": "C25H36CaN3O9PS",
    "molecularWeight": "625.7 g/mol",
    "brandNames": ["Lexiva"],
    "category": "Antiretroviral",
    "drugClass": "Protease Inhibitor (PI)",
    "pubchemCID": "131411",
    "indications": "HIV-1 Infection.",
    "moaSteps": [
      "Prodrug of amprenavir.",
      "Hydrolyzed to amprenavir by cellular phosphatases in the gut epithelium.",
      "Inhibits HIV-1 protease, preventing cleavage of Gag-Pol polyproteins.",
      "Results in immature, non-infectious virions."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly hydrolyzed to amprenavir.",
      "distribution": "90% protein bound.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Feces and Urine. **Half-life: 7.7 hours.**"
    },
    "dose": {
      "initialDose": "1400 mg PO once daily (unboosted) OR 1400 mg + 100 mg Ritonavir (boosted)",
      "maxDose": "Protocol dependent",
      "notes": "Boosting allows once daily dosing."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea",
        "Nausea",
        "Headache",
        "Rash"
      ],
      "serious": [
        "Severe Skin Reactions (SJS - Sulfonamide moiety)",
        "Hyperglycemia",
        "Hyperlipidemia",
        "Nephrolithiasis"
      ]
    },
    "precautions": [
      "**Sulfa Allergy:** Contains sulfonamide. Use caution in allergic patients.",
      "**Hepatotoxicity:** Monitor LFTs.",
      "**Rash:** Discontinue if severe rash occurs."
    ],
    "contraindications": [
      "Concomitant use with drugs highly dependent on CYP3A4 (Simvastatin, Ergot)",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Statins (Toxicity)", "Rifampin (Decreases levels)", "PDE5 inhibitors (Increases levels)"],
      "food": ["None (unless boosted with Ritonavir, then take with food)."]
    },
    "pregnancyCategory": "Category C"
  },
  "fosaprepitant": {
    "name": "Fosaprepitant (Emend IV)",
    "genericName": "Fosaprepitant Dimeglumine",
    "formula": "C23H22F7N4O6P",
    "molecularWeight": "614.4 g/mol",
    "brandNames": ["Emend (Injection)"],
    "category": "Antiemetic",
    "drugClass": "Neurokinin-1 (NK1) Receptor Antagonist",
    "pubchemCID": "135409463",
    "indications": "Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV).",
    "moaSteps": [
      "Water-soluble IV prodrug of aprepitant.",
      "Rapidly converted to aprepitant.",
      "Crosses BBB and selectively blocks NK1 receptors.",
      "Inhibits Substance P binding, preventing delayed emesis."
    ],
    "pharmacokinetics": {
      "absorption": "IV administration.",
      "distribution": "High protein binding.",
      "metabolism": "Rapid conversion to aprepitant (30 min); Aprepitant via CYP3A4.",
      "excretion": "Urine/Feces. **Half-life: 9 to 13 hours (Aprepitant).**"
    },
    "dose": {
      "initialDose": "150 mg IV infusion single dose (Day 1)",
      "maxDose": "150 mg",
      "notes": "Administer 30 min before chemo. Combined with Dexamethasone/5-HT3 antagonist."
    },
    "adverseEffects": {
      "common": [
        "Infusion site pain (Phlebitis)",
        "Fatigue",
        "Hiccups",
        "Constipation"
      ],
      "serious": [
        "Hypersensitivity / Anaphylaxis",
        "Stevens-Johnson Syndrome"
      ]
    },
    "precautions": [
      "**Infusion Site:** Thrombophlebitis is common; dilute properly.",
      "**CYP3A4:** Aprepitant is a CYP3A4 inhibitor. Reduce Dexamethasone dose by 50% when using Emend.",
      "**Warfarin:** Can decrease INR (induction of CYP2C9)."
    ],
    "contraindications": [
      "Concomitant Pimozide or Cisapride",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Dexamethasone (Increase levels - Reduce dose)", "Warfarin (Decrease INR)", " hormonal contraceptives (Reduced efficacy)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "fosinopril": {
    "name": "Fosinopril (Monopril)",
    "genericName": "Fosinopril Sodium",
    "formula": "C30H46NO7P",
    "molecularWeight": "563.7 g/mol",
    "brandNames": ["Monopril"],
    "category": "Antihypertensive",
    "drugClass": "ACE Inhibitor",
    "pubchemCID": "55891",
    "indications": "Hypertension, Heart Failure.",
    "moaSteps": [
      "Prodrug converted to fosinoprilat by esterases.",
      "Inhibits ACE, blocking Angiotensin II formation.",
      "Unique phosphinate-containing ACE inhibitor.",
      "Reduces SVR and aldosterone secretion."
    ],
    "pharmacokinetics": {
      "absorption": "36% bioavailability.",
      "distribution": "99% protein bound.",
      "metabolism": " hepatic/intestinal mucosa hydrolysis.",
      "excretion": "Dual elimination: Urine (50%) and Feces (50%). **Half-life: 11.5 hours.**"
    },
    "dose": {
      "initialDose": "10 mg PO once daily",
      "maxDose": "40-80 mg/day",
      "notes": "Dual elimination makes it safer in renal impairment (compensatory hepatic clearance)."
    },
    "adverseEffects": {
      "common": [
        "Cough",
        "Dizziness",
        "Orthostatic Hypotension"
      ],
      "serious": [
        "Angioedema - BOXED WARNING",
        "Hyperkalemia",
        "Fetal Toxicity - BOXED WARNING",
        "Liver failure (rare)"
      ]
    },
    "precautions": [
      "**Renal Impairment:** Because of dual elimination, accumulation is less than other ACEIs, making it a preferred choice in kidney disease.",
      "**Angioedema:** Stop immediately.",
      "**Pregnancy:** Contraindicated."
    ],
    "contraindications": [
      "History of ACEI angioedema",
      "Pregnancy",
      "Co-administration with Aliskiren in diabetics"
    ],
    "interactions": {
      "drug": ["Antacids (Reduce absorption - separate by 2 hours)", "Lithium", "Potassium supplements"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "fostemsavir": {
    "name": "Fostemsavir (Rukobia)",
    "genericName": "Fostemsavir Tromethamine",
    "formula": "C25H26N7O8P",
    "molecularWeight": "583.5 g/mol",
    "brandNames": ["Rukobia"],
    "category": "Antiretroviral",
    "drugClass": "HIV-1 Attachment Inhibitor",
    "pubchemCID": "71556675",
    "indications": "Multi-drug resistant HIV-1 infection (Heavily Treatment Experienced).",
    "moaSteps": [
      "Prodrug of temsavir.",
      "Binds directly to the gp120 subunit of the HIV-1 envelope glycoprotein.",
      "Inhibits the interaction between the virus and the CD4 receptor.",
      "Prevents viral attachment and entry into the host cell."
    ],
    "pharmacokinetics": {
      "absorption": "Hydrolyzed to temsavir.",
      "distribution": "Extended release.",
      "metabolism": "Hydrolysis/CYP3A4.",
      "excretion": "Urine and Feces. **Half-life: 11 hours (Temsavir).**"
    },
    "dose": {
      "initialDose": "600 mg PO twice daily",
      "maxDose": "600 mg BID",
      "notes": "ER tablets - do not crush."
    },
    "adverseEffects": {
      "common": [
        "Nausea",
        "Diarrhea",
        "Headache",
        "Abdominal pain"
      ],
      "serious": [
        "QTc Prolongation",
        "Hepatotoxicity (in Hep B/C coinfection)",
        "Immune Reconstitution Syndrome"
      ]
    },
    "precautions": [
      "**QTc:** Causes dose-dependent QTc prolongation. Caution with other QT drugs.",
      "**Hepatitis:** Monitor LFTs closely in coinfected patients.",
      "**Odor:** Urine/sweat may smell like sulfonamides (though it is not one)."
    ],
    "contraindications": [
      "Strong CYP3A4 inducers (Rifampin, Carbamazepine - Loss of efficacy)",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inducers (Contraindicated)", "Oral Contraceptives (Increases ethinyl estradiol levels)", "Statins (Increases statin levels)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category No Rating (Benefit/Risk)"
  },
  "frovatriptan": {
    "name": "Frovatriptan (Frova)",
    "genericName": "Frovatriptan Succinate",
    "formula": "C14H17N3O",
    "molecularWeight": "243.3 g/mol",
    "brandNames": ["Frova"],
    "category": "Antimigraine",
    "drugClass": "Serotonin 5-HT1B/1D Receptor Agonist (Triptan)",
    "pubchemCID": "77996",
    "indications": "Acute treatment of Migraine with or without aura.",
    "moaSteps": [
      "Selective agonist at 5-HT1B and 5-HT1D receptors on cranial blood vessels.",
      "Causes vasoconstriction.",
      "Inhibits release of pro-inflammatory neuropeptides.",
      "Distinguished by its very long half-life."
    ],
    "pharmacokinetics": {
      "absorption": "Slow onset (2-3 hours).",
      "distribution": "15% protein bound.",
      "metabolism": "CYP1A2.",
      "excretion": "Urine and Feces. **Half-life: 26 hours (Longest of all triptans).**"
    },
    "dose": {
      "initialDose": "2.5 mg PO at onset",
      "maxDose": "7.5 mg/day",
      "notes": "Often used for menstrual migraine prophylaxis (short term)."
    },
    "adverseEffects": {
      "common": [
        "Dizziness",
        "Fatigue",
        "Paresthesia",
        "Dry mouth"
      ],
      "serious": [
        "Coronary Vasospasm / MI",
        "Stroke",
        "Serotonin Syndrome",
        "Hypertensive Crisis"
      ]
    },
    "precautions": [
      "**Slow Onset:** Not ideal for rapid relief, but good for preventing recurrence due to long half-life.",
      "**Cardiovascular:** Contraindicated in CAD/HTN.",
      "**Overuse:** Medication Overuse Headache risk."
    ],
    "contraindications": [
      "Ischemic heart disease",
      "Uncontrolled hypertension",
      "Hemiplegic/Basilar migraine",
      "Peripheral vascular disease"
    ],
    "interactions": {
      "drug": ["SSRIs/SNRIs (Serotonin syndrome)", "Ergotamine (Vasospasm)", "MAOIs"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },"gabapentin": {
    "name": "Gabapentin (Neurontin)",
    "genericName": "Gabapentin",
    "formula": "C9H17NO2",
    "molecularWeight": "171.24 g/mol",
    "brandNames": ["Neurontin", "Gralise", "Horizant"],
    "category": "Anticonvulsant / Neuropathic Pain Agent",
    "drugClass": "Gabapentinoid",
    "pubchemCID": "3446",
    "indications": "Postherpetic Neuralgia, Focal Seizures. Off-label: Diabetic Neuropathy, Anxiety, Alcohol Withdrawal.",
    "moaSteps": [
      "Structurally related to GABA but does not bind to GABA receptors.",
      "Binds with high affinity to the alpha-2-delta subunit of voltage-gated calcium channels.",
      "Reduces calcium influx at presynaptic terminals.",
      "Decreases release of excitatory neurotransmitters (glutamate, norepinephrine, substance P)."
    ],
    "pharmacokinetics": {
      "absorption": "Saturable absorption via L-amino acid transporter (bioavailability decreases as dose increases).",
      "distribution": "Widely distributed.",
      "metabolism": "Not metabolized.",
      "excretion": "Renal (Unchanged). **Half-life: 5 to 7 hours.**"
    },
    "dose": {
      "initialDose": "300 mg PO TID",
      "maxDose": "3600 mg/day",
      "notes": "Renal adjustment required. Taper to discontinue."
    },
    "adverseEffects": {
      "common": [
        "Somnolence / Sedation",
        "Dizziness / Ataxia",
        "Peripheral Edema",
        "Fatigue"
      ],
      "serious": [
        "Respiratory Depression (with opioids)",
        "Suicidal Ideation",
        "Withdrawal Seizures (if stopped abruptly)",
        "Angioedema"
      ]
    },
    "precautions": [
      "**Respiratory Depression:** FDA warning for serious breathing difficulties when used with opioids or in COPD/elderly.",
      "**Saturable Absorption:** Increasing dose beyond 1800mg/day yields diminishing returns in blood levels.",
      "**Withdrawal:** Taper over at least 1 week."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Opioids (Additive sedation/respiratory depression)", "Antacids (Reduce absorption - separate by 2h)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "galantamine": {
    "name": "Galantamine (Razadyne)",
    "genericName": "Galantamine Hydrobromide",
    "formula": "C17H21NO3",
    "molecularWeight": "287.4 g/mol",
    "brandNames": ["Razadyne", "Razadyne ER"],
    "category": "Anti-Alzheimer's Agent",
    "drugClass": "Acetylcholinesterase Inhibitor",
    "pubchemCID": "9651",
    "indications": "Mild to Moderate Alzheimer's Disease.",
    "moaSteps": [
      "Reversibly and competitively inhibits acetylcholinesterase (AChE).",
      "Increases acetylcholine at cholinergic synapses.",
      "Unique dual mechanism: Also acts as an allosteric modulator at nicotinic acetylcholine receptors.",
      "Enhances cholinergic function in the CNS."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Crosses BBB.",
      "metabolism": "Hepatic (CYP2D6 and CYP3A4).",
      "excretion": "Urine. **Half-life: 7 hours.**"
    },
    "dose": {
      "initialDose": "4 mg PO twice daily (IR) or 8 mg daily (ER)",
      "maxDose": "24 mg/day",
      "notes": "Take with food. Titrate every 4 weeks."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting (High incidence)",
        "Diarrhea",
        "Anorexia / Weight loss",
        "Bradycardia"
      ],
      "serious": [
        "Severe Cutaneous Reactions (SJS/AGEP)",
        "Heart Block / Syncope",
        "GI Bleeding (increased acid)"
      ]
    },
    "precautions": [
      "**GI Effects:** Nausea is very common; ensure dose titration and administration with food.",
      "**Cardiac:** Vagotonic effects can cause bradycardia/heart block.",
      "**Skin:** Watch for serious rashes."
    ],
    "contraindications": [
      "Severe renal or hepatic impairment",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Anticholinergics (Antagonism)", "Beta-blockers (Additive bradycardia)", "Paroxetine/Ketoconazole (Increase levels)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "ganciclovir": {
    "name": "Ganciclovir (Cytovene)",
    "genericName": "Ganciclovir",
    "formula": "C9H13N5O4",
    "molecularWeight": "255.23 g/mol",
    "brandNames": ["Cytovene", "Zirgan (Ophthalmic)"],
    "category": "Antiviral",
    "drugClass": "Nucleoside Analogue",
    "pubchemCID": "3454",
    "indications": "Cytomegalovirus (CMV) Retinitis, CMV prevention in transplant.",
    "moaSteps": [
      "Synthetic analogue of 2'-deoxyguanosine.",
      "Phosphorylated by viral protein kinase (UL97) in CMV-infected cells.",
      "Further phosphorylated by cellular kinases to triphosphate.",
      "Competitively inhibits viral DNA polymerase and terminates DNA elongation."
    ],
    "pharmacokinetics": {
      "absorption": "Poor oral absorption (Valganciclovir preferred for oral). IV used.",
      "distribution": "Widely distributed (CSF/Eye).",
      "metabolism": "Minimal.",
      "excretion": "Renal. **Half-life: 2 to 4 hours (Intracellular T1/2 > 24h).**"
    },
    "dose": {
      "initialDose": "5 mg/kg IV q12h (Induction)",
      "maxDose": "5 mg/kg daily (Maintenance)",
      "notes": "Handle as cytotoxic agent (carcinogen/teratogen)."
    },
    "adverseEffects": {
      "common": [
        "Fever",
        "Diarrhea",
        "Anemia"
      ],
      "serious": [
        "Severe Myelosuppression (Neutropenia, Thrombocytopenia) - BOXED WARNING",
        "Impairment of Fertility - BOXED WARNING",
        "Carcinogenicity / Teratogenicity - BOXED WARNING",
        "Seizures"
      ]
    },
    "precautions": [
      "**Myelosuppression:** Major dose-limiting toxicity. Monitor CBC frequently. Treat with G-CSF if needed.",
      "**Reproduction:** Males and females must use contraception (sperm inhibition/birth defects).",
      "**Renal:** Strict dose adjustment required."
    ],
    "contraindications": [
      "Hypersensitivity to ganciclovir or acyclovir",
      "Absolute neutrophil count < 500"
    ],
    "interactions": {
      "drug": ["Zidovudine (Severe neutropenia - Avoid)", "Imipenem (Seizure risk)", "Mycophenolate (Competition for renal secretion)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C (Teratogenic)"
  },
  "gefitinib": {
    "name": "Gefitinib (Iressa)",
    "genericName": "Gefitinib",
    "formula": "C22H24ClFN4O3",
    "molecularWeight": "446.9 g/mol",
    "brandNames": ["Iressa"],
    "category": "Antineoplastic",
    "drugClass": "EGFR Tyrosine Kinase Inhibitor (TKI)",
    "pubchemCID": "123631",
    "indications": "Metastatic Non-Small Cell Lung Cancer (NSCLC) with EGFR exon 19 deletions or exon 21 substitutions.",
    "moaSteps": [
      "Selectively inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase.",
      "Blocks autophosphorylation of EGFR.",
      "Inhibits downstream signaling (Ras/Raf/MAPK).",
      "Induces apoptosis in cells with EGFR sensitizing mutations."
    ],
    "pharmacokinetics": {
      "absorption": "Slow (60% bioavailable).",
      "distribution": "90% protein bound.",
      "metabolism": "Extensive hepatic (CYP3A4 and CYP2D6).",
      "excretion": "Feces. **Half-life: 48 hours.**"
    },
    "dose": {
      "initialDose": "250 mg PO once daily",
      "maxDose": "250 mg/day",
      "notes": "Can disperse tablet in water if swallowing difficulty."
    },
    "adverseEffects": {
      "common": [
        "Acneiform Rash",
        "Diarrhea",
        "Nausea",
        "Dry skin"
      ],
      "serious": [
        "Interstitial Lung Disease (ILD) - Can be fatal",
        "Hepatotoxicity",
        "GI Perforation",
        "Ocular Disorders (Keratitis)"
      ]
    },
    "precautions": [
      "**ILD:** Monitor for acute onset dyspnea/cough/fever. Discontinue immediately.",
      "**Hepatotoxicity:** Monitor LFTs periodically.",
      "**INR:** Elevations in patients on Warfarin."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inducers (Rifampin - reduces efficacy)", "PPIs/H2 Blockers (Reduce absorption - avoid)", "Warfarin"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "gemcitabine": {
    "name": "Gemcitabine (Gemzar)",
    "genericName": "Gemcitabine HCl",
    "formula": "C9H11F2N3O4",
    "molecularWeight": "263.2 g/mol",
    "brandNames": ["Gemzar"],
    "category": "Antineoplastic",
    "drugClass": "Antimetabolite (Nucleoside Analog)",
    "pubchemCID": "60750",
    "indications": "Pancreatic Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Ovarian Cancer.",
    "moaSteps": [
      "Analogue of deoxycytidine.",
      "Phosphorylated to active metabolites (dFdCDP and dFdCTP).",
      "Inhibits ribonucleotide reductase (reducing deoxynucleotide pools).",
      "Incorporates into DNA, leading to 'masked chain termination' (resistant to repair).",
      "S-phase specific."
    ],
    "pharmacokinetics": {
      "absorption": "IV only.",
      "distribution": "Wide.",
      "metabolism": "Deamination by cytidine deaminase in liver/blood.",
      "excretion": "Urine. **Half-life: 42 to 94 minutes (Short infusion); 4-10 hours (Long infusion).**"
    },
    "dose": {
      "initialDose": "1000 mg/m2 IV weekly",
      "maxDose": "Protocol dependent",
      "notes": "Prolonging infusion time >60 min increases toxicity significantly."
    },
    "adverseEffects": {
      "common": [
        "Myelosuppression",
        "Flu-like symptoms (Fever/Myalgia)",
        "Nausea / Vomiting",
        "Edema / Rash"
      ],
      "serious": [
        "Hemolytic Uremic Syndrome (HUS)",
        "Pulmonary Toxicity (Pneumonitis/ARDS)",
        "Capillary Leak Syndrome",
        "Hepatotoxicity"
      ]
    },
    "precautions": [
      "**Infusion Time:** Do not infuse longer than 60 mins (increases toxicity/half-life).",
      "**Pulmonary:** Stop if severe lung toxicity occurs.",
      "**HUS:** Monitor for anemia with thrombocytopenia and renal failure."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Warfarin (Increases INR)", "Radiotherapy (Radiosensitizer - severe toxicity)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "gemfibrozil": {
    "name": "Gemfibrozil (Lopid)",
    "genericName": "Gemfibrozil",
    "formula": "C15H22O3",
    "molecularWeight": "250.3 g/mol",
    "brandNames": ["Lopid"],
    "category": "Antilipemic",
    "drugClass": "Fibric Acid Derivative (Fibrate)",
    "pubchemCID": "3463",
    "indications": "Hypertriglyceridemia (Types IV and V), Risk reduction of CHD in Type IIb hyperlipidemia.",
    "moaSteps": [
      "Activates PPAR-alpha.",
      "Increases lipoprotein lipase activity, enhancing clearance of VLDL.",
      "Inhibits peripheral lipolysis and decreases hepatic extraction of free fatty acids.",
      "Lowers triglycerides effectively; raises HDL moderately."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic (Glucuronidation).",
      "excretion": "Urine. **Half-life: 1.5 hours.**"
    },
    "dose": {
      "initialDose": "600 mg PO twice daily",
      "maxDose": "1200 mg/day",
      "notes": "Take 30 min before breakfast and dinner."
    },
    "adverseEffects": {
      "common": [
        "Dyspepsia / Abdominal pain",
        "Diarrhea",
        "Nausea"
      ],
      "serious": [
        "Rhabdomyolysis (High risk with statins)",
        "Cholelithiasis (Gallstones)",
        "Hepatotoxicity",
        "Bone marrow hypoplasia (rare)"
      ]
    },
    "precautions": [
      "**Statins:** Concomitant use with statins (especially Simvastatin/Lovastatin) carries HIGH risk of rhabdomyolysis. Fenofibrate is preferred if combo needed.",
      "**Gallstones:** Increases cholesterol excretion into bile.",
      "**Renal:** Contraindicated in severe impairment."
    ],
    "contraindications": [
      "Hepatic or severe renal dysfunction",
      "Pre-existing gallbladder disease",
      "Concurrent use with Simvastatin, Repaglinide, or Dasabuvir"
    ],
    "interactions": {
      "drug": ["Statins (Myopathy)", "Repaglinide (Severe hypoglycemia - Contraindicated)", "Warfarin (Increases INR)"],
      "food": ["Take before meals."]
    },
    "pregnancyCategory": "Category C"
  },
  "gentamicin": {
    "name": "Gentamicin (Garamycin)",
    "genericName": "Gentamicin Sulfate",
    "formula": "Mixture of C1/C2/C1a",
    "molecularWeight": "~477 g/mol",
    "brandNames": ["Garamycin"],
    "category": "Antibiotic",
    "drugClass": "Aminoglycoside",
    "pubchemCID": "3467",
    "indications": "Serious Gram-negative infections (Pseudomonas, E. coli, Klebsiella), Endocarditis (synergy), Sepsis.",
    "moaSteps": [
      "Irreversibly binds to the 30S ribosomal subunit.",
      "Interferes with initiation complex and causes misreading of mRNA.",
      "Bactericidal.",
      "Requires oxygen-dependent transport (ineffective against anaerobes)."
    ],
    "pharmacokinetics": {
      "absorption": "IM/IV (Not absorbed orally).",
      "distribution": "Hydrophilic (low Vd). High concentration in renal cortex/inner ear.",
      "metabolism": "None.",
      "excretion": "Renal (Glomerular filtration). **Half-life: 2 to 3 hours.**"
    },
    "dose": {
      "initialDose": "5-7 mg/kg IV once daily (High dose extended interval)",
      "maxDose": "Based on levels",
      "notes": "Traditional dosing: 1-2.5 mg/kg q8h. Monitor peaks/troughs."
    },
    "adverseEffects": {
      "common": [
        "Injection site pain"
      ],
      "serious": [
        "Nephrotoxicity (Acute Tubular Necrosis) - BOXED WARNING",
        "Ototoxicity (Vestibular/Auditory - often permanent) - BOXED WARNING",
        "Neuromuscular Blockade (Respiratory paralysis) - BOXED WARNING"
      ]
    },
    "precautions": [
      "**Therapeutic Monitoring:** Essential to prevent toxicity. Troughs should be <1-2 mcg/mL (traditional) or undetectable (extended).",
      "**Ototoxicity:** Risk increases with loop diuretics or vancomycin.",
      "**Pregnancy:** Can cause fetal deafness."
    ],
    "contraindications": [
      "Hypersensitivity to aminoglycosides"
    ],
    "interactions": {
      "drug": ["Nephrotoxic drugs (Vancomycin, Amphotericin, NSAIDs)", "Loop Diuretics (Ototoxicity)", "Neuromuscular Blockers"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "gilteritinib": {
    "name": "Gilteritinib (Xospata)",
    "genericName": "Gilteritinib Fumarate",
    "formula": "C29H44N8O3",
    "molecularWeight": "552.7 g/mol",
    "brandNames": ["Xospata"],
    "category": "Antineoplastic",
    "drugClass": "FLT3 Tyrosine Kinase Inhibitor",
    "pubchemCID": "49803313",
    "indications": "Relapsed/Refractory Acute Myeloid Leukemia (AML) with FLT3 mutation.",
    "moaSteps": [
      "Inhibits FMS-like tyrosine kinase 3 (FLT3).",
      "Blocks signaling from both FLT3-ITD and FLT3-TKD mutations.",
      "Inhibits proliferation and induces apoptosis in leukemic cells expressing FLT3 mutations.",
      "Also inhibits AXL kinase (implicated in resistance)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "94% protein bound.",
      "metabolism": "Hepatic via CYP3A4.",
      "excretion": "Feces (65%). **Half-life: 113 hours.**"
    },
    "dose": {
      "initialDose": "120 mg PO once daily",
      "maxDose": "120 mg/day",
      "notes": "Continue for at least 6 months."
    },
    "adverseEffects": {
      "common": [
        "Myalgia / Arthralgia",
        "Transaminase elevation",
        "Fatigue",
        "Diarrhea"
      ],
      "serious": [
        "Differentiation Syndrome (Fatal if untreated) - BOXED WARNING",
        "Posterior Reversible Encephalopathy Syndrome (PRES)",
        "QT Prolongation",
        "Pancreatitis"
      ]
    },
    "precautions": [
      "**Differentiation Syndrome:** Rapid proliferation of differentiating myeloid cells leading to fever, dyspnea, effusions. Treat immediately with corticosteroids.",
      "**QT Prolongation:** Interrupt dosing if QTc > 500 ms.",
      "**Pancreatitis:** Monitor lipase."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inducers (Avoid)", "Strong CYP3A4 Inhibitors (Monitor)", "QT prolonging drugs"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "glatiramer": {
    "name": "Glatiramer Acetate (Copaxone)",
    "genericName": "Glatiramer Acetate",
    "formula": "Synthetic polypeptide mixture",
    "molecularWeight": "5-9 kDa",
    "brandNames": ["Copaxone", "Glatopa"],
    "category": "Multiple Sclerosis Agent",
    "drugClass": "Immunomodulator",
    "pubchemCID": "None (Peptide mixture)",
    "indications": "Relapsing forms of Multiple Sclerosis (RRMS).",
    "moaSteps": [
      "Random polymer of 4 amino acids (Glu, Lys, Ala, Tyr) resembling Myelin Basic Protein (MBP).",
      "Acts as a decoy, diverting autoimmune attack away from myelin.",
      "Induces shift from pro-inflammatory Th1 T-cells to anti-inflammatory Th2 T-cells.",
      "Suppressor T-cells migrate to CNS and release anti-inflammatory cytokines."
    ],
    "pharmacokinetics": {
      "absorption": "SC injection.",
      "distribution": "Local.",
      "metabolism": "Rapid hydrolysis at injection site.",
      "excretion": "Unknown. **Half-life: Rapid hydrolysis (systemic levels negligible).**"
    },
    "dose": {
      "initialDose": "20 mg SC daily or 40 mg SC 3 times weekly",
      "maxDose": "40 mg 3x/week",
      "notes": "Safe for long-term use."
    },
    "adverseEffects": {
      "common": [
        "Injection site reactions (Lipoatrophy, pain)",
        "Flushing",
        "Rash"
      ],
      "serious": [
        "Immediate Post-Injection Reaction (Flushing, Chest pain, Dyspnea - scary but transient)",
        "Hepatic Injury (Rare)"
      ]
    },
    "precautions": [
      "**Post-Injection Reaction:** Occurs in 16% of patients immediately after injection. Symptoms mimic heart attack but resolve in minutes spontaneously. Warn patient.",
      "**Lipoatrophy:** Permanent skin depressions. Rotate sites."
    ],
    "contraindications": [
      "Hypersensitivity to glatiramer or mannitol"
    ],
    "interactions": {
      "drug": ["None specific"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B (Preferred in pregnancy)"
  },
  "glimepiride": {
    "name": "Glimepiride (Amaryl)",
    "genericName": "Glimepiride",
    "formula": "C24H34N4O5S",
    "molecularWeight": "490.6 g/mol",
    "brandNames": ["Amaryl"],
    "category": "Antidiabetic",
    "drugClass": "Sulfonylurea (3rd Generation)",
    "pubchemCID": "3476",
    "indications": "Type 2 Diabetes Mellitus.",
    "moaSteps": [
      "Binds to SUR1 subunit of ATP-sensitive potassium channels on pancreatic beta cells.",
      "Closes K+ channels, leading to depolarization.",
      "Opens voltage-gated Calcium channels.",
      "Influx of calcium triggers insulin release.",
      "Also increases peripheral insulin sensitivity (extrapancreatic effect)."
    ],
    "pharmacokinetics": {
      "absorption": "Complete.",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic via CYP2C9.",
      "excretion": "Urine and Feces. **Half-life: 5 to 9 hours (Duration 24h).**"
    },
    "dose": {
      "initialDose": "1-2 mg PO once daily with breakfast",
      "maxDose": "8 mg/day",
      "notes": "Titrate slowly."
    },
    "adverseEffects": {
      "common": [
        "Hypoglycemia",
        "Weight gain",
        "Nausea",
        "Headache"
      ],
      "serious": [
        "Severe Hypoglycemia",
        " hemolytic anemia (G6PD deficiency)",
        "Hypersensitivity / SJS"
      ]
    },
    "precautions": [
      "**Hypoglycemia:** Risk increased in elderly, renal failure, or skipped meals.",
      "**Sulfa Allergy:** Use caution.",
      "**G6PD:** Risk of hemolysis."
    ],
    "contraindications": [
      "Diabetic Ketoacidosis",
      "Hypersensitivity to sulfonamides"
    ],
    "interactions": {
      "drug": ["Beta-blockers (Mask hypoglycemia)", "Fluconazole/Amiodarone (CYP2C9 inhibition - Hypoglycemia)", "Alcohol"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "glipizide": {
    "name": "Glipizide (Glucotrol)",
    "genericName": "Glipizide",
    "formula": "C21H27N5O4S",
    "molecularWeight": "445.5 g/mol",
    "brandNames": ["Glucotrol", "Glucotrol XL"],
    "category": "Antidiabetic",
    "drugClass": "Sulfonylurea (2nd Generation)",
    "pubchemCID": "3478",
    "indications": "Type 2 Diabetes Mellitus.",
    "moaSteps": [
      "Stimulates insulin release from pancreatic beta cells.",
      "Closes ATP-dependent K+ channels.",
      "Triggers depolarization and calcium influx.",
      "Short acting (lower risk of prolonged hypoglycemia than glyburide)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic (Inactive metabolites).",
      "excretion": "Urine (Metabolites). **Half-life: 2 to 5 hours.**"
    },
    "dose": {
      "initialDose": "5 mg PO daily (2.5 mg in elderly)",
      "maxDose": "40 mg/day (IR); 20 mg/day (XL)",
      "notes": "Take 30 min before meals (IR)."
    },
    "adverseEffects": {
      "common": [
        "Hypoglycemia",
        "Weight gain",
        "GI upset"
      ],
      "serious": [
        "Severe Hypoglycemia",
        "SIADH (rare)",
        "Blood dyscrasias"
      ]
    },
    "precautions": [
      "**Renal Friendly:** Safer than glyburide in renal impairment due to inactive metabolites.",
      "**Elderly:** Preferred sulfonylurea for elderly due to shorter half-life.",
      "**Failure:** Secondary failure (loss of efficacy) occurs over time."
    ],
    "contraindications": [
      "Diabetic Ketoacidosis",
      "Hypersensitivity to sulfonamides"
    ],
    "interactions": {
      "drug": ["Azoles (Hypoglycemia)", "Beta-blockers", "Alcohol (Disulfiram-like reaction - rare)"],
      "food": ["Food delays absorption (Take before meal)."]
    },
    "pregnancyCategory": "Category C"
  },
  "glucagon": {
    "name": "Glucagon (GlucaGen)",
    "genericName": "Glucagon",
    "formula": "Polypeptide (29 amino acids)",
    "molecularWeight": "3483 Da",
    "brandNames": ["GlucaGen", "Baqsimi (Nasal)", "Gvoke"],
    "category": "Antihypoglycemic / Antidote",
    "drugClass": "Glycogenolytic Agent",
    "pubchemCID": "16132305",
    "indications": "Severe Hypoglycemia (when IV glucose not possible), Beta-blocker/Calcium Channel Blocker Overdose, Diagnostic GI imaging.",
    "moaSteps": [
      "Stimulates adenylate cyclase via G-protein coupled receptor.",
      "Increases cAMP levels.",
      "Promotes hepatic glycogenolysis (breakdown of glycogen to glucose) and gluconeogenesis.",
      "In overdose: Increases myocardial contractility via non-adrenergic cAMP pathway (bypasses beta receptors)."
    ],
    "pharmacokinetics": {
      "absorption": "IM/SC/IV/Intranasal.",
      "distribution": "Liver/Kidney/Plasma.",
      "metabolism": "Proteolysis in liver/kidney.",
      "excretion": "Urine. **Half-life: 8 to 18 minutes.**"
    },
    "dose": {
      "initialDose": "1 mg IM/SC/IV",
      "maxDose": "Repeat in 15 min if no response",
      "notes": "High dose (3-10mg) for beta-blocker overdose."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting (very common)",
        "Tachycardia",
        "Hypertension (transient)"
      ],
      "serious": [
        "Hypersensitivity",
        "Hypokalemia (in overdose treatment)"
      ]
    },
    "precautions": [
      "**Glycogen Stores:** Ineffective in starvation, adrenal insufficiency, or chronic alcohol abuse (depleted glycogen). Requires IV Dextrose.",
      "**Vomiting:** Risk of aspiration if patient is unconscious. Place in recovery position.",
      "**Insulinoma:** Can induce rebound hypoglycemia (stimulates insulin)."
    ],
    "contraindications": [
      "Pheochromocytoma (can release catecholamines)",
      "Insulinoma"
    ],
    "interactions": {
      "drug": ["Warfarin (Transient increase in INR)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "glyburide": {
    "name": "Glyburide (Diabeta)",
    "genericName": "Glyburide (Glibenclamide)",
    "formula": "C23H28ClN3O5S",
    "molecularWeight": "494.0 g/mol",
    "brandNames": ["Diabeta", "Glynase"],
    "category": "Antidiabetic",
    "drugClass": "Sulfonylurea (2nd Generation)",
    "pubchemCID": "3488",
    "indications": "Type 2 Diabetes Mellitus.",
    "moaSteps": [
      "Stimulates insulin secretion from beta cells.",
      "Potent inhibitor of ATP-sensitive potassium channels.",
      "Long duration of action."
    ],
    "pharmacokinetics": {
      "absorption": "Significant.",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic to active metabolites.",
      "excretion": "Urine and Bile (50/50). **Half-life: 10 hours (Metabolites accumulate in renal failure).**"
    },
    "dose": {
      "initialDose": "2.5-5 mg PO daily",
      "maxDose": "20 mg/day",
      "notes": "Take with breakfast."
    },
    "adverseEffects": {
      "common": [
        "Hypoglycemia (Higher risk than other sulfonylureas)",
        "Weight gain",
        "Nausea"
      ],
      "serious": [
        "Prolonged / Refractory Hypoglycemia",
        "SIADH",
        "Disulfiram-like reaction"
      ]
    },
    "precautions": [
      "**Renal Impairment:** Active metabolites accumulate. CONTRAINDICATED in CKD due to risk of prolonged, fatal hypoglycemia.",
      "**Elderly:** Beers Criteria - Avoid use. Glipizide is safer.",
      "**Hypoglycemia:** Can last for days."
    ],
    "contraindications": [
      "Severe renal impairment",
      "Diabetic Ketoacidosis",
      "Hypersensitivity to sulfonamides"
    ],
    "interactions": {
      "drug": ["Sulfonamides", "Ciprofloxacin", "Alcohol"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "golimumab": {
    "name": "Golimumab (Simponi)",
    "genericName": "Golimumab",
    "formula": "Human monoclonal antibody",
    "molecularWeight": "147 kDa",
    "brandNames": ["Simponi", "Simponi Aria"],
    "category": "Biologic DMARD",
    "drugClass": "TNF Alpha Inhibitor",
    "pubchemCID": "None (Protein)",
    "indications": "Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis.",
    "moaSteps": [
      "Human monoclonal antibody specific for TNF-alpha.",
      "Neutralizes bioactivity of both soluble and transmembrane TNF-alpha.",
      "Prevents binding to TNF receptors.",
      "Blocks inflammatory cytokine cascade."
    ],
    "pharmacokinetics": {
      "absorption": "Subcutaneous (53% bioavailable).",
      "distribution": "Vascular.",
      "metabolism": "Proteolysis.",
      "excretion": "N/A. **Half-life: ~2 weeks (14 days).**"
    },
    "dose": {
      "initialDose": "50 mg SubQ once monthly",
      "maxDose": "100 mg (UC induction)",
      "notes": "IV formulation (Aria) dosed differently."
    },
    "adverseEffects": {
      "common": [
        "Upper respiratory infection",
        "Injection site reaction",
        "Nasopharyngitis"
      ],
      "serious": [
        "Serious Infections (TB, Fungal) - BOXED WARNING",
        "Malignancy (Lymphoma) - BOXED WARNING",
        "Reactivation of Hepatitis B",
        "Heart Failure worsening"
      ]
    },
    "precautions": [
      "**Infection:** TB screening mandatory. Stop if infection develops.",
      "**Live Vaccines:** Contraindicated.",
      "**Heart Failure:** Caution in Class III/IV CHF."
    ],
    "contraindications": [
      "Active serious infection",
      "Concurrent Anakinra or Abatacept"
    ],
    "interactions": {
      "drug": ["Live Vaccines", "Other immunosuppressants"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "goserelin": {
    "name": "Goserelin (Zoladex)",
    "genericName": "Goserelin Acetate",
    "formula": "C59H84N18O14",
    "molecularWeight": "1269.4 g/mol",
    "brandNames": ["Zoladex"],
    "category": "Antineoplastic / Hormone",
    "drugClass": "GnRH Agonist",
    "pubchemCID": "5311128",
    "indications": "Prostate Cancer, Breast Cancer, Endometriosis.",
    "moaSteps": [
      "Synthetic decapeptide analog of GnRH.",
      "Potent agonist; continuous administration downregulates pituitary GnRH receptors.",
      "Initial 'flare' of LH/FSH and testosterone/estrogen.",
      "Followed by profound suppression of LH/FSH and gonadal steroids (medical castration)."
    ],
    "pharmacokinetics": {
      "absorption": "Subcutaneous implant (Slow release).",
      "distribution": "Rapid.",
      "metabolism": "Hydrolysis.",
      "excretion": "Urine. **Half-life: 4.2 hours (Serum T1/2); Effect lasts 1-3 months.**"
    },
    "dose": {
      "initialDose": "3.6 mg Implant SC every 28 days",
      "maxDose": "10.8 mg every 12 weeks",
      "notes": "Inject into anterior abdominal wall."
    },
    "adverseEffects": {
      "common": [
        "Hot flashes",
        "Decreased libido / Impotence",
        "Vaginal dryness",
        "Gynecomastia"
      ],
      "serious": [
        "Tumor Flare (Bone pain, Spinal Cord Compression, Ureteral Obstruction)",
        "Osteoporosis / Fracture",
        "Hyperglycemia / Diabetes"
      ]
    },
    "precautions": [
      "**Tumor Flare:** Initial T-surge can worsen symptoms (bone pain, paralysis). Anti-androgen (Bicalutamide) co-prescribed for first few weeks to block flare.",
      "**Bone Density:** Monitor BMD.",
      "**Metabolic:** Increases risk of diabetes/CVD."
    ],
    "contraindications": [
      "Pregnancy (unless palliative for breast cancer)",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["QT prolonging drugs (Androgen deprivation prolongs QT)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category X (Endometriosis); D (Cancer)"
  },
  "granisetron": {
    "name": "Granisetron (Kytril, Sancuso)",
    "genericName": "Granisetron",
    "formula": "C18H24N4O",
    "molecularWeight": "312.4 g/mol",
    "brandNames": ["Kytril", "Sancuso", "Sustol"],
    "category": "Antiemetic",
    "drugClass": "5-HT3 Receptor Antagonist",
    "pubchemCID": "3510",
    "indications": "Chemotherapy-Induced Nausea and Vomiting (CINV), Post-op Nausea (PONV), Radiation-induced Nausea.",
    "moaSteps": [
      "Selective antagonist of serotonin 5-HT3 receptors.",
      "Blocks receptors peripherally on vagal nerve terminals and centrally in the Chemoreceptor Trigger Zone (CTZ).",
      "Prevents emesis triggered by cytotoxic drugs."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (Oral). Transdermal (Slow).",
      "distribution": "65% protein bound.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Urine/Feces. **Half-life: 6 hours (Oral/IV).**"
    },
    "dose": {
      "initialDose": "2 mg PO or 10 mcg/kg IV",
      "maxDose": "Varies",
      "notes": "Sancuso patch applied 24-48h before chemo, lasts 7 days."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Constipation",
        "Asthenia"
      ],
      "serious": [
        "QT Prolongation",
        "Serotonin Syndrome",
        "Hypersensitivity"
      ]
    },
    "precautions": [
      "**QT Interval:** Less risk than Ondansetron, but caution still advised.",
      "**Serotonin Syndrome:** Rare; caution with SSRIs/MAOIs.",
      "**Constipation:** Can be severe; monitor bowel movements."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["QT prolonging drugs", "Serotonergic agents"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "griseofulvin": {
    "name": "Griseofulvin (Grifulvin V)",
    "genericName": "Griseofulvin",
    "formula": "C17H17ClO6",
    "molecularWeight": "352.8 g/mol",
    "brandNames": ["Grifulvin V", "Gris-PEG"],
    "category": "Antifungal",
    "drugClass": "Mitotic Inhibitor",
    "pubchemCID": "5281095",
    "indications": "Tinea infections (Ringworm) of skin, hair, and nails (Tinea capitis/unguium).",
    "moaSteps": [
      "Deposited in keratin precursor cells.",
      "Disrupts the fungal mitotic spindle formation.",
      "Inhibits fungal cell division (fungistatic).",
      "Binds to new keratin, making it resistant to fungal invasion."
    ],
    "pharmacokinetics": {
      "absorption": "Enhanced by fatty meals. Ultramicronesized is better absorbed.",
      "distribution": "Concentrates in skin, hair, nails, liver, fat.",
      "metabolism": "Hepatic.",
      "excretion": "Urine/Feces. **Half-life: 24 hours.**"
    },
    "dose": {
      "initialDose": "500 mg (microsize) PO daily",
      "maxDose": "1000 mg/day",
      "notes": "Must be taken with high fat meal."
    },
    "adverseEffects": {
      "common": [
        "Photosensitivity",
        "Headache",
        "GI upset",
        "Fatigue"
      ],
      "serious": [
        "Severe Skin Reactions (SJS/TEN)",
        "Hepatotoxicity",
        "Granulocytopenia",
        "Lupus-like syndrome"
      ]
    },
    "precautions": [
      "**Photosensitivity:** Severe sunburns. Avoid sun.",
      "**Cross-reactivity:** Possible with Penicillin allergy.",
      "**Pregnancy:** Men should wait 6 months after stopping to father a child (sperm effects)."
    ],
    "contraindications": [
      "Severe liver disease",
      "Porphyria",
      "Pregnancy"
    ],
    "interactions": {
      "drug": ["Warfarin (Decreases efficacy - Inducer)", "Oral Contraceptives (Failure - Inducer)", "Alcohol (Disulfiram-like reaction)"],
      "food": ["High fat meal essential for absorption."]
    },
    "pregnancyCategory": "Category X"
  },
  "guanfacine": {
    "name": "Guanfacine (Intuniv)",
    "genericName": "Guanfacine",
    "formula": "C9H9Cl2N3O",
    "molecularWeight": "246.1 g/mol",
    "brandNames": ["Intuniv (ER)", "Tenex (IR)"],
    "category": "ADHD Agent / Antihypertensive",
    "drugClass": "Alpha-2 Adrenergic Agonist",
    "pubchemCID": "3519",
    "indications": "ADHD (ER), Hypertension (IR - rarely used).",
    "moaSteps": [
      "Selectively stimulates alpha-2A adrenergic receptors in the prefrontal cortex.",
      "Strengthens working memory and attention regulation.",
      "Reduces sympathetic outflow (lowering BP).",
      "More selective for alpha-2A than clonidine (less sedation)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "70% protein bound.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Urine. **Half-life: 17 hours.**"
    },
    "dose": {
      "initialDose": "1 mg ER PO daily",
      "maxDose": "4-7 mg/day (Weight based)",
      "notes": "Do not crush ER tablets. Do not take with high fat meal (dumps dose)."
    },
    "adverseEffects": {
      "common": [
        "Somnolence / Sedation",
        "Hypotension",
        "Headache",
        "Dry mouth"
      ],
      "serious": [
        "Bradycardia / Syncope",
        "Rebound Hypertension (if stopped abruptly)",
        "AV Block"
      ]
    },
    "precautions": [
      "**Hypotension/Bradycardia:** Monitor BP and HR.",
      "**Withdrawal:** Taper dose to prevent rebound hypertension and nervousness.",
      "**Diet:** Do not take ER with high fat meal (increases peak levels significantly)."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inhibitors/Inducers (Dose adjustment needed)", "CNS Depressants", "Antihypertensives"],
      "food": ["High fat meal (Increases absorption of ER)."]
    },
    "pregnancyCategory": "Category B"
  },
  "guselkumab": {
    "name": "Guselkumab (Tremfya)",
    "genericName": "Guselkumab",
    "formula": "Human IgG1 lambda monoclonal antibody",
    "molecularWeight": "147 kDa",
    "brandNames": ["Tremfya"],
    "category": "Biologic",
    "drugClass": "IL-23 Inhibitor",
    "pubchemCID": "None (Protein)",
    "indications": "Moderate-to-Severe Plaque Psoriasis, Psoriatic Arthritis.",
    "moaSteps": [
      "Binds selectively to the p19 subunit of Interleukin-23 (IL-23).",
      "Inhibits interaction with the IL-23 receptor.",
      "Blocks release of pro-inflammatory cytokines (IL-17, etc.) driving psoriatic disease.",
      "Does not bind IL-12 (unlike Ustekinumab)."
    ],
    "pharmacokinetics": {
      "absorption": "Subcutaneous.",
      "distribution": "Vascular/Extravascular.",
      "metabolism": "Catabolism.",
      "excretion": "Slow clearance. **Half-life: 15 to 18 days.**"
    },
    "dose": {
      "initialDose": "100 mg SubQ at week 0 and 4",
      "maxDose": "100 mg every 8 weeks",
      "notes": "Maintenance dose every 2 months."
    },
    "adverseEffects": {
      "common": [
        "Upper respiratory infection",
        "Headache",
        "Injection site reactions",
        "Arthralgia"
      ],
      "serious": [
        "Serious Infections (TB, Fungal)",
        "Hypersensitivity"
      ]
    },
    "precautions": [
      "**Infections:** Screen for TB prior to start. Do not start in active infection.",
      "**Live Vaccines:** Avoid during therapy.",
      "**Hypersensitivity:** Discontinue if anaphylaxis occurs."
    ],
    "contraindications": [
      "Active serious infection"
    ],
    "interactions": {
      "drug": ["Live Vaccines (Contraindicated)", "CYP Substrates (Cytokine modulation may alter CYP activity - monitor warfarin/cyclosporine)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B (Likely safe)"
  },"haloperidol": {
    "name": "Haloperidol (Haldol)",
    "genericName": "Haloperidol",
    "formula": "C21H23ClFNO2",
    "molecularWeight": "375.9 g/mol",
    "brandNames": ["Haldol", "Haldol Decanoate"],
    "category": "Antipsychotic",
    "drugClass": "First Generation (Typical) Antipsychotic / Butyrophenone",
    "pubchemCID": "3559",
    "indications": "Schizophrenia, Acute Psychosis/Agitation, Tourette's Syndrome, Hyperactive Delirium.",
    "moaSteps": [
      "Potent antagonist of postsynaptic dopamine D2 receptors in the mesolimbic system.",
      "High affinity binding leads to strong antipsychotic effect.",
      "Also blocks alpha-1 adrenergic receptors.",
      "Minimally blocks cholinergic or histaminergic receptors (less sedation/dry mouth than chlorpromazine)."
    ],
    "pharmacokinetics": {
      "absorption": "60% bioavailability (Oral).",
      "distribution": "92% protein bound.",
      "metabolism": "Hepatic (CYP3A4 and CYP2D6).",
      "excretion": "Urine/Feces. **Half-life: 18 hours (Oral); 3 weeks (Decanoate IM).**"
    },
    "dose": {
      "initialDose": "0.5-5 mg PO/IM 2-3 times daily",
      "maxDose": "100 mg/day (rarely >20mg needed)",
      "notes": "Use Decanoate for long-acting maintenance (monthly)."
    },
    "adverseEffects": {
      "common": [
        "Extrapyramidal Symptoms (Dystonia, Akathisia, Parkinsonism)",
        "Somnolence",
        "Dry mouth"
      ],
      "serious": [
        "Tardive Dyskinesia (Permanent)",
        "Neuroleptic Malignant Syndrome (NMS)",
        "QT Prolongation / Torsades de Pointes (IV)",
        "Seizures"
      ]
    },
    "precautions": [
      "**EPS:** High potency causes high rates of muscle rigidity/tremor. Treat with Benztropine/Diphenhydramine.",
      "**QT Prolongation:** Cumulative dose effect, especially with IV use. Monitor ECG.",
      "**Elderly:** Black Box Warning for increased mortality in dementia-related psychosis."
    ],
    "contraindications": [
      "Severe CNS depression / Coma",
      "Parkinson's Disease (worsens rigidity)",
      "Dementia with Lewy Bodies"
    ],
    "interactions": {
      "drug": ["QT Prolonging drugs (Amiodarone, Zofran)", "Dopamine agonists (Levodopa - Antagonism)", "Anticholinergics (Heat stroke risk)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "heparin": {
    "name": "Heparin (Unfractionated)",
    "genericName": "Heparin Sodium",
    "formula": "Glycosaminoglycan mixture",
    "molecularWeight": "12-15 kDa",
    "brandNames": ["Heparin Sodium"],
    "category": "Anticoagulant",
    "drugClass": "Unfractionated Heparin (UFH)",
    "pubchemCID": "772",
    "indications": "DVT/PE Treatment and Prophylaxis, Acute Coronary Syndrome, Anticoagulation during surgery/dialysis.",
    "moaSteps": [
      "Binds to Antithrombin III (ATIII).",
      "Induces a conformational change in ATIII.",
      "Potentiates the inactivation of Thrombin (Factor IIa) and Factor Xa by 1000-fold.",
      "Prevents the conversion of fibrinogen to fibrin."
    ],
    "pharmacokinetics": {
      "absorption": "IV or SC only (not absorbed orally).",
      "distribution": "Vascular space.",
      "metabolism": "Hepatic and Reticuloendothelial.",
      "excretion": "Urine. **Half-life: 1.5 hours (Dose dependent).**"
    },
    "dose": {
      "initialDose": "80 units/kg IV bolus",
      "maxDose": "18 units/kg/hr infusion (Titrate to aPTT)",
      "notes": "Prophylaxis: 5000 units SC q8h or q12h."
    },
    "adverseEffects": {
      "common": [
        "Bleeding / Bruising",
        "Injection site pain",
        "Transient thrombocytopenia"
      ],
      "serious": [
        "Heparin-Induced Thrombocytopenia (HIT) - Thrombotic risk",
        "Major Hemorrhage",
        "Osteoporosis (Long term use)",
        "Hyperkalemia (Suppression of aldosterone)"
      ]
    },
    "precautions": [
      "**HIT:** Autoimmune reaction causing low platelets and clotting. Monitor platelets q2-3 days. Stop heparin immediately if count drops 50%.",
      "**Bleeding:** Reversal agent is Protamine Sulfate.",
      "**Hyperkalemia:** Can occur in renal failure/diabetes."
    ],
    "contraindications": [
      "Severe thrombocytopenia",
      "History of HIT",
      "Uncontrolled active bleeding"
    ],
    "interactions": {
      "drug": ["Antiplatelets/NSAIDs (Bleeding risk)", "Thrombolytics"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C (Does not cross placenta - Safe)"
  },
  "hydralazine": {
    "name": "Hydralazine (Apresoline)",
    "genericName": "Hydralazine HCl",
    "formula": "C8H8N4",
    "molecularWeight": "160.18 g/mol",
    "brandNames": ["Apresoline"],
    "category": "Antihypertensive / Vasodilator",
    "drugClass": "Direct Vasodilator",
    "pubchemCID": "3637",
    "indications": "Hypertension (Severe/Resistant), Hypertensive Emergency (Pregnancy), Heart Failure (with nitrates).",
    "moaSteps": [
      "Directly relaxes arteriolar smooth muscle.",
      "Decreases systemic vascular resistance (afterload).",
      "Little to no effect on venous smooth muscle (preload).",
      "Triggers sympathetic reflex (tachycardia, renin release)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "87% protein bound.",
      "metabolism": "Hepatic acetylation (Genetically determined: Fast vs Slow Acetylators).",
      "excretion": "Urine. **Half-life: 3 to 7 hours.**"
    },
    "dose": {
      "initialDose": "10-25 mg PO QID",
      "maxDose": "300 mg/day",
      "notes": "IV: 10-20 mg PRN."
    },
    "adverseEffects": {
      "common": [
        "Reflex Tachycardia",
        "Headache / Flushing",
        "Palpitations",
        "Nausea"
      ],
      "serious": [
        "Drug-Induced Lupus Erythematosus (DILE)",
        "Angina Pectoris (due to tachycardia)",
        "Peripheral Neuritis (B6 deficiency)"
      ]
    },
    "precautions": [
      "**Lupus:** DILE occurs in 5-10% of patients (fever, joint pain, rash). Risk higher in slow acetylators and doses >200mg. Reversible upon stopping.",
      "**Reflex Tachycardia:** Must co-administer with beta-blocker to prevent angina/MI.",
      "**Neuritis:** Co-administer Pyridoxine (B6) to prevent neuropathy."
    ],
    "contraindications": [
      "Coronary Artery Disease (without beta-blocker)",
      "Mitral valve rheumatic heart disease"
    ],
    "interactions": {
      "drug": ["Nitrates (Severe hypotension - Beneficial in HF)", "Beta-blockers (Synergistic BP lowering)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C (Drug of choice in Preeclampsia)"
  },
  "hydrochlorothiazide": {
    "name": "Hydrochlorothiazide (HCTZ)",
    "genericName": "Hydrochlorothiazide",
    "formula": "C7H8ClN3O4S2",
    "molecularWeight": "297.7 g/mol",
    "brandNames": ["Microzide"],
    "category": "Diuretic",
    "drugClass": "Thiazide Diuretic",
    "pubchemCID": "3639",
    "indications": "Hypertension, Edema.",
    "moaSteps": [
      "Inhibits the Na+/Cl- symporter in the distal convoluted tubule.",
      "Increases excretion of Sodium, Chloride, and Water.",
      "Promotes Potassium and Magnesium excretion.",
      "Decreases Calcium excretion (useful in kidney stones)."
    ],
    "pharmacokinetics": {
      "absorption": "65-75% absorbed.",
      "distribution": "Crosses placenta.",
      "metabolism": "Not metabolized.",
      "excretion": "Urine (Unchanged). **Half-life: 6 to 15 hours.**"
    },
    "dose": {
      "initialDose": "12.5 - 25 mg PO once daily",
      "maxDose": "50 mg/day",
      "notes": "Higher doses add little efficacy but increase toxicity."
    },
    "adverseEffects": {
      "common": [
        "Frequent urination",
        "Dizziness",
        "Photosensitivity"
      ],
      "serious": [
        "Hypokalemia",
        "Hyponatremia",
        "Hyperuricemia (Gout)",
        "Hyperglycemia",
        "Sulfonamide Allergy (SJS)"
      ]
    },
    "precautions": [
      "**Electrolytes:** Monitor K+ and Na+. Hypokalemia increases digoxin toxicity.",
      "**Gout:** Can precipitate gout attack by retaining uric acid.",
      "**Diabetes:** Can raise blood sugar and lipids.",
      "**Renal:** Ineffective if CrCl < 30 mL/min."
    ],
    "contraindications": [
      "Anuria",
      "Hypersensitivity to sulfonamides"
    ],
    "interactions": {
      "drug": ["Lithium (Toxicity)", "NSAIDs (Reduced efficacy)", "Digoxin (Toxicity)", "Dofetilide (QT prolongation - Contraindicated)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "hydrocodone": {
    "name": "Hydrocodone (Vicodin, Norco)",
    "genericName": "Hydrocodone Bitartrate",
    "formula": "C18H21NO3",
    "molecularWeight": "299.4 g/mol",
    "brandNames": ["Norco", "Lortab", "Vicodin", "Hysingla ER"],
    "category": "Opioid Analgesic",
    "drugClass": "Semi-synthetic Opioid Agonist",
    "pubchemCID": "5284569",
    "indications": "Moderate to severe pain, Cough (antitussive).",
    "moaSteps": [
      "Binds to mu-opioid receptors in the CNS.",
      "Inhibits ascending pain pathways.",
      "Produces generalized CNS depression.",
      "Suppresses cough reflex in medullary center."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "Protein binding 19-45%.",
      "metabolism": "Hepatic via CYP2D6 (to Hydromorphone - active) and CYP3A4.",
      "excretion": "Urine. **Half-life: 3.8 to 6 hours.**"
    },
    "dose": {
      "initialDose": "5-10 mg PO every 4-6 hours",
      "maxDose": "Limited by Acetaminophen content (<4g APAP/day)",
      "notes": "Available mostly in combo with Acetaminophen."
    },
    "adverseEffects": {
      "common": [
        "Constipation",
        "Nausea / Vomiting",
        "Sedation / Drowsiness",
        "Dizziness"
      ],
      "serious": [
        "Respiratory Depression - BOXED WARNING",
        "Hepatotoxicity (from Acetaminophen component) - BOXED WARNING",
        "Addiction / Misuse - BOXED WARNING",
        "Adrenal Insufficiency"
      ]
    },
    "precautions": [
      "**Acetaminophen:** Most formulations contain APAP. Ensure total daily APAP < 3000-4000 mg.",
      "**CYP2D6:** Poor metabolizers may get less pain relief (less conversion to hydromorphone). Ultra-rapid metabolizers risk overdose.",
      "**Constipation:** Bowel regimen required for chronic use."
    ],
    "contraindications": [
      "Severe respiratory depression",
      "Paralytic ileus",
      "Acute or severe bronchial asthma"
    ],
    "interactions": {
      "drug": ["Benzodiazepines (Fatal respiratory depression)", "CYP3A4/2D6 Inhibitors", "Alcohol"],
      "food": ["Alcohol increases plasma levels."]
    },
    "pregnancyCategory": "Category C"
  },
  "hydrocortisone": {
    "name": "Hydrocortisone (Cortef, Solu-Cortef)",
    "genericName": "Hydrocortisone",
    "formula": "C21H30O5",
    "molecularWeight": "362.5 g/mol",
    "brandNames": ["Cortef (Oral)", "Solu-Cortef (IV)", "Anusol-HC"],
    "category": "Corticosteroid",
    "drugClass": "Glucocorticoid (Short-acting)",
    "pubchemCID": "5754",
    "indications": "Adrenal Insufficiency (Addison's), Severe Inflammation, Anaphylaxis, Status Asthmaticus, Thyroid Storm.",
    "moaSteps": [
      "Synthetic equivalent of endogenous cortisol.",
      "Possesses both glucocorticoid (anti-inflammatory) and mineralocorticoid (salt-retaining) activity (1:1 ratio).",
      "Replacement therapy mimics natural circadian rhythm."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "90% protein bound (CBG).",
      "metabolism": "Hepatic.",
      "excretion": "Urine. **Half-life: 1.5 to 2 hours (Serum); 8-12 hours (Biologic).**"
    },
    "dose": {
      "initialDose": "20 mg PO AM + 10 mg PO PM (Replacement)",
      "maxDose": "100 mg IV q8h (Stress dose)",
      "notes": "Dose increases needed during stress/illness."
    },
    "adverseEffects": {
      "common": [
        "Fluid retention",
        "Insomnia",
        "Increased appetite",
        "Hyperglycemia"
      ],
      "serious": [
        "Adrenal Suppression (if stopped abruptly)",
        "Cushing's Syndrome (chronic high dose)",
        "Peptic Ulcer",
        "Osteoporosis"
      ]
    },
    "precautions": [
      "**Adrenal Crisis:** Patients on chronic therapy must carry stress dose kit. Abrupt cessation causes fatal crisis.",
      "**Infection:** Masks signs of infection.",
      "**Vaccines:** Avoid live vaccines in immunosuppressive doses."
    ],
    "contraindications": [
      "Systemic fungal infections"
    ],
    "interactions": {
      "drug": ["NSAIDs (GI bleed)", "Diuretics (Hypokalemia)", "Phenytoin (Reduces steroid levels)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "hydromorphone": {
    "name": "Hydromorphone (Dilaudid)",
    "genericName": "Hydromorphone HCl",
    "formula": "C17H19NO3",
    "molecularWeight": "285.3 g/mol",
    "brandNames": ["Dilaudid", "Exalgo"],
    "category": "Opioid Analgesic",
    "drugClass": "Semi-synthetic Opioid Agonist",
    "pubchemCID": "5284570",
    "indications": "Moderate to Severe Pain (Acute or Chronic).",
    "moaSteps": [
      "Potent agonist at mu-opioid receptors.",
      "Approximately 5-7 times more potent than morphine.",
      "Inhibits pain pathways in CNS.",
      "Lacks active metabolites (safer in renal failure than morphine)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Widely distributed.",
      "metabolism": "Hepatic Glucuronidation (No CYP interactions).",
      "excretion": "Urine. **Half-life: 2 to 3 hours.**"
    },
    "dose": {
      "initialDose": "0.2-1 mg IV q2-3h OR 2-4 mg PO q4-6h",
      "maxDose": "Titrate to effect",
      "notes": "High potency; dosing errors common."
    },
    "adverseEffects": {
      "common": [
        "Sedation",
        "Constipation",
        "Nausea / Vomiting",
        "Pruritus"
      ],
      "serious": [
        "Respiratory Depression - BOXED WARNING",
        "Addiction / Misuse - BOXED WARNING",
        "Severe Hypotension",
        "Seizures (accumulation of metabolite H3G)"
      ]
    },
    "precautions": [
      "**Potency:** Do not confuse with morphine. 1 mg Dilaudid ~= 7 mg Morphine.",
      "**Renal:** Metabolite hydromorphone-3-glucuronide (H3G) is neuroexcitatory and accumulates in renal failure (agitation/seizures).",
      "**Opioid Naive:** Use extreme caution."
    ],
    "contraindications": [
      "Severe respiratory depression",
      " paralytic ileus",
      "Acute asthma"
    ],
    "interactions": {
      "drug": ["Benzodiazepines (Fatal)", "Alcohol", "MAOIs"],
      "food": ["Alcohol (Dumping of ER dose)"]
    },
    "pregnancyCategory": "Category C"
  },
  "hydroxychloroquine": {
    "name": "Hydroxychloroquine (Plaquenil)",
    "genericName": "Hydroxychloroquine Sulfate",
    "formula": "C18H26ClN3O",
    "molecularWeight": "335.9 g/mol",
    "brandNames": ["Plaquenil"],
    "category": "DMARD / Antimalarial",
    "drugClass": "Aminoquinoline",
    "pubchemCID": "3652",
    "indications": "Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), Malaria.",
    "moaSteps": [
      "Accumulates in lysosomes, increasing pH and interfering with antigen processing.",
      "Inhibits toll-like receptors (TLR 7/9) activation.",
      "Reduces production of pro-inflammatory cytokines.",
      "Interferes with parasitic vesicle function (Malaria)."
    ],
    "pharmacokinetics": {
      "absorption": "Complete.",
      "distribution": "Extensive tissue binding (Eye/Skin).",
      "metabolism": "Hepatic.",
      "excretion": "Urine (very slow). **Half-life: 40 to 50 days (Terminal).**"
    },
    "dose": {
      "initialDose": "200-400 mg PO daily",
      "maxDose": "5 mg/kg/day (to prevent retinopathy)",
      "notes": "Takes 3-6 months for full effect in RA/Lupus."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Diarrhea",
        "Headache",
        "Skin rash / Pigmentation",
        "Abdominal pain"
      ],
      "serious": [
        "Retinopathy (Permanent vision loss)",
        "Cardiomyopathy / QT Prolongation",
        "Hypoglycemia (severe)",
        "Neuromyopathy"
      ]
    },
    "precautions": [
      "**Retinopathy:** Dose-dependent (daily and cumulative). Annual eye exam required after 5 years (or sooner if high risk). Max dose 5 mg/kg actual weight.",
      "**Cardiac:** Rare conduction blocks and cardiomyopathy.",
      "**G6PD:** Caution in G6PD deficiency (hemolysis)."
    ],
    "contraindications": [
      "Retinal or visual field changes",
      "Hypersensitivity to 4-aminoquinolines"
    ],
    "interactions": {
      "drug": ["Digoxin (Increases levels)", "Antidiabetics (Hypoglycemia)", "QT prolonging drugs"],
      "food": ["Take with food to reduce nausea."]
    },
    "pregnancyCategory": "Category C (Generally continued in Lupus)"
  },
  "hydroxyurea": {
    "name": "Hydroxyurea (Hydrea)",
    "genericName": "Hydroxyurea",
    "formula": "CH4N2O2",
    "molecularWeight": "76.05 g/mol",
    "brandNames": ["Hydrea", "Droxia", "Siklos"],
    "category": "Antineoplastic",
    "drugClass": "Ribonucleotide Reductase Inhibitor",
    "pubchemCID": "3657",
    "indications": "Chronic Myeloid Leukemia (CML), Sickle Cell Anemia, Polycythemia Vera, Head/Neck Cancer.",
    "moaSteps": [
      "Inhibits the enzyme ribonucleotide reductase.",
      "Prevents conversion of ribonucleotides to deoxyribonucleotides.",
      "Halts DNA synthesis (S-phase specific).",
      "Increases Fetal Hemoglobin (HbF) in Sickle Cell, preventing sickling."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid and complete.",
      "distribution": "Crosses BBB.",
      "metabolism": "Hepatic.",
      "excretion": "Urine / Respiratory (CO2). **Half-life: 2 to 4 hours.**"
    },
    "dose": {
      "initialDose": "15-35 mg/kg PO daily (Sickle Cell)",
      "maxDose": "Based on blood counts",
      "notes": "Handle with gloves (cytotoxic)."
    },
    "adverseEffects": {
      "common": [
        "Myelosuppression",
        "Nausea",
        "Hyperpigmentation",
        "Macrocytosis (High MCV - expected)"
      ],
      "serious": [
        "Severe Bone Marrow Suppression - BOXED WARNING",
        "Secondary Malignancies (Skin cancer/Leukemia) - BOXED WARNING",
        "Cutaneous Ulcers (Leg ulcers)",
        "Teratogenicity"
      ]
    },
    "precautions": [
      "**Myelosuppression:** Monitor CBC every 2 weeks initially. Hold if Neutrophils < 2000 or Platelets < 80k.",
      "**Live Vaccines:** Avoid.",
      "**Ulcers:** Painful leg ulcers/gangrene can occur; requires discontinuation."
    ],
    "contraindications": [
      "Severe bone marrow depression",
      "Pregnancy"
    ],
    "interactions": {
      "drug": ["Antiretrovirals (Pancreatitis risk)", "Live Vaccines"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "hydroxyzine": {
    "name": "Hydroxyzine (Vistaril, Atarax)",
    "genericName": "Hydroxyzine Pamoate/HCl",
    "formula": "C21H27ClN2O2",
    "molecularWeight": "374.9 g/mol",
    "brandNames": ["Vistaril", "Atarax"],
    "category": "Antihistamine / Anxiolytic",
    "drugClass": "H1 Receptor Antagonist (First Generation)",
    "pubchemCID": "3658",
    "indications": "Anxiety, Pruritus (Itching), Preoperative Sedation, Nausea.",
    "moaSteps": [
      "Competes with histamine for H1 receptors in the GI tract, blood vessels, and respiratory tract.",
      "Suppresses activity in subcortical CNS areas (anxiolytic/sedative).",
      "Possesses anticholinergic, antiemetic, and analgesic sparing properties."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Widely distributed.",
      "metabolism": "Hepatic to Cetirizine (active metabolite).",
      "excretion": "Urine. **Half-life: 20 hours (Adults); 29 hours (Elderly).**"
    },
    "dose": {
      "initialDose": "25-50 mg PO 3-4 times daily",
      "maxDose": "400 mg/day",
      "notes": "IM injection must be deep (Z-track)."
    },
    "adverseEffects": {
      "common": [
        "Sedation / Drowsiness",
        "Dry mouth",
        "Dizziness",
        "Confusion (Elderly)"
      ],
      "serious": [
        "QT Prolongation / Torsades de Pointes",
        "Injection site necrosis (if given SubQ/Intra-arterial - CONTRAINDICATED)",
        "Respiratory depression"
      ]
    },
    "precautions": [
      "**Administration:** NEVER give IV or SC. Intra-arterial injection causes gangrene/amputation. Deep IM only.",
      "**QT:** Caution in patients with electrolyte imbalance or cardiac disease.",
      "**Elderly:** Beers Criteria drug; avoid due to anticholinergic effects."
    ],
    "contraindications": [
      "Early pregnancy",
      "Prolonged QT interval",
      "Subcutaneous, Intra-arterial, or IV administration"
    ],
    "interactions": {
      "drug": ["CNS Depressants (Alcohol - Additive)", "Anticholinergics", "QT prolonging drugs"],
      "food": ["Alcohol"]
    },
    "pregnancyCategory": "Category X (Early pregnancy)"
  },
  "ibandronate": {
    "name": "Ibandronate (Boniva)",
    "genericName": "Ibandronate Sodium",
    "formula": "C9H23NO7P2",
    "molecularWeight": "319.2 g/mol",
    "brandNames": ["Boniva"],
    "category": "Bone Resorption Inhibitor",
    "drugClass": "Bisphosphonate",
    "pubchemCID": "60852",
    "indications": "Treatment and prevention of Osteoporosis in postmenopausal women.",
    "moaSteps": [
      "Binds to hydroxyapatite crystals in bone matrix.",
      "Taken up by osteoclasts during resorption.",
      "Inhibits farnesyl pyrophosphate synthase enzyme.",
      "Causes osteoclast apoptosis and inhibits bone resorption."
    ],
    "pharmacokinetics": {
      "absorption": "Poor oral absorption (0.6%).",
      "distribution": "Rapid skeletal uptake (40-50%).",
      "metabolism": "Not metabolized.",
      "excretion": "Renal. **Half-life: 10 to 60 hours (Serum); Years (Bone).**"
    },
    "dose": {
      "initialDose": "150 mg PO once monthly",
      "maxDose": "150 mg/month",
      "notes": "3 mg IV every 3 months is alternative."
    },
    "adverseEffects": {
      "common": [
        "Dyspepsia / Heartburn",
        "Back pain",
        "Flu-like symptoms (IV - Acute phase reaction)"
      ],
      "serious": [
        "Esophagitis / Esophageal Ulcer",
        "Osteonecrosis of the Jaw (ONJ)",
        "Atypical Femoral Fracture",
        "Severe Bone/Joint Pain"
      ]
    },
    "precautions": [
      "**Esophagus:** Strict administration rules: Full glass of water, upright for 60 mins, fasting. Stop if dysphagia occurs.",
      "**ONJ:** Dental exam prior to therapy recommended.",
      "**Renal:** Contraindicated if CrCl < 30 mL/min."
    ],
    "contraindications": [
      "Hypocalcemia",
      "Inability to stand/sit upright for 60 min (Oral)",
      "Esophageal abnormalities",
      "Severe renal impairment"
    ],
    "interactions": {
      "drug": ["Calcium/Antacids/Iron (Block absorption - separate by >60 min)", "NSAIDs (GI irritation)"],
      "food": ["Food blocks absorption completely."]
    },
    "pregnancyCategory": "Category C"
  },
  "ibrutinib": {
    "name": "Ibrutinib (Imbruvica)",
    "genericName": "Ibrutinib",
    "formula": "C25H24N6O2",
    "molecularWeight": "440.5 g/mol",
    "brandNames": ["Imbruvica"],
    "category": "Antineoplastic",
    "drugClass": "Bruton's Tyrosine Kinase (BTK) Inhibitor",
    "pubchemCID": "24821094",
    "indications": "Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia, Chronic Graft vs Host Disease.",
    "moaSteps": [
      "Forms a covalent bond with a cysteine residue in the BTK active site.",
      "Irreversibly inhibits BTK enzyme activity.",
      "Inhibits B-cell receptor signaling, preventing B-cell proliferation and survival.",
      "Causes lymphocytosis (mobilization of cells from nodes to blood)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "97% protein bound.",
      "metabolism": "Extensive hepatic (CYP3A4).",
      "excretion": "Feces. **Half-life: 4 to 6 hours.**"
    },
    "dose": {
      "initialDose": "420 mg PO once daily (CLL)",
      "maxDose": "560 mg/day",
      "notes": "Capsules/Tablets."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea",
        "Bruising / Bleeding",
        "Musculoskeletal pain",
        "Rash",
        "Fatigue"
      ],
      "serious": [
        "Hemorrhage (Major bleeding)",
        "Atrial Fibrillation / Flutter",
        "Hypertension",
        "Tumor Lysis Syndrome",
        "Second Primary Malignancies"
      ]
    },
    "precautions": [
      "**Bleeding:** Inhibits platelet function. Hold 3-7 days before/after surgery.",
      "**Cardiac:** Monitor for arrhythmias (AFib).",
      "**Lymphocytosis:** Transient increase in lymphocyte count is expected (redistribution), not progression."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inhibitors/Inducers (Avoid or dose adjust)", "Anticoagulants/Antiplatelets (Additive bleeding risk)"],
      "food": ["Grapefruit juice (Increases toxicity)"]
    },
    "pregnancyCategory": "Category D"
  },
  "ibuprofen": {
    "name": "Ibuprofen (Advil, Motrin)",
    "genericName": "Ibuprofen",
    "formula": "C13H18O2",
    "molecularWeight": "206.28 g/mol",
    "brandNames": ["Advil", "Motrin", "Caldolor"],
    "category": "NSAID",
    "drugClass": "Propionic Acid Derivative",
    "pubchemCID": "3672",
    "indications": "Pain, Fever, Inflammation (RA, OA), Dysmenorrhea, Patent Ductus Arteriosus closure (IV).",
    "moaSteps": [
      "Reversibly inhibits Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2).",
      "Decreases formation of prostaglandin precursors.",
      "Analgesic, antipyretic, and anti-inflammatory effects.",
      "Inhibits platelet aggregation (reversible)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (80%).",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic oxidation.",
      "excretion": "Urine. **Half-life: 1.8 to 2 hours.**"
    },
    "dose": {
      "initialDose": "200-400 mg PO every 4-6 hours",
      "maxDose": "3200 mg/day (Rx); 1200 mg/day (OTC)",
      "notes": "Take with food."
    },
    "adverseEffects": {
      "common": [
        "Dyspepsia / Heartburn",
        "Nausea",
        "Dizziness"
      ],
      "serious": [
        "GI Bleeding / Perforation - BOXED WARNING",
        "Cardiovascular Thrombotic Events (MI/Stroke) - BOXED WARNING",
        "Renal Failure / Papillary Necrosis",
        "Stevens-Johnson Syndrome"
      ]
    },
    "precautions": [
      "**GI:** Risk of ulceration increases with age, dose, and history. Use lowest effective dose.",
      "**Renal:** Avoid in CKD; inhibits renal prostaglandins causing vasoconstriction.",
      "**Cardiac:** Avoid in Heart Failure and post-MI."
    ],
    "contraindications": [
      "CABG peri-operative pain",
      "Aspirin triad asthma",
      "Active GI bleed",
      "3rd Trimester Pregnancy"
    ],
    "interactions": {
      "drug": ["Aspirin (Ibuprofen blocks cardioprotection if taken first - separate dose)", "Warfarin (Bleeding)", "Lithium (Toxicity)", "ACE Inhibitors (Renal failure)"],
      "food": ["Take with food to reduce GI upset."]
    },
    "pregnancyCategory": "Category C (D in 3rd trimester - PDA closure)"
  },
  "icosapent_ethyl": {
    "name": "Icosapent Ethyl (Vascepa)",
    "genericName": "Icosapent Ethyl",
    "formula": "C22H34O2",
    "molecularWeight": "330.5 g/mol",
    "brandNames": ["Vascepa"],
    "category": "Antilipemic",
    "drugClass": "Omega-3 Fatty Acid (Pure EPA)",
    "pubchemCID": "10947721",
    "indications": "Hypertriglyceridemia (TG > 500), Cardiovascular Risk Reduction (with Statin).",
    "moaSteps": [
      "Ethyl ester of eicosapentaenoic acid (EPA).",
      "Reduces hepatic VLDL-TG synthesis and secretion.",
      "Enhances TG clearance from circulating VLDL particles.",
      "Does NOT raise LDL (unlike DHA-containing fish oils)."
    ],
    "pharmacokinetics": {
      "absorption": "De-esterified to active EPA. Food required.",
      "distribution": ">99% protein bound.",
      "metabolism": "Beta-oxidation in liver.",
      "excretion": "No renal excretion. **Half-life: ~89 hours (Total EPA).**"
    },
    "dose": {
      "initialDose": "2 grams PO twice daily",
      "maxDose": "4 g/day",
      "notes": "Swallow whole."
    },
    "adverseEffects": {
      "common": [
        "Musculoskeletal pain",
        "Peripheral edema",
        "Constipation",
        "Gout"
      ],
      "serious": [
        "Atrial Fibrillation / Flutter (Increased risk)",
        "Bleeding events"
      ]
    },
    "precautions": [
      "**Atrial Fibrillation:** Associated with increased risk of AFib requiring hospitalization.",
      "**Bleeding:** Prolongs bleeding time; caution with anticoagulants.",
      "**Fish Allergy:** Theoretical risk."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Anticoagulants/Antiplatelets (Increased bleeding risk)"],
      "food": ["Take with food."]
    },
    "pregnancyCategory": "Category C"
  },
  "idarucizumab": {
    "name": "Idarucizumab (Praxbind)",
    "genericName": "Idarucizumab",
    "formula": "Humanized Fab fragment",
    "molecularWeight": "47.8 kDa",
    "brandNames": ["Praxbind"],
    "category": "Antidote",
    "drugClass": "Dabigatran Reversal Agent",
    "pubchemCID": "None (Protein)",
    "indications": "Reversal of Dabigatran (Pradaxa) in emergency surgery or life-threatening bleeding.",
    "moaSteps": [
      "Humanized monoclonal antibody fragment (Fab).",
      "Binds to dabigatran with affinity 350x higher than thrombin.",
      "Neutralizes the anticoagulant effect immediately.",
      "Does not reverse other anticoagulants."
    ],
    "pharmacokinetics": {
      "absorption": "IV.",
      "distribution": "Limited to vascular space.",
      "metabolism": "Catabolism.",
      "excretion": "Urine. **Half-life: 47 minutes (Initial); 10.3 hours (Terminal).**"
    },
    "dose": {
      "initialDose": "5 g IV (Two 2.5g vials)",
      "maxDose": "5 g (Usually sufficient)",
      "notes": "Administer as two consecutive infusions or bolus."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Hypokalemia",
        "Delirium"
      ],
      "serious": [
        "Thromboembolic Events (Rebound due to underlying disease)",
        "Hypersensitivity (Hereditary Fructose Intolerance - contains sorbitol)"
      ]
    },
    "precautions": [
      "**Thrombosis:** Reversal exposes patient to thrombotic risk of their underlying condition. Resume anticoagulant ASAP.",
      "**Sorbitol:** Caution in hereditary fructose intolerance (excipient)."
    ],
    "contraindications": [
      "None (Emergency use)"
    ],
    "interactions": {
      "drug": ["Dabigatran (Neutralizes it)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "ifosfamide": {
    "name": "Ifosfamide (Ifex)",
    "genericName": "Ifosfamide",
    "formula": "C7H15Cl2N2O2P",
    "molecularWeight": "261.1 g/mol",
    "brandNames": ["Ifex"],
    "category": "Antineoplastic",
    "drugClass": "Alkylating Agent (Nitrogen Mustard)",
    "pubchemCID": "3696",
    "indications": "Testicular Cancer (Germ cell tumors), Sarcomas, Lymphomas.",
    "moaSteps": [
      "Prodrug activated by hepatic CYP450.",
      "Active metabolites alkylate DNA, forming cross-links.",
      "Inhibits DNA synthesis and cell division.",
      "Produces toxic metabolite Acrolein (bladder toxic) and Chloroacetaldehyde (neurotoxic)."
    ],
    "pharmacokinetics": {
      "absorption": "IV only.",
      "distribution": "Widely distributed (crosses BBB).",
      "metabolism": "Extensive hepatic (CYP3A4).",
      "excretion": "Urine. **Half-life: 7 to 15 hours.**"
    },
    "dose": {
      "initialDose": "1.2 g/m2 IV daily for 5 days",
      "maxDose": "Cycle repeated every 3 weeks",
      "notes": "ALWAYS administer with Mesna to prevent cystitis."
    },
    "adverseEffects": {
      "common": [
        "Alopecia",
        "Nausea / Vomiting",
        "Myelosuppression"
      ],
      "serious": [
        "Hemorrhagic Cystitis - BOXED WARNING",
        "Neurotoxicity (Encephalopathy, Coma) - BOXED WARNING",
        "Myelosuppression - BOXED WARNING",
        "Nephrotoxicity (Fanconi syndrome)"
      ]
    },
    "precautions": [
      "**Hemorrhagic Cystitis:** Acrolein causes severe bladder bleeding. Mesna prophylaxis + hydration mandatory. Monitor urinalysis.",
      "**Neurotoxicity:** Caused by chloroacetaldehyde. Confusion/Hallucinations. Risk increased in low albumin/renal failure. Treat with Methylene Blue (off-label).",
      "**Renal:** Monitor for tubular damage."
    ],
    "contraindications": [
      "Severe bone marrow depression",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inducers (Increase neurotoxic metabolites)", "Warfarin (Increased INR)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "imatinib": {
    "name": "Imatinib (Gleevec)",
    "genericName": "Imatinib Mesylate",
    "formula": "C29H31N7O",
    "molecularWeight": "493.6 g/mol",
    "brandNames": ["Gleevec"],
    "category": "Antineoplastic",
    "drugClass": "Tyrosine Kinase Inhibitor (BCR-ABL)",
    "pubchemCID": "5291",
    "indications": "Chronic Myeloid Leukemia (CML - Ph+), GIST (KIT+), ALL (Ph+).",
    "moaSteps": [
      "Inhibits the BCR-ABL tyrosine kinase (constitutive abnormal kinase in CML).",
      "Competitively binds to the ATP-binding site of the kinase.",
      "Prevents phosphorylation of substrate proteins involved in cell proliferation.",
      "Also inhibits c-KIT and PDGFR."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed (98%).",
      "distribution": "95% protein bound.",
      "metabolism": "Hepatic via CYP3A4.",
      "excretion": "Feces. **Half-life: 18 hours (Parent); 40 hours (Metabolite).**"
    },
    "dose": {
      "initialDose": "400 mg PO daily",
      "maxDose": "800 mg/day",
      "notes": "Take with food and large glass of water to reduce GI irritation."
    },
    "adverseEffects": {
      "common": [
        "Edema (Periorbital/Lower limb)",
        "Nausea / Vomiting",
        "Muscle cramps",
        "Rash",
        "Fatigue"
      ],
      "serious": [
        "Severe Fluid Retention (Pleural effusion/Ascites)",
        "Hepatotoxicity",
        "Myelosuppression",
        "GI Hemorrhage"
      ]
    },
    "precautions": [
      "**Fluid Retention:** Weigh patients regularly. Diuretics may be needed.",
      "**GI:** Take with food to minimize irritation.",
      "**Heart:** Monitor for left ventricular dysfunction."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inhibitors/Inducers", "Warfarin (Bleeding)", "Acetaminophen (Hepatotoxicity potential)"],
      "food": ["Grapefruit juice (Increases levels)"]
    },
    "pregnancyCategory": "Category D"
  },
  "imipenem": {
    "name": "Imipenem/Cilastatin (Primaxin)",
    "genericName": "Imipenem and Cilastatin",
    "formula": "C12H17N3O4S (Imipenem)",
    "molecularWeight": "299.4 g/mol",
    "brandNames": ["Primaxin"],
    "category": "Antibiotic",
    "drugClass": "Carbapenem",
    "pubchemCID": "104838",
    "indications": "Severe infections (intra-abdominal, pneumonia, sepsis, UTI, bone/joint) caused by multidrug-resistant organisms.",
    "moaSteps": [
      "Imipenem: Binds PBPs, inhibiting cell wall synthesis (Bactericidal). Broad spectrum (Gram +/-, Anaerobes, Pseudomonas).",
      "Cilastatin: Inhibits renal dehydropeptidase I.",
      "Cilastatin prevents rapid renal metabolism of imipenem, increasing urinary levels and reducing nephrotoxicity."
    ],
    "pharmacokinetics": {
      "absorption": "IV/IM only.",
      "distribution": "Widely distributed (CSF in inflammation).",
      "metabolism": "Renal hydrolysis (blocked by Cilastatin).",
      "excretion": "Urine. **Half-life: 1 hour.**"
    },
    "dose": {
      "initialDose": "500 mg IV every 6 hours",
      "maxDose": "4 g/day (rarely used)",
      "notes": "Strict renal adjustment."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting (related to infusion rate)",
        "Diarrhea",
        "Phlebitis"
      ],
      "serious": [
        "Seizures (Risk higher than other carbapenems)",
        "Anaphylaxis",
        "Clostridioides difficile colitis"
      ]
    },
    "precautions": [
      "**Seizures:** Risk increases in renal failure, CNS lesions, or high doses. Valproic acid levels drop significantly.",
      "**Renal:** Adjust dose to prevent accumulation/seizures.",
      "**Penicillin Allergy:** Cross-reactivity exists (~1%)."
    ],
    "contraindications": [
      "Hypersensitivity to carbapenems",
      "Severe allergy to local anesthetics (for IM formulation)"
    ],
    "interactions": {
      "drug": ["Valproic Acid (Contraindicated - levels drop -> seizures)", "Ganciclovir (Seizures)", "Probenecid"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "imipramine": {
    "name": "Imipramine (Tofranil)",
    "genericName": "Imipramine HCl",
    "formula": "C19H24N2",
    "molecularWeight": "280.4 g/mol",
    "brandNames": ["Tofranil"],
    "category": "Antidepressant",
    "drugClass": "Tricyclic Antidepressant (Tertiary Amine)",
    "pubchemCID": "3698",
    "indications": "Depression, Nocturnal Enuresis (Childhood bedwetting).",
    "moaSteps": [
      "Inhibits reuptake of serotonin and norepinephrine.",
      "Tertiary amine (metabolized to Desipramine, a secondary amine).",
      "Significant anticholinergic, antihistaminic, and alpha-blocking properties."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "High volume of distribution.",
      "metabolism": "Hepatic (CYP2D6) to active metabolite Desipramine.",
      "excretion": "Urine. **Half-life: 11 to 25 hours.**"
    },
    "dose": {
      "initialDose": "75 mg PO daily (Depression)",
      "maxDose": "300 mg/day",
      "notes": "Enuresis: 25 mg at bedtime."
    },
    "adverseEffects": {
      "common": [
        "Dry mouth",
        "Blurred vision",
        "Constipation",
        "Orthostatic Hypotension",
        "Sedation"
      ],
      "serious": [
        "Suicidality - BOXED WARNING",
        "Arrhythmias / QT Prolongation",
        "Seizures",
        "Glaucoma crisis"
      ]
    },
    "precautions": [
      "**Cardiac:** Overdose is fatal due to arrhythmias (Na+ channel blockade). Baseline ECG required.",
      "**Enuresis:** Risk of accidental overdose in children. Keep secure.",
      "**Anticholinergic:** Caution in elderly/BPH/Glaucoma."
    ],
    "contraindications": [
      "MAOI use within 14 days",
      "Acute recovery phase of MI"
    ],
    "interactions": {
      "drug": ["MAOIs (Fatal)", "Anticholinergics", "CNS Depressants", "CYP2D6 Inhibitors"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "indomethacin": {
    "name": "Indomethacin (Indocin)",
    "genericName": "Indomethacin",
    "formula": "C19H16ClNO4",
    "molecularWeight": "357.8 g/mol",
    "brandNames": ["Indocin", "Tivorbex"],
    "category": "NSAID",
    "drugClass": "Acetic Acid Derivative",
    "pubchemCID": "3715",
    "indications": "Gouty Arthritis (Acute), Rheumatoid Arthritis, Ankylosing Spondylitis, PDA Closure (IV).",
    "moaSteps": [
      "Potent non-selective inhibitor of COX-1 and COX-2.",
      "Decreases prostaglandin synthesis.",
      "One of the most potent NSAIDs, but higher toxicity profile.",
      "Reduces cerebral blood flow."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid and complete.",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic.",
      "excretion": "Urine/Bile. **Half-life: 4.5 hours.**"
    },
    "dose": {
      "initialDose": "25-50 mg PO 2-3 times daily",
      "maxDose": "200 mg/day",
      "notes": "Short-term use preferred."
    },
    "adverseEffects": {
      "common": [
        "Headache (Frontal, severe - frequent)",
        "Dyspepsia / GI pain",
        "Dizziness / Vertigo"
      ],
      "serious": [
        "GI Bleeding / Perforation - BOXED WARNING",
        "CV Thrombotic Events - BOXED WARNING",
        "Renal Failure",
        "Corneal deposits / Retinal disturbances (chronic)"
      ]
    },
    "precautions": [
      "**CNS:** High incidence of CNS side effects (headache, confusion) compared to other NSAIDs. Caution in elderly/psychiatric/epilepsy patients.",
      "**GI:** Very irritating to stomach; take with food.",
      "**Renal:** Potent vasoconstrictor of renal afferent arteriole."
    ],
    "contraindications": [
      "CABG peri-operative pain",
      "Active GI bleed",
      "Aspirin allergy",
      "History of proctitis (Suppository)"
    ],
    "interactions": {
      "drug": ["Lithium (Toxicity)", "ACE Inhibitors (Renal failure)", "Diuretics (Failure)", "Warfarin"],
      "food": ["Take with food/milk to reduce GI upset."]
    },
    "pregnancyCategory": "Category C (D in 3rd trimester - PDA closure)"
  },"infliximab": {
    "name": "Infliximab (Remicade)",
    "genericName": "Infliximab",
    "formula": "Chimeric monoclonal antibody",
    "molecularWeight": "149 kDa",
    "brandNames": ["Remicade", "Inflectra", "Renflexis"],
    "category": "Biologic DMARD",
    "drugClass": "TNF Alpha Inhibitor",
    "pubchemCID": "None (Protein)",
    "indications": "Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis.",
    "moaSteps": [
      "Chimeric (mouse/human) monoclonal antibody.",
      "Binds with high affinity to soluble and transmembrane forms of TNF-alpha.",
      "Inhibits binding of TNF-alpha to its receptors.",
      "Neutralizes the biological activity of TNF-alpha (pro-inflammatory cytokine).",
      "Can induce lysis of cells expressing TNF via complement/ADCC."
    ],
    "pharmacokinetics": {
      "absorption": "IV administration.",
      "distribution": "Vascular compartment.",
      "metabolism": "Degraded by proteolytic enzymes.",
      "excretion": "N/A. **Half-life: 8 to 9.5 days.**"
    },
    "dose": {
      "initialDose": "5 mg/kg IV at weeks 0, 2, and 6 (Induction)",
      "maxDose": "10 mg/kg every 4 weeks (Escalated)",
      "notes": "Pre-medicate (antihistamine/acetaminophen/steroid) to prevent infusion reactions."
    },
    "adverseEffects": {
      "common": [
        "Infusion reactions (Headache, Nausea, Fever)",
        "Upper respiratory infection",
        "Abdominal pain",
        "Fatigue"
      ],
      "serious": [
        "Serious Infections (TB, Fungal, Bacterial) - BOXED WARNING",
        "Malignancy (Hepatosplenic T-cell Lymphoma) - BOXED WARNING",
        "Hepatitis B Reactivation",
        "Heart Failure (New or worsening)",
        "Lupus-like Syndrome"
      ]
    },
    "precautions": [
      "**Infection:** Contraindicated in active infection. TB screening mandatory prior to start.",
      "**Infusion Reactions:** Acute (anaphylactic) or Delayed (serum sickness-like).",
      "**Heart Failure:** Contraindicated in Class III/IV CHF at doses >5 mg/kg."
    ],
    "contraindications": [
      "Severe Heart Failure (High dose)",
      "Active serious infection",
      "Hypersensitivity to murine proteins"
    ],
    "interactions": {
      "drug": ["Live Vaccines (Contraindicated)", "Anakinra/Abatacept (Increased infection risk)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "insulin_glargine": {
    "name": "Insulin Glargine (Lantus, Toujeo)",
    "genericName": "Insulin Glargine",
    "formula": "C267H404N72O78S6",
    "molecularWeight": "6063 Da",
    "brandNames": ["Lantus", "Toujeo", "Basaglar"],
    "category": "Antidiabetic",
    "drugClass": "Long-Acting Insulin (Basal)",
    "pubchemCID": "None (Protein)",
    "indications": "Diabetes Mellitus (Type 1 and Type 2).",
    "moaSteps": [
      "Recombinant human insulin analog.",
      "Regulates glucose metabolism.",
      "Stimulates peripheral glucose uptake by skeletal muscle and fat.",
      "Inhibits hepatic glucose production.",
      "Modifications (Glycine at A21, two Arginines at B30) shift isoelectric point, causing precipitation at neutral pH -> slow dissolution."
    ],
    "pharmacokinetics": {
      "absorption": "Slow, consistent absorption from SC depot.",
      "distribution": "Rapid.",
      "metabolism": "Hepatic/Renal/Muscle degradation.",
      "excretion": "Urine. **Half-life: N/A (Duration 24 hours; 'Peakless').**"
    },
    "dose": {
      "initialDose": "0.2 units/kg or 10 units SC once daily (Type 2 naive)",
      "maxDose": "Titrate to Fasting Glucose goal",
      "notes": "Do NOT mix with other insulins in same syringe."
    },
    "adverseEffects": {
      "common": [
        "Hypoglycemia",
        "Weight gain",
        "Injection site reaction",
        "Lipodystrophy"
      ],
      "serious": [
        "Severe Hypoglycemia (Seizures/Coma)",
        "Hypokalemia (shifts K+ into cells)",
        "Anaphylaxis"
      ]
    },
    "precautions": [
      "**Hypoglycemia:** Most common AE. Educate patient on s/sx.",
      "**Hypokalemia:** Monitor K+ if on potassium-lowering drugs.",
      "**Renal/Hepatic:** Dose reduction often needed."
    ],
    "contraindications": [
      "Hypoglycemia",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Beta-blockers (Mask hypoglycemia)", "Steroids (Increase glucose)", "Thiazides (Increase glucose)"],
      "food": ["Alcohol (Hypoglycemia risk)"]
    },
    "pregnancyCategory": "Category C"
  },
  "insulin_lispro": {
    "name": "Insulin Lispro (Humalog)",
    "genericName": "Insulin Lispro",
    "formula": "C257H383N65O77S6",
    "molecularWeight": "5808 Da",
    "brandNames": ["Humalog", "Admelog"],
    "category": "Antidiabetic",
    "drugClass": "Rapid-Acting Insulin (Bolus)",
    "pubchemCID": "None (Protein)",
    "indications": "Diabetes Mellitus (Type 1 and Type 2).",
    "moaSteps": [
      "Recombinant human insulin analog (Lysine and Proline switched at B28/B29).",
      "Modification prevents self-association into hexamers.",
      "Results in very rapid absorption and onset of action.",
      "Mimics physiological prandial insulin secretion."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (Onset 15 min; Peak 1 hr).",
      "distribution": "Rapid.",
      "metabolism": "Proteolysis.",
      "excretion": "Urine. **Half-life: 1 hour (Duration 3-5 hours).**"
    },
    "dose": {
      "initialDose": "Varies (e.g., 5-10 units or carb-counting ratio) SC",
      "maxDose": "Titrate to post-prandial glucose",
      "notes": "Inject 15 min before or immediately after meal."
    },
    "adverseEffects": {
      "common": [
        "Hypoglycemia",
        "Weight gain",
        "Lipodystrophy"
      ],
      "serious": [
        "Severe Hypoglycemia",
        "Hypokalemia",
        "Anaphylaxis"
      ]
    },
    "precautions": [
      "**Timing:** Must eat within 15 minutes of injection to prevent hypoglycemia ('Shoot and Eat').",
      "**Pump:** Can be used in insulin pumps.",
      "**Renal:** Clearance decreases in renal failure; reduce dose."
    ],
    "contraindications": [
      "Hypoglycemia",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Beta-blockers", "Oral hypoglycemics", "Corticosteroids"],
      "food": ["Must be taken with meal."]
    },
    "pregnancyCategory": "Category B"
  },
  "ipratropium": {
    "name": "Ipratropium (Atrovent)",
    "genericName": "Ipratropium Bromide",
    "formula": "C20H30BrNO3",
    "molecularWeight": "412.4 g/mol",
    "brandNames": ["Atrovent"],
    "category": "Bronchodilator",
    "drugClass": "Short-Acting Muscarinic Antagonist (SAMA)",
    "pubchemCID": "657308",
    "indications": "COPD maintenance, Acute Asthma exacerbation (with Albuterol), Rhinitis (Nasal).",
    "moaSteps": [
      "Antagonizes acetylcholine receptors (muscarinic) on bronchial smooth muscle.",
      "Blocks parasympathetic-mediated bronchoconstriction.",
      "Reduces cyclic GMP concentration.",
      "Dries secretions (Nasal)."
    ],
    "pharmacokinetics": {
      "absorption": "Minimal systemic absorption from lungs.",
      "distribution": "Local.",
      "metabolism": "Partial hepatic hydrolysis.",
      "excretion": "Feces and Urine. **Half-life: 1.6 hours.**"
    },
    "dose": {
      "initialDose": "2 puffs QID (COPD); 500mcg Nebulizer (Acute)",
      "maxDose": "12 puffs/day",
      "notes": "Often combined with Albuterol (DuoNeb)."
    },
    "adverseEffects": {
      "common": [
        "Dry mouth (Xerostomia)",
        "Bitter taste",
        "Headache"
      ],
      "serious": [
        "Paradoxical Bronchospasm",
        "Acute Narrow-Angle Glaucoma (if sprayed in eyes)",
        "Urinary Retention (in BPH)",
        "Anaphylaxis"
      ]
    },
    "precautions": [
      "**Eyes:** Protect eyes during nebulization; direct contact causes pupil dilation and can precipitate glaucoma.",
      "**Soy/Peanut:** Some older inhalers contained soy lecithin (caution in allergy); most HFA inhalers do not.",
      "**BPH:** Use caution in bladder neck obstruction."
    ],
    "contraindications": [
      "Hypersensitivity to atropine derivatives"
    ],
    "interactions": {
      "drug": ["Other Anticholinergics (Additive toxicity)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "irbesartan": {
    "name": "Irbesartan (Avapro)",
    "genericName": "Irbesartan",
    "formula": "C25H28N6O",
    "molecularWeight": "428.5 g/mol",
    "brandNames": ["Avapro"],
    "category": "Antihypertensive",
    "drugClass": "Angiotensin II Receptor Blocker (ARB)",
    "pubchemCID": "3749",
    "indications": "Hypertension, Diabetic Nephropathy.",
    "moaSteps": [
      "Blocks the binding of angiotensin II to the AT1 receptor.",
      "Inhibits vasoconstriction and aldosterone secretion.",
      "Does not inhibit ACE (no bradykinin accumulation -> less cough).",
      "Renoprotective in Type 2 Diabetes."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (60-80% bioavailable).",
      "distribution": "90% protein bound.",
      "metabolism": "Hepatic (CYP2C9) and Glucuronidation.",
      "excretion": "Bile and Urine. **Half-life: 11 to 15 hours.**"
    },
    "dose": {
      "initialDose": "150 mg PO once daily",
      "maxDose": "300 mg/day",
      "notes": "Start 75 mg in volume depleted."
    },
    "adverseEffects": {
      "common": [
        "Dizziness",
        "Hyperkalemia",
        "Fatigue",
        "Dyspepsia"
      ],
      "serious": [
        "Renal Failure (in renal artery stenosis)",
        "Angioedema (Rare)",
        "Fetal Toxicity - BOXED WARNING"
      ]
    },
    "precautions": [
      "**Pregnancy:** Contraindicated. Discontinue ASAP.",
      "**Hyperkalemia:** Monitor Potassium.",
      "**Renal:** Caution in renal artery stenosis."
    ],
    "contraindications": [
      "Pregnancy",
      "Concomitant Aliskiren in diabetics"
    ],
    "interactions": {
      "drug": ["Lithium", "NSAIDs", "K+ sparing diuretics"],
      "food": ["Salt substitutes (K+)"]
    },
    "pregnancyCategory": "Category D"
  },
  "irinotecan": {
    "name": "Irinotecan (Camptosar)",
    "genericName": "Irinotecan HCl",
    "formula": "C33H38N4O6",
    "molecularWeight": "586.7 g/mol",
    "brandNames": ["Camptosar"],
    "category": "Antineoplastic",
    "drugClass": "Topoisomerase I Inhibitor",
    "pubchemCID": "60838",
    "indications": "Metastatic Colorectal Cancer, Pancreatic Cancer.",
    "moaSteps": [
      "Prodrug converted by carboxylesterase to active metabolite SN-38.",
      "SN-38 binds to the Topoisomerase I-DNA complex.",
      "Prevents religation of single-strand DNA breaks.",
      "Accumulation of strand breaks leads to apoptosis (S-phase specific)."
    ],
    "pharmacokinetics": {
      "absorption": "IV administration.",
      "distribution": "30-68% protein bound.",
      "metabolism": "Hepatic (UGT1A1) inactivates SN-38.",
      "excretion": "Biliary/Fecal. **Half-life: 6 to 12 hours (Parent); 10 to 20 hours (SN-38).**"
    },
    "dose": {
      "initialDose": "125 mg/m2 IV weekly or 180 mg/m2 every 2 weeks",
      "maxDose": "Varies by protocol",
      "notes": "Atropine used for early diarrhea; Loperamide for late."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea ('I Run to the Can')",
        "Cholinergic Syndrome (Early - Sweating/Salivation)",
        "Nausea / Vomiting",
        "Alopecia"
      ],
      "serious": [
        "Severe Diarrhea (Late onset - Life threatening) - BOXED WARNING",
        "Myelosuppression (Neutropenia) - BOXED WARNING",
        "Interstitial Lung Disease"
      ]
    },
    "precautions": [
      "**Diarrhea:** Early (Cholinergic) treated with Atropine. Late (>24h) is secretory; treat aggressively with high-dose Loperamide. Dehydration can be fatal.",
      "**Gilbert's Syndrome:** Patients with UGT1A1*28 allele (Gilbert's) metabolize SN-38 slowly -> High toxicity risk. Reduce dose."
    ],
    "contraindications": [
      "Hypersensitivity",
      "Severe bone marrow failure"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inhibitors/Inducers", "Live vaccines"],
      "food": ["St. John's Wort (Decreases efficacy)"]
    },
    "pregnancyCategory": "Category D"
  },
  "isoniazid": {
    "name": "Isoniazid (INH)",
    "genericName": "Isoniazid",
    "formula": "C6H7N3O",
    "molecularWeight": "137.14 g/mol",
    "brandNames": ["Nydrazid"],
    "category": "Antimycobacterial",
    "drugClass": "Antitubercular Agent",
    "pubchemCID": "3767",
    "indications": "Tuberculosis (Treatment and Latent Prophylaxis).",
    "moaSteps": [
      "Prodrug activated by bacterial catalase-peroxidase (KatG).",
      "Inhibits the synthesis of mycolic acids (essential component of mycobacterial cell wall).",
      "Bactericidal against dividing organisms."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (food reduces absorption).",
      "distribution": "Diffuses into all body fluids (CSF).",
      "metabolism": "Hepatic Acetylation (NAT2). Genetic polymorphism (Fast vs Slow acetylators).",
      "excretion": "Urine. **Half-life: 1 hour (Fast); 3-4 hours (Slow).**"
    },
    "dose": {
      "initialDose": "5 mg/kg (300 mg) PO daily",
      "maxDose": "300 mg/day",
      "notes": "Must supplement Pyridoxine (B6)."
    },
    "adverseEffects": {
      "common": [
        "Peripheral Neuropathy (numbness/tingling)",
        "Mild LFT elevation",
        "Nausea"
      ],
      "serious": [
        "Severe Hepatotoxicity (Fatal Hepatitis) - BOXED WARNING",
        "Seizures (Overdose)",
        "Drug-Induced Lupus",
        "Optic Neuritis"
      ]
    },
    "precautions": [
      "**Hepatotoxicity:** Risk increases with age >35 and alcohol use. Monitor LFTs monthly. Stop if ALT > 3x ULN with symptoms or 5x without.",
      "**Neuropathy:** Caused by B6 depletion. Give B6 (10-50mg) daily to prevent.",
      "**Slow Acetylators:** Higher risk of neuropathy and hepatotoxicity."
    ],
    "contraindications": [
      "Acute liver disease",
      "Previous INH-associated hepatitis"
    ],
    "interactions": {
      "drug": ["Phenytoin (INH inhibits metabolism -> Toxicity)", "Carbamazepine (Toxicity)", "Alcohol"],
      "food": ["Tyramine foods (MAOI-like effect)", "Histamine foods (Skipjack tuna)"]
    },
    "pregnancyCategory": "Category C (Safe to use)"
  },
  "isosorbide_mononitrate": {
    "name": "Isosorbide Mononitrate (Imdur)",
    "genericName": "Isosorbide Mononitrate",
    "formula": "C6H9NO6",
    "molecularWeight": "191.14 g/mol",
    "brandNames": ["Imdur", "Monoket"],
    "category": "Antianginal",
    "drugClass": "Nitrate",
    "pubchemCID": "23663396",
    "indications": "Prophylaxis of Angina Pectoris.",
    "moaSteps": [
      "Active metabolite of isosorbide dinitrate.",
      "Metabolized to nitric oxide (NO) in vascular smooth muscle.",
      "NO activates guanylate cyclase -> cGMP.",
      "Causes smooth muscle relaxation (Venodilation > Arteriodilation).",
      "Reduces preload and myocardial oxygen demand."
    ],
    "pharmacokinetics": {
      "absorption": "100% bioavailability (no first-pass).",
      "distribution": "Wide.",
      "metabolism": "Hepatic (Denitration).",
      "excretion": "Urine. **Half-life: 5 hours.**"
    },
    "dose": {
      "initialDose": "30-60 mg ER PO once daily",
      "maxDose": "120-240 mg/day",
      "notes": "Must have nitrate-free interval (10-12h) to prevent tolerance."
    },
    "adverseEffects": {
      "common": [
        "Headache (Common, often resolves)",
        "Dizziness",
        "Flushing",
        "Hypotension"
      ],
      "serious": [
        "Severe Hypotension / Syncope",
        "Methemoglobinemia (rare)",
        "Paradoxical Bradycardia"
      ]
    },
    "precautions": [
      "**Tolerance:** Effectiveness is lost if taken around the clock. Ensure 10-12 hour nitrate-free period daily.",
      "**Hypotension:** Caution with volume depletion or other antihypertensives.",
      "**Headache:** Treat with acetaminophen; usually improves with continued use."
    ],
    "contraindications": [
      "Concomitant PDE-5 Inhibitors (Sildenafil/Tadalafil) - Fatal Hypotension",
      "Severe anemia",
      "Right ventricular infarction"
    ],
    "interactions": {
      "drug": ["PDE-5 Inhibitors (Contraindicated)", "Alcohol (Hypotension)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "isotretinoin": {
    "name": "Isotretinoin (Accutane)",
    "genericName": "Isotretinoin",
    "formula": "C20H28O2",
    "molecularWeight": "300.44 g/mol",
    "brandNames": ["Accutane", "Claravis", "Absorica"],
    "category": "Acne Agent",
    "drugClass": "Retinoid",
    "pubchemCID": "5282379",
    "indications": "Severe Recalcitrant Nodular Acne.",
    "moaSteps": [
      "Reduces sebaceous gland size and sebum production.",
      "Inhibits *Cutibacterium acnes* growth.",
      "Normalizes follicular keratinization (preventing comedones).",
      "Anti-inflammatory properties."
    ],
    "pharmacokinetics": {
      "absorption": "Enhanced by high fat meal.",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic (CYP450).",
      "excretion": "Urine and Feces. **Half-life: 10 to 20 hours.**"
    },
    "dose": {
      "initialDose": "0.5-1 mg/kg/day PO divided BID",
      "maxDose": "2 mg/kg/day",
      "notes": "Cumulative goal 120-150 mg/kg."
    },
    "adverseEffects": {
      "common": [
        "Cheilitis (Dry lips - Universal)",
        "Dry skin / eyes / nose",
        "Epistaxis",
        "Myalgia / Arthralgia"
      ],
      "serious": [
        "Teratogenicity (Major birth defects) - BOXED WARNING",
        "Suicidal Ideation / Depression",
        "Pseudotumor Cerebri (Increased ICP)",
        "Pancreatitis (Hypertriglyceridemia)",
        "Stevens-Johnson Syndrome"
      ]
    },
    "precautions": [
      "**iPLEDGE:** Strict REMS program. Two forms of contraception required 1 month before, during, and 1 month after.",
      "**Psychiatric:** Monitor mood changes.",
      "**Lipids/Liver:** Monitor triglycerides and LFTs.",
      "**Vision:** Night vision may decrease."
    ],
    "contraindications": [
      "Pregnancy",
      "Hypersensitivity to parabens (some forms)",
      "Soybean oil allergy (some forms)"
    ],
    "interactions": {
      "drug": ["Tetracyclines (Pseudotumor Cerebri - Contraindicated)", "Vitamin A supplements (Toxicity)", "Progestin-only contraceptives (Micro-dosed may fail)"],
      "food": ["Take with high fat meal (Absorica excepted)."]
    },
    "pregnancyCategory": "Category X"
  },
  "itraconazole": {
    "name": "Itraconazole (Sporanox)",
    "genericName": "Itraconazole",
    "formula": "C35H38Cl2N8O4",
    "molecularWeight": "705.6 g/mol",
    "brandNames": ["Sporanox", "Tolsura"],
    "category": "Antifungal",
    "drugClass": "Triazole",
    "pubchemCID": "55283",
    "indications": "Onychomycosis, Histoplasmosis, Blastomycosis, Aspergillosis.",
    "moaSteps": [
      "Inhibits fungal cytochrome P450 enzyme 14-alpha-demethylase.",
      "Inhibits ergosterol synthesis.",
      "Disrupts fungal cell membrane permeability."
    ],
    "pharmacokinetics": {
      "absorption": "Highly variable. Capsules require acid/food; Solution requires empty stomach.",
      "distribution": "Lipophilic; high tissue concentration (skin/nail). Poor CSF.",
      "metabolism": "Extensive Hepatic (CYP3A4).",
      "excretion": "Feces/Urine. **Half-life: 34 to 42 hours (Active metabolite hydroxyitraconazole is longer).**"
    },
    "dose": {
      "initialDose": "200 mg PO daily or BID",
      "maxDose": "400 mg/day",
      "notes": "Pulse dosing for nails."
    },
    "adverseEffects": {
      "common": [
        "GI Upset",
        "Headache",
        "Rash"
      ],
      "serious": [
        "Congestive Heart Failure (Negative Inotrope) - BOXED WARNING",
        "Hepatotoxicity",
        "QT Prolongation",
        "Peripheral Neuropathy"
      ]
    },
    "precautions": [
      "**Heart Failure:** Contraindicated for onychomycosis in patients with ventricular dysfunction/CHF history.",
      "**Interactions:** Potent CYP3A4 inhibitor. Serious interactions (simvastatin, etc.).",
      "**Absorption:** Avoid acid reducers with capsules."
    ],
    "contraindications": [
      "Congestive Heart Failure (for nail treatment)",
      "Co-administration with CYP3A4 substrates (Simvastatin, Midazolam, etc.)"
    ],
    "interactions": {
      "drug": ["Statins (Rhabdomyolysis)", "Antacids/PPIs (Reduce capsule absorption)", "Warfarin", "Digoxin"],
      "food": ["Take capsules with food/acidic drink. Take solution on empty stomach."]
    },
    "pregnancyCategory": "Category C"
  },
  "ivermectin": {
    "name": "Ivermectin (Stromectol)",
    "genericName": "Ivermectin",
    "formula": "C48H74O14",
    "molecularWeight": "875.1 g/mol",
    "brandNames": ["Stromectol", "Soolantra (Topical)"],
    "category": "Anthelmintic / Ectoparasiticide",
    "drugClass": "Avermectin",
    "pubchemCID": "6321425",
    "indications": "Strongyloidiasis, Onchocerciasis (River Blindness), Scabies, Lice, Rosacea (Topical).",
    "moaSteps": [
      "Binds to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells.",
      "Increases permeability to chloride ions.",
      "Causes hyperpolarization, paralysis, and death of the parasite.",
      "Mammals lack these channels (selective toxicity)."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "Widely distributed; does not cross BBB in humans (usually).",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Feces. **Half-life: 18 hours.**"
    },
    "dose": {
      "initialDose": "200 mcg/kg PO Single Dose",
      "maxDose": "Repeat in 2 weeks (Scabies)",
      "notes": "Take on empty stomach."
    },
    "adverseEffects": {
      "common": [
        "Mazzotti Reaction (in Onchocerciasis: fever, pruritus, rash due to dying worms)",
        "Dizziness",
        "Nausea"
      ],
      "serious": [
        "Severe Cutaneous Reactions (SJS/TEN)",
        "Encephalopathy (rare, in Loa Loa coinfection)",
        "Hypotension"
      ]
    },
    "precautions": [
      "**Mazzotti Reaction:** Treat severe reactions with steroids/antihistamines.",
      "**Loa Loa:** Patients with heavy Loa Loa burden risk encephalopathy. Screen before treating Onchocerciasis.",
      "**CNS:** Can cross BBB in meningitis or if P-gp transport inhibited."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Warfarin (Increased INR)"],
      "food": ["Take with water on empty stomach (Food increases bioavailability significantly - undesirable for gut worms)."]
    },
    "pregnancyCategory": "Category C"
  },
  "ketoconazole": {
    "name": "Ketoconazole (Nizoral)",
    "genericName": "Ketoconazole",
    "formula": "C26H28Cl2N4O4",
    "molecularWeight": "531.4 g/mol",
    "brandNames": ["Nizoral", "Extina"],
    "category": "Antifungal",
    "drugClass": "Imidazole",
    "pubchemCID": "456201",
    "indications": "Topical: Dandruff, Seborrheic dermatitis, Tinea. Oral: Endemic mycoses (Last line due to toxicity).",
    "moaSteps": [
      "Inhibits 14-alpha-demethylase.",
      "Blocks ergosterol synthesis.",
      "Oral form also inhibits adrenal/gonadal steroid synthesis (testosterone/cortisol blockade).",
      "Potent CYP3A4 inhibitor."
    ],
    "pharmacokinetics": {
      "absorption": "Requires acid. Variable.",
      "distribution": "Poor CSF penetration.",
      "metabolism": "Extensive Hepatic.",
      "excretion": "Bile. **Half-life: 8 hours (increases with dose).**"
    },
    "dose": {
      "initialDose": "200 mg PO daily",
      "maxDose": "400 mg/day",
      "notes": "Oral use severely restricted by FDA."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting",
        "Gynecomastia / Impotence (Anti-androgenic)",
        "Menstrual irregularities"
      ],
      "serious": [
        "Hepatotoxicity (Fatal) - BOXED WARNING",
        "QT Prolongation - BOXED WARNING",
        "Adrenal Insufficiency"
      ]
    },
    "precautions": [
      "**Hepatotoxicity:** Oral tablets indicated ONLY when other antifungals fail. Monitor LFTs weekly.",
      "**Endocrine:** Suppresses testosterone/cortisol. Used off-label for Cushing's/Prostate cancer.",
      "**QT:** Fatal arrhythmias with Cisapride, Terfenadine."
    ],
    "contraindications": [
      "Acute or chronic liver disease",
      "Co-administration with QT prolonging drugs or CYP3A4 substrates"
    ],
    "interactions": {
      "drug": ["Potent CYP3A4 Inhibitor (Many serious interactions)", "Antacids (Prevent absorption)", "Warfarin"],
      "food": ["Take with food."]
    },
    "pregnancyCategory": "Category C"
  },
  "ketorolac": {
    "name": "Ketorolac (Toradol)",
    "genericName": "Ketorolac Tromethamine",
    "formula": "C15H13NO3",
    "molecularWeight": "255.27 g/mol",
    "brandNames": ["Toradol", "Acular (Eye)", "Sprix (Nasal)"],
    "category": "NSAID / Analgesic",
    "drugClass": "Pyrrolizine Carboxylic Acid",
    "pubchemCID": "3826",
    "indications": "Short-term management of moderately severe acute pain (post-op). Ophthalmic: Allergic conjunctivitis.",
    "moaSteps": [
      "Potent inhibitor of COX-1 and COX-2.",
      "Inhibits prostaglandin synthesis.",
      "Analgesic efficacy comparable to morphine/meperidine but without respiratory depression.",
      "Strong anti-inflammatory/antipyretic activity."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid and complete.",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic.",
      "excretion": "Urine. **Half-life: 5 to 6 hours.**"
    },
    "dose": {
      "initialDose": "15-30 mg IV/IM q6h",
      "maxDose": "120 mg/day",
      "notes": "MAX DURATION 5 DAYS (Oral/Injection)."
    },
    "adverseEffects": {
      "common": [
        "Dyspepsia",
        "Headache",
        "Injection site pain"
      ],
      "serious": [
        "GI Bleeding / Perforation (High Risk) - BOXED WARNING",
        "Renal Failure - BOXED WARNING",
        "Bleeding (inhibits platelet function)",
        "Hypersensitivity"
      ]
    },
    "precautions": [
      "**Duration:** Limit systemic use to 5 days total combined (IV/IM/PO) to prevent GI bleed/Renal failure.",
      "**Renal:** Contraindicated in advanced renal impairment or risk of renal failure (volume depleted).",
      "**Bleeding:** Contraindicated as prophylactic analgesic before major surgery."
    ],
    "contraindications": [
      "Active Peptic Ulcer Disease / GI Bleed",
      "Renal impairment",
      "Labor and Delivery",
      "Prophylactic use before surgery"
    ],
    "interactions": {
      "drug": ["Other NSAIDs (Cumulative toxicity)", "ACE Inhibitors (Renal toxicity)", "Warfarin/Lithium"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C (D in 3rd trimester)"
  },
  "labetalol": {
    "name": "Labetalol (Trandate)",
    "genericName": "Labetalol HCl",
    "formula": "C19H24N2O3",
    "molecularWeight": "328.4 g/mol",
    "brandNames": ["Trandate"],
    "category": "Antihypertensive",
    "drugClass": "Non-selective Beta Blocker / Alpha-1 Blocker",
    "pubchemCID": "3869",
    "indications": "Hypertension, Hypertensive Emergency/Urgency (IV), Hypertension in Pregnancy.",
    "moaSteps": [
      "Blocks alpha-1, beta-1, and beta-2 adrenergic receptors.",
      "Alpha-blockade causes vasodilation (decreased SVR).",
      "Beta-blockade prevents reflex tachycardia.",
      "Ratio of Alpha:Beta blockade is 1:3 (Oral) and 1:7 (IV)."
    ],
    "pharmacokinetics": {
      "absorption": "Complete but high first-pass (25% bioavailable).",
      "distribution": "Crosses placenta.",
      "metabolism": "Hepatic glucuronidation.",
      "excretion": "Urine. **Half-life: 6 to 8 hours.**"
    },
    "dose": {
      "initialDose": "100 mg PO BID or 20 mg IV bolus",
      "maxDose": "2400 mg/day (Oral); 300 mg (IV total)",
      "notes": "Safe in pregnancy."
    },
    "adverseEffects": {
      "common": [
        "Dizziness / Orthostatic Hypotension",
        "Fatigue",
        "Scalp tingling",
        "Nausea"
      ],
      "serious": [
        "Hepatotoxicity (Rare but fatal)",
        "Heart Block / Bradycardia",
        "Bronchospasm",
        "Intraoperative Floppy Iris Syndrome"
      ]
    },
    "precautions": [
      "**Hepatic Injury:** Monitor LFTs; stop if jaundice/injury occurs.",
      "**Bronchospasm:** Caution in asthma (beta-2 blockade).",
      "**Surgery:** IFIS risk in cataract surgery (alpha-blockade)."
    ],
    "contraindications": [
      "Bronchial asthma",
      "Overt cardiac failure",
      "2nd/3rd degree heart block",
      "Severe bradycardia"
    ],
    "interactions": {
      "drug": ["Beta-agonists (Antagonism)", "Calcium Channel Blockers (Additive)", "Halothane"],
      "food": ["Food increases bioavailability."]
    },
    "pregnancyCategory": "Category C (Commonly used)"
  },
  "lacosamide": {
    "name": "Lacosamide (Vimpat)",
    "genericName": "Lacosamide",
    "formula": "C13H18N2O3",
    "molecularWeight": "250.3 g/mol",
    "brandNames": ["Vimpat"],
    "category": "Anticonvulsant",
    "drugClass": "Functionalized Amino Acid",
    "pubchemCID": "219078",
    "indications": "Partial-Onset Seizures, Primary Generalized Tonic-Clonic Seizures.",
    "moaSteps": [
      "Selectively enhances slow inactivation of voltage-gated sodium channels.",
      "Stabilizes hyperexcitable neuronal membranes.",
      "Does not affect fast inactivation (unlike traditional Na+ blockers).",
      "Binds to CRMP-2 (Collapsin Response Mediator Protein-2)."
    ],
    "pharmacokinetics": {
      "absorption": "Complete (100% bioavailability).",
      "distribution": "<15% protein bound.",
      "metabolism": "CYP2C19 to inactive metabolite.",
      "excretion": "Urine. **Half-life: 13 hours.**"
    },
    "dose": {
      "initialDose": "50-100 mg PO/IV BID",
      "maxDose": "400 mg/day",
      "notes": "IV:PO ratio is 1:1."
    },
    "adverseEffects": {
      "common": [
        "Dizziness (dose dependent)",
        "Headache",
        "Diplopia",
        "Nausea"
      ],
      "serious": [
        "PR Interval Prolongation / Heart Block",
        "Atrial Fibrillation/Flutter",
        "Suicidal Ideation",
        "DRESS Syndrome"
      ]
    },
    "precautions": [
      "**Cardiac:** Prolongs PR interval. ECG recommended in patients with conduction problems or severe cardiac disease.",
      "**Renal/Hepatic:** Max dose 300mg in severe impairment.",
      "**Withdrawal:** Taper slowly."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Drugs affecting PR interval (Beta-blockers, CCBs, Digoxin)", "Strong CYP inhibitors (Minor effect)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "lactulose": {
    "name": "Lactulose (Enulose)",
    "genericName": "Lactulose",
    "formula": "C12H22O11",
    "molecularWeight": "342.3 g/mol",
    "brandNames": ["Enulose", "Kristalose"],
    "category": "Laxative / Ammonia Detoxicant",
    "drugClass": "Osmotic Laxative",
    "pubchemCID": "11333",
    "indications": "Constipation, Hepatic Encephalopathy (Portal-Systemic Encephalopathy).",
    "moaSteps": [
      "Synthetic disaccharide (galactose + fructose) not absorbed in GI tract.",
      "Broken down by colonic bacteria into low MW acids (lactic, formic, acetic).",
      "Osmotic effect draws water into colon (Laxative).",
      "Acidifies colonic contents, converting Ammonia (NH3) to Ammonium (NH4+). NH4+ cannot be absorbed and is trapped/excreted (Hepatic Encephalopathy)."
    ],
    "pharmacokinetics": {
      "absorption": "<3%.",
      "distribution": "Local.",
      "metabolism": "Colonic bacteria.",
      "excretion": "Feces. **Half-life: N/A (Pharmacologic effect).**"
    },
    "dose": {
      "initialDose": "Constipation: 15-30 mL daily; HE: 30-45 mL q1h until stool, then q6-12h",
      "maxDose": "Titrate to 2-3 soft stools/day (HE)",
      "notes": "Can be given as enema."
    },
    "adverseEffects": {
      "common": [
        "Flatulence / Gas",
        "Abdominal cramping",
        "Diarrhea (Excessive)",
        "Nausea"
      ],
      "serious": [
        "Dehydration / Electrolyte imbalance (Hypernatremia/Hypokalemia)",
        "Hyperglycemia (in diabetics - contains sugars)"
      ]
    },
    "precautions": [
      "**Electrolytes:** Severe diarrhea can cause hypokalemia and dehydration. Monitor elderly.",
      "**Diabetes:** Syrup contains galactose/lactose.",
      "**Procedures:** Do not use during electrocautery procedures (H2 gas accumulation - explosion risk)."
    ],
    "contraindications": [
      "Galactosemia (Low galactose diet)"
    ],
    "interactions": {
      "drug": ["Antacids (Inhibit acidification)", "Antibiotics (Kill bacteria needed for effect - controversial)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "lamivudine": {
    "name": "Lamivudine (Epivir)",
    "genericName": "Lamivudine (3TC)",
    "formula": "C8H11N3O3S",
    "molecularWeight": "229.3 g/mol",
    "brandNames": ["Epivir", "Epivir-HBV"],
    "category": "Antiretroviral",
    "drugClass": "Nucleoside Reverse Transcriptase Inhibitor (NRTI)",
    "pubchemCID": "60838",
    "indications": "HIV-1 Infection, Chronic Hepatitis B.",
    "moaSteps": [
      "Cytosine analogue.",
      "Phosphorylated intracellularly to active triphosphate.",
      "Inhibits HIV reverse transcriptase and HBV polymerase.",
      "Causes DNA chain termination."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (86% bioavailable).",
      "distribution": "Low protein binding.",
      "metabolism": "Minimal.",
      "excretion": "Urine. **Half-life: 5 to 7 hours.**"
    },
    "dose": {
      "initialDose": "HIV: 150 mg BID or 300 mg daily; HBV: 100 mg daily",
      "maxDose": "300 mg/day (HIV)",
      "notes": "HIV dose is higher than HBV dose. Do not underdose HIV patients."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Nausea",
        "Fatigue",
        "Nasal signs"
      ],
      "serious": [
        "Lactic Acidosis / Severe Hepatomegaly - BOXED WARNING",
        "Severe Exacerbation of Hepatitis B (upon withdrawal) - BOXED WARNING",
        "HIV Resistance (if HBV dose used in HIV+ patient)"
      ]
    },
    "precautions": [
      "**Coinfection:** HIV counseling/testing required before treating HBV. Low dose monotherapy induces HIV resistance.",
      "**Hepatitis Flare:** Monitor liver function for months after stopping.",
      "**Renal:** Dose reduction if CrCl < 50."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Emtricitabine (Antagonistic - Avoid combo)", "Trimethoprim/Sulfamethoxazole (Increases lamivudine levels)", "Sorbitol (Decreases lamivudine absorption)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "lamotrigine": {
    "name": "Lamotrigine (Lamictal)",
    "genericName": "Lamotrigine",
    "formula": "C9H7Cl2N5",
    "molecularWeight": "256.1 g/mol",
    "brandNames": ["Lamictal"],
    "category": "Anticonvulsant / Mood Stabilizer",
    "drugClass": "Phenyltriazine",
    "pubchemCID": "3878",
    "indications": "Epilepsy (Partial/Generalized/Lennox-Gastaut), Bipolar I Disorder (Maintenance).",
    "moaSteps": [
      "Inhibits voltage-sensitive sodium channels.",
      "Stabilizes neuronal membranes.",
      "Inhibits release of glutamate (excitatory neurotransmitter).",
      "Weak 5-HT3 inhibition."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid and complete.",
      "distribution": "55% protein bound.",
      "metabolism": "Hepatic Glucuronidation.",
      "excretion": "Urine. **Half-life: 25 hours (Monotherapy). Affected heavily by other drugs.**"
    },
    "dose": {
      "initialDose": "25 mg PO daily",
      "maxDose": "200-400 mg/day",
      "notes": "MUST TITRATE SLOWLY (weeks) to prevent SJS."
    },
    "adverseEffects": {
      "common": [
        "Dizziness",
        "Double vision (Diplopia)",
        "Headache",
        "Rash (Benign)"
      ],
      "serious": [
        "Stevens-Johnson Syndrome / TEN - BOXED WARNING",
        "DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms)",
        "Aseptic Meningitis",
        "Suicidal Ideation",
        "Hemophagocytic Lymphohistiocytosis (HLH)"
      ]
    },
    "precautions": [
      "**Rash:** Boxed Warning. Risk higher with rapid titration, valproate co-use, or children. Stop at first sign of rash.",
      "**Interactions:** Valproate doubles half-life (use lower dose). Carbamazepine/Phenytoin halve half-life (use higher dose).",
      "**Oral Contraceptives:** Estrogens decrease lamotrigine levels by 50%."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Valproate (Inhibits metabolism - High Toxicity Risk)", "Inducing Antiepileptics (Reduce levels)", "Oral Contraceptives"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "lansoprazole": {
    "name": "Lansoprazole (Prevacid)",
    "genericName": "Lansoprazole",
    "formula": "C16H14F3N3O2S",
    "molecularWeight": "369.4 g/mol",
    "brandNames": ["Prevacid"],
    "category": "Acid Reducer",
    "drugClass": "Proton Pump Inhibitor (PPI)",
    "pubchemCID": "3883",
    "indications": "GERD, Duodenal/Gastric Ulcers, H. pylori eradication, NSAID ulcer prophylaxis.",
    "moaSteps": [
      "Prodrug activated in acidic parietal cell canaliculi.",
      "Irreversibly binds to H+/K+ ATPase pump.",
      "Inhibits final step of gastric acid secretion.",
      "Suppresses basal and stimulated acid."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (Acid labile - Enteric coated granules).",
      "distribution": "97% protein bound.",
      "metabolism": "Hepatic (CYP2C19 and CYP3A4).",
      "excretion": "Bile/Urine. **Half-life: 1.5 hours (Duration >24h).**"
    },
    "dose": {
      "initialDose": "15-30 mg PO once daily",
      "maxDose": "30 mg BID (H. pylori)",
      "notes": "Take 30 min before food."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea",
        "Abdominal pain",
        "Headache",
        "Nausea"
      ],
      "serious": [
        "Clostridioides difficile infection",
        "Osteoporosis / Fractures (long term)",
        "Hypomagnesemia",
        "Interstitial Nephritis",
        "B12 Deficiency"
      ]
    },
    "precautions": [
      "**C. diff:** Risk factor for CDAD.",
      "**Bone:** Supplement Calcium/Vitamin D in long-term users.",
      "**Magnesium:** Monitor Mg.",
      "**Liver:** Dose reduce in severe impairment."
    ],
    "contraindications": [
      "Hypersensitivity",
      "Concomitant Rilpivirine"
    ],
    "interactions": {
      "drug": ["Methotrexate (Toxic levels)", "Clopidogrel (Reduces efficacy - avoid)", "Atazanavir/Rilpivirine (Reduced absorption)"],
      "food": ["Food reduces absorption. Take on empty stomach."]
    },
    "pregnancyCategory": "Category B"
  },
  "latanoprost": {
    "name": "Latanoprost (Xalatan)",
    "genericName": "Latanoprost",
    "formula": "C26H40O5",
    "molecularWeight": "432.6 g/mol",
    "brandNames": ["Xalatan"],
    "category": "Glaucoma Agent",
    "drugClass": "Prostaglandin F2-alpha Analog",
    "pubchemCID": "5311221",
    "indications": "Open-angle Glaucoma, Ocular Hypertension.",
    "moaSteps": [
      "Prodrug ester hydrolyzed to latanoprost acid.",
      "Selective FP prostanoid receptor agonist.",
      "Increases uveoscleral outflow of aqueous humor.",
      "Lowers Intraocular Pressure (IOP)."
    ],
    "pharmacokinetics": {
      "absorption": "Through cornea.",
      "distribution": "Local.",
      "metabolism": "Corneal hydrolysis.",
      "excretion": "Urine. **Half-life: 17 minutes (Systemic).**"
    },
    "dose": {
      "initialDose": "1 drop in affected eye(s) once daily in evening",
      "maxDose": "Once daily",
      "notes": "More frequent dosing DECREASES efficacy."
    },
    "adverseEffects": {
      "common": [
        "Iris Pigmentation (Brown darkening - Permanent)",
        "Eyelash changes (Lengthening/Darkening)",
        "Eye irritation / Redness",
        "Foreign body sensation"
      ],
      "serious": [
        "Macular Edema",
        "Herpetic Keratitis reactivation",
        "Uveitis"
      ]
    },
    "precautions": [
      "**Pigmentation:** Iris color change is permanent. Lid skin darkening/lash changes are reversible.",
      "**Inflammation:** Use caution in active intraocular inflammation.",
      "**Contacts:** Remove before use (Wait 15 min)."
    ],
    "contraindications": [
      "Hypersensitivity to benzalkonium chloride"
    ],
    "interactions": {
      "drug": ["Thimerosal eye drops (Precipitation - space by 5 min)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },"leflunomide": {
    "name": "Leflunomide (Arava)",
    "genericName": "Leflunomide",
    "formula": "C12H9F3N2O2",
    "molecularWeight": "270.2 g/mol",
    "brandNames": ["Arava"],
    "category": "DMARD",
    "drugClass": "Pyrimidine Synthesis Inhibitor",
    "pubchemCID": "3899",
    "indications": "Rheumatoid Arthritis (Active).",
    "moaSteps": [
      "Inhibits dihydroorotate dehydrogenase (DHODH), a mitochondrial enzyme.",
      "Prevents de novo pyrimidine synthesis.",
      "Activated T-lymphocytes require de novo pyrimidine synthesis for proliferation (unlike other cells which use salvage pathways).",
      "Inhibits T-cell proliferation and autoantibody production."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic to active metabolite Teriflunomide.",
      "excretion": "Biliary/Renal. **Half-life: 14 to 18 days (Very long).**"
    },
    "dose": {
      "initialDose": "100 mg PO daily x 3 days (Loading - often skipped due to diarrhea)",
      "maxDose": "20 mg/day",
      "notes": "Drug elimination procedure (Cholestyramine) needed for toxicity or pregnancy."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea (Dose-limiting)",
        "Alopecia",
        "Hypertension",
        "Rash"
      ],
      "serious": [
        "Hepatotoxicity (Severe liver injury) - BOXED WARNING",
        "Teratogenicity - BOXED WARNING",
        "Stevens-Johnson Syndrome",
        "Interstitial Lung Disease"
      ]
    },
    "precautions": [
      "**Pregnancy:** Contraindicated. Must have negative test before start. If pregnancy desired, must undergo drug elimination procedure (cholestyramine) to target levels <0.02 mg/L.",
      "**Liver:** Monitor ALT monthly for 6 months.",
      "**Lung:** Stop if new cough/dyspnea occurs."
    ],
    "contraindications": [
      "Pregnancy",
      "Severe hepatic impairment"
    ],
    "interactions": {
      "drug": ["Warfarin (Increases INR)", "Rifampin (Increases leflunomide levels)", "Methotrexate (Hepatotoxicity risk)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category X"
  },
  "lenalidomide": {
    "name": "Lenalidomide (Revlimid)",
    "genericName": "Lenalidomide",
    "formula": "C13H13N3O3",
    "molecularWeight": "259.3 g/mol",
    "brandNames": ["Revlimid"],
    "category": "Antineoplastic / Immunomodulator",
    "drugClass": "Thalidomide Analog",
    "pubchemCID": "216326",
    "indications": "Multiple Myeloma, Myelodysplastic Syndromes (MDS - del 5q), Mantle Cell Lymphoma.",
    "moaSteps": [
      "Analogue of thalidomide with anti-angiogenic and immunomodulatory properties.",
      "Inhibits proliferation of certain hematopoietic tumor cells.",
      "Stimulates T-cell and Natural Killer (NK) cell immunity.",
      "Inhibits angiogenesis (VEGF suppression)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Moderate protein binding.",
      "metabolism": "Minimal.",
      "excretion": "Urine. **Half-life: 3 hours.**"
    },
    "dose": {
      "initialDose": "25 mg PO daily (Days 1-21 of 28-day cycle)",
      "maxDose": "Protocol dependent",
      "notes": "REMS program (Revlimid REMS) mandatory."
    },
    "adverseEffects": {
      "common": [
        "Fatigue",
        "Diarrhea / Constipation",
        "Muscle cramps",
        "Rash"
      ],
      "serious": [
        "Embryo-Fetal Toxicity (Severe birth defects) - BOXED WARNING",
        "Hematologic Toxicity (Neutropenia/Thrombocytopenia) - BOXED WARNING",
        "Venous/Arterial Thromboembolism - BOXED WARNING"
      ]
    },
    "precautions": [
      "**Pregnancy:** Chemical analogue of Thalidomide. Causes phocomelia. Two forms of birth control required 4 weeks before, during, and after.",
      "**Thrombosis:** High risk of DVT/PE. Anticoagulation prophylaxis (Aspirin or Enoxaparin) required.",
      "**Renal:** Dose adjust if CrCl < 60."
    ],
    "contraindications": [
      "Pregnancy"
    ],
    "interactions": {
      "drug": ["Digoxin (Increases digoxin levels)", "Estrogens (Thrombosis risk)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category X"
  },
  "levetiracetam": {
    "name": "Levetiracetam (Keppra)",
    "genericName": "Levetiracetam",
    "formula": "C8H14N2O2",
    "molecularWeight": "170.2 g/mol",
    "brandNames": ["Keppra", "Elepsia XR", "Spritam"],
    "category": "Anticonvulsant",
    "drugClass": "Pyrrolidine Derivative",
    "pubchemCID": "5284583",
    "indications": "Partial onset seizures, Myoclonic seizures (JME), Primary generalized tonic-clonic seizures.",
    "moaSteps": [
      "Binds to Synaptic Vesicle Protein 2A (SV2A).",
      "Modulates neurotransmitter release.",
      "Inhibits N-type calcium channels.",
      "Unique mechanism compared to other AEDs."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid and complete (100%).",
      "distribution": "<10% protein bound.",
      "metabolism": "Enzymatic hydrolysis (not CYP450).",
      "excretion": "Urine. **Half-life: 7 hours.**"
    },
    "dose": {
      "initialDose": "500 mg PO twice daily",
      "maxDose": "3000 mg/day",
      "notes": "IV:PO ratio is 1:1. No titration needed for safety (unlike Lamotrigine)."
    },
    "adverseEffects": {
      "common": [
        "Somnolence",
        "Fatigue / Asthenia",
        "Headache",
        "Nasopharyngitis"
      ],
      "serious": [
        "Psychiatric/Behavioral Symptoms (Aggression, Irritability, 'Kepprage')",
        "Suicidal Ideation",
        "Severe Dermatologic Reactions (SJS/TEN - Rare)"
      ]
    },
    "precautions": [
      "**Behavior:** Monitor for mood changes, aggression, or irritability. Pyridoxine (B6) supplementation may help.",
      "**Renal:** Dose adjustment strictly required for renal impairment.",
      "**Withdrawal:** Taper gradually."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["None significant (No CYP interactions - ideal for complex patients)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C (Widely used)"
  },
  "levofloxacin": {
    "name": "Levofloxacin (Levaquin)",
    "genericName": "Levofloxacin",
    "formula": "C18H20FN3O4",
    "molecularWeight": "361.4 g/mol",
    "brandNames": ["Levaquin"],
    "category": "Antibiotic",
    "drugClass": "Fluoroquinolone (Respiratory)",
    "pubchemCID": "149096",
    "indications": "Community-Acquired Pneumonia (CAP), Pyelonephritis, Skin infections, Prostatitis.",
    "moaSteps": [
      "L-isomer of Ofloxacin.",
      "Inhibits bacterial DNA gyrase (Topoisomerase II) and Topoisomerase IV.",
      "Inhibits DNA replication and repair.",
      "Bactericidal activity against Gram-negatives (Pseudomonas) and Gram-positives (Strep pneumo)."
    ],
    "pharmacokinetics": {
      "absorption": "99% bioavailability.",
      "distribution": "Wide (Lung, Prostate, Skin).",
      "metabolism": "Minimal.",
      "excretion": "Urine. **Half-life: 6 to 8 hours.**"
    },
    "dose": {
      "initialDose": "500-750 mg PO/IV once daily",
      "maxDose": "750 mg/day",
      "notes": "750mg x 5 days for CAP."
    },
    "adverseEffects": {
      "common": [
        "Nausea",
        "Headache",
        "Insomnia",
        "Diarrhea"
      ],
      "serious": [
        "Tendinitis / Tendon Rupture - BOXED WARNING",
        "Peripheral Neuropathy - BOXED WARNING",
        "CNS Effects (Psychosis/Seizures) - BOXED WARNING",
        "Exacerbation of Myasthenia Gravis - BOXED WARNING",
        "QT Prolongation",
        "Aortic Aneurysm"
      ]
    },
    "precautions": [
      "**Tendon:** Risk increases with age >60, steroids, transplant.",
      "**Chelation:** Separate from antacids, iron, zinc, calcium by 2 hours.",
      "**Blood Sugar:** Dysglycemia (hypo/hyper) can occur, especially in elderly diabetics.",
      "**Renal:** Adjust if CrCl < 50."
    ],
    "contraindications": [
      "Hypersensitivity to fluoroquinolones"
    ],
    "interactions": {
      "drug": ["Warfarin (Increases INR)", "Antacids/Cations (Block absorption)", "NSAIDs (Seizure risk)", "Amiodarone (QT risk)"],
      "food": ["None (unlike Cipro, dairy is less of an issue but cations still matter)."]
    },
    "pregnancyCategory": "Category C"
  },
  "levothyroxine": {
    "name": "Levothyroxine (Synthroid)",
    "genericName": "Levothyroxine Sodium (T4)",
    "formula": "C15H10I4NNaO4",
    "molecularWeight": "798.8 g/mol",
    "brandNames": ["Synthroid", "Levoxyl", "Tirosint", "Unithroid"],
    "category": "Thyroid Hormone",
    "drugClass": "Synthetic T4",
    "pubchemCID": "5819",
    "indications": "Hypothyroidism, TSH suppression (Thyroid Cancer).",
    "moaSteps": [
      "Synthetic form of thyroxine (T4).",
      "Converted to triiodothyronine (T3) in peripheral tissues.",
      "T3 binds to nuclear thyroid receptors, modulating gene expression.",
      "Regulates metabolism, growth, and development."
    ],
    "pharmacokinetics": {
      "absorption": "Variable (40-80%). Best on empty stomach.",
      "distribution": ">99% protein bound (TBG/Albumin).",
      "metabolism": "Deiodination to T3 (active) and rT3 (inactive).",
      "excretion": "Feces/Urine. **Half-life: 6 to 7 days.**"
    },
    "dose": {
      "initialDose": "1.6 mcg/kg PO daily",
      "maxDose": "Titrate to TSH",
      "notes": "Elderly/Cardiac disease: Start 12.5-25 mcg daily."
    },
    "adverseEffects": {
      "common": [
        "Hyperthyroid symptoms (if dose too high)",
        "Palpitations",
        "Insomnia",
        "Heat intolerance",
        "Weight loss"
      ],
      "serious": [
        "Arrhythmias / Atrial Fibrillation",
        "Angina / MI (in underlying CAD)",
        "Decreased bone mineral density (Overtreatment)"
      ]
    },
    "precautions": [
      "**Administration:** Take with water 30-60 mins before breakfast OR 4 hours after last meal. Consistency is key.",
      "**Cardiac:** Start low and go slow in CAD to avoid precipitating ischemia.",
      "**Weight Loss:** BOXED WARNING - Do not use for obesity treatment."
    ],
    "contraindications": [
      "Uncorrected adrenal insufficiency (Precipitates crisis)",
      "Acute MI (Caution)",
      "Thyrotoxicosis"
    ],
    "interactions": {
      "drug": ["Calcium/Iron/Antacids (Block absorption - separate by 4h)", "Warfarin (Levothyroxine increases clotting factor catabolism -> Increases INR)", "Estrogens (Increase TBG -> need higher T4 dose)"],
      "food": ["Soy, fiber, coffee, walnuts decrease absorption."]
    },
    "pregnancyCategory": "Category A (Safe - dose usually increases)"
  },
  "lidocaine": {
    "name": "Lidocaine (Xylocaine)",
    "genericName": "Lidocaine HCl",
    "formula": "C14H22N2O",
    "molecularWeight": "234.34 g/mol",
    "brandNames": ["Xylocaine", "Lidoderm"],
    "category": "Anesthetic / Antiarrhythmic",
    "drugClass": "Amide Local Anesthetic / Class IB Antiarrhythmic",
    "pubchemCID": "3676",
    "indications": "Local/Regional Anesthesia, Ventricular Arrhythmias (VT/VF), Postherpetic Neuralgia (Patch).",
    "moaSteps": [
      "Blocks voltage-gated sodium channels.",
      "Anesthetic: Inhibits conduction of nerve impulses.",
      "Antiarrhythmic: Shortens action potential duration and refractory period in ventricular muscle. Suppresses automaticity."
    ],
    "pharmacokinetics": {
      "absorption": "Topical (varies), IV (immediate).",
      "distribution": "High affinity for adipose tissue.",
      "metabolism": "Extensive hepatic (CYP1A2/3A4).",
      "excretion": "Urine. **Half-life: 1.5 to 2 hours.**"
    },
    "dose": {
      "initialDose": "1-1.5 mg/kg IV bolus (Cardiac)",
      "maxDose": "3 mg/kg total",
      "notes": "Patch: 12 hours on / 12 hours off."
    },
    "adverseEffects": {
      "common": [
        "Dizziness / Lightheadedness",
        "Drowsiness",
        "Injection site pain",
        "Metallic taste"
      ],
      "serious": [
        "Lidocaine Toxicity (LAST): Perioral numbness -> Tinnitus -> Seizures -> Cardiac Arrest",
        "Methemoglobinemia",
        "Bradycardia / Hypotension"
      ]
    },
    "precautions": [
      "**Toxicity:** Monitor for CNS signs (slurred speech, confusion). Lipid emulsion is antidote for systemic toxicity.",
      "**Hepatic:** Dose reduce in liver failure or heart failure (reduced liver blood flow).",
      "**Antiarrhythmic:** Ineffective for atrial arrhythmias."
    ],
    "contraindications": [
      "Wolff-Parkinson-White (WPW) syndrome",
      "Severe heart block (without pacemaker)",
      "Hypersensitivity to amide anesthetics"
    ],
    "interactions": {
      "drug": ["Beta-blockers/Cimetidine (Decrease lidocaine clearance -> Toxicity)", "Amiodarone"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "linezolid": {
    "name": "Linezolid (Zyvox)",
    "genericName": "Linezolid",
    "formula": "C16H20FN3O4",
    "molecularWeight": "337.35 g/mol",
    "brandNames": ["Zyvox"],
    "category": "Antibiotic",
    "drugClass": "Oxazolidinone",
    "pubchemCID": "441401",
    "indications": "VRE (Vancomycin-Resistant Enterococcus) infections, MRSA Pneumonia, Skin/Soft Tissue Infections.",
    "moaSteps": [
      "Binds to the 23S ribosomal RNA of the 50S subunit.",
      "Prevents formation of the 70S initiation complex.",
      "Inhibits bacterial protein synthesis.",
      "Bacteriostatic against Enterococci and Staphylococci; Bactericidal against Strep."
    ],
    "pharmacokinetics": {
      "absorption": "100% oral bioavailability.",
      "distribution": "Good tissue penetration (lung/skin).",
      "metabolism": "Non-enzymatic oxidation.",
      "excretion": "Urine. **Half-life: 4 to 5 hours.**"
    },
    "dose": {
      "initialDose": "600 mg PO/IV every 12 hours",
      "maxDose": "1200 mg/day",
      "notes": "IV and PO doses are identical."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea",
        "Nausea",
        "Headache"
      ],
      "serious": [
        "Myelosuppression (Thrombocytopenia > 14 days)",
        "Serotonin Syndrome (MAOI activity)",
        "Peripheral / Optic Neuropathy (Long term > 28 days)",
        "Lactic Acidosis"
      ]
    },
    "precautions": [
      "**Bone Marrow:** Monitor CBC weekly. Platelets drop significantly after 2 weeks.",
      "**Serotonin Syndrome:** Weak MAOI. Avoid with SSRIs, TCAs, Tyramine foods.",
      "**Neuropathy:** Irreversible optic/peripheral neuropathy reported with courses > 28 days."
    ],
    "contraindications": [
      "Use within 14 days of MAOIs"
    ],
    "interactions": {
      "drug": ["SSRIs/SNRIs (Serotonin syndrome)", "Adrenergic agents (Hypertension)", "Tyramine foods"],
      "food": ["Tyramine-rich foods (Hypertensive crisis - rare but possible)."]
    },
    "pregnancyCategory": "Category C"
  },
  "lisinopril": {
    "name": "Lisinopril (Prinivil, Zestril)",
    "genericName": "Lisinopril",
    "formula": "C21H31N3O5",
    "molecularWeight": "405.5 g/mol",
    "brandNames": ["Prinivil", "Zestril", "Qbrelis"],
    "category": "Antihypertensive",
    "drugClass": "ACE Inhibitor",
    "pubchemCID": "5362119",
    "indications": "Hypertension, Heart Failure (HFrEF), Acute MI.",
    "moaSteps": [
      "Inhibits Angiotensin-Converting Enzyme (ACE).",
      "Prevents conversion of Angiotensin I to Angiotensin II.",
      "Decreases vasoconstriction and aldosterone secretion.",
      "Inhibits breakdown of bradykinin.",
      "Not a prodrug (active as administered)."
    ],
    "pharmacokinetics": {
      "absorption": "Slow (25% bioavailable).",
      "distribution": "Not protein bound.",
      "metabolism": "Not metabolized.",
      "excretion": "Urine (Unchanged). **Half-life: 12 hours.**"
    },
    "dose": {
      "initialDose": "10 mg PO once daily",
      "maxDose": "40 mg/day (80mg max per label, rarely used)",
      "notes": "Start 2.5-5 mg in Heart Failure."
    },
    "adverseEffects": {
      "common": [
        "Dry Cough (Bradykinin)",
        "Dizziness / Hypotension",
        "Hyperkalemia",
        "Headache"
      ],
      "serious": [
        "Angioedema (Swelling of face/tongue/larynx)",
        "Renal Failure (Acute)",
        "Fetal Toxicity - BOXED WARNING",
        "Hepatotoxicity (Rare)"
      ]
    },
    "precautions": [
      "**Angioedema:** Can be fatal. More common in Black patients. History of angioedema is absolute contraindication.",
      "**Pregnancy:** Discontinue immediately.",
      "**Renal:** Transient bump in Cr (up to 30%) is acceptable; >30% requires dose reduction/stop."
    ],
    "contraindications": [
      "History of ACEI angioedema",
      "Pregnancy",
      "Concomitant Aliskiren in diabetes"
    ],
    "interactions": {
      "drug": ["Potassium-sparing diuretics (Hyperkalemia)", "Lithium (Toxicity)", "NSAIDs (Renal failure)"],
      "food": ["Salt substitutes"]
    },
    "pregnancyCategory": "Category D"
  },
  "lithium": {
    "name": "Lithium (Lithobid)",
    "genericName": "Lithium Carbonate",
    "formula": "Li2CO3",
    "molecularWeight": "73.89 g/mol",
    "brandNames": ["Lithobid"],
    "category": "Mood Stabilizer",
    "drugClass": "Antimanic Agent",
    "pubchemCID": "11125",
    "indications": "Bipolar I Disorder (Acute Mania and Maintenance).",
    "moaSteps": [
      "Exact mechanism unknown.",
      "Alters cation transport across cell membranes in nerve and muscle cells.",
      "Inhibits Inositol Monophosphatase (IMP), depleting free inositol.",
      "Modulates second messenger systems (cAMP, IP3).",
      "Neuroprotective (increases BDNF)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid and complete.",
      "distribution": "Total body water. No protein binding.",
      "metabolism": "Not metabolized.",
      "excretion": "Urine (reabsorbed in proximal tubule like Sodium). **Half-life: 18 to 36 hours.**"
    },
    "dose": {
      "initialDose": "300 mg PO BID or TID",
      "maxDose": "Titrate to serum level (0.6-1.2 mEq/L)",
      "notes": "Narrow therapeutic index."
    },
    "adverseEffects": {
      "common": [
        "Tremor (Fine hand tremor)",
        "Polyuria / Polydipsia (Nephrogenic DI)",
        "Nausea / Diarrhea",
        "Weight gain",
        "Hypothyroidism"
      ],
      "serious": [
        "Lithium Toxicity (Coarse tremor, Ataxia, Confusion, Seizures, Coma)",
        "Renal Failure (Chronic interstitial nephritis)",
        "Ebstein's Anomaly (Teratogenic)"
      ]
    },
    "precautions": [
      "**Toxicity:** Occurs > 1.5 mEq/L. Dehydration, hyponatremia, and NSAIDs/ACEIs increase levels drastically.",
      "**Kidney/Thyroid:** Monitor TSH and Creatinine every 6-12 months.",
      "**Pregnancy:** Ebstein's anomaly (cardiac defect) risk."
    ],
    "contraindications": [
      "Severe renal impairment",
      "Severe dehydration / Sodium depletion",
      "Significant cardiovascular disease"
    ],
    "interactions": {
      "drug": ["Thiazides/NSAIDs/ACEIs (Increase Lithium levels -> Toxicity)", "Caffeine/Theophylline (Decrease Lithium levels)"],
      "food": ["Maintain consistent salt intake."]
    },
    "pregnancyCategory": "Category D"
  },
  "loperamide": {
    "name": "Loperamide (Imodium)",
    "genericName": "Loperamide",
    "formula": "C29H33ClN2O2",
    "molecularWeight": "477.0 g/mol",
    "brandNames": ["Imodium"],
    "category": "Antidiarrheal",
    "drugClass": "Opioid Agonist (Peripheral)",
    "pubchemCID": "3955",
    "indications": "Acute diarrhea, Chronic diarrhea associated with IBD.",
    "moaSteps": [
      "Acts on mu-opioid receptors in the myenteric plexus of the large intestine.",
      "Inhibits release of acetylcholine and prostaglandins.",
      "Decreases peristalsis and increases transit time.",
      "Increases anal sphincter tone.",
      "Does not cross BBB efficiently (P-gp substrate)."
    ],
    "pharmacokinetics": {
      "absorption": "Poorly absorbed (<40%).",
      "distribution": "97% protein bound.",
      "metabolism": "Hepatic (CYP3A4/2C8).",
      "excretion": "Feces. **Half-life: 10.8 hours.**"
    },
    "dose": {
      "initialDose": "4 mg PO initially, then 2 mg after each loose stool",
      "maxDose": "8 mg/day (OTC); 16 mg/day (Rx)",
      "notes": "FDA warning on high doses."
    },
    "adverseEffects": {
      "common": [
        "Constipation",
        "Abdominal cramps",
        "Nausea"
      ],
      "serious": [
        "Toxic Megacolon (in active colitis)",
        "QT Prolongation / Torsades de Pointes (High doses)",
        "Paralytic Ileus"
      ]
    },
    "precautions": [
      "**Infection:** Do not use in C. diff or invasive bacterial diarrhea (bloody stool/fever). Retaining toxins worsens outcome.",
      "**Cardiac:** FDA warning for QT prolongation/death with abuse (high doses used to cross BBB or treat withdrawal)."
    ],
    "contraindications": [
      "Abdominal pain without diarrhea",
      "Acute dysentery (bloody stool/fever)",
      "Active C. difficile colitis",
      "Children < 2 years"
    ],
    "interactions": {
      "drug": ["P-gp inhibitors (Quinidine/Ritonavir - allow CNS entry)", "QT prolonging drugs"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "loratadine": {
    "name": "Loratadine (Claritin)",
    "genericName": "Loratadine",
    "formula": "C22H23ClN2O2",
    "molecularWeight": "382.9 g/mol",
    "brandNames": ["Claritin"],
    "category": "Antihistamine",
    "drugClass": "H1 Receptor Antagonist (Second Generation)",
    "pubchemCID": "3957",
    "indications": "Allergic Rhinitis, Urticaria.",
    "moaSteps": [
      "Selective peripheral histamine H1-receptor antagonist.",
      "Prevents histamine-induced symptoms (sneezing, itching, runny nose).",
      "Does not readily cross the blood-brain barrier.",
      "Less sedating than first-generation antihistamines."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "97% protein bound.",
      "metabolism": "Hepatic (CYP3A4/2D6) to active Desloratadine.",
      "excretion": "Urine/Feces. **Half-life: 8 hours (Parent); 28 hours (Metabolite).**"
    },
    "dose": {
      "initialDose": "10 mg PO once daily",
      "maxDose": "10 mg/day",
      "notes": "Reduce freq in renal/hepatic impairment."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Dry mouth",
        "Fatigue"
      ],
      "serious": [
        "Hypersensitivity (Rash)",
        "Seizures (very rare)"
      ]
    },
    "precautions": [
      "**Sedation:** Truly non-sedating at recommended dose (unlike cetirizine which can sedate).",
      "**Phenylketonuria:** Some chewable tabs contain phenylalanine."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Erythromycin/Ketoconazole (Increase levels but no QT effect)", "Amiodarone"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "lorazepam": {
    "name": "Lorazepam (Ativan)",
    "genericName": "Lorazepam",
    "formula": "C15H10Cl2N2O2",
    "molecularWeight": "321.2 g/mol",
    "brandNames": ["Ativan"],
    "category": "Anxiolytic / Sedative",
    "drugClass": "Benzodiazepine (Intermediate-acting)",
    "pubchemCID": "3958",
    "indications": "Anxiety Disorders, Status Epilepticus, Alcohol Withdrawal, Preoperative Sedation.",
    "moaSteps": [
      "Binds to benzodiazepine receptors on the GABA-A complex.",
      "Enhances GABA-mediated chloride influx.",
      "Hyperpolarizes neurons.",
      "Produces anxiolysis, sedation, amnesia, and anticonvulsant effects."
    ],
    "pharmacokinetics": {
      "absorption": "Good oral/IM absorption.",
      "distribution": "85% protein bound.",
      "metabolism": "Direct Glucuronidation (No active metabolites).",
      "excretion": "Urine. **Half-life: 10 to 20 hours.**"
    },
    "dose": {
      "initialDose": "0.5-2 mg PO/IV/IM",
      "maxDose": "10 mg/day",
      "notes": "0.1 mg/kg IV for Status Epilepticus."
    },
    "adverseEffects": {
      "common": [
        "Sedation",
        "Dizziness / Ataxia",
        "Weakness",
        "Memory impairment"
      ],
      "serious": [
        "Respiratory Depression - BOXED WARNING",
        "Dependence / Abuse - BOXED WARNING",
        "Paradoxical reaction (Agitation)",
        "Propylene glycol toxicity (High dose IV infusion)"
      ]
    },
    "precautions": [
      "**Liver Disease:** Preferred benzo in liver failure (Metabolized by glucuronidation, not CYP450).",
      "**Withdrawal:** Abrupt cessation can cause seizures.",
      "**Elderly:** Increased falls/confusion risk."
    ],
    "contraindications": [
      "Acute narrow-angle glaucoma",
      "Severe respiratory insufficiency",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Opioids (Fatal respiratory depression)", "Alcohol", "Valproate"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "losartan": {
    "name": "Losartan (Cozaar)",
    "genericName": "Losartan Potassium",
    "formula": "C22H23ClN6O",
    "molecularWeight": "422.9 g/mol",
    "brandNames": ["Cozaar"],
    "category": "Antihypertensive",
    "drugClass": "Angiotensin II Receptor Blocker (ARB)",
    "pubchemCID": "3792",
    "indications": "Hypertension, Diabetic Nephropathy, Stroke Risk Reduction (LVH).",
    "moaSteps": [
      "Selectively blocks AT1 angiotensin II receptors.",
      "Blocks vasoconstriction and aldosterone secretion.",
      "Unique property: Metabolite has uricosuric effect (lowers uric acid).",
      "No effect on bradykinin (no cough)."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed (33% bioavailable - first pass).",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic (CYP2C9/3A4) to active metabolite (E-3174).",
      "excretion": "Bile/Urine. **Half-life: 2 hours (Parent); 6-9 hours (Active Metabolite).**"
    },
    "dose": {
      "initialDose": "50 mg PO once daily",
      "maxDose": "100 mg/day",
      "notes": "Start 25 mg in volume depleted."
    },
    "adverseEffects": {
      "common": [
        "Dizziness",
        "Hypotension",
        "Hyperkalemia",
        "Back pain"
      ],
      "serious": [
        "Renal Failure (in bilateral artery stenosis)",
        "Angioedema (Rare)",
        "Fetal Toxicity - BOXED WARNING",
        "Rhabdomyolysis (Rare)"
      ]
    },
    "precautions": [
      "**Fetal Toxicity:** Discontinue in pregnancy.",
      "**Gout:** Useful in hypertensive patients with gout (lowers uric acid).",
      "**Hyperkalemia:** Less risk than ACEIs but possible."
    ],
    "contraindications": [
      "Pregnancy",
      "Concomitant Aliskiren in diabetes"
    ],
    "interactions": {
      "drug": ["Lithium", "Potassium-sparing diuretics", "NSAIDs", "Fluconazole (Inhibits conversion to active metabolite)"],
      "food": ["Salt substitutes"]
    },
    "pregnancyCategory": "Category D"
  },
  "lovastatin": {
    "name": "Lovastatin (Mevacor)",
    "genericName": "Lovastatin",
    "formula": "C24H36O5",
    "molecularWeight": "404.5 g/mol",
    "brandNames": ["Mevacor", "Altoprev"],
    "category": "Antilipemic",
    "drugClass": "HMG-CoA Reductase Inhibitor (Statin)",
    "pubchemCID": "53232",
    "indications": "Hyperlipidemia, Primary prevention of CAD.",
    "moaSteps": [
      "Prodrug lactone hydrolyzed to active acid form.",
      "Inhibits HMG-CoA reductase.",
      "Reduces cholesterol synthesis.",
      "Upregulates LDL receptors."
    ],
    "pharmacokinetics": {
      "absorption": "30% absorbed; food increases absorption.",
      "distribution": "High protein binding.",
      "metabolism": "Extensive hepatic (CYP3A4).",
      "excretion": "Feces. **Half-life: 1.1 to 1.7 hours.**"
    },
    "dose": {
      "initialDose": "20 mg PO with evening meal",
      "maxDose": "80 mg/day",
      "notes": "Take with dinner (cholesterol synthesis peaks at night and food aids absorption)."
    },
    "adverseEffects": {
      "common": [
        "Myalgia / Muscle cramps",
        "Flatulence",
        "Abdominal pain",
        "Constipation"
      ],
      "serious": [
        "Rhabdomyolysis",
        "Hepatotoxicity",
        "Immune-mediated necrotizing myopathy"
      ]
    },
    "precautions": [
      "**Muscle:** Risk of myopathy is dose-dependent and interaction-dependent.",
      "**Interactions:** Highly sensitive to CYP3A4 inhibitors.",
      "**Liver:** Contraindicated in active liver disease."
    ],
    "contraindications": [
      "Concomitant strong CYP3A4 inhibitors (Ketoconazole, Erythromycin)",
      "Active liver disease",
      "Pregnancy/Nursing"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inhibitors (Contraindicated)", "Gemfibrozil (Contraindicated)", "Diltiazem/Verapamil/Amiodarone (Dose caps apply)"],
      "food": ["Grapefruit juice (Avoid)", "Take with food"]
    },
    "pregnancyCategory": "Category X"
  },
  "magnesium_sulfate": {
    "name": "Magnesium Sulfate",
    "genericName": "Magnesium Sulfate",
    "formula": "MgSO4",
    "molecularWeight": "120.4 g/mol",
    "brandNames": ["Epsom Salt (Oral/Topical)"],
    "category": "Electrolyte / Anticonvulsant",
    "drugClass": "Magnesium Salt",
    "pubchemCID": "24083",
    "indications": "Hypomagnesemia, Eclampsia/Pre-eclampsia seizures, Torsades de Pointes, Asthma exacerbation (severe).",
    "moaSteps": [
      "Essential cofactor for enzyme systems.",
      "Blocks neuromuscular transmission and decreases amount of acetylcholine released (Anticonvulsant).",
      "Calcium channel blocker activity (Bronchodilation/Vasodilation).",
      "Stabilizes cardiac membrane."
    ],
    "pharmacokinetics": {
      "absorption": "IV/IM immediate; Oral ~30%.",
      "distribution": "Bone/Intracellular.",
      "metabolism": "None.",
      "excretion": "Renal. **Half-life: Renal dependent (Approx 4 hours in normal function).**"
    },
    "dose": {
      "initialDose": "Eclampsia: 4-6 g IV load, then 1-2 g/hr",
      "maxDose": "40 g/day",
      "notes": "Asthma: 2 g IV single dose."
    },
    "adverseEffects": {
      "common": [
        "Flushing / Warmth",
        "Hypotension",
        "Sweating"
      ],
      "serious": [
        "Magnesium Toxicity: Loss of Deep Tendon Reflexes -> Respiratory Paralysis -> Cardiac Arrest",
        "Pulmonary Edema",
        "Complete Heart Block"
      ]
    },
    "precautions": [
      "**Toxicity:** Monitor DTRs (patellar reflex), respiratory rate, and urine output. Disappearnce of reflexes is first sign of toxicity.",
      "**Antidote:** Calcium Gluconate.",
      "**Renal:** Accumulates rapidly in renal failure. Reduce dose."
    ],
    "contraindications": [
      "Heart block",
      "Myocardial damage",
      "Severe renal failure (unless dialysis avail)"
    ],
    "interactions": {
      "drug": ["Neuromuscular Blockers (Potentiates blockade)", "Calcium Channel Blockers (Hypotension)", "Digoxin"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D (Safe for short term eclampsia; bone defects if >5 days)"
  },
  "mannitol": {
    "name": "Mannitol (Osmitrol)",
    "genericName": "Mannitol",
    "formula": "C6H14O6",
    "molecularWeight": "182.17 g/mol",
    "brandNames": ["Osmitrol"],
    "category": "Diuretic",
    "drugClass": "Osmotic Diuretic",
    "pubchemCID": "6251",
    "indications": "Reduction of Intracranial Pressure (ICP), Intraocular Pressure (IOP), Renal failure (oliguria promotion - controversial).",
    "moaSteps": [
      "Increases osmolarity of glomerular filtrate.",
      "Inhibits tubular reabsorption of water.",
      "Extracts intracellular water into extracellular space (plasma expansion).",
      "Reduces brain bulk and ICP."
    ],
    "pharmacokinetics": {
      "absorption": "IV only.",
      "distribution": "Extracellular space. Does not cross BBB.",
      "metabolism": "Minimal.",
      "excretion": "Urine (Unchanged). **Half-life: 15 to 100 minutes.**"
    },
    "dose": {
      "initialDose": "0.25 - 1 g/kg IV bolus",
      "maxDose": "Repeat q6-8h",
      "notes": "Use filter needle (crystals form at low temps)."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Nausea",
        "Thirst"
      ],
      "serious": [
        "Pulmonary Edema / CHF (due to initial plasma expansion)",
        "Rebound increased ICP",
        "Severe Dehydration / Electrolyte imbalance",
        "Renal Failure (Osmotic nephrosis)"
      ]
    },
    "precautions": [
      "**Crystallization:** Solution crystallizes at room temp. Inspect and warm if needed. ALWAYS use a filter.",
      "**Heart Failure:** Initial volume expansion can precipitate pulmonary edema.",
      "**Rebound:** Taper to prevent rebound ICP."
    ],
    "contraindications": [
      "Anuria",
      "Severe pulmonary edema / CHF",
      "Active intracranial bleeding",
      "Severe dehydration"
    ],
    "interactions": {
      "drug": ["Diuretics (Potentiate effect)", "Lithium (Increases excretion -> Lowers levels)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "maraviroc": {
    "name": "Maraviroc (Selzentry)",
    "genericName": "Maraviroc",
    "formula": "C29H41F2N5O",
    "molecularWeight": "513.7 g/mol",
    "brandNames": ["Selzentry"],
    "category": "Antiretroviral",
    "drugClass": "CCR5 Antagonist (Entry Inhibitor)",
    "pubchemCID": "3002977",
    "indications": "HIV-1 Infection (CCR5-tropic only).",
    "moaSteps": [
      "Selectively binds to the human chemokine receptor CCR5 on CD4 cells.",
      "Prevents interaction of HIV-1 gp120 and CCR5.",
      "Blocks viral entry into the cell.",
      "Ineffective against CXCR4-tropic or dual-tropic virus."
    ],
    "pharmacokinetics": {
      "absorption": "Variable.",
      "distribution": "76% protein bound.",
      "metabolism": "Hepatic via CYP3A4.",
      "excretion": "Feces and Urine. **Half-life: 14 to 18 hours.**"
    },
    "dose": {
      "initialDose": "300 mg PO BID (Standard)",
      "maxDose": "Varies by interaction",
      "notes": "150mg BID with strong 3A4 inhibitors; 600mg BID with inducers."
    },
    "adverseEffects": {
      "common": [
        "Cough",
        "Pyrexia",
        "Upper respiratory infection",
        "Rash"
      ],
      "serious": [
        "Hepatotoxicity (Severe rash-associated) - BOXED WARNING",
        "Orthostatic Hypotension",
        "Immune Reconstitution Syndrome",
        "Infection risk"
      ]
    },
    "precautions": [
      "**Tropism Assay:** Mandatory Trofile assay required to confirm R5-virus. Useless if X4-virus is present.",
      "**Hepatotoxicity:** Discontinue if signs of hepatitis or systemic allergic reaction (rash/eosinophilia) occur."
    ],
    "contraindications": [
      "Severe renal impairment taking potent CYP3A4 inhibitors"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inhibitors (Ritonavir - decrease dose)", "CYP3A4 Inducers (Efavirenz - increase dose)", "St. John's Wort"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "meclizine": {
    "name": "Meclizine (Antivert)",
    "genericName": "Meclizine HCl",
    "formula": "C25H27ClN2",
    "molecularWeight": "390.9 g/mol",
    "brandNames": ["Antivert", "Bonine"],
    "category": "Antiemetic / Antivertigo",
    "drugClass": "Antihistamine (First Generation - Piperazine)",
    "pubchemCID": "4034",
    "indications": "Vertigo, Motion Sickness.",
    "moaSteps": [
      "H1 receptor antagonist.",
      "Depresses labyrinthine excitability and vestibular stimulation.",
      "Affects the chemoreceptor trigger zone (CTZ).",
      "Possesses anticholinergic activity."
    ],
    "pharmacokinetics": {
      "absorption": "Good.",
      "distribution": "Crosses BBB.",
      "metabolism": "Hepatic (CYP2D6).",
      "excretion": "Urine and Feces. **Half-life: 6 hours.**"
    },
    "dose": {
      "initialDose": "25-100 mg PO daily (divided)",
      "maxDose": "100 mg/day",
      "notes": "Take 1 hour before travel."
    },
    "adverseEffects": {
      "common": [
        "Drowsiness / Sedation",
        "Dry mouth",
        "Blurred vision",
        "Fatigue"
      ],
      "serious": [
        "Anaphylaxis",
        "Urinary Retention (in BPH)",
        "Confusion (Elderly)"
      ]
    },
    "precautions": [
      "**Sedation:** Caution driving.",
      "**Anticholinergic:** Caution in BPH, glaucoma, asthma.",
      "**Elderly:** Beers Criteria - avoid."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Alcohol (Additive sedation)", "Anticholinergics"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "meloxicam": {
    "name": "Meloxicam (Mobic)",
    "genericName": "Meloxicam",
    "formula": "C14H13N3O4S2",
    "molecularWeight": "351.4 g/mol",
    "brandNames": ["Mobic", "Vivlodex"],
    "category": "NSAID",
    "drugClass": "Oxicam Derivative",
    "pubchemCID": "54677470",
    "indications": "Osteoarthritis, Rheumatoid Arthritis.",
    "moaSteps": [
      "Inhibits COX-1 and COX-2 enzymes.",
      "Preferential selectivity for COX-2 (at low doses).",
      "Reduces prostaglandin synthesis.",
      "Less GI toxicity than non-selective NSAIDs, but more than Celecoxib."
    ],
    "pharmacokinetics": {
      "absorption": "High bioavailability (89%).",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic (CYP2C9/3A4).",
      "excretion": "Urine/Feces. **Half-life: 15 to 20 hours (Once daily dosing).**"
    },
    "dose": {
      "initialDose": "7.5 mg PO daily",
      "maxDose": "15 mg/day",
      "notes": "Use lowest effective dose."
    },
    "adverseEffects": {
      "common": [
        "Dyspepsia",
        "Diarrhea",
        "Edema"
      ],
      "serious": [
        "CV Thrombotic Events - BOXED WARNING",
        "GI Bleeding - BOXED WARNING",
        "Renal Failure",
        "Severe Skin Reactions (SJS/TEN)"
      ]
    },
    "precautions": [
      "**Renal:** Avoid in advanced renal disease.",
      "**Cardiovascular:** Contraindicated for CABG pain. Risk of MI/Stroke.",
      "**Asthma:** Avoid in aspirin-sensitive asthma."
    ],
    "contraindications": [
      "Active GI bleed",
      "Aspirin allergy",
      "CABG peri-operative"
    ],
    "interactions": {
      "drug": ["Warfarin (Bleeding)", "ACE Inhibitors (Renal failure)", "Lithium"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C (D > 30 weeks)"
  },
  "memantine": {
    "name": "Memantine (Namenda)",
    "genericName": "Memantine HCl",
    "formula": "C12H21N",
    "molecularWeight": "179.3 g/mol",
    "brandNames": ["Namenda", "Namenda XR"],
    "category": "Anti-Alzheimer's Agent",
    "drugClass": "NMDA Receptor Antagonist",
    "pubchemCID": "4054",
    "indications": "Moderate to Severe Alzheimer's Disease.",
    "moaSteps": [
      "Uncompetitive antagonist at the NMDA (N-methyl-D-aspartate) glutamate receptor.",
      "Blocks chronic, low-level activation of NMDA receptors by glutamate (excitotoxicity).",
      "Prevents neuronal calcium overload and cell death.",
      "Allows physiological signals to pass (low affinity blockade)."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "45% protein bound.",
      "metabolism": "Partial hepatic.",
      "excretion": "Urine (Active tubular secretion). **Half-life: 60 to 80 hours.**"
    },
    "dose": {
      "initialDose": "5 mg PO daily",
      "maxDose": "20 mg/day (IR); 28 mg/day (XR)",
      "notes": "Titrate weekly."
    },
    "adverseEffects": {
      "common": [
        "Dizziness",
        "Headache",
        "Constipation",
        "Confusion"
      ],
      "serious": [
        "Hypersensitivity (SJS)",
        "Seizures (rare)"
      ]
    },
    "precautions": [
      "**Urine pH:** Conditions raising urine pH (UTI, diet, meds) drastically decrease excretion and increase toxicity.",
      "**Renal:** Dose cap at 10mg/day (IR) if CrCl < 30.",
      "**Seizures:** Use with caution."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Carbonic anhydrase inhibitors / Sodium bicarb (Alkalinize urine -> toxicity)", "Amantadine / Ketamine (Additive NMDA effects - psychosis)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "meropenem": {
    "name": "Meropenem (Merrem)",
    "genericName": "Meropenem",
    "formula": "C17H25N3O5S",
    "molecularWeight": "383.5 g/mol",
    "brandNames": ["Merrem"],
    "category": "Antibiotic",
    "drugClass": "Carbapenem",
    "pubchemCID": "441130",
    "indications": "Complicated Intra-abdominal infections, Bacterial Meningitis, Febrile Neutropenia, Sepsis.",
    "moaSteps": [
      "Binds to penicillin-binding proteins (PBPs).",
      "Inhibits bacterial cell wall synthesis.",
      "Resistant to many beta-lactamases.",
      "Broad spectrum (Gram-positives, Gram-negatives including Pseudomonas, Anaerobes)."
    ],
    "pharmacokinetics": {
      "absorption": "IV only.",
      "distribution": "Widely distributed (CSF penetration good).",
      "metabolism": "Hydrolysis.",
      "excretion": "Urine. **Half-life: 1 hour.**"
    },
    "dose": {
      "initialDose": "1 g IV every 8 hours",
      "maxDose": "2 g q8h (Meningitis)",
      "notes": "Dose adjust in renal impairment."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea",
        "Rash",
        "Nausea / Vomiting"
      ],
      "serious": [
        "Seizures (Less risk than Imipenem)",
        "Anaphylaxis",
        "Clostridioides difficile colitis",
        "Thrombocytopenia"
      ]
    },
    "precautions": [
      "**Seizures:** Risk factors include CNS lesions, bacterial meningitis, and renal failure.",
      "**Valproic Acid:** Concurrent use decreases VPA levels by 60-100% within 2 days (seizure risk).",
      "**Hypersensitivity:** Cross-reaction with penicillins."
    ],
    "contraindications": [
      "Hypersensitivity to carbapenems",
      "History of anaphylaxis to beta-lactams"
    ],
    "interactions": {
      "drug": ["Valproic Acid / Divalproex (Contraindicated - Loss of seizure control)", "Probenecid"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },"metformin": {
    "name": "Metformin (Glucophage)",
    "genericName": "Metformin HCl",
    "formula": "C4H11N5",
    "molecularWeight": "129.16 g/mol",
    "brandNames": ["Glucophage", "Fortamet", "Glumetza"],
    "category": "Antidiabetic",
    "drugClass": "Biguanide",
    "pubchemCID": "4091",
    "indications": "Type 2 Diabetes Mellitus (First-line), PCOS, Pre-diabetes.",
    "moaSteps": [
      "Decreases hepatic glucose production (gluconeogenesis).",
      "Decreases intestinal absorption of glucose.",
      "Improves insulin sensitivity by increasing peripheral glucose uptake and utilization.",
      "Activates AMP-activated protein kinase (AMPK)."
    ],
    "pharmacokinetics": {
      "absorption": "Slow and incomplete (50-60% bioavailable).",
      "distribution": "Negligible protein binding.",
      "metabolism": "Not metabolized.",
      "excretion": "Urine (Unchanged). **Half-life: 6.2 hours (Plasma); 17.6 hours (Blood).**"
    },
    "dose": {
      "initialDose": "500 mg PO daily or BID",
      "maxDose": "2000-2550 mg/day",
      "notes": "Take with meals to reduce GI side effects."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea (very common)",
        "Nausea / Vomiting",
        "Flatulence",
        "Metallic taste"
      ],
      "serious": [
        "Lactic Acidosis (Rare but fatal) - BOXED WARNING",
        "Vitamin B12 Deficiency (Long term use)",
        "Megaloblastic Anemia"
      ]
    },
    "precautions": [
      "**Lactic Acidosis:** Accumulation occurs in renal failure, hypoxia, or sepsis. Stop drug in these conditions.",
      "**Contrast Dye:** Hold metformin 48 hours after iodinated contrast procedures to prevent contrast-induced nephropathy/lactic acidosis.",
      "**Renal:** Contraindicated if eGFR < 30 mL/min."
    ],
    "contraindications": [
      "Severe renal impairment (eGFR < 30)",
      "Metabolic acidosis (DKA)",
      "Tissue hypoxia (Heart failure, Shock)"
    ],
    "interactions": {
      "drug": ["Iodinated Contrast Media (Lactic acidosis risk)", "Alcohol (Potentiates lactate)", "Cimetidine/Dolutegravir (Increase metformin levels)"],
      "food": ["Alcohol"]
    },
    "pregnancyCategory": "Category B"
  },
  "methadone": {
    "name": "Methadone (Dolophine)",
    "genericName": "Methadone HCl",
    "formula": "C21H27NO",
    "molecularWeight": "309.4 g/mol",
    "brandNames": ["Dolophine", "Methadose"],
    "category": "Opioid Analgesic / Detox Agent",
    "drugClass": "Synthetic Opioid Agonist",
    "pubchemCID": "4095",
    "indications": "Severe Chronic Pain, Opioid Use Disorder (Detoxification/Maintenance).",
    "moaSteps": [
      "Mu-opioid receptor agonist.",
      "NMDA receptor antagonist (contributes to efficacy in neuropathic pain and prevents tolerance).",
      "Inhibits serotonin and norepinephrine reuptake."
    ],
    "pharmacokinetics": {
      "absorption": "High bioavailability (80%).",
      "distribution": "Lipophilic; accumulates in tissues (reservoir effect).",
      "metabolism": "Hepatic via CYP3A4, 2B6, 2C19.",
      "excretion": "Urine. **Half-life: 8 to 59 hours (Highly variable - Average 24h).**"
    },
    "dose": {
      "initialDose": "2.5-10 mg PO every 8-12 hours (Pain)",
      "maxDose": "Variable (OUD programs)",
      "notes": "Accumulation risk is high due to long half-life."
    },
    "adverseEffects": {
      "common": [
        "Sedation",
        "Constipation",
        "Sweating",
        "Dizziness"
      ],
      "serious": [
        "Respiratory Depression (Fatal, Delayed) - BOXED WARNING",
        "QT Prolongation / Torsades de Pointes - BOXED WARNING",
        "Addiction / Misuse",
        "Serotonin Syndrome"
      ]
    },
    "precautions": [
      "**Accumulation:** Half-life (up to 59h) > Analgesic duration (4-8h). Doses can stack up and cause delayed respiratory arrest days after initiation.",
      "**QT Interval:** Dose-dependent prolongation. ECG recommended.",
      "**Interactions:** Many CYP interactions."
    ],
    "contraindications": [
      "Severe respiratory depression",
      "Acute bronchial asthma",
      "Paralytic ileus"
    ],
    "interactions": {
      "drug": ["QT prolonging drugs (Amiodarone)", "CYP Inducers/Inhibitors", "Benzodiazepines (Fatal)", "MAOIs"],
      "food": ["Grapefruit juice"]
    },
    "pregnancyCategory": "Category C"
  },
  "methotrexate": {
    "name": "Methotrexate (Trexall)",
    "genericName": "Methotrexate",
    "formula": "C20H22N8O5",
    "molecularWeight": "454.4 g/mol",
    "brandNames": ["Trexall", "Otrexup", "Rasuvo"],
    "category": "Antineoplastic / DMARD",
    "drugClass": "Antifolate",
    "pubchemCID": "126941",
    "indications": "Rheumatoid Arthritis, Psoriasis, Leukemias (ALL), Ectopic Pregnancy.",
    "moaSteps": [
      "Irreversibly binds to Dihydrofolate Reductase (DHFR).",
      "Inhibits conversion of dihydrofolate to tetrahydrofolate.",
      "Blocks synthesis of thymidylate, purines, and DNA.",
      "S-phase specific toxin.",
      "Anti-inflammatory via adenosine release."
    ],
    "pharmacokinetics": {
      "absorption": "Dose-dependent (saturable).",
      "distribution": "Slowly accumulates in tissues.",
      "metabolism": "Intracellular polyglutamation (traps drug in cell).",
      "excretion": "Renal. **Half-life: 3 to 10 hours (Low dose); 8-15 hours (High dose).**"
    },
    "dose": {
      "initialDose": "7.5 mg PO once WEEKLY (RA)",
      "maxDose": "20-30 mg/week (RA)",
      "notes": "Daily dosing is fatal in non-cancer use."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting",
        "Stomatitis",
        "Fatigue",
        "Alopecia"
      ],
      "serious": [
        "Hepatotoxicity / Fibrosis - BOXED WARNING",
        "Bone Marrow Suppression - BOXED WARNING",
        "Pneumonitis (Lung fibrosis) - BOXED WARNING",
        "Fetal Death / Teratogenicity - BOXED WARNING",
        "Renal Failure"
      ]
    },
    "precautions": [
      "**Dosing Error:** Fatalities occur when taken daily for RA. Confirm WEEKLY dosing.",
      "**Folic Acid:** Supplement (1mg daily) to reduce GI/Mucosal/Hematologic toxicity.",
      "**Pulmonary:** Dry, non-productive cough requires immediate cessation.",
      "**Pregnancy:** Abortifacient."
    ],
    "contraindications": [
      "Pregnancy / Nursing",
      "Alcoholism / Liver Disease",
      "Pre-existing blood dyscrasias",
      "Immunodeficiency"
    ],
    "interactions": {
      "drug": ["NSAIDs (Decrease renal clearance -> Toxicity)", "PPIs (Delayed elimination)", "Trimethoprim (Additive antifolate -> Marrow suppression)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category X"
  },
  "methylphenidate": {
    "name": "Methylphenidate (Ritalin, Concerta)",
    "genericName": "Methylphenidate HCl",
    "formula": "C14H19NO2",
    "molecularWeight": "233.3 g/mol",
    "brandNames": ["Ritalin", "Concerta", "Daytrana"],
    "category": "CNS Stimulant",
    "drugClass": "Phenethylamine",
    "pubchemCID": "4158",
    "indications": "ADHD, Narcolepsy.",
    "moaSteps": [
      "Blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron.",
      "Increases the release of these monoamines into the extraneuronal space.",
      "Stimulates the cerebral cortex and subcortical structures."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (IR). OROS (Concerta) is biphasic.",
      "distribution": "Crosses BBB.",
      "metabolism": "Rapid de-esterification (Non-CYP).",
      "excretion": "Urine. **Half-life: 3.5 hours.**"
    },
    "dose": {
      "initialDose": "5 mg PO BID (IR); 18 mg PO Daily (Concerta)",
      "maxDose": "60-72 mg/day",
      "notes": "Concerta shell may appear in stool."
    },
    "adverseEffects": {
      "common": [
        "Insomnia",
        "Decreased appetite / Weight loss",
        "Headache",
        "Anxiety"
      ],
      "serious": [
        "Sudden Cardiac Death (Structural heart defects)",
        "Psychosis / Mania",
        "Abuse / Dependence - BOXED WARNING",
        "Priapism",
        "Peripheral Vasculopathy (Raynaud's)"
      ]
    },
    "precautions": [
      "**Cardiac:** Screen for structural heart abnormalities before starting.",
      "**Growth:** Monitor height/weight in children.",
      "**Psych:** Can exacerbate bipolar or psychosis.",
      "**Priapism:** Painful erection >4h is emergency."
    ],
    "contraindications": [
      "Marked anxiety/agitation",
      "Glaucoma",
      "Motor tics / Tourette's",
      "MAOI use within 14 days"
    ],
    "interactions": {
      "drug": ["MAOIs (Hypertensive crisis)", "Antihypertensives (Reduced efficacy)", "Anticonvulsants (Inhibits metabolism)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "methylprednisolone": {
    "name": "Methylprednisolone (Medrol)",
    "genericName": "Methylprednisolone",
    "formula": "C22H30O5",
    "molecularWeight": "374.5 g/mol",
    "brandNames": ["Medrol", "Solu-Medrol", "Depo-Medrol"],
    "category": "Corticosteroid",
    "drugClass": "Glucocorticoid (Intermediate-acting)",
    "pubchemCID": "4166",
    "indications": "Severe Inflammation, Acute Spinal Cord Injury, Multiple Sclerosis flare, COPD exacerbation.",
    "moaSteps": [
      "Potent anti-inflammatory glucocorticoid (5x potency of hydrocortisone).",
      "Minimal mineralocorticoid activity (less salt retention).",
      "Modulates gene expression to suppress immune response."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Widely distributed.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Urine. **Half-life: 18 to 36 hours (Biologic effect).**"
    },
    "dose": {
      "initialDose": "4-48 mg PO daily (Medrol Dosepak tapers)",
      "maxDose": "1000 mg IV (Pulse dose)",
      "notes": "Take with food."
    },
    "adverseEffects": {
      "common": [
        "Hyperglycemia",
        "Insomnia / Agitation",
        "Fluid retention",
        "Increased appetite"
      ],
      "serious": [
        "Adrenal Suppression",
        "Peptic Ulcer",
        "Psychosis",
        "Infection masking",
        "Osteoporosis"
      ]
    },
    "precautions": [
      "**HPA Axis:** Suppression occurs with use > 2 weeks. Taper slowly.",
      "**Diabetes:** Significant hyperglycemia.",
      "**Vaccines:** Avoid live vaccines."
    ],
    "contraindications": [
      "Systemic fungal infections",
      "Intrathecal administration (Depo-Medrol)"
    ],
    "interactions": {
      "drug": ["NSAIDs (GI Bleed)", "Warfarin", "CYP3A4 Inducers (Phenytoin - Decrease steroid levels)"],
      "food": ["Grapefruit juice (Increases levels)"]
    },
    "pregnancyCategory": "Category C"
  },
  "metoclopramide": {
    "name": "Metoclopramide (Reglan)",
    "genericName": "Metoclopramide HCl",
    "formula": "C14H22ClN3O2",
    "molecularWeight": "299.8 g/mol",
    "brandNames": ["Reglan", "Gimoti"],
    "category": "Antiemetic / Prokinetic",
    "drugClass": "Dopamine D2 Antagonist",
    "pubchemCID": "4168",
    "indications": "Diabetic Gastroparesis, GERD (refractory), Chemotherapy-induced nausea.",
    "moaSteps": [
      "Blocks dopamine D2 receptors in the Chemoreceptor Trigger Zone (CTZ) - Antiemetic.",
      "Increases sensitivity to acetylcholine in the GI tract.",
      "Increases lower esophageal sphincter tone and gastric emptying - Prokinetic."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Crosses BBB.",
      "metabolism": "Hepatic (CYP2D6).",
      "excretion": "Urine. **Half-life: 5 to 6 hours.**"
    },
    "dose": {
      "initialDose": "5-10 mg PO/IV QID (30 min before meals)",
      "maxDose": "40 mg/day",
      "notes": "Limit use to < 12 weeks."
    },
    "adverseEffects": {
      "common": [
        "Drowsiness",
        "Restlessness (Akathisia)",
        "Diarrhea",
        "Fatigue"
      ],
      "serious": [
        "Tardive Dyskinesia (Permanent) - BOXED WARNING",
        "Neuroleptic Malignant Syndrome",
        "Depression / Suicide",
        "Hyperprolactinemia"
      ]
    },
    "precautions": [
      "**Tardive Dyskinesia:** Risk increases with duration > 12 weeks and in elderly. Avoid chronic use.",
      "**EPS:** Acute dystonia treatable with diphenhydramine.",
      "**Depression:** May worsen mental status."
    ],
    "contraindications": [
      "GI Obstruction / Perforation / Hemorrhage",
      "Pheochromocytoma",
      "Seizure disorder"
    ],
    "interactions": {
      "drug": ["Antipsychotics (Additive EPS risk)", "Anticholinergics (Antagonize prokinetic effect)", "Levodopa (Antagonized by Reglan)"],
      "food": ["Alcohol (Sedation)"]
    },
    "pregnancyCategory": "Category B"
  },
  "metoprolol": {
    "name": "Metoprolol (Lopressor, Toprol XL)",
    "genericName": "Metoprolol Tartrate / Succinate",
    "formula": "C15H25NO3",
    "molecularWeight": "267.4 g/mol",
    "brandNames": ["Lopressor (Tartrate)", "Toprol XL (Succinate)"],
    "category": "Antihypertensive",
    "drugClass": "Beta-Blocker (Beta-1 Selective)",
    "pubchemCID": "4171",
    "indications": "Hypertension, Angina, Heart Failure (Succinate only), MI.",
    "moaSteps": [
      "Selectively blocks beta-1 adrenergic receptors in the heart.",
      "Decreases heart rate and cardiac contractility.",
      "Reduces myocardial oxygen demand.",
      "At high doses, loses selectivity and blocks beta-2 (bronchial) receptors."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Lipophilic (Crosses BBB).",
      "metabolism": "Extensive hepatic (CYP2D6).",
      "excretion": "Urine. **Half-life: 3 to 7 hours.**"
    },
    "dose": {
      "initialDose": "25-50 mg daily",
      "maxDose": "400 mg/day",
      "notes": "Succinate is once daily; Tartrate is BID. Only Succinate approved for HF."
    },
    "adverseEffects": {
      "common": [
        "Bradycardia",
        "Fatigue / Dizziness",
        "Depression",
        "Sexual dysfunction"
      ],
      "serious": [
        "Heart Block",
        "Bronchospasm",
        "Heart Failure worsening (initial)",
        "Masking Hypoglycemia"
      ]
    },
    "precautions": [
      "**Abrupt Cessation:** BOXED WARNING. Taper over 1-2 weeks to avoid angina/MI.",
      "**Diabetes:** Masks tachycardia of hypoglycemia.",
      "**Asthma:** Use caution (beta-1 selectivity is not absolute)."
    ],
    "contraindications": [
      "Sinus bradycardia",
      "Heart block > 1st degree",
      "Cardiogenic shock",
      "Decompensated HF"
    ],
    "interactions": {
      "drug": ["CYP2D6 Inhibitors (Fluoxetine/Paroxetine - Increase levels)", "Digoxin (Bradycardia)", "Calcium Channel Blockers"],
      "food": ["Food increases bioavailability."]
    },
    "pregnancyCategory": "Category C"
  },
  "metronidazole": {
    "name": "Metronidazole (Flagyl)",
    "genericName": "Metronidazole",
    "formula": "C6H9N3O3",
    "molecularWeight": "171.15 g/mol",
    "brandNames": ["Flagyl", "MetroGel"],
    "category": "Antibiotic / Antiprotozoal",
    "drugClass": "Nitroimidazole",
    "pubchemCID": "4173",
    "indications": "Anaerobic infections (Bacteroides, C. diff), Trichomoniasis, Giardiasis, Amebiasis, Bacterial Vaginosis.",
    "moaSteps": [
      "Diffuses into the organism.",
      "Nitro group is reduced by ferredoxin (only in anaerobes/protozoa) to reactive radicals.",
      "Radicals damage DNA and inhibit nucleic acid synthesis.",
      "Bactericidal."
    ],
    "pharmacokinetics": {
      "absorption": "Excellent (100% bioavailable).",
      "distribution": "Good CNS/Abscess penetration.",
      "metabolism": "Hepatic.",
      "excretion": "Urine. **Half-life: 8 hours.**"
    },
    "dose": {
      "initialDose": "500 mg PO/IV every 8 hours",
      "maxDose": "4 g/day",
      "notes": "Metallic taste common."
    },
    "adverseEffects": {
      "common": [
        "Metallic taste",
        "Nausea",
        "Headache",
        "Dark urine"
      ],
      "serious": [
        "Neurotoxicity (Seizures, Encephalopathy, Peripheral Neuropathy) - with chronic use",
        "Disulfiram-like reaction (with alcohol)",
        "SJS/TEN",
        "Carcinogenicity (Animal data) - BOXED WARNING"
      ]
    },
    "precautions": [
      "**Alcohol:** Severe vomiting/flushing if alcohol consumed during and 3 days after therapy.",
      "**Neuropathy:** Stop if numbness/tingling occurs.",
      "**Pregnancy:** Avoid in 1st trimester."
    ],
    "contraindications": [
      "First trimester of pregnancy (for Trichomoniasis)",
      "Use of alcohol or Disulfiram within 2 weeks"
    ],
    "interactions": {
      "drug": ["Warfarin (Significantly increases INR)", "Alcohol (Disulfiram reaction)", "Lithium (Toxicity)"],
      "food": ["Alcohol (Strictly Avoid)"]
    },
    "pregnancyCategory": "Category B"
  },
  "midazolam": {
    "name": "Midazolam (Versed)",
    "genericName": "Midazolam",
    "formula": "C18H13ClFN3",
    "molecularWeight": "325.8 g/mol",
    "brandNames": ["Versed", "Nayzilam"],
    "category": "Sedative / Anesthetic",
    "drugClass": "Benzodiazepine (Short-acting)",
    "pubchemCID": "4192",
    "indications": "Preoperative sedation/anxiolysis, Anesthesia induction, Status Epilepticus.",
    "moaSteps": [
      "Binds to benzodiazepine receptors on GABA-A complex.",
      "Increases chloride channel opening frequency.",
      "Potent anxiolytic, amnestic, sedative, anticonvulsant, and muscle relaxant properties."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (IV/IM/Intranasal).",
      "distribution": "Highly lipophilic.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Urine. **Half-life: 1.5 to 2.5 hours.**"
    },
    "dose": {
      "initialDose": "1-2.5 mg IV (Sedation)",
      "maxDose": "Titrate to effect",
      "notes": "Reduce dose in elderly."
    },
    "adverseEffects": {
      "common": [
        "Hiccups",
        "Nausea",
        "Sedation",
        "Amnesia (Anterograde)"
      ],
      "serious": [
        "Respiratory Depression / Apnea - BOXED WARNING",
        "Cardiac Arrest",
        "Paradoxical Agitation"
      ]
    },
    "precautions": [
      "**Respiratory Depression:** Continuous monitoring of respiratory/cardiac function required. Have Flumazenil and airway equipment ready.",
      "**Amnesia:** Potent anterograde amnesia (cannot form new memories).",
      "**Elderly:** High risk of apnea/delirium."
    ],
    "contraindications": [
      "Acute narrow-angle glaucoma",
      "Shock / Coma",
      "Intrathecal/Epidural use (Preservative formulation)"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inhibitors (Prolonged sedation)", "Opioids (Synergistic respiratory depression)", "Alcohol"],
      "food": ["Grapefruit juice"]
    },
    "pregnancyCategory": "Category D"
  },
  "mifepristone": {
    "name": "Mifepristone (Mifeprex, Korlym)",
    "genericName": "Mifepristone",
    "formula": "C29H35NO2",
    "molecularWeight": "429.6 g/mol",
    "brandNames": ["Mifeprex", "Korlym"],
    "category": "Endocrine-Metabolic Agent",
    "drugClass": "Progesterone Antagonist / Cortisol Antagonist",
    "pubchemCID": "55245",
    "indications": "Medical termination of pregnancy (Mifeprex), Hyperglycemia in Cushing's Syndrome (Korlym).",
    "moaSteps": [
      "Competitive antagonist at progesterone receptors (Pregnancy termination).",
      "Decidual necrosis and detachment of products of conception.",
      "Sensitizes myometrium to prostaglandins.",
      "At high doses, blocks glucocorticoid (cortisol) receptors (Cushing's)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "98% protein bound.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Feces. **Half-life: 18 hours (Mifeprex); 85 hours (Korlym due to accumulation).**"
    },
    "dose": {
      "initialDose": "200 mg PO single dose (Termination)",
      "maxDose": "300 mg daily (Cushing's)",
      "notes": "Termination requires follow-up Misoprostol."
    },
    "adverseEffects": {
      "common": [
        "Nausea",
        "Weakness",
        "Abdominal pain / Cramping",
        "Vaginal bleeding"
      ],
      "serious": [
        "Serious Bacterial Infection (Clostridium sordellii sepsis) - BOXED WARNING (Rare)",
        "Heavy Bleeding",
        "Hypokalemia (Cushing's use)",
        "Adrenal Insufficiency"
      ]
    },
    "precautions": [
      "**Infection:** Be alert for atypical presentation of sepsis (no fever, just weakness/nausea).",
      "**Bleeding:** Heavy bleeding requiring surgery occurs in 1%.",
      "**Cushing's:** Monitor for adrenal insufficiency and hypokalemia."
    ],
    "contraindications": [
      "Pregnancy (for Korlym)",
      "Chronic adrenal failure",
      "Ectopic pregnancy",
      "IUD in place",
      "Anticoagulant therapy"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inhibitors/Inducers", "Simvastatin/Lovastatin (Mifepristone increases levels - limit dose)"],
      "food": ["Grapefruit juice"]
    },
    "pregnancyCategory": "Category X (Korlym) / Indicated (Mifeprex)"
  },
  "minocycline": {
    "name": "Minocycline (Minocin)",
    "genericName": "Minocycline",
    "formula": "C23H27N3O7",
    "molecularWeight": "457.5 g/mol",
    "brandNames": ["Minocin", "Solodyn"],
    "category": "Antibiotic",
    "drugClass": "Tetracycline",
    "pubchemCID": "54675850",
    "indications": "Acne Vulgaris, MRSA skin infections, Lyme Disease.",
    "moaSteps": [
      "Inhibits bacterial protein synthesis by binding to 30S ribosome.",
      "Bacteriostatic.",
      "More lipophilic than other tetracyclines (better tissue/CNS penetration)."
    ],
    "pharmacokinetics": {
      "absorption": "90-100% bioavailable.",
      "distribution": "High lipid solubility (CNS, skin).",
      "metabolism": "Hepatic.",
      "excretion": "Urine/Feces. **Half-life: 11 to 26 hours.**"
    },
    "dose": {
      "initialDose": "50-100 mg PO twice daily",
      "maxDose": "200 mg/day",
      "notes": "Solodyn is weight-based extended release."
    },
    "adverseEffects": {
      "common": [
        "Dizziness / Vertigo (Vestibular)",
        "Nausea",
        "Photosensitivity"
      ],
      "serious": [
        "Drug-Induced Lupus",
        "Autoimmune Hepatitis",
        "Skin/Tissue Hyperpigmentation (Blue-gray)",
        "Pseudotumor Cerebri",
        "Tooth discoloration (Children)"
      ]
    },
    "precautions": [
      "**Vestibular:** Dizziness/Vertigo common due to CNS penetration. Caution driving.",
      "**Autoimmune:** Lupus-like syndrome and hepatitis associated with long-term acne use.",
      "**Pigmentation:** Permanent blue-gray skin/gum discoloration.",
      "**Cations:** Separate from antacids/iron."
    ],
    "contraindications": [
      "Pregnancy / Children < 8 years",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Isotretinoin (Pseudotumor cerebri - Contraindicated)", "Warfarin", "Oral Contraceptives (Controversial)"],
      "food": ["Dairy reduces absorption (less than tetracycline)."]
    },
    "pregnancyCategory": "Category D"
  },
  "mirtazapine": {
    "name": "Mirtazapine (Remeron)",
    "genericName": "Mirtazapine",
    "formula": "C17H19N3",
    "molecularWeight": "265.4 g/mol",
    "brandNames": ["Remeron"],
    "category": "Antidepressant",
    "drugClass": "Tetracyclic Antidepressant (NaSSA)",
    "pubchemCID": "4205",
    "indications": "Major Depressive Disorder (MDD), Insomnia (Off-label), Appetite stimulation (Off-label).",
    "moaSteps": [
      "Antagonizes central presynaptic alpha-2 adrenergic receptors.",
      "Increases release of norepinephrine and serotonin.",
      "Antagonizes 5-HT2 and 5-HT3 receptors (reduces anxiety/nausea).",
      "Potent H1 antagonist (Sedation)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "85% protein bound.",
      "metabolism": "Hepatic (CYP2D6/3A4/1A2).",
      "excretion": "Urine. **Half-life: 20 to 40 hours.**"
    },
    "dose": {
      "initialDose": "15 mg PO at bedtime",
      "maxDose": "45 mg/day",
      "notes": "Lower doses (7.5-15mg) are MORE sedating than higher doses."
    },
    "adverseEffects": {
      "common": [
        "Sedation / Somnolence",
        "Increased Appetite / Weight Gain",
        "Dry mouth",
        "Constipation"
      ],
      "serious": [
        "Suicidality (Young adults) - BOXED WARNING",
        "Agranulocytosis (Rare)",
        "Serotonin Syndrome"
      ]
    },
    "precautions": [
      "**Paradoxical Sedation:** Higher doses increase norepinephrine release, counteracting the antihistamine sedation. 15mg is best for sleep.",
      "**Weight Gain:** Significant metabolic effects; useful in underweight elderly.",
      "**Neutropenia:** Monitor for signs of infection."
    ],
    "contraindications": [
      "MAOI use within 14 days"
    ],
    "interactions": {
      "drug": ["MAOIs (Fatal)", "CNS Depressants (Additive sedation)", "Clonidine (Hypertensive crisis risk)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "misoprostol": {
    "name": "Misoprostol (Cytotec)",
    "genericName": "Misoprostol",
    "formula": "C22H38O5",
    "molecularWeight": "382.5 g/mol",
    "brandNames": ["Cytotec"],
    "category": "Prostaglandin",
    "drugClass": "Synthetic Prostaglandin E1 Analog",
    "pubchemCID": "5282381",
    "indications": "NSAID-induced Ulcer Prophylaxis, Termination of Pregnancy (with Mifepristone), Postpartum Hemorrhage, Cervical Ripening.",
    "moaSteps": [
      "Replaces protective prostaglandins inhibited by NSAIDs.",
      "Inhibits gastric acid secretion and increases bicarbonate/mucus production.",
      "Induces uterine contractions and cervical ripening (Labor induction/Abortion)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Rapid de-esterification to active acid.",
      "metabolism": "Hepatic.",
      "excretion": "Urine. **Half-life: 20 to 40 minutes.**"
    },
    "dose": {
      "initialDose": "200 mcg PO QID (Ulcer prophylaxis)",
      "maxDose": "800 mcg/day",
      "notes": "Diarrhea often limits compliance."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea (Dose-dependent)",
        "Abdominal cramping",
        "Nausea",
        "Uterine bleeding/cramps"
      ],
      "serious": [
        "Uterine Rupture (if used for labor induction in prior C-section)",
        "Abortion (in pregnancy) - BOXED WARNING"
      ]
    },
    "precautions": [
      "**Pregnancy:** CONTRAINDICATED for ulcer use in pregnancy (abortifacient). Women of childbearing age must have negative pregnancy test and use contraception.",
      "**Diarrhea:** Usually resolves; take with food.",
      "**Rupture:** Caution in labor induction with prior uterine surgery."
    ],
    "contraindications": [
      "Pregnancy (for ulcer indication)",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Antacids (Magnesium-containing antacids worsen diarrhea)"],
      "food": ["Food decreases peak levels (less diarrhea) but not extent of absorption."]
    },
    "pregnancyCategory": "Category X"
  },
  "modafinil": {
    "name": "Modafinil (Provigil)",
    "genericName": "Modafinil",
    "formula": "C15H15NO2S",
    "molecularWeight": "273.35 g/mol",
    "brandNames": ["Provigil"],
    "category": "Wakefulness Promoting Agent",
    "drugClass": "Eugeroic",
    "pubchemCID": "4236",
    "indications": "Narcolepsy, Obstructive Sleep Apnea (adjunct), Shift Work Disorder.",
    "moaSteps": [
      "Exact mechanism unclear.",
      "Inhibits dopamine reuptake via dopamine transporter (DAT).",
      "Increases histamine levels in hypothalamus.",
      "Activates glutamatergic circuits; inhibits GABA.",
      "Less abuse potential than amphetamines."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "60% protein bound.",
      "metabolism": "Hepatic (CYP3A4/2B6 interactions).",
      "excretion": "Urine. **Half-life: 15 hours.**"
    },
    "dose": {
      "initialDose": "200 mg PO once daily",
      "maxDose": "400 mg/day",
      "notes": "Take in morning."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Nausea",
        "Nervousness / Anxiety",
        "Insomnia"
      ],
      "serious": [
        "Severe Rash (SJS/TEN) - Rare",
        "Psychiatric symptoms (Mania/Hallucinations)",
        "Angioedema",
        "Cardiovascular events"
      ]
    },
    "precautions": [
      "**Rash:** Serious rash reported. Discontinue at first sign.",
      "**Contraceptives:** Induces CYP3A4, reducing efficacy of hormonal birth control (failure risk).",
      "**Psychiatric:** Caution in history of psychosis/mania."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Hormonal Contraceptives (Failure)", "Cyclosporine (Reduced levels)", "Warfarin"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "montelukast": {
    "name": "Montelukast (Singulair)",
    "genericName": "Montelukast Sodium",
    "formula": "C35H36ClNO3S",
    "molecularWeight": "586.2 g/mol",
    "brandNames": ["Singulair"],
    "category": "Asthma / Allergy Agent",
    "drugClass": "Leukotriene Receptor Antagonist (LTRA)",
    "pubchemCID": "5281040",
    "indications": "Asthma maintenance, Seasonal Allergic Rhinitis, Exercise-Induced Bronchoconstriction.",
    "moaSteps": [
      "Selectively binds to CysLT1 receptor.",
      "Inhibits physiological actions of leukotriene D4 (LTD4).",
      "Blocks airway edema, smooth muscle contraction, and inflammation.",
      "Less effective than inhaled steroids."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "99% protein bound.",
      "metabolism": "Extensive hepatic (CYP2C8/2C9).",
      "excretion": "Bile/Feces. **Half-life: 2.7 to 5.5 hours.**"
    },
    "dose": {
      "initialDose": "10 mg PO once daily (Adults)",
      "maxDose": "10 mg/day",
      "notes": "Take in evening."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Upper respiratory infection",
        "Abdominal pain"
      ],
      "serious": [
        "Neuropsychiatric Events (Suicide, Depression, Nightmares) - BOXED WARNING",
        "Churg-Strauss Syndrome (Eosinophilic Granulomatosis)",
        "Hypersensitivity"
      ]
    },
    "precautions": [
      "**Neuropsychiatric:** Boxed warning for aggression, agitation, vivid dreams, depression, and suicide. Monitor behavior changes.",
      "**Acute Asthma:** Not for rescue use.",
      "**Granulomatosis:** Rare systemic eosinophilia."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Phenobarbital/Rifampin (Decrease levels)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "morphine": {
    "name": "Morphine (MS Contin)",
    "genericName": "Morphine Sulfate",
    "formula": "C17H19NO3",
    "molecularWeight": "285.3 g/mol",
    "brandNames": ["MS Contin", "Kadian", "Roxanol"],
    "category": "Opioid Analgesic",
    "drugClass": "Opioid Agonist",
    "pubchemCID": "5288826",
    "indications": "Moderate to Severe Pain, Dyspnea in terminal illness, Pulmonary Edema (vasodilation).",
    "moaSteps": [
      "Binds to mu-opioid receptors in the CNS.",
      "Inhibits ascending pain pathways.",
      "Produces analgesia, respiratory depression, and sedation.",
      "Causes histamine release (vasodilation/itching)."
    ],
    "pharmacokinetics": {
      "absorption": "Variable oral absorption (significant first-pass).",
      "distribution": "Widely distributed.",
      "metabolism": "Hepatic Glucuronidation to M3G (neurotoxic) and M6G (active analgesic).",
      "excretion": "Urine. **Half-life: 2 to 4 hours (Accumulates in renal failure).**"
    },
    "dose": {
      "initialDose": "2-4 mg IV q4h or 15 mg PO q4h",
      "maxDose": "Titrate to effect",
      "notes": "Renal accumulation of active metabolites."
    },
    "adverseEffects": {
      "common": [
        "Constipation",
        "Nausea / Vomiting",
        "Pruritus (Histamine)",
        "Sedation"
      ],
      "serious": [
        "Respiratory Depression - BOXED WARNING",
        "Addiction / Misuse - BOXED WARNING",
        "Hypotension",
        "Seizures (M3G accumulation)"
      ]
    },
    "precautions": [
      "**Renal Failure:** Active metabolites M6G (potent analgesic) and M3G (neuroexcitatory/seizures) accumulate. Avoid or reduce dose.",
      "**Hypotension:** Histamine release causes vasodilation; caution in shock.",
      "**Asthma:** Histamine can worsen bronchospasm."
    ],
    "contraindications": [
      "Severe respiratory depression",
      "Paralytic ileus",
      "Severe asthma"
    ],
    "interactions": {
      "drug": ["Benzodiazepines (Fatal)", "Alcohol", "MAOIs", "P2Y12 inhibitors (Morphine delays antiplatelet absorption)"],
      "food": ["Alcohol (Dose dumping)"]
    },
    "pregnancyCategory": "Category C"
  },
  "moxifloxacin": {
    "name": "Moxifloxacin (Avelox)",
    "genericName": "Moxifloxacin",
    "formula": "C21H24FN3O4",
    "molecularWeight": "401.4 g/mol",
    "brandNames": ["Avelox", "Vigamox (Eye)"],
    "category": "Antibiotic",
    "drugClass": "Fluoroquinolone (Respiratory)",
    "pubchemCID": "152946",
    "indications": "Community-Acquired Pneumonia, Sinusitis, Intra-abdominal infections, Skin infections.",
    "moaSteps": [
      "Inhibits bacterial DNA gyrase and Topoisomerase IV.",
      "Inhibits DNA replication/transcription.",
      "Bactericidal.",
      "Enhanced Gram-positive and Anaerobic activity compared to Ciprofloxacin."
    ],
    "pharmacokinetics": {
      "absorption": "Good oral bioavailability.",
      "distribution": "Good tissue penetration.",
      "metabolism": "Hepatic (Glucuronidation/Sulfation).",
      "excretion": "Feces and Urine. **Half-life: 12 hours.**"
    },
    "dose": {
      "initialDose": "400 mg PO/IV once daily",
      "maxDose": "400 mg/day",
      "notes": "No renal adjustment needed (unique among quinolones)."
    },
    "adverseEffects": {
      "common": [
        "Nausea",
        "Diarrhea",
        "Dizziness"
      ],
      "serious": [
        "Tendinitis / Rupture - BOXED WARNING",
        "QT Prolongation (Highest risk among quinolones)",
        "CNS Toxicity (Seizures/Psychosis)",
        "Aortic Aneurysm Rupture"
      ]
    },
    "precautions": [
      "**QT Prolongation:** Highest risk in class. Avoid in known QT issues/hypokalemia.",
      "**UTI:** Do NOT use for UTIs (low urinary concentration due to hepatic elimination).",
      "**No Renal Adjust:** Good for patients with renal failure."
    ],
    "contraindications": [
      "Hypersensitivity to fluoroquinolones"
    ],
    "interactions": {
      "drug": ["Warfarin (Increased INR)", "Cations (Antacids/Iron - Block absorption)", "Class Ia/III Antiarrhythmics (Contraindicated)"],
      "food": ["Dairy/Calcium (Decrease absorption)"]
    },
    "pregnancyCategory": "Category C"
  },
  "mupirocin": {
    "name": "Mupirocin (Bactroban)",
    "genericName": "Mupirocin",
    "formula": "C26H44O9",
    "molecularWeight": "500.6 g/mol",
    "brandNames": ["Bactroban"],
    "category": "Antibiotic (Topical)",
    "drugClass": "RNA Synthetase Inhibitor",
    "pubchemCID": "446596",
    "indications": "Impetigo (Staph/Strep), MRSA decolonization (Nasal), Secondary skin infections.",
    "moaSteps": [
      "Reversibly binds to bacterial isoleucyl-tRNA synthetase.",
      "Inhibits bacterial protein synthesis.",
      "Bacteriostatic at low concentrations; Bactericidal at high concentrations.",
      "Active against S. aureus (including MRSA) and Strep pyogenes."
    ],
    "pharmacokinetics": {
      "absorption": "Minimal systemic absorption through intact skin.",
      "distribution": "Local.",
      "metabolism": "Rapidly metabolized if absorbed.",
      "excretion": "Urine. **Half-life: 20 to 40 minutes (Systemic).**"
    },
    "dose": {
      "initialDose": "Apply TID for 3-10 days",
      "maxDose": "N/A",
      "notes": "Nasal ointment is specific formulation."
    },
    "adverseEffects": {
      "common": [
        "Burning / Stinging",
        "Pruritus",
        "Rash"
      ],
      "serious": [
        "Severe Allergic Reaction",
        "C. diff colitis (rare, extensive use)"
      ]
    },
    "precautions": [
      "**Open Wounds:** PEG vehicle in ointment can be absorbed from large burns/wounds causing renal toxicity.",
      "**Eyes:** Avoid contact with eyes.",
      "**Resistance:** Long-term use leads to resistance."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["None significant"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "mycophenolate": {
    "name": "Mycophenolate (CellCept)",
    "genericName": "Mycophenolate Mofetil",
    "formula": "C23H31NO7",
    "molecularWeight": "433.5 g/mol",
    "brandNames": ["CellCept", "Myfortic"],
    "category": "Immunosuppressant",
    "drugClass": "IMPDH Inhibitor",
    "pubchemCID": "5281078",
    "indications": "Prophylaxis of organ rejection (Kidney, Heart, Liver), Lupus Nephritis.",
    "moaSteps": [
      "Prodrug hydrolyzed to Mycophenolic Acid (MPA).",
      "Inhibits Inosine Monophosphate Dehydrogenase (IMPDH).",
      "Inhibits de novo guanosine nucleotide synthesis.",
      "T and B lymphocytes rely on this pathway (selective cytostatic effect)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid. Myfortic is enteric coated.",
      "distribution": "97% protein bound.",
      "metabolism": "Hepatic glucuronidation. Enterohepatic recirculation.",
      "excretion": "Urine. **Half-life: 18 hours.**"
    },
    "dose": {
      "initialDose": "1000 mg PO twice daily (CellCept)",
      "maxDose": "2-3 g/day",
      "notes": "Myfortic dose is different (720mg BID)."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea (Dose limiting)",
        "Nausea",
        "Leukopenia",
        "Anemia"
      ],
      "serious": [
        "Embryofetal Toxicity (Miscarriage/Defects) - BOXED WARNING",
        "Serious Infections (CMV/PML/Opportunistic) - BOXED WARNING",
        "Malignancy (Lymphoma) - BOXED WARNING",
        "GI Bleeding"
      ]
    },
    "precautions": [
      "**Pregnancy:** REMS program. High risk of first trimester loss and congenital malformations.",
      "**GI:** Diarrhea/Vomiting common. Dose reduction or switching to enteric-coated (Myfortic) may help.",
      "**Infection:** Monitor CBC."
    ],
    "contraindications": [
      "Pregnancy (unless no alternative)",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Antacids/Magnesium (Decrease absorption)", "Cholestyramine (Decreases levels)", "Acyclovir/Ganciclovir (Competition for renal excretion)", "Oral Contraceptives (Reduced efficacy)"],
      "food": ["Food decreases Cmax but not extent."]
    },
    "pregnancyCategory": "Category D"
  },
  "naloxone": {
    "name": "Naloxone (Narcan)",
    "genericName": "Naloxone HCl",
    "formula": "C19H21NO4",
    "molecularWeight": "327.4 g/mol",
    "brandNames": ["Narcan", "Kloxxado", "Evzio"],
    "category": "Antidote",
    "drugClass": "Opioid Antagonist",
    "pubchemCID": "5284596",
    "indications": "Opioid Overdose (Respiratory Depression), Opioid reversal.",
    "moaSteps": [
      "Competitive antagonist at mu, kappa, and delta opioid receptors.",
      "High affinity for the mu receptor.",
      "Displaces opioids from receptors, reversing sedation and respiratory depression.",
      "No agonist activity."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (IV/IM/Intranasal). Poor oral bioavailability (high first pass).",
      "distribution": "Rapid CNS entry.",
      "metabolism": "Hepatic Glucuronidation.",
      "excretion": "Urine. **Half-life: 30 to 81 minutes (Shorter than most opioids).**"
    },
    "dose": {
      "initialDose": "0.4-2 mg IV/IM/SC or 4 mg Intranasal",
      "maxDose": "Repeat q2-3 min",
      "notes": "May need infusion for long-acting opioids."
    },
    "adverseEffects": {
      "common": [
        "Acute Opioid Withdrawal (Pain, Agitation, Goosebumps, Vomiting)"
      ],
      "serious": [
        "Pulmonary Edema (rare, flash)",
        "Cardiac Arrhythmias / Arrest (due to catecholamine surge from pain/withdrawal)",
        "Seizures"
      ]
    },
    "precautions": [
      "**Renarcotization:** Half-life is short (30-80 min). Patients may lapse back into coma after naloxone wears off (especially with Methadone/Fentanyl patch). Observation required.",
      "**Combative:** Patients may wake up agitated/violent.",
      "**Precipitated Withdrawal:** Can be life-threatening in neonates."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Opioids (Reversal of analgesia)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },"naltrexone": {
    "name": "Naltrexone (ReVia, Vivitrol)",
    "genericName": "Naltrexone HCl",
    "formula": "C20H23NO4",
    "molecularWeight": "341.4 g/mol",
    "brandNames": ["ReVia", "Vivitrol"],
    "category": "Antidote / Alcohol Deterrent",
    "drugClass": "Opioid Antagonist",
    "pubchemCID": "5360515",
    "indications": "Alcohol Use Disorder, Opioid Use Disorder (prevention of relapse).",
    "moaSteps": [
      "Pure opioid antagonist with highest affinity for the mu-opioid receptor.",
      "Displaces opioids and blocks their effects.",
      "Reduces the reinforcing effects (craving/euphoria) of alcohol via endogenous opioid blockade.",
      "Does not cause physical dependence."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (96% absorbed) but high first-pass.",
      "distribution": "21% protein bound.",
      "metabolism": "Hepatic to active metabolite 6-beta-naltrexol.",
      "excretion": "Urine. **Half-life: 4 hours (Parent); 13 hours (Active Metabolite).**"
    },
    "dose": {
      "initialDose": "50 mg PO daily",
      "maxDose": "380 mg IM every 4 weeks (Vivitrol)",
      "notes": "Must be opioid-free for 7-10 days before starting."
    },
    "adverseEffects": {
      "common": [
        "Nausea",
        "Headache",
        "Fatigue",
        "Insomnia"
      ],
      "serious": [
        "Hepatotoxicity (High doses) - BOXED WARNING (Historical)",
        "Severe Injection Site Reactions (Vivitrol)",
        "Precipitated Opioid Withdrawal",
        "Depression / Suicidality"
      ]
    },
    "precautions": [
      "**Withdrawal:** Will precipitate severe withdrawal if patient is physically dependent on opioids. Naloxone challenge test recommended.",
      "**Liver:** Monitor LFTs.",
      "**Pain Management:** Patients will be insensitive to opioids in emergencies; requires regional anesthesia or high-dose override (dangerous)."
    ],
    "contraindications": [
      "Current opioid use or dependence",
      "Acute opioid withdrawal",
      "Acute hepatitis or liver failure"
    ],
    "interactions": {
      "drug": ["Opioids (Antagonism)", "Thioridazine (Lethargy)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "naproxen": {
    "name": "Naproxen (Aleve, Naprosyn)",
    "genericName": "Naproxen",
    "formula": "C14H14O3",
    "molecularWeight": "230.26 g/mol",
    "brandNames": ["Aleve", "Naprosyn", "Anaprox"],
    "category": "NSAID",
    "drugClass": "Propionic Acid Derivative",
    "pubchemCID": "156391",
    "indications": "Pain, Inflammation (RA/OA), Dysmenorrhea, Acute Gout.",
    "moaSteps": [
      "Reversibly inhibits COX-1 and COX-2 enzymes.",
      "Inhibits prostaglandin synthesis.",
      "Longer half-life than ibuprofen allowing BID dosing.",
      "Generally considered to have the lowest cardiovascular risk among NSAIDs."
    ],
    "pharmacokinetics": {
      "absorption": "Complete.",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic (CYP2C9/1A2).",
      "excretion": "Urine. **Half-life: 12 to 17 hours.**"
    },
    "dose": {
      "initialDose": "250-500 mg PO twice daily",
      "maxDose": "1000-1500 mg/day (short term)",
      "notes": "Take with food."
    },
    "adverseEffects": {
      "common": [
        "Dyspepsia / Heartburn",
        "Abdominal pain",
        "Dizziness",
        "Tinnitus"
      ],
      "serious": [
        "GI Bleeding / Perforation - BOXED WARNING",
        "CV Thrombotic Events - BOXED WARNING",
        "Renal Failure / Nephritis",
        "Stevens-Johnson Syndrome"
      ]
    },
    "precautions": [
      "**GI:** Risk of ulceration. Gastroprotection (PPI) needed for chronic use.",
      "**Cardiovascular:** Safest NSAID for CV risk, but risk still exists.",
      "**Renal:** Avoid in advanced kidney disease."
    ],
    "contraindications": [
      "CABG peri-operative pain",
      "Active GI bleed",
      "Aspirin allergy (Asthma triad)"
    ],
    "interactions": {
      "drug": ["Warfarin", "Lithium", "Methotrexate", "ACE Inhibitors"],
      "food": ["Food delays absorption but reduces GI upset."]
    },
    "pregnancyCategory": "Category C (D in 3rd trimester)"
  },
  "nebivolol": {
    "name": "Nebivolol (Bystolic)",
    "genericName": "Nebivolol",
    "formula": "C22H25F2NO4",
    "molecularWeight": "405.4 g/mol",
    "brandNames": ["Bystolic"],
    "category": "Antihypertensive",
    "drugClass": "Beta-1 Selective Blocker (Vasodilating)",
    "pubchemCID": "5284598",
    "indications": "Hypertension.",
    "moaSteps": [
      "Highest beta-1 selectivity of all beta-blockers.",
      "Stimulates endothelial Nitric Oxide Synthase (eNOS).",
      "Increases Nitric Oxide (NO) levels causing vasodilation.",
      "Reduces SVR with less negative inotropy/chronotropy than older agents."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "98% protein bound.",
      "metabolism": "Hepatic via CYP2D6 (Genetic polymorphism).",
      "excretion": "Urine/Feces. **Half-life: 12 hours (Extensive Metabolizers); 19 hours (Poor Metabolizers).**"
    },
    "dose": {
      "initialDose": "5 mg PO once daily",
      "maxDose": "40 mg/day",
      "notes": "Less fatigue/ED than other beta-blockers."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Fatigue",
        "Dizziness",
        "Diarrhea"
      ],
      "serious": [
        "Bradycardia / Heart Block",
        "Bronchospasm (low risk)",
        "Masking Hypoglycemia"
      ]
    },
    "precautions": [
      "**Abrupt Cessation:** BOXED WARNING. Taper to avoid angina/MI.",
      "**Metabolism:** CYP2D6 Poor Metabolizers have significantly higher exposure.",
      "**Diabetes:** Better metabolic profile than other beta-blockers (doesn't worsen insulin sensitivity)."
    ],
    "contraindications": [
      "Severe bradycardia",
      "Heart block > 1st degree",
      "Cardiogenic shock",
      "Decompensated HF"
    ],
    "interactions": {
      "drug": ["CYP2D6 Inhibitors (Fluoxetine - Increases levels)", "Digoxin", "CCBs"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "nifedipine": {
    "name": "Nifedipine (Procardia)",
    "genericName": "Nifedipine",
    "formula": "C17H18N2O6",
    "molecularWeight": "346.3 g/mol",
    "brandNames": ["Procardia XL", "Adalat CC"],
    "category": "Antihypertensive / Antianginal",
    "drugClass": "Calcium Channel Blocker (Dihydropyridine)",
    "pubchemCID": "4485",
    "indications": "Hypertension, Stable Angina, Raynaud's Phenomenon, Preterm Labor (Tocolytic).",
    "moaSteps": [
      "Inhibits calcium ion influx across cell membranes in vascular smooth muscle.",
      "Potent peripheral arterial vasodilator.",
      "Reduces afterload.",
      "Immediate Release (IR) causes reflex tachycardia; ER does not."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "92-98% protein bound.",
      "metabolism": "Extensive Hepatic (CYP3A4).",
      "excretion": "Urine. **Half-life: 2 hours (IR); effect prolonged by ER formulation.**"
    },
    "dose": {
      "initialDose": "30-60 mg ER PO once daily",
      "maxDose": "120 mg/day",
      "notes": "IR formulation mostly abandoned for HTN due to stroke/MI risk."
    },
    "adverseEffects": {
      "common": [
        "Peripheral Edema (Dose dependent)",
        "Flushing / Headache",
        "Dizziness",
        "Gingival Hyperplasia"
      ],
      "serious": [
        "Severe Hypotension",
        "Reflex Tachycardia (IR)",
        "Myocardial Infarction (IR in hypertensive crisis)"
      ]
    },
    "precautions": [
      "**IR Formulation:** Avoid sublingual/IR nifedipine for hypertensive urgencies (stroke/MI risk).",
      "**Heart Failure:** Avoid in HFrEF (negative inotropy).",
      "**Edema:** Common and resistant to diuretics."
    ],
    "contraindications": [
      "ST-Elevation MI",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inhibitors/Inducers", "Beta-blockers (Increased HF risk)", "Digoxin"],
      "food": ["Grapefruit juice (Increases levels)", "High fat meal (Alters ER release)"]
    },
    "pregnancyCategory": "Category C (Used as tocolytic)"
  },
  "nitrofurantoin": {
    "name": "Nitrofurantoin (Macrobid)",
    "genericName": "Nitrofurantoin Monohydrate/Macrocrystals",
    "formula": "C8H6N4O5",
    "molecularWeight": "238.16 g/mol",
    "brandNames": ["Macrobid", "Macrodantin"],
    "category": "Antibiotic",
    "drugClass": "Nitrofuran",
    "pubchemCID": "6604200",
    "indications": "Uncomplicated Urinary Tract Infection (Cystitis).",
    "moaSteps": [
      "Reduced by bacterial flavoproteins to reactive intermediates.",
      "Intermediates damage bacterial DNA, RNA, and proteins.",
      "Inhibits bacterial metabolism.",
      "Concentrates in urine; low serum levels."
    ],
    "pharmacokinetics": {
      "absorption": "Enhanced by food.",
      "distribution": "High in urine/kidney; low in serum.",
      "metabolism": "Body tissues.",
      "excretion": "Urine. **Half-life: 20 minutes (Short).**"
    },
    "dose": {
      "initialDose": "100 mg PO BID x 5 days",
      "maxDose": "100 mg QID (Macrodantin)",
      "notes": "Macrobid is BID; Macrodantin is QID."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting",
        "Brown urine",
        "Headache"
      ],
      "serious": [
        "Pulmonary Fibrosis (Chronic use)",
        "Peripheral Neuropathy",
        " hemolytic anemia (G6PD deficiency)",
        "Hepatotoxicity"
      ]
    },
    "precautions": [
      "**Renal:** Contraindicated if CrCl < 60 mL/min (inadequate urine concentration + systemic toxicity).",
      "**Pulmonary:** Acute pneumonitis or chronic fibrosis possible. Stop if cough/dyspnea develops.",
      "**Pyelonephritis:** Do not use (poor tissue penetration)."
    ],
    "contraindications": [
      "Renal impairment (CrCl < 60)",
      "Pregnancy at term (38-42 weeks) - Hemolysis risk in newborn",
      "Neonates < 1 month"
    ],
    "interactions": {
      "drug": ["Antacids (Magnesium - reduces absorption)", "Fluconazole (Pulmonary toxicity risk increase)"],
      "food": ["Take with food to improve absorption and tolerability."]
    },
    "pregnancyCategory": "Category B"
  },
  "nitroglycerin": {
    "name": "Nitroglycerin (Nitrostat)",
    "genericName": "Nitroglycerin",
    "formula": "C3H5N3O9",
    "molecularWeight": "227.09 g/mol",
    "brandNames": ["Nitrostat", "Nitro-Dur", "Nitrolingual"],
    "category": "Antianginal",
    "drugClass": "Nitrate",
    "pubchemCID": "4510",
    "indications": "Angina Pectoris (Acute and Prophylaxis), Acute Coronary Syndrome, Heart Failure, Hypertensive Emergency.",
    "moaSteps": [
      "Forms free radical nitric oxide (NO).",
      "NO activates guanylate cyclase, increasing cGMP.",
      "Dephosphorylation of myosin light chains causes smooth muscle relaxation.",
      "Venodilation predominates (decreased preload/MVO2)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (SL/IV/Transdermal).",
      "distribution": "Wide.",
      "metabolism": "Extensive hepatic first-pass.",
      "excretion": "Urine. **Half-life: 1 to 4 minutes.**"
    },
    "dose": {
      "initialDose": "0.4 mg SL every 5 min x 3 doses",
      "maxDose": "IV titration",
      "notes": "Patch: 12 hours on / 12 hours off."
    },
    "adverseEffects": {
      "common": [
        "Headache (Throbbing)",
        "Hypotension / Syncope",
        "Flushing",
        "Tachycardia (Reflex)"
      ],
      "serious": [
        "Severe Hypotension (with PDE5 inhibitors)",
        "Methemoglobinemia",
        "Paradoxical Bradycardia"
      ]
    },
    "precautions": [
      "**Tolerance:** Tachyphylaxis develops rapidly (24h). Nitrate-free interval of 10-12 hours required daily.",
      "**PDE5 Inhibitors:** Viagra/Cialis strictly contraindicated (Fatal hypotension).",
      "**Inferior MI:** Avoid in RV infarction (preload dependent)."
    ],
    "contraindications": [
      "Use of PDE5 inhibitors (Sildenafil, etc.)",
      "Increased Intracranial Pressure",
      "Severe Anemia"
    ],
    "interactions": {
      "drug": ["PDE5 Inhibitors (CONTRAINDICATED)", "Alcohol", "Antihypertensives"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "norepinephrine": {
    "name": "Norepinephrine (Levophed)",
    "genericName": "Norepinephrine Bitartrate",
    "formula": "C8H11NO3",
    "molecularWeight": "169.18 g/mol",
    "brandNames": ["Levophed"],
    "category": "Vasopressor",
    "drugClass": "Catecholamine",
    "pubchemCID": "439260",
    "indications": "Septic Shock (First line), Cardiogenic Shock, Severe Hypotension.",
    "moaSteps": [
      "Predominant alpha-1 adrenergic agonist (Potent vasoconstriction).",
      "Modest beta-1 adrenergic agonist (Increased contractility/HR).",
      "Increases SVR and BP.",
      "Increases cardiac output (minimal compared to epi)."
    ],
    "pharmacokinetics": {
      "absorption": "IV only.",
      "distribution": "Sympathetic tissues.",
      "metabolism": "MAO and COMT in liver/kidney/plasma.",
      "excretion": "Urine. **Half-life: 1 to 2 minutes.**"
    },
    "dose": {
      "initialDose": "8-12 mcg/min IV infusion",
      "maxDose": "Titrate to MAP > 65",
      "notes": "Central line preferred."
    },
    "adverseEffects": {
      "common": [
        "Hypertension",
        "Bradycardia (Reflex)",
        "Anxiety"
      ],
      "serious": [
        "Ischemic Necrosis (Peripheral/Visceral)",
        "Arrhythmias",
        "Extravasation Necrosis (Phentolamine antidote)"
      ]
    },
    "precautions": [
      "**Extravasation:** Vesicant. Causes severe necrosis if leaked. Infiltrate area with Phentolamine.",
      "**Hypovolemia:** Correct fluid status first (pressors don't work in empty pipes).",
      "**Peripheral Ischemia:** Monitor fingers/toes."
    ],
    "contraindications": [
      "Hypovolemia (uncorrected)",
      "Mesenteric/Peripheral vascular thrombosis (Relative)"
    ],
    "interactions": {
      "drug": ["MAOIs (Hypertensive crisis)", "TCAs (Potentiate pressor effect)", "Beta-blockers"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "nortriptyline": {
    "name": "Nortriptyline (Pamelor)",
    "genericName": "Nortriptyline HCl",
    "formula": "C19H21N",
    "molecularWeight": "263.4 g/mol",
    "brandNames": ["Pamelor"],
    "category": "Antidepressant",
    "drugClass": "Tricyclic Antidepressant (Secondary Amine)",
    "pubchemCID": "4543",
    "indications": "Depression, Neuropathic Pain (off-label), Migraine Prophylaxis (off-label).",
    "moaSteps": [
      "Inhibits reuptake of norepinephrine and serotonin.",
      "Active metabolite of Amitriptyline.",
      "Secondary amine: More selective for Norepinephrine.",
      "Less anticholinergic/sedative/hypotensive side effects than Amitriptyline."
    ],
    "pharmacokinetics": {
      "absorption": "Good.",
      "distribution": "92% protein bound.",
      "metabolism": "Hepatic (CYP2D6).",
      "excretion": "Urine. **Half-life: 18 to 44 hours.**"
    },
    "dose": {
      "initialDose": "25 mg PO at bedtime",
      "maxDose": "150 mg/day",
      "notes": "Therapeutic window 50-150 ng/mL."
    },
    "adverseEffects": {
      "common": [
        "Dry mouth",
        "Constipation",
        "Sedation (Mild)",
        "Orthostasis"
      ],
      "serious": [
        "Suicidality - BOXED WARNING",
        "Arrhythmias / QT Prolongation",
        "Seizures",
        "Glaucoma / Urinary Retention"
      ]
    },
    "precautions": [
      "**Therapeutic Window:** Unlike other antidepressants, has a 'curvilinear' response (too high is ineffective/toxic).",
      "**Cardiac:** Baseline ECG. Avoid in conduction disease.",
      "**Elderly:** Preferred TCA for elderly due to lower side effect profile."
    ],
    "contraindications": [
      "MAOI use within 14 days",
      "Acute recovery phase of MI"
    ],
    "interactions": {
      "drug": ["MAOIs (Fatal)", "CYP2D6 Inhibitors (Toxicity)", "Anticholinergics"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "nystatin": {
    "name": "Nystatin (Mycostatin)",
    "genericName": "Nystatin",
    "formula": "C47H75NO17",
    "molecularWeight": "926.1 g/mol",
    "brandNames": ["Mycostatin", "Nystop"],
    "category": "Antifungal",
    "drugClass": "Polyene",
    "pubchemCID": "6433272",
    "indications": "Candida infections (Oral Thrush, Intestinal, Cutaneous).",
    "moaSteps": [
      "Binds to sterols (ergosterol) in the fungal cell membrane.",
      "Changes membrane permeability.",
      "Allows leakage of intracellular components.",
      "Fungistatic or fungicidal."
    ],
    "pharmacokinetics": {
      "absorption": "Not absorbed from skin or GI tract.",
      "distribution": "Local action only.",
      "metabolism": "None.",
      "excretion": "Feces (Unchanged). **Half-life: N/A (Systemic absorption negligible).**"
    },
    "dose": {
      "initialDose": "500,000 units Swish and Swallow QID (Thrush)",
      "maxDose": "N/A",
      "notes": "Topical powder for skin folds."
    },
    "adverseEffects": {
      "common": [
        "Nausea (large oral doses)",
        "Diarrhea",
        "Bad taste"
      ],
      "serious": [
        "Rare hypersensitivity (SJS)"
      ]
    },
    "precautions": [
      "**Contact Time:** For thrush, must hold in mouth as long as possible before swallowing.",
      "**Sugar:** Suspensions contain sucrose (caution in diabetes/dental caries)."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["None (No systemic absorption)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "ocrelizumab": {
    "name": "Ocrelizumab (Ocrevus)",
    "genericName": "Ocrelizumab",
    "formula": "Humanized IgG1 monoclonal antibody",
    "molecularWeight": "145 kDa",
    "brandNames": ["Ocrevus"],
    "category": "Multiple Sclerosis Agent",
    "drugClass": "Anti-CD20 Monoclonal Antibody",
    "pubchemCID": "None (Protein)",
    "indications": "Relapsing or Primary Progressive Multiple Sclerosis (RMS/PPMS).",
    "moaSteps": [
      "Binds to CD20 surface antigen on pre-B and mature B lymphocytes.",
      "Induces B-cell lysis via CDC and ADCC.",
      "Depletes B-cells implicated in MS pathogenesis.",
      "Does not bind stem cells or plasma cells."
    ],
    "pharmacokinetics": {
      "absorption": "IV administration.",
      "distribution": "Vascular.",
      "metabolism": "Proteolysis.",
      "excretion": "Long duration. **Half-life: 26 days.**"
    },
    "dose": {
      "initialDose": "300 mg IV Day 1 and Day 15",
      "maxDose": "600 mg every 6 months",
      "notes": "Premedicate with methylprednisolone/antihistamine."
    },
    "adverseEffects": {
      "common": [
        "Infusion reactions (Itching, rash, dyspnea)",
        "Upper respiratory infections",
        "Skin infections"
      ],
      "serious": [
        "Malignancy (Breast Cancer risk)",
        "Serious Infections (Hepatitis B reactivation)",
        "PML (Progressive Multifocal Leukoencephalopathy)"
      ]
    },
    "precautions": [
      "**Infusion Reaction:** Highest risk with first dose. Monitor for 1 hour post-infusion.",
      "**Hepatitis B:** Screening required. Contraindicated in active HBV.",
      "**Vaccines:** Live vaccines contraindicated.",
      "**Malignancy:** Increased risk observed."
    ],
    "contraindications": [
      "Active Hepatitis B infection",
      "History of life-threatening infusion reaction"
    ],
    "interactions": {
      "drug": ["Immunosuppressants (Additive risk)", "Live vaccines"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "octreotide": {
    "name": "Octreotide (Sandostatin)",
    "genericName": "Octreotide Acetate",
    "formula": "C49H66N10O10S2",
    "molecularWeight": "1019.2 g/mol",
    "brandNames": ["Sandostatin", "Sandostatin LAR"],
    "category": "Endocrine-Metabolic Agent",
    "drugClass": "Somatostatin Analog",
    "pubchemCID": "442085",
    "indications": "Acromegaly, Carcinoid Syndrome, Vasoactive Intestinal Peptide Tumors (VIPomas), Esophageal Varices (off-label).",
    "moaSteps": [
      "Mimics natural somatostatin.",
      "Inhibits secretion of Growth Hormone, Insulin, Glucagon, Gastrin, VIP, and Serotonin.",
      "Decreases splanchnic blood flow (Varices)."
    ],
    "pharmacokinetics": {
      "absorption": "SC/IV rapid. LAR is depot.",
      "distribution": "65% protein bound.",
      "metabolism": "Hepatic.",
      "excretion": "Urine. **Half-life: 1.7 to 1.9 hours.**"
    },
    "dose": {
      "initialDose": "50 mcg SC/IV TID",
      "maxDose": "1500 mcg/day",
      "notes": "LAR (Long Acting) given monthly."
    },
    "adverseEffects": {
      "common": [
        "Gallstones / Sludge (Biliary stasis)",
        "Nausea / Diarrhea / Steatorrhea",
        "Injection site pain",
        "Hyper/Hypoglycemia"
      ],
      "serious": [
        "Bradycardia / Conduction abnormalities",
        "Pancreatitis",
        "Hypothyroidism"
      ]
    },
    "precautions": [
      "**Gallbladder:** Inhibits gallbladder contractility. Ultrasound monitoring needed.",
      "**Glucose:** Alters insulin/glucagon balance; monitor glucose closely.",
      "**Cardiac:** Can cause bradycardia."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Cyclosporine (Decreases levels)", "Insulin/Oral Hypoglycemics (Requirements change)", "Beta-blockers (Additive bradycardia)"],
      "food": ["Dietary fat (Steatorrhea)"]
    },
    "pregnancyCategory": "Category B"
  },
  "olanzapine": {
    "name": "Olanzapine (Zyprexa)",
    "genericName": "Olanzapine",
    "formula": "C17H20N4S",
    "molecularWeight": "312.4 g/mol",
    "brandNames": ["Zyprexa", "Zydis"],
    "category": "Antipsychotic",
    "drugClass": "Atypical Antipsychotic (Second Generation)",
    "pubchemCID": "135398745",
    "indications": "Schizophrenia, Bipolar I Disorder, Agitation, CINV (off-label).",
    "moaSteps": [
      "Antagonist at Dopamine D2 and Serotonin 5-HT2A receptors.",
      "Also blocks Muscarinic M1, Histamine H1, and Alpha-1 adrenergic receptors.",
      "Broad receptor profile contributes to efficacy and metabolic side effects."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "93% protein bound.",
      "metabolism": "Hepatic (CYP1A2/2D6) and Glucuronidation.",
      "excretion": "Urine/Feces. **Half-life: 30 hours (Range 21-54h).**"
    },
    "dose": {
      "initialDose": "5-10 mg PO daily",
      "maxDose": "20 mg/day",
      "notes": "Zydis is orally disintegrating."
    },
    "adverseEffects": {
      "common": [
        "Weight Gain (Significant)",
        "Somnolence",
        "Dry mouth",
        "Constipation",
        "Increased Appetite"
      ],
      "serious": [
        "Metabolic Syndrome (Diabetes, Dyslipidemia) - BOXED WARNING",
        "Tardive Dyskinesia",
        "Neuroleptic Malignant Syndrome",
        "DRESS (Drug Reaction)"
      ]
    },
    "precautions": [
      "**Metabolic:** Highest risk of weight gain and diabetes in class (along with clozapine). Monitor metabolic panel regularly.",
      "**DRESS:** Rare but fatal skin reaction.",
      "**Elderly:** Increased mortality in dementia-related psychosis."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Smoking (Induces CYP1A2 -> decreases levels)", "Benzodiazepines (Excessive sedation/Respiratory depression)", "Anticholinergics"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "olmesartan": {
    "name": "Olmesartan (Benicar)",
    "genericName": "Olmesartan Medoxomil",
    "formula": "C29H30N6O6",
    "molecularWeight": "558.6 g/mol",
    "brandNames": ["Benicar"],
    "category": "Antihypertensive",
    "drugClass": "Angiotensin II Receptor Blocker (ARB)",
    "pubchemCID": "158781",
    "indications": "Hypertension.",
    "moaSteps": [
      "Prodrug hydrolyzed to olmesartan.",
      "Selectively blocks the binding of angiotensin II to the AT1 receptor.",
      "Blocks vasoconstriction and aldosterone secretion.",
      "Does not affect bradykinin."
    ],
    "pharmacokinetics": {
      "absorption": "26% bioavailable.",
      "distribution": "99% protein bound.",
      "metabolism": "None (Hydrolysis only).",
      "excretion": "Urine and Bile. **Half-life: 13 hours.**"
    },
    "dose": {
      "initialDose": "20 mg PO once daily",
      "maxDose": "40 mg/day",
      "notes": "Assess volume status first."
    },
    "adverseEffects": {
      "common": [
        "Dizziness",
        "Back pain",
        "Diarrhea"
      ],
      "serious": [
        "Sprue-like Enteropathy (Severe chronic diarrhea/weight loss) - FDA Warning",
        "Renal Failure",
        "Fetal Toxicity - BOXED WARNING",
        "Angioedema"
      ]
    },
    "precautions": [
      "**Enteropathy:** Unique side effect. Causes villous atrophy and malabsorption. Can occur months/years after starting. Stop drug if unexplained diarrhea occurs.",
      "**Fetal:** Stop immediately in pregnancy.",
      "**Renal:** Monitor Cr/K."
    ],
    "contraindications": [
      "Pregnancy",
      "Concomitant Aliskiren in diabetes"
    ],
    "interactions": {
      "drug": ["Lithium", "NSAIDs (Renal failure)", "Colesevelam (Decreases absorption)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "omalizumab": {
    "name": "Omalizumab (Xolair)",
    "genericName": "Omalizumab",
    "formula": "Humanized IgG1 monoclonal antibody",
    "molecularWeight": "149 kDa",
    "brandNames": ["Xolair"],
    "category": "Asthma Biologic",
    "drugClass": "Anti-IgE Antibody",
    "pubchemCID": "None (Protein)",
    "indications": "Moderate to Severe Persistent Asthma (Allergic), Chronic Idiopathic Urticaria, Nasal Polyps.",
    "moaSteps": [
      "Binds to free human IgE in the blood and interstitial fluid.",
      "Prevents IgE binding to the high-affinity IgE receptor (Fc-epsilon-RI) on mast cells and basophils.",
      "Downregulates receptor expression.",
      "Inhibits release of allergic mediators."
    ],
    "pharmacokinetics": {
      "absorption": "Subcutaneous (Slow).",
      "distribution": "Vascular.",
      "metabolism": "IgG degradation.",
      "excretion": "Clearance involves IgG complexing. **Half-life: 26 days.**"
    },
    "dose": {
      "initialDose": "75-375 mg SubQ every 2 or 4 weeks",
      "maxDose": "Based on Weight and IgE level",
      "notes": "Dosing charts required."
    },
    "adverseEffects": {
      "common": [
        "Injection site reaction",
        "Headache",
        "Arthralgia"
      ],
      "serious": [
        "Anaphylaxis (Can be delayed) - BOXED WARNING",
        "Serum Sickness",
        "Malignancy (slight increase seen in trials)",
        "Cardiovascular/Cerebrovascular events (possible)"
      ]
    },
    "precautions": [
      "**Anaphylaxis:** Can occur after first dose or beyond 1 year. Observe patient for 2 hours after first 3 injections.",
      "**Parasites:** IgE defends against helminthes; caution in parasitic infection areas.",
      "**Acute Asthma:** Not for acute bronchospasm."
    ],
    "contraindications": [
      "Severe hypersensitivity to omalizumab"
    ],
    "interactions": {
      "drug": ["None specific"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "omeprazole": {
    "name": "Omeprazole (Prilosec)",
    "genericName": "Omeprazole",
    "formula": "C17H19N3O3S",
    "molecularWeight": "345.4 g/mol",
    "brandNames": ["Prilosec", "Zegerid"],
    "category": "Acid Reducer",
    "drugClass": "Proton Pump Inhibitor (PPI)",
    "pubchemCID": "4594",
    "indications": "GERD, Peptic Ulcer Disease, H. pylori eradication, Zollinger-Ellison Syndrome.",
    "moaSteps": [
      "Prodrug activated in acidic environment of parietal cell.",
      "Irreversibly binds to H+/K+ ATPase enzyme (proton pump).",
      "Inhibits basal and stimulated gastric acid secretion.",
      "Acid suppression lasts until new pumps are synthesized."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (Enteric coated).",
      "distribution": "95% protein bound.",
      "metabolism": "Extensive Hepatic (CYP2C19/3A4).",
      "excretion": "Urine. **Half-life: 0.5 to 1 hour (Duration > 24h).**"
    },
    "dose": {
      "initialDose": "20-40 mg PO daily",
      "maxDose": "120 mg/day (ZES)",
      "notes": "Take 30-60 min before breakfast."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Abdominal pain",
        "Diarrhea",
        "Nausea"
      ],
      "serious": [
        "Clostridioides difficile infection",
        "Osteoporosis / Fractures (Chronic)",
        "Hypomagnesemia",
        "B12 Deficiency",
        "Interstitial Nephritis"
      ]
    },
    "precautions": [
      "**Infection:** Acid suppression increases risk of pneumonia and C. diff.",
      "**Bone:** Calcium Citrate preferred supplement (absorption pH independent).",
      "**Magnesium:** Check Mg in long-term users."
    ],
    "contraindications": [
      "Hypersensitivity",
      "Concomitant Rilpivirine"
    ],
    "interactions": {
      "drug": ["Clopidogrel (Inhibits activation -> Cardiac risk)", "Rilpivirine/Atazanavir (Reduced efficacy)", "Methotrexate (Toxicity)"],
      "food": ["Food reduces absorption. Take on empty stomach."]
    },
    "pregnancyCategory": "Category C"
  },
  "ondansetron": {
    "name": "Ondansetron (Zofran)",
    "genericName": "Ondansetron",
    "formula": "C18H19N3O",
    "molecularWeight": "293.4 g/mol",
    "brandNames": ["Zofran", "Zuplenz"],
    "category": "Antiemetic",
    "drugClass": "5-HT3 Receptor Antagonist",
    "pubchemCID": "4595",
    "indications": "Chemotherapy-Induced Nausea/Vomiting (CINV), Post-op Nausea (PONV), Radiation Nausea.",
    "moaSteps": [
      "Selective antagonist of serotonin 5-HT3 receptors.",
      "Blocks receptors peripherally on vagal nerve terminals and centrally in the Chemoreceptor Trigger Zone (CTZ).",
      "Prevents serotonin-mediated emetic reflex."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (Oral).",
      "distribution": "70-76% protein bound.",
      "metabolism": "Extensive Hepatic (CYP3A4/2D6/1A2).",
      "excretion": "Urine. **Half-life: 3 to 6 hours.**"
    },
    "dose": {
      "initialDose": "4-8 mg PO/IV every 8 hours",
      "maxDose": "16 mg/dose (IV risk of QT)",
      "notes": "Single IV dose >16mg no longer recommended due to QT risk."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Constipation",
        "Fatigue"
      ],
      "serious": [
        "QT Prolongation / Torsades de Pointes",
        "Serotonin Syndrome",
        "Hypersensitivity (Anaphylaxis)"
      ]
    },
    "precautions": [
      "**QT Interval:** Dose-dependent prolongation. Avoid in Long QT syndrome. Monitor electrolytes.",
      "**Serotonin Syndrome:** Rare; caution with SSRIs/MAOIs.",
      "**Masking:** May mask ileus/gastric distension."
    ],
    "contraindications": [
      "Congenital Long QT Syndrome",
      "Concomitant Apomorphine"
    ],
    "interactions": {
      "drug": ["Apomorphine (Profound hypotension - Contraindicated)", "QT prolonging drugs", "Tramadol (Reduced analgesic efficacy)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "oseltamivir": {
    "name": "Oseltamivir (Tamiflu)",
    "genericName": "Oseltamivir Phosphate",
    "formula": "C16H28N2O4",
    "molecularWeight": "312.4 g/mol",
    "brandNames": ["Tamiflu"],
    "category": "Antiviral",
    "drugClass": "Neuraminidase Inhibitor",
    "pubchemCID": "65028",
    "indications": "Influenza A and B (Treatment and Prophylaxis).",
    "moaSteps": [
      "Prodrug hydrolyzed to oseltamivir carboxylate.",
      "Inhibits influenza virus neuraminidase enzyme.",
      "Prevents release of new viral particles from infected cells.",
      "Prevents spread of virus across respiratory tract."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (75% bioavailable).",
      "distribution": "Middle ear/Sinuses/Lung.",
      "metabolism": "Hepatic esterases.",
      "excretion": "Urine. **Half-life: 6 to 10 hours (Active metabolite).**"
    },
    "dose": {
      "initialDose": "75 mg PO BID x 5 days (Tx); 75 mg Daily x 10 days (Prophylaxis)",
      "maxDose": "150 mg/day",
      "notes": "Renal adjustment required."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting",
        "Headache",
        "Pain"
      ],
      "serious": [
        "Neuropsychiatric Events (Delirium, Self-injury) - especially in children/Japan",
        "Severe Skin Reactions (SJS/TEN)"
      ]
    },
    "precautions": [
      "**Neuropsychiatric:** Monitor for abnormal behavior, especially in pediatric patients. Not clear if drug or virus induced.",
      "**Timing:** Must start within 48 hours of symptoms for benefit.",
      "**Vaccine:** Do not give live flu vaccine within 2 weeks before or 48h after."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Probenecid (Doubles exposure)", "Live Flu Vaccine (Inactivates vaccine)"],
      "food": ["Take with food to reduce nausea."]
    },
    "pregnancyCategory": "Category C"
  },
  "oxybutynin": {
    "name": "Oxybutynin (Ditropan)",
    "genericName": "Oxybutynin Chloride",
    "formula": "C22H31NO3",
    "molecularWeight": "357.5 g/mol",
    "brandNames": ["Ditropan", "Oxytrol", "Gelnique"],
    "category": "Urinary Antispasmodic",
    "drugClass": "Antimuscarinic",
    "pubchemCID": "4634",
    "indications": "Overactive Bladder (Urge incontinence, Frequency, Urgency).",
    "moaSteps": [
      "Direct antispasmodic effect on smooth muscle.",
      "Inhibits action of acetylcholine on smooth muscle (muscarinic M1/M2/M3 antagonist).",
      "Increases bladder capacity and delays desire to void.",
      "Decreases uninhibited contractions."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Lipophilic (Crosses BBB).",
      "metabolism": "Extensive hepatic (CYP3A4). High first pass.",
      "excretion": "Urine. **Half-life: 2 to 3 hours (IR); 12-13 hours (ER/Patch).**"
    },
    "dose": {
      "initialDose": "5 mg PO BID/TID (IR) or 5-10 mg daily (ER)",
      "maxDose": "30 mg/day",
      "notes": "Patch applied twice weekly."
    },
    "adverseEffects": {
      "common": [
        "Dry mouth (Very common)",
        "Constipation",
        "Blurred vision",
        "Drowsiness / Dizziness"
      ],
      "serious": [
        "Angioedema",
        "Heat Stroke (Decreased sweating)",
        "Cognitive Impairment / Delirium",
        "Urinary Retention"
      ]
    },
    "precautions": [
      "**Cognition:** High risk of confusion/dementia in elderly (crosses BBB). Newer agents (trospium/beta-3s) preferred.",
      "**Heat:** Caution in hot weather.",
      "**GI:** Caution in GERD (decreases motility)."
    ],
    "contraindications": [
      "Urinary retention",
      "Gastric retention",
      "Uncontrolled narrow-angle glaucoma"
    ],
    "interactions": {
      "drug": ["Anticholinergics (Additive toxicity)", "CYP3A4 Inhibitors", "Cholinesterase Inhibitors (Antagonism)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "oxycodone": {
    "name": "Oxycodone (OxyContin, Roxicodone)",
    "genericName": "Oxycodone HCl",
    "formula": "C18H21NO4",
    "molecularWeight": "315.4 g/mol",
    "brandNames": ["OxyContin", "Roxicodone", "Xtampza ER"],
    "category": "Opioid Analgesic",
    "drugClass": "Semi-synthetic Opioid Agonist",
    "pubchemCID": "5284603",
    "indications": "Moderate to Severe Pain.",
    "moaSteps": [
      "Pure agonist at mu-opioid receptors.",
      "Analgesia, sedation, and respiratory depression.",
      "High oral bioavailability compared to morphine.",
      "No ceiling effect for analgesia."
    ],
    "pharmacokinetics": {
      "absorption": "High oral bioavailability (60-87%).",
      "distribution": "Widely distributed.",
      "metabolism": "Hepatic via CYP3A4 (to noroxycodone) and CYP2D6 (to oxymorphone).",
      "excretion": "Urine. **Half-life: 3 to 5 hours (IR); 4.5 hours (ER - but absorption prolonged).**"
    },
    "dose": {
      "initialDose": "5-15 mg PO every 4-6 hours (Naive)",
      "maxDose": "Titrate to effect",
      "notes": "OxyContin is q12h. Do not crush."
    },
    "adverseEffects": {
      "common": [
        "Constipation",
        "Nausea / Vomiting",
        "Somnolence",
        "Pruritus"
      ],
      "serious": [
        "Respiratory Depression - BOXED WARNING",
        "Addiction / Misuse - BOXED WARNING",
        "Hypotension",
        "Adrenal Insufficiency"
      ]
    },
    "precautions": [
      "**Abuse:** High potential. OxyContin reformulations are abuse-deterrent (hard to crush).",
      "**CYP Interactions:** 3A4 inhibitors can cause fatal overdose. 3A4 inducers can cause withdrawal.",
      "**Respiratory:** Monitor closely."
    ],
    "contraindications": [
      "Significant respiratory depression",
      "Acute or severe bronchial asthma",
      "Paralytic ileus"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inhibitors (Macrolides/Azoles - Fatal)", "Benzodiazepines (Fatal)", "Alcohol"],
      "food": ["High fat meal may increase absorption of ER."]
    },
    "pregnancyCategory": "Category C"
  },
  "oxytocin": {
    "name": "Oxytocin (Pitocin)",
    "genericName": "Oxytocin",
    "formula": "C43H66N12O12S2",
    "molecularWeight": "1007.2 g/mol",
    "brandNames": ["Pitocin"],
    "category": "Uterotonic",
    "drugClass": "Peptide Hormone",
    "pubchemCID": "439302",
    "indications": "Induction of labor, Augmentation of labor, Postpartum hemorrhage control.",
    "moaSteps": [
      "Stimulates oxytocin receptors on the myometrium.",
      "Increases intracellular calcium.",
      "Increases frequency and force of uterine contractions.",
      "Promotes milk ejection (letdown) - Nasal."
    ],
    "pharmacokinetics": {
      "absorption": "IV or IM.",
      "distribution": "Rapid.",
      "metabolism": "Hepatic/Renal (Oxytocinase).",
      "excretion": "Urine. **Half-life: 1 to 6 minutes.**"
    },
    "dose": {
      "initialDose": "0.5-1 mU/min IV titration (Induction)",
      "maxDose": "20 mU/min (rarely up to 40)",
      "notes": "10-40 units IV/IM for Postpartum Hemorrhage."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting",
        "Uterine cramping"
      ],
      "serious": [
        "Uterine Rupture",
        "Water Intoxication (ADH-like effect)",
        "Fetal Distress (Bradycardia)",
        "Postpartum Hemorrhage (Uterine atony/fatigue)"
      ]
    },
    "precautions": [
      "**Fetal Monitoring:** Continuous monitoring of FHR required during induction.",
      "**Water Intoxication:** Structurally similar to ADH. High doses with electrolyte-free fluids can cause seizures/coma.",
      "**Hyperstimulation:** Stop infusion if contractions too frequent."
    ],
    "contraindications": [
      "Cephalopelvic disproportion",
      "Fetal distress when delivery not imminent",
      "Hyperactive uterus"
    ],
    "interactions": {
      "drug": ["Vasoconstrictors ( severe hypertension)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category X (Not for elective use; Indicated for medical use)"
  },"paclitaxel": {
    "name": "Paclitaxel (Taxol)",
    "genericName": "Paclitaxel",
    "formula": "C47H51NO14",
    "molecularWeight": "853.9 g/mol",
    "brandNames": ["Taxol", "Abraxane (Albumin-bound)"],
    "category": "Antineoplastic",
    "drugClass": "Taxane (Microtubule Stabilizer)",
    "pubchemCID": "36314",
    "indications": "Ovarian Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Kaposi's Sarcoma.",
    "moaSteps": [
      "Promotes assembly of microtubules from tubulin dimers.",
      "Stabilizes microtubules by preventing depolymerization.",
      "Results in the formation of abnormal bundles of microtubules.",
      "Blocks cells in the G2/M phase of the cell cycle (Mitotic arrest) leading to apoptosis."
    ],
    "pharmacokinetics": {
      "absorption": "IV only.",
      "distribution": "90-95% protein bound. Wide tissue distribution.",
      "metabolism": "Hepatic via CYP2C8 and CYP3A4.",
      "excretion": "Feces (Biliary). **Half-life: 13 to 52 hours (Non-linear elimination).**"
    },
    "dose": {
      "initialDose": "175 mg/m2 IV over 3 hours every 3 weeks",
      "maxDose": "Protocol dependent",
      "notes": "Standard Taxol requires pre-medication with steroids/antihistamines (Cremophor solvent causes hypersensitivity). Abraxane does not."
    },
    "adverseEffects": {
      "common": [
        "Alopecia (Total body hair loss)",
        "Peripheral Neuropathy (Glove-and-stocking)",
        "Myalgia / Arthralgia",
        "Nausea"
      ],
      "serious": [
        "Anaphylaxis / Severe Hypersensitivity - BOXED WARNING",
        "Neutropenia (Dose-limiting) - BOXED WARNING",
        "Bradycardia / Heart Block",
        "Extravasation necrosis"
      ]
    },
    "precautions": [
      "**Hypersensitivity:** Pre-medicate with Dexamethasone, Diphenhydramine, and H2 blocker to prevent reaction to solvent (Cremophor EL).",
      "**Neuropathy:** Sensory neuropathy is dose-dependent and cumulative.",
      "**Cardiac:** Monitor ECG during infusion."
    ],
    "contraindications": [
      "Neutrophil count < 1500",
      "Hypersensitivity to castor oil (Cremophor EL)"
    ],
    "interactions": {
      "drug": ["Cisplatin (Administer Paclitaxel FIRST to prevent increased toxicity)", "CYP2C8/3A4 Inhibitors"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "paliperidone": {
    "name": "Paliperidone (Invega)",
    "genericName": "Paliperidone",
    "formula": "C23H27FN4O3",
    "molecularWeight": "426.5 g/mol",
    "brandNames": ["Invega", "Invega Sustenna", "Invega Trinza"],
    "category": "Antipsychotic",
    "drugClass": "Atypical Antipsychotic (Second Generation)",
    "pubchemCID": "115237",
    "indications": "Schizophrenia, Schizoaffective Disorder.",
    "moaSteps": [
      "Active metabolite of Risperidone (9-hydroxyrisperidone).",
      "Antagonizes Dopamine D2 receptors (treating positive symptoms).",
      "Antagonizes Serotonin 5-HT2A receptors (treating negative symptoms).",
      "Also blocks alpha-1 and H1 receptors."
    ],
    "pharmacokinetics": {
      "absorption": "28% bioavailable (Oral).",
      "distribution": "74% protein bound.",
      "metabolism": "Minimal hepatic metabolism (unlike Risperidone).",
      "excretion": "Urine (59% unchanged). **Half-life: 23 hours (Oral); 25-49 days (IM Sustenna).**"
    },
    "dose": {
      "initialDose": "6 mg PO once daily",
      "maxDose": "12 mg/day",
      "notes": "ER shell may appear in stool."
    },
    "adverseEffects": {
      "common": [
        "Extrapyramidal Symptoms (Akathisia, parkinsonism)",
        "Hyperprolactinemia (Highest in class)",
        "Tachycardia",
        "Weight gain"
      ],
      "serious": [
        "Tardive Dyskinesia",
        "Neuroleptic Malignant Syndrome",
        "QT Prolongation",
        "Increased mortality in elderly dementia - BOXED WARNING"
      ]
    },
    "precautions": [
      "**Prolactin:** Causes significant elevation; monitor for galactorrhea/gynecomastia.",
      "**Renal:** Dose reduction required in renal impairment (Primary elimination route).",
      "**Metabolic:** Monitor glucose and lipids."
    ],
    "contraindications": [
      "Hypersensitivity to paliperidone or risperidone"
    ],
    "interactions": {
      "drug": ["Carbamazepine (Decreases levels)", "QT prolonging drugs"],
      "food": ["None (Take with or without food)"]
    },
    "pregnancyCategory": "Category C"
  },
  "pantoprazole": {
    "name": "Pantoprazole (Protonix)",
    "genericName": "Pantoprazole Sodium",
    "formula": "C16H15F2N3O4S",
    "molecularWeight": "383.4 g/mol",
    "brandNames": ["Protonix"],
    "category": "Acid Reducer",
    "drugClass": "Proton Pump Inhibitor (PPI)",
    "pubchemCID": "4679",
    "indications": "GERD, Erosive Esophagitis, Zollinger-Ellison Syndrome, GI Bleed prophylaxis.",
    "moaSteps": [
      "Irreversibly binds to the H+/K+ ATPase enzyme system (proton pump) on the surface of the gastric parietal cell.",
      "Suppresses the final step in gastric acid production.",
      "Inhibits both basal and stimulated acid secretion."
    ],
    "pharmacokinetics": {
      "absorption": "Delayed release (Enteric coated).",
      "distribution": "98% protein bound.",
      "metabolism": "Hepatic via CYP2C19.",
      "excretion": "Urine. **Half-life: 1 hour (Duration >24 hours due to irreversible binding).**"
    },
    "dose": {
      "initialDose": "40 mg PO/IV once daily",
      "maxDose": "240 mg/day (Hypersecretory states)",
      "notes": "Can be taken with or without food (unlike Omeprazole)."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Diarrhea",
        "Abdominal pain",
        "Flatulence"
      ],
      "serious": [
        "Clostridioides difficile infection",
        "Osteoporosis / Bone Fractures (long term)",
        "Hypomagnesemia",
        "Acute Interstitial Nephritis (AIN)"
      ]
    },
    "precautions": [
      "**C. diff:** Associated with increased risk of CDAD.",
      "**Bone Health:** Supplement Calcium Citrate and Vitamin D in chronic users.",
      "**False Positive:** Can cause false positive THC urine screens."
    ],
    "contraindications": [
      "Hypersensitivity",
      "Concomitant Rilpivirine"
    ],
    "interactions": {
      "drug": ["Methotrexate (Toxic levels)", "Clopidogrel (Lowest interaction risk of all PPIs - Preferred PPI for Plavix users)", "Rilpivirine (Failure)"],
      "food": ["None (Flexible dosing)."]
    },
    "pregnancyCategory": "Category B"
  },
  "paroxetine": {
    "name": "Paroxetine (Paxil)",
    "genericName": "Paroxetine HCl",
    "formula": "C19H20FNO3",
    "molecularWeight": "329.4 g/mol",
    "brandNames": ["Paxil", "Brisdelle"],
    "category": "Antidepressant",
    "drugClass": "SSRI",
    "pubchemCID": "43815",
    "indications": "Depression, OCD, Panic Disorder, Social Anxiety, PTSD, Vasomotor symptoms of menopause (Brisdelle).",
    "moaSteps": [
      "Highly selective and potent inhibitor of serotonin reuptake (SERT).",
      "Enhances serotonergic transmission.",
      "Has mild anticholinergic (muscarinic antagonist) properties (unique among SSRIs).",
      "Mild NET inhibition at high doses."
    ],
    "pharmacokinetics": {
      "absorption": "Complete.",
      "distribution": "95% protein bound.",
      "metabolism": "Hepatic via CYP2D6 (Potent inhibitor and substrate).",
      "excretion": "Urine. **Half-life: 21 hours.**"
    },
    "dose": {
      "initialDose": "20 mg PO once daily",
      "maxDose": "60 mg/day",
      "notes": "Most sedating SSRI."
    },
    "adverseEffects": {
      "common": [
        "Sexual Dysfunction (Highest rate among SSRIs)",
        "Weight gain",
        "Sedation / Somnolence",
        "Dry mouth / Constipation (Anticholinergic)"
      ],
      "serious": [
        "Suicidality (Young adults) - BOXED WARNING",
        "Serotonin Syndrome",
        "Severe Withdrawal Syndrome",
        "Hyponatremia"
      ]
    },
    "precautions": [
      "**Withdrawal:** Shortest half-life of SSRIs + no active metabolite = Severe withdrawal (dizziness, zaps, nausea). Do not stop abruptly.",
      "**Pregnancy:** Category D (Cardiac septal defects). Generally avoided in pregnancy.",
      "**CYP2D6:** Potent inhibitor; interacts with Tamoxifen."
    ],
    "contraindications": [
      "MAOI use within 14 days",
      "Pregnancy (Relative)",
      "Concomitant Pimozide or Thioridazine"
    ],
    "interactions": {
      "drug": ["Tamoxifen (Paroxetine blocks activation -> Breast cancer recurrence risk - AVOID)", "MAOIs (Fatal)", "Metoprolol (Increased levels)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "pembrolizumab": {
    "name": "Pembrolizumab (Keytruda)",
    "genericName": "Pembrolizumab",
    "formula": "Humanized monoclonal antibody",
    "molecularWeight": "149 kDa",
    "brandNames": ["Keytruda"],
    "category": "Antineoplastic",
    "drugClass": "PD-1 Inhibitor (Immune Checkpoint Inhibitor)",
    "pubchemCID": "None (Protein)",
    "indications": "Melanoma, NSCLC, Head/Neck Cancer, Hodgkin Lymphoma, MSI-H cancers (Tissue agnostic).",
    "moaSteps": [
      "Binds to the Programmed Death-1 (PD-1) receptor on T-cells.",
      "Blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, on tumor cells.",
      "Removes the 'brakes' from the immune system.",
      "Restores T-cell mediated immune response against the tumor."
    ],
    "pharmacokinetics": {
      "absorption": "IV administration.",
      "distribution": "Vascular/Extravascular.",
      "metabolism": "Catabolism.",
      "excretion": "Clearance ~0.2 L/day. **Half-life: ~22 days.**"
    },
    "dose": {
      "initialDose": "200 mg IV every 3 weeks OR 400 mg every 6 weeks",
      "maxDose": "Fixed dose",
      "notes": "Monitor for immune-mediated adverse events (irAEs)."
    },
    "adverseEffects": {
      "common": [
        "Fatigue",
        "Pruritus / Rash",
        "Diarrhea",
        "Arthralgia"
      ],
      "serious": [
        "Immune-Mediated Pneumonitis (Fatal)",
        "Immune-Mediated Colitis",
        "Immune-Mediated Hepatitis / Nephritis",
        "Endocrinopathies (Hypothyroidism, Type 1 Diabetes, Adrenal Insufficiency)"
      ]
    },
    "precautions": [
      "**irAEs:** Immune-related Adverse Events can affect ANY organ. Treat grade 2+ with corticosteroids. Withhold/discontinue drug based on severity.",
      "**Thyroid:** Monitor TSH every cycle.",
      "**Infusion:** Mild reactions possible."
    ],
    "contraindications": [
      "None (other than hypersensitivity)"
    ],
    "interactions": {
      "drug": ["Corticosteroids (May reduce efficacy if given *before* starting - use only for treating side effects)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D (Mechanism suggests fetal harm)"
  },
  "penicillin_g": {
    "name": "Penicillin G (Pfizerpen)",
    "genericName": "Penicillin G Potassium/Sodium/Benzathine",
    "formula": "C16H18N2O4S",
    "molecularWeight": "334.4 g/mol",
    "brandNames": ["Pfizerpen (IV)", "Bicillin L-A (IM Benzathine)"],
    "category": "Antibiotic",
    "drugClass": "Natural Penicillin",
    "pubchemCID": "5904",
    "indications": "Syphilis (Benzathine), Strep infections, Meningococcal meningitis, Neurosyphilis (IV).",
    "moaSteps": [
      "Binds to Penicillin-Binding Proteins (PBPs).",
      "Interferes with the final stage of bacterial cell wall synthesis (transpeptidation).",
      "Causes cell lysis.",
      "Bactericidal against non-resistant Gram-positives and some Gram-negatives (Neisseria/Treponema)."
    ],
    "pharmacokinetics": {
      "absorption": "IV (Rapid); IM Benzathine (Depot - weeks). Acid labile (poor oral).",
      "distribution": "Widely distributed.",
      "metabolism": "Minimal.",
      "excretion": "Urine. **Half-life: 30 to 60 minutes (IV); 14-30 days (IM Benzathine).**"
    },
    "dose": {
      "initialDose": "Syphilis: 2.4 million units IM x 1; Neurosyphilis: 3-4 MU IV q4h.",
      "maxDose": "24 million units/day (IV)",
      "notes": "NEVER give Bicillin L-A intravenously (Cardiac arrest)."
    },
    "adverseEffects": {
      "common": [
        "Injection site pain",
        "Diarrhea",
        "Rash"
      ],
      "serious": [
        "Anaphylaxis (Type I Hypersensitivity)",
        "Jarisch-Herxheimer Reaction (Syphilis treatment)",
        "Seizures (High dose/Renal failure)",
        "Hemolytic Anemia"
      ]
    },
    "precautions": [
      "**Administration Error:** Boxed Warning for Bicillin L-A: IV administration causes cardiorespiratory arrest and death. IM ONLY.",
      "**Herxheimer:** Fever/chills/myalgia after syphilis tx; self-limiting.",
      "**Renal:** Accumulation causes seizures."
    ],
    "contraindications": [
      "Hypersensitivity to penicillins"
    ],
    "interactions": {
      "drug": ["Probenecid (Increases levels)", "Methotrexate (Increased toxicity)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "phenytoin": {
    "name": "Phenytoin (Dilantin)",
    "genericName": "Phenytoin Sodium",
    "formula": "C15H12N2O2",
    "molecularWeight": "252.27 g/mol",
    "brandNames": ["Dilantin", "Phenytek"],
    "category": "Anticonvulsant",
    "drugClass": "Hydantoin",
    "pubchemCID": "1775",
    "indications": "Generalized Tonic-Clonic Seizures, Complex Partial Seizures, Status Epilepticus.",
    "moaSteps": [
      "Stabilizes neuronal membranes.",
      "Blocks voltage-gated sodium channels in the inactivated state.",
      "Prevents repetitive firing of action potentials.",
      "Reduces spread of seizure activity."
    ],
    "pharmacokinetics": {
      "absorption": "Slow and variable.",
      "distribution": "90% protein bound (sensitive to albumin levels).",
      "metabolism": "Hepatic (CYP2C9/2C19). Saturable (Zero-order kinetics).",
      "excretion": "Bile/Urine. **Half-life: 7 to 42 hours (Concentration dependent).**"
    },
    "dose": {
      "initialDose": "100 mg PO TID; Load 15-20 mg/kg",
      "maxDose": "Titrate to levels (10-20 mcg/mL)",
      "notes": "Small dose increases cause large level jumps (Michaelis-Menten kinetics)."
    },
    "adverseEffects": {
      "common": [
        "Gingival Hyperplasia",
        "Nystagmus / Ataxia",
        "Hirsutism",
        "Confusion"
      ],
      "serious": [
        "Stevens-Johnson Syndrome (SJS/TEN)",
        "Purple Glove Syndrome (IV extravasation)",
        "Hepatotoxicity",
        "Agranulocytosis"
      ]
    },
    "precautions": [
      "**Kinetics:** Zero-order kinetics means toxicity occurs easily. Monitor levels.",
      "**Albumin:** Correct levels for hypoalbuminemia.",
      "**Infusion:** Max rate 50 mg/min to prevent hypotension/arrhythmias (Propylene glycol). Fosphenytoin is safer."
    ],
    "contraindications": [
      "Sinus bradycardia",
      "2nd/3rd degree AV block",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Warfarin/Contraceptives (Phenytoin Induces CYP - Failure)", "Amiodarone (Increases phenytoin levels)", "Tube feeds (Bind phenytoin - hold 2h)"],
      "food": ["Enteral feeds decrease absorption."]
    },
    "pregnancyCategory": "Category D (Fetal Hydantoin Syndrome)"
  },
  "piperacillin_tazobactam": {
    "name": "Piperacillin/Tazobactam (Zosyn)",
    "genericName": "Piperacillin and Tazobactam",
    "formula": "Combination",
    "molecularWeight": "N/A",
    "brandNames": ["Zosyn"],
    "category": "Antibiotic",
    "drugClass": "Extended-spectrum Penicillin + Beta-lactamase Inhibitor",
    "pubchemCID": "23663974",
    "indications": "Intra-abdominal infections, Nosocomial Pneumonia, Sepsis, Complicated Skin Infections.",
    "moaSteps": [
      "Piperacillin: Inhibits cell wall synthesis (PBP binding). Broad spectrum including Pseudomonas.",
      "Tazobactam: Irreversibly binds to beta-lactamase enzymes.",
      "Protects piperacillin from degradation.",
      "Restores activity against beta-lactamase producing bacteria."
    ],
    "pharmacokinetics": {
      "absorption": "IV only.",
      "distribution": "Widely distributed.",
      "metabolism": "Minimal.",
      "excretion": "Renal. **Half-life: 0.7 to 1.2 hours.**"
    },
    "dose": {
      "initialDose": "3.375 g or 4.5 g IV every 6-8 hours",
      "maxDose": "18 g/day",
      "notes": "Renal adjustment required. Extended infusion (4h) improves outcomes."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea",
        "Headache",
        "Constipation",
        "Insomnia"
      ],
      "serious": [
        "Anaphylaxis",
        "Clostridioides difficile colitis",
        "Acute Interstitial Nephritis",
        "Thrombocytopenia"
      ]
    },
    "precautions": [
      "**Renal:** Accumulation causes seizures. Adjust dose.",
      "**Vancomycin:** Co-administration increases risk of Acute Kidney Injury (AKI).",
      "**Sodium:** High sodium content (caution in HF)."
    ],
    "contraindications": [
      "Hypersensitivity to penicillins/cephalosporins"
    ],
    "interactions": {
      "drug": ["Vancomycin (Synergistic Nephrotoxicity)", "Methotrexate (Toxicity)", "Vecuronium (Prolonged blockade)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "prednisone": {
    "name": "Prednisone (Deltasone)",
    "genericName": "Prednisone",
    "formula": "C21H26O5",
    "molecularWeight": "358.4 g/mol",
    "brandNames": ["Deltasone", "Rayos"],
    "category": "Corticosteroid",
    "drugClass": "Glucocorticoid",
    "pubchemCID": "5865",
    "indications": "Asthma exacerbation, Rheumatoid Arthritis, Autoimmune diseases, COPD, Allergic reactions.",
    "moaSteps": [
      "Prodrug converted to Prednisolone in the liver.",
      "Binds to intracellular glucocorticoid receptors.",
      "Modulates gene expression to inhibit inflammation (cytokines, chemokines).",
      "Suppress immune system."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Widely distributed.",
      "metabolism": "Hepatic conversion to prednisolone.",
      "excretion": "Urine. **Half-life: 2 to 3 hours (Biologic T1/2: 12-36 hours).**"
    },
    "dose": {
      "initialDose": "5-60 mg PO daily",
      "maxDose": "Varies by condition",
      "notes": "Taper required for long courses."
    },
    "adverseEffects": {
      "common": [
        "Hyperglycemia",
        "Insomnia / Mood changes",
        "Fluid retention",
        "Increased appetite"
      ],
      "serious": [
        "Adrenal Suppression",
        "Cushing's Syndrome",
        "Peptic Ulcer",
        "Osteoporosis / Avascular Necrosis"
      ]
    },
    "precautions": [
      "**HPA Axis:** Chronic use suppresses adrenal glands. Abrupt stop causes adrenal crisis. Taper slowly.",
      "**Diabetes:** Spikes blood sugar.",
      "**Infection:** Reactivation of TB/Hep B."
    ],
    "contraindications": [
      "Systemic fungal infections",
      "Live vaccines"
    ],
    "interactions": {
      "drug": ["NSAIDs (GI Bleed)", "Warfarin (Variable INR)", "Fluoroquinolones (Tendon rupture risk)"],
      "food": ["Take with food."]
    },
    "pregnancyCategory": "Category C"
  },
  "pregabalin": {
    "name": "Pregabalin (Lyrica)",
    "genericName": "Pregabalin",
    "formula": "C8H17NO2",
    "molecularWeight": "159.23 g/mol",
    "brandNames": ["Lyrica"],
    "category": "Anticonvulsant / Analgesic",
    "drugClass": "Gabapentinoid",
    "pubchemCID": "5486971",
    "indications": "Diabetic Neuropathy, Postherpetic Neuralgia, Fibromyalgia, Spinal Cord Injury Pain, Partial Seizures.",
    "moaSteps": [
      "Binds with high affinity to the alpha-2-delta subunit of voltage-gated calcium channels in CNS.",
      "Reduces calcium influx at nerve terminals.",
      "Decreases release of excitatory neurotransmitters (glutamate, norepinephrine, substance P).",
      "More potent and better absorbed than Gabapentin."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (Linear kinetics - unlike gabapentin).",
      "distribution": "Crosses BBB.",
      "metabolism": "Negligible.",
      "excretion": "Urine (Unchanged). **Half-life: 6.3 hours.**"
    },
    "dose": {
      "initialDose": "50-75 mg PO BID",
      "maxDose": "600 mg/day",
      "notes": "Renal adjustment required. Schedule V controlled substance."
    },
    "adverseEffects": {
      "common": [
        "Dizziness",
        "Somnolence",
        "Peripheral Edema",
        "Weight gain"
      ],
      "serious": [
        "Respiratory Depression (with opioids)",
        "Suicidal Ideation",
        "Angioedema",
        "Withdrawal Seizures"
      ]
    },
    "precautions": [
      "**Respiratory:** FDA warning for respiratory depression when combined with opioids/CNS depressants.",
      "**Edema:** Caution in Heart Failure.",
      "**Withdrawal:** Taper over 1 week."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Opioids/Benzodiazepines (Additive sedation/respiratory depression)", "ACE Inhibitors (Angioedema risk)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "propofol": {
    "name": "Propofol (Diprivan)",
    "genericName": "Propofol",
    "formula": "C12H18O",
    "molecularWeight": "178.27 g/mol",
    "brandNames": ["Diprivan"],
    "category": "Anesthetic",
    "drugClass": "General Anesthetic (IV)",
    "pubchemCID": "4946",
    "indications": "Induction/Maintenance of Anesthesia, ICU Sedation.",
    "moaSteps": [
      "Potentiates GABA-A receptor activity.",
      "Slows channel closing time.",
      "Also blocks sodium channels.",
      "Causes global CNS depression."
    ],
    "pharmacokinetics": {
      "absorption": "IV only.",
      "distribution": "Rapid redistribution from brain to fat (awakening).",
      "metabolism": "Hepatic conjugation.",
      "excretion": "Urine. **Half-life: 2 to 4 minutes (Distribution/Wake-up); 4-7 hours (Elimination).**"
    },
    "dose": {
      "initialDose": "1-2.5 mg/kg IV induction",
      "maxDose": "Titrate infusion",
      "notes": "Contains egg/soybean oil."
    },
    "adverseEffects": {
      "common": [
        "Hypotension (Significant)",
        "Apnea",
        "Injection site pain"
      ],
      "serious": [
        "Propofol Infusion Syndrome (PRIS) - Fatal metabolic acidosis/rhabdo/cardiac failure",
        "Respiratory Arrest",
        "Anaphylaxis"
      ]
    },
    "precautions": [
      "**PRIS:** Risk with high doses (>4mg/kg/hr) for >48h. Monitor lactate/triglycerides.",
      "**Contamination:** Emulsion supports bacterial growth; discard tubing q12h.",
      "**Allergy:** Caution in egg/soy allergy (though rare reaction)."
    ],
    "contraindications": [
      "Hypersensitivity to eggs/soy/propofol"
    ],
    "interactions": {
      "drug": ["Opioids/Benzos (Synergistic hypotension/apnea)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "propranolol": {
    "name": "Propranolol (Inderal)",
    "genericName": "Propranolol HCl",
    "formula": "C16H21NO2",
    "molecularWeight": "259.34 g/mol",
    "brandNames": ["Inderal", "Inderal LA", "Hemangeol"],
    "category": "Antihypertensive / Antiarrhythmic",
    "drugClass": "Non-selective Beta Blocker",
    "pubchemCID": "4946",
    "indications": "Hypertension, Migraine prophylaxis, Essential Tremor, Anxiety (Performance), Thyrotoxicosis, Hemangioma.",
    "moaSteps": [
      "Non-selective antagonist of beta-1 and beta-2 adrenergic receptors.",
      "Decreases HR and contractility.",
      "Bronchoconstriction (beta-2).",
      "Reduces peripheral conversion of T4 to T3 (Thyroid storm benefit).",
      "Lipophilic: Crosses BBB (CNS effects)."
    ],
    "pharmacokinetics": {
      "absorption": "Complete but extensive first-pass.",
      "distribution": "High CNS penetration.",
      "metabolism": "Hepatic.",
      "excretion": "Urine. **Half-life: 3 to 6 hours.**"
    },
    "dose": {
      "initialDose": "40 mg PO BID",
      "maxDose": "320 mg/day",
      "notes": "Hemangeol specific for infants."
    },
    "adverseEffects": {
      "common": [
        "Fatigue / Lethargy",
        "Cold extremities",
        "Nightmares / Insomnia (CNS)",
        "Bradycardia"
      ],
      "serious": [
        "Bronchospasm (Asthma exacerbation)",
        "Heart Block",
        "Masking Hypoglycemia",
        "Depression"
      ]
    },
    "precautions": [
      "**Asthma:** Contraindicated due to beta-2 blockade.",
      "**Diabetes:** Masks hypoglycemia signs; delays recovery.",
      "**Withdrawal:** Taper to avoid thyroid storm/angina."
    ],
    "contraindications": [
      "Asthma / COPD",
      "Sinus bradycardia / Heart block",
      "Cardiogenic shock"
    ],
    "interactions": {
      "drug": ["Epinephrine (Hypertensive crisis - unopposed alpha)", "Calcium Channel Blockers", "Insulin"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "quetiapine": {
    "name": "Quetiapine (Seroquel)",
    "genericName": "Quetiapine Fumarate",
    "formula": "C21H25N3O2S",
    "molecularWeight": "383.5 g/mol",
    "brandNames": ["Seroquel", "Seroquel XR"],
    "category": "Antipsychotic",
    "drugClass": "Atypical Antipsychotic (Second Generation)",
    "pubchemCID": "5002",
    "indications": "Schizophrenia, Bipolar Disorder, Major Depressive Disorder (Adjunct).",
    "moaSteps": [
      "Antagonist at serotonin 5-HT2A and dopamine D2 receptors.",
      "Hit-and-run D2 binding (loose binding) leads to lower EPS risk.",
      "Potent H1 and Alpha-1 antagonist (Sedation/Orthostasis).",
      "Active metabolite (Norquetiapine) inhibits NET (antidepressant effect)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "83% protein bound.",
      "metabolism": "Hepatic via CYP3A4.",
      "excretion": "Urine/Feces. **Half-life: 6 hours (Parent); 12 hours (Active metabolite).**"
    },
    "dose": {
      "initialDose": "25-50 mg PO BID (titrate up)",
      "maxDose": "800 mg/day",
      "notes": "Low doses (<100mg) act mainly as antihistamine (sedative)."
    },
    "adverseEffects": {
      "common": [
        "Somnolence / Sedation (Very common)",
        "Dry mouth",
        "Weight gain",
        "Orthostatic Hypotension"
      ],
      "serious": [
        "Metabolic Syndrome (Diabetes/Lipids) - BOXED WARNING",
        "Suicidality (Young adults) - BOXED WARNING",
        "Tardive Dyskinesia",
        "QT Prolongation",
        "Cataracts (Animal studies)"
      ]
    },
    "precautions": [
      "**Sedation:** Very sedating; caution driving.",
      "**Metabolic:** Monitor weight/glucose/lipids.",
      "**QT:** Avoid in combo with other QT drugs."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inhibitors (Ketoconazole - Increase levels)", "CYP3A4 Inducers (Phenytoin - Decrease levels)", "CNS Depressants"],
      "food": ["Grapefruit juice"]
    },
    "pregnancyCategory": "Category C"
  },"quinapril": {
    "name": "Quinapril (Accupril)",
    "genericName": "Quinapril HCl",
    "formula": "C25H30N2O5",
    "molecularWeight": "438.5 g/mol",
    "brandNames": ["Accupril"],
    "category": "Antihypertensive",
    "drugClass": "ACE Inhibitor",
    "pubchemCID": "54892",
    "indications": "Hypertension, Heart Failure.",
    "moaSteps": [
      "Prodrug hydrolyzed to Quinaprilat.",
      "Inhibits Angiotensin-Converting Enzyme (ACE).",
      "Prevents conversion of Angiotensin I to Angiotensin II.",
      "Reduces peripheral vascular resistance and aldosterone secretion."
    ],
    "pharmacokinetics": {
      "absorption": "60% bioavailable. High fat meal reduces absorption.",
      "distribution": "97% protein bound.",
      "metabolism": "Hepatic hydrolysis to quinaprilat.",
      "excretion": "Urine/Feces. **Half-life: 1-2 hours (Parent); 25 hours (Quinaprilat).**"
    },
    "dose": {
      "initialDose": "10-20 mg PO once daily",
      "maxDose": "80 mg/day",
      "notes": "Reduce dose in renal impairment."
    },
    "adverseEffects": {
      "common": [
        "Dry Cough",
        "Dizziness",
        "Hypotension",
        "Headache"
      ],
      "serious": [
        "Angioedema (Head/Neck/Intestinal) - BOXED WARNING",
        "Fetal Toxicity - BOXED WARNING",
        "Hyperkalemia",
        "Renal Failure"
      ]
    },
    "precautions": [
      "**Angioedema:** Stop immediately. Higher risk in Black patients.",
      "**Pregnancy:** Contraindicated.",
      "**Renal:** Monitor K+ and Cr."
    ],
    "contraindications": [
      "History of ACEI angioedema",
      "Pregnancy",
      "Concomitant Aliskiren in diabetics"
    ],
    "interactions": {
      "drug": ["Tetracycline (Quinapril contains Magnesium - reduces absorption)", "Lithium", "NSAIDs", "K+ sparing diuretics"],
      "food": ["High fat meal reduces absorption."]
    },
    "pregnancyCategory": "Category D"
  },
  "quinine": {
    "name": "Quinine (Qualaquin)",
    "genericName": "Quinine Sulfate",
    "formula": "C20H24N2O2",
    "molecularWeight": "324.4 g/mol",
    "brandNames": ["Qualaquin"],
    "category": "Antimalarial",
    "drugClass": "Cinchona Alkaloid",
    "pubchemCID": "3034034",
    "indications": "Uncomplicated Malaria (P. falciparum). Off-label: Leg cramps (Not recommended due to safety).",
    "moaSteps": [
      "Interferes with the parasite's ability to digest hemoglobin.",
      "Inhibits spontaneous nucleation of hemozoin.",
      "Accumulation of free cytotoxic heme kills the parasite.",
      "Also acts on skeletal muscle to increase refractory period (muscle relaxant)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Crosses placenta/BBB.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Urine. **Half-life: 11 to 18 hours.**"
    },
    "dose": {
      "initialDose": "648 mg PO every 8 hours for 7 days",
      "maxDose": "1944 mg/day",
      "notes": "FDA warning against use for leg cramps."
    },
    "adverseEffects": {
      "common": [
        "Cinchonism (Tinnitus, Headache, Nausea, Visual changes)",
        "Hypoglycemia"
      ],
      "serious": [
        "Thrombocytopenia / HUS / TTP (Hematologic toxicity)",
        "QT Prolongation",
        "Blackwater fever (Massive hemolysis)",
        "Blindness"
      ]
    },
    "precautions": [
      "**Hematologic:** Severe, life-threatening thrombocytopenia can occur. Discontinue if bleeding/bruising occurs.",
      "**Cardiac:** Monitor ECG for QT prolongation.",
      "**Glucose:** Stimulates insulin release; risk of hypoglycemia."
    ],
    "contraindications": [
      "Prolonged QT interval",
      "G6PD Deficiency",
      "Myasthenia Gravis",
      "Optic Neuritis"
    ],
    "interactions": {
      "drug": ["Digoxin (Increases digoxin levels)", "Warfarin", "Neuromuscular Blockers (Potentiates blockade)", "Ritonavir (Increases quinine levels)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "quizartinib": {
    "name": "Quizartinib (Vanflyta)",
    "genericName": "Quizartinib",
    "formula": "C29H32N6O4S",
    "molecularWeight": "560.7 g/mol",
    "brandNames": ["Vanflyta"],
    "category": "Antineoplastic",
    "drugClass": "FLT3 Inhibitor (Tyrosine Kinase Inhibitor)",
    "pubchemCID": "24889392",
    "indications": "Acute Myeloid Leukemia (AML) with FLT3-ITD mutation.",
    "moaSteps": [
      "Potent and selective inhibitor of FLT3 kinase.",
      "Inhibits FLT3 phosphorylation and downstream signaling (STAT5, MAPK, AKT).",
      "Induces apoptosis in leukemic cells carrying FLT3-ITD mutations.",
      "Type II inhibitor (binds inactive conformation)."
    ],
    "pharmacokinetics": {
      "absorption": "Good oral absorption.",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic via CYP3A4.",
      "excretion": "Feces. **Half-life: 73 hours (Active metabolite AC886: 135 hours).**"
    },
    "dose": {
      "initialDose": "35.4 mg PO once daily",
      "maxDose": "53 mg/day",
      "notes": "Available only through REMS program."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting",
        "Diarrhea",
        "Mucositis",
        "Abdominal pain"
      ],
      "serious": [
        "QT Prolongation / Torsades de Pointes - BOXED WARNING",
        "Severe Myelosuppression",
        "Differentiation Syndrome"
      ]
    },
    "precautions": [
      "**QT Prolongation:** Significant risk. ECG monitoring required before start, weekly during induction, and periodically. Correct electrolytes.",
      "**CYP3A4:** Strong inhibitors increase QT risk significantly.",
      "**Differentiation Syndrome:** Fever, dyspnea, hypoxia. Treat with steroids."
    ],
    "contraindications": [
      "Severe Hypokalemia / Hypomagnesemia (uncorrected)",
      "Long QT Syndrome"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inhibitors (Reduce dose)", "QT prolonging agents (Avoid)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "quazepam": {
    "name": "Quazepam (Doral)",
    "genericName": "Quazepam",
    "formula": "C17H11ClF4N2S",
    "molecularWeight": "386.8 g/mol",
    "brandNames": ["Doral"],
    "category": "Sedative/Hypnotic",
    "drugClass": "Benzodiazepine (Long-acting)",
    "pubchemCID": "4986",
    "indications": "Insomnia (Sleep induction and maintenance).",
    "moaSteps": [
      "Selectively targets Type 1 Benzodiazepine receptors (BNZ1) on GABA-A complex.",
      "Enhances GABAergic inhibition.",
      "Induces sleep with less muscle relaxation/ataxia than non-selective benzos (initially).",
      "Metabolites are non-selective."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Lipophilic.",
      "metabolism": "Hepatic to active metabolites (2-oxoquazepam and N-desalkyl-2-oxoquazepam).",
      "excretion": "Urine/Feces. **Half-life: 39 hours (Parent); 73 hours (Metabolites).**"
    },
    "dose": {
      "initialDose": "7.5-15 mg PO at bedtime",
      "maxDose": "15 mg/day",
      "notes": "Daytime drowsiness likely due to long half-life."
    },
    "adverseEffects": {
      "common": [
        "Daytime Drowsiness ('Hangover')",
        "Dizziness",
        "Fatigue",
        "Dry mouth"
      ],
      "serious": [
        "Complex Sleep Behaviors (Sleep-driving) - BOXED WARNING",
        "Respiratory Depression",
        "Dependence / Abuse"
      ]
    },
    "precautions": [
      "**Accumulation:** Long half-life metabolites accumulate over days. Watch for increasing sedation.",
      "**Elderly:** Avoid use (Beers Criteria). High risk of falls/confusion.",
      "**Sleep Behaviors:** Stop immediately if sleep-driving occurs."
    ],
    "contraindications": [
      "Sleep Apnea",
      "Pregnancy",
      "History of complex sleep behaviors"
    ],
    "interactions": {
      "drug": ["CNS Depressants (Alcohol/Opioids)", "CYP3A4 Inhibitors"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category X"
  },
  "quinupristin_dalfopristin": {
    "name": "Quinupristin/Dalfopristin (Synercid)",
    "genericName": "Quinupristin and Dalfopristin",
    "formula": "Streptogramin Combination (30:70)",
    "molecularWeight": "N/A",
    "brandNames": ["Synercid"],
    "category": "Antibiotic",
    "drugClass": "Streptogramin",
    "pubchemCID": "N/A (Combo)",
    "indications": "Vancomycin-Resistant Enterococcus faecium (VREF) bacteremia, Complicated Skin Infections (MSSA/Strep).",
    "moaSteps": [
      "Dalfopristin inhibits the early phase of protein synthesis (50S ribosome).",
      "Quinupristin inhibits the late phase of protein synthesis (50S ribosome).",
      "Synergistic binding causes permanent ribosome conformational change.",
      "Bactericidal against Staph/Strep; Bacteriostatic against Enterococcus."
    ],
    "pharmacokinetics": {
      "absorption": "IV only.",
      "distribution": "Extensive.",
      "metabolism": "Non-enzymatic conversion to active metabolites.",
      "excretion": "Feces (75%). **Half-life: 0.85 hours (Quinupristin); 0.7 hours (Dalfopristin).**"
    },
    "dose": {
      "initialDose": "7.5 mg/kg IV every 8 hours",
      "maxDose": "22.5 mg/kg/day",
      "notes": "Must be administered via Central Line (severe phlebitis)."
    },
    "adverseEffects": {
      "common": [
        "Infusion Site Pain / Phlebitis (Very common)",
        "Arthralgia / Myalgia (Severe)",
        "Nausea"
      ],
      "serious": [
        "Hyperbilirubinemia",
        "Angioedema",
        "Superinfection"
      ]
    },
    "precautions": [
      "**Administration:** Venous irritation is severe. Central venous catheter required. Flush only with D5W (incompatible with Saline).",
      "**Arthralgia:** May require discontinuation.",
      "**Hepatic:** Potent CYP3A4 inhibitor."
    ],
    "contraindications": [
      "Hypersensitivity to streptogramins"
    ],
    "interactions": {
      "drug": ["CYP3A4 Substrates (Cyclosporine/Tacrolimus/Midazolam - Toxicity)", "Statins (Rhabdomyolysis)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },"rabeprazole": {
    "name": "Rabeprazole (Aciphex)",
    "genericName": "Rabeprazole Sodium",
    "formula": "C18H21N3O3S",
    "molecularWeight": "359.4 g/mol",
    "brandNames": ["Aciphex"],
    "category": "Acid Reducer",
    "drugClass": "Proton Pump Inhibitor (PPI)",
    "pubchemCID": "5029",
    "indications": "GERD, Duodenal Ulcers, H. pylori eradication, Zollinger-Ellison Syndrome.",
    "moaSteps": [
      "Accumulates in the acidic parietal cell.",
      "Sulfenamide active form binds irreversibly to cysteines on H+/K+ ATPase.",
      "Inhibits acid secretion.",
      "Faster onset of acid suppression than omeprazole."
    ],
    "pharmacokinetics": {
      "absorption": "52% bioavailability. Enteric coated.",
      "distribution": "96% protein bound.",
      "metabolism": "Non-enzymatic reduction and CYP2C19/3A4.",
      "excretion": "Urine. **Half-life: 1 to 2 hours (Duration > 24h).**"
    },
    "dose": {
      "initialDose": "20 mg PO once daily",
      "maxDose": "60 mg/day (ZES)",
      "notes": "Swallow whole."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Diarrhea",
        "Nausea"
      ],
      "serious": [
        "Clostridioides difficile colitis",
        "Hypomagnesemia",
        "Acute Interstitial Nephritis",
        "Osteoporosis (Chronic)"
      ]
    },
    "precautions": [
      "**Metabolism:** Primarily non-enzymatic degradation; less CYP2C19 interaction potential than omeprazole/lansoprazole.",
      "**Infection:** Risk of pneumonia/C. diff.",
      "**Bone:** Monitor bone health."
    ],
    "contraindications": [
      "Hypersensitivity",
      "Concomitant Rilpivirine"
    ],
    "interactions": {
      "drug": ["Rilpivirine (Failure)", "Methotrexate (Toxicity)", "Digoxin (Increased absorption)"],
      "food": ["None (Can take with or without food - unique among PPIs)."]
    },
    "pregnancyCategory": "Category C"
  },
  "ranolazine": {
    "name": "Ranolazine (Ranexa)",
    "genericName": "Ranolazine",
    "formula": "C24H33N3O4",
    "molecularWeight": "427.5 g/mol",
    "brandNames": ["Ranexa"],
    "category": "Antianginal",
    "drugClass": "Late Sodium Current Inhibitor",
    "pubchemCID": "123098",
    "indications": "Chronic Angina.",
    "moaSteps": [
      "Inhibits the late phase of the inward sodium current (I-Na) in ischemic cardiac cells.",
      "Reduces intracellular sodium accumulation.",
      "Prevents calcium overload (via Na/Ca exchanger).",
      "Reduces myocardial wall tension and oxygen consumption without affecting heart rate or blood pressure."
    ],
    "pharmacokinetics": {
      "absorption": "Variable (73%).",
      "distribution": "62% protein bound.",
      "metabolism": "Extensive Hepatic (CYP3A4/2D6).",
      "excretion": "Urine. **Half-life: 7 hours.**"
    },
    "dose": {
      "initialDose": "500 mg ER PO BID",
      "maxDose": "1000 mg BID",
      "notes": "Do not crush."
    },
    "adverseEffects": {
      "common": [
        "Dizziness",
        "Headache",
        "Constipation",
        "Nausea"
      ],
      "serious": [
        "QT Prolongation",
        "Syncope",
        "Renal Failure (Acute)"
      ]
    },
    "precautions": [
      "**QT Interval:** Dose-dependent prolongation. Caution in Long QT syndrome.",
      "**Liver:** Contraindicated in cirrhosis.",
      "**Renal:** Monitor serum creatinine."
    ],
    "contraindications": [
      "Hepatic cirrhosis",
      "Strong CYP3A4 inhibitors/inducers"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inhibitors (Toxicity - Contraindicated)", "Simvastatin (Limit simvastatin to 20mg)", "Metformin (Increases metformin levels)"],
      "food": ["Grapefruit juice"]
    },
    "pregnancyCategory": "Category C"
  },
  "rasagiline": {
    "name": "Rasagiline (Azilect)",
    "genericName": "Rasagiline",
    "formula": "C12H13N",
    "molecularWeight": "171.24 g/mol",
    "brandNames": ["Azilect"],
    "category": "Antiparkinson Agent",
    "drugClass": "MAO-B Inhibitor (Irreversible)",
    "pubchemCID": "3052776",
    "indications": "Parkinson's Disease.",
    "moaSteps": [
      "Potent, irreversible inhibitor of Monoamine Oxidase B (MAO-B).",
      "Inhibits the breakdown of dopamine in the striatum.",
      "Increases extracellular dopamine levels.",
      "Possible neuroprotective activity."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "High volume.",
      "metabolism": "Hepatic (CYP1A2). No amphetamine metabolites (unlike Selegiline).",
      "excretion": "Urine. **Half-life: 3 hours (Pharmacologic effect lasts days due to irreversible binding).**"
    },
    "dose": {
      "initialDose": "1 mg PO daily (Monotherapy)",
      "maxDose": "1 mg/day",
      "notes": "0.5 mg if on levodopa."
    },
    "adverseEffects": {
      "common": [
        "Dyskinesia (enhances levodopa)",
        "Headache",
        "Nausea",
        "Orthostatic Hypotension"
      ],
      "serious": [
        "Serotonin Syndrome",
        "Hypertensive Crisis (Tyramine interaction)",
        "Hallucinations"
      ]
    },
    "precautions": [
      "**Serotonin Syndrome:** Caution with antidepressants, cyclobenzaprine, dextromethorphan.",
      "**Tyramine:** Dietary restriction usually not needed at recommended doses (MAO-B selective), but caution advised.",
      "**Melanoma:** Monitor skin."
    ],
    "contraindications": [
      "Concomitant Meperidine, Tramadol, Methadone, Dextromethorphan, St. John's Wort, Cyclobenzaprine, MAOIs"
    ],
    "interactions": {
      "drug": ["Ciprofloxacin (CYP1A2 inhibitor - doubles levels)", "Serotonergic agents"],
      "food": ["Tyramine-rich foods (Cheese/Wine) - High risk if dose exceeded."]
    },
    "pregnancyCategory": "Category C"
  },
  "regorafenib": {
    "name": "Regorafenib (Stivarga)",
    "genericName": "Regorafenib",
    "formula": "C21H15ClF4N4O3",
    "molecularWeight": "482.8 g/mol",
    "brandNames": ["Stivarga"],
    "category": "Antineoplastic",
    "drugClass": "Multikinase Inhibitor",
    "pubchemCID": "11167602",
    "indications": "Metastatic Colorectal Cancer, GIST, Hepatocellular Carcinoma.",
    "moaSteps": [
      "Inhibits multiple membrane-bound and intracellular kinases (VEGFR, TIE2, KIT, RET, RAF, BRAF).",
      "Inhibits angiogenesis (VEGFR/TIE2).",
      "Inhibits tumor cell proliferation (KIT/RAF).",
      "Inhibits tumor microenvironment signaling."
    ],
    "pharmacokinetics": {
      "absorption": "High fat meal alters absorption (Take with low-fat meal).",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic (CYP3A4/UGT1A9).",
      "excretion": "Feces. **Half-life: 28 hours.**"
    },
    "dose": {
      "initialDose": "160 mg PO daily for 21 days (28 day cycle)",
      "maxDose": "160 mg/day",
      "notes": "Swallow whole."
    },
    "adverseEffects": {
      "common": [
        "Hand-Foot Skin Reaction (HFSR)",
        "Fatigue",
        "Diarrhea",
        "Hypertension",
        "Dysphonia"
      ],
      "serious": [
        "Hepatotoxicity (Fatal) - BOXED WARNING",
        "GI Perforation / Fistula",
        "Hemorrhage",
        "Reversible Posterior Leukoencephalopathy Syndrome (RPLS)"
      ]
    },
    "precautions": [
      "**Hepatotoxicity:** Monitor LFTs every 2 weeks for first 2 months. Severe injury can occur.",
      "**HFSR:** Prophylactic moisturizing/keratolytics recommended.",
      "**Wound Healing:** Stop 2 weeks before surgery."
    ],
    "contraindications": [
      "None specific (Hypersensitivity)"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inhibitors/Inducers", "Warfarin (Bleeding)"],
      "food": ["Take with LOW fat meal (<30% fat). High fat increases toxicity; Fasting reduces efficacy."]
    },
    "pregnancyCategory": "Category D"
  },
  "repaglinide": {
    "name": "Repaglinide (Prandin)",
    "genericName": "Repaglinide",
    "formula": "C27H36N2O4",
    "molecularWeight": "452.6 g/mol",
    "brandNames": ["Prandin"],
    "category": "Antidiabetic",
    "drugClass": "Meglitinide",
    "pubchemCID": "65981",
    "indications": "Type 2 Diabetes Mellitus.",
    "moaSteps": [
      "Binds to ATP-dependent potassium channels on pancreatic beta cells (distinct site from sulfonylureas).",
      "Closes K+ channels, depolarizing the membrane.",
      "Opens Calcium channels, triggering insulin release.",
      "Short-acting insulin secretagogue (Post-prandial control)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid and complete.",
      "distribution": "98% protein bound.",
      "metabolism": "Hepatic (CYP2C8/3A4).",
      "excretion": "Feces (90%). **Half-life: 1 hour.**"
    },
    "dose": {
      "initialDose": "0.5 mg PO before each meal",
      "maxDose": "4 mg/dose (16 mg/day)",
      "notes": "Skip dose if skipping meal."
    },
    "adverseEffects": {
      "common": [
        "Hypoglycemia",
        "Weight gain",
        "Headache",
        "Arthralgia"
      ],
      "serious": [
        "Severe Hypoglycemia",
        "Serious Cardiovascular Events (Historical concern)"
      ]
    },
    "precautions": [
      "**Hypoglycemia:** 'Skip a meal, skip a dose' rule prevents lows.",
      "**Renal:** Safe in renal impairment (mostly biliary excretion).",
      "**Interactions:** Gemfibrozil interaction is dangerous."
    ],
    "contraindications": [
      "DKA",
      "Concomitant Gemfibrozil",
      "Type 1 Diabetes"
    ],
    "interactions": {
      "drug": ["Gemfibrozil (Inhibits CYP2C8 - Prolonged severe hypoglycemia - CONTRAINDICATED)", "Clopidogrel (Increases levels)", "Trimethoprim"],
      "food": ["Take 15-30 min before meal."]
    },
    "pregnancyCategory": "Category C"
  },
  "rifabutin": {
    "name": "Rifabutin (Mycobutin)",
    "genericName": "Rifabutin",
    "formula": "C46H62N4O11",
    "molecularWeight": "847.0 g/mol",
    "brandNames": ["Mycobutin"],
    "category": "Antimycobacterial",
    "drugClass": "Rifamycin",
    "pubchemCID": "5361810",
    "indications": "MAC (Mycobacterium avium complex) prophylaxis, Tuberculosis (Alternative to Rifampin in HIV patients).",
    "moaSteps": [
      "Inhibits DNA-dependent RNA polymerase in susceptible bacteria.",
      "Prevents chain initiation.",
      "Less potent inducer of CYP450 than Rifampin (preferred in HIV patients on Protease Inhibitors)."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "High intracellular concentration.",
      "metabolism": "Hepatic (CYP3A4). Induces CYP3A4.",
      "excretion": "Urine/Feces. **Half-life: 45 hours.**"
    },
    "dose": {
      "initialDose": "300 mg PO daily",
      "maxDose": "600 mg/day",
      "notes": "Urine/skin discoloration."
    },
    "adverseEffects": {
      "common": [
        "Red-orange discoloration of urine/tears",
        "Rash",
        "GI upset",
        "Neutropenia"
      ],
      "serious": [
        "Uveitis (dose-dependent)",
        "Leukopenia / Thrombocytopenia",
        "Hepatotoxicity",
        "C. diff colitis"
      ]
    },
    "precautions": [
      "**Uveitis:** Eye pain/redness/vision loss. Risk increases with high doses or macrolide co-administration.",
      "**Discoloration:** Stains contact lenses and clothing red-orange.",
      "**Interactions:** Still an inducer (check ARV interactions)."
    ],
    "contraindications": [
      "Hypersensitivity to rifamycins"
    ],
    "interactions": {
      "drug": ["Protease Inhibitors (Requires dose adjustment)", "Oral Contraceptives (Failure)", "Warfarin (Decreased INR)"],
      "food": ["High fat meal slows absorption."]
    },
    "pregnancyCategory": "Category B"
  },
  "rifampin": {
    "name": "Rifampin (Rifadin)",
    "genericName": "Rifampin",
    "formula": "C43H58N4O12",
    "molecularWeight": "822.9 g/mol",
    "brandNames": ["Rifadin"],
    "category": "Antimycobacterial",
    "drugClass": "Rifamycin",
    "pubchemCID": "135398735",
    "indications": "Tuberculosis (Active/Latent), Meningococcal Prophylaxis, Staph aureus Endocarditis (Biofilm penetration).",
    "moaSteps": [
      "Binds to the beta subunit of DNA-dependent RNA polymerase.",
      "Inhibits initiation of RNA synthesis.",
      "Bactericidal.",
      "Excellent penetration into biofilms."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "Wide (CSF, Abscesses).",
      "metabolism": "Hepatic. VERY POTENT CYP INDUCER.",
      "excretion": "Bile/Feces. **Half-life: 3-4 hours (shortens to 2h with autoinduction).**"
    },
    "dose": {
      "initialDose": "10 mg/kg (600 mg) PO/IV daily",
      "maxDose": "600 mg/day",
      "notes": "Take on empty stomach."
    },
    "adverseEffects": {
      "common": [
        "Red-orange body fluids (Urine/Sweat/Tears)",
        "GI upset",
        "Flu-like syndrome (intermittent dosing)"
      ],
      "serious": [
        "Hepatotoxicity",
        "Acute Renal Failure",
        "Thrombocytopenia / Hemolytic Anemia",
        "Severe skin reactions"
      ]
    },
    "precautions": [
      "**Interactions:** One of the most potent CYP inducers known. Renders many drugs ineffective (OCPs, Anticoagulants, Anticonvulsants, ARVs).",
      "**Hepatotoxicity:** Monitor LFTs.",
      "**Staining:** Permanently stains soft contact lenses."
    ],
    "contraindications": [
      "Concurrent use with Protease Inhibitors (mostly)",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Oral Contraceptives (Failure)", "Warfarin (Massive INR drop)", "Direct Oral Anticoagulants (Failure)", "Azoles/Macrolides"],
      "food": ["Take 1 hour before or 2 hours after meals."]
    },
    "pregnancyCategory": "Category C"
  },
  "rifaximin": {
    "name": "Rifaximin (Xifaxan)",
    "genericName": "Rifaximin",
    "formula": "C43H51N3O11",
    "molecularWeight": "785.9 g/mol",
    "brandNames": ["Xifaxan"],
    "category": "Antibiotic",
    "drugClass": "Rifamycin (Non-absorbable)",
    "pubchemCID": "6436173",
    "indications": "Traveler's Diarrhea (E. coli), Hepatic Encephalopathy (Risk reduction), IBS-D.",
    "moaSteps": [
      "Inhibits bacterial RNA synthesis (binds RNA polymerase).",
      "Broad spectrum bactericidal activity in the GI tract.",
      "Reduces ammonia-producing bacteria in Hepatic Encephalopathy.",
      "Minimal systemic absorption (<0.4%)."
    ],
    "pharmacokinetics": {
      "absorption": "Negligible.",
      "distribution": "Gut lumen.",
      "metabolism": "Minimal.",
      "excretion": "Feces (97%). **Half-life: 6 hours (Systemic - negligible significance).**"
    },
    "dose": {
      "initialDose": "550 mg PO BID (HE); 550 mg TID (IBS-D)",
      "maxDose": "1650 mg/day",
      "notes": "HE: Used with Lactulose."
    },
    "adverseEffects": {
      "common": [
        "Nausea",
        "Peripheral edema",
        "Dizziness",
        "Fatigue"
      ],
      "serious": [
        "Clostridioides difficile colitis",
        "Hypersensitivity"
      ]
    },
    "precautions": [
      "**Systemic Infection:** Not effective for invasive diarrhea (fever/blood).",
      "**Liver Disease:** Systemic exposure increases in severe hepatic impairment (Caution).",
      "**Resistance:** Low risk of cross-resistance with Rifampin."
    ],
    "contraindications": [
      "Hypersensitivity to rifamycins"
    ],
    "interactions": {
      "drug": ["P-gp Inhibitors (Cyclosporine - increases rifaximin exposure)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "rilpivirine": {
    "name": "Rilpivirine (Edurant)",
    "genericName": "Rilpivirine",
    "formula": "C22H18N6",
    "molecularWeight": "366.4 g/mol",
    "brandNames": ["Edurant", "Odefsey", "Complera"],
    "category": "Antiretroviral",
    "drugClass": "Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)",
    "pubchemCID": "6451164",
    "indications": "HIV-1 Infection (Treatment naive with viral load < 100,000).",
    "moaSteps": [
      "Binds non-competitively to HIV-1 reverse transcriptase.",
      "Induces conformational change disrupting the enzyme's catalytic site.",
      "Blocks RNA/DNA-dependent DNA polymerase activity."
    ],
    "pharmacokinetics": {
      "absorption": "pH dependent. Food increases absorption.",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Feces. **Half-life: 50 hours.**"
    },
    "dose": {
      "initialDose": "25 mg PO once daily",
      "maxDose": "25 mg/day",
      "notes": "MUST TAKE WITH A MEAL (Protein/Fat)."
    },
    "adverseEffects": {
      "common": [
        "Depressive disorders",
        "Insomnia",
        "Headache",
        "Rash"
      ],
      "serious": [
        "Severe Skin Reactions (DRESS)",
        "QT Prolongation (High doses)",
        "Hepatotoxicity",
        "Suicidality"
      ]
    },
    "precautions": [
      "**Acid Suppression:** PPIs are CONTRAINDICATED (Significant reduction in levels -> Resistance). H2 blockers must be spaced 12 hours.",
      "**Viral Load:** Do not use if baseline HIV RNA > 100,000 copies/mL (High failure rate).",
      "**Mental Health:** Monitor for depression."
    ],
    "contraindications": [
      "Concurrent PPIs (Omeprazole, etc.)",
      "Strong CYP3A4 inducers",
      "Viral load > 100k (Clinical limitation)"
    ],
    "interactions": {
      "drug": ["PPIs (Contraindicated)", "H2 Blockers (Space 12h)", "CYP3A4 Inducers"],
      "food": ["Take with full meal (500+ kcal)."]
    },
    "pregnancyCategory": "Category B"
  },
  "rimegepant": {
    "name": "Rimegepant (Nurtec ODT)",
    "genericName": "Rimegepant",
    "formula": "C28H28F2N6O3",
    "molecularWeight": "534.6 g/mol",
    "brandNames": ["Nurtec ODT"],
    "category": "Antimigraine",
    "drugClass": "CGRP Receptor Antagonist (Gepant)",
    "pubchemCID": "58520660",
    "indications": "Acute treatment of Migraine, Prevention of Episodic Migraine.",
    "moaSteps": [
      "Small molecule antagonist of the Calcitonin Gene-Related Peptide (CGRP) receptor.",
      "CGRP is a potent vasodilator and pain signal transmitter in the trigeminal system.",
      "Blockade prevents neurogenic inflammation and pain transmission.",
      "Does not cause vasoconstriction (unlike Triptans)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (ODT).",
      "distribution": "96% protein bound.",
      "metabolism": "Hepatic (CYP3A4/2C9).",
      "excretion": "Feces/Urine. **Half-life: 11 hours.**"
    },
    "dose": {
      "initialDose": "75 mg ODT (Acute or Every other day for Prev)",
      "maxDose": "75 mg/day",
      "notes": "Safe in patients with vascular disease."
    },
    "adverseEffects": {
      "common": [
        "Nausea",
        "Stomach pain",
        "Indigestion"
      ],
      "serious": [
        "Hypersensitivity (Dyspnea/Rash)"
      ]
    },
    "precautions": [
      "**Interactions:** Avoid strong CYP3A4 inhibitors/inducers.",
      "**Safety:** No vasoconstrictive liability (Safe in CAD/Stroke history)."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inhibitors (Avoid or space dose)", "Strong CYP3A4 Inducers (Avoid)"],
      "food": ["High fat meal delays Tmax."]
    },
    "pregnancyCategory": "Category No Rating (Avoid)"
  },
  "risankizumab": {
    "name": "Risankizumab (Skyrizi)",
    "genericName": "Risankizumab-rzaa",
    "formula": "Humanized IgG1 monoclonal antibody",
    "molecularWeight": "148 kDa",
    "brandNames": ["Skyrizi"],
    "category": "Biologic",
    "drugClass": "IL-23 Inhibitor",
    "pubchemCID": "None (Protein)",
    "indications": "Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease.",
    "moaSteps": [
      "Binds to the p19 subunit of human interleukin-23 (IL-23).",
      "Inhibits interaction with the IL-23 receptor.",
      "Inhibits release of pro-inflammatory cytokines/chemokines.",
      "Specific for IL-23 (p19); does not bind IL-12 (p40)."
    ],
    "pharmacokinetics": {
      "absorption": "Subcutaneous.",
      "distribution": "Vascular/Interstitial.",
      "metabolism": "Proteolysis.",
      "excretion": "Long elimination. **Half-life: 28 days.**"
    },
    "dose": {
      "initialDose": "150 mg SubQ at week 0 and 4",
      "maxDose": "150 mg every 12 weeks (Psoriasis)",
      "notes": "Crohn's induction is IV."
    },
    "adverseEffects": {
      "common": [
        "Upper respiratory infection",
        "Headache",
        "Fatigue",
        "Injection site reaction"
      ],
      "serious": [
        "Serious Infections (TB, Fungal)",
        "Hypersensitivity",
        "Liver Injury (Crohn's induction)"
      ]
    },
    "precautions": [
      "**Infection:** Test for TB before starting. Monitor for infection.",
      "**Vaccines:** Avoid live vaccines.",
      "**Liver:** Monitor LFTs during Crohn's induction."
    ],
    "contraindications": [
      "Active serious infection",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Live vaccines"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B (Likely safe)"
  },
  "risperidone": {
    "name": "Risperidone (Risperdal)",
    "genericName": "Risperidone",
    "formula": "C23H27FN4O2",
    "molecularWeight": "410.5 g/mol",
    "brandNames": ["Risperdal", "Perseris"],
    "category": "Antipsychotic",
    "drugClass": "Atypical Antipsychotic (Second Generation)",
    "pubchemCID": "5073",
    "indications": "Schizophrenia, Bipolar Mania, Irritability in Autism.",
    "moaSteps": [
      "Potent antagonist at Serotonin 5-HT2A and Dopamine D2 receptors.",
      "Also blocks Alpha-1, Alpha-2, and Histamine H1 receptors.",
      "High affinity for D2 receptors makes it more 'typical-like' (EPS risk) at high doses."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "90% protein bound.",
      "metabolism": "Hepatic (CYP2D6) to active metabolite Paliperidone.",
      "excretion": "Urine. **Half-life: 3 hours (Parent); 24 hours (Active metabolite).**"
    },
    "dose": {
      "initialDose": "1-2 mg PO daily",
      "maxDose": "6-8 mg/day",
      "notes": "Doses >6mg act like Typical Antipsychotics (EPS)."
    },
    "adverseEffects": {
      "common": [
        "EPS (Parkinsonism, Akathisia)",
        "Hyperprolactinemia (Gynecomastia/Galactorrhea)",
        "Weight gain",
        "Sedation"
      ],
      "serious": [
        "Tardive Dyskinesia",
        "Neuroleptic Malignant Syndrome",
        "Increased mortality in elderly dementia - BOXED WARNING",
        "Metabolic Syndrome"
      ]
    },
    "precautions": [
      "**Prolactin:** Highest risk of elevation among atypicals.",
      "**EPS:** Dose-dependent. Keep dose low.",
      "**Orthostasis:** Alpha-blockade causes hypotension; titrate slowly."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["CYP2D6 Inhibitors (Fluoxetine - Increase levels)", "Levodopa (Antagonism)", "Antihypertensives"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "ritonavir": {
    "name": "Ritonavir (Norvir)",
    "genericName": "Ritonavir",
    "formula": "C37H48N6O5S2",
    "molecularWeight": "720.9 g/mol",
    "brandNames": ["Norvir"],
    "category": "Antiretroviral / Pharmacokinetic Enhancer",
    "drugClass": "Protease Inhibitor (Booster)",
    "pubchemCID": "392622",
    "indications": "HIV-1 Infection (as a booster for other PIs).",
    "moaSteps": [
      "Inhibits HIV protease (rarely used for this anymore).",
      "Potent inhibitor of CYP3A4.",
      "Used primarily to boost the serum concentrations of other protease inhibitors (Lopinavir, Darunavir, Atazanavir) by inhibiting their metabolism.",
      "Allows for lower doses and less frequent dosing of the primary ARV."
    ],
    "pharmacokinetics": {
      "absorption": "Good with food.",
      "distribution": "98% protein bound.",
      "metabolism": "Hepatic (CYP3A4/2D6). Potent Inhibitor.",
      "excretion": "Feces. **Half-life: 3 to 5 hours.**"
    },
    "dose": {
      "initialDose": "100-200 mg PO daily/BID (Booster dose)",
      "maxDose": "1200 mg (Therapeutic - Toxic)",
      "notes": "Take with food."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting / Diarrhea (Severe at therapeutic doses)",
        "Taste perversion",
        "Paresthesias"
      ],
      "serious": [
        "Drug Interactions (Fatal)",
        "Hyperlipidemia (Triglycerides)",
        "Hyperglycemia",
        "Hepatotoxicity"
      ]
    },
    "precautions": [
      "**Interactions:** The most potent CYP3A4 inhibitor available. Review ALL medications. Many are contraindicated (statins, antiarrhythmics, sedatives).",
      "**Lipids:** Significant elevation of TG/Cholesterol.",
      "**Liver:** Monitor LFTs."
    ],
    "contraindications": [
      "Concomitant Amiodarone, Flecainide, Propafenone, Simvastatin, Lovastatin, Midazolam, Ergotamine, St. John's Wort"
    ],
    "interactions": {
      "drug": ["Virtually everything metabolized by CYP3A4 (Inhibits metabolism -> Toxicity)"],
      "food": ["Take with food."]
    },
    "pregnancyCategory": "Category B"
  },
  "rivastigmine": {
    "name": "Rivastigmine (Exelon)",
    "genericName": "Rivastigmine Tartrate",
    "formula": "C14H22N2O2",
    "molecularWeight": "250.3 g/mol",
    "brandNames": ["Exelon"],
    "category": "Anti-Alzheimer's Agent",
    "drugClass": "Acetylcholinesterase Inhibitor",
    "pubchemCID": "77991",
    "indications": "Alzheimer's Disease (Mild-Severe), Parkinson's Disease Dementia.",
    "moaSteps": [
      "Reversibly inhibits acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE).",
      "Increases acetylcholine in the brain.",
      "Improves cognitive function and behavior.",
      "Pseudo-irreversible inhibition (carbamylation)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Crosses BBB.",
      "metabolism": "Hydrolysis by cholinesterase (Not CYP450).",
      "excretion": "Urine. **Half-life: 1.5 hours (Effect lasts 10h due to slow dissociation).**"
    },
    "dose": {
      "initialDose": "1.5 mg PO BID or 4.6 mg/24h Patch",
      "maxDose": "12 mg/day (PO) or 13.3 mg/24h (Patch)",
      "notes": "Patch has fewer GI side effects."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting (Severe with oral)",
        "Anorexia / Weight Loss",
        "Diarrhea",
        "Skin irritation (Patch)"
      ],
      "serious": [
        "Bradycardia / Syncope",
        "Esophageal Rupture (from severe vomiting)",
        "Seizures",
        "Worsening of COPD"
      ]
    },
    "precautions": [
      "**GI:** Oral form causes high rates of N/V. Titrate slowly. Patch preferred.",
      "**Weight:** Monitor for malnutrition.",
      "**Cardiac:** Caution in Sick Sinus Syndrome.",
      "**Patch:** Remove old patch before applying new one (Overdose risk)."
    ],
    "contraindications": [
      "Hypersensitivity to carbamates",
      "History of severe allergic reaction to patch"
    ],
    "interactions": {
      "drug": ["Beta-blockers (Bradycardia)", "Anticholinergics (Antagonism)", "Metoclopramide (EPS risk)"],
      "food": ["Take oral with food."]
    },
    "pregnancyCategory": "Category B"
  },
  "ropinirole": {
    "name": "Ropinirole (Requip)",
    "genericName": "Ropinirole HCl",
    "formula": "C16H24N2O",
    "molecularWeight": "260.4 g/mol",
    "brandNames": ["Requip", "Requip XL"],
    "category": "Antiparkinson Agent",
    "drugClass": "Dopamine Agonist (Non-ergot)",
    "pubchemCID": "5095",
    "indications": "Parkinson's Disease, Restless Legs Syndrome (RLS).",
    "moaSteps": [
      "Direct agonist activity at dopamine D2 and D3 receptors in the striatum.",
      "Stimulates dopamine receptors, bypassing degenerating neurons.",
      "Improves motor symptoms.",
      "Non-ergot structure (low fibrosis risk)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (50% bioavailable).",
      "distribution": "40% protein bound.",
      "metabolism": "Hepatic (CYP1A2).",
      "excretion": "Urine. **Half-life: 6 hours.**"
    },
    "dose": {
      "initialDose": "0.25 mg PO TID (PD); 0.25 mg PO daily (RLS)",
      "maxDose": "24 mg/day (PD); 4 mg/day (RLS)",
      "notes": "Titrate weekly."
    },
    "adverseEffects": {
      "common": [
        "Nausea",
        "Somnolence / Sleep attacks",
        "Dizziness / Orthostasis",
        "Edema"
      ],
      "serious": [
        "Sudden Sleep Onset (while driving)",
        "Impulse Control Disorders (Gambling/Sex)",
        "Hallucinations",
        "Fibrosis (rare compared to ergot)"
      ]
    },
    "precautions": [
      "**Sleep Attacks:** Patients may fall asleep without warning. Caution driving.",
      "**Impulse Control:** Ask about gambling, spending, sexual urges.",
      "**Withdrawal:** Taper to avoid Neuroleptic Malignant-like syndrome.",
      "**Augmentation:** In RLS, symptoms may worsen/occur earlier in day with long-term use."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["CYP1A2 Inhibitors (Ciprofloxacin - Increases levels)", "Estrogens (Reduce clearance)", "Dopamine antagonists"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "rotigotine": {
    "name": "Rotigotine (Neupro)",
    "genericName": "Rotigotine",
    "formula": "C19H25NOS",
    "molecularWeight": "315.5 g/mol",
    "brandNames": ["Neupro"],
    "category": "Antiparkinson Agent",
    "drugClass": "Dopamine Agonist (Transdermal)",
    "pubchemCID": "59227",
    "indications": "Parkinson's Disease, Restless Legs Syndrome (RLS).",
    "moaSteps": [
      "Non-ergot dopamine agonist.",
      "Stimulates D3, D2, and D1 receptors.",
      "Continuous transdermal delivery provides stable plasma levels.",
      "Reduces motor fluctuations."
    ],
    "pharmacokinetics": {
      "absorption": "Transdermal (45% released/24h).",
      "distribution": "High Vd.",
      "metabolism": "Conjugation and N-dealkylation.",
      "excretion": "Urine and Feces. **Half-life: 5 to 7 hours (after patch removal); 3 hours (IV).**"
    },
    "dose": {
      "initialDose": "2 mg/24h Patch (PD); 1 mg/24h Patch (RLS)",
      "maxDose": "8 mg/24h (PD)",
      "notes": "Rotate sites daily (14 day cycle)."
    },
    "adverseEffects": {
      "common": [
        "Application site reactions",
        "Nausea",
        "Somnolence",
        "Headache"
      ],
      "serious": [
        "Sudden Sleep Onset",
        "Impulse Control Disorders",
        "Hallucinations",
        "Sulfite Sensitivity (contains metabisulfite)"
      ]
    },
    "precautions": [
      "**Sulfite Allergy:** Patch contains sulfites; caution in sensitive asthmatics.",
      "**MRI:** Patch contains aluminum; REMOVE before MRI to prevent burns.",
      "**Heat:** Heat sources increase absorption."
    ],
    "contraindications": [
      "Sulfite allergy",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Dopamine antagonists (Antipsychotics/Metoclopramide)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "ruxolitinib": {
    "name": "Ruxolitinib (Jakafi)",
    "genericName": "Ruxolitinib Phosphate",
    "formula": "C17H18N6",
    "molecularWeight": "306.4 g/mol",
    "brandNames": ["Jakafi", "Opzelura (Topical)"],
    "category": "Antineoplastic",
    "drugClass": "Janus Kinase (JAK) Inhibitor",
    "pubchemCID": "25126798",
    "indications": "Myelofibrosis, Polycythemia Vera, Graft vs Host Disease (GVHD). Topical: Eczema, Vitiligo.",
    "moaSteps": [
      "Inhibits Janus Associated Kinases (JAK1 and JAK2).",
      "Disrupts the JAK-STAT signaling pathway.",
      "Inhibits proliferation of leukemic cells.",
      "Reduces inflammatory cytokine levels.",
      "Reduces splenomegaly."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "97% protein bound.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Urine/Feces. **Half-life: 3 hours.**"
    },
    "dose": {
      "initialDose": "5-20 mg PO BID (Platelet dependent)",
      "maxDose": "25 mg BID",
      "notes": "Monitor CBC."
    },
    "adverseEffects": {
      "common": [
        "Anemia",
        "Thrombocytopenia",
        "Bruising",
        "Dizziness"
      ],
      "serious": [
        "Serious Infections (TB, Fungal, Viral)",
        "Non-Melanoma Skin Cancer",
        "Lipid Elevations",
        "Major Adverse Cardiovascular Events (Class effect)"
      ]
    },
    "precautions": [
      "**Withdrawal:** Withdrawal syndrome (return of splenomegaly/fever/shock) possible. Taper over 1-2 weeks.",
      "**Infection:** Screen for TB. Herpes zoster prophylaxis may be needed.",
      "**Blood Counts:** Dose reduction required for low platelets."
    ],
    "contraindications": [
      "None (other than hypersensitivity)"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inhibitors (Reduce dose by 50%)", "Fluconazole (Reduce dose)"],
      "food": ["Grapefruit juice (Increases levels)"]
    },
    "pregnancyCategory": "Category C"
  },
  "sacubitril_valsartan": {
    "name": "Sacubitril/Valsartan (Entresto)",
    "genericName": "Sacubitril and Valsartan",
    "formula": "Co-crystal complex",
    "molecularWeight": "N/A",
    "brandNames": ["Entresto"],
    "category": "Heart Failure Agent",
    "drugClass": "Angiotensin Receptor-Neprilysin Inhibitor (ARNI)",
    "pubchemCID": "N/A (Combo)",
    "indications": "Heart Failure with reduced Ejection Fraction (HFrEF), HFpEF (selected cases).",
    "moaSteps": [
      "Valsartan: Blocks Angiotensin II (AT1) receptor (Vasodilation, Reduced aldosterone).",
      "Sacubitril: Prodrug inhibitor of Neprilysin.",
      "Neprilysin degrades natriuretic peptides (BNP).",
      "Inhibition increases BNP levels -> Natriuresis, Vasodilation, antifibrotic effects."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "High protein binding.",
      "metabolism": "Sacubitril: Esterases to LBQ657. Valsartan: Minimal.",
      "excretion": "Urine/Feces. **Half-life: Sacubitril (1.4h), LBQ657 (11.5h), Valsartan (9.9h).**"
    },
    "dose": {
      "initialDose": "24/26 mg or 49/51 mg PO BID",
      "maxDose": "97/103 mg BID",
      "notes": "36-hour washout of ACE Inhibitor required before starting."
    },
    "adverseEffects": {
      "common": [
        "Hypotension",
        "Hyperkalemia",
        "Cough",
        "Dizziness"
      ],
      "serious": [
        "Angioedema - BOXED WARNING (Avoid if hx of ACEI angioedema)",
        "Renal Failure",
        "Fetal Toxicity - BOXED WARNING"
      ]
    },
    "precautions": [
      "**ACE Washout:** Must wait 36 hours after last ACE inhibitor dose before starting Entresto to prevent Angioedema.",
      "**BNP:** BNP levels will be falsely elevated (drug mechanism). Use NT-proBNP for monitoring HF status.",
      "**Hypotension:** More common than with ACE/ARB alone."
    ],
    "contraindications": [
      "History of Angioedema with ACEI/ARB",
      "Concomitant ACE Inhibitors",
      "Pregnancy"
    ],
    "interactions": {
      "drug": ["ACE Inhibitors (Contraindicated)", "Potassium-sparing diuretics (Hyperkalemia)", "NSAIDs (Renal failure)", "Lithium"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "quinidine": {
    "name": "Quinidine",
    "genericName": "Quinidine Sulfate/Gluconate",
    "formula": "C20H24N2O2",
    "molecularWeight": "324.4 g/mol",
    "brandNames": ["Quinidex"],
    "category": "Antiarrhythmic",
    "drugClass": "Class IA Antiarrhythmic",
    "pubchemCID": "441074",
    "indications": "Malaria (IV), Atrial Fibrillation/Flutter conversion (Rarely used now).",
    "moaSteps": [
      "Blocks fast sodium channels (Phase 0 depression).",
      "Blocks potassium channels (Prolongs repolarization/QT).",
      "Anticholinergic (Vagolytic) activity increases AV conduction (dangerous in A-flutter).",
      "Antimalarial: Similar to chloroquine."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "High protein binding.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Urine. **Half-life: 6 to 8 hours.**"
    },
    "dose": {
      "initialDose": "200-300 mg PO q6-8h",
      "maxDose": "Variable",
      "notes": "IV for severe malaria."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea (severe)",
        "Cinchonism (Tinnitus, Headache, Vertigo)",
        "Nausea"
      ],
      "serious": [
        "Torsades de Pointes (QT Prolongation) - BOXED WARNING",
        "Thrombocytopenia",
        "Hemolytic Anemia",
        "Hepatotoxicity"
      ]
    },
    "precautions": [
      "**Proarrhythmia:** High risk of Torsades. Monitor QT.",
      "**Cinchonism:** Signs of toxicity include ringing ears/blurred vision.",
      "**Vagolytic:** In A-Flutter, can increase AV conduction leading to 1:1 conduction and rapid ventricular rate. Pre-treat with Digoxin/Beta-blocker."
    ],
    "contraindications": [
      "Thrombocytopenia with prior use",
      "Complete heart block",
      "Long QT syndrome"
    ],
    "interactions": {
      "drug": ["Digoxin (Quinidine doubles digoxin levels - Halve digoxin dose)", "Warfarin", "CYP3A4 Inhibitors"],
      "food": ["Grapefruit juice"]
    },
    "pregnancyCategory": "Category C"
  },
  "raloxifene": {
    "name": "Raloxifene (Evista)",
    "genericName": "Raloxifene HCl",
    "formula": "C28H27NO4S",
    "molecularWeight": "473.6 g/mol",
    "brandNames": ["Evista"],
    "category": "SERM",
    "drugClass": "Selective Estrogen Receptor Modulator",
    "pubchemCID": "5035",
    "indications": "Osteoporosis (prevention/treatment) in postmenopausal women, Breast Cancer reduction in high-risk women.",
    "moaSteps": [
      "Estrogen Agonist in Bone: Decreases bone resorption and turnover.",
      "Estrogen Antagonist in Breast/Uterus: Blocks estrogen effects, reducing cancer risk.",
      "Does not increase risk of endometrial cancer (unlike Tamoxifen)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid but 2% bioavailability (First pass).",
      "distribution": "95% protein bound.",
      "metabolism": "Hepatic Glucuronidation.",
      "excretion": "Feces. **Half-life: 27.7 hours.**"
    },
    "dose": {
      "initialDose": "60 mg PO once daily",
      "maxDose": "60 mg/day",
      "notes": "Supplemental Calcium/Vitamin D recommended."
    },
    "adverseEffects": {
      "common": [
        "Hot flashes",
        "Leg cramps",
        "Peripheral edema"
      ],
      "serious": [
        "Venous Thromboembolism (DVT/PE) - BOXED WARNING",
        "Stroke (Fatal) - BOXED WARNING"
      ]
    },
    "precautions": [
      "**Thrombosis:** Contraindicated in history of VTE. Stop 72 hours prior to prolonged immobilization/surgery.",
      "**Stroke:** Increased risk of fatal stroke in women with CHD.",
      "**Hot Flashes:** May worsen menopausal symptoms."
    ],
    "contraindications": [
      "Active or past history of VTE (DVT, PE, Retinal vein thrombosis)",
      "Pregnancy / Nursing"
    ],
    "interactions": {
      "drug": ["Cholestyramine (Reduces absorption)", "Warfarin (Minor PT decrease)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category X"
  },
  "raltegravir": {
    "name": "Raltegravir (Isentress)",
    "genericName": "Raltegravir",
    "formula": "C20H21FN6O5",
    "molecularWeight": "444.4 g/mol",
    "brandNames": ["Isentress", "Isentress HD"],
    "category": "Antiretroviral",
    "drugClass": "Integrase Strand Transfer Inhibitor (INSTI)",
    "pubchemCID": "54671008",
    "indications": "HIV-1 Infection.",
    "moaSteps": [
      "Inhibits HIV-1 integrase enzyme.",
      "Prevents the covalent insertion (integration) of unintegrated linear HIV-1 DNA into the host cell genome.",
      "Prevents formation of the HIV-1 provirus."
    ],
    "pharmacokinetics": {
      "absorption": "Variable.",
      "distribution": "83% protein bound.",
      "metabolism": "Hepatic Glucuronidation (UGT1A1). Not a CYP substrate.",
      "excretion": "Feces/Urine. **Half-life: 9 hours.**"
    },
    "dose": {
      "initialDose": "400 mg PO BID or 1200 mg (HD) once daily",
      "maxDose": "1200 mg/day",
      "notes": "Chewable tablets available for peds."
    },
    "adverseEffects": {
      "common": [
        "Insomnia",
        "Headache",
        "Nausea",
        "Fatigue"
      ],
      "serious": [
        "Severe Skin Reactions (SJS/TEN)",
        "Myopathy / Rhabdomyolysis (CK elevation)",
        "Immune Reconstitution Syndrome"
      ]
    },
    "precautions": [
      "**Myopathy:** Monitor CPK, especially if on statins.",
      "**Interactions:** Fewer than other ARVs (no CYP), but UGT interactions exist.",
      "**Antacids:** Avoid Aluminum/Magnesium antacids (chelation)."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Aluminum/Magnesium Antacids (Decrease absorption)", "Rifampin (Decreases levels - Double dose of Raltegravir)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C (Preferred in pregnancy)"
  },
  "ramipril": {
    "name": "Ramipril (Altace)",
    "genericName": "Ramipril",
    "formula": "C23H32N2O5",
    "molecularWeight": "416.5 g/mol",
    "brandNames": ["Altace"],
    "category": "Antihypertensive",
    "drugClass": "ACE Inhibitor",
    "pubchemCID": "5362129",
    "indications": "Hypertension, Heart Failure post-MI, CV Risk Reduction (HOPE Trial).",
    "moaSteps": [
      "Prodrug converted to Ramiprilat.",
      "Inhibits ACE.",
      "Blocks formation of Angiotensin II.",
      "High tissue affinity (vascular wall penetration).",
      "Reduces CV events in high-risk patients."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (50-60%).",
      "distribution": "73% protein bound.",
      "metabolism": "Hepatic hydrolysis to Ramiprilat.",
      "excretion": "Urine/Feces. **Half-life: 13 to 17 hours (Effective).**"
    },
    "dose": {
      "initialDose": "2.5 mg PO once daily",
      "maxDose": "20 mg/day",
      "notes": "Capsules can be opened and sprinkled."
    },
    "adverseEffects": {
      "common": [
        "Cough",
        "Hypotension",
        "Dizziness"
      ],
      "serious": [
        "Angioedema - BOXED WARNING",
        "Fetal Toxicity - BOXED WARNING",
        "Renal Failure",
        "Hyperkalemia",
        "Cholestatic Jaundice (Rare)"
      ]
    },
    "precautions": [
      "**Fetal:** Stop in pregnancy.",
      "**Angioedema:** Can be visceral (abdominal pain).",
      "**Renal:** Caution in renal artery stenosis."
    ],
    "contraindications": [
      "History of ACEI angioedema",
      "Pregnancy",
      "Concomitant Aliskiren in diabetes"
    ],
    "interactions": {
      "drug": ["K+ sparing diuretics", "NSAIDs", "Lithium"],
      "food": ["Salt substitutes"]
    },
    "pregnancyCategory": "Category D"
  },
  "rituximab": {
    "name": "Rituximab (Rituxan)",
    "genericName": "Rituximab",
    "formula": "Chimeric monoclonal antibody",
    "molecularWeight": "145 kDa",
    "brandNames": ["Rituxan", "Truxima", "Ruxience"],
    "category": "Antineoplastic / Immunosuppressant",
    "drugClass": "Anti-CD20 Monoclonal Antibody",
    "pubchemCID": "None (Protein)",
    "indications": "Non-Hodgkin Lymphoma (NHL), CLL, Rheumatoid Arthritis, GPA/MPA (Vasculitis), Pemphigus Vulgaris.",
    "moaSteps": [
      "Binds to CD20 antigen on B-lymphocytes.",
      "Induces cell lysis via Complement-Dependent Cytotoxicity (CDC), Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), and apoptosis.",
      "Depletes B-cells for 6-9 months."
    ],
    "pharmacokinetics": {
      "absorption": "IV administration.",
      "distribution": "Lymphoid tissue.",
      "metabolism": "Catabolism.",
      "excretion": "Slow. **Half-life: ~22 days (Increases with dosing).**"
    },
    "dose": {
      "initialDose": "375 mg/m2 IV weekly x 4 (Lymphoma)",
      "maxDose": "Protocol dependent",
      "notes": "Premedicate with Acetaminophen/Diphenhydramine/Steroid."
    },
    "adverseEffects": {
      "common": [
        "Infusion Reactions (Fever/Chills/Rigors)",
        "Lymphopenia",
        "Infection"
      ],
      "serious": [
        "Fatal Infusion Reactions - BOXED WARNING",
        "Severe Mucocutaneous Reactions (SJS/TEN) - BOXED WARNING",
        "Hepatitis B Reactivation (Fatal) - BOXED WARNING",
        "PML (Progressive Multifocal Leukoencephalopathy) - BOXED WARNING"
      ]
    },
    "precautions": [
      "**Hep B:** Screening (HBsAg and anti-HBc) mandatory. Reactivation causes fulminant hepatitis/death. Prophylaxis required if positive.",
      "**Infusion:** Monitor vitals closely. Stop for severe reaction.",
      "**Vaccines:** No live vaccines."
    ],
    "contraindications": [
      "None (except severe hypersensitivity)",
      "Active Hepatitis B"
    ],
    "interactions": {
      "drug": ["Antihypertensives (Hold 12h prior - Hypotension risk)", "Live vaccines"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "rivaroxaban": {
    "name": "Rivaroxaban (Xarelto)",
    "genericName": "Rivaroxaban",
    "formula": "C19H18ClN3O5S",
    "molecularWeight": "435.9 g/mol",
    "brandNames": ["Xarelto"],
    "category": "Anticoagulant",
    "drugClass": "Factor Xa Inhibitor (DOAC)",
    "pubchemCID": "9875401",
    "indications": "Stroke prophylaxis in AFib, DVT/PE Treatment and Prophylaxis, CAD/PAD (low dose).",
    "moaSteps": [
      "Selectively blocks the active site of Factor Xa.",
      "Inhibits both free and clot-bound Factor Xa.",
      "Prevents thrombin generation and thrombus formation.",
      "Does not require cofactor Antithrombin."
    ],
    "pharmacokinetics": {
      "absorption": "Dose dependent. 10mg is 100% bioavailable w/o food. 20mg requires food.",
      "distribution": "95% protein bound.",
      "metabolism": "Hepatic (CYP3A4/2J2) and P-gp.",
      "excretion": "Urine (66%) and Feces. **Half-life: 5 to 9 hours (Young); 11-13 hours (Elderly).**"
    },
    "dose": {
      "initialDose": "15 mg PO BID x 21 days (DVT/PE)",
      "maxDose": "20 mg/day (AFib)",
      "notes": "MUST TAKE WITH FOOD (doses >10mg) for absorption."
    },
    "adverseEffects": {
      "common": [
        "Bleeding (Epistaxis/Gum/GI)",
        "Back pain",
        "Pruritus"
      ],
      "serious": [
        "Major Hemorrhage (Intracranial/GI)",
        "Spinal/Epidural Hematoma - BOXED WARNING",
        "Thrombosis (Premature discontinuation) - BOXED WARNING"
      ]
    },
    "precautions": [
      "**Food:** 15mg and 20mg tabs must be taken with food to ensure absorption. 10mg can be without.",
      "**Renal:** Avoid if CrCl < 30 (DVT/PE) or < 15 (AFib).",
      "**Reversal:** Andexanet alfa (Andexxa)."
    ],
    "contraindications": [
      "Active pathological bleeding",
      "Severe hypersensitivity"
    ],
    "interactions": {
      "drug": ["Combined P-gp/CYP3A4 Inhibitors (Ketoconazole/Ritonavir - Avoid)", "Combined Inducers (Rifampin/Carbamazepine - Avoid)", "Antiplatelets"],
      "food": ["Take >10mg doses with food."]
    },
    "pregnancyCategory": "Category C"
  },
  "rosuvastatin": {
    "name": "Rosuvastatin (Crestor)",
    "genericName": "Rosuvastatin Calcium",
    "formula": "C22H28FN3O6S",
    "molecularWeight": "481.5 g/mol",
    "brandNames": ["Crestor", "Ezallor"],
    "category": "Antilipemic",
    "drugClass": "HMG-CoA Reductase Inhibitor (Statin)",
    "pubchemCID": "446157",
    "indications": "Hyperlipidemia, Dysbetalipoproteinemia, CVD Prevention.",
    "moaSteps": [
      "Inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis.",
      "Increases LDL receptor expression on hepatocytes.",
      "Potent reduction of LDL-C.",
      "Hydrophilic (less muscle penetration theoretically, but still causes myalgia)."
    ],
    "pharmacokinetics": {
      "absorption": "20% bioavailable.",
      "distribution": "88% protein bound.",
      "metabolism": "Minimal (10% via CYP2C9). Not a major CYP3A4 substrate.",
      "excretion": "Feces (90%). **Half-life: 19 hours.**"
    },
    "dose": {
      "initialDose": "10-20 mg PO once daily",
      "maxDose": "40 mg/day",
      "notes": "Start 5 mg in Asians (higher systemic exposure)."
    },
    "adverseEffects": {
      "common": [
        "Myalgia",
        "Headache",
        "Abdominal pain",
        "Nausea"
      ],
      "serious": [
        "Rhabdomyolysis",
        "Hepatotoxicity",
        "Proteinuria / Hematuria (High dose)",
        "Immune-mediated necrotizing myopathy"
      ]
    },
    "precautions": [
      "**Asians:** 2-fold higher exposure in Asian patients. Start at 5mg.",
      "**Kidney:** Renal excretion is significant (unlike Atorvastatin). Dose adjust in severe CKD.",
      "**Proteinuria:** Dipstick positive proteinuria/hematuria seen with 40mg dose."
    ],
    "contraindications": [
      "Active liver disease",
      "Pregnancy / Nursing"
    ],
    "interactions": {
      "drug": ["Cyclosporine (Cap dose at 5mg)", "Gemfibrozil (Avoid)", "Antacids (Aluminum/Magnesium - Separate by 2h)", "Warfarin (Increases INR)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category X"
  },"salmeterol": {
    "name": "Salmeterol (Serevent)",
    "genericName": "Salmeterol Xinafoate",
    "formula": "C25H37NO4",
    "molecularWeight": "415.6 g/mol",
    "brandNames": ["Serevent", "Advair (combo)"],
    "category": "Bronchodilator",
    "drugClass": "Long-Acting Beta-2 Agonist (LABA)",
    "pubchemCID": "5152",
    "indications": "Asthma maintenance (with ICS), COPD, Exercise-Induced Bronchospasm prevention.",
    "moaSteps": [
      "Selective beta-2 adrenergic agonist.",
      "Lipophilic tail anchors it to the membrane near the receptor.",
      "Allows repeated receptor stimulation.",
      "Slow onset (10-20 min), Long duration (12 hours)."
    ],
    "pharmacokinetics": {
      "absorption": "Systemic levels low.",
      "distribution": "96% protein bound.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Feces. **Half-life: 5.5 hours.**"
    },
    "dose": {
      "initialDose": "50 mcg Inhaled BID",
      "maxDose": "100 mcg/day",
      "notes": "Not a rescue inhaler."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Throat irritation",
        "Tremor",
        "Palpitations"
      ],
      "serious": [
        "Asthma-related death (Monotherapy) - BOXED WARNING (Historical)",
        "Paradoxical Bronchospasm",
        "Hypokalemia / Arrhythmias"
      ]
    },
    "precautions": [
      "**Monotherapy:** Contraindicated in Asthma without ICS. Safe in COPD monotherapy.",
      "**Onset:** Do not use for acute attacks (onset too slow).",
      "**Cardiovascular:** Caution in arrhythmia/ischemia."
    ],
    "contraindications": [
      "Asthma monotherapy",
      "Status asthmaticus"
    ],
    "interactions": {
      "drug": ["Beta-blockers (Antagonism)", "Strong CYP3A4 inhibitors (Ketoconazole - Increases systemic levels/QT risk)", "Diuretics (Hypokalemia)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "scopolamine": {
    "name": "Scopolamine (Transderm Scop)",
    "genericName": "Scopolamine",
    "formula": "C17H21NO4",
    "molecularWeight": "303.35 g/mol",
    "brandNames": ["Transderm Scop"],
    "category": "Antiemetic / Anticholinergic",
    "drugClass": "Muscarinic Antagonist",
    "pubchemCID": "3000322",
    "indications": "Motion Sickness prevention, Postoperative Nausea/Vomiting (PONV), Secretion drying (hospice).",
    "moaSteps": [
      "Belladonna alkaloid.",
      "Competitively inhibits muscarinic receptors in the parasympathetic nervous system.",
      "Acts on the vestibular system and vomiting center to prevent nausea.",
      "Dries secretions."
    ],
    "pharmacokinetics": {
      "absorption": "Good (Transdermal).",
      "distribution": "Crosses BBB.",
      "metabolism": "Hepatic.",
      "excretion": "Urine. **Half-life: 9.5 hours.**"
    },
    "dose": {
      "initialDose": "1.5 mg Patch every 3 days",
      "maxDose": "Continuous",
      "notes": "Apply 4 hours before exposure behind ear."
    },
    "adverseEffects": {
      "common": [
        "Dry mouth",
        "Drowsiness",
        "Blurred vision (Mydriasis)",
        "Dizziness"
      ],
      "serious": [
        "Acute Narrow-Angle Glaucoma",
        "Psychosis / Delirium",
        "Urinary Retention",
        "Withdrawal Symptoms (Dizziness/Nausea)"
      ]
    },
    "precautions": [
      "**Eyes:** Wash hands after applying. Touching eyes causes fixed dilated pupil (anisocoria).",
      "**Elderly:** High risk of confusion/delirium.",
      "**MRI:** Remove patch (aluminum backing)."
    ],
    "contraindications": [
      "Narrow-angle glaucoma",
      "Hypersensitivity to belladonna alkaloids"
    ],
    "interactions": {
      "drug": ["Anticholinergics (Additive)", "CNS Depressants"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "secukinumab": {
    "name": "Secukinumab (Cosentyx)",
    "genericName": "Secukinumab",
    "formula": "Human IgG1 monoclonal antibody",
    "molecularWeight": "151 kDa",
    "brandNames": ["Cosentyx"],
    "category": "Biologic",
    "drugClass": "IL-17A Inhibitor",
    "pubchemCID": "None (Protein)",
    "indications": "Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis.",
    "moaSteps": [
      "Binds specifically to Interleukin-17A (IL-17A) cytokine.",
      "Prevents interaction with the IL-17 receptor.",
      "Inhibits release of pro-inflammatory cytokines/chemokines.",
      "Reduces epidermal hyperplasia and inflammation."
    ],
    "pharmacokinetics": {
      "absorption": "Subcutaneous (55-77% bioavailable).",
      "distribution": "Vascular/Interstitial.",
      "metabolism": "Catabolism.",
      "excretion": "Long. **Half-life: 22 to 31 days.**"
    },
    "dose": {
      "initialDose": "300 mg SubQ at weeks 0, 1, 2, 3, 4",
      "maxDose": "300 mg every 4 weeks",
      "notes": "Sensoready pen."
    },
    "adverseEffects": {
      "common": [
        "Nasopharyngitis",
        "Diarrhea",
        "Upper respiratory infection"
      ],
      "serious": [
        "Serious Infections (TB, Fungal)",
        "Inflammatory Bowel Disease (Exacerbation)",
        "Anaphylaxis"
      ]
    },
    "precautions": [
      "**IBD:** Can exacerbate Crohn's/UC. Avoid in these patients.",
      "**Infection:** TB screen required. Do not start in active infection.",
      "**Latex:** Some caps contain latex."
    ],
    "contraindications": [
      "Active serious infection",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Live vaccines (Contraindicated)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "selegiline": {
    "name": "Selegiline (Eldepryl, Zelapar)",
    "genericName": "Selegiline HCl",
    "formula": "C13H17N",
    "molecularWeight": "187.28 g/mol",
    "brandNames": ["Eldepryl", "Zelapar (ODT)", "Emsam (Patch)"],
    "category": "Antiparkinson / Antidepressant",
    "drugClass": "MAO-B Inhibitor (Irreversible)",
    "pubchemCID": "26757",
    "indications": "Parkinson's Disease (Adjunct), Major Depressive Disorder (Patch).",
    "moaSteps": [
      "Irreversibly inhibits Monoamine Oxidase B (MAO-B).",
      "Inhibits dopamine breakdown in the brain.",
      "At high doses (or patch), loses selectivity and inhibits MAO-A (Antidepressant effect).",
      "Metabolized to amphetamine derivatives."
    ],
    "pharmacokinetics": {
      "absorption": "Low oral bioavailability (high first pass). Patch bypasses gut.",
      "distribution": "Lipophilic.",
      "metabolism": "Hepatic to L-methamphetamine and L-amphetamine.",
      "excretion": "Urine. **Half-life: 10 hours (Oral); 18-25 hours (Patch).**"
    },
    "dose": {
      "initialDose": "5 mg PO BID (Parkinson's)",
      "maxDose": "10 mg/day (PD); 12 mg/24h (Depression patch)",
      "notes": "Take with breakfast/lunch (avoid insomnia)."
    },
    "adverseEffects": {
      "common": [
        "Insomnia",
        "Nausea",
        "Dizziness / Orthostasis",
        "Application site reaction"
      ],
      "serious": [
        "Serotonin Syndrome",
        "Hypertensive Crisis (Tyramine)",
        "Impulse Control Disorders",
        "Suicidality (Patch)"
      ]
    },
    "precautions": [
      "**Diet:** Oral dose (selective MAO-B) does not require Tyramine restriction. Patch 6mg/24h does not. Higher patch doses DO require restriction.",
      "**Amphetamine:** Drug screen positive. Insomnia/jitters.",
      "**Serotonin:** Contraindicated with SSRIs, SNRIs, TCAs, Meperidine, Tramadol."
    ],
    "contraindications": [
      "Concomitant Meperidine, Tramadol, Methadone, Dextromethorphan, St. John's Wort, Cyclobenzaprine, Other MAOIs"
    ],
    "interactions": {
      "drug": ["Serotonergic Agents (Fatal)", "Sympathomimetics (HTN)"],
      "food": ["Tyramine rich foods (Cheese/Wine) - Risk depends on dose/formulation."]
    },
    "pregnancyCategory": "Category C"
  },
  "sertraline": {
    "name": "Sertraline (Zoloft)",
    "genericName": "Sertraline HCl",
    "formula": "C17H17Cl2N",
    "molecularWeight": "306.2 g/mol",
    "brandNames": ["Zoloft"],
    "category": "Antidepressant",
    "drugClass": "SSRI",
    "pubchemCID": "68617",
    "indications": "MDD, OCD, Panic Disorder, PTSD, Social Anxiety, PMDD.",
    "moaSteps": [
      "Potent and selective inhibitor of CNS neuronal serotonin reuptake (SERT).",
      "Weak inhibitor of dopamine uptake (Sigma-1 receptor binding).",
      "Enhances serotonergic transmission.",
      "Downregulates beta-adrenergic receptors."
    ],
    "pharmacokinetics": {
      "absorption": "Slow (Peak 4-8h). Food increases absorption.",
      "distribution": "98% protein bound.",
      "metabolism": "Hepatic (CYP2C19/2B6/2C9/3A4).",
      "excretion": "Urine/Feces. **Half-life: 26 hours (Parent); 62-104 hours (Metabolite).**"
    },
    "dose": {
      "initialDose": "50 mg PO daily",
      "maxDose": "200 mg/day",
      "notes": "Start 25 mg in Panic/PTSD."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea ('Squirtraline' - GI motility increased)",
        "Nausea",
        "Insomnia / Somnolence",
        "Sexual Dysfunction",
        "Sweating"
      ],
      "serious": [
        "Suicidality - BOXED WARNING",
        "Serotonin Syndrome",
        "Hyponatremia / SIADH",
        "Bleeding risk"
      ]
    },
    "precautions": [
      "**GI:** High rate of diarrhea compared to other SSRIs.",
      "**Suicide:** Monitor closely.",
      "**Pregnancy:** Generally considered one of the safer SSRIs.",
      "**Bleeding:** Impairs platelet aggregation."
    ],
    "contraindications": [
      "MAOI use within 14 days",
      "Concomitant Pimozide",
      "Oral concentrate + Disulfiram (contains alcohol)"
    ],
    "interactions": {
      "drug": ["MAOIs (Fatal)", "Pimozide (QT risk)", "Warfarin (Increased bleeding)", "NSAIDs"],
      "food": ["Food increases absorption (beneficial)."]
    },
    "pregnancyCategory": "Category C"
  },
  "sevelamer": {
    "name": "Sevelamer (Renvela)",
    "genericName": "Sevelamer Carbonate",
    "formula": "Polyallylamine cross-linked polymer",
    "molecularWeight": "High MW Polymer",
    "brandNames": ["Renvela", "Renagel (HCl)"],
    "category": "Phosphate Binder",
    "drugClass": "Polymer",
    "pubchemCID": "N/A (Polymer)",
    "indications": "Hyperphosphatemia in Chronic Kidney Disease (Dialysis).",
    "moaSteps": [
      "Non-absorbed, cross-linked polymer.",
      "Binds dietary phosphate in the GI tract.",
      "Prevents phosphate absorption.",
      "Lowers serum phosphorus without adding Calcium or Aluminum.",
      "Also binds bile acids (lowers LDL)."
    ],
    "pharmacokinetics": {
      "absorption": "Not absorbed.",
      "distribution": "GI Tract.",
      "metabolism": "None.",
      "excretion": "Feces (100%). **Half-life: N/A.**"
    },
    "dose": {
      "initialDose": "800-1600 mg PO TID with meals",
      "maxDose": "Titrate to Phosphorus level",
      "notes": "Carbonate (Renvela) preferred over HCl (Renagel) to avoid acidosis."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting",
        "Constipation / Impaction",
        "Flatulence",
        "Abdominal pain"
      ],
      "serious": [
        "Bowel Obstruction / Perforation",
        "Dysphagia (Tablet size)"
      ]
    },
    "precautions": [
      "**GI:** Caution in dysphagia, motility disorders, or active bowel disease. Tablets expand in water.",
      "**Vitamins:** Can reduce absorption of D, E, K, Folic acid. Supplement.",
      "**Administration:** Must be taken with food to bind phosphate."
    ],
    "contraindications": [
      "Bowel obstruction",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Ciprofloxacin/Levothyroxine (Decreased absorption - separate by hours)", "Cyclosporine/Tacrolimus (Reduced levels)"],
      "food": ["Take with meals."]
    },
    "pregnancyCategory": "Category C"
  },
 
  "sildenafil": {
    "name": "Sildenafil (Viagra)",
    "genericName": "Sildenafil Citrate",
    "formula": "C22H30N6O4S",
    "molecularWeight": "474.6 g/mol",
    "brandNames": ["Viagra", "Revatio"],
    "category": "Erectile Dysfunction / PAH Agent",
    "drugClass": "PDE-5 Inhibitor",
    "pubchemCID": "135398744",
    "indications": "Erectile Dysfunction (Viagra), Pulmonary Arterial Hypertension (Revatio).",
    "moaSteps": [
      "Inhibits Phosphodiesterase type 5 (PDE-5).",
      "Prevents breakdown of cGMP in the corpus cavernosum and pulmonary vasculature.",
      "Prolongs NO-mediated smooth muscle relaxation.",
      "Increases blood flow (erection) and lowers pulmonary pressure."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid. High fat meal delays absorption.",
      "distribution": "96% protein bound.",
      "metabolism": "Hepatic (CYP3A4/2C9).",
      "excretion": "Feces/Urine. **Half-life: 4 hours.**"
    },
    "dose": {
      "initialDose": "50 mg PO PRN (ED); 20 mg PO TID (PAH)",
      "maxDose": "100 mg/day (ED)",
      "notes": "Take 1 hour before activity."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Flushing",
        "Dyspepsia",
        "Visual disturbances (Blue tinge)"
      ],
      "serious": [
        "Hypotension (Severe)",
        "Priapism (>4 hours)",
        "Hearing Loss (Sudden)",
        "Vision Loss (NAION)"
      ]
    },
    "precautions": [
      "**Nitrates:** ABSOLUTELY CONTRAINDICATED. Fatal hypotension.",
      "**Vision:** Stop if sudden loss of vision occurs (Ischemic Optic Neuropathy).",
      "**Alpha-blockers:** Additive hypotension; stabilize on alpha-blocker first."
    ],
    "contraindications": [
      "Concomitant use of Nitrates (Nitro, Isosorbide)",
      "Concomitant use of Riociguat"
    ],
    "interactions": {
      "drug": ["Nitrates (Fatal)", "Alpha-blockers (Hypotension)", "CYP3A4 Inhibitors (Increase levels - reduce dose)"],
      "food": ["High fat meal delays onset."]
    },
    "pregnancyCategory": "Category B"
  },
  "silodosin": {
    "name": "Silodosin (Rapaflo)",
    "genericName": "Silodosin",
    "formula": "C25H32F3N3O4",
    "molecularWeight": "495.5 g/mol",
    "brandNames": ["Rapaflo"],
    "category": "BPH Agent",
    "drugClass": "Alpha-1 Adrenergic Blocker (Uroselective)",
    "pubchemCID": "5312125",
    "indications": "Benign Prostatic Hyperplasia (BPH).",
    "moaSteps": [
      " highly selective antagonist for alpha-1A adrenergic receptors.",
      "Alpha-1A receptors are localized in the prostate, bladder base, and prostatic urethra.",
      "Relaxes smooth muscle in these tissues, improving urine flow.",
      "Minimal affinity for alpha-1B (vascular) receptors (less hypotension)."
    ],
    "pharmacokinetics": {
      "absorption": "Good.",
      "distribution": "97% protein bound.",
      "metabolism": "Hepatic (UGT and CYP3A4).",
      "excretion": "Feces and Urine. **Half-life: 13.3 hours.**"
    },
    "dose": {
      "initialDose": "8 mg PO once daily with a meal",
      "maxDose": "8 mg/day",
      "notes": "Reduce to 4 mg if CrCl 30-50."
    },
    "adverseEffects": {
      "common": [
        "Retrograde Ejaculation (Very common - 'Dry orgasm')",
        "Dizziness",
        "Diarrhea",
        "Nasal congestion"
      ],
      "serious": [
        "Intraoperative Floppy Iris Syndrome (IFIS)",
        "Hypotension (less than non-selective agents)"
      ]
    },
    "precautions": [
      "**Ejaculation:** Retrograde ejaculation occurs in ~28% of patients; reversible upon stopping.",
      "**Surgery:** Cataract surgery risk (IFIS).",
      "**Renal/Hepatic:** Contraindicated in severe impairment."
    ],
    "contraindications": [
      "Severe renal impairment (CrCl < 30)",
      "Severe hepatic impairment",
      "Concomitant strong CYP3A4 inhibitors"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inhibitors (Contraindicated)", "Alpha-blockers (Additive hypotension)", "PDE5 inhibitors"],
      "food": ["Take with food."]
    },
    "pregnancyCategory": "Category B"
  },
  "simethicone": {
    "name": "Simethicone (Gas-X)",
    "genericName": "Simethicone",
    "formula": "Polydimethylsiloxane / Silicon Dioxide",
    "molecularWeight": "Mixture",
    "brandNames": ["Gas-X", "Mylicon"],
    "category": "Antiflatulent",
    "drugClass": "Surfactant",
    "pubchemCID": "6433516",
    "indications": "Relief of painful symptoms of excess gas in the GI tract (Bloating, Flatulence).",
    "moaSteps": [
      "Decreases the surface tension of gas bubbles.",
      "Causes small bubbles to coalesce into larger bubbles.",
      "Facilitates the expulsion of gas via belching or passing flatus.",
      "Does not prevent gas formation."
    ],
    "pharmacokinetics": {
      "absorption": "Not absorbed.",
      "distribution": "GI tract.",
      "metabolism": "None.",
      "excretion": "Feces (Unchanged). **Half-life: N/A (Physiologic).**"
    },
    "dose": {
      "initialDose": "40-125 mg PO after meals/bedtime",
      "maxDose": "500 mg/day",
      "notes": "Safe for infants (Mylicon)."
    },
    "adverseEffects": {
      "common": [
        "Loose stools"
      ],
      "serious": [
        "None significant"
      ]
    },
    "precautions": [
      "**Safe:** Inert and non-systemic.",
      "**Diagnosis:** Persistent gas/pain may indicate serious GI pathology."
    ],
    "contraindications": [
      "Known perforation or obstruction (Relative)"
    ],
    "interactions": {
      "drug": ["Levothyroxine (May chelate/bind - separate dose by 4h)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C (Considered safe)"
  },
  "simvastatin": {
    "name": "Simvastatin (Zocor)",
    "genericName": "Simvastatin",
    "formula": "C25H38O5",
    "molecularWeight": "418.6 g/mol",
    "brandNames": ["Zocor"],
    "category": "Antilipemic",
    "drugClass": "HMG-CoA Reductase Inhibitor (Statin)",
    "pubchemCID": "54454",
    "indications": "Hyperlipidemia, CVD Prevention.",
    "moaSteps": [
      "Prodrug hydrolyzed to active acid form.",
      "Inhibits HMG-CoA reductase.",
      "Decreases hepatic cholesterol synthesis.",
      "Upregulates LDL receptors."
    ],
    "pharmacokinetics": {
      "absorption": "High extraction (5% systemic availability).",
      "distribution": "95% protein bound.",
      "metabolism": "Extensive Hepatic (CYP3A4).",
      "excretion": "Feces/Urine. **Half-life: 1.9 hours.**"
    },
    "dose": {
      "initialDose": "10-20 mg PO at bedtime",
      "maxDose": "40 mg/day (80 mg restricted)",
      "notes": "Take in evening."
    },
    "adverseEffects": {
      "common": [
        "Myalgia",
        "Headache",
        "Abdominal pain",
        "Constipation"
      ],
      "serious": [
        "Rhabdomyolysis",
        "Hepatotoxicity",
        "Immune-mediated necrotizing myopathy"
      ]
    },
    "precautions": [
      "**Muscle:** Highest risk of myopathy among statins, especially at 80mg. 80mg dose restricted to those on it for >12 months without issues.",
      "**Interactions:** CYP3A4 substrate; many restrictions.",
      "**Asians:** Lower doses needed."
    ],
    "contraindications": [
      "Active liver disease",
      "Pregnancy / Nursing",
      "Concomitant strong CYP3A4 inhibitors",
      "Gemfibrozil, Cyclosporine, Danazol"
    ],
    "interactions": {
      "drug": ["Amiodarone/Amlodipine/Ranolazine (Cap dose at 20mg)", "Diltiazem/Verapamil (Cap dose at 10mg)", "Gemfibrozil (Contraindicated)", "Azoles/Macrolides (Contraindicated)"],
      "food": ["Grapefruit juice (Avoid >1 quart/day)"]
    },
    "pregnancyCategory": "Category X"
  },
  "sirolimus": {
    "name": "Sirolimus (Rapamune)",
    "genericName": "Sirolimus",
    "formula": "C51H79NO13",
    "molecularWeight": "914.2 g/mol",
    "brandNames": ["Rapamune"],
    "category": "Immunosuppressant",
    "drugClass": "mTOR Inhibitor",
    "pubchemCID": "5284616",
    "indications": "Prophylaxis of organ rejection (Kidney), Lymphangioleiomyomatosis (LAM).",
    "moaSteps": [
      "Binds to FKBP-12.",
      "Complex inhibits the Mammalian Target of Rapamycin (mTOR) kinase.",
      "Inhibits T-lymphocyte activation and proliferation in response to IL-2.",
      "Inhibits antibody production."
    ],
    "pharmacokinetics": {
      "absorption": "Low (14%). High fat increases AUC.",
      "distribution": "Concentrates in RBCs (Whole blood levels monitored).",
      "metabolism": "Extensive Hepatic (CYP3A4) and P-gp.",
      "excretion": "Feces. **Half-life: 62 hours.**"
    },
    "dose": {
      "initialDose": "6 mg loading, then 2 mg daily",
      "maxDose": "Adjust to trough levels",
      "notes": "Target trough 6-12 ng/mL."
    },
    "adverseEffects": {
      "common": [
        "Hyperlipidemia (Triglycerides/Cholesterol)",
        "Peripheral Edema",
        "Mouth Ulcers (Aphthous)",
        "Hypertension"
      ],
      "serious": [
        "Impaired Wound Healing (Dehiscence)",
        "Interstitial Lung Disease (Pneumonitis)",
        "Increased risk of Infection/Malignancy"
      ]
    },
    "precautions": [
      "**Wound Healing:** Delays healing. Avoid in immediate post-transplant period (wait weeks/months).",
      "**Lungs:** Cough/dyspnea may indicate pneumonitis; discontinue.",
      "**Lipids:** Monitor and treat hyperlipidemia."
    ],
    "contraindications": [
      "Hypersensitivity",
      "Lung transplant (Black Box Warning - Dehiscence)"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inhibitors (Ketoconazole - Increase toxicity)", "CYP3A4 Inducers (Rifampin - Rejection)", "Cyclosporine (Increases sirolimus levels)"],
      "food": ["Grapefruit juice (Avoid)"]
    },
    "pregnancyCategory": "Category C"
  },
  "sitagliptin": {
    "name": "Sitagliptin (Januvia)",
    "genericName": "Sitagliptin",
    "formula": "C16H15F6N5O",
    "molecularWeight": "407.3 g/mol",
    "brandNames": ["Januvia"],
    "category": "Antidiabetic",
    "drugClass": "DPP-4 Inhibitor",
    "pubchemCID": "4369359",
    "indications": "Type 2 Diabetes Mellitus.",
    "moaSteps": [
      "Inhibits Dipeptidyl Peptidase-4 (DPP-4).",
      "Prevents degradation of endogenous incretin hormones (GLP-1 and GIP).",
      "Enhances glucose-dependent insulin secretion.",
      "Suppresses glucagon secretion."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (87% bioavailable).",
      "distribution": "Low protein binding.",
      "metabolism": "Minor hepatic (CYP3A4/2C8).",
      "excretion": "Urine (Active tubular secretion). **Half-life: 12.4 hours.**"
    },
    "dose": {
      "initialDose": "100 mg PO once daily",
      "maxDose": "100 mg/day",
      "notes": "Reduce to 50 or 25 mg in renal impairment."
    },
    "adverseEffects": {
      "common": [
        "Nasopharyngitis",
        "Upper respiratory infection",
        "Headache"
      ],
      "serious": [
        "Acute Pancreatitis",
        "Severe Arthralgia",
        "Hypersensitivity (SJS/Anaphylaxis)",
        "Bullous Pemphigoid"
      ]
    },
    "precautions": [
      "**Pancreatitis:** Post-marketing reports. Stop if abdominal pain/vomiting occurs.",
      "**Renal:** Dose adjust based on eGFR.",
      "**Joints:** Severe disabling arthralgia reported; resolves on discontinuation."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Digoxin (Slight increase in levels)", "Insulin/Sulfonylureas (Hypoglycemia risk)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "sodium_bicarbonate": {
    "name": "Sodium Bicarbonate",
    "genericName": "Sodium Bicarbonate",
    "formula": "NaHCO3",
    "molecularWeight": "84.01 g/mol",
    "brandNames": ["Neut", "Soda Mint"],
    "category": "Electrolyte / Alkalinizing Agent",
    "drugClass": "Alkalis",
    "pubchemCID": "516892",
    "indications": "Metabolic Acidosis, Hyperkalemia, TCA Overdose, Urine Alkalinization (Salicylate/Methotrexate toxicity).",
    "moaSteps": [
      "Dissociates to provide Bicarbonate ion (HCO3-).",
      "Neutralizes hydrogen ions concentrations.",
      "Raises blood and urinary pH.",
      "Drives potassium intracellularly."
    ],
    "pharmacokinetics": {
      "absorption": "Oral/IV.",
      "distribution": "Extracellular.",
      "metabolism": "Neutralization reaction.",
      "excretion": "Renal (HCO3) and Lung (CO2). **Half-life: Physiological.**"
    },
    "dose": {
      "initialDose": "1 mEq/kg IV (Arrest/Acidosis)",
      "maxDose": "Titrate to pH",
      "notes": "Oral: 325-650 mg."
    },
    "adverseEffects": {
      "common": [
        "Bloating / Belching (Oral)",
        "Edema (Sodium load)"
      ],
      "serious": [
        "Metabolic Alkalosis",
        "Hypernatremia",
        "Hypokalemia",
        "Tissue Necrosis (Extravasation)",
        "Paradoxical CNS Acidosis"
      ]
    },
    "precautions": [
      "**Extravasation:** Hypertonic solution; causes necrosis. Flush well.",
      "**Fluid Overload:** Large sodium load; caution in CHF.",
      "**Mixing:** Incompatible with Calcium (precipitates) and Catecholamines."
    ],
    "contraindications": [
      "Metabolic/Respiratory Alkalosis",
      "Hypocalcemia (precipitates tetany)",
      "Hypernatremia"
    ],
    "interactions": {
      "drug": ["Aspirin/Lithium/Methotrexate (Alkalinization increases excretion)", "Amphetamines/Quinidine (Alkalinization decreases excretion -> Toxicity)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "sodium_nitroprusside": {
    "name": "Sodium Nitroprusside (Nitropress)",
    "genericName": "Sodium Nitroprusside",
    "formula": "Na2[Fe(CN)5NO]",
    "molecularWeight": "261.9 g/mol",
    "brandNames": ["Nitropress", "Nipride"],
    "category": "Antihypertensive",
    "drugClass": "Direct Vasodilator (Nitrate)",
    "pubchemCID": "11963579",
    "indications": "Hypertensive Emergency, Acute Heart Failure.",
    "moaSteps": [
      "Interacts with oxyhemoglobin to release Nitric Oxide (NO).",
      "NO activates guanylate cyclase.",
      "Relaxes vascular smooth muscle.",
      "Dilates both arteries and veins (Balanced vasodilator).",
      "Rapid reduction of BP."
    ],
    "pharmacokinetics": {
      "absorption": "IV only.",
      "distribution": "Vascular.",
      "metabolism": "Rapid RBC metabolism to Cyanide, then Hepatic to Thiocyanate.",
      "excretion": "Urine (Thiocyanate). **Half-life: < 2 minutes (Parent); 3 days (Thiocyanate).**"
    },
    "dose": {
      "initialDose": "0.3-0.5 mcg/kg/min IV infusion",
      "maxDose": "10 mcg/kg/min (Max 10 mins)",
      "notes": "Protect from light."
    },
    "adverseEffects": {
      "common": [
        "Hypotension",
        "Headache",
        "Nausea"
      ],
      "serious": [
        "Cyanide Toxicity (Acidosis, Coma) - BOXED WARNING",
        "Thiocyanate Toxicity (Psychosis, Tinnitus)",
        "Methemoglobinemia",
        "Intracranial Pressure increase"
      ]
    },
    "precautions": [
      "**Cyanide Toxicity:** Risk with high doses (>2mcg/kg/min), prolonged use, or hepatic/renal failure. Monitor lactate/gases. Treat with Sodium Thiosulfate/Nitrite.",
      "**Light:** Must wrap bag in foil (degrades in light).",
      "**BP:** Continuous arterial line monitoring recommended."
    ],
    "contraindications": [
      "Compensatory hypertension (AV shunt, Coarctation)",
      "PDE5 inhibitor use"
    ],
    "interactions": {
      "drug": ["Antihypertensives (Additive hypotension)", "PDE5 inhibitors (Severe hypotension)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "sodium_oxybate": {
    "name": "Sodium Oxybate (Xyrem)",
    "genericName": "Sodium Oxybate",
    "formula": "C4H7NaO3",
    "molecularWeight": "126.09 g/mol",
    "brandNames": ["Xyrem", "Xywav"],
    "category": "CNS Depressant",
    "drugClass": "GABA-B Receptor Agonist",
    "pubchemCID": "23663407",
    "indications": "Cataplexy and Excessive Daytime Sleepiness in Narcolepsy.",
    "moaSteps": [
      "Sodium salt of gamma-hydroxybutyrate (GHB).",
      "Binds to GABA-B receptors and specific GHB receptors.",
      "Promotes slow-wave sleep and consolidates sleep architecture.",
      "Exact mechanism in narcolepsy unknown."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid. High fat meal delays absorption.",
      "distribution": "Crosses BBB.",
      "metabolism": "Krebs cycle (to CO2 and Water).",
      "excretion": "Respiratory. **Half-life: 0.5 to 1 hour.**"
    },
    "dose": {
      "initialDose": "2.25 g PO at bedtime, repeat 2.25 g 2.5-4 hours later",
      "maxDose": "9 g/night",
      "notes": "Patient must be in bed when taking."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting",
        "Dizziness",
        "Enuresis (Bedwetting)",
        "Tremor"
      ],
      "serious": [
        "Respiratory Depression - BOXED WARNING",
        "Abuse / Misuse (GHB) - BOXED WARNING",
        "Confusion / Parasomnias",
        "Seizures"
      ]
    },
    "precautions": [
      "**REMS:** Strict restricted distribution program due to abuse potential (Date rape drug).",
      "**CNS Depression:** Do not use with alcohol or sedatives.",
      "**Salt:** High sodium content (Xyrem); Xywav is low sodium option."
    ],
    "contraindications": [
      "Concomitant use with Sedative Hypnotics or Alcohol",
      "Succinic semialdehyde dehydrogenase deficiency"
    ],
    "interactions": {
      "drug": ["CNS Depressants (Contraindicated)", "Divalproex (Increases oxybate levels)"],
      "food": ["Take on empty stomach (2h after eating)."]
    },
    "pregnancyCategory": "Category C"
  },
  "sodium_zirconium_cyclosilicate": {
    "name": "Sodium Zirconium Cyclosilicate (Lokelma)",
    "genericName": "Sodium Zirconium Cyclosilicate",
    "formula": "Inorganic crystal",
    "molecularWeight": "N/A",
    "brandNames": ["Lokelma"],
    "category": "Electrolyte Modifier",
    "drugClass": "Potassium Binder",
    "pubchemCID": "N/A",
    "indications": "Hyperkalemia.",
    "moaSteps": [
      "Non-absorbed inorganic crystal.",
      "Selectively captures potassium ions in exchange for hydrogen and sodium ions.",
      "Acts throughout the entire GI tract.",
      "Increases fecal potassium excretion."
    ],
    "pharmacokinetics": {
      "absorption": "Not absorbed.",
      "distribution": "GI Tract.",
      "metabolism": "None.",
      "excretion": "Feces. **Half-life: N/A.**"
    },
    "dose": {
      "initialDose": "10 g PO TID for 48 hours (Loading)",
      "maxDose": "10 g daily (Maintenance)",
      "notes": "Faster onset than Kayexalate."
    },
    "adverseEffects": {
      "common": [
        "Edema (Sodium load)",
        "Hypokalemia"
      ],
      "serious": [
        "GI Motility disorders (rare)",
        "X-ray interference (Radio-opaque)"
      ]
    },
    "precautions": [
      "**Sodium:** Each 10g dose contains ~800mg sodium. Caution in Heart Failure/Edema.",
      "**Interaction:** Can transiently increase gastric pH. Separate from pH-dependent drugs by 2 hours."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Drugs needing Acidic pH (Ketoconazole/Atazanavir - separate dose)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C (Not absorbed)"
  },
  "sofosbuvir": {
    "name": "Sofosbuvir (Sovaldi)",
    "genericName": "Sofosbuvir",
    "formula": "C22H29FN3O9P",
    "molecularWeight": "529.5 g/mol",
    "brandNames": ["Sovaldi", "Epclusa (combo)", "Harvoni (combo)"],
    "category": "Antiviral",
    "drugClass": "Hepatitis C NS5B Polymerase Inhibitor",
    "pubchemCID": "45375808",
    "indications": "Chronic Hepatitis C (Genotypes 1-6) - In combination.",
    "moaSteps": [
      "Nucleotide prodrug.",
      "Metabolized to active uridine analog triphosphate.",
      "Inhibits HCV NS5B RNA-dependent RNA polymerase.",
      "Acts as a chain terminator.",
      "Cures Hepatitis C."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "61-65% protein bound.",
      "metabolism": "Intracellular activation.",
      "excretion": "Urine/Feces. **Half-life: 0.4 hours (Parent); 27 hours (Active metabolite).**"
    },
    "dose": {
      "initialDose": "400 mg PO once daily",
      "maxDose": "400 mg/day",
      "notes": "Never used as monotherapy."
    },
    "adverseEffects": {
      "common": [
        "Fatigue",
        "Headache",
        "Nausea"
      ],
      "serious": [
        "Hepatitis B Reactivation - BOXED WARNING",
        "Severe Bradycardia (with Amiodarone)"
      ]
    },
    "precautions": [
      "**Hep B:** Reactivation of HBV can occur during clearance of HCV. Screen all patients.",
      "**Amiodarone:** Fatal bradycardia/arrest reported when used together. Avoid combo."
    ],
    "contraindications": [
      "Concurrent Amiodarone (unless no alternative)",
      "Monotherapy"
    ],
    "interactions": {
      "drug": ["Amiodarone (Fatal Bradycardia)", "P-gp Inducers (Rifampin/St. John's Wort - Reduced efficacy)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "solifenacin": {
    "name": "Solifenacin (Vesicare)",
    "genericName": "Solifenacin Succinate",
    "formula": "C23H26N2O2",
    "molecularWeight": "362.5 g/mol",
    "brandNames": ["Vesicare"],
    "category": "Urinary Antispasmodic",
    "drugClass": "Antimuscarinic",
    "pubchemCID": "154063",
    "indications": "Overactive Bladder (OAB).",
    "moaSteps": [
      "Competitive muscarinic receptor antagonist.",
      "Selectivity for M3 receptors (bladder/salivary glands) over M1/M2.",
      "Relaxes detrusor muscle.",
      "Reduces urinary frequency and urgency."
    ],
    "pharmacokinetics": {
      "absorption": "90% bioavailable.",
      "distribution": "98% protein bound.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Urine/Feces. **Half-life: 45 to 68 hours.**"
    },
    "dose": {
      "initialDose": "5 mg PO once daily",
      "maxDose": "10 mg/day",
      "notes": "Swallow whole."
    },
    "adverseEffects": {
      "common": [
        "Dry mouth",
        "Constipation",
        "Blurred vision"
      ],
      "serious": [
        "Urinary Retention",
        "Angioedema",
        "QT Prolongation (High dose)"
      ]
    },
    "precautions": [
      "**Retention:** Contraindicated in urinary retention/gastric retention.",
      "**QT:** Can prolong QT at high doses.",
      "**Renal/Hepatic:** Max 5mg in moderate impairment."
    ],
    "contraindications": [
      "Urinary/Gastric retention",
      "Uncontrolled narrow-angle glaucoma"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inhibitors (Cap dose at 5mg)", "Anticholinergics"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "somatropin": {
    "name": "Somatropin (Genotropin)",
    "genericName": "Somatropin (Recombinant hGH)",
    "formula": "Protein",
    "molecularWeight": "22 kDa",
    "brandNames": ["Genotropin", "Norditropin", "Humatrope"],
    "category": "Hormone",
    "drugClass": "Growth Hormone",
    "pubchemCID": "None (Protein)",
    "indications": "Growth Failure (Pediatric), Adult GH Deficiency, Short Bowel Syndrome, HIV Wasting.",
    "moaSteps": [
      "Recombinant Human Growth Hormone.",
      "Binds to GH receptors.",
      "Stimulates production of Insulin-like Growth Factor-1 (IGF-1) in liver/tissues.",
      "Promotes skeletal, visceral, and somatic growth.",
      "Anabolic effect."
    ],
    "pharmacokinetics": {
      "absorption": "Subcutaneous (70-90%).",
      "distribution": "Vascular/Interstitial.",
      "metabolism": "Proteolysis.",
      "excretion": "Urine. **Half-life: 2 to 3 hours.**"
    },
    "dose": {
      "initialDose": "0.16-0.24 mg/kg/week SC (Pediatric)",
      "maxDose": "Titrate to IGF-1",
      "notes": "Rotate sites."
    },
    "adverseEffects": {
      "common": [
        "Edema / Fluid retention",
        "Arthralgia / Myalgia",
        "Injection site reaction",
        "Headache"
      ],
      "serious": [
        "Intracranial Hypertension (Pseudotumor Cerebri)",
        "Slipped Capital Femoral Epiphysis (SCFE)",
        "Hyperglycemia / Diabetes",
        "Neoplasm growth"
      ]
    },
    "precautions": [
      "**Malignancy:** Do not use in active malignancy. Risk of second neoplasm.",
      "**Bones:** Monitor for limp (SCFE).",
      "**Diabetes:** Induces insulin resistance."
    ],
    "contraindications": [
      "Active Malignancy",
      "Acute Critical Illness",
      "Closed Epiphyses (Growth plates)",
      "Diabetic Retinopathy"
    ],
    "interactions": {
      "drug": ["Glucocorticoids (Inhibit growth effect)", "Insulin (Needs adjustment)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B/C"
  },
  "sorafenib": {
    "name": "Sorafenib (Nexavar)",
    "genericName": "Sorafenib",
    "formula": "C21H16ClF3N4O3",
    "molecularWeight": "464.8 g/mol",
    "brandNames": ["Nexavar"],
    "category": "Antineoplastic",
    "drugClass": "Tyrosine Kinase Inhibitor (Multikinase)",
    "pubchemCID": "216239",
    "indications": "Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC), Thyroid Cancer.",
    "moaSteps": [
      "Inhibits multiple intracellular and cell surface kinases (RAF, VEGFR, PDGFR, FLT-3, KIT).",
      "Inhibits tumor growth (RAF/MEK/ERK pathway).",
      "Inhibits angiogenesis (VEGF/PDGF).",
      "Induces apoptosis."
    ],
    "pharmacokinetics": {
      "absorption": "Moderate (High fat meal reduces).",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic (CYP3A4 and UGT1A9).",
      "excretion": "Feces. **Half-life: 25 to 48 hours.**"
    },
    "dose": {
      "initialDose": "400 mg PO BID",
      "maxDose": "800 mg/day",
      "notes": "Take on empty stomach."
    },
    "adverseEffects": {
      "common": [
        "Hand-Foot Skin Reaction",
        "Diarrhea",
        "Fatigue",
        "Hypertension"
      ],
      "serious": [
        "Cardiac Ischemia / Infarction",
        "Hemorrhage",
        "Hepatotoxicity",
        "GI Perforation",
        "QT Prolongation"
      ]
    },
    "precautions": [
      "**Cardiac:** Monitor for ischemia/MI.",
      "**Skin:** Toxic epidermal necrolysis/SJS reported. HFSR is very common.",
      "**Wound Healing:** Stop before surgery.",
      "**Liver:** Monitor LFTs."
    ],
    "contraindications": [
      "Hypersensitivity",
      "Use with Carboplatin/Paclitaxel in Squamous Cell Lung Cancer (increased mortality)"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inducers (Reduce efficacy)", "Warfarin (Bleeding)"],
      "food": ["High fat meal reduces bioavailability."]
    },
    "pregnancyCategory": "Category D"
  },
  "sotalol": {
    "name": "Sotalol (Betapace)",
    "genericName": "Sotalol HCl",
    "formula": "C12H20N2O3S",
    "molecularWeight": "272.4 g/mol",
    "brandNames": ["Betapace", "Betapace AF", "Sorine"],
    "category": "Antiarrhythmic",
    "drugClass": "Class III (with Class II Beta-blocker properties)",
    "pubchemCID": "5253",
    "indications": "Atrial Fibrillation/Flutter (Rhythm control), Ventricular Arrhythmias.",
    "moaSteps": [
      "Racemic mixture.",
      "L-isomer: Non-selective beta-blocker (Class II).",
      "D-isomer: Potassium channel blocker (Class III).",
      "Prolongs action potential duration and refractory period (QT prolongation).",
      "Slows heart rate and AV conduction."
    ],
    "pharmacokinetics": {
      "absorption": "90-100% bioavailable.",
      "distribution": "Not protein bound.",
      "metabolism": "Not metabolized.",
      "excretion": "Urine (Unchanged). **Half-life: 12 hours.**"
    },
    "dose": {
      "initialDose": "80 mg PO BID",
      "maxDose": "160 mg BID (AFib); Higher for VT",
      "notes": "Must initiate in hospital for 3 days (QT monitoring)."
    },
    "adverseEffects": {
      "common": [
        "Bradycardia",
        "Fatigue",
        "Dyspnea",
        "Dizziness"
      ],
      "serious": [
        "Torsades de Pointes (Proarrhythmia) - BOXED WARNING",
        "Heart Block",
        "Bronchospasm",
        "Heart Failure worsening"
      ]
    },
    "precautions": [
      "**QT Prolongation:** Boxed Warning. Risk is dose-dependent and renal-dependent. Correct electrolytes.",
      "**Renal:** Contraindicated if CrCl < 40 mL/min (Betapace AF). Drug accumulates.",
      "**Asthma:** Contraindicated (Beta-blocker)."
    ],
    "contraindications": [
      "CrCl < 40 mL/min (AFib indication)",
      "QTc > 440 ms",
      "Asthma / Severe COPD",
      "Sinus bradycardia / 2nd-3rd degree block"
    ],
    "interactions": {
      "drug": ["QT prolonging drugs (Contraindicated)", "Diuretics (Hypokalemia risk)", "Calcium Channel Blockers"],
      "food": ["Food decreases absorption by 20%."]
    },
    "pregnancyCategory": "Category B"
  },
  "spironolactone": {
    "name": "Spironolactone (Aldactone)",
    "genericName": "Spironolactone",
    "formula": "C24H32O4S",
    "molecularWeight": "416.6 g/mol",
    "brandNames": ["Aldactone", "CaroSpir"],
    "category": "Diuretic / Antihypertensive",
    "drugClass": "Aldosterone Antagonist (Potassium-Sparing)",
    "pubchemCID": "5833",
    "indications": "Heart Failure (HFrEF), Hypertension, Edema (Cirrhosis), Hyperaldosteronism, Acne/Hirsutism (Off-label).",
    "moaSteps": [
      "Competes with aldosterone for receptor sites in the distal renal tubules.",
      "Increases sodium and water excretion.",
      "Conserves potassium.",
      "Blocks androgen receptors (Anti-androgenic side effects).",
      "Reduces cardiac fibrosis in HF."
    ],
    "pharmacokinetics": {
      "absorption": "60-90% bioavailable.",
      "distribution": "90% protein bound.",
      "metabolism": "Extensive hepatic to active metabolite (Canrenone).",
      "excretion": "Urine/Feces. **Half-life: 1.4 hours (Parent); 16 hours (Canrenone).**"
    },
    "dose": {
      "initialDose": "25 mg PO once daily",
      "maxDose": "100 mg/day (HF); 400 mg/day (Hyperaldosteronism)",
      "notes": "Hyperkalemia risk."
    },
    "adverseEffects": {
      "common": [
        "Gynecomastia (Breast pain in men)",
        "Hyperkalemia",
        "Menstrual irregularities"
      ],
      "serious": [
        "Severe Hyperkalemia (Arrhythmias)",
        "Renal Failure",
        "SJS / TEN (Rare)",
        "Tumorigenic in rats - BOXED WARNING"
      ]
    },
    "precautions": [
      "**Hyperkalemia:** Monitor K+ at 1 week and 1 month. Risk high with ACEIs/ARBs/Renal disease.",
      "**Renal:** Contraindicated in severe impairment (CrCl < 30).",
      "**Gynecomastia:** Switch to Eplerenone if bothersome."
    ],
    "contraindications": [
      "Hyperkalemia",
      "Severe renal impairment / Anuria",
      "Addison's disease"
    ],
    "interactions": {
      "drug": ["ACEIs/ARBs (Hyperkalemia)", "NSAIDs (Renal failure)", "Lithium", "Digoxin (Increases half-life)"],
      "food": ["Salt substitutes (High potassium)."]
    },
    "pregnancyCategory": "Category C (Feminization of male fetus)"
  },
  "stavudine": {
    "name": "Stavudine (d4T)",
    "genericName": "Stavudine",
    "formula": "C10H12N2O4",
    "molecularWeight": "224.2 g/mol",
    "brandNames": ["Zerit"],
    "category": "Antiretroviral",
    "drugClass": "Nucleoside Reverse Transcriptase Inhibitor (NRTI)",
    "pubchemCID": "18283",
    "indications": "HIV-1 Infection (Rarely used now due to toxicity).",
    "moaSteps": [
      "Thymidine analogue.",
      "Phosphorylated intracellularly to triphosphate.",
      "Inhibits HIV reverse transcriptase by competing with natural substrate.",
      "Causes DNA chain termination.",
      "Inhibits mitochondrial DNA polymerase gamma (Toxicity)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Crosses BBB.",
      "metabolism": "Minor.",
      "excretion": "Urine. **Half-life: 1.4 hours (Intracellular: 3.5 hours).**"
    },
    "dose": {
      "initialDose": "40 mg PO BID (>60kg)",
      "maxDose": "40 mg BID",
      "notes": "Dose adjust in renal failure."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "GI upset"
      ],
      "serious": [
        "Lactic Acidosis / Hepatomegaly (Mitochondrial toxicity) - BOXED WARNING",
        "Pancreatitis (Fatal) - BOXED WARNING",
        "Peripheral Neuropathy (Severe) - Dose limiting",
        "Lipoatrophy (Fat wasting)"
      ]
    },
    "precautions": [
      "**Mitochondrial Toxicity:** Highest risk among NRTIs. Lactic acidosis can be fatal.",
      "**Neuropathy:** Motor/Sensory. Often irreversible.",
      "**Lipoatrophy:** Significant facial wasting."
    ],
    "contraindications": [
      "Co-administration with Zidovudine (Antagonistic)",
      "Didanosine (Enhanced toxicity)"
    ],
    "interactions": {
      "drug": ["Zidovudine (Antagonistic)", "Didanosine (Pancreatitis risk)", "Hydroxyurea"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "streptomycin": {
    "name": "Streptomycin",
    "genericName": "Streptomycin Sulfate",
    "formula": "C21H39N7O12",
    "molecularWeight": "581.6 g/mol",
    "brandNames": ["Streptomycin"],
    "category": "Antibiotic",
    "drugClass": "Aminoglycoside",
    "pubchemCID": "19649",
    "indications": "Tuberculosis (2nd line), Tularemia, Plague, Endocarditis (Enterococcal synergy).",
    "moaSteps": [
      "Binds to 30S ribosomal subunit.",
      "Inhibits protein synthesis.",
      "Causes misreading of mRNA.",
      "Bactericidal.",
      "Requires oxygen for uptake."
    ],
    "pharmacokinetics": {
      "absorption": "IM only (Poor oral).",
      "distribution": "Extracellular fluid.",
      "metabolism": "None.",
      "excretion": "Urine. **Half-life: 2.5 hours.**"
    },
    "dose": {
      "initialDose": "15 mg/kg IM daily",
      "maxDose": "1 g/day",
      "notes": "Limit total dose to 120g to reduce ototoxicity."
    },
    "adverseEffects": {
      "common": [
        "Pain at injection site",
        "Paresthesia (Face)"
      ],
      "serious": [
        "Ototoxicity (Vestibular > Auditory) - BOXED WARNING",
        "Nephrotoxicity - BOXED WARNING",
        "Neuromuscular Blockade - BOXED WARNING"
      ]
    },
    "precautions": [
      "**Vestibular:** Causes vertigo/balance issues more than hearing loss (unlike other aminoglycosides). Permanent.",
      "**Renal:** Monitor Cr. Accumulation increases toxicity.",
      "**Pregnancy:** Congenital deafness."
    ],
    "contraindications": [
      "Hypersensitivity to aminoglycosides"
    ],
    "interactions": {
      "drug": ["Loop Diuretics (Ototoxicity)", "Neuromuscular Blockers (Paralysis)", "Nephrotoxins"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "succinylcholine": {
    "name": "Succinylcholine (Anectine)",
    "genericName": "Succinylcholine Chloride",
    "formula": "C14H30Cl2N2O4",
    "molecularWeight": "361.3 g/mol",
    "brandNames": ["Anectine", "Quelicin"],
    "category": "Neuromuscular Blocker",
    "drugClass": "Depolarizing Agent",
    "pubchemCID": "5311",
    "indications": "Tracheal Intubation (RSI), Skeletal Muscle Relaxation during surgery.",
    "moaSteps": [
      "Mimics acetylcholine at the neuromuscular junction.",
      "Binds to nicotinic receptors causing persistent depolarization.",
      "Results in fasciculations (muscle twitching) followed by flaccid paralysis.",
      "Rapid onset (30-60 sec) and short duration."
    ],
    "pharmacokinetics": {
      "absorption": "IV/IM.",
      "distribution": "Rapid.",
      "metabolism": "Plasma Pseudocholinesterase (Rapid).",
      "excretion": "Urine. **Half-life: < 1 minute.**"
    },
    "dose": {
      "initialDose": "1-1.5 mg/kg IV",
      "maxDose": "Varies",
      "notes": "IM dose: 3-4 mg/kg."
    },
    "adverseEffects": {
      "common": [
        "Muscle Fasciculations",
        "Myalgia (Post-op)",
        "Increased Intraocular/Intragastric Pressure"
      ],
      "serious": [
        "Malignant Hyperthermia (Fatal) - BOXED WARNING",
        "Hyperkalemia (Cardiac Arrest)",
        "Prolonged Apnea (Pseudocholinesterase deficiency)",
        "Bradycardia"
      ]
    },
    "precautions": [
      "**Hyperkalemia:** Increases K+ by 0.5-1.0 mEq/L. CAUSES CARDIAC ARREST in burns, trauma, crush injuries, or denervation (receptor upregulation).",
      "**Malignant Hyperthermia:** Trigger agent. Have Dantrolene ready.",
      "**Genetics:** Prolonged paralysis in patients with atypical pseudocholinesterase."
    ],
    "contraindications": [
      "Personal/Family history of Malignant Hyperthermia",
      "Skeletal muscle myopathies",
      "Acute phase of major burns/trauma (after 24-48h)",
      "Hyperkalemia"
    ],
    "interactions": {
      "drug": ["Inhaled Anesthetics (MH risk)", "Cholinesterase Inhibitors (Prolong effect)", "Digoxin (Arrhythmias)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "sucralfate": {
    "name": "Sucralfate (Carafate)",
    "genericName": "Sucralfate",
    "formula": "C12H30Al5O29S8",
    "molecularWeight": "2086.7 g/mol",
    "brandNames": ["Carafate"],
    "category": "Gastrointestinal Agent",
    "drugClass": "Mucosal Protective Agent",
    "pubchemCID": "6323",
    "indications": "Duodenal Ulcer (Active/Maintenance).",
    "moaSteps": [
      "Complex of aluminum hydroxide and sulfated sucrose.",
      "In acidic environment (pH < 4), polymerizes to a viscous sticky gel.",
      "Adheres to ulcer craters (affinity for necrotic protein).",
      "Forms a protective barrier against acid/pepsin.",
      "Does not alter gastric pH."
    ],
    "pharmacokinetics": {
      "absorption": "Minimal (<5%).",
      "distribution": "Local.",
      "metabolism": "None.",
      "excretion": "Feces (90%). **Half-life: 6 to 20 hours (Systemic portion).**"
    },
    "dose": {
      "initialDose": "1 g PO QID",
      "maxDose": "4 g/day",
      "notes": "Take on empty stomach (1 hr before meals)."
    },
    "adverseEffects": {
      "common": [
        "Constipation (Aluminum)",
        "Dry mouth",
        "Nausea"
      ],
      "serious": [
        "Bezoar formation (rare)",
        "Aluminum toxicity (in renal failure)"
      ]
    },
    "precautions": [
      "**Renal Failure:** Contains aluminum. Accumulation/toxicity (osteodystrophy/encephalopathy) possible in dialysis patients.",
      "**Administration:** Space other drugs by 2 hours (binds to them).",
      "**NG Tube:** Can clog tubes."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Fluoroquinolones/Tetracyclines (Reduced absorption)", "Warfarin", "Digoxin", "Levothyroxine (Bind - Separate by 2-4h)"],
      "food": ["Food prevents activation (requires acid)."]
    },
    "pregnancyCategory": "Category B"
  },
  "sugammadex": {
    "name": "Sugammadex (Bridion)",
    "genericName": "Sugammadex",
    "formula": "C72H104Na8O48S8",
    "molecularWeight": "2178 g/mol",
    "brandNames": ["Bridion"],
    "category": "Antidote",
    "drugClass": "Selective Relaxant Binding Agent",
    "pubchemCID": "6918584",
    "indications": "Reversal of Neuromuscular Blockade (Rocuronium or Vecuronium).",
    "moaSteps": [
      "Modified gamma-cyclodextrin.",
      "Forms a complex with steroidal neuromuscular blocking agents (Rocuronium > Vecuronium).",
      "Encapsulates the drug in plasma, creating a concentration gradient.",
      "Pulls drug away from the neuromuscular junction.",
      "Rapid reversal without cholinergic side effects."
    ],
    "pharmacokinetics": {
      "absorption": "IV.",
      "distribution": "ECF.",
      "metabolism": "None.",
      "excretion": "Urine (Unchanged complex). **Half-life: 2 hours.**"
    },
    "dose": {
      "initialDose": "2-4 mg/kg IV (Standard); 16 mg/kg (Rescue)",
      "maxDose": "16 mg/kg",
      "notes": "Dose based on depth of block (TOF count)."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting",
        "Headache",
        "Pain at injection site"
      ],
      "serious": [
        "Hypersensitivity / Anaphylaxis",
        "Bradycardia (Cardiac arrest reported)",
        "Recurrence of blockade (if underdosed)"
      ]
    },
    "precautions": [
      "**Contraception:** Binds oral contraceptives (progesterone). Equivalent to one missed pill. Advise backup method for 7 days.",
      "**Bradycardia:** Monitor cardiac rhythm; atropine may be needed.",
      "**Renal:** Not recommended in severe renal impairment (complex not cleared)."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Hormonal Contraceptives (Efficacy reduced)", "Toremifene (Displacement)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category N/A"
  },
  "sulfamethoxazole": {
    "name": "Sulfamethoxazole/Trimethoprim (Bactrim)",
    "genericName": "Sulfamethoxazole and Trimethoprim (SMX-TMP)",
    "formula": "Combination",
    "molecularWeight": "N/A",
    "brandNames": ["Bactrim", "Septra"],
    "category": "Antibiotic",
    "drugClass": "Sulfonamide",
    "pubchemCID": "5329",
    "indications": "UTI, PCP Pneumonia (Tx/Prophylaxis), MRSA skin infections, Bronchitis.",
    "moaSteps": [
      "Sulfamethoxazole: Inhibits dihydropteroate synthase (folic acid synthesis).",
      "Trimethoprim: Inhibits dihydrofolate reductase (folic acid activation).",
      "Sequential blockade of bacterial folate pathway.",
      "Synergistic bactericidal effect."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Wide (CSF, Sputum, Urine).",
      "metabolism": "Hepatic acetylation.",
      "excretion": "Urine. **Half-life: 10 hours (SMX); 10 hours (TMP).**"
    },
    "dose": {
      "initialDose": "1 DS tablet (800/160) PO BID",
      "maxDose": "15-20 mg/kg (TMP) for PCP",
      "notes": "Drink plenty of water."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting",
        "Rash",
        "Hyperkalemia (TMP component)",
        "Photosensitivity"
      ],
      "serious": [
        "Stevens-Johnson Syndrome (SJS/TEN) - High risk",
        "Blood dyscrasias (Agranulocytosis/Aplastic Anemia)",
        "Kernicterus (Neonates)",
        "Crystalluria / Renal Failure"
      ]
    },
    "precautions": [
      "**Skin:** Discontinue at FIRST sign of rash (SJS risk).",
      "**Hyperkalemia:** Trimethoprim acts like a K+ sparing diuretic. Caution with ACEIs/ARBs.",
      "**Pregnancy:** Avoid in 1st trimester (folate antagonist) and Term (Kernicterus)."
    ],
    "contraindications": [
      "Sulfa allergy",
      "Pregnancy at term / Nursing",
      "Infants < 2 months",
      "Megaloblastic anemia due to folate deficiency"
    ],
    "interactions": {
      "drug": ["Warfarin (Significant INR increase - reduce warfarin)", "Methotrexate (Toxicity)", "ACE Inhibitors (Hyperkalemia)", "Phenytoin"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "sulfasalazine": {
    "name": "Sulfasalazine (Azulfidine)",
    "genericName": "Sulfasalazine",
    "formula": "C18H14N4O5S",
    "molecularWeight": "398.4 g/mol",
    "brandNames": ["Azulfidine"],
    "category": "DMARD / Anti-inflammatory",
    "drugClass": "5-Aminosalicylate",
    "pubchemCID": "5359476",
    "indications": "Ulcerative Colitis, Rheumatoid Arthritis.",
    "moaSteps": [
      "Prodrug cleaved by colonic bacteria into Sulfapyridine and 5-ASA (Mesalamine).",
      "5-ASA: Anti-inflammatory action in the colon (UC).",
      "Sulfapyridine: Systemic absorption; mechanism in RA unclear (immunomodulation).",
      "Inhibits prostaglandin synthesis."
    ],
    "pharmacokinetics": {
      "absorption": "Parent drug <15%. Sulfapyridine absorbed.",
      "distribution": "Wide.",
      "metabolism": "Colonic cleavage; Hepatic acetylation (Sulfapyridine).",
      "excretion": "Urine. **Half-life: 6-10 hours (Sulfapyridine - Slow acetylators longer).**"
    },
    "dose": {
      "initialDose": "500-1000 mg PO daily (Titrate)",
      "maxDose": "3-4 g/day",
      "notes": "Take with food."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Dyspepsia (Dose limiting)",
        "Headache",
        "Orange urine/skin",
        "Reversible oligospermia (Male infertility)"
      ],
      "serious": [
        "Stevens-Johnson Syndrome",
        "Agranulocytosis / Hemolysis (G6PD)",
        "Hepatotoxicity",
        "Pulmonary Fibrosis"
      ]
    },
    "precautions": [
      "**Sulfa Allergy:** Contains sulfonamide moiety.",
      "**G6PD:** Hemolysis risk.",
      "**Fertility:** Causes reversible low sperm count.",
      "**Color:** Stains urine/tears orange (permanently stains contacts)."
    ],
    "contraindications": [
      "Hypersensitivity to Sulfa or Salicylates (Aspirin)",
      "Porphyria",
      "GI/GU Obstruction"
    ],
    "interactions": {
      "drug": ["Digoxin (Reduced absorption)", "Folic Acid (Reduced absorption - Supplement required)", "Warfarin"],
      "food": ["Take with food."]
    },
    "pregnancyCategory": "Category B"
  },
  "sumatriptan": {
    "name": "Sumatriptan (Imitrex)",
    "genericName": "Sumatriptan Succinate",
    "formula": "C14H21N3O2S",
    "molecularWeight": "295.4 g/mol",
    "brandNames": ["Imitrex", "Onzetra"],
    "category": "Antimigraine",
    "drugClass": "Serotonin 5-HT1B/1D Receptor Agonist (Triptan)",
    "pubchemCID": "5358",
    "indications": "Acute Migraine, Cluster Headache.",
    "moaSteps": [
      "Agonist at 5-HT1B and 5-HT1D receptors on cranial blood vessels.",
      "Causes vasoconstriction.",
      "Inhibits release of pro-inflammatory neuropeptides (CGRP).",
      "Reduces transmission in the trigeminal pain pathway."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (SC > Nasal > Oral).",
      "distribution": "Low protein binding.",
      "metabolism": "MAO-A.",
      "excretion": "Urine. **Half-life: 2 hours.**"
    },
    "dose": {
      "initialDose": "50-100 mg PO or 6 mg SC",
      "maxDose": "200 mg/day PO; 12 mg/day SC",
      "notes": "Take at onset."
    },
    "adverseEffects": {
      "common": [
        "Chest tightness / pressure (non-cardiac)",
        "Paresthesia / Tingling",
        "Warmth / Flushing",
        "Dizziness"
      ],
      "serious": [
        "Coronary Vasospasm / MI",
        "Hypertensive Crisis",
        "Stroke",
        "Serotonin Syndrome",
        "Seizures"
      ]
    },
    "precautions": [
      "**Chest Symptoms:** Sensations of tightness/pressure are common ('Triptan sensations') but must distinguish from angina.",
      "**Cardiovascular:** Contraindicated in CAD. Risk of vasospasm.",
      "**Overuse:** Limit to < 10 days/month."
    ],
    "contraindications": [
      "Ischemic heart disease (MI, Angina)",
      "Uncontrolled hypertension",
      "Stroke/TIA history",
      "MAOI use within 14 days",
      "Hemiplegic migraine"
    ],
    "interactions": {
      "drug": ["MAOIs (Toxic levels)", "SSRIs/SNRIs (Serotonin syndrome risk)", "Ergotamine (Vasospasm - space 24h)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "sunitinib": {
    "name": "Sunitinib (Sutent)",
    "genericName": "Sunitinib Malate",
    "formula": "C22H27FN4O2",
    "molecularWeight": "398.5 g/mol",
    "brandNames": ["Sutent"],
    "category": "Antineoplastic",
    "drugClass": "Tyrosine Kinase Inhibitor (Multikinase)",
    "pubchemCID": "5329102",
    "indications": "GIST, Advanced Renal Cell Carcinoma, Pancreatic Neuroendocrine Tumors.",
    "moaSteps": [
      "Inhibits multiple receptor tyrosine kinases: PDGFR, VEGFR, KIT, FLT3.",
      "Inhibits angiogenesis (VEGF).",
      "Inhibits tumor cell proliferation.",
      "Starves tumor of blood supply."
    ],
    "pharmacokinetics": {
      "absorption": "Good.",
      "distribution": "95% protein bound.",
      "metabolism": "Hepatic (CYP3A4) to active metabolite.",
      "excretion": "Feces. **Half-life: 40 to 60 hours (Parent); 80 to 110 hours (Metabolite).**"
    },
    "dose": {
      "initialDose": "50 mg PO daily (4 weeks on / 2 weeks off)",
      "maxDose": "50 mg/day",
      "notes": "Continuous dosing for pancreatic NET."
    },
    "adverseEffects": {
      "common": [
        "Fatigue (Severe)",
        "Yellow skin discoloration",
        "Hand-Foot Syndrome",
        "Hypertension",
        "Diarrhea"
      ],
      "serious": [
        "Hepatotoxicity - BOXED WARNING",
        "Heart Failure / Left Ventricular Dysfunction",
        "Hemorrhage",
        "Thyroid dysfunction",
        "Osteonecrosis of the Jaw"
      ]
    },
    "precautions": [
      "**Hepatotoxicity:** Fatal liver failure reported. Monitor LFTs.",
      "**Cardiac:** Monitor EF baseline and periodically. Hypertension common.",
      "**Color:** Can turn skin/hair yellow (depigmentation).",
      "**Thyroid:** Hypothyroidism common."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inhibitors/Inducers (Dose adjust)", "QT prolonging drugs"],
      "food": ["Grapefruit juice"]
    },
    "pregnancyCategory": "Category D"
  },
  "suvorexant": {
    "name": "Suvorexant (Belsomra)",
    "genericName": "Suvorexant",
    "formula": "C23H23ClN6O2",
    "molecularWeight": "450.9 g/mol",
    "brandNames": ["Belsomra"],
    "category": "Sedative/Hypnotic",
    "drugClass": "Orexin Receptor Antagonist",
    "pubchemCID": "24965990",
    "indications": "Insomnia (Difficulty with onset and/or maintenance).",
    "moaSteps": [
      "Antagonizes Orexin A and Orexin B receptors (OX1R and OX2R).",
      "Orexins are neuropeptides that sustain wakefulness.",
      "Blocking orexin suppresses the 'wake drive' rather than inducing global CNS depression (like benzos).",
      "Preserves sleep architecture."
    ],
    "pharmacokinetics": {
      "absorption": "Time to peak 2h (Delayed by food).",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Feces. **Half-life: 12 hours.**"
    },
    "dose": {
      "initialDose": "10 mg PO at bedtime",
      "maxDose": "20 mg",
      "notes": "Must have 7 hours available for sleep."
    },
    "adverseEffects": {
      "common": [
        "Somnolence (Next day)",
        "Headache",
        "Dizziness"
      ],
      "serious": [
        "Sleep Paralysis / Hypnagogic Hallucinations",
        "Complex Sleep Behaviors (Sleep-driving)",
        "Worsening depression/suicidality",
        "Cataplexy-like symptoms"
      ]
    },
    "precautions": [
      "**Narcolepsy:** Contraindicated (mechanism mimics narcolepsy pathology).",
      "**Sleep Behaviors:** Stop if complex behaviors occur.",
      "**Next Day Impairment:** Doses of 20mg can impair driving the next morning."
    ],
    "contraindications": [
      "Narcolepsy"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inhibitors (Contraindicated)", "Moderate CYP3A4 Inhibitors (Reduce dose to 5mg)", "CNS Depressants"],
      "food": ["Food delays onset (Take on empty stomach)."]
    },
    "pregnancyCategory": "Category C"
  },"tacrolimus": {
    "name": "Tacrolimus (Prograf)",
    "genericName": "Tacrolimus",
    "formula": "C44H69NO12",
    "molecularWeight": "804.0 g/mol",
    "brandNames": ["Prograf", "Envarsus XR", "Protopic"],
    "category": "Immunosuppressant",
    "drugClass": "Calcineurin Inhibitor",
    "pubchemCID": "445643",
    "indications": "Prophylaxis of organ rejection (Kidney, Liver, Heart), Atopic Dermatitis (Topical).",
    "moaSteps": [
      "Binds to FKBP-12 (FK506 Binding Protein).",
      "Complex inhibits calcineurin (a phosphatase).",
      "Prevents dephosphorylation of NF-AT (Nuclear Factor of Activated T-cells).",
      "Blocks IL-2 transcription and T-cell activation."
    ],
    "pharmacokinetics": {
      "absorption": "Variable/Poor (Food reduces absorption).",
      "distribution": "99% protein bound (concentrates in RBCs).",
      "metabolism": "Extensive Hepatic (CYP3A4).",
      "excretion": "Feces. **Half-life: 12 hours (Ranges 4-40h).**"
    },
    "dose": {
      "initialDose": "0.1-0.15 mg/kg/day PO divided BID",
      "maxDose": "Titrate to Trough levels",
      "notes": "Therapeutic Drug Monitoring (TDM) essential."
    },
    "adverseEffects": {
      "common": [
        "Tremor",
        "Headache",
        "Hypertension",
        "Diarrhea"
      ],
      "serious": [
        "Nephrotoxicity (Acute/Chronic)",
        "Neurotoxicity (Seizures/PRES)",
        "Post-Transplant Lymphoproliferative Disorder (PTLD)",
        "Hyperkalemia",
        "New Onset Diabetes After Transplant (NODAT)"
      ]
    },
    "precautions": [
      "**Nephrotoxicity:** Vasoconstriction of afferent arteriole. Monitor Cr closely.",
      "**Diabetes:** More diabetogenic than cyclosporine.",
      "**Neurotoxicity:** Tremor is common; seizures/PRES indicate high levels.",
      "**Interactions:** CYP3A4 substrate (Grapefruit is dangerous)."
    ],
    "contraindications": [
      "Hypersensitivity to macrolides (structurally related)"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inhibitors (Azoles/Diltiazem - Toxicity)", "CYP3A4 Inducers (Rifampin - Rejection)", "NSAIDs (Nephrotoxicity)"],
      "food": ["Grapefruit juice (Avoid)", "Take consistently with/without food."]
    },
    "pregnancyCategory": "Category C"
  },
  "tadalafil": {
    "name": "Tadalafil (Cialis)",
    "genericName": "Tadalafil",
    "formula": "C22H19N3O4",
    "molecularWeight": "389.4 g/mol",
    "brandNames": ["Cialis", "Adcirca"],
    "category": "Erectile Dysfunction / PAH Agent",
    "drugClass": "PDE-5 Inhibitor",
    "pubchemCID": "110635",
    "indications": "Erectile Dysfunction, BPH, Pulmonary Arterial Hypertension (Adcirca).",
    "moaSteps": [
      "Inhibits Phosphodiesterase type 5 (PDE-5).",
      "Prevents breakdown of cGMP.",
      "Enhances NO-mediated vasodilation in corpus cavernosum and pulmonary vessels.",
      "Long half-life allows for 'weekend' dosing or daily use."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid. Unaffected by food.",
      "distribution": "94% protein bound.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Feces/Urine. **Half-life: 17.5 hours.**"
    },
    "dose": {
      "initialDose": "10 mg PO PRN or 2.5-5 mg Daily",
      "maxDose": "20 mg/day",
      "notes": "For BPH: 5 mg Daily."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Dyspepsia",
        "Back pain / Myalgia (unique to Tadalafil)",
        "Flushing"
      ],
      "serious": [
        "Hypotension (Severe with nitrates)",
        "Priapism",
        "Sudden Hearing/Vision Loss"
      ]
    },
    "precautions": [
      "**Nitrates:** Contraindicated. Wait 48 hours after Tadalafil before using nitrates.",
      "**Back Pain:** Caused by PDE-11 inhibition in skeletal muscle.",
      "**Alpha-blockers:** Caution with simultaneous use."
    ],
    "contraindications": [
      "Concomitant Nitrates",
      "Concomitant Guanylate Cyclase Stimulators (Riociguat)"
    ],
    "interactions": {
      "drug": ["Nitrates (Fatal hypotension)", "Alpha-blockers (Hypotension)", "CYP3A4 Inhibitors"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "tamoxifen": {
    "name": "Tamoxifen (Nolvadex)",
    "genericName": "Tamoxifen Citrate",
    "formula": "C26H29NO",
    "molecularWeight": "371.5 g/mol",
    "brandNames": ["Nolvadex", "Soltamox"],
    "category": "Antineoplastic",
    "drugClass": "Selective Estrogen Receptor Modulator (SERM)",
    "pubchemCID": "2733526",
    "indications": "Estrogen Receptor Positive (ER+) Breast Cancer (Treatment and Prophylaxis).",
    "moaSteps": [
      "Competes with estrogen for binding to estrogen receptors (ER).",
      "Antagonist in Breast tissue (blocks tumor growth).",
      "Agonist in Uterus (Endometrial proliferation risk).",
      "Agonist in Bone (Protects density).",
      "Prodrug activated by CYP2D6 to Endoxifen."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic (CYP2D6/3A4) to potent Endoxifen.",
      "excretion": "Feces. **Half-life: 5-7 days (Parent); 14 days (Metabolites).**"
    },
    "dose": {
      "initialDose": "20 mg PO daily",
      "maxDose": "40 mg/day",
      "notes": "Used for 5-10 years."
    },
    "adverseEffects": {
      "common": [
        "Hot flashes",
        "Vaginal discharge",
        "Fluid retention",
        "Nausea"
      ],
      "serious": [
        "Uterine Malignancies (Endometrial Cancer/Sarcoma) - BOXED WARNING",
        "Thromboembolism (DVT/PE/Stroke) - BOXED WARNING",
        "Cataracts"
      ]
    },
    "precautions": [
      "**Endometrial Cancer:** Monitor for abnormal vaginal bleeding.",
      "**Thrombosis:** Stop drug if immobilization/surgery planned.",
      "**CYP2D6:** Poor metabolizers may have reduced efficacy (less Endoxifen). Avoid strong inhibitors (Fluoxetine/Paroxetine)."
    ],
    "contraindications": [
      "Concomitant Warfarin (Preventative use)",
      "History of DVT/PE (Preventative use)",
      "Pregnancy"
    ],
    "interactions": {
      "drug": ["CYP2D6 Inhibitors (Fluoxetine/Paroxetine/Bupropion - Reduce efficacy)", "Warfarin (INR increase)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "tamsulosin": {
    "name": "Tamsulosin (Flomax)",
    "genericName": "Tamsulosin HCl",
    "formula": "C20H28N2O5S",
    "molecularWeight": "408.5 g/mol",
    "brandNames": ["Flomax"],
    "category": "BPH Agent",
    "drugClass": "Alpha-1 Blocker (Uroselective)",
    "pubchemCID": "129211",
    "indications": "Benign Prostatic Hyperplasia (BPH), Ureteral Stones (Off-label expulsion).",
    "moaSteps": [
      "Selectively blocks alpha-1A adrenergic receptors in the prostate and bladder neck.",
      "Relaxes smooth muscle.",
      "Improves urine flow rate.",
      "Minimal effect on alpha-1B receptors in blood vessels (less hypotension than Terazosin)."
    ],
    "pharmacokinetics": {
      "absorption": ">90% absorbed. Fasting increases bioavailability.",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic (CYP3A4/2D6).",
      "excretion": "Urine. **Half-life: 9 to 13 hours (Effect lasts 24h).**"
    },
    "dose": {
      "initialDose": "0.4 mg PO once daily",
      "maxDose": "0.8 mg/day",
      "notes": "Take 30 min after same meal each day."
    },
    "adverseEffects": {
      "common": [
        "Retrograde Ejaculation",
        "Dizziness",
        "Rhinitis",
        "Headache"
      ],
      "serious": [
        "Intraoperative Floppy Iris Syndrome (IFIS)",
        "Priapism",
        "Orthostatic Hypotension (First dose)"
      ]
    },
    "precautions": [
      "**Sulfa:** Structurally related to sulfonamides; rare cross-reactivity.",
      "**Cataract Surgery:** IFIS can complicate surgery. Inform ophthalmologist.",
      "**Hypotension:** Less common than non-selective agents but possible."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 inhibitors (Ketoconazole)", "PDE5 Inhibitors (Additive hypotension)", "Alpha-blockers"],
      "food": ["Take after meal (Lowers peak concentration/side effects)."]
    },
    "pregnancyCategory": "Category B"
  },
  "telmisartan": {
    "name": "Telmisartan (Micardis)",
    "genericName": "Telmisartan",
    "formula": "C33H30N4O2",
    "molecularWeight": "514.6 g/mol",
    "brandNames": ["Micardis"],
    "category": "Antihypertensive",
    "drugClass": "Angiotensin II Receptor Blocker (ARB)",
    "pubchemCID": "65999",
    "indications": "Hypertension, Cardiovascular Risk Reduction.",
    "moaSteps": [
      "Selectively blocks AT1 receptor.",
      "Blocks vasoconstriction and aldosterone release.",
      "Unique property: Partial PPAR-gamma agonist activity (improves insulin sensitivity).",
      "Longest half-life of all ARBs."
    ],
    "pharmacokinetics": {
      "absorption": "40-60% bioavailable.",
      "distribution": "High Vd. >99% protein bound.",
      "metabolism": "Minimal (Glucuronidation). Not CYP metabolized.",
      "excretion": "Feces (>97%). **Half-life: 24 hours.**"
    },
    "dose": {
      "initialDose": "40 mg PO once daily",
      "maxDose": "80 mg/day",
      "notes": "Effective for full 24-hour cycle."
    },
    "adverseEffects": {
      "common": [
        "Dizziness",
        "Back pain",
        "Sinusitis",
        "Diarrhea"
      ],
      "serious": [
        "Hyperkalemia",
        "Renal Failure",
        "Angioedema (Rare)",
        "Fetal Toxicity - BOXED WARNING"
      ]
    },
    "precautions": [
      "**Pregnancy:** Discontinue immediately.",
      "**Renal:** Monitor Cr and K+.",
      "**Metabolic:** May be preferred in metabolic syndrome due to PPAR activity."
    ],
    "contraindications": [
      "Pregnancy",
      "Concomitant Aliskiren in diabetes"
    ],
    "interactions": {
      "drug": ["Lithium", "NSAIDs", "K+ Sparing Diuretics", "Digoxin (Increases levels)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "tenofovir_disoproxil": {
    "name": "Tenofovir Disoproxil Fumarate (Viread)",
    "genericName": "Tenofovir Disoproxil Fumarate (TDF)",
    "formula": "C19H30N5O10P",
    "molecularWeight": "635.5 g/mol",
    "brandNames": ["Viread", "Truvada (combo)"],
    "category": "Antiretroviral",
    "drugClass": "Nucleotide Reverse Transcriptase Inhibitor (NtRTI)",
    "pubchemCID": "5481350",
    "indications": "HIV-1 Infection, Chronic Hepatitis B.",
    "moaSteps": [
      "Acyclic nucleoside phosphonate diester analog of adenosine monophosphate.",
      "Hydrolyzed to tenofovir then phosphorylated to active diphosphate.",
      "Inhibits HIV-1 reverse transcriptase and HBV polymerase by chain termination.",
      "Higher plasma levels than TAF (newer prodrug)."
    ],
    "pharmacokinetics": {
      "absorption": "25% bioavailable (increased by high fat meal).",
      "distribution": "<1% protein bound.",
      "metabolism": "Intracellular phosphorylation.",
      "excretion": "Renal (Glomerular/Tubular). **Half-life: 17 hours.**"
    },
    "dose": {
      "initialDose": "300 mg PO once daily",
      "maxDose": "300 mg/day",
      "notes": "Renal adjustment essential."
    },
    "adverseEffects": {
      "common": [
        "Nausea",
        "Diarrhea",
        "Headache",
        "Flatulence"
      ],
      "serious": [
        "Nephrotoxicity (Fanconi Syndrome/Acute Renal Failure)",
        "Decreased Bone Mineral Density (Osteoporosis)",
        "Lactic Acidosis / Hepatomegaly",
        "Hep B Exacerbation (upon withdrawal)"
      ]
    },
    "precautions": [
      "**Bone/Kidney:** TDF causes more renal and bone toxicity than TAF (Tenofovir Alafenamide). Monitor Cr, Phos, and DEXA.",
      "**Hep B:** Test all HIV patients. Discontinuation can cause flare."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Didanosine (Increases levels - Toxicity)", "Atazanavir/Lopinavir (Boosted PIs increase Tenofovir levels)", "NSAIDs (Renal risk)"],
      "food": ["Take with food to increase absorption."]
    },
    "pregnancyCategory": "Category B"
  },
  "terbinafine": {
    "name": "Terbinafine (Lamisil)",
    "genericName": "Terbinafine HCl",
    "formula": "C21H25N",
    "molecularWeight": "291.4 g/mol",
    "brandNames": ["Lamisil"],
    "category": "Antifungal",
    "drugClass": "Allylamine",
    "pubchemCID": "1549008",
    "indications": "Onychomycosis (Nail fungus), Tinea Capitis.",
    "moaSteps": [
      "Inhibits squalene epoxidase.",
      "Prevents conversion of squalene to lanosterol.",
      "Accumulation of toxic squalene kills the fungus (Fungicidal).",
      "Deficiency of ergosterol prevents membrane formation."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "Lipophilic; concentrates in sebum, hair, and nail beds.",
      "metabolism": "Hepatic (multiple CYP enzymes).",
      "excretion": "Urine. **Half-life: 36 hours (Terminal T1/2: 200-400 hours due to tissue release).**"
    },
    "dose": {
      "initialDose": "250 mg PO daily",
      "maxDose": "250 mg/day",
      "notes": "Duration: 6 weeks (Fingernail); 12 weeks (Toenail)."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "GI upset",
        "Taste disturbance (Dysgeusia/Ageusia) - can be permanent",
        "Rash"
      ],
      "serious": [
        "Hepatotoxicity (Liver failure - rare)",
        "Stevens-Johnson Syndrome",
        "Neutropenia",
        "Lupus-like reaction"
      ]
    },
    "precautions": [
      "**Liver:** Hepatic failure (some fatal) reported. Baseline LFTs required. Stop if symptoms occur.",
      "**Taste:** Loss of taste can be permanent.",
      "**Smell:** Loss of smell reported."
    ],
    "contraindications": [
      "Chronic or active liver disease"
    ],
    "interactions": {
      "drug": ["CYP2D6 Substrates (Terbinafine inhibits 2D6 - increases TCAs/Beta-blockers)", "Rifampin (decreases levels)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "teriparatide": {
    "name": "Teriparatide (Forteo)",
    "genericName": "Teriparatide",
    "formula": "Recombinant human PTH (1-34)",
    "molecularWeight": "4117 Da",
    "brandNames": ["Forteo"],
    "category": "Bone Anabolic Agent",
    "drugClass": "Parathyroid Hormone Analog",
    "pubchemCID": "None (Peptide)",
    "indications": "Osteoporosis (High fracture risk), Glucocorticoid-induced osteoporosis.",
    "moaSteps": [
      "Recombinant formulation of the first 34 amino acids of human Parathyroid Hormone.",
      "Intermittent administration stimulates osteoblast activity more than osteoclast activity.",
      "Increases new bone formation (Anabolic) and bone mineral density.",
      "Restores bone architecture."
    ],
    "pharmacokinetics": {
      "absorption": "Subcutaneous (95% bioavailable).",
      "distribution": "Rapid.",
      "metabolism": "Proteolysis.",
      "excretion": "Urine. **Half-life: 1 hour (serum).**"
    },
    "dose": {
      "initialDose": "20 mcg SC daily",
      "maxDose": "20 mcg/day",
      "notes": "Lifetime duration limit: 2 years."
    },
    "adverseEffects": {
      "common": [
        "Nausea",
        "Orthostatic Hypotension (transient post-dose)",
        "Leg cramps",
        "Hypercalcemia (Transient)"
      ],
      "serious": [
        "Osteosarcoma (Rat studies) - BOXED WARNING (Removed in some regions, but caution remains)",
        "Urolithiasis"
      ]
    },
    "precautions": [
      "**Osteosarcoma:** Avoid in Paget's disease, unexplained alkaline phosphatase elevation, prior skeletal radiation, or bone metastasis.",
      "**Duration:** Limited to 2 years cumulative lifetime use.",
      "**Orthostasis:** Administer lying down initially."
    ],
    "contraindications": [
      "Paget's disease of bone",
      "Pediatric/Young adults (Open epiphyses)",
      "Prior skeletal radiation",
      "Hypercalcemia"
    ],
    "interactions": {
      "drug": ["Digoxin (Hypercalcemia potentiates toxicity)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "ticagrelor": {
    "name": "Ticagrelor (Brilinta)",
    "genericName": "Ticagrelor",
    "formula": "C23H28F2N6O4S",
    "molecularWeight": "522.6 g/mol",
    "brandNames": ["Brilinta"],
    "category": "Antiplatelet",
    "drugClass": "P2Y12 ADP Receptor Inhibitor (Reversible)",
    "pubchemCID": "9871419",
    "indications": "Acute Coronary Syndrome (ACS), MI/Stroke Prevention.",
    "moaSteps": [
      "Direct-acting P2Y12 receptor antagonist.",
      "Reversibly binds to the P2Y12 ADP receptor on platelets.",
      "Prevents signal transduction and platelet activation.",
      "Does not require metabolic activation (unlike Clopidogrel).",
      "Faster onset and offset than Clopidogrel."
    ],
    "pharmacokinetics": {
      "absorption": "36% bioavailable.",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Feces/Urine. **Half-life: 7 hours (Parent); 9 hours (Active metabolite).**"
    },
    "dose": {
      "initialDose": "180 mg Loading, then 90 mg PO BID",
      "maxDose": "90 mg BID (1st year); 60 mg BID (after 1 year)",
      "notes": "Use with Aspirin < 100 mg."
    },
    "adverseEffects": {
      "common": [
        "Dyspnea (Shortness of breath - dose related)",
        "Bleeding / Bruising"
      ],
      "serious": [
        "Major Hemorrhage - BOXED WARNING",
        "Ventricular Pauses / Bradycardia",
        "Thrombotic Thrombocytopenic Purpura (TTP)"
      ]
    },
    "precautions": [
      "**Aspirin Dose:** Boxed Warning. Maintenance aspirin > 100 mg/day reduces Ticagrelor efficacy. Use 81 mg.",
      "**Dyspnea:** Common (14%). Usually mild/moderate but can lead to discontinuation.",
      "**Surgery:** Stop 5 days prior."
    ],
    "contraindications": [
      "Active pathological bleeding",
      "History of Intracranial Hemorrhage",
      "Severe hepatic impairment"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inhibitors/Inducers", "Aspirin > 100mg (Decreased efficacy)", "Opioids (Delayed absorption of Ticagrelor)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "timolol": {
    "name": "Timolol (Timoptic)",
    "genericName": "Timolol Maleate",
    "formula": "C13H24N4O3S",
    "molecularWeight": "316.4 g/mol",
    "brandNames": ["Timoptic", "Betimol", "Istalol"],
    "category": "Glaucoma Agent / Antihypertensive",
    "drugClass": "Non-selective Beta Blocker",
    "pubchemCID": "33624",
    "indications": "Open-angle Glaucoma (Ophthalmic), Migraine prophylaxis (Oral), Hypertension (Oral).",
    "moaSteps": [
      "Non-selective beta-1 and beta-2 adrenergic antagonist.",
      "Ophthalmic: Reduces aqueous humor production by the ciliary body.",
      "Systemic: Reduces cardiac output and sympathetic tone."
    ],
    "pharmacokinetics": {
      "absorption": "Systemic absorption via nasolacrimal duct.",
      "distribution": "Low protein binding.",
      "metabolism": "Hepatic (CYP2D6).",
      "excretion": "Urine. **Half-life: 4 hours (Systemic).**"
    },
    "dose": {
      "initialDose": "1 drop 0.25-0.5% BID",
      "maxDose": "1 drop BID",
      "notes": "Gel forming solution is QD."
    },
    "adverseEffects": {
      "common": [
        "Eye irritation / Stinging",
        "Blurred vision"
      ],
      "serious": [
        "Systemic Beta-Blockade: Bradycardia, Heart Block, Bronchospasm (Asthma attacks)",
        "Heart Failure exacerbation"
      ]
    },
    "precautions": [
      "**Systemic Absorption:** Drops can cause severe systemic effects. Contraindicated in asthma/COPD/Heart Block.",
      "**Technique:** Nasolacrimal occlusion reduces systemic absorption."
    ],
    "contraindications": [
      "Bronchial Asthma / Severe COPD",
      "Sinus bradycardia",
      "2nd/3rd degree AV block",
      "Overt Heart Failure"
    ],
    "interactions": {
      "drug": ["Oral Beta-blockers (Additive)", "Calcium Channel Blockers", "Quinidine (Increases timolol levels via CYP2D6)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "tiotropium": {
    "name": "Tiotropium (Spiriva)",
    "genericName": "Tiotropium Bromide",
    "formula": "C19H22BrNO4S2",
    "molecularWeight": "472.4 g/mol",
    "brandNames": ["Spiriva HandiHaler", "Spiriva Respimat"],
    "category": "Bronchodilator",
    "drugClass": "Long-Acting Muscarinic Antagonist (LAMA)",
    "pubchemCID": "5487427",
    "indications": "COPD maintenance, Asthma maintenance.",
    "moaSteps": [
      "Long-acting antimuscarinic agent (Anticholinergic).",
      "Binds to M3 muscarinic receptors in smooth muscle of airways.",
      "Inhibits acetylcholine-induced bronchoconstriction.",
      "Dissociates slowly from M3 receptors (long duration).",
      "Dissociates rapidly from M2 receptors (autoreceptors)."
    ],
    "pharmacokinetics": {
      "absorption": "Minimal systemic absorption.",
      "distribution": "Local.",
      "metabolism": "Non-enzymatic.",
      "excretion": "Urine. **Half-life: 25 to 44 hours (Effective T1/2).**"
    },
    "dose": {
      "initialDose": "1 capsule (18 mcg) inhaled daily (HandiHaler)",
      "maxDose": "1 dose/day",
      "notes": "Do not swallow capsules."
    },
    "adverseEffects": {
      "common": [
        "Dry mouth (Most common)",
        "Upper respiratory infection",
        "Constipation",
        "Pharyngitis"
      ],
      "serious": [
        "Paradoxical Bronchospasm",
        "Worsening of Narrow-Angle Glaucoma",
        "Urinary Retention",
        "Anaphylaxis"
      ]
    },
    "precautions": [
      "**Capsules:** Instruct patient NOT to swallow capsules (HandiHaler).",
      "**Renal:** Monitor in moderate/severe impairment.",
      "**Eyes:** Avoid contact with eyes (pupil dilation/glaucoma)."
    ],
    "contraindications": [
      "Hypersensitivity to atropine derivatives"
    ],
    "interactions": {
      "drug": ["Other Anticholinergics (Additive toxicity - Avoid combo)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "tizanidine": {
    "name": "Tizanidine (Zanaflex)",
    "genericName": "Tizanidine HCl",
    "formula": "C9H8ClN5S",
    "molecularWeight": "253.7 g/mol",
    "brandNames": ["Zanaflex"],
    "category": "Muscle Relaxant",
    "drugClass": "Alpha-2 Adrenergic Agonist",
    "pubchemCID": "5488",
    "indications": "Spasticity (MS, Spinal cord injury).",
    "moaSteps": [
      "Centrally acting alpha-2 adrenergic agonist.",
      "Increases presynaptic inhibition of motor neurons.",
      "Reduces facilitation of spinal motor neurons.",
      "Reduces spasticity with less muscle weakness than Baclofen (sometimes)."
    ],
    "pharmacokinetics": {
      "absorption": "Good but high first pass (40% bioavailable).",
      "distribution": "30% protein bound.",
      "metabolism": "Extensive Hepatic (CYP1A2).",
      "excretion": "Urine/Feces. **Half-life: 2.5 hours.**"
    },
    "dose": {
      "initialDose": "2 mg PO q6-8h PRN",
      "maxDose": "36 mg/day",
      "notes": "Capsules and tablets are not bioequivalent with food."
    },
    "adverseEffects": {
      "common": [
        "Dry mouth",
        "Somnolence / Sedation",
        "Hypotension / Bradycardia",
        "Dizziness"
      ],
      "serious": [
        "Hepatotoxicity",
        "Severe Hypotension / Syncope (with CYP1A2 inhibitors)",
        "Hallucinations"
      ]
    },
    "precautions": [
      "**CYP1A2 Interaction:** Ciprofloxacin/Fluvoxamine inhibit metabolism drastically, increasing levels 10-33 fold. CONTRAINDICATED.",
      "**Hypotension:** Dose-related. Monitor BP.",
      "**Withdrawal:** Rebound hypertension/tachycardia if stopped abruptly."
    ],
    "contraindications": [
      "Concomitant Ciprofloxacin or Fluvoxamine"
    ],
    "interactions": {
      "drug": ["Ciprofloxacin/Fluvoxamine (Contraindicated)", "Oral Contraceptives (Increase tizanidine levels)", "Antihypertensives"],
      "food": ["Food changes absorption profile (Tablet vs Capsule difference)."]
    },
    "pregnancyCategory": "Category C"
  },
  "tofacitinib": {
    "name": "Tofacitinib (Xeljanz)",
    "genericName": "Tofacitinib Citrate",
    "formula": "C16H20N6O",
    "molecularWeight": "312.4 g/mol",
    "brandNames": ["Xeljanz", "Xeljanz XR"],
    "category": "DMARD",
    "drugClass": "Janus Kinase (JAK) Inhibitor",
    "pubchemCID": "9926791",
    "indications": "Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, Polyarticular Course Juvenile Idiopathic Arthritis.",
    "moaSteps": [
      "Inhibits Janus Kinases (JAK1 and JAK3).",
      "Interferes with the JAK-STAT signaling pathway.",
      "Prevents phosphorylation and activation of STATs.",
      "Blocks cytokine signaling involved in immune response."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (74% bioavailable).",
      "distribution": "40% protein bound.",
      "metabolism": "Hepatic (CYP3A4 and CYP2C19).",
      "excretion": "Urine. **Half-life: 3 hours.**"
    },
    "dose": {
      "initialDose": "5 mg PO BID or 11 mg XR daily",
      "maxDose": "10 mg BID (UC induction only)",
      "notes": "10mg BID has higher clotting risk."
    },
    "adverseEffects": {
      "common": [
        "Upper respiratory infection",
        "Headache",
        "Diarrhea",
        "Nasopharyngitis"
      ],
      "serious": [
        "Serious Infections (TB/Fungal) - BOXED WARNING",
        "Thrombosis (DVT/PE) - BOXED WARNING",
        "Malignancy (Lymphoma) - BOXED WARNING",
        "Major Adverse Cardiovascular Events - BOXED WARNING",
        "GI Perforation"
      ]
    },
    "precautions": [
      "**Thrombosis:** Higher doses (10mg BID) associated with PE/Death. Avoid in patients with thrombosis risk factors.",
      "**Infection:** Screen for TB. Herpes Zoster reactivation common.",
      "**Lymphocytes:** Monitor ALC; stop if <500."
    ],
    "contraindications": [
      "Active serious infection"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inhibitors (Reduce dose)", "Live Vaccines"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "topiramate": {
    "name": "Topiramate (Topamax)",
    "genericName": "Topiramate",
    "formula": "C12H21NO8S",
    "molecularWeight": "339.4 g/mol",
    "brandNames": ["Topamax", "Qudexy XR", "Trokendi XR"],
    "category": "Anticonvulsant",
    "drugClass": "Sulfamate",
    "pubchemCID": "5284627",
    "indications": "Epilepsy (Partial/Generalized), Migraine Prophylaxis, Weight Loss (off-label/combo).",
    "moaSteps": [
      "Blocks voltage-dependent sodium channels.",
      "Enhances GABA activity at non-benzodiazepine sites.",
      "Antagonizes AMPA/Kainate glutamate receptors.",
      "Weak Carbonic Anhydrase inhibitor."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (80% bioavailable).",
      "distribution": "15-41% protein bound.",
      "metabolism": "Minor hepatic.",
      "excretion": "Urine. **Half-life: 21 hours.**"
    },
    "dose": {
      "initialDose": "25 mg PO daily/BID",
      "maxDose": "400 mg/day",
      "notes": "Titrate slowly ('Dopamax' effect)."
    },
    "adverseEffects": {
      "common": [
        "Paresthesia (Tingling - Very common)",
        "Cognitive slowing ('Dopamax' - word finding difficulty)",
        "Weight loss",
        "Taste perversion"
      ],
      "serious": [
        "Metabolic Acidosis (Carbonic anhydrase inhibition)",
        "Kidney Stones",
        "Acute Angle-Closure Glaucoma (Emergency)",
        "Oligohidrosis (Reduced sweating - Hyperthermia)",
        "Suicidal Ideation"
      ]
    },
    "precautions": [
      "**Cognition:** Memory/concentration issues are dose-related.",
      "**Vision:** Acute myopia/angle closure glaucoma. Stop drug immediately if eye pain/blurred vision occurs.",
      "**Acidosis:** Monitor Bicarb levels.",
      "**Pregnancy:** Cleft lip/palate risk."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Oral Contraceptives (Reduced efficacy)", "Valproate (Hyperammonemia)", "Carbonic Anhydrase Inhibitors (stones/acidosis)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "tramadol": {
    "name": "Tramadol (Ultram)",
    "genericName": "Tramadol HCl",
    "formula": "C16H25NO2",
    "molecularWeight": "263.4 g/mol",
    "brandNames": ["Ultram", "ConZip"],
    "category": "Opioid Analgesic",
    "drugClass": "Weak Opioid / SNRI",
    "pubchemCID": "33741",
    "indications": "Moderate to Severe Pain.",
    "moaSteps": [
      "Weak agonist at mu-opioid receptors.",
      "Inhibits reuptake of Serotonin and Norepinephrine.",
      "Analgesia provided by both opioid and non-opioid mechanisms.",
      "Prodrug requiring CYP2D6 activation (O-desmethyltramadol is more potent opioid)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Widely distributed.",
      "metabolism": "Hepatic (CYP2D6/3A4).",
      "excretion": "Urine. **Half-life: 6 hours (Parent); 7.5 hours (Active metabolite).**"
    },
    "dose": {
      "initialDose": "25-50 mg PO q4-6h",
      "maxDose": "400 mg/day (300 mg in elderly)",
      "notes": "Schedule IV."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting",
        "Constipation",
        "Dizziness",
        "Somnolence"
      ],
      "serious": [
        "Seizures (Lowers threshold)",
        "Serotonin Syndrome",
        "Respiratory Depression (Boxed Warning)",
        "Suicidality"
      ]
    },
    "precautions": [
      "**Seizures:** Risk increases with dose >400mg or with other seizure-lowering drugs (antipsychotics/bupropion). Avoid in epilepsy.",
      "**CYP2D6:** Ultra-rapid metabolizers convert to opioid metabolite rapidly -> Respiratory depression (Children - Contraindicated).",
      "**Serotonin:** Caution with SSRIs/MAOIs."
    ],
    "contraindications": [
      "Children < 12 years (or <18 after tonsillectomy)",
      "Acute intoxication with alcohol/sedatives",
      "Severe respiratory depression",
      "MAOI use within 14 days"
    ],
    "interactions": {
      "drug": ["SSRIs/SNRIs (Serotonin syndrome)", "Warfarin (Increased INR)", "Carbamazepine (Reduces efficacy)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "trastuzumab": {
    "name": "Trastuzumab (Herceptin)",
    "genericName": "Trastuzumab",
    "formula": "Humanized IgG1 monoclonal antibody",
    "molecularWeight": "145 kDa",
    "brandNames": ["Herceptin", "Kanjinti", "Ogivri"],
    "category": "Antineoplastic",
    "drugClass": "HER2/neu Receptor Inhibitor",
    "pubchemCID": "None (Protein)",
    "indications": "HER2-Overexpressing Breast Cancer, HER2+ Metastatic Gastric Cancer.",
    "moaSteps": [
      "Binds to the extracellular domain of the Human Epidermal Growth Factor Receptor 2 (HER2).",
      "Inhibits HER2-mediated cell signaling (PI3K/AKT pathway).",
      "Mediates Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC).",
      "Inhibits tumor cell proliferation."
    ],
    "pharmacokinetics": {
      "absorption": "IV.",
      "distribution": "Vascular.",
      "metabolism": "Catabolism.",
      "excretion": "Clearance decreases with multiple doses. **Half-life: 28 days (Maintenance phase).**"
    },
    "dose": {
      "initialDose": "8 mg/kg Loading Dose",
      "maxDose": "6 mg/kg every 3 weeks",
      "notes": "Do not mix with Dextrose."
    },
    "adverseEffects": {
      "common": [
        "Infusion reactions (Fever/Chills)",
        "Nausea",
        "Headache"
      ],
      "serious": [
        "Cardiomyopathy (LVEF reduction/Heart Failure) - BOXED WARNING",
        "Infusion Reactions (Fatal) - BOXED WARNING",
        "Pulmonary Toxicity - BOXED WARNING",
        "Embryo-Fetal Toxicity - BOXED WARNING"
      ]
    },
    "precautions": [
      "**Cardiac:** LVEF monitoring at baseline and every 3 months. High risk if combined with Anthracyclines (Doxorubicin). Often reversible.",
      "**Infusion:** Stop for dyspnea or hypotension.",
      "**Pregnancy:** Oligohydramnios/Fetal death."
    ],
    "contraindications": [
      "None (except hypersensitivity)"
    ],
    "interactions": {
      "drug": ["Anthracyclines (Cardiotoxicity - Avoid concurrent use)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "trazodone": {
    "name": "Trazodone (Desyrel)",
    "genericName": "Trazodone HCl",
    "formula": "C19H22ClN5O",
    "molecularWeight": "371.9 g/mol",
    "brandNames": ["Desyrel"],
    "category": "Antidepressant / Sedative",
    "drugClass": "Serotonin Modulator (SARI)",
    "pubchemCID": "5533",
    "indications": "Major Depressive Disorder, Insomnia (Off-label).",
    "moaSteps": [
      "Inhibits serotonin reuptake (SERT) - weak compared to SSRIs.",
      "Potent antagonist of 5-HT2A receptors.",
      "Blocks Histamine H1 and Alpha-1 adrenergic receptors.",
      "Sedative effects dominate at lower doses."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "90% protein bound.",
      "metabolism": "Hepatic (CYP3A4) to active metabolite mCPP.",
      "excretion": "Urine. **Half-life: 5 to 9 hours.**"
    },
    "dose": {
      "initialDose": "50-150 mg PO at bedtime",
      "maxDose": "400 mg/day (Depression)",
      "notes": "Insomnia dose usually 50-100mg."
    },
    "adverseEffects": {
      "common": [
        "Sedation / Drowsiness",
        "Dizziness",
        "Dry mouth",
        "Orthostatic Hypotension"
      ],
      "serious": [
        "Priapism (Medical Emergency)",
        "Suicidality - BOXED WARNING",
        "Serotonin Syndrome",
        "Arrhythmias"
      ]
    },
    "precautions": [
      "**Priapism:** Painful erection >4 hours. Rare (1/6000) but requires surgical intervention.",
      "**Orthostasis:** Alpha-1 blockade causes hypotension. Take at bedtime.",
      "**Sedation:** Severe next-day grogginess."
    ],
    "contraindications": [
      "MAOI use within 14 days",
      "Acute recovery phase of MI"
    ],
    "interactions": {
      "drug": ["MAOIs (Fatal)", "CNS Depressants", "CYP3A4 Inhibitors/Inducers"],
      "food": ["Take with food to reduce dizziness."]
    },
    "pregnancyCategory": "Category C"
  },
  "ustekinumab": {
    "name": "Ustekinumab (Stelara)",
    "genericName": "Ustekinumab",
    "formula": "Human IgG1k monoclonal antibody",
    "molecularWeight": "149 kDa",
    "brandNames": ["Stelara"],
    "category": "Biologic DMARD",
    "drugClass": "IL-12/IL-23 Inhibitor",
    "pubchemCID": "None (Protein)",
    "indications": "Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, Ulcerative Colitis.",
    "moaSteps": [
      "Binds to the p40 subunit common to both IL-12 and IL-23.",
      "Prevents IL-12 and IL-23 from binding to receptors on T-cells and NK cells.",
      "Inhibits Th1 and Th17 cytokine pathways.",
      "Reduces inflammation."
    ],
    "pharmacokinetics": {
      "absorption": "Subcutaneous.",
      "distribution": "Vascular.",
      "metabolism": "Degradation.",
      "excretion": "Slow. **Half-life: 15 to 32 days.**"
    },
    "dose": {
      "initialDose": "45 mg or 90 mg SubQ at 0, 4 weeks",
      "maxDose": "Every 12 weeks (Maintenance)",
      "notes": "Weight-based dosing for induction."
    },
    "adverseEffects": {
      "common": [
        "Nasopharyngitis",
        "Upper respiratory infection",
        "Headache",
        "Fatigue"
      ],
      "serious": [
        "Serious Infections (TB, Fungal, Viral)",
        "Malignancy (Skin cancer)",
        "Reversible Posterior Leukoencephalopathy Syndrome (RPLS)",
        "Anaphylaxis"
      ]
    },
    "precautions": [
      "**Infection:** TB screening mandatory. Risk of opportunistic infections.",
      "**Malignancy:** Non-melanoma skin cancers reported.",
      "**Vaccines:** No live vaccines."
    ],
    "contraindications": [
      "Clinically significant active infection",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Live Vaccines (Contraindicated)", "Allergy Immunotherapy (May decrease efficacy)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "valacyclovir": {
    "name": "Valacyclovir (Valtrex)",
    "genericName": "Valacyclovir HCl",
    "formula": "C13H20N6O4",
    "molecularWeight": "324.3 g/mol",
    "brandNames": ["Valtrex"],
    "category": "Antiviral",
    "drugClass": "Nucleoside Analogue",
    "pubchemCID": "60773",
    "indications": "Herpes Zoster (Shingles), Genital Herpes, Cold Sores.",
    "moaSteps": [
      "Prodrug of Acyclovir.",
      "Rapidly converted to Acyclovir by first-pass intestinal/hepatic metabolism.",
      "Acyclovir is phosphorylated by viral thymidine kinase.",
      "Inhibits viral DNA polymerase and terminates DNA chain."
    ],
    "pharmacokinetics": {
      "absorption": "55% bioavailable (3-5x higher than acyclovir).",
      "distribution": "Similar to acyclovir.",
      "metabolism": "Rapid hydrolysis to Acyclovir.",
      "excretion": "Urine. **Half-life: 2.5 to 3.3 hours.**"
    },
    "dose": {
      "initialDose": "1 g PO TID x 7 days (Shingles)",
      "maxDose": "3 g/day",
      "notes": "Herpes Simplex: 500mg-1g daily/BID."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Nausea",
        "Abdominal pain"
      ],
      "serious": [
        "Acute Renal Failure (Precipitation in tubules)",
        "TTP / HUS (in immunocompromised)",
        "Neurotoxicity (Confusion/Hallucinations in renal failure)"
      ]
    },
    "precautions": [
      "**Renal:** Dose reduction essential in renal impairment to prevent neurotoxicity/nephrotoxicity.",
      "**Hydration:** Maintain adequate hydration.",
      "**TTP:** Thrombotic thrombocytopenic purpura risk in HIV/Transplant patients."
    ],
    "contraindications": [
      "Hypersensitivity to valacyclovir or acyclovir"
    ],
    "interactions": {
      "drug": ["Probenecid/Cimetidine (Reduce clearance)", "Nephrotoxic drugs"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "valganciclovir": {
    "name": "Valganciclovir (Valcyte)",
    "genericName": "Valganciclovir HCl",
    "formula": "C14H22N6O5",
    "molecularWeight": "354.4 g/mol",
    "brandNames": ["Valcyte"],
    "category": "Antiviral",
    "drugClass": "Nucleoside Analogue",
    "pubchemCID": "64147",
    "indications": "CMV Retinitis (AIDS), CMV Prophylaxis (Transplant).",
    "moaSteps": [
      "L-valyl ester prodrug of Ganciclovir.",
      "Rapidly hydrolyzed to Ganciclovir.",
      "Phosphorylated by CMV kinase UL97.",
      "Inhibits viral DNA polymerase.",
      "Oral formulation achieving IV-like levels."
    ],
    "pharmacokinetics": {
      "absorption": "60% bioavailable (with food).",
      "distribution": "Wide.",
      "metabolism": "Hydrolysis to Ganciclovir.",
      "excretion": "Renal. **Half-life: 4 hours.**"
    },
    "dose": {
      "initialDose": "900 mg PO BID x 21 days (Induction)",
      "maxDose": "900 mg daily (Maintenance)",
      "notes": "Handle as carcinogen."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea",
        "Fever",
        "Nausea",
        "Headache"
      ],
      "serious": [
        "Severe Myelosuppression (Neutropenia/Anemia) - BOXED WARNING",
        "Impairment of Fertility - BOXED WARNING",
        "Carcinogenicity / Teratogenicity - BOXED WARNING"
      ]
    },
    "precautions": [
      "**Myelosuppression:** Strict CBC monitoring. Do not start if ANC < 500 or Plt < 25k.",
      "**Renal:** Dose adjustment critical.",
      "**Handling:** Do not break/crush tablets (Toxic)."
    ],
    "contraindications": [
      "Hypersensitivity to ganciclovir/acyclovir"
    ],
    "interactions": {
      "drug": ["Zidovudine (Additive neutropenia - Avoid)", "Imipenem (Seizures)", "Didanosine (Increased levels)"],
      "food": ["Take with food to increase absorption."]
    },
    "pregnancyCategory": "Category C (Teratogenic)"
  },
  "valsartan": {
    "name": "Valsartan (Diovan)",
    "genericName": "Valsartan",
    "formula": "C24H29N5O3",
    "molecularWeight": "435.5 g/mol",
    "brandNames": ["Diovan"],
    "category": "Antihypertensive",
    "drugClass": "Angiotensin II Receptor Blocker (ARB)",
    "pubchemCID": "60846",
    "indications": "Hypertension, Heart Failure (HFrEF), Post-MI.",
    "moaSteps": [
      "Selectively blocks the AT1 receptor.",
      "Blocks vasoconstriction and aldosterone release caused by Angiotensin II.",
      "Lowers BP and reduces cardiac remodeling.",
      "No effect on bradykinin."
    ],
    "pharmacokinetics": {
      "absorption": "25% bioavailable. Food decreases AUC.",
      "distribution": "95% protein bound.",
      "metabolism": "Minimal (Valeryl-4-hydroxy valsartan).",
      "excretion": "Feces (83%) and Urine. **Half-life: 6 hours.**"
    },
    "dose": {
      "initialDose": "40-80 mg PO daily",
      "maxDose": "320 mg/day",
      "notes": "BID dosing for Heart Failure (Target 160mg BID)."
    },
    "adverseEffects": {
      "common": [
        "Dizziness",
        "Hypotension",
        "Hyperkalemia (in HF)",
        "Viral infection"
      ],
      "serious": [
        "Renal Failure (in renal artery stenosis)",
        "Angioedema (Rare)",
        "Fetal Toxicity - BOXED WARNING"
      ]
    },
    "precautions": [
      "**Fetal:** Discontinue in pregnancy.",
      "**Hyperkalemia:** Monitor K+.",
      "**Renal:** Monitor Cr. Caution in renal stenosis."
    ],
    "contraindications": [
      "Pregnancy",
      "Concomitant Aliskiren in diabetics"
    ],
    "interactions": {
      "drug": ["Lithium", "NSAIDs", "Potassium-sparing diuretics"],
      "food": ["Food decreases absorption (Take consistently)."]
    },
    "pregnancyCategory": "Category D"
  },
  "vancomycin": {
    "name": "Vancomycin (Vancocin)",
    "genericName": "Vancomycin HCl",
    "formula": "C66H75Cl2N9O24",
    "molecularWeight": "1449.3 g/mol",
    "brandNames": ["Vancocin", "Firvanq"],
    "category": "Antibiotic",
    "drugClass": "Glycopeptide",
    "pubchemCID": "14969",
    "indications": "MRSA infections (Pneumonia, Sepsis, Skin), C. difficile Colitis (Oral).",
    "moaSteps": [
      "Inhibits cell wall synthesis by binding to D-alanyl-D-alanine terminus of cell wall precursor.",
      "Blocks transglycosylation and cross-linking.",
      "Bactericidal (slow) against Gram-positive bacteria.",
      "Oral form acts locally in the gut."
    ],
    "pharmacokinetics": {
      "absorption": "Poor oral absorption (<5%). IV for systemic use.",
      "distribution": "Widely distributed.",
      "metabolism": "Minimal.",
      "excretion": "Renal. **Half-life: 4 to 6 hours.**"
    },
    "dose": {
      "initialDose": "15-20 mg/kg IV q8-12h",
      "maxDose": "Pharmacy dosed",
      "notes": "Oral: 125 mg QID for C. diff. TDM: Trough 15-20 mcg/mL for severe infections."
    },
    "adverseEffects": {
      "common": [
        "Red Man Syndrome (Flushing/Itching - histamine release)",
        "Phlebitis"
      ],
      "serious": [
        "Nephrotoxicity (Dose/Trough related)",
        "Ototoxicity (High levels)",
        "Neutropenia (Prolonged use)",
        "Anaphylaxis"
      ]
    },
    "precautions": [
      "**Red Man Syndrome:** Infuse slowly (over 60 min) to prevent histamine release. Not a true allergy.",
      "**Nephrotoxicity:** Risk increases with high troughs (>20) or concomitant Piperacillin/Tazobactam.",
      "**Renal:** Dose adjust per nomogram."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Aminoglycosides/Piperacillin-Tazobactam (Additive Nephrotoxicity)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B (Oral); C (IV)"
  },
  "varenicline": {
    "name": "Varenicline (Chantix)",
    "genericName": "Varenicline Tartrate",
    "formula": "C13H13N3",
    "molecularWeight": "211.3 g/mol",
    "brandNames": ["Chantix", "Tyrvaya (Nasal)"],
    "category": "Smoking Cessation Agent",
    "drugClass": "Nicotinic Receptor Partial Agonist",
    "pubchemCID": "5310966",
    "indications": "Smoking Cessation, Dry Eye (Nasal spray).",
    "moaSteps": [
      "Partial agonist at alpha-4-beta-2 nicotinic acetylcholine receptors.",
      "Agonist activity: Stimulates low-level dopamine release to reduce craving/withdrawal.",
      "Antagonist activity: Blocks nicotine from binding, preventing reward if patient smokes."
    ],
    "pharmacokinetics": {
      "absorption": "High bioavailability.",
      "distribution": "Low protein binding.",
      "metabolism": "Minimal.",
      "excretion": "Urine. **Half-life: 24 hours.**"
    },
    "dose": {
      "initialDose": "Titration pack: 0.5 mg daily -> BID -> 1 mg BID",
      "maxDose": "1 mg BID",
      "notes": "Start 1 week before quit date."
    },
    "adverseEffects": {
      "common": [
        "Nausea (Very common)",
        "Abnormal dreams / Insomnia",
        "Headache",
        "Taste change"
      ],
      "serious": [
        "Neuropsychiatric events (Depression, Suicide) - BOXED WARNING REMOVED but risk remains",
        "Cardiovascular events (slight increase)",
        "Seizures",
        "Skin reactions (SJS)"
      ]
    },
    "precautions": [
      "**Neuropsychiatric:** Monitor for changes in mood, psychosis, or suicidal ideation.",
      "**Seizures:** Use caution in history of seizures.",
      "**Alcohol:** Increases intoxication effect; some patients lose tolerance.",
      "**Nausea:** Take with food and full glass of water."
    ],
    "contraindications": [
      "Severe hypersensitivity"
    ],
    "interactions": {
      "drug": ["Alcohol (Increased impairment)", "Nicotine Replacement (Increased nausea)"],
      "food": ["Take with food."]
    },
    "pregnancyCategory": "Category C"
  },
  "venlafaxine": {
    "name": "Venlafaxine (Effexor)",
    "genericName": "Venlafaxine HCl",
    "formula": "C17H27NO2",
    "molecularWeight": "277.4 g/mol",
    "brandNames": ["Effexor XR"],
    "category": "Antidepressant",
    "drugClass": "SNRI",
    "pubchemCID": "5656",
    "indications": "Major Depressive Disorder, GAD, Panic Disorder, Social Anxiety.",
    "moaSteps": [
      "Potent inhibitor of Serotonin reuptake.",
      "Inhibitor of Norepinephrine reuptake (at higher doses).",
      "Weak inhibitor of Dopamine reuptake.",
      "Dose-dependent pharmacology: SSRI at low dose, SNRI at high dose."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "27% protein bound.",
      "metabolism": "Hepatic (CYP2D6) to active metabolite Desvenlafaxine.",
      "excretion": "Urine. **Half-life: 5 hours (Parent); 11 hours (Metabolite).**"
    },
    "dose": {
      "initialDose": "37.5-75 mg PO daily (XR)",
      "maxDose": "225 mg/day",
      "notes": "Swallow XR whole."
    },
    "adverseEffects": {
      "common": [
        "Nausea",
        "Sweating",
        "Insomnia",
        "Sexual dysfunction",
        "Hypertension (Dose-related)"
      ],
      "serious": [
        "Suicidality - BOXED WARNING",
        "Serotonin Syndrome",
        "Severe Withdrawal Syndrome ('Brain zaps')",
        "Bleeding risk"
      ]
    },
    "precautions": [
      "**Withdrawal:** Very short half-life. Missing a single dose can cause withdrawal symptoms. Taper very slowly.",
      "**Hypertension:** Monitor BP regularly, especially at doses > 150 mg.",
      "**Suicide:** Monitor for worsening."
    ],
    "contraindications": [
      "MAOI use within 14 days",
      "Uncontrolled narrow-angle glaucoma"
    ],
    "interactions": {
      "drug": ["MAOIs (Fatal)", "CYP2D6 Inhibitors (Increase parent/decrease metabolite)", "Antiplatelets"],
      "food": ["Take with food."]
    },
    "pregnancyCategory": "Category C"
  },
  "verapamil": {
    "name": "Verapamil (Calan, Verelan)",
    "genericName": "Verapamil HCl",
    "formula": "C27H38N2O4",
    "molecularWeight": "454.6 g/mol",
    "brandNames": ["Calan", "Verelan"],
    "category": "Antihypertensive / Antiarrhythmic",
    "drugClass": "Calcium Channel Blocker (Non-Dihydropyridine)",
    "pubchemCID": "2520",
    "indications": "Hypertension, Angina, Atrial Fibrillation (Rate control), Cluster Headache prophylaxis.",
    "moaSteps": [
      "Blocks L-type calcium channels in the heart and vascular smooth muscle.",
      "Potent negative inotrope (contractility) and negative chronotrope (heart rate/conduction).",
      "Vasodilator.",
      "Most cardiac-selective CCB."
    ],
    "pharmacokinetics": {
      "absorption": "90% absorbed (20% bioavailable due to first pass).",
      "distribution": "90% protein bound.",
      "metabolism": "Extensive Hepatic (CYP3A4).",
      "excretion": "Urine. **Half-life: 3 to 7 hours.**"
    },
    "dose": {
      "initialDose": "180 mg ER PO daily",
      "maxDose": "480 mg/day",
      "notes": "Constipation limiting factor."
    },
    "adverseEffects": {
      "common": [
        "Constipation (Severe)",
        "Dizziness",
        "Edema",
        "Gingival hyperplasia"
      ],
      "serious": [
        "Heart Block / Bradycardia",
        "Worsening Heart Failure",
        "Hepatotoxicity"
      ]
    },
    "precautions": [
      "**Heart Failure:** Contraindicated in HFrEF due to negative inotropy.",
      "**Constipation:** Aggressive bowel regimen needed, especially in elderly.",
      "**Interactions:** Potent CYP3A4 inhibitor."
    ],
    "contraindications": [
      "Severe Left Ventricular Dysfunction",
      "Hypotension (SBP < 90)",
      "2nd/3rd degree AV block (without pacemaker)",
      "Sick Sinus Syndrome"
    ],
    "interactions": {
      "drug": ["Beta-blockers (Heart block/arrest)", "Digoxin (Increases levels)", "Simvastatin/Lovastatin (Limit statin dose)", "Grapefruit"],
      "food": ["Alcohol (Increases alcohol levels)"]
    },
    "pregnancyCategory": "Category C"
  },
  "voriconazole": {
    "name": "Voriconazole (Vfend)",
    "genericName": "Voriconazole",
    "formula": "C16H14F3N5O",
    "molecularWeight": "349.3 g/mol",
    "brandNames": ["Vfend"],
    "category": "Antifungal",
    "drugClass": "Triazole",
    "pubchemCID": "71616",
    "indications": "Invasive Aspergillosis (Drug of Choice), Candidemia, Scedosporium.",
    "moaSteps": [
      "Inhibits fungal cytochrome P450-mediated 14-alpha-lanosterol demethylation.",
      "Accumulation of methylsterols disrupts fungal cell membrane.",
      "Broad spectrum activity."
    ],
    "pharmacokinetics": {
      "absorption": "96% bioavailable. Non-linear kinetics.",
      "distribution": "Good tissue/CSF penetration.",
      "metabolism": "Hepatic (CYP2C19/2C9/3A4).",
      "excretion": "Urine. **Half-life: Dose dependent (approx 6 hours).**"
    },
    "dose": {
      "initialDose": "6 mg/kg IV q12h x 2 doses (Load)",
      "maxDose": "4 mg/kg IV q12h (Maint) or 200 mg PO q12h",
      "notes": "IV vehicle (SBECD) accumulates in renal failure."
    },
    "adverseEffects": {
      "common": [
        "Visual Disturbances (Photopsia, Color change - 30% of patients)",
        "Rash",
        "Nausea"
      ],
      "serious": [
        "Hepatotoxicity",
        "QT Prolongation",
        "Phototoxicity / Skin Cancer (SCC) with long-term use",
        "Fluorosis / Periostitis (Bone pain)"
      ]
    },
    "precautions": [
      "**Vision:** Reversible visual changes occur; caution driving.",
      "**Sun:** Severe photosensitivity. Sun avoidance mandatory. Skin cancer risk.",
      "**Renal:** IV formulation contraindicated if CrCl < 50 (cyclodextrin accumulation). Switch to oral.",
      "**Interactions:** CYP2C19 polymorphisms affect levels."
    ],
    "contraindications": [
      "Co-administration with Rifampin, Carbamazepine, Long-acting Barbiturates, Ritonavir (High dose), St. John's Wort"
    ],
    "interactions": {
      "drug": ["Warfarin (Increase INR)", "Cyclosporine/Tacrolimus (Increase levels - reduce dose)", "Phenytoin"],
      "food": ["Take 1 hour before or 1 hour after meal."]
    },
    "pregnancyCategory": "Category D"
  },
  "vortioxetine": {
    "name": "Vortioxetine (Trintellix)",
    "genericName": "Vortioxetine Hydrobromide",
    "formula": "C18H22N2S",
    "molecularWeight": "298.4 g/mol",
    "brandNames": ["Trintellix"],
    "category": "Antidepressant",
    "drugClass": "Serotonin Modulator and Stimulator (SMS)",
    "pubchemCID": "9966051",
    "indications": "Major Depressive Disorder (MDD).",
    "moaSteps": [
      "Inhibits Serotonin Reuptake (SERT).",
      "Agonist at 5-HT1A.",
      "Partial agonist at 5-HT1B.",
      "Antagonist at 5-HT3, 5-HT1D, and 5-HT7 receptors.",
      "Multimodal activity targets cognitive dysfunction in depression."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "98% protein bound.",
      "metabolism": "Hepatic (CYP2D6).",
      "excretion": "Urine/Feces. **Half-life: 66 hours.**"
    },
    "dose": {
      "initialDose": "10 mg PO once daily",
      "maxDose": "20 mg/day",
      "notes": "Can stop abruptly if dose <= 10mg."
    },
    "adverseEffects": {
      "common": [
        "Nausea (Very common)",
        "Constipation",
        "Vomiting"
      ],
      "serious": [
        "Suicidality - BOXED WARNING",
        "Serotonin Syndrome",
        "Hyponatremia",
        "Bleeding"
      ]
    },
    "precautions": [
      "**Nausea:** Occurs in ~30%. Dose-dependent. Transient.",
      "**Sexual Function:** Less sexual dysfunction than SSRIs.",
      "**CYP2D6:** Poor metabolizers need dose reduction."
    ],
    "contraindications": [
      "MAOI use within 14 days",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["MAOIs", "Strong CYP2D6 Inhibitors (Bupropion/Fluoxetine - Halve dose)", "Strong CYP Inducers (Increase dose)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "warfarin": {
    "name": "Warfarin (Coumadin)",
    "genericName": "Warfarin Sodium",
    "formula": "C19H15NaO4",
    "molecularWeight": "330.3 g/mol",
    "brandNames": ["Coumadin", "Jantoven"],
    "category": "Anticoagulant",
    "drugClass": "Vitamin K Antagonist",
    "pubchemCID": "54678486",
    "indications": "Prophylaxis/Treatment of Venous Thrombosis, PE, AFib embolization, Heart Valve replacement.",
    "moaSteps": [
      "Inhibits Vitamin K Epoxide Reductase (VKORC1).",
      "Interferes with hepatic synthesis of Vitamin K-dependent clotting factors (II, VII, IX, X) and proteins C and S.",
      "Depletion of factors takes days.",
      "Initial prothrombotic state (Protein C depletion) requires bridging with heparin."
    ],
    "pharmacokinetics": {
      "absorption": "Complete.",
      "distribution": "99% albumin bound.",
      "metabolism": "Hepatic (CYP2C9 - S-isomer; CYP1A2/3A4 - R-isomer).",
      "excretion": "Urine. **Half-life: 20 to 60 hours (Mean 40h).**"
    },
    "dose": {
      "initialDose": "2-5 mg PO daily",
      "maxDose": "Titrate to INR",
      "notes": "Target INR usually 2.0-3.0."
    },
    "adverseEffects": {
      "common": [
        "Bleeding (Minor)",
        "Bruising"
      ],
      "serious": [
        "Fatal Bleeding (Intracranial/GI) - BOXED WARNING",
        "Skin Necrosis / Gangrene (Protein C deficiency)",
        "Purple Toe Syndrome",
        "Teratogenicity"
      ]
    },
    "precautions": [
      "**Monitoring:** Narrow therapeutic index. Frequent INR checks required. Affected by diet (Vitamin K) and many drugs.",
      "**Skin Necrosis:** Rare but fatal. Stop if painful rash appears.",
      "**Bridging:** Must bridge with parenteral anticoagulant for 5 days AND until INR therapeutic."
    ],
    "contraindications": [
      "Pregnancy (Fetal Warfarin Syndrome) - except mechanical valves in certain cases",
      "Hemorrhagic tendencies",
      "Uncontrolled hypertension",
      "Recent CNS surgery"
    ],
    "interactions": {
      "drug": ["Antibiotics (Increase INR)", "Amiodarone (Increases INR - Reduce warfarin 50%)", "Inducers (Rifampin - Clotting)", "NSAIDs (Bleeding)"],
      "food": ["Vitamin K rich foods (Leafy greens) decrease effect. Consistency is key."]
    },
    "pregnancyCategory": "Category X (D for mechanical valves)"
  },
  "zidovudine": {
    "name": "Zidovudine (Retrovir)",
    "genericName": "Zidovudine (AZT)",
    "formula": "C10H13N5O4",
    "molecularWeight": "267.2 g/mol",
    "brandNames": ["Retrovir"],
    "category": "Antiretroviral",
    "drugClass": "Nucleoside Reverse Transcriptase Inhibitor (NRTI)",
    "pubchemCID": "35370",
    "indications": "HIV-1 Infection, Prevention of Maternal-Fetal HIV Transmission.",
    "moaSteps": [
      "Thymidine analogue.",
      "Phosphorylated by cellular kinases to triphosphate.",
      "Competes with thymidine triphosphate for HIV reverse transcriptase.",
      "Causes DNA chain termination.",
      "First approved HIV drug."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "Good CNS penetration (crosses placenta).",
      "metabolism": "Hepatic Glucuronidation.",
      "excretion": "Urine. **Half-life: 1 hour (Plasma); 3 hours (Intracellular).**"
    },
    "dose": {
      "initialDose": "300 mg PO BID",
      "maxDose": "600 mg/day",
      "notes": "IV used during labor."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting",
        "Headache",
        "Fatigue / Malaise"
      ],
      "serious": [
        "Bone Marrow Suppression (Severe Anemia/Neutropenia) - BOXED WARNING",
        "Myopathy (Mitochondrial toxicity) - BOXED WARNING",
        "Lactic Acidosis / Hepatomegaly - BOXED WARNING",
        "Lipoatrophy"
      ]
    },
    "precautions": [
      "**Hematologic:** Monitor CBC. Transfusions/EPO may be needed. Avoid in baseline anemia.",
      "**Muscle:** Long-term use causes myopathy (CK elevation).",
      "**Liver:** Lactic acidosis risk."
    ],
    "contraindications": [
      "Life-threatening allergic reactions"
    ],
    "interactions": {
      "drug": ["Ganciclovir (Additive myelosuppression - Avoid)", "Probenecid (Increases levels)", "Stavudine (Antagonistic)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C (Standard of care for labor)"
  },
  "ziprasidone": {
    "name": "Ziprasidone (Geodon)",
    "genericName": "Ziprasidone",
    "formula": "C21H21ClN4OS",
    "molecularWeight": "412.9 g/mol",
    "brandNames": ["Geodon"],
    "category": "Antipsychotic",
    "drugClass": "Atypical Antipsychotic (Second Generation)",
    "pubchemCID": "60854",
    "indications": "Schizophrenia, Bipolar I Disorder (Manic/Mixed).",
    "moaSteps": [
      "Antagonist at Dopamine D2 and Serotonin 5-HT2A receptors.",
      "Agonist at 5-HT1A receptors.",
      "Inhibits reuptake of serotonin and norepinephrine.",
      "Low affinity for muscarinic/histaminic receptors (Low weight gain/sedation)."
    ],
    "pharmacokinetics": {
      "absorption": "Food increases absorption by 100%.",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic (Aldehyde oxidase, CYP3A4).",
      "excretion": "Feces/Urine. **Half-life: 7 hours.**"
    },
    "dose": {
      "initialDose": "20 mg PO BID",
      "maxDose": "80 mg BID",
      "notes": "MUST BE TAKEN WITH FOOD (500 calories) for absorption."
    },
    "adverseEffects": {
      "common": [
        "Somnolence",
        "Respiratory Tract Infection",
        "EPS (Akathisia)",
        "Dizziness"
      ],
      "serious": [
        "QT Prolongation (Highest among atypicals)",
        "Tardive Dyskinesia",
        "Neuroleptic Malignant Syndrome",
        "DRESS"
      ]
    },
    "precautions": [
      "**QT Interval:** Contraindicated in QT history. Monitor ECG.",
      "**Food:** Failure to take with food results in subtherapeutic levels.",
      "**Metabolic:** Weight neutral (advantage)."
    ],
    "contraindications": [
      "QT prolongation",
      "Recent MI",
      "Uncompensated Heart Failure",
      "Arrhythmias"
    ],
    "interactions": {
      "drug": ["QT Prolonging drugs (Contraindicated)", "CNS Depressants"],
      "food": ["Take with meals."]
    },
    "pregnancyCategory": "Category C"
  },
  "zolpidem": {
    "name": "Zolpidem (Ambien)",
    "genericName": "Zolpidem Tartrate",
    "formula": "C19H21N3O",
    "molecularWeight": "307.4 g/mol",
    "brandNames": ["Ambien", "Ambien CR", "Edluar", "Intermezzo"],
    "category": "Sedative/Hypnotic",
    "drugClass": "Non-benzodiazepine (Z-drug)",
    "pubchemCID": "5732",
    "indications": "Insomnia (Short-term treatment).",
    "moaSteps": [
      "Selectively binds to the omega-1 subtype of the GABA-A receptor.",
      "Modulates chloride channel complex.",
      "Sedative effects with minimal muscle relaxant/anticonvulsant properties.",
      "Preserves deep sleep stages better than benzos."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "92% protein bound.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Urine. **Half-life: 2.5 hours (Prolonged in women/elderly).**"
    },
    "dose": {
      "initialDose": "5 mg PO (Women/Elderly); 10 mg (Men) at bedtime",
      "maxDose": "10 mg/day (IR); 12.5 mg (CR)",
      "notes": "FDA lowered women's dose due to AM impairment."
    },
    "adverseEffects": {
      "common": [
        "Drowsiness / Dizziness",
        "Headache",
        "Nausea",
        "Amnesia"
      ],
      "serious": [
        "Complex Sleep Behaviors (Sleep-driving/eating) - BOXED WARNING",
        "Next-day impairment",
        "Hallucinations",
        "Falls / Confusion (Elderly)"
      ]
    },
    "precautions": [
      "**Sleep Behaviors:** Stop immediately if sleep-driving/eating occurs.",
      "**Gender:** Women clear drug slower; lower dose mandatory.",
      "**Elderly:** Beers Criteria - avoid due to falls/delirium."
    ],
    "contraindications": [
      "History of complex sleep behaviors after zolpidem"
    ],
    "interactions": {
      "drug": ["CNS Depressants (Additive - avoid)", "CYP3A4 Inhibitors"],
      "food": ["Take on empty stomach (Food delays sleep onset)."]
    },
    "pregnancyCategory": "Category C"
  },"cefotaxime": {
    "name": "Cefotaxime (Claforan)",
    "genericName": "Cefotaxime",
    "formula": "C16H17N5O7S2",
    "molecularWeight": "455.5 g/mol",
    "brandNames": ["Claforan"],
    "category": "Antibiotic",
    "drugClass": "Cephalosporin (3rd Generation)",
    "pubchemCID": "5742673",
    "indications": "Meningitis, Sepsis, Gonorrhea, Lower Respiratory Tract Infections.",
    "moaSteps": [
      "Binds to penicillin-binding proteins (PBPs).",
      "Inhibits bacterial cell wall synthesis.",
      "Bactericidal.",
      "Excellent BBB penetration (Drug of choice for spontaneous bacterial peritonitis)."
    ],
    "pharmacokinetics": {
      "absorption": "IV/IM only.",
      "distribution": "Widely distributed (CSF).",
      "metabolism": "Hepatic (to active metabolite desacetylcefotaxime).",
      "excretion": "Urine. **Half-life: 1 hour (Parent); 1.5 hours (Metabolite).**"
    },
    "dose": {
      "initialDose": "1-2 g IV every 4-12 hours",
      "maxDose": "12 g/day (Meningitis)",
      "notes": "Preferred over Ceftriaxone in neonates (no biliary sludging)."
    },
    "adverseEffects": {
      "common": [
        "Injection site pain",
        "Diarrhea",
        "Rash"
      ],
      "serious": [
        "Anaphylaxis",
        "Arrhythmias (Rapid bolus)",
        "C. diff colitis",
        "Seizures (in renal failure)"
      ]
    },
    "precautions": [
      "**Neonates:** Safe for use (unlike Ceftriaxone).",
      "**Arrhythmia:** Rapid IV injection can cause arrhythmia; infuse over 3-5 min.",
      "**Renal:** Dose adjustment required."
    ],
    "contraindications": [
      "Hypersensitivity to cephalosporins"
    ],
    "interactions": {
      "drug": ["Probenecid (Increases levels)", "Aminoglycosides (Nephrotoxicity)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "ceftaroline": {
    "name": "Ceftaroline (Teflaro)",
    "genericName": "Ceftaroline Fosamil",
    "formula": "C22H21N8O8PS4",
    "molecularWeight": "684.7 g/mol",
    "brandNames": ["Teflaro"],
    "category": "Antibiotic",
    "drugClass": "Cephalosporin (5th Generation / Anti-MRSA)",
    "pubchemCID": "9852981",
    "indications": "Acute Bacterial Skin and Skin Structure Infections (ABSSSI), Community-Acquired Pneumonia (CAP).",
    "moaSteps": [
      "Binds to PBPs, including PBP2a (MRSA) and PBP2x (Strep pneumo).",
      "Inhibits cell wall synthesis.",
      "Only beta-lactam with activity against MRSA.",
      "Does NOT cover Pseudomonas."
    ],
    "pharmacokinetics": {
      "absorption": "IV only (Prodrug).",
      "distribution": "Rapid conversion to active ceftaroline.",
      "metabolism": "Phosphatases.",
      "excretion": "Urine. **Half-life: 2.6 hours.**"
    },
    "dose": {
      "initialDose": "600 mg IV every 12 hours",
      "maxDose": "600 mg q8h (Off-label for severe infection)",
      "notes": "Infuse over 1 hour."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea",
        "Nausea",
        "Rash"
      ],
      "serious": [
        "Anaphylaxis",
        "C. diff colitis",
        "Neutropenia (Prolonged use)",
        "Direct Coombs test positivity"
      ]
    },
    "precautions": [
      "**Spectrum:** Excellent Gram-positive (MRSA/VRSA) but lacks Pseudomonas coverage.",
      "**Renal:** Adjust if CrCl < 50 mL/min.",
      "**Seroconversion:** Can cause positive Coombs test (hemolytic anemia risk)."
    ],
    "contraindications": [
      "Hypersensitivity to cephalosporins"
    ],
    "interactions": {
      "drug": ["Probenecid"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "chloramphenicol": {
    "name": "Chloramphenicol",
    "genericName": "Chloramphenicol",
    "formula": "C11H12Cl2N2O5",
    "molecularWeight": "323.1 g/mol",
    "brandNames": ["Chloromycetin"],
    "category": "Antibiotic",
    "drugClass": "Amphenicol",
    "pubchemCID": "5959",
    "indications": "Serious infections where other drugs fail (Typhoid, Meningitis, Rickettsia).",
    "moaSteps": [
      "Binds reversibly to the 50S ribosomal subunit.",
      "Inhibits peptidyl transferase.",
      "Prevents amino acid transfer to growing peptide chains.",
      "Bacteriostatic."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (Oral/IV).",
      "distribution": "Excellent (CSF, Eye).",
      "metabolism": "Hepatic glucuronidation.",
      "excretion": "Urine. **Half-life: 1.5 to 4 hours.**"
    },
    "dose": {
      "initialDose": "12.5 mg/kg PO/IV every 6 hours",
      "maxDose": "4 g/day",
      "notes": "Monitor serum levels."
    },
    "adverseEffects": {
      "common": [
        "Nausea",
        "Diarrhea"
      ],
      "serious": [
        "Aplastic Anemia (Idiosyncratic/Fatal) - BOXED WARNING",
        "Gray Baby Syndrome (Fatal in neonates)",
        "Bone Marrow Suppression (Dose-related)",
        "Optic Neuritis"
      ]
    },
    "precautions": [
      "**Gray Baby Syndrome:** Neonates lack glucuronyl transferase. Drug accumulates causing hypotension, cyanosis (gray color), and death. Contraindicated in neonates.",
      "**Bone Marrow:** Reversible suppression (dose-related) vs Irreversible Aplastic Anemia (Idiosyncratic, rare). Monitor CBC."
    ],
    "contraindications": [
      "Minor infections",
      "Neonates",
      "Pre-existing bone marrow depression"
    ],
    "interactions": {
      "drug": ["Warfarin (Increases INR)", "Phenytoin (Toxicity)", "Phenobarbital (Reduces chloramphenicol levels)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "chlordiazepoxide": {
    "name": "Chlordiazepoxide (Librium)",
    "genericName": "Chlordiazepoxide",
    "formula": "C16H14ClN3O",
    "molecularWeight": "299.8 g/mol",
    "brandNames": ["Librium"],
    "category": "Anxiolytic",
    "drugClass": "Benzodiazepine (Long-acting)",
    "pubchemCID": "2712",
    "indications": "Alcohol Withdrawal Syndrome, Anxiety.",
    "moaSteps": [
      "Binds to benzodiazepine receptors on GABA-A complex.",
      "Potentiates GABA inhibitory effects.",
      "Sedative, anxiolytic, anticonvulsant.",
      "Long half-life provides 'self-tapering' effect in alcohol withdrawal."
    ],
    "pharmacokinetics": {
      "absorption": "Good oral absorption. IM is erratic (avoid).",
      "distribution": "Lipophilic.",
      "metabolism": "Extensive Hepatic to active metabolites.",
      "excretion": "Urine. **Half-life: 24 to 48 hours (Parent); up to 100h (Metabolites).**"
    },
    "dose": {
      "initialDose": "25-100 mg PO q6-8h (Alcohol withdrawal)",
      "maxDose": "300 mg/day",
      "notes": "Taper over days."
    },
    "adverseEffects": {
      "common": [
        "Drowsiness",
        "Ataxia",
        "Confusion"
      ],
      "serious": [
        "Respiratory Depression (with opioids) - BOXED WARNING",
        "Dependence / Abuse",
        "Paradoxical Excitation",
        "Jaundice (rare)"
      ]
    },
    "precautions": [
      "**Accumulation:** Active metabolites accumulate. Caution in elderly or liver failure (use Lorazepam instead).",
      "**IM Use:** Erratic absorption; use oral or IV.",
      "**Fall Risk:** High risk in elderly."
    ],
    "contraindications": [
      "Hypersensitivity",
      "Severe respiratory insufficiency"
    ],
    "interactions": {
      "drug": ["Opioids (Fatal)", "Alcohol (Additive)", "Cimetidine (Increases levels)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "clobetasol": {
    "name": "Clobetasol (Temovate)",
    "genericName": "Clobetasol Propionate",
    "formula": "C25H32ClFO5",
    "molecularWeight": "466.9 g/mol",
    "brandNames": ["Temovate", "Clobex"],
    "category": "Corticosteroid (Topical)",
    "drugClass": "Super-High Potency (Class 1) Steroid",
    "pubchemCID": "5311051",
    "indications": "Severe inflammatory dermatoses (Psoriasis, Eczema).",
    "moaSteps": [
      "Binds to glucocorticoid receptors in skin cells.",
      "Suppresses inflammation, vasoconstriction, and cell proliferation.",
      "Most potent topical steroid class."
    ],
    "pharmacokinetics": {
      "absorption": "Systemic absorption occurs (increased by occlusion).",
      "distribution": "Skin layers.",
      "metabolism": "Hepatic (if absorbed).",
      "excretion": "Urine. **Half-life: N/A (Systemic absorption limited).**"
    },
    "dose": {
      "initialDose": "Apply thin layer BID",
      "maxDose": "50 g/week",
      "notes": "Limit use to 2 consecutive weeks."
    },
    "adverseEffects": {
      "common": [
        "Skin atrophy (Thinning)",
        "Striae (Stretch marks)",
        "Telangiectasia",
        "Acne"
      ],
      "serious": [
        "HPA Axis Suppression (Cushing's Syndrome - Systemic effect)",
        "Glaucoma (if used near eyes)",
        "Superinfection"
      ]
    },
    "precautions": [
      "**Duration:** Do not use > 2 weeks. Do not use on face, groin, or axilla (thin skin absorbs too much).",
      "**Occlusion:** Do not bandage (increases absorption 10x).",
      "**Systemic:** Can cause adrenal suppression even topically."
    ],
    "contraindications": [
      "Viral/Fungal skin infections",
      "Rosacea / Perioral dermatitis"
    ],
    "interactions": {
      "drug": ["None (Topical)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "codeine": {
    "name": "Codeine",
    "genericName": "Codeine Sulfate",
    "formula": "C18H21NO3",
    "molecularWeight": "299.4 g/mol",
    "brandNames": ["Tylenol #3 (combo)"],
    "category": "Opioid Analgesic / Antitussive",
    "drugClass": "Opiate Agonist (Prodrug)",
    "pubchemCID": "5284371",
    "indications": "Mild-Moderate Pain, Cough suppression.",
    "moaSteps": [
      "Prodrug with low affinity for opioid receptors.",
      "Metabolized by CYP2D6 to Morphine (active).",
      "Morphine binds mu-receptors providing analgesia/sedation.",
      "Directly suppresses cough center."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "Crosses BBB.",
      "metabolism": "Hepatic (CYP2D6 to Morphine; CYP3A4 to Norcodeine).",
      "excretion": "Urine. **Half-life: 3 hours.**"
    },
    "dose": {
      "initialDose": "15-60 mg PO q4h",
      "maxDose": "360 mg/day",
      "notes": "Ceiling effect for analgesia."
    },
    "adverseEffects": {
      "common": [
        "Constipation (High incidence)",
        "Nausea",
        "Drowsiness"
      ],
      "serious": [
        "Respiratory Depression (Fatal in Ultra-Rapid Metabolizers) - BOXED WARNING",
        "Addiction",
        "Severe Hypotension"
      ]
    },
    "precautions": [
      "**CYP2D6:** Ultra-rapid metabolizers convert codeine to morphine rapidly, leading to fatal overdose (Children post-tonsillectomy). CONTRAINDICATED in children < 12.",
      "**Nursing:** Contraindicated; morphine passes to infant.",
      "**Efficacy:** Poor metabolizers get no pain relief."
    ],
    "contraindications": [
      "Children < 12 years",
      "Post-op tonsillectomy/adenoidectomy in peds",
      "Breastfeeding"
    ],
    "interactions": {
      "drug": ["CYP2D6 Inhibitors (Blocks effect)", "Alcohol/Benzos (Fatal)", "MAOIs"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "darbepoetin": {
    "name": "Darbepoetin Alfa (Aranesp)",
    "genericName": "Darbepoetin Alfa",
    "formula": "Glycoprotein",
    "molecularWeight": "37 kDa",
    "brandNames": ["Aranesp"],
    "category": "Hematopoietic Agent",
    "drugClass": "ESA (Long-acting)",
    "pubchemCID": "None (Protein)",
    "indications": "Anemia of CKD, Chemotherapy-induced Anemia.",
    "moaSteps": [
      "Recombinant erythropoietin with 5 N-linked oligosaccharide chains (Epoetin has 3).",
      "Additional carbohydrates increase metabolic stability.",
      "Stimulates erythroid progenitor division and differentiation.",
      "Has 3x longer half-life than Epoetin alfa."
    ],
    "pharmacokinetics": {
      "absorption": "SC (Slow) or IV.",
      "distribution": "Vascular/Marrow.",
      "metabolism": "Degradation.",
      "excretion": "Urine. **Half-life: 48 hours (IV); 70-140 hours (SC).**"
    },
    "dose": {
      "initialDose": "0.45 mcg/kg SC weekly or 0.75 mcg/kg every 2 weeks",
      "maxDose": "Titrate to Hgb",
      "notes": "Target Hgb < 11 g/dL."
    },
    "adverseEffects": {
      "common": [
        "Hypertension",
        "Edema",
        "Injection site pain"
      ],
      "serious": [
        "Cardiovascular Events (MI/Stroke) - BOXED WARNING",
        "Thromboembolism - BOXED WARNING",
        "Pure Red Cell Aplasia (PRCA)",
        "Tumor Progression"
      ]
    },
    "precautions": [
      "**Hgb Target:** Do not exceed 11 g/dL (CV death risk).",
      "**Hypertension:** Control BP before use.",
      "**Seizures:** Monitoring required."
    ],
    "contraindications": [
      "Uncontrolled hypertension",
      "Pure Red Cell Aplasia"
    ],
    "interactions": {
      "drug": ["None specific"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "digoxin_immune_fab": {
    "name": "Digoxin Immune Fab (Digibind)",
    "genericName": "Digoxin Immune Fab",
    "formula": "Ovine Antibody Fragments",
    "molecularWeight": "46 kDa",
    "brandNames": ["Digibind", "DigiFab"],
    "category": "Antidote",
    "drugClass": "Antibody Fragment",
    "pubchemCID": "None (Protein)",
    "indications": "Life-threatening Digoxin Toxicity (Arrhythmias, Hyperkalemia).",
    "moaSteps": [
      "Antigen-binding fragments (Fab) derived from sheep antibodies.",
      "Binds free digoxin with higher affinity than Na+/K+ ATPase.",
      "Pulls digoxin from tissues into blood (redistribution).",
      "Complex is renally excreted."
    ],
    "pharmacokinetics": {
      "absorption": "IV.",
      "distribution": "Vascular/Extracellular.",
      "metabolism": "None.",
      "excretion": "Urine (Complex). **Half-life: 15 to 20 hours.**"
    },
    "dose": {
      "initialDose": "# Vials = (Serum Dig x Weight kg) / 100",
      "maxDose": "20 vials (Empiric for acute)",
      "notes": "1 vial binds 0.5 mg digoxin."
    },
    "adverseEffects": {
      "common": [
        "Hypokalemia (Rapid)",
        "Worsening Heart Failure (Loss of inotropy)"
      ],
      "serious": [
        "Anaphylaxis (Ovine protein)",
        "Rapid Ventricular Response (in AFib)"
      ]
    },
    "precautions": [
      "**Potassium:** Serum K+ drops rapidly as digoxin inhibition is removed. Monitor closely.",
      "**Digoxin Levels:** Total levels rise massively after Fab (bound drug). Levels are meaningless for weeks.",
      "**Renal:** Complex can dissociate if not cleared (re-toxicity)."
    ],
    "contraindications": [
      "None in life-threatening situation"
    ],
    "interactions": {
      "drug": ["Digoxin (Neutralized)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "dihydroergotamine": {
    "name": "Dihydroergotamine (DHE 45)",
    "genericName": "Dihydroergotamine Mesylate",
    "formula": "C33H37N5O5",
    "molecularWeight": "583.7 g/mol",
    "brandNames": ["D.H.E. 45", "Migranal"],
    "category": "Antimigraine",
    "drugClass": "Ergot Alkaloid",
    "pubchemCID": "10531",
    "indications": "Acute Migraine, Cluster Headache.",
    "moaSteps": [
      "Agonist at serotonin 5-HT1D receptors on intracranial blood vessels.",
      "Causes vasoconstriction.",
      "Inhibits pro-inflammatory neuropeptide release.",
      "Also binds alpha-adrenergic and dopamine receptors."
    ],
    "pharmacokinetics": {
      "absorption": "Poor oral. Given IV/IM/SC/Nasal.",
      "distribution": "93% protein bound.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Bile/Feces. **Half-life: 9 hours.**"
    },
    "dose": {
      "initialDose": "1 mg IV/IM (repeat in 1h)",
      "maxDose": "3 mg/day (IV/IM); 4 mg/week",
      "notes": "Nasal spray available."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting (Pre-treat with antiemetic)",
        "Rhinitis (Nasal)",
        "Dizziness"
      ],
      "serious": [
        "Ergotism (Intense vasoconstriction - Gangrene) - BOXED WARNING",
        "Fibrosis (Retroperitoneal/Pleural - Chronic use)",
        "Coronary Vasospasm"
      ]
    },
    "precautions": [
      "**Vasoconstriction:** Contraindicated in PAD, CAD, and uncontrolled HTN.",
      "**Interactions:** Life-threatening ischemia with CYP3A4 inhibitors (Boxed Warning).",
      "**Triptans:** Do not use within 24 hours of a triptan."
    ],
    "contraindications": [
      "Strong CYP3A4 Inhibitors",
      "Ischemic Heart Disease / PAD / HTN",
      "Pregnancy",
      "Use within 24h of Triptans"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inhibitors (Macrolides/Azoles/PIs - Fatal Ischemia)", "Triptans (Vasospasm)", "Beta-blockers (Potentiate vasoconstriction)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category X"
  },
  "diphenoxylate_atropine": {
    "name": "Diphenoxylate/Atropine (Lomotil)",
    "genericName": "Diphenoxylate and Atropine",
    "formula": "C30H32N2O2 (Diphenoxylate)",
    "molecularWeight": "452.6 g/mol",
    "brandNames": ["Lomotil"],
    "category": "Antidiarrheal",
    "drugClass": "Opioid Agonist / Anticholinergic",
    "pubchemCID": "13505",
    "indications": "Diarrhea (adjunct).",
    "moaSteps": [
      "Diphenoxylate: Meperidine congener. Stimulates mu-opioid receptors in gut to slow motility.",
      "Atropine: Added in sub-therapeutic dose to discourage abuse (causes tachycardia/dry mouth if overdosed).",
      "Slows peristalsis."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "Diphenoxylate enters CNS (high dose).",
      "metabolism": "Hepatic to Difenoxin (Active).",
      "excretion": "Feces. **Half-life: 2.5 hours (Parent); 12 hours (Difenoxin).**"
    },
    "dose": {
      "initialDose": "5 mg PO QID",
      "maxDose": "20 mg/day",
      "notes": "Schedule V controlled substance."
    },
    "adverseEffects": {
      "common": [
        "Dry mouth",
        "Drowsiness",
        "Urinary retention"
      ],
      "serious": [
        "Toxic Megacolon (in active colitis)",
        "Respiratory Depression (Overdose - especially children)",
        "Atropinism"
      ]
    },
    "precautions": [
      "**Infection:** Do not use in infectious diarrhea (C. diff/E. coli).",
      "**Children:** Contraindicated < 6 years (Respiratory depression).",
      "**Dehydration:** Correct fluids/electrolytes first."
    ],
    "contraindications": [
      "Diarrhea due to C. diff or enterotoxin bacteria",
      "Children < 6 years",
      "Obstructive Jaundice"
    ],
    "interactions": {
      "drug": ["MAOIs (Hypertensive crisis)", "CNS Depressants", "Anticholinergics"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "dopamine": {
    "name": "Dopamine",
    "genericName": "Dopamine HCl",
    "formula": "C8H11NO2",
    "molecularWeight": "153.18 g/mol",
    "brandNames": ["Intropin"],
    "category": "Vasopressor / Inotrope",
    "drugClass": "Catecholamine",
    "pubchemCID": "681",
    "indications": "Shock (Cardiogenic, Septic), Heart Failure, Renal Failure (Historical).",
    "moaSteps": [
      "Low Dose (1-3 mcg/kg/min): Dopamine-1 agonist (Renal vasodilation - 'Renal Dose' proven ineffective for outcome).",
      "Medium Dose (3-10 mcg/kg/min): Beta-1 agonist (Inotropic/Chronotropic).",
      "High Dose (>10 mcg/kg/min): Alpha-1 agonist (Vasoconstriction)."
    ],
    "pharmacokinetics": {
      "absorption": "IV only.",
      "distribution": "Does not cross BBB.",
      "metabolism": "MAO and COMT (Rapid).",
      "excretion": "Urine. **Half-life: 2 minutes.**"
    },
    "dose": {
      "initialDose": "2-5 mcg/kg/min IV",
      "maxDose": "20-50 mcg/kg/min",
      "notes": "Central line preferred."
    },
    "adverseEffects": {
      "common": [
        "Tachycardia",
        "Palpitations",
        "Nausea"
      ],
      "serious": [
        "Ventricular Arrhythmias",
        "Tissue Necrosis (Extravasation)",
        "Gangrene (Peripheral ischemia)"
      ]
    },
    "precautions": [
      "**Extravasation:** Vesicant. Causes necrosis. Phentolamine antidote.",
      "**Arrhythmias:** Highly arrhythmogenic compared to Norepinephrine.",
      "**Hypovolemia:** Correct first."
    ],
    "contraindications": [
      "Pheochromocytoma",
      "Uncorrected tachyarrhythmias"
    ],
    "interactions": {
      "drug": ["MAOIs (Potentiation - Reduce dose to 10%)", "Phenytoin (Hypotension)", "Beta-blockers (Antagonism)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "dornase_alfa": {
    "name": "Dornase Alfa (Pulmozyme)",
    "genericName": "Dornase Alfa",
    "formula": "Recombinant human DNase I",
    "molecularWeight": "37 kDa",
    "brandNames": ["Pulmozyme"],
    "category": "Mucolytic",
    "drugClass": "Recombinant DNase",
    "pubchemCID": "None (Enzyme)",
    "indications": "Cystic Fibrosis (CF).",
    "moaSteps": [
      "Recombinant human Deoxyribonuclease I (rhDNase).",
      "Cleaves extracellular DNA derived from degenerating neutrophils in CF mucus.",
      "Reduces mucus viscoelasticity (thins mucus).",
      "Improves airflow and reduces infection risk."
    ],
    "pharmacokinetics": {
      "absorption": "Inhaled (Minimal systemic).",
      "distribution": "Lungs.",
      "metabolism": "Unknown.",
      "excretion": "Unknown. **Half-life: 11 hours (in sputum).**"
    },
    "dose": {
      "initialDose": "2.5 mg Inhaled daily",
      "maxDose": "2.5 mg BID",
      "notes": "Use specific nebulizer. Do not mix."
    },
    "adverseEffects": {
      "common": [
        "Pharyngitis / Sore throat",
        "Voice alteration",
        "Chest pain"
      ],
      "serious": [
        "None significant",
        "Hypersensitivity"
      ]
    },
    "precautions": [
      "**Storage:** Refrigerate. Protect from light.",
      "**Mixing:** Do not mix with other drugs in nebulizer."
    ],
    "contraindications": [
      "Hypersensitivity to CHO cell products"
    ],
    "interactions": {
      "drug": ["None known"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "dronedarone": {
    "name": "Dronedarone (Multaq)",
    "genericName": "Dronedarone",
    "formula": "C31H44N2O5S",
    "molecularWeight": "556.8 g/mol",
    "brandNames": ["Multaq"],
    "category": "Antiarrhythmic",
    "drugClass": "Class III Antiarrhythmic",
    "pubchemCID": "208898",
    "indications": "Paroxysmal or persistent Atrial Fibrillation (to maintain sinus rhythm).",
    "moaSteps": [
      "Structural analog of Amiodarone (lacks Iodine).",
      "Multichannel blocker: Potassium (Class III), Sodium (Class I), Calcium (Class IV), and Alpha/Beta adrenergic blocking activity.",
      "Less toxic than Amiodarone but less effective.",
      "Non-iodinated = No thyroid/lung toxicity."
    ],
    "pharmacokinetics": {
      "absorption": "Bioavailability 4% w/o food, 15% w/ food.",
      "distribution": "98% protein bound.",
      "metabolism": "Extensive Hepatic (CYP3A4).",
      "excretion": "Feces. **Half-life: 13 to 19 hours.**"
    },
    "dose": {
      "initialDose": "400 mg PO BID",
      "maxDose": "400 mg BID",
      "notes": "Take with food. No load needed."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea / Nausea",
        "Weakness",
        "Rash"
      ],
      "serious": [
        "Worsening Heart Failure (Increased mortality) - BOXED WARNING",
        "Liver Failure (Acute)",
        "Pulmonary Toxicity (Rare compared to Amiodarone)",
        "QT Prolongation"
      ]
    },
    "precautions": [
      "**Heart Failure:** Contraindicated in NYHA Class IV or decompensated HF (Increased death).",
      "**Liver:** Monitor LFTs frequently for first 6 months. Fatal failure reported.",
      "**AFib:** Contraindicated in permanent AFib (Increased death/stroke)."
    ],
    "contraindications": [
      "Permanent AFib",
      "Decompensated Heart Failure",
      "Severe hepatic impairment",
      "Strong CYP3A4 inhibitors"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inhibitors (Ketoconazole - Contraindicated)", "Digoxin (Increases levels)", "Warfarin (Increases INR)", "Statins"],
      "food": ["Must take with food. Grapefruit juice contraindicated."]
    },
    "pregnancyCategory": "Category X"
  },
  "dulaglutide": {
    "name": "Dulaglutide (Trulicity)",
    "genericName": "Dulaglutide",
    "formula": "GLP-1 Fc fusion protein",
    "molecularWeight": "60 kDa",
    "brandNames": ["Trulicity"],
    "category": "Antidiabetic",
    "drugClass": "GLP-1 Receptor Agonist",
    "pubchemCID": "None (Protein)",
    "indications": "Type 2 Diabetes Mellitus, CV Risk Reduction.",
    "moaSteps": [
      "Recombinant GLP-1 analog fused to IgG4 Fc fragment.",
      "Stimulates glucose-dependent insulin secretion.",
      "Suppresses glucagon.",
      "Slows gastric emptying.",
      "Resistant to DPP-4 degradation."
    ],
    "pharmacokinetics": {
      "absorption": "Subcutaneous.",
      "distribution": "Vascular.",
      "metabolism": "Protein catabolism.",
      "excretion": "N/A. **Half-life: 5 days (Weekly dosing).**"
    },
    "dose": {
      "initialDose": "0.75 mg SC weekly",
      "maxDose": "4.5 mg/week",
      "notes": "Single use pen."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting",
        "Diarrhea",
        "Decreased appetite",
        "Abdominal pain"
      ],
      "serious": [
        "Thyroid C-Cell Tumors - BOXED WARNING",
        "Pancreatitis",
        "Acute Kidney Injury (from dehydration)",
        "Hypersensitivity"
      ]
    },
    "precautions": [
      "**Thyroid:** Contraindicated in history of MTC or MEN 2.",
      "**GI:** Gastroparesis risk. Nausea improves over time.",
      "**Kidney:** Monitor renal function if severe GI side effects occur."
    ],
    "contraindications": [
      "Personal/Family history of Medullary Thyroid Carcinoma",
      "MEN 2 Syndrome"
    ],
    "interactions": {
      "drug": ["Oral medications (Delayed absorption)", "Insulin (Hypoglycemia)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "dupilumab": {
    "name": "Dupilumab (Dupixent)",
    "genericName": "Dupilumab",
    "formula": "Human monoclonal antibody",
    "molecularWeight": "147 kDa",
    "brandNames": ["Dupixent"],
    "category": "Biologic",
    "drugClass": "IL-4/IL-13 Receptor Antagonist",
    "pubchemCID": "None (Protein)",
    "indications": "Atopic Dermatitis, Asthma (Eosinophilic), Chronic Rhinosinusitis with Polyps, Eosinophilic Esophagitis.",
    "moaSteps": [
      "Binds to the IL-4 receptor alpha subunit (IL-4Ra).",
      "Inhibits signaling of both IL-4 and IL-13.",
      "Blocks the Th2 inflammatory pathway responsible for allergic/atopic disease.",
      "Reduces IgE and eosinophils (indirectly)."
    ],
    "pharmacokinetics": {
      "absorption": "Subcutaneous (64% bioavailable).",
      "distribution": "Vascular.",
      "metabolism": "Catabolism.",
      "excretion": "Target-mediated. **Half-life: ~11 weeks (Steady state clearance is slow).**"
    },
    "dose": {
      "initialDose": "600 mg SC loading",
      "maxDose": "300 mg every 2 weeks",
      "notes": "Dose varies by indication/age."
    },
    "adverseEffects": {
      "common": [
        "Injection site reactions",
        "Conjunctivitis (Pink eye - specific to atopic dermatitis)",
        "Herpes simplex"
      ],
      "serious": [
        "Hypersensitivity",
        "Helminth infections (theoretical)",
        "Eosinophilia (Transient rise)"
      ]
    },
    "precautions": [
      "**Conjunctivitis:** Treat with eye drops; usually manageable.",
      "**Parasites:** Treat pre-existing helminth infections.",
      "**Vaccines:** Avoid live vaccines."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Live Vaccines"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B (Likely safe)"
  },
  "dutasteride": {
    "name": "Dutasteride (Avodart)",
    "genericName": "Dutasteride",
    "formula": "C27H30F6N2O2",
    "molecularWeight": "528.5 g/mol",
    "brandNames": ["Avodart"],
    "category": "BPH Agent / Alopecia",
    "drugClass": "5-Alpha Reductase Inhibitor (Dual)",
    "pubchemCID": "6918296",
    "indications": "Benign Prostatic Hyperplasia (BPH), Androgenetic Alopecia (Off-label).",
    "moaSteps": [
      "Inhibits both Type 1 and Type 2 isoforms of 5-alpha reductase.",
      "Blocks conversion of testosterone to DHT.",
      "Reduces serum DHT by >90% (Finasteride only blocks Type 2, ~70% reduction).",
      "Shrinks prostate volume."
    ],
    "pharmacokinetics": {
      "absorption": "60% bioavailable.",
      "distribution": "99% protein bound. High volume.",
      "metabolism": "Extensive Hepatic (CYP3A4).",
      "excretion": "Feces. **Half-life: 5 weeks (Very long).**"
    },
    "dose": {
      "initialDose": "0.5 mg PO daily",
      "maxDose": "0.5 mg/day",
      "notes": "Takes 3-6 months for effect."
    },
    "adverseEffects": {
      "common": [
        "Impotence",
        "Decreased libido",
        "Ejaculation disorders",
        "Gynecomastia"
      ],
      "serious": [
        "High-grade Prostate Cancer (FDA Warning)",
        "Male Breast Cancer",
        "Angioedema"
      ]
    },
    "precautions": [
      "**Blood Donation:** Do not donate blood for 6 months after stopping (Teratogenic to recipient).",
      "**PSA:** Decreases PSA by 50%. Double the value for cancer screening.",
      "**Handling:** Pregnant women should not handle capsules."
    ],
    "contraindications": [
      "Women and Children",
      "Pregnancy (Category X)",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inhibitors (Increase levels - caution)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category X"
  },
  "eculizumab": {
    "name": "Eculizumab (Soliris)",
    "genericName": "Eculizumab",
    "formula": "Humanized monoclonal antibody",
    "molecularWeight": "148 kDa",
    "brandNames": ["Soliris"],
    "category": "Biologic",
    "drugClass": "Complement Inhibitor",
    "pubchemCID": "None (Protein)",
    "indications": "Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Myasthenia Gravis (Refractory).",
    "moaSteps": [
      "Binds to complement protein C5.",
      "Prevents cleavage of C5 to C5a and C5b.",
      "Blocks formation of the Membrane Attack Complex (MAC - C5b-9).",
      "Inhibits intravascular hemolysis in PNH."
    ],
    "pharmacokinetics": {
      "absorption": "IV.",
      "distribution": "Vascular.",
      "metabolism": "Catabolism.",
      "excretion": "Rapid clearance in PNH. **Half-life: ~11 days.**"
    },
    "dose": {
      "initialDose": "600-900 mg IV weekly (Induction)",
      "maxDose": "1200 mg every 2 weeks (Maintenance)",
      "notes": "REMS program."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Nasopharyngitis",
        "Back pain",
        "Nausea"
      ],
      "serious": [
        "Meningococcal Infection (Fatal) - BOXED WARNING",
        "Infusion Reactions",
        "Sepsis"
      ]
    },
    "precautions": [
      "**Meningitis:** Blocks MAC, essential for killing Neisseria. Meningococcal vaccination MANDATORY 2 weeks prior. Prophylactic antibiotics often used.",
      "**Infection:** Monitor for all infections.",
      "**Discontinuation:** Stopping in PNH can cause severe hemolysis."
    ],
    "contraindications": [
      "Unresolved Meningococcal infection",
      "Unvaccinated patients (unless emergency)"
    ],
    "interactions": {
      "drug": ["None specific"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "epinephrine": {
    "name": "Epinephrine (Adrenalin, EpiPen)",
    "genericName": "Epinephrine",
    "formula": "C9H13NO3",
    "molecularWeight": "183.2 g/mol",
    "brandNames": ["Adrenalin", "EpiPen"],
    "category": "Vasopressor / Bronchodilator",
    "drugClass": "Catecholamine",
    "pubchemCID": "5816",
    "indications": "Anaphylaxis, Cardiac Arrest, Severe Asthma, Hypotension/Shock.",
    "moaSteps": [
      "Non-selective agonist at Alpha-1, Beta-1, and Beta-2 receptors.",
      "Alpha-1: Vasoconstriction (increases BP/SVR).",
      "Beta-1: Positive inotropy/chronotropy (Cardiac stim).",
      "Beta-2: Bronchodilation and mast cell stabilization."
    ],
    "pharmacokinetics": {
      "absorption": "IM (Rapid), IV (Immediate), SC (Slow).",
      "distribution": "Rapid.",
      "metabolism": "MAO and COMT in liver/tissues.",
      "excretion": "Urine. **Half-life: 2 to 3 minutes.**"
    },
    "dose": {
      "initialDose": "0.3 mg IM (Anaphylaxis); 1 mg IV (Cardiac Arrest)",
      "maxDose": "Titrate (Infusion 2-10 mcg/min)",
      "notes": "IM: Anterolateral thigh preferred."
    },
    "adverseEffects": {
      "common": [
        "Palpitations / Tachycardia",
        "Anxiety / Tremor",
        "Headache",
        "Sweating"
      ],
      "serious": [
        "Hypertensive Crisis (Stroke/Hemorrhage)",
        "Arrhythmias (VT/VF)",
        "Myocardial Ischemia",
        "Tissue Necrosis (Extravasation)"
      ]
    },
    "precautions": [
      "**Concentration:** CAUTION! Cardiac arrest uses 1:10,000 (0.1mg/mL). Anaphylaxis IM uses 1:1,000 (1mg/mL). Mixing them up is fatal.",
      "**Extravasation:** Phentolamine antidote.",
      "**Interactions:** Beta-blockers can cause unopposed alpha stimulation (severe HTN)."
    ],
    "contraindications": [
      "None in life-threatening situations",
      "Narrow-angle glaucoma (Relative)",
      "Shock (non-anaphylactic)"
    ],
    "interactions": {
      "drug": ["Beta-blockers (Unopposed alpha -> HTN Crisis)", "MAOIs (HTN Crisis)", "Digoxin (Arrhythmias)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C (Use if benefit > risk)"
  },
  "epoprostenol": {
    "name": "Epoprostenol (Flolan)",
    "genericName": "Epoprostenol Sodium",
    "formula": "C20H32O5",
    "molecularWeight": "352.5 g/mol",
    "brandNames": ["Flolan", "Veletri"],
    "category": "Pulmonary Hypertension Agent",
    "drugClass": "Prostacyclin (PGI2)",
    "pubchemCID": "5282490",
    "indications": "Pulmonary Arterial Hypertension (PAH) (WHO Group 1).",
    "moaSteps": [
      "Direct vasodilation of pulmonary and systemic arterial vascular beds.",
      "Inhibits platelet aggregation.",
      "Mimics natural prostacyclin.",
      "Improves exercise capacity and hemodynamics."
    ],
    "pharmacokinetics": {
      "absorption": "IV Continuous Infusion.",
      "distribution": "Rapid.",
      "metabolism": "Rapid enzymatic hydrolysis.",
      "excretion": "Urine. **Half-life: 6 minutes (Ultra short).**"
    },
    "dose": {
      "initialDose": "2 ng/kg/min IV",
      "maxDose": "Titrate to tolerance (20-40+ ng/kg/min)",
      "notes": "Requires permanent central line and continuous pump. Flolan requires ice packs; Veletri is room temp stable."
    },
    "adverseEffects": {
      "common": [
        "Flushing",
        "Jaw pain (characteristic)",
        "Diarrhea / Nausea",
        "Headache"
      ],
      "serious": [
        "Rebound Pulmonary Hypertension (if stopped abruptly - Fatal)",
        "Catheter-related Sepsis",
        "Bleeding / Thrombocytopenia",
        "Hypotension"
      ]
    },
    "precautions": [
      "**Abrupt Cessation:** Pump failure or line occlusion causes rapid return of PAH symptoms and death. Backup pump required.",
      "**Line Infection:** High risk of sepsis due to central line.",
      "**Bleeding:** Inhibits platelets."
    ],
    "contraindications": [
      "Heart Failure with reduced EF (HFrEF) due to LV dysfunction",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Anticoagulants (Additive bleeding)", "Diuretics (Hypotension)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "ergotamine": {
    "name": "Ergotamine (Ergomar)",
    "genericName": "Ergotamine Tartrate",
    "formula": "C33H35N5O5",
    "molecularWeight": "581.7 g/mol",
    "brandNames": ["Ergomar", "Cafergot (with Caffeine)"],
    "category": "Antimigraine",
    "drugClass": "Ergot Alkaloid",
    "pubchemCID": "8223",
    "indications": "Acute Migraine, Cluster Headache (Abortive).",
    "moaSteps": [
      "Non-selective agonist at 5-HT1 receptors.",
      "Potent vasoconstrictor of intracranial blood vessels.",
      "Also stimulates alpha-adrenergic and dopamine receptors.",
      "Depresses central vasomotor centers."
    ],
    "pharmacokinetics": {
      "absorption": "Poor oral (enhanced by caffeine).",
      "distribution": "Wide.",
      "metabolism": "Extensive Hepatic (CYP3A4).",
      "excretion": "Bile/Feces. **Half-life: 2 hours (Effects last 24h due to tissue binding).**"
    },
    "dose": {
      "initialDose": "2 mg Sublingual at onset",
      "maxDose": "6 mg/day; 10 mg/week",
      "notes": "Strict dose limits to prevent ergotism."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting (Direct CTZ stimulation)",
        "Paresthesia",
        "Dizziness"
      ],
      "serious": [
        "Ergotism (St. Anthony's Fire) - Intense vasoconstriction, gangrene",
        "Myocardial Ischemia / MI",
        "Fibrosis (Retroperitoneal/Valve - Chronic use)"
      ]
    },
    "precautions": [
      "**Ergotism:** Cold/numb extremities indicates toxicity. Vasospasm can cause amputation.",
      "**Cardiovascular:** Contraindicated in CAD/HTN/PAD.",
      "**Interactions:** CYP3A4 inhibitors cause fatal ischemia."
    ],
    "contraindications": [
      "Peripheral Vascular Disease / CAD / HTN",
      "Pregnancy (Oxytocic)",
      "Strong CYP3A4 inhibitors",
      "Use within 24h of Triptans"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inhibitors (Fatal Ischemia - BOXED WARNING)", "Beta-blockers (Potentiate vasoconstriction)", "Triptans"],
      "food": ["Grapefruit juice (Avoid)"]
    },
    "pregnancyCategory": "Category X"
  },
  "esmolol": {
    "name": "Esmolol (Brevibloc)",
    "genericName": "Esmolol HCl",
    "formula": "C16H25NO4",
    "molecularWeight": "295.4 g/mol",
    "brandNames": ["Brevibloc"],
    "category": "Antiarrhythmic",
    "drugClass": "Beta-Blocker (Beta-1 Selective)",
    "pubchemCID": "59768",
    "indications": "Supraventricular Tachycardia (SVT), Atrial Fibrillation/Flutter (Rapid control), Intraoperative Hypertension/Tachycardia.",
    "moaSteps": [
      "Ultra-short acting cardioselective beta-1 blocker.",
      "Inhibits beta-1 receptors in heart.",
      "Decreases heart rate, contractility, and BP.",
      "Rapid onset and offset."
    ],
    "pharmacokinetics": {
      "absorption": "IV only.",
      "distribution": "Rapid.",
      "metabolism": "Hydrolysis by RBC esterases (Organ-independent).",
      "excretion": "Urine (Metabolite). **Half-life: 9 minutes.**"
    },
    "dose": {
      "initialDose": "500 mcg/kg load over 1 min",
      "maxDose": "50-200 mcg/kg/min infusion",
      "notes": "Titrate every 4 mins."
    },
    "adverseEffects": {
      "common": [
        "Hypotension (Dose-related)",
        "Injection site reaction"
      ],
      "serious": [
        "Bradycardia / Heart Block",
        "Heart Failure",
        "Bronchospasm (High doses lose selectivity)"
      ]
    },
    "precautions": [
      "**Hypotension:** Can be profound. Stops quickly upon discontinuation due to short half-life.",
      "**Extravasation:** Can cause necrosis.",
      "**Usage:** Ideal for unstable patients where quick on/off is needed."
    ],
    "contraindications": [
      "Sinus bradycardia",
      "Heart block > 1st degree",
      "Cardiogenic shock",
      "Decompensated HF"
    ],
    "interactions": {
      "drug": ["Calcium Channel Blockers (Additive)", "Digoxin"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "eszopiclone": {
    "name": "Eszopiclone (Lunesta)",
    "genericName": "Eszopiclone",
    "formula": "C17H17ClN6O3",
    "molecularWeight": "388.8 g/mol",
    "brandNames": ["Lunesta"],
    "category": "Sedative/Hypnotic",
    "drugClass": "Non-benzodiazepine (Z-drug)",
    "pubchemCID": "969472",
    "indications": "Insomnia (Sleep onset and maintenance).",
    "moaSteps": [
      "S-isomer of zopiclone.",
      "Binds to GABA-A receptor complexes near benzodiazepine site.",
      "Enhances GABAergic inhibition.",
      "Longer half-life than Zolpidem/Zaleplon (better for sleep maintenance)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "52-59% protein bound.",
      "metabolism": "Hepatic (CYP3A4/2E1).",
      "excretion": "Urine. **Half-life: 6 hours.**"
    },
    "dose": {
      "initialDose": "1 mg PO at bedtime",
      "maxDose": "3 mg/day",
      "notes": "Start 1mg (less hangover)."
    },
    "adverseEffects": {
      "common": [
        "Dysgeusia (Unpleasant metallic taste - very common)",
        "Headache",
        "Somnolence (Next day)"
      ],
      "serious": [
        "Complex Sleep Behaviors (Sleep-driving) - BOXED WARNING",
        "Suicidal ideation",
        "Anaphylaxis"
      ]
    },
    "precautions": [
      "**Taste:** Metallic taste is a major cause of discontinuation.",
      "**Sleep Behaviors:** Stop if sleep-driving occurs.",
      "**Elderly:** Max dose 2mg."
    ],
    "contraindications": [
      "History of complex sleep behaviors",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inhibitors (Increase levels)", "CNS Depressants (Additive)"],
      "food": ["High fat meal delays onset."]
    },
    "pregnancyCategory": "Category C"
  },
  "ethosuximide": {
    "name": "Ethosuximide (Zarontin)",
    "genericName": "Ethosuximide",
    "formula": "C7H11NO2",
    "molecularWeight": "141.17 g/mol",
    "brandNames": ["Zarontin"],
    "category": "Anticonvulsant",
    "drugClass": "Succinimide",
    "pubchemCID": "3291",
    "indications": "Absence Seizures (Petit Mal).",
    "moaSteps": [
      "Inhibits T-type calcium channels in thalamic neurons.",
      "Reduces the low-threshold calcium current (IT) which generates the 3-Hz spike-and-wave rhythm.",
      "Specific for absence seizures; ineffective for tonic-clonic."
    ],
    "pharmacokinetics": {
      "absorption": "Complete.",
      "distribution": "Not protein bound.",
      "metabolism": "Extensive Hepatic (CYP3A4).",
      "excretion": "Urine. **Half-life: 30 hours (Children); 60 hours (Adults).**"
    },
    "dose": {
      "initialDose": "250 mg PO daily (Child < 6y); 500 mg daily (Older)",
      "maxDose": "1.5 g/day",
      "notes": "Target 40-100 mcg/mL."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting / GI Pain",
        "Drowsiness",
        "Hiccups"
      ],
      "serious": [
        "Stevens-Johnson Syndrome / DRESS",
        "SLE-like Syndrome",
        "Blood Dyscrasias (Agranulocytosis/Pancytopenia)",
        "Suicidal Ideation"
      ]
    },
    "precautions": [
      "**Blood:** Periodic CBC required.",
      "**Behavior:** Can cause aggression/night terrors.",
      "**Mixed Seizures:** May exacerbate tonic-clonic seizures if not used with another AED."
    ],
    "contraindications": [
      "Hypersensitivity to succinimides"
    ],
    "interactions": {
      "drug": ["Valproic Acid (Variable effect)", "CNS Depressants"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "etomidate": {
    "name": "Etomidate (Amidate)",
    "genericName": "Etomidate",
    "formula": "C14H16N2O2",
    "molecularWeight": "244.29 g/mol",
    "brandNames": ["Amidate"],
    "category": "General Anesthetic",
    "drugClass": "Imidaxole Derivative (IV)",
    "pubchemCID": "3304",
    "indications": "Induction of General Anesthesia (especially in hemodynamically unstable patients).",
    "moaSteps": [
      "Potentiates GABA-A receptors.",
      "Depresses Reticular Activating System.",
      "Rapid onset (30-60 sec) hypnosis.",
      "Hemodynamically stable (minimal BP/HR effect)."
    ],
    "pharmacokinetics": {
      "absorption": "IV.",
      "distribution": "Rapid redistribution.",
      "metabolism": "Rapid hepatic/plasma esterase hydrolysis.",
      "excretion": "Urine. **Half-life: 75 minutes (Effect duration 3-10 min).**"
    },
    "dose": {
      "initialDose": "0.3 mg/kg IV push",
      "maxDose": "Titrate",
      "notes": "Pain on injection (propylene glycol)."
    },
    "adverseEffects": {
      "common": [
        "Myoclonus (Transient muscle jerks)",
        "Pain at injection site",
        "Nausea / Vomiting (High PONV risk)"
      ],
      "serious": [
        "Adrenocortical Suppression (Inhibits 11-beta-hydroxylase)",
        "Apnea (Transient)"
      ]
    },
    "precautions": [
      "**Adrenal:** Even single dose suppresses cortisol synthesis for 4-8 hours. Not recommended for septic shock infusions.",
      "**Myoclonus:** Can mimic seizure; reduce with opioid pretreatment.",
      "**PONV:** High rate of post-op vomiting."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Other CNS depressants (Additive)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "etoposide": {
    "name": "Etoposide (VePesid)",
    "genericName": "Etoposide (VP-16)",
    "formula": "C29H32O13",
    "molecularWeight": "588.6 g/mol",
    "brandNames": ["VePesid", "Toposar"],
    "category": "Antineoplastic",
    "drugClass": "Topoisomerase II Inhibitor",
    "pubchemCID": "36462",
    "indications": "Small Cell Lung Cancer, Testicular Cancer.",
    "moaSteps": [
      "Forms a ternary complex with DNA and Topoisomerase II.",
      "Prevents religation of double-strand DNA breaks.",
      "Accumulation of breaks leads to apoptosis.",
      "Late S-G2 phase specific."
    ],
    "pharmacokinetics": {
      "absorption": "50% oral bioavailability.",
      "distribution": "94% protein bound.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Urine. **Half-life: 4 to 11 hours.**"
    },
    "dose": {
      "initialDose": "50-100 mg/m2 IV days 1-5",
      "maxDose": "Cycle dependent",
      "notes": "Oral dose is 2x IV dose."
    },
    "adverseEffects": {
      "common": [
        "Alopecia (Universal)",
        "Nausea / Vomiting",
        "Hypotension (Rapid infusion)"
      ],
      "serious": [
        "Myelosuppression (Leukopenia) - Dose limiting",
        "Secondary Leukemia (AML - 1-3 years later)",
        "Anaphylaxis"
      ]
    },
    "precautions": [
      "**Infusion:** Infuse over 30-60 min to prevent hypotension.",
      "**Secondary Cancer:** Risk of AML with 11q23 translocation.",
      "**Renal:** Dose reduce if CrCl < 50."
    ],
    "contraindications": [
      "Severe bone marrow depression",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Warfarin (Increase INR)", "CYP3A4 Inhibitors/Inducers"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "everolimus": {
    "name": "Everolimus (Afinitor, Zortress)",
    "genericName": "Everolimus",
    "formula": "C53H83NO14",
    "molecularWeight": "958.2 g/mol",
    "brandNames": ["Afinitor (Cancer)", "Zortress (Transplant)"],
    "category": "Antineoplastic / Immunosuppressant",
    "drugClass": "mTOR Inhibitor",
    "pubchemCID": "6442177",
    "indications": "Breast Cancer, RCC, Neuroendocrine tumors, Transplant rejection prophylaxis.",
    "moaSteps": [
      "Inhibits Mammalian Target of Rapamycin (mTOR).",
      "Binds FKBP-12.",
      "Inhibits downstream signaling (S6K1/4EBP1).",
      "Blocks cell cycle progression (G1 to S) and angiogenesis."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid. High fat decreases AUC.",
      "distribution": "74% protein bound.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Feces. **Half-life: 30 hours.**"
    },
    "dose": {
      "initialDose": "10 mg PO daily (Cancer)",
      "maxDose": "10 mg/day",
      "notes": "Transplant dose titrated to trough (0.75mg BID start)."
    },
    "adverseEffects": {
      "common": [
        "Stomatitis (Mouth ulcers - very common)",
        "Rash",
        "Fatigue",
        "Hyperlipidemia"
      ],
      "serious": [
        "Non-infectious Pneumonitis",
        "Infections",
        "Renal Failure",
        "Angioedema"
      ]
    },
    "precautions": [
      "**Stomatitis:** Dexamethasone mouth rinse prophylaxis recommended.",
      "**Pneumonitis:** Monitor for cough/dyspnea. Corticosteroids may be needed.",
      "**Wound Healing:** Impairs healing."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inhibitors/Inducers (Avoid)", "ACE Inhibitors (Angioedema risk)", "Live Vaccines"],
      "food": ["Grapefruit juice"]
    },
    "pregnancyCategory": "Category D"
  },
  "evolocumab": {
    "name": "Evolocumab (Repatha)",
    "genericName": "Evolocumab",
    "formula": "Human monoclonal antibody",
    "molecularWeight": "144 kDa",
    "brandNames": ["Repatha"],
    "category": "Antilipemic",
    "drugClass": "PCSK9 Inhibitor",
    "pubchemCID": "None (Protein)",
    "indications": "Hyperlipidemia, Homozygous Familial Hypercholesterolemia (HoFH), CVD Prevention.",
    "moaSteps": [
      "Binds to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).",
      "Inhibits binding of PCSK9 to LDL receptors (LDLR).",
      "Prevents LDLR degradation, allowing them to recycle to the liver surface.",
      "Increases clearance of LDL from blood (lowers LDL ~60%)."
    ],
    "pharmacokinetics": {
      "absorption": "Subcutaneous (72% bioavailable).",
      "distribution": "Vascular.",
      "metabolism": "Proteolysis.",
      "excretion": "Saturable. **Half-life: 11 to 17 days.**"
    },
    "dose": {
      "initialDose": "140 mg SC every 2 weeks OR 420 mg monthly",
      "maxDose": "420 mg/month",
      "notes": "420 mg required for HoFH."
    },
    "adverseEffects": {
      "common": [
        "Nasopharyngitis",
        "Injection site reactions",
        "Flu-like symptoms"
      ],
      "serious": [
        "Hypersensitivity",
        "Neutralizing Antibodies (Rare)"
      ]
    },
    "precautions": [
      "**Needle Phobia:** Requires self-injection.",
      "**latex:** Needle cover contains dry natural rubber (latex allergy)."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["None specific"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B (Likely safe)"
  },
  "exenatide": {
    "name": "Exenatide (Byetta, Bydureon)",
    "genericName": "Exenatide",
    "formula": "Synthetic exendin-4",
    "molecularWeight": "4186 Da",
    "brandNames": ["Byetta (BID)", "Bydureon (Weekly)"],
    "category": "Antidiabetic",
    "drugClass": "GLP-1 Receptor Agonist",
    "pubchemCID": "45588096",
    "indications": "Type 2 Diabetes Mellitus.",
    "moaSteps": [
      "Synthetic analog of exendin-4 (from Gila monster saliva).",
      "Agonist at GLP-1 receptors.",
      "Increases glucose-dependent insulin secretion.",
      "Suppresses glucagon.",
      "Slows gastric emptying."
    ],
    "pharmacokinetics": {
      "absorption": "SC.",
      "distribution": "Rapid.",
      "metabolism": "Proteolysis via glomerular filtration.",
      "excretion": "Urine. **Half-life: 2.4 hours (Byetta); 2 weeks (Bydureon - microspheres).**"
    },
    "dose": {
      "initialDose": "5 mcg SC BID (Byetta); 2 mg weekly (Bydureon)",
      "maxDose": "10 mcg BID / 2 mg weekly",
      "notes": "Byetta taken 60 min before meals."
    },
    "adverseEffects": {
      "common": [
        "Nausea (High rate)",
        "Vomiting",
        "Diarrhea",
        "Injection site nodules (Bydureon)"
      ],
      "serious": [
        "Pancreatitis",
        "Acute Kidney Injury",
        "Thyroid C-Cell Tumors (Bydureon only - BOXED WARNING)",
        "Antibody formation"
      ]
    },
    "precautions": [
      "**Renal:** Contraindicated if CrCl < 30 mL/min.",
      "**GI:** Not recommended in severe gastroparesis.",
      "**Thyroid:** Bydureon contraindicated in MTC history (Byetta is not, but caution used)."
    ],
    "contraindications": [
      "Severe renal impairment",
      "History of MTC/MEN 2 (Bydureon)"
    ],
    "interactions": {
      "drug": ["Oral meds (Delayed absorption - Oral contraceptives/Antibiotics)", "Warfarin (Increased INR)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "fomepizole": {
    "name": "Fomepizole (Antizol)",
    "genericName": "Fomepizole",
    "formula": "C4H6N2",
    "molecularWeight": "82.1 g/mol",
    "brandNames": ["Antizol"],
    "category": "Antidote",
    "drugClass": "Alcohol Dehydrogenase Inhibitor",
    "pubchemCID": "3406",
    "indications": "Methanol or Ethylene Glycol Poisoning.",
    "moaSteps": [
      "Competitive inhibitor of Alcohol Dehydrogenase (ADH).",
      "Affinity for ADH is 8000x higher than methanol.",
      "Prevents formation of toxic metabolites (Formaldehyde/Formic acid from Methanol; Glycolic/Oxalic acid from Ethylene Glycol).",
      "Allows parents alcohols to be excreted safely by kidneys."
    ],
    "pharmacokinetics": {
      "absorption": "IV.",
      "distribution": "Total body water.",
      "metabolism": "Hepatic.",
      "excretion": "Urine. **Half-life: Dose dependent (varies).**"
    },
    "dose": {
      "initialDose": "15 mg/kg IV loading dose",
      "maxDose": "10 mg/kg q12h x 4, then 15 mg/kg q12h",
      "notes": "Dialysis removes drug; increase frequency to q4h during dialysis."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Nausea",
        "Dizziness"
      ],
      "serious": [
        "None significant (much safer than Ethanol infusion)"
      ]
    },
    "precautions": [
      "**Monitoring:** Monitor ABG, Anion Gap, Osmolar Gap, and toxic alcohol levels.",
      "**Dialysis:** Often needed concurrently to remove toxic metabolites already formed or if renal failure present."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Ethanol (Decreases elimination of both)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "foscarnet": {
    "name": "Foscarnet (Foscavir)",
    "genericName": "Foscarnet Sodium",
    "formula": "CH3O5PNa3",
    "molecularWeight": "300.1 g/mol",
    "brandNames": ["Foscavir"],
    "category": "Antiviral",
    "drugClass": "Pyrophosphate Analog",
    "pubchemCID": "3415",
    "indications": "CMV Retinitis (AIDS), Acyclovir-resistant HSV/VZV.",
    "moaSteps": [
      "Structural mimic of pyrophosphate.",
      "Binds to the pyrophosphate-binding site on viral DNA polymerase.",
      "Inhibits cleavage of pyrophosphate from deoxynucleotide triphosphates.",
      "Does not require intracellular phosphorylation (effective against Thymidine Kinase deficient mutants)."
    ],
    "pharmacokinetics": {
      "absorption": "IV only.",
      "distribution": "Bone/CSF.",
      "metabolism": "None.",
      "excretion": "Urine. **Half-life: 3 to 4 hours (Plasma); Months (Bone).**"
    },
    "dose": {
      "initialDose": "60 mg/kg IV q8h or 90 mg/kg q12h (Induction)",
      "maxDose": "90-120 mg/kg/day (Maint)",
      "notes": "Pre-hydration with 1L Saline mandatory."
    },
    "adverseEffects": {
      "common": [
        "Electrolyte abnormalities (Hypo Ca/Mg/K/Phos)",
        "Nausea",
        "Genital ulcers (contact dermatitis from urine)"
      ],
      "serious": [
        "Nephrotoxicity - BOXED WARNING",
        "Seizures (from electrolytes) - BOXED WARNING",
        "Arrhythmias"
      ]
    },
    "precautions": [
      "**Renal:** Highly nephrotoxic. Dose adjust and hydrate aggressively.",
      "**Electrolytes:** Chelates divalent cations. Severe hypocalcemia can occur. Monitor daily.",
      "**Seizures:** Due to electrolyte shifts."
    ],
    "contraindications": [
      "Clinically significant hypersensitivity"
    ],
    "interactions": {
      "drug": ["Pentamidine (Severe hypocalcemia)", "Nephrotoxic drugs", "QT prolonging drugs"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },"mebendazole": {
    "name": "Mebendazole (Vermox)",
    "genericName": "Mebendazole",
    "formula": "C16H13N3O3",
    "molecularWeight": "295.3 g/mol",
    "brandNames": ["Vermox", "Emverm"],
    "category": "Anthelmintic",
    "drugClass": "Benzimidazole",
    "pubchemCID": "4030",
    "indications": "Pinworm, Roundworm, Hookworm, Whipworm infections.",
    "moaSteps": [
      "Inhibits formation of the worm's microtubules.",
      "Selectively and irreversibly blocks glucose uptake by susceptible helminths.",
      "Depletes glycogen stores, leading to parasite death.",
      "Poorly absorbed by humans (selective toxicity)."
    ],
    "pharmacokinetics": {
      "absorption": "Poor (increased by fatty meal).",
      "distribution": "High protein binding.",
      "metabolism": "Hepatic.",
      "excretion": "Feces (Primary). **Half-life: 2.5 to 5.5 hours.**"
    },
    "dose": {
      "initialDose": "100 mg PO single dose (Pinworm)",
      "maxDose": "100 mg BID x 3 days (Others)",
      "notes": "Repeat pinworm dose in 2 weeks."
    },
    "adverseEffects": {
      "common": [
        "Abdominal pain",
        "Diarrhea"
      ],
      "serious": [
        "Convulsions (Infants)",
        "Severe Skin Reactions (SJS/TEN - Rare)",
        "Neutropenia (High doses)"
      ]
    },
    "precautions": [
      "**Pediatrics:** Contraindicated < 1 year due to convulsion risk.",
      "**Systemic Use:** High doses (for cysts) require bone marrow/liver monitoring."
    ],
    "contraindications": [
      "Hypersensitivity",
      "Children < 1 year"
    ],
    "interactions": {
      "drug": ["Metronidazole (SJS risk - Avoid combo)"],
      "food": ["Fatty food increases absorption (good for systemic, bad for gut worms)."]
    },
    "pregnancyCategory": "Category C"
  },
  "medroxyprogesterone": {
    "name": "Medroxyprogesterone (Provera, Depo-Provera)",
    "genericName": "Medroxyprogesterone Acetate",
    "formula": "C24H34O4",
    "molecularWeight": "386.5 g/mol",
    "brandNames": ["Provera", "Depo-Provera"],
    "category": "Hormone",
    "drugClass": "Progestin",
    "pubchemCID": "6279",
    "indications": "Contraception, Endometriosis, Secondary Amenorrhea, Endometrial Cancer.",
    "moaSteps": [
      "Synthetic derivative of progesterone.",
      "Inhibits secretion of pituitary gonadotropins (LH/FSH).",
      "Prevents follicular maturation and ovulation.",
      "Thins endometrium."
    ],
    "pharmacokinetics": {
      "absorption": "Oral (Rapid); IM (Slow depot).",
      "distribution": "90% protein bound.",
      "metabolism": "Hepatic.",
      "excretion": "Urine. **Half-life: 30 days (Oral); 50 days (IM Depot).**"
    },
    "dose": {
      "initialDose": "150 mg IM every 3 months (Contraception)",
      "maxDose": "10 mg/day PO (Amenorrhea)",
      "notes": "Depo injection provides 3 months protection."
    },
    "adverseEffects": {
      "common": [
        "Menstrual irregularities / Amenorrhea",
        "Weight gain",
        "Headache",
        "Injection site reaction"
      ],
      "serious": [
        "Bone Mineral Density Loss - BOXED WARNING",
        "Thromboembolism",
        "Breast Cancer risk"
      ]
    },
    "precautions": [
      "**Bone Density:** Long-term Depo use (>2 years) causes significant BMD loss. Ensure Calcium/Vitamin D.",
      "**Thrombosis:** Avoid in history of DVT/PE.",
      "**Bleeding:** Breakthrough bleeding common initially."
    ],
    "contraindications": [
      "Pregnancy",
      "Undiagnosed vaginal bleeding",
      "Breast cancer",
      "Active thromboembolism"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inducers (Rifampin - may decrease efficacy)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category X"
  },
  "megestrol": {
    "name": "Megestrol (Megace)",
    "genericName": "Megestrol Acetate",
    "formula": "C24H32O4",
    "molecularWeight": "384.5 g/mol",
    "brandNames": ["Megace", "Megace ES"],
    "category": "Appetite Stimulant / Antineoplastic",
    "drugClass": "Progestin",
    "pubchemCID": "4032",
    "indications": "Appetite stimulation (AIDS Wasting, Cancer Cachexia), Palliative treatment of Breast/Endometrial Cancer.",
    "moaSteps": [
      "Synthetic progestin.",
      "Appetite mechanism unknown (possibly NPY stimulation).",
      "Antineoplastic: Antiestrogenic effect via pituitary suppression."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "Fat tissue.",
      "metabolism": "Hepatic.",
      "excretion": "Urine. **Half-life: 34 hours.**"
    },
    "dose": {
      "initialDose": "400-800 mg PO daily (Appetite)",
      "maxDose": "800 mg/day",
      "notes": "Suspension preferred."
    },
    "adverseEffects": {
      "common": [
        "Weight gain (intended)",
        "Edema",
        "Impotence"
      ],
      "serious": [
        "Thromboembolism (DVT/PE)",
        "Adrenal Suppression (Glucocorticoid activity)",
        "Worsening Diabetes"
      ]
    },
    "precautions": [
      "**Thrombosis:** Increased risk of clots.",
      "**Diabetes:** Can cause hyperglycemia.",
      "**Adrenal:** Chronic use can suppress HPA axis."
    ],
    "contraindications": [
      "Pregnancy",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Dofetilide (Increased levels)"],
      "food": ["Take with food."]
    },
    "pregnancyCategory": "Category X"
  },
  "melphalan": {
    "name": "Melphalan (Alkeran)",
    "genericName": "Melphalan",
    "formula": "C13H18Cl2N2O2",
    "molecularWeight": "305.2 g/mol",
    "brandNames": ["Alkeran", "Evomela"],
    "category": "Antineoplastic",
    "drugClass": "Alkylating Agent (Nitrogen Mustard)",
    "pubchemCID": "460612",
    "indications": "Multiple Myeloma (Palliative or Conditioning), Ovarian Cancer.",
    "moaSteps": [
      "Bifunctional alkylating agent.",
      "Forms cross-links between DNA strands (guanine bases).",
      "Inhibits DNA and RNA synthesis.",
      "Cytotoxic to both dividing and non-dividing cells."
    ],
    "pharmacokinetics": {
      "absorption": "Variable oral absorption.",
      "distribution": "Total body water.",
      "metabolism": "Spontaneous hydrolysis.",
      "excretion": "Urine. **Half-life: 1.5 hours (IV).**"
    },
    "dose": {
      "initialDose": "0.15 mg/kg/day for 7 days (Oral cycles)",
      "maxDose": "High dose for transplant (100-200 mg/m2)",
      "notes": "Give on empty stomach."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting",
        "Oral ulceration",
        "Alopecia (mild)"
      ],
      "serious": [
        "Bone Marrow Suppression (Severe) - BOXED WARNING",
        "Secondary Malignancy (Leukemia) - BOXED WARNING",
        "Pulmonary Fibrosis",
        "Hypersensitivity (IV)"
      ]
    },
    "precautions": [
      "**Myelosuppression:** Dose-limiting. Nadir at 4 weeks.",
      "**Secondary Cancer:** Leukemogenic (AML).",
      "**Renal:** Dose reduce in renal failure."
    ],
    "contraindications": [
      "Severe bone marrow depression",
      "Prior resistance"
    ],
    "interactions": {
      "drug": ["Cyclosporine (Renal toxicity)", "Live vaccines"],
      "food": ["Food decreases absorption significantly."]
    },
    "pregnancyCategory": "Category D"
  },
  "meperidine": {
    "name": "Meperidine (Demerol)",
    "genericName": "Meperidine HCl",
    "formula": "C15H21NO2",
    "molecularWeight": "247.3 g/mol",
    "brandNames": ["Demerol"],
    "category": "Opioid Analgesic",
    "drugClass": "Synthetic Opioid Agonist",
    "pubchemCID": "4058",
    "indications": "Moderate to Severe Pain (Short-term), Preoperative sedation, Post-op shivering.",
    "moaSteps": [
      "Agonist at mu-opioid receptors.",
      "Anticholinergic properties.",
      "Local anesthetic properties.",
      "Metabolite Normeperidine is neurotoxic."
    ],
    "pharmacokinetics": {
      "absorption": "Poor oral effectiveness.",
      "distribution": "Wide.",
      "metabolism": "Hepatic to Normeperidine (Toxic).",
      "excretion": "Urine. **Half-life: 3 hours (Parent); 15-30 hours (Normeperidine).**"
    },
    "dose": {
      "initialDose": "50-150 mg IM/SC/PO every 3-4 hours",
      "maxDose": "600 mg/day",
      "notes": "Limit use to < 48 hours."
    },
    "adverseEffects": {
      "common": [
        "Sedation",
        "Dry mouth",
        "Nausea",
        "Tachycardia"
      ],
      "serious": [
        "Seizures (Normeperidine accumulation)",
        "Serotonin Syndrome (with MAOIs)",
        "Respiratory Depression",
        "Delirium"
      ]
    },
    "precautions": [
      "**Neurotoxicity:** Metabolite Normeperidine causes tremors/seizures. Accumulates in renal failure and with chronic use. Avoid in kidney disease and elderly.",
      "**MAOI Interaction:** Fatal reaction (Serotonin syndrome/Coma). Absolute contraindication.",
      "**Short Term:** Do not use for chronic pain."
    ],
    "contraindications": [
      "MAOI use within 14 days",
      "Renal failure",
      "Seizure disorder"
    ],
    "interactions": {
      "drug": ["MAOIs (Fatal)", "SSRIs (Serotonin syndrome)", "Acyclovir/Cimetidine (Increase toxicity)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "mepolizumab": {
    "name": "Mepolizumab (Nucala)",
    "genericName": "Mepolizumab",
    "formula": "Humanized IgG1 monoclonal antibody",
    "molecularWeight": "149 kDa",
    "brandNames": ["Nucala"],
    "category": "Asthma Biologic",
    "drugClass": "IL-5 Antagonist",
    "pubchemCID": "None (Protein)",
    "indications": "Severe Eosinophilic Asthma, Eosinophilic Granulomatosis with Polyangiitis (EGPA), HES.",
    "moaSteps": [
      "Binds to IL-5 cytokine.",
      "Prevents IL-5 from binding to its receptor on eosinophils.",
      "Inhibits eosinophil maturation, survival, and activation.",
      "Reduces blood and tissue eosinophil counts."
    ],
    "pharmacokinetics": {
      "absorption": "Subcutaneous (80% bioavailable).",
      "distribution": "Vascular.",
      "metabolism": "Catabolism.",
      "excretion": "Slow. **Half-life: 16 to 22 days.**"
    },
    "dose": {
      "initialDose": "100 mg SubQ every 4 weeks",
      "maxDose": "300 mg every 4 weeks (EGPA/HES)",
      "notes": "Fixed dose."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Injection site reaction",
        "Back pain",
        "Fatigue"
      ],
      "serious": [
        "Hypersensitivity / Anaphylaxis",
        "Herpes Zoster Infection",
        "Helminth Infection"
      ]
    },
    "precautions": [
      "**Parasites:** Treat pre-existing helminth infections before starting.",
      "**Herpes Zoster:** Vaccination recommended if appropriate.",
      "**Acute Asthma:** Not for rescue use."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["None specific"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "mercaptopurine": {
    "name": "Mercaptopurine (Purinethol)",
    "genericName": "6-Mercaptopurine (6-MP)",
    "formula": "C5H4N4S",
    "molecularWeight": "152.18 g/mol",
    "brandNames": ["Purinethol", "Purixan"],
    "category": "Antineoplastic / Immunosuppressant",
    "drugClass": "Purine Antimetabolite",
    "pubchemCID": "667608",
    "indications": "Acute Lymphoblastic Leukemia (ALL), Crohn's Disease / Ulcerative Colitis.",
    "moaSteps": [
      "Converted to Thio-IMP by HGPRT.",
      "Inhibits purine synthesis.",
      "Incorporates into DNA/RNA as false nucleotide.",
      "Induces cell cycle arrest and apoptosis."
    ],
    "pharmacokinetics": {
      "absorption": "Variable.",
      "distribution": "Crosses BBB.",
      "metabolism": "Hepatic (Xanthine Oxidase and TPMT).",
      "excretion": "Urine. **Half-life: 1.5 hours (Parent); 5 hours (Active metabolites).**"
    },
    "dose": {
      "initialDose": "1.5-2.5 mg/kg PO daily",
      "maxDose": "Titrate to WBC",
      "notes": "Genetic testing for TPMT/NUDT15 required."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting",
        "Rash",
        "Malaise"
      ],
      "serious": [
        "Bone Marrow Suppression - BOXED WARNING",
        "Hepatotoxicity",
        "Malignancy (Lymphoma/Skin Cancer)",
        "Pancreatitis"
      ]
    },
    "precautions": [
      "**TPMT Deficiency:** Patients with low TPMT enzyme activity risk fatal myelosuppression. Test before starting.",
      "**Allopurinol:** Inhibits Xanthine Oxidase (major pathway for 6-MP breakdown). Co-use increases 6-MP levels 400%. Reduce 6-MP dose by 75%.",
      "**Liver:** Monitor LFTs."
    ],
    "contraindications": [
      "Pregnancy (unless benefit > risk)",
      "Prior resistance"
    ],
    "interactions": {
      "drug": ["Allopurinol/Febuxostat (Fatal toxicity - Dose adjustment mandatory)", "Warfarin"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "mesalamine": {
    "name": "Mesalamine (Lialda, Apriso)",
    "genericName": "Mesalamine (5-ASA)",
    "formula": "C7H7NO3",
    "molecularWeight": "153.14 g/mol",
    "brandNames": ["Lialda", "Apriso", "Canasa", "Pentasa"],
    "category": "GI Agent",
    "drugClass": "5-Aminosalicylate",
    "pubchemCID": "4075",
    "indications": "Ulcerative Colitis (Induction/Maintenance), Crohn's Disease.",
    "moaSteps": [
      "Local anti-inflammatory action in the colon.",
      "Inhibits cyclooxygenase and lipoxygenase.",
      "Reduces prostaglandin and leukotriene production.",
      "Scavenges free radicals."
    ],
    "pharmacokinetics": {
      "absorption": "Variable (20-30%). Formulation dependent release.",
      "distribution": "Colon tissue.",
      "metabolism": "Intestinal/Hepatic acetylation.",
      "excretion": "Urine and Feces. **Half-life: 7 to 12 hours.**"
    },
    "dose": {
      "initialDose": "2.4-4.8 g PO daily (Induction)",
      "maxDose": "4.8 g/day",
      "notes": "Canasa is suppository; Rowasa is enema."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Abdominal pain",
        "Flatulence",
        "Nausea"
      ],
      "serious": [
        "Renal Impairment (Interstitial Nephritis)",
        "Mesalamine-induced Acute Intolerance Syndrome (Cramps/Bloody diarrhea)",
        "Hypersensitivity (Myocarditis/Pneumonitis)"
      ]
    },
    "precautions": [
      "**Intolerance Syndrome:** Mimics IBD flare. Discontinue if symptoms worsen.",
      "**Renal:** Monitor renal function annually.",
      "**Formulations:** Different brands release at different pH levels; not interchangeable."
    ],
    "contraindications": [
      "Hypersensitivity to salicylates (aspirin) or aminosalicylates"
    ],
    "interactions": {
      "drug": ["NSAIDs (Additive renal risk)", "Azathioprine (Bone marrow suppression risk)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "methimazole": {
    "name": "Methimazole (Tapazole)",
    "genericName": "Methimazole",
    "formula": "C4H6N2S",
    "molecularWeight": "114.17 g/mol",
    "brandNames": ["Tapazole"],
    "category": "Antithyroid",
    "drugClass": "Thionamide",
    "pubchemCID": "1349907",
    "indications": "Hyperthyroidism (Graves' Disease), Thyroid Storm (after PTU), Prep for thyroidectomy.",
    "moaSteps": [
      "Inhibits thyroid peroxidase enzyme.",
      "Prevents oxidation of iodide and coupling of iodotyrosines.",
      "Blocks synthesis of T3 and T4.",
      "Does not block peripheral conversion (unlike PTU)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Concentrates in thyroid.",
      "metabolism": "Hepatic.",
      "excretion": "Urine. **Half-life: 4 to 6 hours.**"
    },
    "dose": {
      "initialDose": "15-60 mg PO daily (divided)",
      "maxDose": "120 mg/day",
      "notes": "Maintenance 5-15 mg daily."
    },
    "adverseEffects": {
      "common": [
        "Rash / Pruritus",
        "GI upset",
        "Arthralgia"
      ],
      "serious": [
        "Agranulocytosis (Life-threatening)",
        "Hepatotoxicity (Cholestatic)",
        "Vasculitis (ANCA-positive)",
        "Teratogenicity (Aplasia cutis)"
      ]
    },
    "precautions": [
      "**Agranulocytosis:** Occurs in 0.5%. Patients must report sore throat/fever immediately. Stop drug and check WBC.",
      "**Pregnancy:** Teratogenic (Aplasia cutis/Choanal atresia) in 1st Trimester. Use PTU in 1st trimester, then switch to Methimazole.",
      "**Liver:** Cholestatic jaundice."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Warfarin (Hypothyroid state reduces catabolism of clotting factors -> lower INR. Treating hyperthyroidism increases INR requirement)."],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "methocarbamol": {
    "name": "Methocarbamol (Robaxin)",
    "genericName": "Methocarbamol",
    "formula": "C11H15NO5",
    "molecularWeight": "241.2 g/mol",
    "brandNames": ["Robaxin"],
    "category": "Muscle Relaxant",
    "drugClass": "Centrally Acting Skeletal Muscle Relaxant",
    "pubchemCID": "4107",
    "indications": "Muscle Spasm (Acute painful musculoskeletal conditions), Tetanus (IV adjunct).",
    "moaSteps": [
      "Exact mechanism unknown.",
      "Causes general CNS depression.",
      "Does not directly relax skeletal muscle.",
      "Sedative effect contributes to muscle relaxation."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Wide.",
      "metabolism": "Hepatic.",
      "excretion": "Urine. **Half-life: 1 to 2 hours.**"
    },
    "dose": {
      "initialDose": "1500 mg PO QID (First 48h)",
      "maxDose": "8 g/day",
      "notes": "Maintenance 750mg-1g QID."
    },
    "adverseEffects": {
      "common": [
        "Drowsiness",
        "Dizziness",
        "Discoloration of urine (Black/Brown/Green)",
        "Nausea"
      ],
      "serious": [
        "Seizures (IV use)",
        "Bradycardia (IV)",
        "Anaphylaxis"
      ]
    },
    "precautions": [
      "**Sedation:** Avoid driving. Additive with alcohol.",
      "**IV Use:** Infuse slowly. Keep recumbent (hypotension). Contraindicated in renal impairment (IV vehicle contains polyethylene glycol).",
      "**Urine:** Harmless discoloration."
    ],
    "contraindications": [
      "Renal impairment (IV form only)",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["CNS Depressants", "Pyridostigmine (May exacerbate Myasthenia Gravis)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "methyldopa": {
    "name": "Methyldopa",
    "genericName": "Methyldopa",
    "formula": "C10H13NO4",
    "molecularWeight": "211.2 g/mol",
    "brandNames": ["Aldomet"],
    "category": "Antihypertensive",
    "drugClass": "Central Alpha-2 Agonist",
    "pubchemCID": "4138",
    "indications": "Hypertension (Preferred in Pregnancy).",
    "moaSteps": [
      "Metabolized to alpha-methylnorepinephrine.",
      "Stimulates central alpha-2 adrenergic receptors.",
      "Decreases sympathetic outflow to heart, kidneys, and blood vessels.",
      "Reduces BP."
    ],
    "pharmacokinetics": {
      "absorption": "Variable.",
      "distribution": "Crosses BBB and Placenta.",
      "metabolism": "Hepatic/GI.",
      "excretion": "Urine. **Half-life: 1.8 hours (Effect lasts longer).**"
    },
    "dose": {
      "initialDose": "250 mg PO BID/TID",
      "maxDose": "3 g/day",
      "notes": "First line for Preeclampsia/Chronic HTN in pregnancy."
    },
    "adverseEffects": {
      "common": [
        "Sedation (Transient)",
        "Dry mouth",
        "Edema",
        "Depression"
      ],
      "serious": [
        "Hemolytic Anemia (Coombs Positive)",
        "Hepatotoxicity (Hepatitis)",
        "Drug-induced Lupus",
        "Myocarditis"
      ]
    },
    "precautions": [
      "**Coombs Test:** 10-20% develop positive Coombs test; <1% develop hemolytic anemia. Monitor CBC/Coombs.",
      "**Liver:** Monitor LFTs periodically.",
      "**CNS:** Sedation usually improves."
    ],
    "contraindications": [
      "Active liver disease",
      "MAOI use"
    ],
    "interactions": {
      "drug": ["Iron (Decreases absorption)", "MAOIs (Hypertensive crisis)", "Lithium (Toxicity)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "methylergonovine": {
    "name": "Methylergonovine (Methergine)",
    "genericName": "Methylergonovine Maleate",
    "formula": "C20H25N3O2",
    "molecularWeight": "339.4 g/mol",
    "brandNames": ["Methergine"],
    "category": "Uterotonic",
    "drugClass": "Ergot Alkaloid",
    "pubchemCID": "8226",
    "indications": "Postpartum Hemorrhage (due to uterine atony/subinvolution).",
    "moaSteps": [
      "Directly stimulates uterine smooth muscle.",
      "Increases tone, rate, and amplitude of rhythmic contractions.",
      "Induces sustained tetanic contraction.",
      "Compresses uterine blood vessels to stop bleeding."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (IM/PO).",
      "distribution": "Rapid.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Urine/Feces. **Half-life: 3.4 hours.**"
    },
    "dose": {
      "initialDose": "0.2 mg IM (Emergency); 0.2 mg PO TID (Maintenance)",
      "maxDose": "1 week duration",
      "notes": "IV use restricted to life-threatening hemorrhage (Stroke risk)."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting",
        "Abdominal pain"
      ],
      "serious": [
        "Hypertension (Severe)",
        "Seizures",
        "Stroke (IV use)",
        "MI / Coronary Vasospasm",
        "Ergotism"
      ]
    },
    "precautions": [
      "**Hypertension:** Contraindicated in Preeclampsia/HTN. Monitor BP before each dose.",
      "**IV Route:** Use with extreme caution (slow push > 1 min). High risk of hypertensive crisis/stroke.",
      "**Lactation:** Excreted in milk; avoid breastfeeding for 12h."
    ],
    "contraindications": [
      "Hypertension / Preeclampsia",
      "Pregnancy (Induction of labor)",
      "Ischemic Heart Disease"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inhibitors (Ergotism)", "Vasoconstrictors"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C (Indicated Postpartum)"
  },
  "metolazone": {
    "name": "Metolazone (Zaroxolyn)",
    "genericName": "Metolazone",
    "formula": "C16H16ClN3O3S",
    "molecularWeight": "365.8 g/mol",
    "brandNames": ["Zaroxolyn"],
    "category": "Diuretic",
    "drugClass": "Thiazide-like Diuretic",
    "pubchemCID": "4170",
    "indications": "Edema (Heart Failure, Renal Disease), Hypertension.",
    "moaSteps": [
      "Inhibits Na+/Cl- reabsorption in the distal convoluted tubule.",
      "Unique: Retains efficacy even in severe renal impairment (GFR < 30).",
      "Often used in combination with Loop Diuretics for synergistic diuresis."
    ],
    "pharmacokinetics": {
      "absorption": "65% absorbed.",
      "distribution": "95% protein bound.",
      "metabolism": "Minimal.",
      "excretion": "Urine. **Half-life: 14 hours.**"
    },
    "dose": {
      "initialDose": "2.5-5 mg PO daily",
      "maxDose": "20 mg/day",
      "notes": "Give 30 min before Loop diuretic ('Booster')."
    },
    "adverseEffects": {
      "common": [
        "Dizziness",
        "Dry mouth",
        "Muscle cramps"
      ],
      "serious": [
        "Severe Electrolyte Imbalance (Hypokalemia, Hyponatremia, Hypochloremic Alkalosis)",
        "Hyperuricemia (Gout)",
        "Hyperglycemia"
      ]
    },
    "precautions": [
      "**Electrolytes:** Potent synergy with loops causes massive electrolyte loss. Monitor daily. Potassium supplementation usually required.",
      "**Renal:** Effective in low GFR, but watch for dehydration."
    ],
    "contraindications": [
      "Anuria",
      "Hepatic Coma"
    ],
    "interactions": {
      "drug": ["Loop Diuretics (Massive diuresis)", "Digoxin (Toxicity via low K)", "Lithium"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "mexiletine": {
    "name": "Mexiletine",
    "genericName": "Mexiletine HCl",
    "formula": "C11H17NO",
    "molecularWeight": "179.26 g/mol",
    "brandNames": ["Mexitil"],
    "category": "Antiarrhythmic",
    "drugClass": "Class IB Antiarrhythmic",
    "pubchemCID": "4178",
    "indications": "Ventricular Arrhythmias (VT), Neuropathic Pain/Myotonia (Off-label).",
    "moaSteps": [
      "Oral analog of Lidocaine.",
      "Blocks fast sodium channels in cardiac tissues.",
      "Shortens Phase 3 repolarization.",
      "Effective for ventricular arrhythmias only."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "Large Vd.",
      "metabolism": "Hepatic (CYP2D6/1A2).",
      "excretion": "Urine. **Half-life: 10 to 12 hours.**"
    },
    "dose": {
      "initialDose": "200 mg PO q8h",
      "maxDose": "1200 mg/day",
      "notes": "Take with food."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting (Dose limiting)",
        "Tremor",
        "Dizziness / Ataxia",
        "Heartburn"
      ],
      "serious": [
        "Proarrhythmia",
        "Seizures",
        "Hepatotoxicity (Rare)",
        "Blood dyscrasias"
      ]
    },
    "precautions": [
      "**GI:** Severe GI upset is common; take with food/antacids.",
      "**CNS:** Tremor/Ataxia indicate toxicity.",
      "**Liver:** Metabolism impaired in liver disease."
    ],
    "contraindications": [
      "2nd/3rd degree AV block",
      "Cardiogenic shock"
    ],
    "interactions": {
      "drug": ["CYP1A2 Inducers (Smoking/Rifampin - Decrease levels)", "Caffeine (Mexiletine increases caffeine levels)", "Lidocaine (Additive CNS toxicity)"],
      "food": ["Take with food to reduce nausea."]
    },
    "pregnancyCategory": "Category C"
  },
  "micafungin": {
    "name": "Micafungin (Mycamine)",
    "genericName": "Micafungin Sodium",
    "formula": "C56H71N9O23S",
    "molecularWeight": "1270.3 g/mol",
    "brandNames": ["Mycamine"],
    "category": "Antifungal",
    "drugClass": "Echinocandin",
    "pubchemCID": "477468",
    "indications": "Candidemia, Esophageal Candidiasis, Prophylaxis in stem cell transplant.",
    "moaSteps": [
      "Inhibits synthesis of 1,3-beta-D-glucan.",
      "Disrupts fungal cell wall integrity.",
      "Fungicidal against Candida.",
      "Active against Azole-resistant strains."
    ],
    "pharmacokinetics": {
      "absorption": "IV only.",
      "distribution": "High protein binding.",
      "metabolism": "Hepatic (Arylsulfatase/COMT - Not CYP).",
      "excretion": "Feces. **Half-life: 15 hours.**"
    },
    "dose": {
      "initialDose": "100 mg IV daily",
      "maxDose": "150 mg/day",
      "notes": "No loading dose needed (unlike Caspofungin)."
    },
    "adverseEffects": {
      "common": [
        "Nausea",
        "Headache",
        "Phlebitis",
        "Diarrhea"
      ],
      "serious": [
        "Hepatotoxicity",
        "Anaphylaxis / Histamine release",
        "Hemolysis"
      ]
    },
    "precautions": [
      "**Liver:** Rat tumors observed; clinical relevance unknown. Monitor LFTs.",
      "**Hemolysis:** Monitor for anemia/hemoglobinuria."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Sirolimus/Nifedipine (Weak inhibition of CYP3A4 - monitor levels)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "midodrine": {
    "name": "Midodrine (ProAmatine)",
    "genericName": "Midodrine HCl",
    "formula": "C12H18N2O4",
    "molecularWeight": "254.3 g/mol",
    "brandNames": ["ProAmatine", "Orvaten"],
    "category": "Vasopressor",
    "drugClass": "Alpha-1 Adrenergic Agonist",
    "pubchemCID": "4195",
    "indications": "Symptomatic Orthostatic Hypotension.",
    "moaSteps": [
      "Prodrug converted to Desglymidodrine.",
      "Selective alpha-1 receptor agonist.",
      "Causes arteriolar and venous vasoconstriction.",
      "Increases standing blood pressure."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Poor CNS penetration.",
      "metabolism": "Hydrolysis to active metabolite.",
      "excretion": "Urine. **Half-life: 3 to 4 hours (Active metabolite).**"
    },
    "dose": {
      "initialDose": "2.5-10 mg PO TID",
      "maxDose": "10 mg TID",
      "notes": "Dose during daytime hours only (e.g., 8am, 12pm, 4pm). Last dose 4h before bed."
    },
    "adverseEffects": {
      "common": [
        "Paresthesia (Scalp tingling/Pruritus - Piloerection)",
        "Supine Hypertension",
        "Urinary urgency / Retention"
      ],
      "serious": [
        "Severe Supine Hypertension - BOXED WARNING",
        "Bradycardia (Reflex)"
      ]
    },
    "precautions": [
      "**Supine HTN:** Boxed Warning. Do not take before bed. Elevate head of bed. Monitor sitting/supine BP.",
      "**Renal:** Accumulates in renal failure."
    ],
    "contraindications": [
      "Severe organic heart disease",
      "Acute renal disease",
      "Urinary retention",
      "Supine hypertension"
    ],
    "interactions": {
      "drug": ["Digoxin/Beta-blockers (Bradycardia)", "Alpha-blockers (Antagonism)", "Vasoconstrictors"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "milrinone": {
    "name": "Milrinone (Primacor)",
    "genericName": "Milrinone Lactate",
    "formula": "C12H9N3O",
    "molecularWeight": "211.2 g/mol",
    "brandNames": ["Primacor"],
    "category": "Inotrope",
    "drugClass": "Phosphodiesterase 3 (PDE3) Inhibitor",
    "pubchemCID": "4197",
    "indications": "Acute Decompensated Heart Failure (short term).",
    "moaSteps": [
      "Selectively inhibits PDE3 in cardiac and vascular muscle.",
      "Increases cAMP.",
      "Heart: Increases calcium influx -> Positive Inotropy.",
      "Vessels: Vasodilation (Decreased Preload/Afterload).",
      "'Inodilator'."
    ],
    "pharmacokinetics": {
      "absorption": "IV only.",
      "distribution": "Wide.",
      "metabolism": "Minimal.",
      "excretion": "Urine (Unchanged). **Half-life: 2.3 hours (Prolonged in renal failure).**"
    },
    "dose": {
      "initialDose": "50 mcg/kg load (often skipped), then 0.375-0.75 mcg/kg/min",
      "maxDose": "1.13 mg/kg/day",
      "notes": "Adjust infusion rate in renal impairment."
    },
    "adverseEffects": {
      "common": [
        "Hypotension",
        "Headache"
      ],
      "serious": [
        "Ventricular Arrhythmias (VT/VF) - High risk",
        "Thrombocytopenia (rare)",
        "Hepatotoxicity"
      ]
    },
    "precautions": [
      "**Arrhythmias:** Continuous ECG monitoring required. Proarrhythmic.",
      "**Hypotension:** Vasodilation can drop BP. Correct volume or add pressor.",
      "**Renal:** Drug accumulates significantly. Reduce rate."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["None specific (Standard HF drug cautions)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "minoxidil": {
    "name": "Minoxidil (Rogaine, Loniten)",
    "genericName": "Minoxidil",
    "formula": "C9H15N5O",
    "molecularWeight": "209.25 g/mol",
    "brandNames": ["Rogaine (Topical)", "Loniten (Oral)"],
    "category": "Antihypertensive / Hair Growth",
    "drugClass": "Direct Vasodilator (Potassium Channel Opener)",
    "pubchemCID": "4201",
    "indications": "Severe Hypertension (Oral), Androgenetic Alopecia (Topical).",
    "moaSteps": [
      "Opens ATP-sensitive potassium channels in smooth muscle.",
      "Hyperpolarization relaxes arteriolar smooth muscle.",
      "Potent vasodilation (Oral).",
      "Stimulates hair follicle growth (mechanism unclear, likely vascular)."
    ],
    "pharmacokinetics": {
      "absorption": "Oral (90%); Topical (Minimally absorbed).",
      "distribution": "Wide.",
      "metabolism": "Hepatic conjugation.",
      "excretion": "Urine. **Half-life: 4.2 hours.**"
    },
    "dose": {
      "initialDose": "5 mg PO daily (HTN)",
      "maxDose": "100 mg/day",
      "notes": "Topical: Apply BID."
    },
    "adverseEffects": {
      "common": [
        "Hypertrichosis (Excess hair growth - systemic)",
        "Fluid Retention / Edema",
        "Tachycardia (Reflex)"
      ],
      "serious": [
        "Pericardial Effusion / Tamponade - BOXED WARNING",
        "Angina exacerbation",
        "Severe hypotension"
      ]
    },
    "precautions": [
      "**Reflex Tachycardia:** Must use with Beta-blocker.",
      "**Fluid:** Must use with Diuretic (Loop).",
      "**Pericardial Effusion:** Monitor echocardiogram.",
      "**Hair:** Topical use dangerous to pets (cats)."
    ],
    "contraindications": [
      "Pheochromocytoma"
    ],
    "interactions": {
      "drug": ["Guanethidine (Profound orthostasis)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "mirabegron": {
    "name": "Mirabegron (Myrbetriq)",
    "genericName": "Mirabegron",
    "formula": "C21H24N4O2S",
    "molecularWeight": "396.5 g/mol",
    "brandNames": ["Myrbetriq"],
    "category": "Urinary Antispasmodic",
    "drugClass": "Beta-3 Adrenergic Agonist",
    "pubchemCID": "9865528",
    "indications": "Overactive Bladder (OAB).",
    "moaSteps": [
      "Selectively stimulates beta-3 adrenergic receptors in the detrusor muscle.",
      "Relaxes the detrusor muscle during the storage phase.",
      "Increases bladder capacity.",
      "Avoids anticholinergic side effects (dry mouth/confusion)."
    ],
    "pharmacokinetics": {
      "absorption": "30% bioavailable.",
      "distribution": "71% protein bound.",
      "metabolism": "Hepatic (CYP3A4/2D6).",
      "excretion": "Urine. **Half-life: 50 hours.**"
    },
    "dose": {
      "initialDose": "25 mg PO daily",
      "maxDose": "50 mg/day",
      "notes": "Swallow whole."
    },
    "adverseEffects": {
      "common": [
        "Hypertension",
        "Nasopharyngitis",
        "UTI",
        "Headache"
      ],
      "serious": [
        "Urinary Retention (in obstruction)",
        "Angioedema",
        "Atrial Fibrillation"
      ]
    },
    "precautions": [
      "**Hypertension:** Can increase BP. Monitor periodically. Avoid in severe uncontrolled HTN.",
      "**Retention:** Caution in bladder outlet obstruction.",
      "**CYP2D6:** Moderate inhibitor (increases Metoprolol/Digoxin)."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["CYP2D6 Substrates (Metoprolol/Desipramine - Increased levels)", "Digoxin"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "mitoxantrone": {
    "name": "Mitoxantrone",
    "genericName": "Mitoxantrone HCl",
    "formula": "C22H28N4O6",
    "molecularWeight": "444.5 g/mol",
    "brandNames": ["Novantrone"],
    "category": "Antineoplastic",
    "drugClass": "Anthracenedione (Topoisomerase II Inhibitor)",
    "pubchemCID": "4212",
    "indications": "Acute Myeloid Leukemia (AML), Prostate Cancer, Multiple Sclerosis (Secondary Progressive).",
    "moaSteps": [
      "Intercalates into DNA.",
      "Inhibits Topoisomerase II, causing DNA strand breaks.",
      "Immunosuppressive (suppresses T/B cells/Macrophages).",
      "Less cardiotoxic than Doxorubicin, but risk exists."
    ],
    "pharmacokinetics": {
      "absorption": "IV only.",
      "distribution": "Deep tissue compartment.",
      "metabolism": "Hepatic.",
      "excretion": "Bile/Urine. **Half-life: 75 hours (Terminal); 5-18 days (Tissue).**"
    },
    "dose": {
      "initialDose": "12 mg/m2 IV (Cancer); 140 mg/m2 Lifetime Limit (MS)",
      "maxDose": "Lifetime cumulative limit strict",
      "notes": "Blue-green urine."
    },
    "adverseEffects": {
      "common": [
        "Blue-green urine/sclera",
        "Nausea / Vomiting",
        "Alopecia",
        "Amenorrhea"
      ],
      "serious": [
        "Cardiotoxicity (CHF) - BOXED WARNING",
        "Myelosuppression - BOXED WARNING",
        "Secondary Leukemia (AML) - BOXED WARNING"
      ]
    },
    "precautions": [
      "**Cardiac:** Irreversible CHF. LVEF monitoring mandatory. Lifetime cumulative dose limits apply.",
      "**Secondary AML:** Risk of therapy-related leukemia.",
      "**Extravasation:** Vesicant."
    ],
    "contraindications": [
      "LVEF < 50%",
      "Prior anthracycline exposure reaching cumulative limit"
    ],
    "interactions": {
      "drug": ["Live Vaccines"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "mometasone": {
    "name": "Mometasone (Nasonex, Elocon)",
    "genericName": "Mometasone Furoate",
    "formula": "C27H30Cl2O6",
    "molecularWeight": "521.4 g/mol",
    "brandNames": ["Nasonex", "Asmanex", "Elocon"],
    "category": "Corticosteroid",
    "drugClass": "Glucocorticoid",
    "pubchemCID": "441336",
    "indications": "Allergic Rhinitis (Nasal), Asthma (Inhaled), Dermatoses (Topical).",
    "moaSteps": [
      "Potent corticosteroid with high affinity for glucocorticoid receptor.",
      "Anti-inflammatory, antipruritic, and vasoconstrictive properties.",
      "Very low systemic bioavailability (<1%)."
    ],
    "pharmacokinetics": {
      "absorption": "Negligible systemic absorption.",
      "distribution": "Local.",
      "metabolism": "Hepatic (CYP3A4) if swallowed.",
      "excretion": "Feces. **Half-life: 5 hours (IV).**"
    },
    "dose": {
      "initialDose": "2 sprays/nostril daily",
      "maxDose": "Varies",
      "notes": "Topical: Once daily."
    },
    "adverseEffects": {
      "common": [
        "Epistaxis (Nasal)",
        "Headache",
        "Viral infection",
        "Burning (Topical)"
      ],
      "serious": [
        "Nasal Septal Perforation",
        "Glaucoma / Cataracts",
        "Adrenal Suppression (rare)"
      ]
    },
    "precautions": [
      "**Nasal:** Direct spray away from septum to avoid perforation.",
      "**Infection:** Avoid exposure to chickenpox/measles.",
      "**Growth:** Monitor pediatric growth."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inhibitors (Ketoconazole - Potential systemic increase)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "nabumetone": {
    "name": "Nabumetone (Relafen)",
    "genericName": "Nabumetone",
    "formula": "C15H16O2",
    "molecularWeight": "228.3 g/mol",
    "brandNames": ["Relafen"],
    "category": "NSAID",
    "drugClass": "Naphthylalkanone (Prodrug)",
    "pubchemCID": "4409",
    "indications": "Osteoarthritis, Rheumatoid Arthritis.",
    "moaSteps": [
      "Non-acidic prodrug.",
      "Metabolized in liver to active metabolite (6-MNA).",
      "6-MNA inhibits COX-1 and COX-2 enzymes.",
      "Prodrug nature leads to less direct gastric irritation than other NSAIDs."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic (Active metabolite).",
      "excretion": "Urine. **Half-life: 24 hours (Active Metabolite).**"
    },
    "dose": {
      "initialDose": "1000 mg PO once daily",
      "maxDose": "2000 mg/day",
      "notes": "Take with food."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea",
        "Dyspepsia",
        "Abdominal pain",
        "Edema"
      ],
      "serious": [
        "GI Bleeding / Ulceration - BOXED WARNING",
        "CV Thrombosis - BOXED WARNING",
        "Renal Failure",
        "SJS / TEN"
      ]
    },
    "precautions": [
      "**GI:** Lower risk of ulcers than other NSAIDs, but risk remains.",
      "**Renal:** Avoid in advanced renal disease.",
      "**CV:** Avoid in heart failure/CAD."
    ],
    "contraindications": [
      "CABG peri-operative pain",
      "Aspirin allergy"
    ],
    "interactions": {
      "drug": ["Warfarin", "ACE Inhibitors", "Lithium"],
      "food": ["Increases absorption rate."]
    },
    "pregnancyCategory": "Category C (D > 30 weeks)"
  },
  "nadolol": {
    "name": "Nadolol (Corgard)",
    "genericName": "Nadolol",
    "formula": "C17H27NO4",
    "molecularWeight": "309.4 g/mol",
    "brandNames": ["Corgard"],
    "category": "Antihypertensive",
    "drugClass": "Non-selective Beta Blocker",
    "pubchemCID": "4413",
    "indications": "Hypertension, Angina, Migraine prophylaxis, Esophageal Varices (Portal HTN).",
    "moaSteps": [
      "Non-selective beta-1 and beta-2 antagonist.",
      "Reduces heart rate and cardiac output.",
      "Causes splanchnic vasoconstriction (beta-2 blockade), reducing portal pressure (Varices).",
      "Low lipid solubility (less CNS effects)."
    ],
    "pharmacokinetics": {
      "absorption": "30% bioavailable.",
      "distribution": "Hydrophilic (Low CNS entry).",
      "metabolism": "None.",
      "excretion": "Urine (Unchanged). **Half-life: 20 to 24 hours.**"
    },
    "dose": {
      "initialDose": "40 mg PO daily",
      "maxDose": "320 mg/day",
      "notes": "Renal adjustment needed."
    },
    "adverseEffects": {
      "common": [
        "Bradycardia",
        "Fatigue",
        "Cold extremities",
        "Dizziness"
      ],
      "serious": [
        "Bronchospasm",
        "Heart Block",
        "Masking Hypoglycemia",
        "Heart Failure"
      ]
    },
    "precautions": [
      "**Renal:** Accumulates in renal failure (long half-life). Dose interval adjustment required.",
      "**Asthma:** Contraindicated due to beta-2 blockade.",
      "**Withdrawal:** Taper."
    ],
    "contraindications": [
      "Asthma / COPD",
      "Sinus bradycardia / Heart Block"
    ],
    "interactions": {
      "drug": ["Calcium Channel Blockers", "Insulin", "NSAIDS (Reduce efficacy)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "nafcillin": {
    "name": "Nafcillin",
    "genericName": "Nafcillin Sodium",
    "formula": "C21H22N2O5S",
    "molecularWeight": "414.5 g/mol",
    "brandNames": ["Nallpen"],
    "category": "Antibiotic",
    "drugClass": "Penicillinase-Resistant Penicillin",
    "pubchemCID": "4415",
    "indications": "Staphylococcal infections (MSSA) - Bacteremia, Endocarditis, Osteomyelitis.",
    "moaSteps": [
      "Binds to PBPs.",
      "Inhibits cell wall synthesis.",
      "Resistant to staphylococcal penicillinase (beta-lactamase).",
      "Drug of choice for MSSA (better than Vancomycin)."
    ],
    "pharmacokinetics": {
      "absorption": "IV/IM.",
      "distribution": "Good (except CSF/Eye).",
      "metabolism": "Hepatic.",
      "excretion": "Bile (Primary). **Half-life: 0.5 to 1 hour.**"
    },
    "dose": {
      "initialDose": "1-2 g IV q4h",
      "maxDose": "12 g/day",
      "notes": "Vesicant."
    },
    "adverseEffects": {
      "common": [
        "Phlebitis (Severe)",
        "Rash",
        "Nausea"
      ],
      "serious": [
        "Neutropenia (High dose/Long term)",
        "Interstitial Nephritis",
        "Anaphylaxis",
        "Extravasation Necrosis"
      ]
    },
    "precautions": [
      "**Phlebitis:** Very irritating to veins. Central line preferred.",
      "**Neutropenia:** Monitor CBC weekly.",
      "**Hepatic:** No renal adjustment needed (Biliary excretion)."
    ],
    "contraindications": [
      "Hypersensitivity to penicillins"
    ],
    "interactions": {
      "drug": ["Warfarin (Reduces effect - Enzyme inducer)", "Cyclosporine (Reduces levels)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "nalbuphine": {
    "name": "Nalbuphine (Nubain)",
    "genericName": "Nalbuphine HCl",
    "formula": "C21H27NO4",
    "molecularWeight": "357.4 g/mol",
    "brandNames": ["Nubain"],
    "category": "Opioid Analgesic",
    "drugClass": "Mixed Agonist-Antagonist",
    "pubchemCID": "5311304",
    "indications": "Moderate to Severe Pain, Labor Pain, Opioid-induced Pruritus.",
    "moaSteps": [
      "Kappa-opioid receptor Agonist (Analgesia/Sedation).",
      "Mu-opioid receptor Antagonist (Respiratory depression ceiling/Withdrawal).",
      "Less respiratory depression than pure agonists."
    ],
    "pharmacokinetics": {
      "absorption": "IV/IM/SC.",
      "distribution": "Crosses placenta.",
      "metabolism": "Hepatic.",
      "excretion": "Feces. **Half-life: 5 hours.**"
    },
    "dose": {
      "initialDose": "10 mg IV/IM/SC q3-6h",
      "maxDose": "160 mg/day",
      "notes": "Ceiling effect on respiratory depression."
    },
    "adverseEffects": {
      "common": [
        "Sedation",
        "Sweating",
        "Nausea",
        "Dizziness"
      ],
      "serious": [
        "Precipitated Withdrawal (in opioid-dependent patients)",
        "Psychomimetic effects (Dysphoria - Kappa effect)",
        "Respiratory Depression (Ceiling)"
      ]
    },
    "precautions": [
      "**Dependence:** Will precipitate withdrawal in patients physically dependent on mu-agonists (Morphine/Fentanyl).",
      "**Labor:** Can cause fetal bradycardia/respiratory depression."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Mu-Opioids (Antagonizes analgesia)", "CNS Depressants"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B (D in labor/prolonged use)"
  },
  "naloxegol": {
    "name": "Naloxegol (Movantik)",
    "genericName": "Naloxegol Oxalate",
    "formula": "C34H53NO11",
    "molecularWeight": "651.8 g/mol",
    "brandNames": ["Movantik"],
    "category": "GI Agent",
    "drugClass": "Peripheral Opioid Antagonist (PAMORA)",
    "pubchemCID": "24866678",
    "indications": "Opioid-Induced Constipation (OIC) in chronic pain.",
    "moaSteps": [
      "PEGylated derivative of Naloxone.",
      "Peripherally acting mu-opioid receptor antagonist.",
      "PEG chain prevents crossing the Blood-Brain Barrier.",
      "Reverses opioid constipation without reversing central analgesia."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid. Take on empty stomach.",
      "distribution": "Limited CNS entry.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Feces. **Half-life: 6 to 11 hours.**"
    },
    "dose": {
      "initialDose": "25 mg PO once daily",
      "maxDose": "25 mg/day",
      "notes": "Stop laxatives before starting."
    },
    "adverseEffects": {
      "common": [
        "Abdominal pain",
        "Diarrhea",
        "Nausea",
        "Flatulence"
      ],
      "serious": [
        "Opioid Withdrawal (Rare, if BBB crossed)",
        "GI Perforation",
        "Severe abdominal cramping"
      ]
    },
    "precautions": [
      "**GI Obstruction:** Contraindicated in known/suspected obstruction (Perforation risk).",
      "**BBB:** Disruption of BBB may allow CNS entry -> Withdrawal/Pain return.",
      "**Interactions:** CYP3A4 inhibitors increase risk of CNS entry."
    ],
    "contraindications": [
      "GI Obstruction",
      "Concomitant strong CYP3A4 inhibitors"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inhibitors (Contraindicated)", "Opioid Antagonists (Additive)"],
      "food": ["Food increases absorption too much. Take on empty stomach."]
    },
    "pregnancyCategory": "Category C"
  },
  "natalizumab": {
    "name": "Natalizumab (Tysabri)",
    "genericName": "Natalizumab",
    "formula": "Humanized monoclonal antibody",
    "molecularWeight": "149 kDa",
    "brandNames": ["Tysabri"],
    "category": "Multiple Sclerosis Agent",
    "drugClass": "Integrin Receptor Antagonist",
    "pubchemCID": "None (Protein)",
    "indications": "Relapsing Multiple Sclerosis (MS), Crohn's Disease.",
    "moaSteps": [
      "Binds to alpha-4-beta-1 integrin (VLA-4) on leukocytes.",
      "Prevents adhesion to VCAM-1 on endothelial cells.",
      "Blocks leukocytes from crossing the Blood-Brain Barrier and gut mucosa.",
      "Reduces inflammation in CNS/Gut."
    ],
    "pharmacokinetics": {
      "absorption": "IV administration.",
      "distribution": "Vascular.",
      "metabolism": "Catabolism.",
      "excretion": "Slow. **Half-life: 11 days.**"
    },
    "dose": {
      "initialDose": "300 mg IV every 4 weeks",
      "maxDose": "300 mg/month",
      "notes": "REMS (TOUCH) program mandatory."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Fatigue",
        "Infusion reactions",
        "Arthralgia"
      ],
      "serious": [
        "PML (Progressive Multifocal Leukoencephalopathy) - BOXED WARNING",
        "Herpes Encephalitis / Meningitis",
        "Hepatotoxicity",
        "Hypersensitivity"
      ]
    },
    "precautions": [
      "**PML:** Fatal brain infection by JC Virus. Risk factors: JCV antibody positive, prior immunosuppressants, duration > 2 years. MRI monitoring required.",
      "**Immunosuppression:** Do not combine with other immunosuppressants."
    ],
    "contraindications": [
      "History of PML",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Immunosuppressants (Increase PML risk)", "Live Vaccines"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "nateglinide": {
    "name": "Nateglinide (Starlix)",
    "genericName": "Nateglinide",
    "formula": "C19H27NO3",
    "molecularWeight": "317.4 g/mol",
    "brandNames": ["Starlix"],
    "category": "Antidiabetic",
    "drugClass": "Meglitinide (D-phenylalanine derivative)",
    "pubchemCID": "5282456",
    "indications": "Type 2 Diabetes Mellitus.",
    "moaSteps": [
      "Blocks ATP-dependent potassium channels on pancreatic beta cells.",
      "Depolarizes membrane, opening calcium channels.",
      "Stimulates rapid, short-acting insulin release.",
      "Targets post-prandial hyperglycemia."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "98% protein bound.",
      "metabolism": "Hepatic (CYP2C9/3A4).",
      "excretion": "Urine/Feces. **Half-life: 1.5 hours.**"
    },
    "dose": {
      "initialDose": "120 mg PO TID before meals",
      "maxDose": "360 mg/day",
      "notes": "Skip dose if meal skipped."
    },
    "adverseEffects": {
      "common": [
        "Hypoglycemia",
        "Weight gain",
        "URI"
      ],
      "serious": [
        "Severe Hypoglycemia"
      ]
    },
    "precautions": [
      "**Hypoglycemia:** Risk lower than sulfonylureas due to short half-life, but possible.",
      "**Liver:** Use caution in moderate/severe hepatic impairment.",
      "**Renal:** Safe, but active metabolite accumulates slightly."
    ],
    "contraindications": [
      "Type 1 Diabetes",
      "DKA"
    ],
    "interactions": {
      "drug": ["CYP2C9 Inhibitors (Fluconazole - Hypoglycemia)", "Beta-blockers"],
      "food": ["Take 1-30 mins before meal."]
    },
    "pregnancyCategory": "Category C"
  },
  "neomycin": {
    "name": "Neomycin",
    "genericName": "Neomycin Sulfate",
    "formula": "C23H46N6O13",
    "molecularWeight": "614.6 g/mol",
    "brandNames": ["Neo-Fradin"],
    "category": "Antibiotic",
    "drugClass": "Aminoglycoside",
    "pubchemCID": "8378",
    "indications": "Hepatic Encephalopathy, Pre-op Bowel Prep, Topical infections.",
    "moaSteps": [
      "Binds to 30S ribosome.",
      "Inhibits bacterial protein synthesis.",
      "Oral form acts locally in gut to reduce ammonia-producing bacteria.",
      "Bactericidal."
    ],
    "pharmacokinetics": {
      "absorption": "Poor oral (<3%).",
      "distribution": "Local.",
      "metabolism": "None.",
      "excretion": "Feces. **Half-life: 2 to 3 hours (Systemic if absorbed).**"
    },
    "dose": {
      "initialDose": "1 g PO q6h (Hepatic Coma)",
      "maxDose": "12 g/day",
      "notes": "Systemic toxicity possible even with oral dosing in renal failure/inflamed gut."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea",
        "Nausea",
        "Malabsorption (Vitamins)"
      ],
      "serious": [
        "Ototoxicity / Nephrotoxicity (Systemic absorption) - BOXED WARNING",
        "Neuromuscular Blockade"
      ]
    },
    "precautions": [
      "**Absorption:** In ulcerative colitis or renal failure, significant absorption occurs leading to deafness/renal failure.",
      "**Neuromuscular:** Can potentiate blockade.",
      "**Superinfection:** C. diff risk."
    ],
    "contraindications": [
      "Intestinal obstruction",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Loop Diuretics (Ototoxicity)", "Warfarin (Increased INR due to Vitamin K reduction)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "neostigmine": {
    "name": "Neostigmine (Bloxiverz)",
    "genericName": "Neostigmine Methylsulfate",
    "formula": "C12H19N2O2",
    "molecularWeight": "223.29 g/mol",
    "brandNames": ["Bloxiverz", "Prostigmin"],
    "category": "Reversal Agent / Cholinergic",
    "drugClass": "Acetylcholinesterase Inhibitor",
    "pubchemCID": "4456",
    "indications": "Reversal of Nondepolarizing Neuromuscular Blockade, Myasthenia Gravis, Ileus/Urinary Retention.",
    "moaSteps": [
      "Inhibits acetylcholinesterase.",
      "Prevents breakdown of acetylcholine.",
      "Increases ACh concentration at neuromuscular junction.",
      "Overcomes competitive blockade of nondepolarizing relaxants."
    ],
    "pharmacokinetics": {
      "absorption": "Poor oral. IV used.",
      "distribution": "Extracellular.",
      "metabolism": "Plasma esterases/Hepatic.",
      "excretion": "Urine. **Half-life: 50 to 90 minutes.**"
    },
    "dose": {
      "initialDose": "0.03-0.07 mg/kg IV (Reversal)",
      "maxDose": "5 mg (Total)",
      "notes": "Must administer with Glycopyrrolate or Atropine to prevent bradycardia."
    },
    "adverseEffects": {
      "common": [
        "Salivation",
        "Bradycardia",
        "Nausea / Cramping"
      ],
      "serious": [
        "Severe Bradycardia / Asystole",
        "Bronchospasm",
        "Cholinergic Crisis",
        "Seizures"
      ]
    },
    "precautions": [
      "**Bradycardia:** Muscarinic effects can be fatal. Always co-administer anticholinergic.",
      "**Asthma:** Can precipitate bronchoconstriction.",
      "**Obstruction:** Contraindicated in mechanical GI/GU obstruction."
    ],
    "contraindications": [
      "Mechanical GI/GU obstruction",
      "Peritonitis",
      "Hypersensitivity to bromides"
    ],
    "interactions": {
      "drug": ["Succinylcholine (Prolongs phase 1 block)", "Beta-blockers (Bradycardia)", "Corticosteroids (Weakness in MG)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "nevirapine": {
    "name": "Nevirapine (Viramune)",
    "genericName": "Nevirapine",
    "formula": "C15H14N4O",
    "molecularWeight": "266.3 g/mol",
    "brandNames": ["Viramune", "Viramune XR"],
    "category": "Antiretroviral",
    "drugClass": "NNRTI",
    "pubchemCID": "4463",
    "indications": "HIV-1 Infection.",
    "moaSteps": [
      "Binds directly to HIV-1 reverse transcriptase (hydrophobic pocket).",
      "Induces conformational change.",
      "Disrupts catalytic site.",
      "Non-competitive inhibition."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (>90% bioavailable).",
      "distribution": "Lipophilic (Crosses placenta/breast milk).",
      "metabolism": "Hepatic (CYP3A4/2B6). Autoinducer.",
      "excretion": "Urine. **Half-life: 45 hours (Single dose); 25 hours (Chronic).**"
    },
    "dose": {
      "initialDose": "200 mg PO daily x 14 days (Lead-in)",
      "maxDose": "200 mg BID or 400 mg XR Daily",
      "notes": "Lead-in period mandatory to induce enzymes and reduce rash risk."
    },
    "adverseEffects": {
      "common": [
        "Rash",
        "Nausea",
        "Fatigue"
      ],
      "serious": [
        "Severe Hepatotoxicity (Fatal) - BOXED WARNING",
        "Stevens-Johnson Syndrome / TEN - BOXED WARNING",
        "Hypersensitivity Reaction"
      ]
    },
    "precautions": [
      "**Hepatotoxicity:** High risk in women with CD4 > 250 and men > 400. Do not initiate in these groups. Monitor LFTs intensely.",
      "**Rash:** Stop if severe rash occurs. Do not escalate dose.",
      "**Lead-in:** Essential to prevent toxicity."
    ],
    "contraindications": [
      "Moderate/Severe hepatic impairment",
      "Occupational Post-Exposure Prophylaxis (PEP) - due to toxicity risk"
    ],
    "interactions": {
      "drug": ["Rifampin (Lowers levels)", "Oral Contraceptives (Failure)", "Warfarin"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "niacin": {
    "name": "Niacin (Niaspan)",
    "genericName": "Niacin (Vitamin B3/Nicotinic Acid)",
    "formula": "C6H5NO2",
    "molecularWeight": "123.11 g/mol",
    "brandNames": ["Niaspan", "Slo-Niacin"],
    "category": "Antilipemic",
    "drugClass": "Nicotinic Acid",
    "pubchemCID": "938",
    "indications": "Dyslipidemia (High TG, Low HDL).",
    "moaSteps": [
      "Inhibits lipolysis in adipose tissue.",
      "Decreases hepatic production of VLDL and LDL.",
      "Increases lipoprotein lipase activity.",
      "Most effective agent for raising HDL."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Wide.",
      "metabolism": "Hepatic (Conjugative pathway saturable -> Toxicity).",
      "excretion": "Urine. **Half-life: 45 minutes.**"
    },
    "dose": {
      "initialDose": "500 mg ER PO at bedtime",
      "maxDose": "2000 mg/day",
      "notes": "Aspirin 30 min prior reduces flushing."
    },
    "adverseEffects": {
      "common": [
        "Flushing (Prostaglandin mediated)",
        "Pruritus",
        "GI upset"
      ],
      "serious": [
        "Hepatotoxicity (Severe with Sustained Release OTC)",
        "Hyperglycemia / Diabetes",
        "Hyperuricemia / Gout",
        "Myopathy (with statins)"
      ]
    },
    "precautions": [
      "**Flushing:** Very common. Tolerance develops. Do not take with hot fluids/alcohol.",
      "**Diabetes:** Worsens glycemic control.",
      "**Hepatotoxicity:** Risk highest with slow-release/sustained release OTC forms. Niaspan (ER) is safer.",
      "**Gout:** Increases uric acid."
    ],
    "contraindications": [
      "Active liver disease",
      "Active peptic ulcer",
      "Arterial bleeding"
    ],
    "interactions": {
      "drug": ["Statins (Myopathy)", "Antidiabetics (Hyperglycemia)", "Anti-gout agents"],
      "food": ["Alcohol/Hot drinks worsen flushing."]
    },
    "pregnancyCategory": "Category C"
  },
  "nicardipine": {
    "name": "Nicardipine (Cardene)",
    "genericName": "Nicardipine HCl",
    "formula": "C26H29N3O6",
    "molecularWeight": "479.5 g/mol",
    "brandNames": ["Cardene", "Cardene IV"],
    "category": "Antihypertensive",
    "drugClass": "Calcium Channel Blocker (Dihydropyridine)",
    "pubchemCID": "4474",
    "indications": "Hypertensive Emergency/Urgency, Chronic Stable Angina.",
    "moaSteps": [
      "Inhibits calcium ion influx in vascular smooth muscle.",
      "More selective for vascular smooth muscle than myocardium.",
      "Potent vasodilator (coronary and peripheral).",
      "Little effect on cardiac conduction."
    ],
    "pharmacokinetics": {
      "absorption": "Complete (35% bioavailable).",
      "distribution": "95% protein bound.",
      "metabolism": "Extensive Hepatic (CYP3A4).",
      "excretion": "Urine. **Half-life: 2 to 4 hours (short - good for titration); 8.6 hours (Oral).**"
    },
    "dose": {
      "initialDose": "5 mg/hr IV infusion",
      "maxDose": "15 mg/hr",
      "notes": "Titrate every 5-15 min."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Flushing",
        "Peripheral edema",
        "Hypotension"
      ],
      "serious": [
        "Reflex Tachycardia",
        "Angina exacerbation",
        "Heart Failure (rare)"
      ]
    },
    "precautions": [
      "**Ischemia:** Reflex tachycardia can worsen angina.",
      "**Heart Failure:** Use with caution (negative inotropy is minimal but present).",
      "**Infusion Site:** Irritating; change site q12h or use central line."
    ],
    "contraindications": [
      "Advanced Aortic Stenosis",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Cyclosporine (Increases levels)", "Beta-blockers (Additive)", "CYP3A4 Inhibitors"],
      "food": ["High fat meal affects absorption."]
    },
    "pregnancyCategory": "Category C"
  },
  "nimodipine": {
    "name": "Nimodipine (Nymalize)",
    "genericName": "Nimodipine",
    "formula": "C21H26N2O7",
    "molecularWeight": "418.4 g/mol",
    "brandNames": ["Nymalize", "Nimotop"],
    "category": "Neuroprotective / CCB",
    "drugClass": "Calcium Channel Blocker (Dihydropyridine)",
    "pubchemCID": "4497",
    "indications": "Subarachnoid Hemorrhage (SAH) - prevention of vasospasm.",
    "moaSteps": [
      "Lipophilic CCB causing cerebral arterial dilation.",
      "Blocks calcium influx in cerebral vessels.",
      "Prevents delayed ischemic deficits due to vasospasm after SAH.",
      "Improves neurological outcomes."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Crosses BBB effectively.",
      "metabolism": "Extensive Hepatic (CYP3A4).",
      "excretion": "Urine. **Half-life: 1 to 2 hours (Short).**"
    },
    "dose": {
      "initialDose": "60 mg PO/NG every 4 hours for 21 days",
      "maxDose": "360 mg/day",
      "notes": "Start within 96 hours of SAH."
    },
    "adverseEffects": {
      "common": [
        "Hypotension (Systemic)",
        "Headache",
        "Bradycardia",
        "Nausea"
      ],
      "serious": [
        "Heart Failure",
        "Ileus",
        "Death (if given IV)"
      ]
    },
    "precautions": [
      "**Administration:** BOXED WARNING - DO NOT ADMINISTER IV. Fatal cardiovascular collapse. Extract from capsule with syringe for NG tube but label 'For Oral Use Only'.",
      "**Hypotension:** Monitor BP closely.",
      "**Liver:** Dose reduce to 30mg in cirrhosis."
    ],
    "contraindications": [
      "IV Administration (Fatal)",
      "Concurrent strong CYP3A4 inhibitors"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inhibitors (Contraindicated)", "Antihypertensives"],
      "food": ["Grapefruit juice (Avoid)"]
    },
    "pregnancyCategory": "Category C"
  },
  "nintedanib": {
    "name": "Nintedanib (Ofev)",
    "genericName": "Nintedanib Esylate",
    "formula": "C31H33N5O4",
    "molecularWeight": "539.6 g/mol",
    "brandNames": ["Ofev"],
    "category": "Antifibrotic",
    "drugClass": "Tyrosine Kinase Inhibitor",
    "pubchemCID": "135423438",
    "indications": "Idiopathic Pulmonary Fibrosis (IPF), SSc-ILD, Chronic Fibrosing ILDs.",
    "moaSteps": [
      "Triple Angiokinase Inhibitor.",
      "Inhibits FGFR, PDGFR, and VEGFR tyrosine kinases.",
      "Blocks signaling pathways involved in fibroblast proliferation, migration, and differentiation.",
      "Slows decline in lung function."
    ],
    "pharmacokinetics": {
      "absorption": "47% bioavailable. Food increases exposure.",
      "distribution": "97% protein bound.",
      "metabolism": "Hydrolysis/Glucuronidation (Not CYP).",
      "excretion": "Feces. **Half-life: 9.5 hours.**"
    },
    "dose": {
      "initialDose": "150 mg PO BID",
      "maxDose": "300 mg/day",
      "notes": "Take with food."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea (Very common)",
        "Nausea / Vomiting",
        "Abdominal pain",
        "Weight loss"
      ],
      "serious": [
        "Liver Enzyme Elevation / Drug-Induced Liver Injury",
        "GI Perforation",
        "Bleeding events",
        "Arterial Thromboembolism (MI)"
      ]
    },
    "precautions": [
      "**Liver:** Monitor LFTs regularly. Dose reduce or stop if elevated.",
      "**Diarrhea:** Hydration and anti-diarrheals often needed.",
      "**Bleeding/Clotting:** VEGFR inhibition affects vascular integrity.",
      "**Surgery:** Stop for wound healing."
    ],
    "contraindications": [
      "Severe hepatic impairment"
    ],
    "interactions": {
      "drug": ["P-gp Inhibitors (Increase levels)", "P-gp Inducers (Decrease levels)", "Anticoagulants (Bleeding)"],
      "food": ["Take with food."]
    },
    "pregnancyCategory": "Category D"
  },
  "nitazoxanide": {
    "name": "Nitazoxanide (Alinia)",
    "genericName": "Nitazoxanide",
    "formula": "C12H9N3O5S",
    "molecularWeight": "307.3 g/mol",
    "brandNames": ["Alinia"],
    "category": "Antiprotozoal",
    "drugClass": "Thiazolide",
    "pubchemCID": "41684",
    "indications": "Diarrhea caused by Giardia or Cryptosporidium.",
    "moaSteps": [
      "Interferes with the Pyruvate:Ferredoxin Oxidoreductase (PFOR) enzyme-dependent electron transfer reaction.",
      "Essential for anaerobic energy metabolism in protozoa and bacteria.",
      "Inhibits growth."
    ],
    "pharmacokinetics": {
      "absorption": "Rapidly hydrolyzed to active metabolite Tizoxanide.",
      "distribution": "99% protein bound.",
      "metabolism": "Glucuronidation.",
      "excretion": "Bile/Urine. **Half-life: 1 to 1.6 hours (Tizoxanide).**"
    },
    "dose": {
      "initialDose": "500 mg PO BID x 3 days",
      "maxDose": "1000 mg/day",
      "notes": "Take with food."
    },
    "adverseEffects": {
      "common": [
        "Abdominal pain",
        "Headache",
        "Greenish urine",
        "Nausea"
      ],
      "serious": [
        "Hypersensitivity"
      ]
    },
    "precautions": [
      "**Diabetes:** Suspension contains high sugar.",
      "**Effectiveness:** May not be effective in HIV patients with Cryptosporidiosis."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Warfarin (High protein binding - displacement potential)"],
      "food": ["Take with food."]
    },
    "pregnancyCategory": "Category B"
  },
  "nivolumab": {
    "name": "Nivolumab (Opdivo)",
    "genericName": "Nivolumab",
    "formula": "Human IgG4 monoclonal antibody",
    "molecularWeight": "146 kDa",
    "brandNames": ["Opdivo"],
    "category": "Antineoplastic",
    "drugClass": "PD-1 Inhibitor (Immune Checkpoint Inhibitor)",
    "pubchemCID": "None (Protein)",
    "indications": "Melanoma, NSCLC, RCC, Hodgkin Lymphoma, Head/Neck Cancer, Urothelial Cancer.",
    "moaSteps": [
      "Binds to the Programmed Death-1 (PD-1) receptor on T-cells.",
      "Blocks interaction with PD-L1 and PD-L2 ligands on tumor cells.",
      "Reverses T-cell suppression and induces anti-tumor immune response.",
      "Immune-mediated tumor killing."
    ],
    "pharmacokinetics": {
      "absorption": "IV administration.",
      "distribution": "Vascular.",
      "metabolism": "Catabolism.",
      "excretion": "Slow. **Half-life: 25 days.**"
    },
    "dose": {
      "initialDose": "240 mg IV every 2 weeks OR 480 mg every 4 weeks",
      "maxDose": "Fixed dose",
      "notes": "Monitor for irAEs."
    },
    "adverseEffects": {
      "common": [
        "Fatigue",
        "Rash / Pruritus",
        "Diarrhea",
        "Musculoskeletal pain"
      ],
      "serious": [
        "Immune-Mediated Pneumonitis (Fatal)",
        "Immune-Mediated Colitis / Hepatitis / Nephritis",
        "Endocrinopathies (Thyroid/ adrenal/ pituitary)",
        "Type 1 Diabetes",
        "Encephalitis"
      ]
    },
    "precautions": [
      "**irAEs:** Immune-related Adverse Events can affect any organ. Early recognition and steroid treatment (Prednisone 1-2mg/kg) are critical.",
      "**Transplant:** Can cause rejection of solid organ transplants.",
      "**Infusion:** Reaction possible."
    ],
    "contraindications": [
      "None (Hypersensitivity)"
    ],
    "interactions": {
      "drug": ["Immunosuppressants (Interfere with efficacy - avoid baseline steroids)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "norethindrone": {
    "name": "Norethindrone (Aygestin)",
    "genericName": "Norethindrone Acetate",
    "formula": "C22H28O3",
    "molecularWeight": "340.5 g/mol",
    "brandNames": ["Aygestin", "Camila (POP)"],
    "category": "Hormone",
    "drugClass": "Progestin",
    "pubchemCID": "6133",
    "indications": "Endometriosis, Abnormal Uterine Bleeding, Contraception (Progestin-only pill), Secondary Amenorrhea.",
    "moaSteps": [
      "Synthetic progesterone.",
      "Transforms proliferative endometrium into secretory endometrium.",
      "Inhibits pituitary gonadotropins, preventing ovulation.",
      "Thickens cervical mucus (Contraception)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "SHBG bound.",
      "metabolism": "Hepatic.",
      "excretion": "Urine/Feces. **Half-life: 8 to 14 hours.**"
    },
    "dose": {
      "initialDose": "5 mg PO daily (Endometriosis)",
      "maxDose": "15 mg/day",
      "notes": "Contraceptive dose is much lower (0.35 mg)."
    },
    "adverseEffects": {
      "common": [
        "Breakthrough bleeding",
        "Amenorrhea",
        "Breast tenderness",
        "Edema"
      ],
      "serious": [
        "Thromboembolism",
        "Anaphylaxis",
        "Depression",
        "Vision loss (Retinal thrombosis)"
      ]
    },
    "precautions": [
      "**Thrombosis:** Stop if DVT/PE occurs. Caution in high risk.",
      "**Timing:** For contraception ('Mini-pill'), must be taken at exact same time daily. >3h delay requires backup.",
      "**Liver:** Avoid in liver dysfunction."
    ],
    "contraindications": [
      "Thromboembolic disorders",
      "Breast cancer",
      "Pregnancy (known)",
      "Liver impairment"
    ],
    "interactions": {
      "drug": ["Rifampin/Anticonvulsants (Reduce efficacy)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category X"
  },
  "ofloxacin": {
    "name": "Ofloxacin (Ocuflox)",
    "genericName": "Ofloxacin",
    "formula": "C18H20FN3O4",
    "molecularWeight": "361.4 g/mol",
    "brandNames": ["Floxin (Disc)", "Ocuflox (Eye)"],
    "category": "Antibiotic",
    "drugClass": "Fluoroquinolone",
    "pubchemCID": "4583",
    "indications": "Bacterial Conjunctivitis, Otitis Externa, PID, UTIs.",
    "moaSteps": [
      "Inhibits bacterial DNA gyrase and Topoisomerase IV.",
      "Inhibits DNA replication.",
      "Racemic mixture (Levofloxacin is the active L-isomer).",
      "Bactericidal."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed (Oral).",
      "distribution": "Wide.",
      "metabolism": "Minimal.",
      "excretion": "Urine. **Half-life: 4 to 5 hours (Oral); Eye/Ear topical systemic levels low.**"
    },
    "dose": {
      "initialDose": "400 mg PO BID",
      "maxDose": "800 mg/day",
      "notes": "Topical: 1-2 drops."
    },
    "adverseEffects": {
      "common": [
        "Nausea",
        "Insomnia",
        "Eye irritation (topical)"
      ],
      "serious": [
        "Tendinitis / Rupture (Systemic) - BOXED WARNING",
        "Peripheral Neuropathy - BOXED WARNING",
        "CNS Effects - BOXED WARNING",
        "QT Prolongation"
      ]
    },
    "precautions": [
      "**Systemic Risks:** Black Box Warnings apply to oral form. Topical is generally safe.",
      "**Photosensitivity:** Avoid sun.",
      "**Renal:** Adjust oral dose."
    ],
    "contraindications": [
      "Hypersensitivity to quinolones"
    ],
    "interactions": {
      "drug": ["Cations (Oral absorption block)", "Warfarin"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "olaparib": {
    "name": "Olaparib (Lynparza)",
    "genericName": "Olaparib",
    "formula": "C24H23F2N5O3",
    "molecularWeight": "434.5 g/mol",
    "brandNames": ["Lynparza"],
    "category": "Antineoplastic",
    "drugClass": "PARP Inhibitor",
    "pubchemCID": "23725621",
    "indications": "Ovarian Cancer (BRCA-mutated), Breast Cancer (BRCA+), Pancreatic Cancer, Prostate Cancer.",
    "moaSteps": [
      "Inhibits Poly (ADP-ribose) Polymerase (PARP) enzymes (PARP1/2/3).",
      "PARP enzymes repair single-strand DNA breaks.",
      "In BRCA-mutated cells (which lack homologous recombination repair for double-strand breaks), PARP inhibition leads to 'Synthetic Lethality'.",
      "Accumulation of DNA damage kills tumor cells."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "82% protein bound.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Urine/Feces. **Half-life: 11.9 hours.**"
    },
    "dose": {
      "initialDose": "300 mg PO BID (Tablets)",
      "maxDose": "600 mg/day",
      "notes": "Capsules and Tablets not interchangeable."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting",
        "Fatigue / Anemia",
        "Diarrhea",
        "Dysgeusia"
      ],
      "serious": [
        "Myelodysplastic Syndrome / AML (Secondary malignancy)",
        "Pneumonitis",
        "Severe Anemia (requiring transfusion)"
      ]
    },
    "precautions": [
      "**MDS/AML:** Rare but fatal long-term risk. Monitor CBC baseline and monthly.",
      "**Pneumonitis:** Stop if dyspnea/fever/cough occurs.",
      "**Renal:** Dose reduce if CrCl 31-50."
    ],
    "contraindications": [
      "None (Hypersensitivity)"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inhibitors (Avoid or reduce dose)", "Inducers (Avoid)"],
      "food": ["Grapefruit juice (Avoid)"]
    },
    "pregnancyCategory": "Category D"
  },
  "olopatadine": {
    "name": "Olopatadine (Patanol)",
    "genericName": "Olopatadine HCl",
    "formula": "C21H23NO3",
    "molecularWeight": "337.4 g/mol",
    "brandNames": ["Patanol", "Pataday", "Pazeo"],
    "category": "Ophthalmic Antihistamine",
    "drugClass": "H1 Antagonist / Mast Cell Stabilizer",
    "pubchemCID": "5282138",
    "indications": "Allergic Conjunctivitis.",
    "moaSteps": [
      "Selective H1 receptor antagonist.",
      "Inhibits histamine release from mast cells.",
      "Prevents ocular itching and redness.",
      "Dual mechanism acts quickly and provides long duration."
    ],
    "pharmacokinetics": {
      "absorption": "Minimal systemic absorption.",
      "distribution": "Local.",
      "metabolism": "Minimal.",
      "excretion": "Urine. **Half-life: 3 hours (Systemic).**"
    },
    "dose": {
      "initialDose": "1 drop in affected eye(s) daily or BID",
      "maxDose": "Varies by product concentration",
      "notes": "Pataday is once daily."
    },
    "adverseEffects": {
      "common": [
        "Eye burning / Stinging",
        "Headache",
        "Dry eye",
        "Bad taste (Nasolacrimal drainage)"
      ],
      "serious": [
        "Hypersensitivity"
      ]
    },
    "precautions": [
      "**Contacts:** Contains benzalkonium chloride; remove lenses before use, wait 10 mins.",
      "**Contamination:** Do not touch tip to eye."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["None"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "oxaliplatin": {
    "name": "Oxaliplatin (Eloxatin)",
    "genericName": "Oxaliplatin",
    "formula": "C8H14N2O4Pt",
    "molecularWeight": "397.3 g/mol",
    "brandNames": ["Eloxatin"],
    "category": "Antineoplastic",
    "drugClass": "Platinum Coordination Complex",
    "pubchemCID": "9887053",
    "indications": "Colorectal Cancer (Stage III adjuvant or Metastatic).",
    "moaSteps": [
      "Forms reactive platinum complexes.",
      "Creates intra-strand and inter-strand DNA cross-links.",
      "Inhibits DNA replication and transcription.",
      "Synergistic with 5-Fluorouracil (FOLFOX regimen)."
    ],
    "pharmacokinetics": {
      "absorption": "IV only.",
      "distribution": "High tissue binding/RBC binding.",
      "metabolism": "Non-enzymatic degradation.",
      "excretion": "Renal. **Half-life: 391 hours (Terminal - Platinum accumulation).**"
    },
    "dose": {
      "initialDose": "85 mg/m2 IV every 2 weeks",
      "maxDose": "Protocol dependent",
      "notes": "Pre-medicate with antiemetics."
    },
    "adverseEffects": {
      "common": [
        "Peripheral Neuropathy (Cold-induced)",
        "Nausea / Vomiting",
        "Fatigue",
        "Diarrhea"
      ],
      "serious": [
        "Anaphylaxis (Risk increases with cycles) - BOXED WARNING",
        "Acute Sensory Neuropathy (Laryngospasm - Cold triggered)",
        "Persistent Neuropathy",
        "Hepatotoxicity",
        "Pulmonary Fibrosis"
      ]
    },
    "precautions": [
      "**Cold Sensitivity:** Acute neuropathy is triggered by cold (drinks/air). Avoid cold exposure for days after infusion.",
      "**Neuropathy:** Cumulative dose-limiting toxicity. Can be permanent.",
      "**Hypersensitivity:** Watch for reaction after multiple cycles."
    ],
    "contraindications": [
      "Hypersensitivity to platinum",
      "Severe renal impairment (relative)"
    ],
    "interactions": {
      "drug": ["Nephrotoxins (Aminoglycosides)", "Warfarin (Increases INR)"],
      "food": ["Avoid cold drinks post-infusion."]
    },
    "pregnancyCategory": "Category D"
  },
  "oxcarbazepine": {
    "name": "Oxcarbazepine (Trileptal)",
    "genericName": "Oxcarbazepine",
    "formula": "C15H12N2O2",
    "molecularWeight": "252.3 g/mol",
    "brandNames": ["Trileptal", "Oxtellar XR"],
    "category": "Anticonvulsant",
    "drugClass": "Carboxamide",
    "pubchemCID": "34312",
    "indications": "Partial Seizures, Trigeminal Neuralgia (Off-label), Bipolar (Off-label).",
    "moaSteps": [
      "Keto-analog of Carbamazepine.",
      "Blocks voltage-sensitive sodium channels.",
      "Stabilizes hyperexcited neuronal membranes.",
      "Inhibits repetitive neuronal firing.",
      "Modulates Calcium channels."
    ],
    "pharmacokinetics": {
      "absorption": "Complete.",
      "distribution": "40% protein bound.",
      "metabolism": "Rapid hepatic reduction to active metabolite (MHD - 10-hydroxy metabolite).",
      "excretion": "Urine. **Half-life: 2 hours (Parent); 9 hours (MHD - Active).**"
    },
    "dose": {
      "initialDose": "300 mg PO BID",
      "maxDose": "2400 mg/day",
      "notes": "Titrate weekly."
    },
    "adverseEffects": {
      "common": [
        "Dizziness / Ataxia",
        "Diplopia",
        "Nausea",
        "Somnolence"
      ],
      "serious": [
        "Hyponatremia (More common than Carbamazepine)",
        "Severe Skin Reactions (SJS/TEN)",
        "Suicidality",
        "Pancytopenia"
      ]
    },
    "precautions": [
      "**Hyponatremia:** Clinically significant low sodium (<125) in 2.5% of patients. Monitor Na+.",
      "**Hypersensitivity:** 25-30% cross-reactivity with Carbamazepine.",
      "**HLA-B*1502:** Screen Asians for allele (SJS risk)."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Oral Contraceptives (Failure - CYP3A4 inducer)", "Phenytoin (Increases phenytoin levels)", "Diuretics (Hyponatremia)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "oxymetazoline": {
    "name": "Oxymetazoline (Afrin)",
    "genericName": "Oxymetazoline HCl",
    "formula": "C16H24N2O",
    "molecularWeight": "260.4 g/mol",
    "brandNames": ["Afrin", "Visine LR"],
    "category": "Decongestant / Vasoconstrictor",
    "drugClass": "Alpha-Adrenergic Agonist",
    "pubchemCID": "4636",
    "indications": "Nasal Congestion, Ocular Redness, Rosacea (Topical cream - Rhofade).",
    "moaSteps": [
      "Direct-acting alpha-1 and alpha-2A adrenergic agonist.",
      "Constricts arterioles in the nasal mucosa/conjunctiva.",
      "Reduces blood flow and edema.",
      "Relieves congestion."
    ],
    "pharmacokinetics": {
      "absorption": "Minimal systemic (unless overused/swallowed).",
      "distribution": "Local.",
      "metabolism": "Unknown.",
      "excretion": "Urine/Feces. **Half-life: 5 to 8 hours.**"
    },
    "dose": {
      "initialDose": "2-3 sprays per nostril BID",
      "maxDose": "2 doses/24h",
      "notes": "MAX DURATION 3 DAYS."
    },
    "adverseEffects": {
      "common": [
        "Burning / Stinging",
        "Dryness",
        "Sneezing"
      ],
      "serious": [
        "Rhinitis Medicamentosa (Rebound Congestion)",
        "Hypertension / Palpitations (Systemic absorption)",
        "CNS Depression (Children - if swallowed)"
      ]
    },
    "precautions": [
      "**Rebound:** Use > 3 days causes severe rebound congestion (addiction).",
      "**Children:** Swallow ingestion can cause coma/bradycardia/hypothermia in young kids.",
      "**Cardiac:** Caution in HTN/Hyperthyroidism."
    ],
    "contraindications": [
      "Use with MAOIs"
    ],
    "interactions": {
      "drug": ["MAOIs (Hypertensive crisis)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "palbociclib": {
    "name": "Palbociclib (Ibrance)",
    "genericName": "Palbociclib",
    "formula": "C24H29N7O2",
    "molecularWeight": "447.5 g/mol",
    "brandNames": ["Ibrance"],
    "category": "Antineoplastic",
    "drugClass": "CDK4/6 Inhibitor",
    "pubchemCID": "5330286",
    "indications": "HR+/HER2- Metastatic Breast Cancer (with hormonal therapy).",
    "moaSteps": [
      "Selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6).",
      "Blocks progression from G1 to S phase of cell cycle.",
      "Prevents DNA replication in tumor cells.",
      "Synergistic with anti-estrogens."
    ],
    "pharmacokinetics": {
      "absorption": "Moderate (Capsules with food; Tablets w/o).",
      "distribution": "85% protein bound.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Feces. **Half-life: 29 hours.**"
    },
    "dose": {
      "initialDose": "125 mg PO daily for 21 days, 7 days off",
      "maxDose": "125 mg/day",
      "notes": "Cycle is 28 days. Take with food (Capsules)."
    },
    "adverseEffects": {
      "common": [
        "Neutropenia (Very common)",
        "Infections",
        "Fatigue",
        "Nausea",
        "Alopecia"
      ],
      "serious": [
        "Severe Neutropenia / Febrile Neutropenia",
        "Interstitial Lung Disease / Pneumonitis",
        "Pulmonary Embolism"
      ]
    },
    "precautions": [
      "**Neutropenia:** Dose-limiting. Monitor CBC every 2 weeks for first 2 cycles. Hold dose for Grade 3/4.",
      "**Infection:** Monitor for signs of infection.",
      "**Lungs:** Monitor for respiratory symptoms."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inhibitors/Inducers (Avoid)"],
      "food": ["Grapefruit juice (Increases toxicity)"]
    },
    "pregnancyCategory": "Category D"
  },
  "palonosetron": {
    "name": "Palonosetron (Aloxi)",
    "genericName": "Palonosetron HCl",
    "formula": "C19H24N2O",
    "molecularWeight": "296.4 g/mol",
    "brandNames": ["Aloxi"],
    "category": "Antiemetic",
    "drugClass": "5-HT3 Receptor Antagonist",
    "pubchemCID": "6337615",
    "indications": "Chemotherapy-Induced Nausea/Vomiting (CINV - Acute/Delayed), PONV.",
    "moaSteps": [
      "Selective serotonin 5-HT3 receptor antagonist.",
      "Higher binding affinity than ondansetron.",
      "Long half-life allows for prevention of delayed emesis.",
      "Blocks serotonin both peripherally and centrally."
    ],
    "pharmacokinetics": {
      "absorption": "IV.",
      "distribution": "62% protein bound.",
      "metabolism": "Hepatic (CYP2D6/3A4/1A2).",
      "excretion": "Urine. **Half-life: 40 hours (Long acting).**"
    },
    "dose": {
      "initialDose": "0.25 mg IV single dose (Chemo)",
      "maxDose": "0.25 mg",
      "notes": "Give 30 min before chemo."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Constipation"
      ],
      "serious": [
        "Serotonin Syndrome",
        "Hypersensitivity",
        "QT Prolongation (Lower risk than others)"
      ]
    },
    "precautions": [
      "**Serotonin:** Caution with other serotonergic drugs.",
      "**QT:** Though safer than 1st gen, caution still advised.",
      "**Constipation:** Can be severe."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Serotonergic agents"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "pamidronate": {
    "name": "Pamidronate (Aredia)",
    "genericName": "Pamidronate Disodium",
    "formula": "C3H11NO7P2",
    "molecularWeight": "235.1 g/mol",
    "brandNames": ["Aredia"],
    "category": "Bone Resorption Inhibitor",
    "drugClass": "Bisphosphonate",
    "pubchemCID": "4674",
    "indications": "Hypercalcemia of Malignancy, Osteolytic Bone Metastases (Breast/Myeloma), Paget's Disease.",
    "moaSteps": [
      "Adsorbs to calcium phosphate crystals in bone.",
      "Inhibits osteoclast activity.",
      "Prevents bone resorption.",
      "Lowers serum calcium."
    ],
    "pharmacokinetics": {
      "absorption": "IV only.",
      "distribution": "Rapid bone uptake (50%).",
      "metabolism": "None.",
      "excretion": "Urine (Unchanged). **Half-life: 28 hours (Plasma); Years (Bone).**"
    },
    "dose": {
      "initialDose": "60-90 mg IV over 2-24 hours",
      "maxDose": "90 mg",
      "notes": "Hydrate patient first."
    },
    "adverseEffects": {
      "common": [
        "Fever (Acute phase reaction)",
        "Hypocalcemia / Hypophosphatemia",
        "Infusion site reaction"
      ],
      "serious": [
        "Renal Failure (Acute Tubular Necrosis)",
        "Osteonecrosis of the Jaw (ONJ)",
        "Atypical Femoral Fracture"
      ]
    },
    "precautions": [
      "**Renal:** Nephrotoxic. Infuse slowly (>2h). Monitor Cr. Withhold if renal function deteriorates.",
      "**ONJ:** Dental exam needed.",
      "**Electrolytes:** Monitor Ca, Mg, Phos, K."
    ],
    "contraindications": [
      "Hypersensitivity to bisphosphonates"
    ],
    "interactions": {
      "drug": ["Aminoglycosides (Additive hypocalcemia)", "Nephrotoxins"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },"ketamine": {
    "name": "Ketamine (Ketalar)",
    "genericName": "Ketamine HCl",
    "formula": "C13H16ClNO",
    "molecularWeight": "274.2 g/mol",
    "brandNames": ["Ketalar", "Spravato (Esketamine)"],
    "category": "Anesthetic / Antidepressant",
    "drugClass": "NMDA Receptor Antagonist",
    "pubchemCID": "3821",
    "indications": "Anesthesia induction/maintenance, Procedural sedation, Treatment-Resistant Depression (Spravato), Severe Pain.",
    "moaSteps": [
      "Non-competitive antagonist at the NMDA receptor.",
      "Blocks glutamate signaling.",
      "Creates 'dissociative anesthesia' (disconnection between thalamocortical and limbic systems).",
      "Preserves respiratory drive and airway reflexes (unique among anesthetics)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (IV/IM/Intranasal).",
      "distribution": "Lipophilic (Rapid brain entry).",
      "metabolism": "Hepatic (Norketamine - active).",
      "excretion": "Urine. **Half-life: 2 to 3 hours.**"
    },
    "dose": {
      "initialDose": "1-2 mg/kg IV (Induction)",
      "maxDose": "Titrate to effect",
      "notes": "Sub-anesthetic doses used for pain/depression."
    },
    "adverseEffects": {
      "common": [
        "Hallucinations / Vivid dreams (Emergence delirium)",
        "Hypertension / Tachycardia",
        "Nausea",
        "Diplopia"
      ],
      "serious": [
        "Laryngospasm",
        "Respiratory Depression (Rapid IV)",
        "Increased Intracranial Pressure (Controversial)",
        "Cystitis (Chronic abuse)"
      ]
    },
    "precautions": [
      "**Emergence:** Benzodiazepines reduce emergence delirium.",
      "**Cardiac:** Sympathomimetic (increases BP/HR). Caution in angina/HTN/ aneurysms.",
      "**Abuse:** Dissociative hallucinogen."
    ],
    "contraindications": [
      "Severe hypertension (Bp > 180/110)",
      "History of schizophrenia (relative)",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["CNS Depressants (Additive)", "Thyroid hormones (Hypertension)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "liraglutide": {
    "name": "Liraglutide (Victoza, Saxenda)",
    "genericName": "Liraglutide",
    "formula": "C172H265N43O51",
    "molecularWeight": "3751 Da",
    "brandNames": ["Victoza (Diabetes)", "Saxenda (Weight Loss)"],
    "category": "Antidiabetic",
    "drugClass": "GLP-1 Receptor Agonist",
    "pubchemCID": "16134956",
    "indications": "Type 2 Diabetes Mellitus, Chronic Weight Management, CV Risk Reduction.",
    "moaSteps": [
      "Analogue of human GLP-1 (97% homology).",
      "Binds to albumin (fatty acid side chain) to prolong half-life.",
      "Stimulates glucose-dependent insulin secretion.",
      "Suppresses glucagon and slows gastric emptying."
    ],
    "pharmacokinetics": {
      "absorption": "Subcutaneous (Slow).",
      "distribution": "Vascular.",
      "metabolism": "Proteolysis.",
      "excretion": "Urine/Feces. **Half-life: 13 hours.**"
    },
    "dose": {
      "initialDose": "0.6 mg SC daily x 1 week",
      "maxDose": "1.8 mg (Diabetes); 3.0 mg (Weight loss)",
      "notes": "Titrate weekly to reduce nausea."
    },
    "adverseEffects": {
      "common": [
        "Nausea (Dose-limiting)",
        "Diarrhea",
        "Vomiting",
        "Decreased appetite"
      ],
      "serious": [
        "Thyroid C-Cell Tumors - BOXED WARNING",
        "Acute Pancreatitis",
        "Gallbladder disease",
        "Renal Impairment"
      ]
    },
    "precautions": [
      "**Thyroid:** Contraindicated in MTC/MEN 2 history.",
      "**Pancreas:** Stop if pancreatitis suspected.",
      "**Renal:** Caution in renal impairment (dehydration risk)."
    ],
    "contraindications": [
      "Medullary Thyroid Carcinoma history",
      "MEN 2 Syndrome"
    ],
    "interactions": {
      "drug": ["Insulin/Sulfonylureas (Hypoglycemia)", "Oral drugs (Delayed absorption)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "lisdexamfetamine": {
    "name": "Lisdexamfetamine (Vyvanse)",
    "genericName": "Lisdexamfetamine Dimesylate",
    "formula": "C15H25N3O",
    "molecularWeight": "263.4 g/mol",
    "brandNames": ["Vyvanse"],
    "category": "CNS Stimulant",
    "drugClass": "Amphetamine Prodrug",
    "pubchemCID": "11597698",
    "indications": "ADHD, Binge Eating Disorder.",
    "moaSteps": [
      "Prodrug: Lysine attached to Dextroamphetamine.",
      "Inactive until cleaved by red blood cells.",
      "Active Dextroamphetamine blocks NE/DA reuptake and stimulates release.",
      "Gradual release reduces abuse potential (snorting/injecting doesn't work)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (Prodrug).",
      "distribution": "Wide.",
      "metabolism": "Hydrolysis in blood to active drug.",
      "excretion": "Urine. **Half-life: <1 hour (Parent); 12 hours (Active Dextroamphetamine).**"
    },
    "dose": {
      "initialDose": "30 mg PO daily",
      "maxDose": "70 mg/day",
      "notes": "Duration 10-14 hours."
    },
    "adverseEffects": {
      "common": [
        "Insomnia",
        "Decreased appetite",
        "Dry mouth",
        "Anxiety"
      ],
      "serious": [
        "Sudden Cardiac Death (Structural defects)",
        "Psychosis / Mania",
        "Abuse / Dependence - BOXED WARNING",
        "Peripheral Vasculopathy"
      ]
    },
    "precautions": [
      "**Cardiac:** Avoid in structural heart disease.",
      "**Growth:** Monitor height/weight in children.",
      "**Abuse:** Schedule II controlled substance."
    ],
    "contraindications": [
      "MAOI use within 14 days",
      "Symptomatic cardiovascular disease",
      "Glaucoma"
    ],
    "interactions": {
      "drug": ["MAOIs (Hypertensive crisis)", "Acidifying agents (Increase excretion)", "Alkalinizing agents (Decrease excretion)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "lurasidone": {
    "name": "Lurasidone (Latuda)",
    "genericName": "Lurasidone HCl",
    "formula": "C28H36N4O2S",
    "molecularWeight": "492.7 g/mol",
    "brandNames": ["Latuda"],
    "category": "Antipsychotic",
    "drugClass": "Atypical Antipsychotic (Second Generation)",
    "pubchemCID": "213046",
    "indications": "Schizophrenia, Bipolar Depression.",
    "moaSteps": [
      "Antagonist at Dopamine D2 and Serotonin 5-HT2A receptors.",
      "Potent antagonist at 5-HT7 (procognitive).",
      "Partial agonist at 5-HT1A.",
      "Low affinity for H1/M1 receptors (Low sedation/weight gain)."
    ],
    "pharmacokinetics": {
      "absorption": "Food increases absorption 2-3 fold.",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Feces. **Half-life: 18 hours.**"
    },
    "dose": {
      "initialDose": "20-40 mg PO once daily",
      "maxDose": "160 mg/day",
      "notes": "MUST TAKE WITH FOOD (>350 calories)."
    },
    "adverseEffects": {
      "common": [
        "Akathisia (High rate)",
        "Nausea",
        "Somnolence",
        "Parkinsonism"
      ],
      "serious": [
        "Metabolic Syndrome (Lower risk than others)",
        "Tardive Dyskinesia",
        "Neuroleptic Malignant Syndrome",
        "Leukopenia"
      ]
    },
    "precautions": [
      "**Food:** Essential for absorption. Without food, drug is ineffective.",
      "**Akathisia:** Dose-dependent and common.",
      "**CYP3A4:** Contraindicated with strong inhibitors/inducers."
    ],
    "contraindications": [
      "Strong CYP3A4 Inhibitors (Ketoconazole) or Inducers (Rifampin)",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["CYP3A4 agents (Contraindicated)", "CNS Depressants"],
      "food": ["Grapefruit juice (Avoid). Take with meal."]
    },
    "pregnancyCategory": "Category B"
  },
  "penicillin_v": {
    "name": "Penicillin V (Pen-Vee K)",
    "genericName": "Penicillin V Potassium",
    "formula": "C16H18N2O5S",
    "molecularWeight": "350.4 g/mol",
    "brandNames": ["Pen-Vee K"],
    "category": "Antibiotic",
    "drugClass": "Natural Penicillin",
    "pubchemCID": "5904",
    "indications": "Strep Pharyngitis, Mild Skin Infections, Rheumatic Fever Prophylaxis.",
    "moaSteps": [
      "Phenoxymethylpenicillin (Acid stable).",
      "Binds to Penicillin-Binding Proteins (PBPs).",
      "Inhibits bacterial cell wall synthesis.",
      "Narrow spectrum (Strep, some oral anaerobes)."
    ],
    "pharmacokinetics": {
      "absorption": "Good (60-73%). Acid stable.",
      "distribution": "Wide.",
      "metabolism": "Hepatic.",
      "excretion": "Urine. **Half-life: 30 to 60 minutes.**"
    },
    "dose": {
      "initialDose": "250-500 mg PO QID",
      "maxDose": "2 g/day",
      "notes": "Take on empty stomach."
    },
    "adverseEffects": {
      "common": [
        "Nausea",
        "Vomiting",
        "Black hairy tongue"
      ],
      "serious": [
        "Anaphylaxis",
        "C. diff colitis"
      ]
    },
    "precautions": [
      "**Allergy:** Cross-reactivity with cephalosporins.",
      "**Renal:** Adjust in severe impairment."
    ],
    "contraindications": [
      "Hypersensitivity to penicillins"
    ],
    "interactions": {
      "drug": ["Probenecid", "Methotrexate"],
      "food": ["Food reduces absorption."]
    },
    "pregnancyCategory": "Category B"
  },
  "phenobarbital": {
    "name": "Phenobarbital (Luminal)",
    "genericName": "Phenobarbital",
    "formula": "C12H12N2O3",
    "molecularWeight": "232.24 g/mol",
    "brandNames": ["Luminal"],
    "category": "Anticonvulsant / Barbiturate",
    "drugClass": "Barbiturate (Long-acting)",
    "pubchemCID": "4763",
    "indications": "Seizures (Generalized/Partial), Status Epilepticus, Sedation.",
    "moaSteps": [
      "Binds to GABA-A receptor at a distinct site.",
      "Increases duration of chloride channel opening.",
      "Potentiates GABA inhibition.",
      "Depresses sensory cortex, decreases motor activity."
    ],
    "pharmacokinetics": {
      "absorption": "Good.",
      "distribution": "Wide.",
      "metabolism": "Hepatic (CYP2C9/2C19). Potent Inducer.",
      "excretion": "Urine. **Half-life: 53 to 118 hours (Very long).**"
    },
    "dose": {
      "initialDose": "1-3 mg/kg/day PO",
      "maxDose": "Monitor levels (15-40 mcg/mL)",
      "notes": "Takes weeks to reach steady state."
    },
    "adverseEffects": {
      "common": [
        "Sedation / Drowsiness",
        "Hyperactivity (Paradoxical in kids)",
        "Cognitive dulling"
      ],
      "serious": [
        "Respiratory Depression",
        "Stevens-Johnson Syndrome",
        "Blood Dyscrasias",
        "Dependence / Withdrawal"
      ]
    },
    "precautions": [
      "**Inducer:** Potent CYP inducer; renders many drugs ineffective (Warfarin, OCPs).",
      "**Withdrawal:** Fatal seizures if stopped abruptly.",
      "**Cognition:** Lowers IQ in children with chronic use."
    ],
    "contraindications": [
      "Porphyria",
      "Severe respiratory disease",
      "Hepatic impairment"
    ],
    "interactions": {
      "drug": ["Warfarin (Decreased INR)", "Oral Contraceptives (Failure)", "CNS Depressants"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "phenylephrine": {
    "name": "Phenylephrine (Neo-Synephrine)",
    "genericName": "Phenylephrine HCl",
    "formula": "C9H13NO2",
    "molecularWeight": "167.21 g/mol",
    "brandNames": ["Neo-Synephrine", "Sudafed PE"],
    "category": "Vasopressor / Decongestant",
    "drugClass": "Alpha-1 Adrenergic Agonist",
    "pubchemCID": "6041",
    "indications": "Hypotension/Shock (IV), Nasal Congestion (Oral/Spray), Pupil Dilation (Eye).",
    "moaSteps": [
      "Selective alpha-1 receptor agonist.",
      "Potent vasoconstriction (increases SVR and BP).",
      "Little to no beta-adrenergic activity (doesn't increase HR directly).",
      "Causes reflex bradycardia."
    ],
    "pharmacokinetics": {
      "absorption": "Low oral bioavailability (first pass).",
      "distribution": "Rapid.",
      "metabolism": "MAO in liver/gut.",
      "excretion": "Urine. **Half-life: 2 to 3 hours.**"
    },
    "dose": {
      "initialDose": "10 mg PO q4h (Congestion); 40-100 mcg IV bolus (Hypotension)",
      "maxDose": "Titrate IV infusion",
      "notes": "Oral efficacy for congestion is debated."
    },
    "adverseEffects": {
      "common": [
        "Reflex Bradycardia",
        "Headache",
        "Restlessness"
      ],
      "serious": [
        "Severe Hypertension",
        "Tissue Necrosis (Extravasation)",
        "Arrhythmias"
      ]
    },
    "precautions": [
      "**Bradycardia:** Reflex vagal response can be significant.",
      "**Extravasation:** Vesicant. Phentolamine antidote.",
      "**Oral:** Caution in HTN/BPH."
    ],
    "contraindications": [
      "Severe hypertension",
      "Ventricular tachycardia"
    ],
    "interactions": {
      "drug": ["MAOIs (Hypertensive crisis)", "Beta-blockers (Unopposed alpha)", "TCAs"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "pioglitazone": {
    "name": "Pioglitazone (Actos)",
    "genericName": "Pioglitazone HCl",
    "formula": "C19H20N2O3S",
    "molecularWeight": "356.4 g/mol",
    "brandNames": ["Actos"],
    "category": "Antidiabetic",
    "drugClass": "Thiazolidinedione (TZD)",
    "pubchemCID": "4829",
    "indications": "Type 2 Diabetes Mellitus.",
    "moaSteps": [
      "Agonist at Peroxisome Proliferator-Activated Receptor Gamma (PPAR-gamma).",
      "Regulates gene transcription for glucose/lipid metabolism.",
      "Increases insulin sensitivity in muscle and fat.",
      "Decreases hepatic glucose production."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic (CYP2C8/3A4).",
      "excretion": "Bile/Feces. **Half-life: 3 to 7 hours (Parent); 16-24 hours (Active metabolite).**"
    },
    "dose": {
      "initialDose": "15-30 mg PO once daily",
      "maxDose": "45 mg/day",
      "notes": "Takes weeks for full effect."
    },
    "adverseEffects": {
      "common": [
        "Edema / Fluid Retention",
        "Weight Gain",
        "Upper respiratory infection"
      ],
      "serious": [
        "Congestive Heart Failure - BOXED WARNING",
        "Bladder Cancer (Long term use)",
        "Bone Fractures",
        "Hepatotoxicity"
      ]
    },
    "precautions": [
      "**Heart Failure:** Contraindicated in NYHA Class III/IV. Can precipitate HF.",
      "**Bladder Cancer:** Do not use in active bladder cancer or history of.",
      "**Liver:** Monitor LFTs."
    ],
    "contraindications": [
      "NYHA Class III/IV Heart Failure",
      "Active Bladder Cancer",
      "History of hypersensitivity"
    ],
    "interactions": {
      "drug": ["Gemfibrozil (Increases levels)", "Rifampin (Decreases levels)", "Insulin (Edema/HF risk)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "pramipexole": {
    "name": "Pramipexole (Mirapex)",
    "genericName": "Pramipexole Dihydrochloride",
    "formula": "C10H17N3S",
    "molecularWeight": "211.3 g/mol",
    "brandNames": ["Mirapex", "Mirapex ER"],
    "category": "Antiparkinson Agent",
    "drugClass": "Dopamine Agonist (Non-ergot)",
    "pubchemCID": "119570",
    "indications": "Parkinson's Disease, Restless Legs Syndrome (RLS).",
    "moaSteps": [
      "Direct agonist at dopamine D2 and D3 receptors.",
      "Stimulates dopamine receptors in the striatum.",
      "High affinity for D3 receptors (limbic implication).",
      "Improves motor deficits."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (90%).",
      "distribution": "15% protein bound.",
      "metabolism": "Minimal.",
      "excretion": "Urine (90% unchanged). **Half-life: 8 hours (12h in elderly).**"
    },
    "dose": {
      "initialDose": "0.125 mg PO TID (PD); 0.125 mg daily (RLS)",
      "maxDose": "4.5 mg/day (PD)",
      "notes": "Titrate slowly to avoid nausea/orthostasis."
    },
    "adverseEffects": {
      "common": [
        "Nausea",
        "Dizziness / Orthostasis",
        "Somnolence / Sleep Attacks",
        "Dyskinesia"
      ],
      "serious": [
        "Sudden Sleep Onset",
        "Impulse Control Disorders (Gambling/Sex)",
        "Hallucinations",
        "Heart Failure (weak association)"
      ]
    },
    "precautions": [
      "**Sleep:** Sudden sleep attacks while driving. Warning required.",
      "**Renal:** Dose reduction if CrCl < 60.",
      "**Impulse Control:** Pathological gambling/hypersexuality."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Cimetidine (Reduces clearance)", "Dopamine Antagonists (Antipsychotics - Block effect)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "pravastatin": {
    "name": "Pravastatin (Pravachol)",
    "genericName": "Pravastatin Sodium",
    "formula": "C23H36O7",
    "molecularWeight": "424.5 g/mol",
    "brandNames": ["Pravachol"],
    "category": "Antilipemic",
    "drugClass": "HMG-CoA Reductase Inhibitor (Statin)",
    "pubchemCID": "54687",
    "indications": "Hyperlipidemia, CVD Prevention.",
    "moaSteps": [
      "Hydrophilic statin.",
      "Inhibits HMG-CoA reductase.",
      "Reduces hepatic cholesterol synthesis.",
      "Upregulates LDL receptors."
    ],
    "pharmacokinetics": {
      "absorption": "35% absorbed.",
      "distribution": "50% protein bound (Low). Hydrophilic.",
      "metabolism": "Not metabolized by CYP450 (Sulfation).",
      "excretion": "Urine/Feces. **Half-life: 77 hours.**"
    },
    "dose": {
      "initialDose": "40 mg PO once daily",
      "maxDose": "80 mg/day",
      "notes": "Take at bedtime."
    },
    "adverseEffects": {
      "common": [
        "Myalgia (Lower risk than lipophilic statins)",
        "Headache",
        "Nausea"
      ],
      "serious": [
        "Rhabdomyolysis",
        "Hepatotoxicity",
        "Immune-mediated necrotizing myopathy"
      ]
    },
    "precautions": [
      "**Interactions:** Safer profile than Atorvastatin/Simvastatin due to lack of CYP3A4 metabolism.",
      "**Liver:** Contraindicated in active disease.",
      "**Muscle:** Stop if CPK elevates."
    ],
    "contraindications": [
      "Active liver disease",
      "Pregnancy / Nursing"
    ],
    "interactions": {
      "drug": ["Cyclosporine (Cap at 20mg)", "Clarithromycin (Cap at 40mg)", "Gemfibrozil (Avoid)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category X"
  },
  "prazosin": {
    "name": "Prazosin (Minipress)",
    "genericName": "Prazosin HCl",
    "formula": "C19H21N5O4",
    "molecularWeight": "383.4 g/mol",
    "brandNames": ["Minipress"],
    "category": "Antihypertensive / PTSD Agent",
    "drugClass": "Alpha-1 Blocker",
    "pubchemCID": "4893",
    "indications": "Hypertension, PTSD Nightmares (Off-label), BPH.",
    "moaSteps": [
      "Selective alpha-1 adrenergic antagonist.",
      "Dilates arterioles and veins.",
      "Reduces peripheral resistance.",
      "Blocks central alpha-1 receptors to reduce sleep disturbance/nightmares in PTSD."
    ],
    "pharmacokinetics": {
      "absorption": "Variable.",
      "distribution": "97% protein bound.",
      "metabolism": "Hepatic.",
      "excretion": "Bile/Feces. **Half-life: 2 to 3 hours.**"
    },
    "dose": {
      "initialDose": "1 mg PO at bedtime",
      "maxDose": "20 mg/day",
      "notes": "Titrate slowly to prevent syncope."
    },
    "adverseEffects": {
      "common": [
        "Dizziness",
        "Orthostatic Hypotension (First-dose)",
        "Drowsiness",
        "Palpitations"
      ],
      "serious": [
        "Syncope (First-dose effect)",
        "Priapism",
        "IFIS (Floppy Iris)"
      ]
    },
    "precautions": [
      "**First-Dose Syncope:** 1% risk. Give first dose at bedtime. Caution standing up.",
      "**Tolerance:** Tachyphylaxis can occur.",
      "**Cataract:** IFIS risk."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["PDE5 Inhibitors (Additive hypotension)", "Beta-blockers (Hypotension)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "prednisolone": {
    "name": "Prednisolone (Orapred, Prelone)",
    "genericName": "Prednisolone",
    "formula": "C21H28O5",
    "molecularWeight": "360.4 g/mol",
    "brandNames": ["Orapred", "Prelone", "Pred Forte (Eye)"],
    "category": "Corticosteroid",
    "drugClass": "Glucocorticoid",
    "pubchemCID": "5755",
    "indications": "Inflammation, Asthma (liquid for kids), Autoimmune disorders.",
    "moaSteps": [
      "Active metabolite of Prednisone.",
      "Anti-inflammatory and immunosuppressive.",
      "Preferred in liver failure (no conversion needed).",
      "Modulates protein synthesis."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "90-95% protein bound.",
      "metabolism": "Hepatic.",
      "excretion": "Urine. **Half-life: 2 to 4 hours.**"
    },
    "dose": {
      "initialDose": "5-60 mg PO daily",
      "maxDose": "Varies",
      "notes": "Liquid palatability varies (Orapred tastes better)."
    },
    "adverseEffects": {
      "common": [
        "Hyperglycemia",
        "Mood changes",
        "Gastritis",
        "Insomnia"
      ],
      "serious": [
        "Adrenal Suppression",
        "Peptic Ulcer",
        "Growth suppression (Children)",
        "Osteoporosis"
      ]
    },
    "precautions": [
      "**HPA Axis:** Taper after long courses.",
      "**Liver:** Preferred over prednisone in hepatic failure.",
      "**Infection:** Masks signs."
    ],
    "contraindications": [
      "Systemic fungal infections",
      "Live vaccines"
    ],
    "interactions": {
      "drug": ["NSAIDs (GI bleed)", "Warfarin", "Phenytoin (Decreases steroid)"],
      "food": ["Take with food."]
    },
    "pregnancyCategory": "Category C"
  },
  "prochlorperazine": {
    "name": "Prochlorperazine (Compazine)",
    "genericName": "Prochlorperazine",
    "formula": "C20H24ClN3S",
    "molecularWeight": "373.9 g/mol",
    "brandNames": ["Compazine"],
    "category": "Antiemetic / Antipsychotic",
    "drugClass": "Phenothiazine",
    "pubchemCID": "4917",
    "indications": "Severe Nausea/Vomiting, Schizophrenia, Migraine (IV adjunct).",
    "moaSteps": [
      "Blocks dopamine D2 receptors in the CTZ (Antiemetic).",
      "Blocks alpha-1 and H1 receptors.",
      "Anticholinergic effects."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Crosses BBB.",
      "metabolism": "Hepatic.",
      "excretion": "Urine. **Half-life: 6 to 9 hours.**"
    },
    "dose": {
      "initialDose": "5-10 mg PO/IV q6h",
      "maxDose": "40 mg/day",
      "notes": "Rectal suppository available."
    },
    "adverseEffects": {
      "common": [
        "Sedation",
        "Extrapyramidal Symptoms (Dystonia)",
        "Dry mouth",
        "Hypotension"
      ],
      "serious": [
        "Neuroleptic Malignant Syndrome",
        "Tardive Dyskinesia",
        "Agranulocytosis",
        "Seizures"
      ]
    },
    "precautions": [
      "**Dystonia:** Acute dystonic reactions common in young patients. Treat with Diphenhydramine.",
      "**Elderly:** Black Box Warning (Dementia psychosis).",
      "**IV:** Give slow to avoid hypotension."
    ],
    "contraindications": [
      "Coma",
      "Bone marrow depression",
      "Pediatric surgery (Risk of EPS)"
    ],
    "interactions": {
      "drug": ["CNS Depressants", "Anticholinergics"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "promethazine": {
    "name": "Promethazine (Phenergan)",
    "genericName": "Promethazine HCl",
    "formula": "C17H20N2S",
    "molecularWeight": "284.4 g/mol",
    "brandNames": ["Phenergan"],
    "category": "Antiemetic / Antihistamine",
    "drugClass": "Phenothiazine",
    "pubchemCID": "4927",
    "indications": "Nausea/Vomiting, Motion Sickness, Sedation, Allergic reactions.",
    "moaSteps": [
      "Blocks H1 receptors (Antihistamine).",
      "Blocks Dopamine D2 receptors in CTZ (Antiemetic).",
      "Strong anticholinergic and sedative effects."
    ],
    "pharmacokinetics": {
      "absorption": "Well absorbed.",
      "distribution": "Wide.",
      "metabolism": "Hepatic.",
      "excretion": "Urine. **Half-life: 10 to 19 hours.**"
    },
    "dose": {
      "initialDose": "12.5-25 mg PO/IV/PR q4h",
      "maxDose": "Variable",
      "notes": "IV: Dilute and give slow."
    },
    "adverseEffects": {
      "common": [
        "Severe Sedation",
        "Dry mouth",
        "Confusion"
      ],
      "serious": [
        "Respiratory Depression (Fatal in kids) - BOXED WARNING",
        "Tissue Gangrene (Intra-arterial/SC injection) - BOXED WARNING",
        "NMS",
        "Seizures"
      ]
    },
    "precautions": [
      "**Children:** Contraindicated < 2 years (Fatal respiratory depression).",
      "**IV Administration:** Vesicant. Deep IM preferred. If IV, dilute and give via running line. Extravasation causes gangrene.",
      "**Sedation:** Additive with opioids."
    ],
    "contraindications": [
      "Children < 2 years",
      "Intra-arterial or SC administration",
      "Coma"
    ],
    "interactions": {
      "drug": ["Opioids (Potentiation)", "Anticholinergics", "CNS Depressants"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "propylthiouracil": {
    "name": "Propylthiouracil (PTU)",
    "genericName": "Propylthiouracil",
    "formula": "C7H10N2OS",
    "molecularWeight": "170.23 g/mol",
    "brandNames": ["PTU"],
    "category": "Antithyroid",
    "drugClass": "Thionamide",
    "pubchemCID": "4933",
    "indications": "Hyperthyroidism (Graves'), Thyroid Storm, First Trimester of Pregnancy.",
    "moaSteps": [
      "Inhibits thyroid peroxidase (blocks T3/T4 synthesis).",
      "Inhibits peripheral conversion of T4 to T3 (unique to PTU vs Methimazole).",
      "Preferred in Thyroid Storm due to peripheral effect."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Concentrates in thyroid.",
      "metabolism": "Hepatic.",
      "excretion": "Urine. **Half-life: 1 to 2 hours (Short).**"
    },
    "dose": {
      "initialDose": "50-150 mg PO q8h",
      "maxDose": "1200 mg/day (Storm)",
      "notes": "Short half-life requires TID dosing."
    },
    "adverseEffects": {
      "common": [
        "Rash",
        "GI upset",
        "Arthralgia",
        "Taste perversion"
      ],
      "serious": [
        "Severe Hepatotoxicity (Fatal) - BOXED WARNING",
        "Agranulocytosis",
        "Vasculitis (ANCA)"
      ]
    },
    "precautions": [
      "**Hepatotoxicity:** Boxed warning. Sudden liver failure. Monitor LFTs. Methimazole preferred for most patients (except 1st trimester/Storm).",
      "**Agranulocytosis:** Sore throat/fever requires immediate stop/CBC.",
      "**Pregnancy:** Drug of choice in 1st trimester (less teratogenic than Methimazole)."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Warfarin (Thyroid status alters catabolism)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D (But safer than Methimazole in 1st trim)"
  },
  "pseudoephedrine": {
    "name": "Pseudoephedrine (Sudafed)",
    "genericName": "Pseudoephedrine",
    "formula": "C10H15NO",
    "molecularWeight": "165.23 g/mol",
    "brandNames": ["Sudafed"],
    "category": "Decongestant",
    "drugClass": "Alpha/Beta Adrenergic Agonist",
    "pubchemCID": "7028",
    "indications": "Nasal Congestion.",
    "moaSteps": [
      "Stimulates alpha-adrenergic receptors in respiratory mucosa.",
      "Causes vasoconstriction.",
      "Shrinks swollen mucous membranes.",
      "Weak beta-agonist activity (tachycardia)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Crosses BBB.",
      "metabolism": "Partial hepatic.",
      "excretion": "Urine. **Half-life: 9 to 16 hours (pH dependent).**"
    },
    "dose": {
      "initialDose": "60 mg PO q4-6h",
      "maxDose": "240 mg/day",
      "notes": "Restricted sale (Meth precursor)."
    },
    "adverseEffects": {
      "common": [
        "Insomnia / Stimulation",
        "Nervousness",
        "Palpitations"
      ],
      "serious": [
        "Hypertension",
        "Arrhythmias",
        "Ischemic Colitis",
        "Seizures"
      ]
    },
    "precautions": [
      "**Hypertension:** Caution in uncontrolled HTN.",
      "**BPH:** Can cause urinary retention.",
      "**Stimulation:** Do not take at bedtime."
    ],
    "contraindications": [
      "MAOI use within 14 days",
      "Severe hypertension / CAD"
    ],
    "interactions": {
      "drug": ["MAOIs (Hypertensive crisis)", "Stimulants"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "pyridostigmine": {
    "name": "Pyridostigmine (Mestinon)",
    "genericName": "Pyridostigmine Bromide",
    "formula": "C9H13BrN2O2",
    "molecularWeight": "261.12 g/mol",
    "brandNames": ["Mestinon"],
    "category": "Cholinergic",
    "drugClass": "Acetylcholinesterase Inhibitor",
    "pubchemCID": "4991",
    "indications": "Myasthenia Gravis (MG), Reversal of muscle relaxants.",
    "moaSteps": [
      "Reversibly inhibits acetylcholinesterase.",
      "Prevents breakdown of acetylcholine in the synaptic cleft.",
      "Increases ACh available to stimulate muscle contraction.",
      "Longer duration than Neostigmine."
    ],
    "pharmacokinetics": {
      "absorption": "Poor and variable.",
      "distribution": "Does not cross BBB.",
      "metabolism": "Hepatic.",
      "excretion": "Urine. **Half-life: 3 to 4 hours.**"
    },
    "dose": {
      "initialDose": "60 mg PO TID (MG)",
      "maxDose": "1500 mg/day",
      "notes": "Timing is critical for MG symptom control."
    },
    "adverseEffects": {
      "common": [
        "Abdominal cramping / Diarrhea",
        "Salivation / Lacrimation",
        "Muscle twitching",
        "Nausea"
      ],
      "serious": [
        "Cholinergic Crisis (Respiratory paralysis)",
        "Bradycardia",
        "Seizures",
        "Bronchospasm"
      ]
    },
    "precautions": [
      "**Cholinergic Crisis:** Overdose looks like Myasthenic Crisis (weakness). Distinguish by Edrophonium test (historic).",
      "**Asthma:** Can trigger bronchoconstriction.",
      "**Renal:** Clearance reduced."
    ],
    "contraindications": [
      "Mechanical GI/GU obstruction",
      "Hypersensitivity to bromides"
    ],
    "interactions": {
      "drug": ["Anticholinergics (Antagonism)", "Beta-blockers (Bradycardia)", "Steroids (Temporary weakness)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "rizatriptan": {
    "name": "Rizatriptan (Maxalt)",
    "genericName": "Rizatriptan Benzoate",
    "formula": "C15H19N5",
    "molecularWeight": "269.4 g/mol",
    "brandNames": ["Maxalt", "Maxalt-MLT"],
    "category": "Antimigraine",
    "drugClass": "Serotonin 5-HT1B/1D Receptor Agonist (Triptan)",
    "pubchemCID": "5063",
    "indications": "Acute Migraine with or without Aura.",
    "moaSteps": [
      "Selective agonist at 5-HT1B/1D receptors.",
      "Constricts intracranial blood vessels.",
      "Inhibits pro-inflammatory neuropeptide release.",
      "Faster onset than Sumatriptan."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (45% bioavailable).",
      "distribution": "14% protein bound.",
      "metabolism": "MAO-A.",
      "excretion": "Urine. **Half-life: 2 to 3 hours.**"
    },
    "dose": {
      "initialDose": "5-10 mg PO at onset",
      "maxDose": "30 mg/day",
      "notes": "Maxalt-MLT is orally disintegrating."
    },
    "adverseEffects": {
      "common": [
        "Dizziness",
        "Somnolence",
        "Paresthesia",
        "Chest tightness"
      ],
      "serious": [
        "Coronary Vasospasm / MI",
        "Stroke",
        "Serotonin Syndrome",
        "Hypertensive Crisis"
      ]
    },
    "precautions": [
      "**Cardiovascular:** Contraindicated in CAD/Stroke history.",
      "**Propranolol Interaction:** Propranolol inhibits Rizatriptan metabolism. Max dose 5mg if on Propranolol.",
      "**Phenylketonuria:** MLT tabs contain phenylalanine."
    ],
    "contraindications": [
      "Ischemic heart disease / HTN / Stroke",
      "MAOI use within 14 days",
      "Hemiplegic migraine"
    ],
    "interactions": {
      "drug": ["Propranolol (Increases levels 70% - Reduce dose)", "MAOIs (Toxic)", "SSRIs (Serotonin syndrome)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "rocuronium": {
    "name": "Rocuronium (Zemuron)",
    "genericName": "Rocuronium Bromide",
    "formula": "C32H53BrN2O4",
    "molecularWeight": "609.7 g/mol",
    "brandNames": ["Zemuron"],
    "category": "Neuromuscular Blocker",
    "drugClass": "Non-depolarizing Agent (Steroid)",
    "pubchemCID": "441296",
    "indications": "Tracheal Intubation (RSI alternative to Succinylcholine), Surgery.",
    "moaSteps": [
      "Competes with acetylcholine for nicotinic receptors at the motor end plate.",
      "Blocks depolarization.",
      "Causes flaccid paralysis.",
      "Rapid onset (60-90 sec) allows for RSI."
    ],
    "pharmacokinetics": {
      "absorption": "IV only.",
      "distribution": "ECF.",
      "metabolism": "Hepatic (minimal).",
      "excretion": "Bile/Urine. **Half-life: 1.4 hours (Duration 30-60 min).**"
    },
    "dose": {
      "initialDose": "0.6-1.2 mg/kg IV",
      "maxDose": "Maintenance",
      "notes": "Reversal with Sugammadex or Neostigmine."
    },
    "adverseEffects": {
      "common": [
        "Injection site pain",
        "Hypertension (transient)"
      ],
      "serious": [
        "Anaphylaxis",
        "Prolonged Paralysis (in liver failure)",
        "Apnea"
      ]
    },
    "precautions": [
      "**Airway:** Must be able to secure airway before giving.",
      "**Liver:** Prolonged duration in hepatic failure.",
      "**Awareness:** No sedation/analgesia. Patient is awake but paralyzed."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Aminoglycosides (Potentiate block)", "Magnesium (Potentiates block)", "Sugammadex (Reversal)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "roflumilast": {
    "name": "Roflumilast (Daliresp)",
    "genericName": "Roflumilast",
    "formula": "C17H14Cl2F2N2O3",
    "molecularWeight": "403.2 g/mol",
    "brandNames": ["Daliresp"],
    "category": "COPD Agent",
    "drugClass": "Phosphodiesterase-4 (PDE4) Inhibitor",
    "pubchemCID": "153966",
    "indications": "Severe COPD (to reduce exacerbations).",
    "moaSteps": [
      "Inhibits PDE4, increasing intracellular cAMP in lung cells.",
      "Reduces inflammation (anti-inflammatory).",
      "Does not have direct bronchodilator activity.",
      "Reduces neutrophil/eosinophil counts in lungs."
    ],
    "pharmacokinetics": {
      "absorption": "80% bioavailable.",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic (CYP3A4/1A2) to active N-oxide metabolite.",
      "excretion": "Urine. **Half-life: 17 hours (Parent); 30 hours (Metabolite).**"
    },
    "dose": {
      "initialDose": "250 mcg PO daily x 4 weeks",
      "maxDose": "500 mcg daily",
      "notes": "Titrate to reduce GI effects."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea (Dose-limiting)",
        "Weight Loss",
        "Nausea",
        "Headache"
      ],
      "serious": [
        "Psychiatric Events (Depression, Anxiety, Suicide)",
        "Atrial Fibrillation (rare)"
      ]
    },
    "precautions": [
      "**Psychiatric:** Associated with increased risk of suicide/depression. Monitor behavior.",
      "**Weight:** Monitor weight regularly.",
      "**Liver:** Contraindicated in moderate/severe impairment."
    ],
    "contraindications": [
      "Moderate to severe hepatic impairment"
    ],
    "interactions": {
      "drug": ["Strong CYP Inducers (Reduce efficacy)", "Theophylline (Additive toxicity)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "temazepam": {
    "name": "Temazepam (Restoril)",
    "genericName": "Temazepam",
    "formula": "C16H13ClN2O2",
    "molecularWeight": "300.7 g/mol",
    "brandNames": ["Restoril"],
    "category": "Sedative/Hypnotic",
    "drugClass": "Benzodiazepine (Intermediate-acting)",
    "pubchemCID": "5391",
    "indications": "Insomnia (Short-term).",
    "moaSteps": [
      "Potentiates GABA-A receptors.",
      "Increases chloride influx.",
      "Decreases sleep latency and number of awakenings.",
      "No active metabolites."
    ],
    "pharmacokinetics": {
      "absorption": "Slow (Peak 1.5h).",
      "distribution": "Lipophilic.",
      "metabolism": "Direct Conjugation (Glucuronidation).",
      "excretion": "Urine. **Half-life: 8 to 15 hours.**"
    },
    "dose": {
      "initialDose": "15 mg PO at bedtime",
      "maxDose": "30 mg/day",
      "notes": "7.5 mg in elderly."
    },
    "adverseEffects": {
      "common": [
        "Drowsiness / Hangover",
        "Dizziness",
        "Confusion"
      ],
      "serious": [
        "Complex Sleep Behaviors - BOXED WARNING",
        "Respiratory Depression",
        "Dependence"
      ]
    },
    "precautions": [
      "**Safety:** No active metabolites make it safer for liver disease/elderly (LOT benzo).",
      "**Sleep Behaviors:** Stop if sleep-driving occurs.",
      "**Abuse:** Schedule IV."
    ],
    "contraindications": [
      "Pregnancy",
      "Sleep apnea"
    ],
    "interactions": {
      "drug": ["CNS Depressants (Alcohol, Opioids)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category X"
  },
  "terazosin": {
    "name": "Terazosin (Hytrin)",
    "genericName": "Terazosin",
    "formula": "C19H25N5O4",
    "molecularWeight": "387.4 g/mol",
    "brandNames": ["Hytrin"],
    "category": "Antihypertensive / BPH Agent",
    "drugClass": "Alpha-1 Blocker (Non-selective)",
    "pubchemCID": "5403",
    "indications": "Benign Prostatic Hyperplasia (BPH), Hypertension.",
    "moaSteps": [
      "Blocks alpha-1 adrenergic receptors in prostate and vessels.",
      "Relaxes smooth muscle in bladder neck.",
      "Dilates arteries and veins (decreases BP).",
      "Requires dose titration."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "90% protein bound.",
      "metabolism": "Hepatic.",
      "excretion": "Bile/Urine. **Half-life: 12 hours.**"
    },
    "dose": {
      "initialDose": "1 mg PO at bedtime",
      "maxDose": "10-20 mg/day",
      "notes": "Must titrate to avoid syncope."
    },
    "adverseEffects": {
      "common": [
        "Dizziness",
        "Orthostatic Hypotension (First dose)",
        "Nasal Congestion",
        "Fatigue"
      ],
      "serious": [
        "Syncope",
        "Priapism",
        "IFIS (Floppy Iris)"
      ]
    },
    "precautions": [
      "**First Dose:** Give at bedtime to prevent syncope.",
      "**Titration:** If stopped for days, restart at 1mg.",
      "**Hypotension:** Additive with other BP meds/PDE5s."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["PDE5 Inhibitors (Hypotension)", "Beta-blockers"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "testosterone": {
    "name": "Testosterone (AndroGel)",
    "genericName": "Testosterone",
    "formula": "C19H28O2",
    "molecularWeight": "288.4 g/mol",
    "brandNames": ["AndroGel", "Depo-Testosterone", "Testim"],
    "category": "Androgen",
    "drugClass": "Androgen",
    "pubchemCID": "6013",
    "indications": "Hypogonadism (Primary/Secondary), Delayed Puberty, Breast Cancer (Palliative).",
    "moaSteps": [
      "Endogenous androgen.",
      "Binds to androgen receptors.",
      "Promotes growth/development of male sex organs and secondary characteristics.",
      "Anabolic effects (muscle/bone)."
    ],
    "pharmacokinetics": {
      "absorption": "Transdermal/IM.",
      "distribution": "SHBG bound.",
      "metabolism": "Hepatic.",
      "excretion": "Urine. **Half-life: 10-100 mins (Free); 8 days (Cypionate IM).**"
    },
    "dose": {
      "initialDose": "50 mg Gel Daily; 200 mg IM q2 weeks",
      "maxDose": "Titrate to serum T",
      "notes": "Avoid transfer to women/children."
    },
    "adverseEffects": {
      "common": [
        "Acne",
        "Injection site pain",
        "Edema",
        "Increased Hematocrit"
      ],
      "serious": [
        "Polycythemia (Stroke/Clot risk)",
        "Worsening BPH / Prostate Cancer",
        "Hepatotoxicity (Oral)",
        "Virilization of partners/children (Gel transfer) - BOXED WARNING"
      ]
    },
    "precautions": [
      "**Transfer:** Boxed warning for secondary exposure. Cover application site.",
      "**Prostate:** Screen for cancer/PSA before start.",
      "**Blood:** Monitor Hct; stop if polycythemia occurs."
    ],
    "contraindications": [
      "Prostate Cancer",
      "Male Breast Cancer",
      "Pregnancy",
      "Severe untreated sleep apnea"
    ],
    "interactions": {
      "drug": ["Warfarin (Increases INR)", "Insulin (Lower glucose)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category X"
  },
  "tetracycline": {
    "name": "Tetracycline",
    "genericName": "Tetracycline HCl",
    "formula": "C22H24N2O8",
    "molecularWeight": "444.4 g/mol",
    "brandNames": ["Sumycin (Disc)"],
    "category": "Antibiotic",
    "drugClass": "Tetracycline",
    "pubchemCID": "54675776",
    "indications": "Acne, H. pylori, Rickettsia, Chlamydia (Alternatives preferred).",
    "moaSteps": [
      "Binds 30S ribosomal subunit.",
      "Inhibits protein synthesis.",
      "Bacteriostatic.",
      "Short acting compared to Doxycycline."
    ],
    "pharmacokinetics": {
      "absorption": "60-80% (Fasting).",
      "distribution": "Wide (Bone/Teeth).",
      "metabolism": "None.",
      "excretion": "Urine. **Half-life: 6 to 11 hours.**"
    },
    "dose": {
      "initialDose": "250-500 mg PO QID",
      "maxDose": "2 g/day",
      "notes": "Take on empty stomach."
    },
    "adverseEffects": {
      "common": [
        "GI upset",
        "Photosensitivity",
        "Discoloration of teeth/nails"
      ],
      "serious": [
        "Hepatotoxicity",
        "Pseudotumor Cerebri",
        "Fanconi Syndrome (Expired drug)",
        "Esophageal ulceration"
      ]
    },
    "precautions": [
      "**Expired:** Taking expired tetracycline causes Fanconi Syndrome (renal tubular acidosis).",
      "**Teeth:** Contraindicated < 8 years (permanent staining).",
      "**Cations:** Chelation with calcium/iron."
    ],
    "contraindications": [
      "Pregnancy / Children < 8",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Isotretinoin (Pseudotumor - Avoid)", "Antacids/Dairy (Block absorption)", "Warfarin"],
      "food": ["Dairy decreases absorption."]
    },
    "pregnancyCategory": "Category D"
  },
  "theophylline": {
    "name": "Theophylline (Theo-24)",
    "genericName": "Theophylline",
    "formula": "C7H8N4O2",
    "molecularWeight": "180.16 g/mol",
    "brandNames": ["Theo-24", "Elixophyllin"],
    "category": "Bronchodilator",
    "drugClass": "Methylxanthine",
    "pubchemCID": "2153",
    "indications": "Asthma, COPD (Maintenance).",
    "moaSteps": [
      "Inhibits phosphodiesterase (PDE).",
      "Increases cAMP -> Bronchodilation.",
      "Adenosine receptor antagonist.",
      "Increases diaphragm contractility."
    ],
    "pharmacokinetics": {
      "absorption": "Complete.",
      "distribution": "40% protein bound.",
      "metabolism": "Extensive Hepatic (CYP1A2).",
      "excretion": "Urine. **Half-life: 8 hours (Smokers: 4-5 hours; Non-smokers: 8h).**"
    },
    "dose": {
      "initialDose": "300-400 mg PO daily",
      "maxDose": "Level dependent",
      "notes": "Target serum: 10-20 mcg/mL."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting",
        "Insomnia / Jitteriness",
        "Headache"
      ],
      "serious": [
        "Seizures (Toxicity)",
        "Arrhythmias (Tachycardia)",
        "Hypokalemia"
      ]
    },
    "precautions": [
      "**Narrow Index:** Toxicity occurs near therapeutic range. Monitor levels.",
      "**Smoking:** Smoking induces CYP1A2, lowering levels. Quitting smoking can cause toxicity.",
      "**Viral Illness:** Fever decreases clearance."
    ],
    "contraindications": [
      "Peptic ulcer",
      "Uncontrolled Seizure disorder"
    ],
    "interactions": {
      "drug": ["Ciprofloxacin (Inhibits metabolism -> Toxicity)", "Phenytoin/Rifampin (Decrease levels)", "Smoking"],
      "food": ["Charbroiled food (Inducer)", "Caffeine (Additive)"]
    },
    "pregnancyCategory": "Category C"
  },
  "tobramycin": {
    "name": "Tobramycin (Tobi)",
    "genericName": "Tobramycin",
    "formula": "C18H37N5O9",
    "molecularWeight": "467.5 g/mol",
    "brandNames": ["Tobi", "Bethkis"],
    "category": "Antibiotic",
    "drugClass": "Aminoglycoside",
    "pubchemCID": "36294",
    "indications": "Cystic Fibrosis (Inhaled), Serious Gram-negative infections (IV).",
    "moaSteps": [
      "Binds to 30S ribosome.",
      "Inhibits protein synthesis.",
      "Bactericidal.",
      "Especially active against Pseudomonas aeruginosa."
    ],
    "pharmacokinetics": {
      "absorption": "IV/Inhaled.",
      "distribution": "ECF. Poor CSF.",
      "metabolism": "None.",
      "excretion": "Urine. **Half-life: 2 to 3 hours.**"
    },
    "dose": {
      "initialDose": "300 mg Inhaled BID (28 days on/off); 1-2.5 mg/kg IV q8h",
      "maxDose": "Level dependent",
      "notes": "Inhaled form minimizes systemic toxicity."
    },
    "adverseEffects": {
      "common": [
        "Voice alteration (Inhaled)",
        "Cough",
        "Pharyngitis"
      ],
      "serious": [
        "Ototoxicity (IV) - BOXED WARNING",
        "Nephrotoxicity (IV) - BOXED WARNING",
        "Bronchospasm (Inhaled)",
        "Neuromuscular Blockade"
      ]
    },
    "precautions": [
      "**Toxicity:** IV form requires peak/trough monitoring. Inhaled form has low systemic absorption but can cause bronchospasm.",
      "**Renal:** Adjust IV dose."
    ],
    "contraindications": [
      "Hypersensitivity to aminoglycosides"
    ],
    "interactions": {
      "drug": ["Loop Diuretics (Ototoxicity)", "Vancomycin (Nephrotoxicity)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "torsemide": {
    "name": "Torsemide (Demadex)",
    "genericName": "Torsemide",
    "formula": "C16H20N4O3S",
    "molecularWeight": "348.4 g/mol",
    "brandNames": ["Demadex"],
    "category": "Diuretic",
    "drugClass": "Loop Diuretic",
    "pubchemCID": "41967",
    "indications": "Edema (Heart Failure, Renal/Hepatic disease), Hypertension.",
    "moaSteps": [
      "Inhibits Na+/K+/2Cl- cotransporter in Loop of Henle.",
      "Increases excretion of water/electrolytes.",
      "Higher oral bioavailability (80%) than Furosemide.",
      "Longer duration of action."
    ],
    "pharmacokinetics": {
      "absorption": "Reliable (80%).",
      "distribution": "99% protein bound.",
      "metabolism": "Hepatic (CYP2C9).",
      "excretion": "Urine. **Half-life: 3.5 to 4 hours.**"
    },
    "dose": {
      "initialDose": "10-20 mg PO daily",
      "maxDose": "200 mg/day",
      "notes": "20 mg Torsemide = 40 mg Furosemide."
    },
    "adverseEffects": {
      "common": [
        "Polyuria",
        "Dizziness",
        "Cramps"
      ],
      "serious": [
        "Electrolyte Imbalance (Hypokalemia)",
        "Dehydration",
        "Ototoxicity (Rare compared to Lasix)",
        "SJS"
      ]
    },
    "precautions": [
      "**Absorption:** Preferred over Furosemide in gut edema (CHF) due to consistent bioavailability.",
      "**Electrolytes:** Monitor K+.",
      "**Sulfa:** Caution in allergy."
    ],
    "contraindications": [
      "Anuria",
      "Hepatic Coma"
    ],
    "interactions": {
      "drug": ["Lithium", "Digoxin", "NSAIDs"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "tranexamic_acid": {
    "name": "Tranexamic Acid (Lysteda, Cyklokapron)",
    "genericName": "Tranexamic Acid",
    "formula": "C8H15NO2",
    "molecularWeight": "157.21 g/mol",
    "brandNames": ["Lysteda (Oral)", "Cyklokapron (IV)"],
    "category": "Hemostatic Agent",
    "drugClass": "Antifibrinolytic",
    "pubchemCID": "5526",
    "indications": "Heavy Menstrual Bleeding, Trauma/Hemorrhage, Tooth Extraction (Hemophilia), Hereditary Angioedema.",
    "moaSteps": [
      "Synthetic lysine amino acid derivative.",
      "Competitively inhibits activation of plasminogen to plasmin.",
      "Prevents degradation of fibrin clots (stabilizes clot).",
      "Reduces bleeding."
    ],
    "pharmacokinetics": {
      "absorption": "45% bioavailable.",
      "distribution": "Crosses BBB/Placenta.",
      "metabolism": "Minimal.",
      "excretion": "Urine. **Half-life: 2 to 11 hours.**"
    },
    "dose": {
      "initialDose": "1300 mg PO TID (Menorrhagia); 1 g IV (Trauma)",
      "maxDose": "Protocol dependent",
      "notes": "Dose reduce in renal impairment."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Back pain",
        "Abdominal pain",
        "Nasal symptoms"
      ],
      "serious": [
        "Thrombosis (DVT/PE/Stroke)",
        "Seizures (High IV doses)",
        "Visual defects (Retinal)"
      ]
    },
    "precautions": [
      "**Thrombosis:** Contraindicated in active thrombosis. Caution with hormonal contraceptives (additive risk).",
      "**Vision:** Retinal venous/arterial occlusion reported.",
      "**Renal:** Reduce dose."
    ],
    "contraindications": [
      "Active Thromboembolic Disease",
      "Intracranial bleeding",
      "Acquired defective color vision"
    ],
    "interactions": {
      "drug": ["Hormonal Contraceptives (Thrombosis risk)", "Factor IX Complex (Thrombosis)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "tretinoin": {
    "name": "Tretinoin (Retin-A)",
    "genericName": "Tretinoin (Retinoic Acid)",
    "formula": "C20H28O2",
    "molecularWeight": "300.44 g/mol",
    "brandNames": ["Retin-A", "Vesanoid (Oral)"],
    "category": "Acne / Antineoplastic",
    "drugClass": "Retinoid",
    "pubchemCID": "444795",
    "indications": "Acne Vulgaris (Topical), Acute Promyelocytic Leukemia (Oral - APL).",
    "moaSteps": [
      "Binds to nuclear retinoic acid receptors (RAR).",
      "Topical: Increases skin turnover, expels comedones.",
      "Oral: Induces differentiation of leukemic promyelocytes into mature cells.",
      "Vitamin A derivative."
    ],
    "pharmacokinetics": {
      "absorption": "Topical (Minimal). Oral (Good).",
      "distribution": "High protein binding.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Urine/Feces. **Half-life: 0.5 to 2 hours (Oral).**"
    },
    "dose": {
      "initialDose": "Apply nightly (Acne); 45 mg/m2/day PO (APL)",
      "maxDose": "Varies",
      "notes": "Topical causes initial flare."
    },
    "adverseEffects": {
      "common": [
        "Skin peeling / Redness / Burning (Topical)",
        "Photosensitivity",
        "Headache (Oral)"
      ],
      "serious": [
        "Retinoic Acid Syndrome (APL Differentiation Syndrome - Fatal)",
        "Pseudotumor Cerebri",
        "Teratogenicity - BOXED WARNING (Oral)"
      ]
    },
    "precautions": [
      "**Differentiation Syndrome:** Fever/Dyspnea/Weight gain in APL. Treat with Dexamethasone immediately.",
      "**Pregnancy:** Oral is highly teratogenic. Topical likely safe but usually avoided.",
      "**Sun:** Avoid sun exposure."
    ],
    "contraindications": [
      "Pregnancy (Oral)",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Tetracyclines (Pseudotumor Cerebri)", "Ketoconazole (Increases oral levels)"],
      "food": ["Take oral with food."]
    },
    "pregnancyCategory": "Category C (Topical); D (Oral)"
  },
  "triamcinolone": {
    "name": "Triamcinolone (Kenalog)",
    "genericName": "Triamcinolone Acetonide",
    "formula": "C24H31FO6",
    "molecularWeight": "434.5 g/mol",
    "brandNames": ["Kenalog", "Nasacort"],
    "category": "Corticosteroid",
    "drugClass": "Glucocorticoid (Intermediate)",
    "pubchemCID": "6436",
    "indications": "Inflammation (Topical/Injection), Allergic Rhinitis (Nasal), Joint pain (Intra-articular).",
    "moaSteps": [
      "Potent anti-inflammatory glucocorticoid.",
      "Inhibits arachidonic acid pathway.",
      "Suppresses immune response.",
      "Zero mineralocorticoid activity."
    ],
    "pharmacokinetics": {
      "absorption": "Systemic absorption varies by route.",
      "distribution": "Local depot (Joint/Muscle).",
      "metabolism": "Hepatic.",
      "excretion": "Urine. **Half-life: 88 minutes (Plasma); Biologic effect longer.**"
    },
    "dose": {
      "initialDose": "Varies (e.g., 40 mg IM or 10 mg Intra-articular)",
      "maxDose": "Varies",
      "notes": "Shake suspension well."
    },
    "adverseEffects": {
      "common": [
        "Local atrophy / Depigmentation (Injection)",
        "Nasal bleeding",
        "Hyperglycemia (Systemic)"
      ],
      "serious": [
        "Adrenal Suppression",
        "Tendon Rupture (Injection)",
        "Infection"
      ]
    },
    "precautions": [
      "**Injection:** Can cause skin dimpling/whitening if not deep IM or intra-articular.",
      "**Joints:** Frequent injections damage cartilage. Limit to 3-4/year.",
      "**Nasal:** Spray away from septum."
    ],
    "contraindications": [
      "ITP (IM use)",
      "Fungal infection"
    ],
    "interactions": {
      "drug": ["Vaccines (Live)", "NSAIDs"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },"ubrogepant": {
    "name": "Ubrogepant (Ubrelvy)",
    "genericName": "Ubrogepant",
    "formula": "C29H26F3N5O3",
    "molecularWeight": "549.6 g/mol",
    "brandNames": ["Ubrelvy"],
    "category": "Antimigraine",
    "drugClass": "CGRP Receptor Antagonist (Gepant)",
    "pubchemCID": "76900350",
    "indications": "Acute treatment of migraine with or without aura in adults.",
    "moaSteps": [
      "Binds to the calcitonin gene-related peptide (CGRP) receptor.",
      "Acts as a competitive antagonist.",
      "Blocks the binding of endogenous CGRP, a potent vasodilator and pain signal transmitter.",
      "Inhibits neurogenic inflammation and pain transmission in the trigeminal system.",
      "Does not cause vasoconstriction (unlike triptans)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid absorption. Tmax ~1.5 hours. High fat meal delays absorption.",
      "distribution": "87% protein bound.",
      "metabolism": "Extensive hepatic metabolism via CYP3A4.",
      "excretion": "Feces (42%) and Urine (6%). **Half-life: 5 to 7 hours.**"
    },
    "dose": {
      "initialDose": "50 mg or 100 mg PO at onset",
      "maxDose": "200 mg/24 hours",
      "notes": "May repeat dose after 2 hours if needed. Safe in CAD patients."
    },
    "adverseEffects": {
      "common": [
        "Nausea",
        "Somnolence / Drowsiness",
        "Dry mouth"
      ],
      "serious": [
        "Hypersensitivity reactions (Rash, Dyspnea, Angioedema)"
      ]
    },
    "precautions": [
      "**CYP3A4 Interactions:** Dose adjustments required with strong/moderate CYP3A4 inhibitors and inducers.",
      "**Renal/Hepatic:** Dose adjustment needed in severe renal or hepatic impairment."
    ],
    "contraindications": [
      "Concomitant use with strong CYP3A4 inhibitors (e.g., Ketoconazole, Clarithromycin)"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inhibitors (Contraindicated)", "Strong CYP3A4 Inducers (Avoid - Loss of efficacy)"],
      "food": ["Grapefruit juice (Increases toxicity)"]
    },
    "pregnancyCategory": "Category B"
  },
  "ublituximab": {
    "name": "Ublituximab (Briumvi)",
    "genericName": "Ublituximab-xiiy",
    "formula": "Chimeric monoclonal antibody",
    "molecularWeight": "147 kDa",
    "brandNames": ["Briumvi"],
    "category": "Multiple Sclerosis Agent",
    "drugClass": "Anti-CD20 Monoclonal Antibody",
    "pubchemCID": "None (Protein)",
    "indications": "Relapsing forms of Multiple Sclerosis (RMS), including CIS, RRMS, and active SPMS.",
    "moaSteps": [
      "Binds to a specific epitope on the CD20 antigen found on pre-B and mature B lymphocytes.",
      "Glycoengineered to have low fucose content, enhancing affinity for Fc receptors on immune effector cells.",
      "Triggers Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Complement-Dependent Cytotoxicity (CDC).",
      "Results in profound depletion of B-cells."
    ],
    "pharmacokinetics": {
      "absorption": "IV administration.",
      "distribution": "Vascular space.",
      "metabolism": "Catabolism.",
      "excretion": "Clearance decreases over time. **Half-life: ~22 days.**"
    },
    "dose": {
      "initialDose": "150 mg IV Day 1, then 450 mg IV Day 15",
      "maxDose": "450 mg every 24 weeks (Maintenance)",
      "notes": "Pre-medicate with steroid and antihistamine."
    },
    "adverseEffects": {
      "common": [
        "Infusion reactions (Fever, Chills, Headache)",
        "Upper respiratory tract infections",
        "Pain in extremities"
      ],
      "serious": [
        "Hepatitis B Reactivation (Fatal) - Warning",
        "PML (Progressive Multifocal Leukoencephalopathy)",
        "Reduced Immunoglobulins"
      ]
    },
    "precautions": [
      "**Hepatitis B:** Screening required before initiation. Contraindicated in active HBV.",
      "**Infection:** Do not start in patients with active infection.",
      "**Vaccines:** Live vaccines are contraindicated during and after treatment."
    ],
    "contraindications": [
      "Active Hepatitis B Virus infection",
      "History of life-threatening infusion reaction to ublituximab"
    ],
    "interactions": {
      "drug": ["Immunosuppressants (Additive risk)", "Live Vaccines (Contraindicated)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C (Fetal B-cell depletion)"
  },
  "ulipristal": {
    "name": "Ulipristal (Ella)",
    "genericName": "Ulipristal Acetate",
    "formula": "C30H37NO4",
    "molecularWeight": "475.6 g/mol",
    "brandNames": ["Ella", "Fibristal"],
    "category": "Contraceptive / Gynecologic Agent",
    "drugClass": "Selective Progesterone Receptor Modulator (SPRM)",
    "pubchemCID": "130904",
    "indications": "Emergency Contraception (up to 120 hours/5 days), Uterine Fibroids (Pre-op - in some countries).",
    "moaSteps": [
      "Binds with high affinity to progesterone receptors.",
      "Inhibits or delays ovulation by suppressing the LH surge.",
      "Alters the endometrium, potentially affecting implantation (controversial/secondary).",
      "Effective even when taken close to ovulation (unlike Levonorgestrel)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "98% protein bound.",
      "metabolism": "Hepatic via CYP3A4.",
      "excretion": "Feces. **Half-life: 32 hours.**"
    },
    "dose": {
      "initialDose": "30 mg PO single dose (Emergency Contraception)",
      "maxDose": "30 mg per cycle",
      "notes": "If vomiting occurs within 3 hours, repeat dose."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Nausea",
        "Abdominal pain",
        "Dysmenorrhea (Painful period)"
      ],
      "serious": [
        "Liver Injury (Observed in chronic daily dosing for fibroids - rare in single dose EC)",
        "Ectopic Pregnancy (Risk factor)"
      ]
    },
    "precautions": [
      "**Efficacy:** Less effective in BMI > 30 (Obesity).",
      "**Hormonal Contraception:** Progestin-containing contraceptives may reduce efficacy of Ulipristal. Avoid hormonal birth control for 5 days after taking Ella.",
      "**Existing Pregnancy:** Do not use if already pregnant."
    ],
    "contraindications": [
      "Known or suspected pregnancy",
      "Breastfeeding (Avoid for 1 week)"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inducers (Reduce efficacy - Avoid)", "Progestin Contraceptives (Antagonism - Wait 5 days)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category X"
  },
  "umeclidinium": {
    "name": "Umeclidinium (Incruse Ellipta)",
    "genericName": "Umeclidinium Bromide",
    "formula": "C29H34BrNO2",
    "molecularWeight": "508.5 g/mol",
    "brandNames": ["Incruse Ellipta", "Anoro (combo with Vilanterol)", "Trelegy (Triple combo)"],
    "category": "Bronchodilator",
    "drugClass": "Long-Acting Muscarinic Antagonist (LAMA)",
    "pubchemCID": "16220172",
    "indications": "Chronic Obstructive Pulmonary Disease (COPD) maintenance treatment.",
    "moaSteps": [
      "Long-acting antagonist at muscarinic receptors (M1-M5).",
      "Exhibits potency at M3 receptors on bronchial smooth muscle.",
      "Inhibits acetylcholine-induced bronchoconstriction.",
      "Provides 24-hour bronchodilation."
    ],
    "pharmacokinetics": {
      "absorption": "Minimal systemic absorption.",
      "distribution": "Local (Lung).",
      "metabolism": "Hepatic (CYP2D6) and P-gp.",
      "excretion": "Feces/Urine. **Half-life: 11 hours.**"
    },
    "dose": {
      "initialDose": "1 inhalation (62.5 mcg) once daily",
      "maxDose": "1 inhalation/day",
      "notes": "Not for acute bronchospasm."
    },
    "adverseEffects": {
      "common": [
        "Nasopharyngitis",
        "Upper respiratory infection",
        "Cough",
        "Arthralgia"
      ],
      "serious": [
        "Paradoxical Bronchospasm",
        "Worsening of Narrow-Angle Glaucoma",
        "Urinary Retention",
        "Anaphylaxis (Milk protein allergy)"
      ]
    },
    "precautions": [
      "**Acute Asthma:** Do not use as a rescue inhaler.",
      "**Anticholinergic Effects:** Caution in BPH and Glaucoma.",
      "**Milk Allergy:** Inhaler contains lactose (milk proteins); caution in severe allergy."
    ],
    "contraindications": [
      "Severe hypersensitivity to milk proteins"
    ],
    "interactions": {
      "drug": ["Other Anticholinergics (Additive toxicity - Avoid combo)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "undecylenic_acid": {
    "name": "Undecylenic Acid (Desenex)",
    "genericName": "Undecylenic Acid",
    "formula": "C11H20O2",
    "molecularWeight": "184.28 g/mol",
    "brandNames": ["Desenex", "Fungi-Nail"],
    "category": "Antifungal (Topical)",
    "drugClass": "Fatty Acid",
    "pubchemCID": "5633",
    "indications": "Tinea pedis (Athlete's foot), Tinea cruris (Jock itch), Tinea corporis (Ringworm).",
    "moaSteps": [
      "Unsaturated fatty acid.",
      "Interferes with fungal cell membrane formation.",
      "Inhibits morphogenesis of Candida albicans (prevents hyphae formation).",
      "Fungistatic."
    ],
    "pharmacokinetics": {
      "absorption": "Minimal.",
      "distribution": "Local skin surface.",
      "metabolism": "N/A.",
      "excretion": "N/A. **Half-life: N/A.**"
    },
    "dose": {
      "initialDose": "Apply BID",
      "maxDose": "Use for 4 weeks",
      "notes": "Clean and dry area before application."
    },
    "adverseEffects": {
      "common": [
        "Skin irritation",
        "Burning sensation"
      ],
      "serious": [
        "None significant"
      ]
    },
    "precautions": [
      "**External Use:** Do not use on broken skin or near eyes.",
      "**Diabetes:** Diabetics should consult MD before self-treating foot fungus."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["None"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "unithiol": {
    "name": "Unithiol (DMPS)",
    "genericName": "Unithiol (2,3-Dimercapto-1-propanesulfonic acid)",
    "formula": "C3H7NaO3S3",
    "molecularWeight": "210.27 g/mol",
    "brandNames": ["Dimaval"],
    "category": "Antidote / Chelator",
    "drugClass": "Dithiol Chelating Agent",
    "pubchemCID": "16760567",
    "indications": "Heavy Metal Poisoning (Mercury, Arsenic, Lead, Gold).",
    "moaSteps": [
      "Water-soluble analog of Dimercaprol (BAL).",
      "Contains two sulfhydryl (-SH) groups.",
      "Forms stable, water-soluble complexes with heavy metal ions.",
      "Promotes urinary excretion of the metals."
    ],
    "pharmacokinetics": {
      "absorption": "Good oral bioavailability.",
      "distribution": "Extracellular space (Mainly kidney).",
      "metabolism": "Oxidation to disulfide forms.",
      "excretion": "Urine (80-90%). **Half-life: 20 hours.**"
    },
    "dose": {
      "initialDose": "250 mg PO or IV every 4-8 hours",
      "maxDose": "Protocol dependent",
      "notes": "Less toxic than Dimercaprol (BAL)."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting",
        "Skin rash (allergic dermatitis)",
        "Garlic-like breath"
      ],
      "serious": [
        "Stevens-Johnson Syndrome",
        "Mineral depletion (Zinc/Copper)"
      ]
    },
    "precautions": [
      "**Hydration:** Ensure adequate urine output to flush chelated metals.",
      "**Minerals:** Long-term use requires Zinc/Copper supplementation.",
      "**Allergy:** Cross-reactivity with sulfa drugs is theoretical."
    ],
    "contraindications": [
      "Severe renal failure (relative - dialysis needed)",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Mineral supplements (Chelation - separate doses)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "unoprostone": {
    "name": "Unoprostone (Rescula)",
    "genericName": "Unoprostone Isopropyl",
    "formula": "C22H38O5",
    "molecularWeight": "382.5 g/mol",
    "brandNames": ["Rescula"],
    "category": "Glaucoma Agent",
    "drugClass": "Prostaglandin Analog (Docosanoid)",
    "pubchemCID": "5282228",
    "indications": "Open-angle Glaucoma, Ocular Hypertension.",
    "moaSteps": [
      "Synthetic docosanoid (related to Prostaglandin F2-alpha).",
      "Activates BK (Big Potassium) channels in the trabecular meshwork.",
      "Increases trabecular outflow of aqueous humor.",
      "Lowers Intraocular Pressure (IOP)."
    ],
    "pharmacokinetics": {
      "absorption": "Corneal.",
      "distribution": "Local.",
      "metabolism": "Corneal esterases to unoprostone acid.",
      "excretion": "Urine (Metabolites). **Half-life: 14 minutes.**"
    },
    "dose": {
      "initialDose": "1 drop BID",
      "maxDose": "BID",
      "notes": "Less potent than Latanoprost; BID dosing required (Latanoprost is QD)."
    },
    "adverseEffects": {
      "common": [
        "Burning / Stinging",
        "Dry eyes",
        "Itching"
      ],
      "serious": [
        "Macular Edema",
        "Iris Pigmentation (Permanent)",
        "Eyelash changes"
      ]
    },
    "precautions": [
      "**Pigmentation:** Can increase brown pigment in iris (permanent).",
      "**Contacts:** Remove lenses before use."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["None"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "upadacitinib": {
    "name": "Upadacitinib (Rinvoq)",
    "genericName": "Upadacitinib",
    "formula": "C17H19F3N6O",
    "molecularWeight": "380.4 g/mol",
    "brandNames": ["Rinvoq"],
    "category": "DMARD",
    "drugClass": "Janus Kinase (JAK) Inhibitor",
    "pubchemCID": "66567367",
    "indications": "Rheumatoid Arthritis, Psoriatic Arthritis, Atopic Dermatitis, Ulcerative Colitis, Crohn's Disease.",
    "moaSteps": [
      "Selective and reversible inhibitor of JAK1.",
      "Inhibits the JAK-STAT signaling pathway.",
      "Blocks cytokine signaling (Interleukins/Interferons) involved in inflammation and immune response.",
      "More selective for JAK1 than JAK2 or JAK3 (potentially safer profile)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid (80% bioavailable).",
      "distribution": "52% protein bound.",
      "metabolism": "Hepatic via CYP3A4.",
      "excretion": "Urine (24%) and Feces (38%). **Half-life: 8 to 14 hours.**"
    },
    "dose": {
      "initialDose": "15 mg PO once daily (RA)",
      "maxDose": "30-45 mg/day (UC/Crohn's induction)",
      "notes": "ER tablets; do not crush."
    },
    "adverseEffects": {
      "common": [
        "Upper respiratory infection",
        "Acne",
        "Herpes Zoster (Shingles)",
        "Headache",
        "Nausea"
      ],
      "serious": [
        "Serious Infections (TB, Fungal) - BOXED WARNING",
        "Mortality (CV Death) - BOXED WARNING",
        "Malignancy (Lymphoma/Lung) - BOXED WARNING",
        "Thrombosis (DVT/PE) - BOXED WARNING",
        "GI Perforation"
      ]
    },
    "precautions": [
      "**Infection:** Screen for TB and Hepatitis. Avoid in active infection. Shingles vaccination recommended prior to start.",
      "**Cardiovascular:** Use caution in high-risk CV patients (smokers, elderly).",
      "**Blood:** Monitor CBC (Lymphopenia, Anemia, Neutropenia) and Lipids."
    ],
    "contraindications": [
      "Active serious infection",
      "Severe hepatic impairment"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inhibitors (Increase toxicity - Avoid or dose adjust)", "Strong CYP3A4 Inducers (Reduce efficacy)", "Live Vaccines"],
      "food": ["Grapefruit juice (Increases levels)"]
    },
    "pregnancyCategory": "Category D (Based on animal data)"
  },
  "uracil_mustard": {
    "name": "Uracil Mustard",
    "genericName": "Uracil Mustard",
    "formula": "C8H11Cl2N3O2",
    "molecularWeight": "252.1 g/mol",
    "brandNames": ["Uracil Mustard Capsules"],
    "category": "Antineoplastic",
    "drugClass": "Alkylating Agent (Nitrogen Mustard)",
    "pubchemCID": "5654",
    "indications": "Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin Lymphoma (NHL), Polycythemia Vera (older agent).",
    "moaSteps": [
      "Bifunctional alkylating agent.",
      "Uracil moiety facilitates uptake into cells (tumor cells use uracil for DNA synthesis).",
      "Forms cross-links between DNA strands (guanine alkylation).",
      "Inhibits DNA replication and cell division."
    ],
    "pharmacokinetics": {
      "absorption": "Oral (Incomplete).",
      "distribution": "Rapid tissue uptake.",
      "metabolism": "Hepatic.",
      "excretion": "Urine (minimal unchanged). **Half-life: Unknown.**"
    },
    "dose": {
      "initialDose": "1-2 mg PO daily",
      "maxDose": "Varies",
      "notes": "Historical drug, largely replaced by Chlorambucil/Cyclophosphamide."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting",
        "Diarrhea",
        "Alopecia"
      ],
      "serious": [
        "Bone Marrow Suppression (Cumulative and severe) - BOXED WARNING",
        "Secondary Malignancies (Leukemia)",
        "Hepatotoxicity"
      ]
    },
    "precautions": [
      "**Myelosuppression:** Severe and delayed. Platelets and WBCs may continue to drop weeks after stopping.",
      "**Uric Acid:** Can cause hyperuricemia (Tumor Lysis)."
    ],
    "contraindications": [
      "Severe leukopenia/thrombocytopenia"
    ],
    "interactions": {
      "drug": ["Live Vaccines"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category X"
  },
  "urea": {
    "name": "Urea (Ureacin, Carmol)",
    "genericName": "Urea",
    "formula": "CH4N2O",
    "molecularWeight": "60.06 g/mol",
    "brandNames": ["Ureacin", "Carmol 40", "Keralac"],
    "category": "Keratolytic / Osmotic Diuretic",
    "drugClass": "Keratolytic Agent",
    "pubchemCID": "1176",
    "indications": "Hyperkeratosis (Corns, Calluses, Psoriasis), Onychomycosis (nail softening), Raised ICP (IV - rarely used now).",
    "moaSteps": [
      "Topical: Dissolves the intercellular matrix of the stratum corneum.",
      "Hydrates and softens keratin (hygroscopic/humectant).",
      "Promotes desquamation of scaly skin.",
      "Systemic (IV): Osmotic diuretic (increases plasma osmolarity, pulls water from brain)."
    ],
    "pharmacokinetics": {
      "absorption": "Topical: Minimal systemic absorption.",
      "distribution": "Local (Topical); Total body water (IV).",
      "metabolism": "Hydrolysis to ammonia/CO2.",
      "excretion": "Urine. **Half-life: 1 hour (IV).**"
    },
    "dose": {
      "initialDose": "Apply 40% cream BID",
      "maxDose": "Use as directed",
      "notes": "Apply to affected areas only."
    },
    "adverseEffects": {
      "common": [
        "Burning / Stinging",
        "Itching",
        "Irritation"
      ],
      "serious": [
        "None (Topical)",
        "Electrolyte imbalance (IV)"
      ]
    },
    "precautions": [
      "**Irritation:** Do not apply to broken or inflamed skin.",
      "**Eyes:** Avoid eye contact."
    ],
    "contraindications": [
      "Severe active inflammation (Topical)",
      "Severe renal failure (IV)"
    ],
    "interactions": {
      "drug": ["Increases absorption of other topicals (e.g., corticosteroids, antifungals)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "uridine_triacetate": {
    "name": "Uridine Triacetate (Vistogard)",
    "genericName": "Uridine Triacetate",
    "formula": "C17H22O9",
    "molecularWeight": "370.4 g/mol",
    "brandNames": ["Vistogard", "Xuriden"],
    "category": "Antidote",
    "drugClass": "Pyrimidine Analog",
    "pubchemCID": "11954229",
    "indications": "Emergency treatment of Fluorouracil (5-FU) or Capecitabine overdose/toxicity; Hereditary Orotic Aciduria (Xuriden).",
    "moaSteps": [
      "Prodrug deacetylated to Uridine.",
      "Uridine competes with 5-FU metabolites (F-dUMP) for incorporation into RNA.",
      "Overwhelms the toxic effects of 5-FU.",
      "Reduces cell death caused by 5-FU."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Intracellular.",
      "metabolism": "Hydrolysis to Uridine.",
      "excretion": "Urine. **Half-life: 2 to 2.5 hours (Uridine).**"
    },
    "dose": {
      "initialDose": "10 g PO every 6 hours x 20 doses",
      "maxDose": "20 doses total",
      "notes": "Must start within 96 hours of 5-FU exposure. Mix granules with food."
    },
    "adverseEffects": {
      "common": [
        "Nausea / Vomiting",
        "Diarrhea"
      ],
      "serious": [
        "None significant (Safety profile is excellent; risk is untreated 5-FU toxicity)"
      ]
    },
    "precautions": [
      "**Timing:** Efficacy declines if started >96 hours after overdose.",
      "**Administration:** Mix granules with soft food (applesauce/yogurt). Do not chew."
    ],
    "contraindications": [
      "None (Emergency antidote)"
    ],
    "interactions": {
      "drug": ["None significant"],
      "food": ["Administer with food."]
    },
    "pregnancyCategory": "Category C"
  },
  "urofollitropin": {
    "name": "Urofollitropin (Bravelle)",
    "genericName": "Urofollitropin (FSH)",
    "formula": "Purified hFSH",
    "molecularWeight": "Glycoprotein",
    "brandNames": ["Bravelle"],
    "category": "Hormone",
    "drugClass": "Gonadotropin (FSH)",
    "pubchemCID": "None (Biologic)",
    "indications": "Infertility (Induction of Ovulation), Assisted Reproductive Technologies (IVF).",
    "moaSteps": [
      " highly purified human Follicle Stimulating Hormone (hFSH) extracted from urine of postmenopausal women.",
      "Stimulates ovarian follicular growth and maturation.",
      "Stimulates gonadal steroid production.",
      "Used with hCG to trigger ovulation."
    ],
    "pharmacokinetics": {
      "absorption": "SC/IM.",
      "distribution": "Ovaries.",
      "metabolism": "Renal/Hepatic.",
      "excretion": "Urine. **Half-life: 32 to 37 hours.**"
    },
    "dose": {
      "initialDose": "150 IU SC/IM daily x 5 days",
      "maxDose": "450 IU/day",
      "notes": "Dose adjusted based on ultrasound/estradiol levels."
    },
    "adverseEffects": {
      "common": [
        "Abdominal pain/bloating",
        "Headache",
        "Nausea",
        "Injection site reaction"
      ],
      "serious": [
        "Ovarian Hyperstimulation Syndrome (OHSS) - Life threatening",
        "Multiple births (Twins/Triplets)",
        "Thromboembolism",
        "Ovarian Torsion"
      ]
    },
    "precautions": [
      "**OHSS:** Rapid weight gain, severe pain, dyspnea. Withhold hCG if estradiol is too high.",
      "**Multiples:** High risk of multiple gestation.",
      "**Monitoring:** Requires daily ultrasound/estradiol monitoring."
    ],
    "contraindications": [
      "High FSH (Primary ovarian failure)",
      "Uncontrolled thyroid/adrenal dysfunction",
      "Pregnancy",
      "Ovarian cysts (not PCOS)"
    ],
    "interactions": {
      "drug": ["Clomiphene (Additive follicular stimulation)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category X"
  },
  "urokinase": {
    "name": "Urokinase (Kinlytic)",
    "genericName": "Urokinase",
    "formula": "Enzyme",
    "molecularWeight": "54 kDa",
    "brandNames": ["Kinlytic"],
    "category": "Thrombolytic",
    "drugClass": "Thrombolytic Enzyme",
    "pubchemCID": "None (Enzyme)",
    "indications": "Pulmonary Embolism (PE), Catheter clearance (occluded central lines - Abbokinase).",
    "moaSteps": [
      "Serine protease enzyme derived from human kidney cells.",
      "Directly converts plasminogen to plasmin.",
      "Plasmin degrades fibrin clots, fibrinogen, and other procoagulant plasma proteins.",
      "Non-fibrin specific (systemic lytic state)."
    ],
    "pharmacokinetics": {
      "absorption": "IV/Intra-catheter.",
      "distribution": "Intravascular.",
      "metabolism": "Hepatic.",
      "excretion": "Bile/Urine. **Half-life: 10 to 20 minutes.**"
    },
    "dose": {
      "initialDose": "4400 IU/kg IV load over 10 min",
      "maxDose": "4400 IU/kg/hr infusion for 12 hours (PE)",
      "notes": "Catheter clearance: 5000 IU per lumen."
    },
    "adverseEffects": {
      "common": [
        "Bleeding ( puncture sites)",
        "Fever"
      ],
      "serious": [
        "Major Hemorrhage (Intracranial/GI)",
        "Anaphylaxis (rare compared to Streptokinase)",
        "Cholesterol Embolization"
      ]
    },
    "precautions": [
      "**Bleeding:** Contraindicated in active bleed, recent stroke (<2mo), or surgery (<10 days).",
      "**Allergy:** Low risk as it is a human protein, but possible."
    ],
    "contraindications": [
      "Active internal bleeding",
      "Recent CVA",
      "Intracranial neoplasm",
      "Recent trauma/surgery"
    ],
    "interactions": {
      "drug": ["Anticoagulants (Heparin/Warfarin) - Severe bleeding risk", "Antiplatelets"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category B"
  },
  "ursodiol": {
    "name": "Ursodiol (Actigall, Urso)",
    "genericName": "Ursodiol (Ursodeoxycholic Acid)",
    "formula": "C24H40O4",
    "molecularWeight": "392.6 g/mol",
    "brandNames": ["Actigall", "Urso", "Urso Forte"],
    "category": "Gallstone Dissolution Agent",
    "drugClass": "Bile Acid",
    "pubchemCID": "31401",
    "indications": "Gallstone Dissolution (Cholesterol stones), Primary Biliary Cholangitis (PBC), Prevention of gallstones during rapid weight loss.",
    "moaSteps": [
      "Naturally occurring hydrophilic bile acid.",
      "Suppresses hepatic synthesis and secretion of cholesterol.",
      "Inhibits intestinal absorption of cholesterol.",
      "Replaces toxic hydrophobic bile acids in the pool, protecting hepatocytes (PBC).",
      "Solubilizes cholesterol gallstones."
    ],
    "pharmacokinetics": {
      "absorption": "90% absorbed.",
      "distribution": "Enterohepatic circulation.",
      "metabolism": "Hepatic conjugation.",
      "excretion": "Feces. **Half-life: 3 to 6 days.**"
    },
    "dose": {
      "initialDose": "8-10 mg/kg/day PO divided BID/TID (Gallstones)",
      "maxDose": "13-15 mg/kg/day (PBC)",
      "notes": "Take with food."
    },
    "adverseEffects": {
      "common": [
        "Diarrhea / Loose stools",
        "Back pain",
        "Nausea",
        "Headache"
      ],
      "serious": [
        "None significant"
      ]
    },
    "precautions": [
      "**Monitoring:** Liver enzymes and bilirubin. Ultrasound for stones every 6 months.",
      "**Efficacy:** Only works on cholesterol stones (radiolucent). Calcified stones will not dissolve."
    ],
    "contraindications": [
      "Calcified gallstones",
      "Biliary obstruction (complete)",
      "Acute cholecystitis"
    ],
    "interactions": {
      "drug": ["Aluminum Antacids/Cholestyramine (Bind Ursodiol - separate by 2h)", "Estrogens/Fibrates (Increase biliary cholesterol - counteract effect)"],
      "food": ["Take with food to improve absorption."]
    },
    "pregnancyCategory": "Category B"
  },
  "wegovy": {
    "name": "Wegovy (Semaglutide)",
    "genericName": "Semaglutide",
    "formula": "C187H291N45O59",
    "molecularWeight": "4113.6 Da",
    "brandNames": ["Wegovy", "Ozempic", "Rybelsus"],
    "category": "Anti-Obesity Agent",
    "drugClass": "GLP-1 Receptor Agonist",
    "pubchemCID": "56843331",
    "indications": "Chronic Weight Management (Obesity/Overweight with comorbidities), Cardiovascular Risk Reduction in Obesity.",
    "moaSteps": [
      "Analogue of human Glucagon-Like Peptide-1 (GLP-1) with 94% homology.",
      "Binds to and activates the GLP-1 receptor.",
      "Acts on the brain (hypothalamus) to increase satiety and reduce hunger.",
      "Slows gastric emptying.",
      "Stimulates glucose-dependent insulin secretion (mechanism for diabetes)."
    ],
    "pharmacokinetics": {
      "absorption": "Subcutaneous.",
      "distribution": "High albumin binding.",
      "metabolism": "Proteolytic cleavage and beta-oxidation.",
      "excretion": "Urine and Feces. **Half-life: ~1 week.**"
    },
    "dose": {
      "initialDose": "0.25 mg SC once weekly",
      "maxDose": "2.4 mg once weekly",
      "notes": "Strict titration schedule (every 4 weeks) to mitigate GI side effects."
    },
    "adverseEffects": {
      "common": [
        "Nausea (Very common)",
        "Diarrhea / Vomiting",
        "Constipation",
        "Fatigue"
      ],
      "serious": [
        "Thyroid C-Cell Tumors (Animal studies) - BOXED WARNING",
        "Acute Pancreatitis",
        "Gallbladder Disease (Cholelithiasis)",
        "Suicidal Ideation (Monitor mood)"
      ]
    },
    "precautions": [
      "**Thyroid:** Contraindicated in personal/family history of Medullary Thyroid Carcinoma (MTC) or MEN 2.",
      "**Pancreatitis:** Discontinue if suspected.",
      "**Dehydration:** Severe GI symptoms can lead to AKI."
    ],
    "contraindications": [
      "History of MTC or MEN 2",
      "Pregnancy",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Insulin/Sulfonylureas (Hypoglycemia risk)", "Oral medications (Delayed gastric emptying may impact absorption)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category X (Weight loss not indicated in pregnancy)"
  },
  "welchol": {
    "name": "Welchol (Colesevelam)",
    "genericName": "Colesevelam",
    "formula": "Polyallylamine polymer",
    "molecularWeight": "High MW Polymer",
    "brandNames": ["Welchol"],
    "category": "Antilipemic / Antidiabetic",
    "drugClass": "Bile Acid Sequestrant",
    "pubchemCID": "N/A (Polymer)",
    "indications": "Hyperlipidemia (LDL reduction), Type 2 Diabetes (Glycemic control).",
    "moaSteps": [
      "Non-absorbed, lipid-lowering polymer.",
      "Binds bile acids in the intestine, impeding their reabsorption.",
      "Forces liver to convert cholesterol into bile acids, upregulating LDL receptors.",
      "Mechanism for glucose lowering is unclear (possibly incretin modulation)."
    ],
    "pharmacokinetics": {
      "absorption": "Not absorbed.",
      "distribution": "GI Tract.",
      "metabolism": "None.",
      "excretion": "Feces (100%). **Half-life: N/A.**"
    },
    "dose": {
      "initialDose": "3.75 g PO daily (divided)",
      "maxDose": "3.75 g/day (6 tablets)",
      "notes": "Take with meal and liquid."
    },
    "adverseEffects": {
      "common": [
        "Constipation",
        "Dyspepsia",
        "Nausea"
      ],
      "serious": [
        "Bowel Obstruction",
        "Hypertriglyceridemia (Can raise TG levels)",
        "Pancreatitis (due to high TG)"
      ]
    },
    "precautions": [
      "**Triglycerides:** Contraindicated if TG > 500. Monitor lipids (can increase TG).",
      "**GI Motility:** Caution in gastroparesis/motility disorders.",
      "**Absorption:** Can bind other drugs (phenytoin, levothyroxine, contraceptives). Take other meds 4 hours prior."
    ],
    "contraindications": [
      "History of bowel obstruction",
      "Serum Triglycerides > 500 mg/dL",
      "History of hypertriglyceridemia-induced pancreatitis"
    ],
    "interactions": {
      "drug": ["Levothyroxine (Reduced absorption)", "Oral Contraceptives (Reduced absorption)", "Cyclosporine"],
      "food": ["Take with food."]
    },
    "pregnancyCategory": "Category B"
  },
  "wakix": {
    "name": "Wakix (Pitolisant)",
    "genericName": "Pitolisant",
    "formula": "C17H26ClNO",
    "molecularWeight": "295.8 g/mol",
    "brandNames": ["Wakix"],
    "category": "CNS Agent",
    "drugClass": "Histamine H3 Receptor Antagonist/Inverse Agonist",
    "pubchemCID": "9800049",
    "indications": "Narcolepsy (Excessive daytime sleepiness and Cataplexy).",
    "moaSteps": [
      "First-in-class H3 receptor antagonist/inverse agonist.",
      "H3 receptors are presynaptic autoreceptors that inhibit histamine release.",
      "Blocking H3 increases histamine synthesis and release in the brain.",
      "Enhances wakefulness (histamine is a wake-promoting neurotransmitter)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "90% protein bound.",
      "metabolism": "Extensive hepatic (CYP2D6 and CYP3A4).",
      "excretion": "Urine. **Half-life: 20 hours.**"
    },
    "dose": {
      "initialDose": "8.9 mg PO once daily",
      "maxDose": "35.6 mg/day",
      "notes": "Titrate over 3 weeks. Non-scheduled (Not a controlled substance)."
    },
    "adverseEffects": {
      "common": [
        "Insomnia",
        "Nausea",
        "Anxiety",
        "Headache"
      ],
      "serious": [
        "QT Prolongation"
      ]
    },
    "precautions": [
      "**QT Interval:** Prolongs QT. Avoid in patients with QT history or on other QT-prolonging drugs.",
      "**Hepatic/Renal:** Dose adjustment required.",
      "**Contraception:** Induces CYP3A4; reduces efficacy of hormonal birth control."
    ],
    "contraindications": [
      "Severe hepatic impairment"
    ],
    "interactions": {
      "drug": ["QT Prolonging drugs (Avoid)", "Hormonal Contraceptives (Failure)", "Strong CYP2D6 Inhibitors (Double exposure - reduce dose)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "winlevi": {
    "name": "Winlevi (Clascoterone)",
    "genericName": "Clascoterone",
    "formula": "C24H34O5",
    "molecularWeight": "402.5 g/mol",
    "brandNames": ["Winlevi"],
    "category": "Acne Agent",
    "drugClass": "Androgen Receptor Inhibitor (Topical)",
    "pubchemCID": "10175350",
    "indications": "Acne Vulgaris (Age 12+).",
    "moaSteps": [
      "Competes with androgens (specifically DHT) for binding to androgen receptors in the sebaceous gland.",
      "Inhibits androgen-driven sebum production and inflammation.",
      "First topical androgen antagonist for acne.",
      "Minimal systemic effect compared to oral anti-androgens."
    ],
    "pharmacokinetics": {
      "absorption": "Minimal systemic absorption.",
      "distribution": "Local skin.",
      "metabolism": "Rapid hydrolysis in skin/plasma to inactive cortexolone.",
      "excretion": "Urine/Feces. **Half-life: Unknown (Local).**"
    },
    "dose": {
      "initialDose": "Apply thin layer BID",
      "maxDose": "N/A",
      "notes": "Apply to clean skin."
    },
    "adverseEffects": {
      "common": [
        "Erythema / Redness",
        "Pruritus",
        "Scaling / Dryness"
      ],
      "serious": [
        "HPA Axis Suppression (Rare, reversible, seen in high surface area use)",
        "Hyperkalemia (Theoretical - metabolite related to spironolactone)"
      ]
    },
    "precautions": [
      "**HPA Axis:** Systemic absorption can occur with extensive use, potentially suppressing adrenal function.",
      "**Local Irritation:** Avoid contact with eyes/mouth."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["None known (Topical)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "welireg": {
    "name": "Welireg (Belzutifan)",
    "genericName": "Belzutifan",
    "formula": "C17H13F3N2O4S",
    "molecularWeight": "398.4 g/mol",
    "brandNames": ["Welireg"],
    "category": "Antineoplastic",
    "drugClass": "HIF-2alpha Inhibitor",
    "pubchemCID": "134823763",
    "indications": "Von Hippel-Lindau (VHL) disease-associated tumors (RCC, CNS hemangioblastomas, pNETs).",
    "moaSteps": [
      "Inhibits Hypoxia-Inducible Factor 2 alpha (HIF-2α).",
      "In VHL disease, HIF-2α accumulates, driving tumor growth and angiogenesis.",
      "Belzutifan binds to HIF-2α, preventing its interaction with HIF-1β.",
      "Reduces transcription of pro-tumorigenic genes."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "High protein binding.",
      "metabolism": "UGT2B17 (Glucuronidation) and CYP2C19.",
      "excretion": "Feces/Urine. **Half-life: 14 hours.**"
    },
    "dose": {
      "initialDose": "120 mg PO once daily",
      "maxDose": "120 mg/day",
      "notes": "Swallow whole."
    },
    "adverseEffects": {
      "common": [
        "Anemia (Severe - Class effect)",
        "Fatigue",
        "Nausea",
        "Headache"
      ],
      "serious": [
        "Severe Anemia (Transfusion requirement)",
        "Hypoxia",
        "Embryo-Fetal Toxicity - BOXED WARNING"
      ]
    },
    "precautions": [
      "**Anemia:** Inhibits Erythropoietin (EPO) production. Hemoglobin drop is expected. Monitor Hgb prior to start and periodically. Transfuse or use ESA if needed.",
      "**Hypoxia:** Monitor O2 saturation."
    ],
    "contraindications": [
      "Pregnancy"
    ],
    "interactions": {
      "drug": ["UGT2B17 Inhibitors/Inducers", "Hormonal Contraceptives (Failure - Belzutifan induces CYP3A4)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "wilate": {
    "name": "Wilate (von Willebrand Factor)",
    "genericName": "von Willebrand Factor/Coagulation Factor VIII Complex",
    "formula": "Human Plasma Derivative",
    "molecularWeight": "High MW Complex",
    "brandNames": ["Wilate"],
    "category": "Hematologic Agent",
    "drugClass": "Clotting Factor",
    "pubchemCID": "None (Biologic)",
    "indications": "Von Willebrand Disease (VWD), Hemophilia A.",
    "moaSteps": [
      "Replaces missing von Willebrand Factor (vWF) and Factor VIII.",
      "vWF promotes platelet aggregation and adhesion to damaged endothelium.",
      "vWF acts as a carrier for Factor VIII, protecting it from degradation.",
      "Restores hemostasis."
    ],
    "pharmacokinetics": {
      "absorption": "IV administration.",
      "distribution": "Vascular space.",
      "metabolism": "Catabolism.",
      "excretion": "Clearance. **Half-life: ~12 hours (vWF).**"
    },
    "dose": {
      "initialDose": "20-40 IU/kg IV (VWD - Minor hemorrhage)",
      "maxDose": "Load 40-60 IU/kg (Major)",
      "notes": "Ratio of vWF:FVIII is 1:1."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Nausea",
        "Injection site reaction"
      ],
      "serious": [
        "Thromboembolism (if FVIII accumulates excessively)",
        "Hypersensitivity / Anaphylaxis",
        "Inhibitor development (Antibodies)"
      ]
    },
    "precautions": [
      "**Thrombosis:** Monitor Factor VIII levels. Excessive FVIII increases clot risk.",
      "**Viral Safety:** Derived from human plasma (screened/treated, but theoretical risk remains).",
      "**Inhibitors:** Monitor for lack of efficacy."
    ],
    "contraindications": [
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["None specific"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "xylometazoline": {
    "name": "Xylometazoline (Otrivin)",
    "genericName": "Xylometazoline HCl",
    "formula": "C16H24N2",
    "molecularWeight": "244.4 g/mol",
    "brandNames": ["Otrivin", "Balminil"],
    "category": "Decongestant",
    "drugClass": "Alpha-Adrenergic Agonist",
    "pubchemCID": "5709",
    "indications": "Nasal Congestion (Cold, Allergy, Sinusitis).",
    "moaSteps": [
      "Direct agonist at alpha-adrenergic receptors in nasal arterioles.",
      "Causes rapid vasoconstriction.",
      "Reduces blood flow and edema in nasal mucosa.",
      "Improves nasal airflow."
    ],
    "pharmacokinetics": {
      "absorption": "Minimal systemic.",
      "distribution": "Local.",
      "metabolism": "Unknown.",
      "excretion": "Urine. **Half-life: 5 to 8 hours.**"
    },
    "dose": {
      "initialDose": "1-2 sprays/drops per nostril q8-10h",
      "maxDose": "3 doses/day",
      "notes": "MAX DURATION 3 DAYS."
    },
    "adverseEffects": {
      "common": [
        "Burning / Stinging",
        "Dryness",
        "Sneezing"
      ],
      "serious": [
        "Rhinitis Medicamentosa (Rebound Congestion - Severe addiction)",
        "Hypertension (Systemic absorption)",
        "CNS Depression (in children)"
      ]
    },
    "precautions": [
      "**Rebound:** Use >3-5 days causes dependency and worsening congestion.",
      "**Cardiac:** Caution in uncontrolled HTN/Arrhythmias.",
      "**Pediatrics:** Toxic if swallowed."
    ],
    "contraindications": [
      "Narrow-angle glaucoma",
      "Post-transsphenoidal surgery"
    ],
    "interactions": {
      "drug": ["MAOIs (Hypertensive crisis)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "xenazine": {
    "name": "Xenazine (Tetrabenazine)",
    "genericName": "Tetrabenazine",
    "formula": "C19H27NO3",
    "molecularWeight": "317.4 g/mol",
    "brandNames": ["Xenazine"],
    "category": "VMAT2 Inhibitor",
    "drugClass": "Monoamine Depletor",
    "pubchemCID": "6018",
    "indications": "Chorea associated with Huntington's Disease.",
    "moaSteps": [
      "Reversibly inhibits Vesicular Monoamine Transporter 2 (VMAT2).",
      "Prevents uptake of monoamines (dopamine, serotonin, norepi) into synaptic vesicles.",
      "Leads to depletion of monoamine stores.",
      "Depletion of dopamine reduces hyperkinetic movements (Chorea)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Crosses BBB.",
      "metabolism": "Extensive Hepatic (CYP2D6).",
      "excretion": "Urine. **Half-life: 5 to 7 hours (Active metabolites).**"
    },
    "dose": {
      "initialDose": "12.5 mg PO daily",
      "maxDose": "50 mg/day (requires CYP2D6 testing for >50mg)",
      "notes": "Titrate weekly."
    },
    "adverseEffects": {
      "common": [
        "Sedation / Somnolence",
        "Fatigue",
        "Insomnia",
        "Akathisia"
      ],
      "serious": [
        "Depression / Suicidality - BOXED WARNING",
        "Parkinsonism",
        "Neuroleptic Malignant Syndrome",
        "QT Prolongation"
      ]
    },
    "precautions": [
      "**Suicide:** High risk in Huntington's; drug exacerbates this. Monitor closely.",
      "**CYP2D6:** Genotyping required for doses > 50 mg/day.",
      "**Parkinsonism:** Can cause rigidity/tremor; reduce dose."
    ],
    "contraindications": [
      "Actively suicidal / Untreated depression",
      "Hepatic impairment",
      "MAOI use"
    ],
    "interactions": {
      "drug": ["MAOIs (Contraindicated)", "Strong CYP2D6 Inhibitors (Increase levels - Cap dose)", "Reserpine"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "yohimbine": {
    "name": "Yohimbine",
    "genericName": "Yohimbine HCl",
    "formula": "C21H26N2O3",
    "molecularWeight": "354.4 g/mol",
    "brandNames": ["Yocon", "Aphrodyne"],
    "category": "Alpha-Blocker / Mydriatic",
    "drugClass": "Alpha-2 Adrenergic Antagonist",
    "pubchemCID": "8969",
    "indications": "Erectile Dysfunction (Historical), Mydriasis (Eye drops), Xerostomia.",
    "moaSteps": [
      "Blocks presynaptic alpha-2 adrenergic receptors.",
      "Increases sympathetic outflow (norepinephrine release).",
      "Increases penile blood flow (weak effect).",
      "Causes pupil dilation (Mydriasis)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid.",
      "distribution": "Wide.",
      "metabolism": "Hepatic.",
      "excretion": "Urine. **Half-life: 0.6 hours.**"
    },
    "dose": {
      "initialDose": "5.4 mg PO TID",
      "maxDose": "16.2 mg/day",
      "notes": "Largely replaced by PDE5 inhibitors."
    },
    "adverseEffects": {
      "common": [
        "Anxiety / Nervousness",
        "Hypertension / Tachycardia",
        "Tremor",
        "Headache"
      ],
      "serious": [
        "Hypertensive Crisis",
        "Arrhythmias",
        "Renal Failure (high dose)"
      ]
    },
    "precautions": [
      "**Cardiac:** Avoid in HTN/Heart disease due to sympathetic stimulation.",
      "**Psych:** Can precipitate panic attacks/anxiety.",
      "**Renal:** Contraindicated in renal disease."
    ],
    "contraindications": [
      "Renal disease",
      "Angina / MI history",
      "Gastric/Duodenal ulcer"
    ],
    "interactions": {
      "drug": ["Antihypertensives (Antagonism)", "MAOIs (Additive stimulation)", "Clonidine (Antagonism)"],
      "food": ["Tyramine foods (Hypertension)"]
    },
    "pregnancyCategory": "Category C"
  },
  "zafirlukast": {
    "name": "Zafirlukast (Accolate)",
    "genericName": "Zafirlukast",
    "formula": "C31H33N3O6S",
    "molecularWeight": "575.7 g/mol",
    "brandNames": ["Accolate"],
    "category": "Asthma Agent",
    "drugClass": "Leukotriene Receptor Antagonist (LTRA)",
    "pubchemCID": "5719",
    "indications": "Asthma maintenance prophylaxis.",
    "moaSteps": [
      "Selective and competitive antagonist of leukotriene receptors D4 and E4 (CysLT1 and CysLT2).",
      "Inhibits bronchoconstriction and inflammation caused by leukotrienes.",
      "Reduces airway edema."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid. Food reduces bioavailability by 40%.",
      "distribution": "99% protein bound.",
      "metabolism": "Extensive Hepatic (CYP2C9).",
      "excretion": "Feces. **Half-life: 10 hours.**"
    },
    "dose": {
      "initialDose": "20 mg PO BID",
      "maxDose": "40 mg/day",
      "notes": "Must take on empty stomach (1h before or 2h after meals)."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Nausea",
        "Infection"
      ],
      "serious": [
        "Hepatotoxicity (Liver failure reported)",
        "Churg-Strauss Syndrome (Eosinophilic vasculitis)",
        "Neuropsychiatric events"
      ]
    },
    "precautions": [
      "**Liver:** Serious liver failure reported. Monitor LFTs immediately if symptoms occur.",
      "**Food:** Unlike Montelukast, Zafirlukast MUST be taken on empty stomach.",
      "**Warfarin:** Zafirlukast inhibits CYP2C9, increasing Warfarin levels/INR."
    ],
    "contraindications": [
      "Hepatic impairment",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Warfarin (Significant INR increase)", "Theophylline/Erythromycin (Decrease zafirlukast levels)", "Aspirin (Increases zafirlukast levels)"],
      "food": ["Food decreases absorption significantly."]
    },
    "pregnancyCategory": "Category B"
  },
  "zaleplon": {
    "name": "Zaleplon (Sonata)",
    "genericName": "Zaleplon",
    "formula": "C17H15N5O",
    "molecularWeight": "305.3 g/mol",
    "brandNames": ["Sonata"],
    "category": "Sedative/Hypnotic",
    "drugClass": "Non-benzodiazepine (Z-drug)",
    "pubchemCID": "5734",
    "indications": "Insomnia (Short-term, specifically sleep onset).",
    "moaSteps": [
      "Selectively binds to the omega-1 subtype of GABA-A receptor.",
      "Modulates chloride channel opening.",
      "Ultra-short duration of action.",
      "Induces sleep without maintenance effect (good for falling asleep, bad for staying asleep)."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid. High fat meal delays onset.",
      "distribution": "60% protein bound.",
      "metabolism": "Hepatic (Aldehyde oxidase/CYP3A4).",
      "excretion": "Urine. **Half-life: 1 hour (Ultra-short).**"
    },
    "dose": {
      "initialDose": "10 mg PO at bedtime",
      "maxDose": "20 mg",
      "notes": "Can be taken in middle of night if 4 hours remain."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Dizziness",
        "Somnolence"
      ],
      "serious": [
        "Complex Sleep Behaviors (Sleep-driving) - BOXED WARNING",
        "Anaphylaxis",
        " abnormal thinking"
      ]
    },
    "precautions": [
      "**Sleep Behaviors:** Stop if complex behaviors occur.",
      "**Rebound:** Short half-life may cause rebound insomnia later in night.",
      "**Diet:** High fat meal delays absorption (patient stays awake longer)."
    ],
    "contraindications": [
      "History of complex sleep behaviors",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Cimetidine (Increases levels)", "CNS Depressants (Additive)"],
      "food": ["High fat meal delays onset."]
    },
    "pregnancyCategory": "Category C"
  },
  "zileuton": {
    "name": "Zileuton (Zyflo)",
    "genericName": "Zileuton",
    "formula": "C11H12N2O2S",
    "molecularWeight": "236.3 g/mol",
    "brandNames": ["Zyflo", "Zyflo CR"],
    "category": "Asthma Agent",
    "drugClass": "5-Lipoxygenase Inhibitor",
    "pubchemCID": "60490",
    "indications": "Asthma prophylaxis and chronic treatment.",
    "moaSteps": [
      "Inhibits the enzyme 5-lipoxygenase.",
      "Prevents the formation of leukotrienes (LTB4, LTC4, LTD4, LTE4) from arachidonic acid.",
      "Blocks the inflammatory pathway upstream of receptor antagonists (like Montelukast).",
      "Reduces airway edema and mucus."
    ],
    "pharmacokinetics": {
      "absorption": "Rapid. Food increases absorption.",
      "distribution": "93% protein bound.",
      "metabolism": "Hepatic (Glucuronidation/CYP).",
      "excretion": "Urine. **Half-life: 2.5 hours.**"
    },
    "dose": {
      "initialDose": "600 mg PO QID (IR) or 1200 mg BID (CR)",
      "maxDose": "2400 mg/day",
      "notes": "Take with food (CR)."
    },
    "adverseEffects": {
      "common": [
        "Headache",
        "Dyspepsia",
        "Nausea"
      ],
      "serious": [
        "Hepatotoxicity (ALT elevation) - Significant risk",
        "Neuropsychiatric events"
      ]
    },
    "precautions": [
      "**Liver:** ALT elevation >3x ULN occurs in ~2-4%. Monitor LFTs monthly for 3 months, then quarterly. Contraindicated in active liver disease.",
      "**Interactions:** Inhibits CYP1A2 and CYP3A4."
    ],
    "contraindications": [
      "Active liver disease",
      "Persistent ALT elevation > 3x ULN"
    ],
    "interactions": {
      "drug": ["Theophylline (Doubles theophylline levels - Toxicity)", "Warfarin (Increases INR)", "Propranolol (Increased levels)"],
      "food": ["Take CR with food."]
    },
    "pregnancyCategory": "Category C"
  },
  "zoledronic_acid": {
    "name": "Zoledronic Acid (Reclast, Zometa)",
    "genericName": "Zoledronic Acid",
    "formula": "C5H10N2O7P2",
    "molecularWeight": "272.1 g/mol",
    "brandNames": ["Reclast", "Zometa"],
    "category": "Bone Resorption Inhibitor",
    "drugClass": "Bisphosphonate (IV)",
    "pubchemCID": "68740",
    "indications": "Osteoporosis (Reclast), Hypercalcemia of Malignancy (Zometa), Multiple Myeloma, Bone Metastases.",
    "moaSteps": [
      "Potent inhibitor of osteoclast-mediated bone resorption.",
      "Inhibits farnesyl pyrophosphate synthase in osteoclasts.",
      "Induces osteoclast apoptosis.",
      "Reduces serum calcium and skeletal fractures."
    ],
    "pharmacokinetics": {
      "absorption": "IV administration.",
      "distribution": "Rapidly binds to bone.",
      "metabolism": "Not metabolized.",
      "excretion": "Urine. **Half-life: 146 hours (Terminal elimination from bone takes years).**"
    },
    "dose": {
      "initialDose": "5 mg IV once yearly (Osteoporosis)",
      "maxDose": "4 mg IV (Zometa - Hypercalcemia)",
      "notes": "Must be hydrated."
    },
    "adverseEffects": {
      "common": [
        "Acute Phase Reaction (Fever/Flu-like symptoms post-infusion)",
        "Bone pain",
        "Nausea"
      ],
      "serious": [
        "Renal Failure (Acute)",
        "Osteonecrosis of the Jaw (ONJ)",
        "Atypical Femoral Fracture",
        "Severe Hypocalcemia"
      ]
    },
    "precautions": [
      "**Renal:** Nephrotoxic. Hydrate patient well. Infuse slowly (>15 min). Contraindicated if CrCl < 35.",
      "**ONJ:** Invasive dental work should be avoided.",
      "**Calcium:** Correct hypocalcemia before administration."
    ],
    "contraindications": [
      "Severe renal impairment (CrCl < 35)",
      "Hypocalcemia",
      "Hypersensitivity"
    ],
    "interactions": {
      "drug": ["Aminoglycosides (Additive nephrotoxicity/hypocalcemia)", "Loop Diuretics (Hypocalcemia)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category D"
  },
  "zonisamide": {
    "name": "Zonisamide (Zonegran)",
    "genericName": "Zonisamide",
    "formula": "C8H8N2O3S",
    "molecularWeight": "212.2 g/mol",
    "brandNames": ["Zonegran"],
    "category": "Anticonvulsant",
    "drugClass": "Sulfonamide",
    "pubchemCID": "5734",
    "indications": "Partial Seizures (Adjunct).",
    "moaSteps": [
      "Blocks voltage-sensitive sodium channels.",
      "Reduces T-type calcium currents.",
      "Weak Carbonic Anhydrase inhibitor.",
      "Scavenges free radicals."
    ],
    "pharmacokinetics": {
      "absorption": "Good.",
      "distribution": "Binds to RBCs (concentrates).",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Urine. **Half-life: 63 hours (Long).**"
    },
    "dose": {
      "initialDose": "100 mg PO daily",
      "maxDose": "400-600 mg/day",
      "notes": "Titrate every 2 weeks."
    },
    "adverseEffects": {
      "common": [
        "Somnolence",
        "Anorexia / Weight Loss",
        "Dizziness",
        "Cognitive slowing"
      ],
      "serious": [
        "Stevens-Johnson Syndrome (Sulfa)",
        "Kidney Stones (Carbonic anhydrase inhibition)",
        "Oligohidrosis / Hyperthermia (in children)",
        "Metabolic Acidosis"
      ]
    },
    "precautions": [
      "**Sulfa Allergy:** Contraindicated in severe allergy.",
      "**Hydration:** Maintain fluids to prevent kidney stones.",
      "**Sweating:** Reduced sweating risks heat stroke in children.",
      "**Cognition:** Can cause difficulty concentrating."
    ],
    "contraindications": [
      "Hypersensitivity to sulfonamides"
    ],
    "interactions": {
      "drug": ["CYP3A4 Inducers (Phenytoin/Carbamazepine - Decrease levels)", "Carbonic Anhydrase Inhibitors (Additive stone risk)"],
      "food": ["None"]
    },
    "pregnancyCategory": "Category C"
  },
  "zuranolone": {
    "name": "Zuranolone (Zurzuvae)",
    "genericName": "Zuranolone",
    "formula": "C25H35N3O2",
    "molecularWeight": "409.6 g/mol",
    "brandNames": ["Zurzuvae"],
    "category": "Antidepressant",
    "drugClass": "Neuroactive Steroid / GABA-A Receptor Positive Modulator",
    "pubchemCID": "134818672",
    "indications": "Postpartum Depression (PPD).",
    "moaSteps": [
      "Neuroactive steroid (NAS).",
      "Positive allosteric modulator of GABA-A receptors.",
      "Targets both synaptic and extrasynaptic GABA-A receptors.",
      "Rapid improvement in depressive symptoms (days vs weeks for SSRIs)."
    ],
    "pharmacokinetics": {
      "absorption": "Food increases absorption 3.5-fold.",
      "distribution": ">99% protein bound.",
      "metabolism": "Hepatic (CYP3A4).",
      "excretion": "Urine/Feces. **Half-life: 19.7 to 24.6 hours.**"
    },
    "dose": {
      "initialDose": "50 mg PO once daily in evening for 14 days",
      "maxDose": "50 mg/day",
      "notes": "MUST TAKE WITH FATTY FOOD. 14-day course only."
    },
    "adverseEffects": {
      "common": [
        "Somnolence / Sedation (Severe)",
        "Dizziness",
        "Diarrhea",
        "Fatigue"
      ],
      "serious": [
        "CNS Depression (Driving impairment)",
        "Suicidal Ideation"
      ]
    },
    "precautions": [
      "**Driving:** Do not drive for at least 12 hours after dose. Warning is strict.",
      "**Food:** Must take with fat (e.g., 400-1000 calories, 25% fat) for efficacy.",
      "**Sedation:** Additive with other CNS depressants."
    ],
    "contraindications": [
      "None specific"
    ],
    "interactions": {
      "drug": ["Strong CYP3A4 Inhibitors (Reduce dose to 30mg)", "CYP3A4 Inducers (Avoid - Loss of efficacy)", "CNS Depressants"],
      "food": ["Must take with fatty meal."]
    },
    "pregnancyCategory": "Category C (Use contraception during treatment)"
  }
}
